
<html lang="en"     class="pb-page"  data-request-id="abb4f2ac-ea91-4452-8114-27dde39e8dbb"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-5;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.0c01786;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="U.S. FDA Approved Drugs from 2015–June 2020: A Perspective" /></meta><meta name="dc.Creator" content="Priyadeep  Bhutani" /></meta><meta name="dc.Creator" content="Gaurav  Joshi" /></meta><meta name="dc.Creator" content="Nivethitha  Raja" /></meta><meta name="dc.Creator" content="Namrata  Bachhav" /></meta><meta name="dc.Creator" content="Prabhakar K.  Rajanna" /></meta><meta name="dc.Creator" content="Hemant  Bhutani" /></meta><meta name="dc.Creator" content="Atish T.  Paul" /></meta><meta name="dc.Creator" content="Raj  Kumar" /></meta><meta name="dc.Description" content="In the present work, we report compilation and analysis of 245 drugs, including small and macromolecules approved by the U.S. FDA from 2015 until June 2020. Nearly 29% of the drugs were approved fo..." /></meta><meta name="Description" content="In the present work, we report compilation and analysis of 245 drugs, including small and macromolecules approved by the U.S. FDA from 2015 until June 2020. Nearly 29% of the drugs were approved fo..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 22, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01786" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01786" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01786" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01786" /></link>
        
    
    

<title>U.S. FDA Approved Drugs from 2015–June 2020: A Perspective | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01786" /></meta><meta property="og:title" content="U.S. FDA Approved Drugs from 2015–June 2020: A Perspective" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0042.jpeg" /></meta><meta property="og:description" content="In the present work, we report compilation and analysis of 245 drugs, including small and macromolecules approved by the U.S. FDA from 2015 until June 2020. Nearly 29% of the drugs were approved for the treatment of various types of cancers. Other major therapeutic areas of focus were infectious diseases (14%); neurological conditions (12%); and genetic, metabolic, and cardiovascular disorders (7–8% each). Itemization of the approved drugs according to the year of approval, sponsor, target, chemical class, major drug-metabolizing enzyme(s), route of administration/elimination, and drug–drug interaction liability (perpetrator or/and victim) is presented and discussed. An effort has been made to analyze the pharmacophores to identify the structural (e.g., aromatic, heterocycle, and aliphatic), elemental (e.g., boron, sulfur, fluorine, phosphorus, and deuterium), and functional group (e.g., nitro drugs) diversity among the approved drugs. Further, descriptor-based chemical space analysis of FDA approved drugs and several strategies utilized for optimizing metabolism leading to their discoveries have been emphasized. Finally, an analysis of drug-likeness for the approved drugs is presented." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01786"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01786">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01786&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01786&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01786&amp;href=/doi/10.1021/acs.jmedchem.0c01786" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2339-2381</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01516" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01180" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">U.S. FDA Approved Drugs from 2015–June 2020: A Perspective</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Priyadeep Bhutani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Priyadeep Bhutani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre, Syngene International Limited, Bangalore 560099, India</div><div class="loa-info-affiliations-info">Department of Pharmacy, Birla Institute of Technology and Science (BITS) Pilani, Pilani Campus, Rajasthan 333031, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Priyadeep++Bhutani">Priyadeep Bhutani</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gaurav Joshi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gaurav Joshi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda 151001, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gaurav++Joshi">Gaurav Joshi</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7812-2871" title="Orcid link">http://orcid.org/0000-0002-7812-2871</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nivethitha Raja</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nivethitha Raja</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre, Syngene International Limited, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nivethitha++Raja">Nivethitha Raja</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Namrata Bachhav</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Namrata Bachhav</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">1015 E Cozza Drive # 12, Spokane Washington 99208, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Namrata++Bachhav">Namrata Bachhav</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Prabhakar K. Rajanna</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Prabhakar K. Rajanna</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre, Syngene International Limited, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Prabhakar+K.++Rajanna">Prabhakar K. Rajanna</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0765-8609" title="Orcid link">http://orcid.org/0000-0003-0765-8609</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hemant Bhutani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hemant Bhutani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Development, Biocon Bristol-Myers Squibb R&D Centre, Bristol-Myers Squibb India Private Limited, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hemant++Bhutani">Hemant Bhutani</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5443-7257" title="Orcid link">http://orcid.org/0000-0001-5443-7257</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Atish T. Paul</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Atish T. Paul</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacy, Birla Institute of Technology and Science (BITS) Pilani, Pilani Campus, Rajasthan 333031, India</div></div><span class="conrtib-corresp"><strong>*</strong>Email for A.T.P.: <a href="/cdn-cgi/l/email-protection#7415001d071c5a0415011834041d18151a1d5a161d000759041d18151a1d5a15175a1d1a"><span class="__cf_email__" data-cfemail="c0a1b4a9b3a8eeb0a1b5ac80b0a9aca1aea9eea2a9b4b3edb0a9aca1aea9eea1a3eea9ae">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Atish+T.++Paul">Atish T. Paul</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Raj Kumar</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Raj Kumar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda 151001, India</div></div><span class="conrtib-corresp"><strong>*</strong>Emails for R.K.: <a href="/cdn-cgi/l/email-protection#ed9f8c87c3868598838a889fad8a808c8481c38e8280"><span class="__cf_email__" data-cfemail="8ffdeee5a1e4e7fae1e8eafdcfe8e2eee6e3a1ece0e2">[email protected]</span></a>; <a href="/cdn-cgi/l/email-protection#1c6e7d7632777469727b796e5c7f696c32797869327572"><span class="__cf_email__" data-cfemail="c6b4a7ace8adaeb3a8a1a3b486a5b3b6e8a3a2b3e8afa8">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Raj++Kumar">Raj Kumar</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5113-6627" title="Orcid link">http://orcid.org/0000-0001-5113-6627</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01786&amp;href=/doi/10.1021%2Facs.jmedchem.0c01786" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2339–2381</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 22, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 October 2020</li><li><span class="item_label"><b>Published</b> online</span>22 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 March 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01786" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01786</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2339%26pageCount%3D43%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPriyadeep%2BBhutani%252C%2BGaurav%2BJoshi%252C%2BNivethitha%2BRaja%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D5%26contentID%3Dacs.jmedchem.0c01786%26title%3DU.S.%2BFDA%2BApproved%2BDrugs%2Bfrom%2B2015%25E2%2580%2593June%2B2020%253A%2BA%2BPerspective%26numPages%3D43%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2381%26publicationDate%3DMarch%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01786"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">7857</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">11</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01786" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;U.S. FDA Approved Drugs from 2015–June 2020: A Perspective&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Priyadeep&quot;,&quot;last_name&quot;:&quot;Bhutani&quot;},{&quot;first_name&quot;:&quot;Gaurav&quot;,&quot;last_name&quot;:&quot;Joshi&quot;},{&quot;first_name&quot;:&quot;Nivethitha&quot;,&quot;last_name&quot;:&quot;Raja&quot;},{&quot;first_name&quot;:&quot;Namrata&quot;,&quot;last_name&quot;:&quot;Bachhav&quot;},{&quot;first_name&quot;:&quot;Prabhakar&quot;,&quot;last_name&quot;:&quot;K. Rajanna&quot;},{&quot;first_name&quot;:&quot;Hemant&quot;,&quot;last_name&quot;:&quot;Bhutani&quot;},{&quot;first_name&quot;:&quot;Atish&quot;,&quot;last_name&quot;:&quot;T. Paul&quot;},{&quot;first_name&quot;:&quot;Raj&quot;,&quot;last_name&quot;:&quot;Kumar&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;2339-2381&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01786&quot;},&quot;abstract&quot;:&quot;In the present work, we report compilation and analysis of 245 drugs, including small and macromolecules approved by the U.S. FDA from 2015 until June 2020. Nearly 29% of the drugs were approved for the treatment of various types of cancers. Other major therapeutic areas of focus were infectious diseases (14%); neurological conditions (12%); and genetic, metabolic, and cardiovascular disorders (7–8% each). Itemization of the approved drugs according to the year of approval, sponsor, target, chemical class, major drug-metabolizing enzyme(s), route of administration/elimination, and drug–drug interaction liability (perpetrator or/and victim) is presented and discussed. An effort has been made to analyze the pharmacophores to identify the structural (e.g., aromatic, heterocycle, and aliphatic), elemental (e.g., boron, sulfur, fluorine, phosphorus, and deuterium), and functional group (e.g., nitro drugs) diversity among the approved drugs. Further, descriptor-based chemical space analysis of FDA approved drugs an&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01786&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01786" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01786&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01786" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01786&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01786" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01786&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01786&amp;href=/doi/10.1021/acs.jmedchem.0c01786" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01786" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01786" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (24 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01786%26sid%3Dliteratum%253Aachs%26pmid%3D33617716%26genre%3Darticle%26aulast%3DBhutani%26date%3D2021%26atitle%3DU.S.%2BFDA%2BApproved%2BDrugs%2Bfrom%2B2015%25E2%2580%2593June%2B2020%253A%2BA%2BPerspective%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D5%26spage%3D2339%26epage%3D2381%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292276" title="Small molecules">Small molecules</a>,</li><li><a href="/action/doSearch?ConceptID=290982" title="Diseases and disorders">Diseases and disorders</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/jmcmar.2021.64.issue-5/20210311/jmcmar.2021.64.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0042.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">In the present work, we report compilation and analysis of 245 drugs, including small and macromolecules approved by the U.S. FDA from 2015 until June 2020. Nearly 29% of the drugs were approved for the treatment of various types of cancers. Other major therapeutic areas of focus were infectious diseases (14%); neurological conditions (12%); and genetic, metabolic, and cardiovascular disorders (7–8% each). Itemization of the approved drugs according to the year of approval, sponsor, target, chemical class, major drug-metabolizing enzyme(s), route of administration/elimination, and drug–drug interaction liability (perpetrator or/and victim) is presented and discussed. An effort has been made to analyze the pharmacophores to identify the structural (e.g., aromatic, heterocycle, and aliphatic), elemental (e.g., boron, sulfur, fluorine, phosphorus, and deuterium), and functional group (e.g., nitro drugs) diversity among the approved drugs. Further, descriptor-based chemical space analysis of FDA approved drugs and several strategies utilized for optimizing metabolism leading to their discoveries have been emphasized. Finally, an analysis of drug-likeness for the approved drugs is presented.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54381" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54381" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Drug discovery is a complex interdisciplinary process, and it continues to pose a plethora of challenges for the pharmaceutical industry and allied fields.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In recent times, the expectations from new drugs to exhibit better performance over the existing ones in the market has increased tremendously.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The main reason attributed to this is probably the strict requirements imposed by different regulatory agencies around the world.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Considering the last five years of approvals (2015–June 2020) by the Centre for Drug Evaluation and Research (CDER) of the U.S. FDA, a total of 245 drugs were approved including small and macromolecules (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Of these, a record number of drugs were approved in 2018 (59), and a minimum of approvals came through in 2016 (22). For all the other years of the study (i.e., 2015, 2017, and 2019), the number of new drug approvals from the agency remained in the range of 45–48. Approval of 25 drugs until June 2020 indicates that this year also might end up with a similar number of approvals.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5−7)</a> Among the different therapeutic categories, anticancer drugs accounted for 29% of drug approvals followed by anti-infectives (14%) and drugs for neurological disorders (12%). Other major areas of focus from the pharmaceutical industry wherein approvals came through were genetic, autoimmune, cardiac, and metabolic disorders (each ranging between 6 and 8%).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Bar graph illustration of the number of year-wise drug approvals for various diseases/disorders. The data pertains to 2015–June 2020. The source of the data is the U.S. FDA Web site<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and DrugBank database.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Considering the drug discovery, on an average, one drug out of every 8000–10 000 compounds is approved for the market.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The drug-likeness for any compound is largely determined by its pharmacokinetics (PK), safety, and efficacy. The goal of PK studies is to ascertain and eventually help achieve the desired efficacy and safety profile.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11−13)</a> Efficacy, safety, and PK are interconnected, and assigning the cause of failure of a compound to any one of these factors could be misleading. For example, extensive metabolism could be one of the reasons for not achieving the desired efficacy, and toxicity might be observed because of the formation of metabolites.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The benzylic C–H bond and the allylic methyl and <i>O-, N-, S-</i>methyl groups, when not sterically hindered, are ideal metabolic soft spots and substrates of cytochrome (CYP) P450 mediated oxidative and reductive metabolism reactions. Overall, CYP enzymes are responsible for the metabolism of most of the small molecules. However, the structure–metabolism relationship of drugs metabolized through CYPs is complex. Hydrophobic, steric, hydrogen bonding, or ionic interactions with specific amino acids at the active site of the enzyme determine the affinity of the substrate with the active site of an enzyme. Common methods to decrease and/or block metabolism are (1) replacing the H atom of the C–H bond with a bulky group, bioisostere, a deuterium, or a halogen atom; or (2) place a bulky group in a neighboring site to decrease or block the accessibility of the enzyme. For example, when a benzylic methyl group is identified as a metabolic soft spot, a halogen atom, or a −CF<sub>3</sub> group, could be used to replace the H atom of the benzylic methyl group.</div><div class="NLM_p">An ideal drug candidate should be able to provide sustained exposure to have increased patient compliance due to decreased dosing frequency. It should undergo balanced clearance pathways and should not interfere with DMEs (drug-metabolizing enzymes) and transporters. In general, drugs are classified as either victims (directly affected) or perpetrators (cause interactions) in DDI (drug–drug interactions).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Medicinal chemists optimizing their compounds for candidate selection are often posed with the following questions: (1) What is the elimination pathway for the molecule of interest? (2) What are the metabolic liabilities of the molecule? (3) Does the compound of interest have the chance to undergo bioactivation to form a reactive metabolite? (4) Do any of the metabolites have either on- or off-target activity?<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Two other essential parameters controlling rate and extent of absorption of drugs are solubility and permeability, and a Biopharmaceutics Classification System (BCS) for correlating <i>in vitro</i> dissolution and <i>in vivo</i> bioavailability has been proposed.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Several theories are available on predicting the “requisite” physicochemical properties for “drug-like” absorption potential for new chemical entities. As per Lipinski’s rule, reduced intestinal permeability is reported for compounds (intended to be administered orally) with more than two out-of-range parameters from the following: more than five hydrogen-bond donors (sum of OH and NH groups), more than 10 hydrogen-bond acceptors (sum of N and O), molecular weight (MW) > 500, and log <i>P</i> > 5.<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18−20)</a></div><div class="NLM_p last">While compiling this Perspective, we came across many worthy reviews on FDA approved drugs which are either yearly publications focusing on a particular issue<a onclick="showRef(event, 'ref6 ref7 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref21 ref22">(6,7,21,22)</a> or are relatively old.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In this Perspective, we broadly categorized and discussed in the first section the U.S. FDA approved drug candidates of the last five years (2015–June 2020) based on their therapeutic areas, year of approval, sponsor, target, chemical class (small and macromolecules including antibody–drug conjugates), major drug-metabolizing enzyme(s), route of administration/elimination, and DDI liability (perpetrator and victim). The data was collected from the U.S. FDA Web site and the DrugBank database. In a later section, we comprehensively analyzed the structural (e.g., aromatic, heterocycle, and aliphatic), elemental (e.g., boron, sulfur, fluorine, phosphorus and deuterium), and functional (e.g., nitro drugs) diversity and frequency, and chemical space among the approved drugs and finally pharmacokinetic aspects and market outlook are discussed.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Anti-Cancer Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46425" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46425" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">According to the WHO, more than 100 types of cancer are currently known, and the five most common cancers in 2018 were lung, colorectal, stomach, breast, and liver.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Total deaths due to various types of cancer were more than 9 million in that year. Each cancer type requires a separate diagnosis and treatment strategy, which further creates an additional burden on and challenge for the discovery of anticancer drugs. Since the advent of the first anticancer therapy in the 1940s using nitrogen mustards and antifolate drugs,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> there has been an incredible improvement in the design of new anticancer drugs.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The last five years have witnessed the FDA approving a total of 69 drug/drug combinations for the treatment of various types of cancers including 51 small molecules (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) and 19 macromolecules (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Illustrative Compilation of U.S. FDA Approved Anti-Cancer Drugs (Small Molecules) from the Year 2015 until June 2020, Featuring Their Indication, Year of Approval, Sponsor, Target, Chemical Class, Major Drug Metabolizing Enzyme(s), Route of Administration/Elimination, and Drug Interactions (Perpetrator or/and Victim)<a class="ref internalNav" href="#t1fn2" aria-label="¶">¶</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0024.gif" alt="" id="GRAPHIC-d7e389-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0025.gif" alt="" id="GRAPHIC-d7e390-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0026.gif" alt="" id="GRAPHIC-d7e391-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">No interaction reported.</p></div><div class="footnote" id="t1fn2"><sup><sup>¶</sup></sup><p class="last">ALK: anaplastic lymphoma kinase; HR: hormone receptor; HER: human epidermal growth factor; CDK: cyclin dependent kinase; EGFR: epidermal growth factor receptor; NSCLC: nonsmall-cell lung carcinoma; EGFR: epidermal growth factor receptor;TK: Tyrosine kinase; MAPK: mitogen-activated protein kinase; VEGFR: vascular endothelial growth factor receptor; PARP: polyadenosine 5′-diphosphoribose polymerase; CLL: chronic lymphocytic leukemia; BCL: B-cell lymphoma; AML: acute myeloid leukemia; IDH: isocitrate dehydrogenase; AR: Androgen receptor; MCL: mantle cell lymphoma; BTK: bruton tyrosine kinase; FL: follicular lymphoma; PI3K: phosphatidylinositol-3-kinase; NTRK: neurotrophin receptor kinase; SLL: small lymphocytic lymphoma; FGFR: fibroblast growth factor receptor; CSF: colony-stimulating factor; ROS: reactive oxygen species; A, accelerated; B, breakthrough; O, orphan; P, priority; S, standard CYP: cytochrome; PO: peroral; IV: intravenous.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Illustrative Compilation of U.S. FDA Approved Anti-Cancer Drugs (Macromolecules) from the Year 2015 until June 2020, Featuring Their Indication, Year of Approval, Sponsor, Target, Route of Administration, and Class<a class="ref internalNav" href="#t2fn1" aria-label="¶">¶</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0027.gif" alt="" id="GRAPHIC-d7e410-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>¶</sup></sup><p class="last">SLAMF: signaling lymphocytic activation molecule family member 7; EGFR: epidermal growth factor receptor; NSCLC: nonsmall cell lung cancer; CD38: cluster of differentiation 38; PDGFR-α:platelet-derived growth factor receptor alpha; PD-L1: programmed death-ligand 1; ALL: acute lymphoblastic leukemia; IL-3: Interleukin-3; CD22: cluster of differentiation-22; CCR4: CC chemokine receptor type 4; ADC: antibody drug conjugate; HER2: human epidermal growth factor receptor 2; CD79b: cluster of differentiation-79b; CD38: cluster of differentiation-38; A, accelerated; B, breakthrough; O, orphan; P, priority; S, standard; IV: intravenous.</p></div></div><div></div></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of small molecules as anticancer agents approved by FDA between 2015 and 2017 (Part-1).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of small molecules approved as anticancer agents approved by FDA between 2018 and June 2020 (Part-2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Neratinib (<b>15</b>), a kinase inhibitor, was approved for the treatment of HER2-overexpressed/amplified breast cancer. The other approved anticancer kinase inhibitor drugs included cobimetinib (<b>4</b>), copanlisib (<b>22</b>), and acalabrutib (<b>19</b>) as inhibitors of MAPK, PI3K/AKT, and BTK, respectively. Drugs targeting vascular endothelial growth factor (VEGF; lenvatinib, <b>7</b> and brolucizumab), basic fibroblast growth factor (bFGF; erdafitinib, <b>40</b> and pemigatinib, <b>43</b>), platelet-derived endothelial growth factor (PDGFR; olaratumab), and granulocyte colony-stimulating factor (CSF; pexidartinib, <b>37</b>) were approved in the study period to prevent the formation of new blood vessels and thus subsequently suppress tumor growth. There was one antiapoptotic drug; venetoclax (<b>12</b>) targeting Bcl-2 was approved in the year 2017<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> for the treatment of chronic lymphocytic leukemia. The agency approved first-in-class enasidenib (<b>14</b>), an inhibitor of mutated isocitrate dehydrogenase 2 (IDH2) for acute myeloid leukemia, confirming metabolism-altering drugs as a means of targeting and killing cancer cells. The agency also approved Amgen’s talimogene laherparepvec, the first cancer-killing virus. Several monoclonal antibodies (mAbs) including but not limited to atezolizumab, avelumab, durvalumab, and cemiplimab targeting PD-L1 (immune checkpoints) were approved in the last five years. The approvals also include other immunotherapies and chimeric antigen receptor therapies.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">We noticed increased approvals for antibody–drug conjugates (ADCs) since 2015.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> ADCs are highly selective and allow specific delivery of cytotoxic agents to the intended cancer cell target.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> Their success has been marked by FDA approval of five ADCs in the last five years including inotuzumab ozogamicin for acute lymphoblastic leukemia, fam-trastuzumab deruxtecan for metastatic breast cancer, enfortumab vedotin for refractory bladder cancer, sacituzumab govitecan for metastatic triple-negative breast cancer, and polatuzumab vedotin for relapsed or refractory diffuse large B-cell lymphoma.</div><div class="NLM_p">Typically, anticancer drugs are coadministered with other drugs and therefore have a high propensity to undergo DDI either as victim and/or perpetrator. Some of the drugs used for cancer therapy act as a victim in the presence of CYP3A4 modulators (both inhibitor as well as inducer) and P-gp (P-glycoprotein) and BCRP (breast cancer resistance protein) inhibitors, while others may be a perpetrator (impact the systemic exposure of coadministered drugs through inhibition of various enzymes like CYP3A4, CYP2C9. CYP2D6, CYP2C19 and transporters like P-gp, BCRP, OATP1B1; see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Overall, CYPs played a significant role in the metabolism of 43 out of 51 small molecules, and for almost all the drugs (42 out of 43), the major enzyme involved is CYP3A4. Rucaparib (<b>13</b>), a first-in-class PARP inhibitor, is metabolized primarily by CYP2D6. Carboxylesterase-mediated amide hydrolysis is the major pathway for the metabolism of niraparib (<b>20</b>), leading to the formation of an inactive acid metabolite followed by glucuronidation. Aldehyde oxidase (AO) along with CYP3A4 are involved in the metabolism of capmatinib (<b>46</b>) and <b>7</b> (quinoline derivatives). Catabolism is primarily responsible for the elimination of all the macromolecules. A total of 47 out of 51 anticancer small-molecule drugs were approved for administration through the peroral route and 4 (trabectedin (<b>5</b>), copanlisib (<b>22</b>), lurbinectedin, and lutetium Lu 177 dotatate) through the intravenous route, and all the macromolecules were approved for use through the intravenous route.</div><div class="NLM_p last">Drug design for anticancer drugs has shifted from traditional cytotoxic chemotherapy to targeted cancer drugs,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> which is further supported with increased understanding of the disease at the molecular level.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> The overall success rate for the oncology drugs in the clinical development is estimated at ∼10%, while the cost of introducing a new drug to the market is estimated at greater than 1 billion US$.<a onclick="showRef(event, 'ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37">(35−37)</a> Unfortunately, the major challenge is the development of drug resistance that leads to mortality and morbidity.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Considering the global market, it is anticipated that the targeted anticancer therapy would acquire the highest revenue contribution in cancer drug market by 2026. It is also anticipated that five regions (i.e., North America, Latin America, Europe, Asia Pacific excluding Japan, Middle East, and Africa) would drive anticancer research. AbbVie, Bayer, Pfizer, Bristol Myers Squibb, Roche, Eli Lilly, Novartis, AstraZeneca, and Johnson & Johnson will continue to be major players in the area and would contribute toward more than 2/3rd market share of anticancer drugs.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Drugs for Neurological Disorders</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50807" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50807" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Neurological disorders can be classified into three groups: neurotraumatic diseases (strokes and epilepsy), neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), and neuropsychiatric diseases (depression, schizophrenia).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Neurological disorders are reported to contribute 11.6% of global disability adjusted life years (DALYs) and 16.5% (2nd leading cause) of deaths from all causes.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><div class="NLM_p">Until 2015, there were 79 FDA approved new molecular entities for the treatment of neurological disorders.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Over the past five years, FDA has approved a total of 23 small molecules, one each of cyclodextrin derivative and toxin; two oligonucleotides and four monoclonal antibodies (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) for the treatment of neurological disorders. Chemical structures of small molecules approved for the treatment of various neurological disorders are collated in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Illustrative Compilation of U.S. FDA Approved Neurological Agents, Featuring Their Indication, Year of Approval, Sponsor, Target, Chemical Class, Major Drug Metabolizing Enzyme(s), Route of Administration/Elimination, and Drug Interactions (Perpetrator or/and Victim)<a class="ref internalNav" href="#t3fn3" aria-label="¶">¶</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0028.gif" alt="" id="GRAPHIC-d7e549-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0029.gif" alt="" id="GRAPHIC-d7e550-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">No interaction reported.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">No information available.</p></div><div class="footnote" id="t3fn3"><sup><sup>¶</sup></sup><p class="last">D2: dopamine receptor isoform 2; 5-HT: 5-hydroxytryptamine; SV2A: synaptic vesicle protein 2A; VMAT2: vesicular monoamine transporter 2; MAO: monoamine oxidase; GABA: gamma-aminobutyric acid; CGRP: calcitonin gene-related peptide; OX: orexin; DNRI: dopamine and norepinephrine reuptake inhibitor; COMT: catechol-<i>o</i>-methyltransferase; A, accelerated; B, breakthrough; O, orphan; P, priority; S, standard; PO: peroral; IV: intravenous; SC: subcutaneous; IT: intrathecal; IM: intramuscular; CYP: cytochrome P450; UGT: UDP-glucuronosyltransferase; P-gp: P-glycoprotein; BCRP: breast cancer resistance protein.</p></div></div><div></div></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of small molecules approved for the treatment of various neurological disorders by FDA from the year 2015 until June 2020.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is evident that serotonin (5-HT<sub>1F</sub>) and calcitonin gene-related peptide (CGRP) targets were explored for the management of migraine in the last five years. Lasmiditan, (<b>64</b>), a 5-HT<sub>1F</sub> receptor agonist, exerts effects by inhibition of trigeminal nerve firing and hyperpolarization of nerve terminals.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Calcitonin gene-related peptide (CGRP) release produces local vasodilation and extravasation of plasma and plasma proteins into the surrounding tissue.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> A total of six CGRP antagonists containing two small molecules, ubrogepant (<b>67</b>) and rimegepant sulfate (<b>72</b>), and four monoclonal antibodies, namely, erenumab, fremanezumab, galcanezumab, and eptinezumab, were approved. Further, to circumvent the extrapyramidal motor side effects (EPS) due to full inhibition of dopamine D2 receptors by first-generation antipsychotics, four small molecules with serotonin 5-HT2A receptor antagonism in combination with D2 receptor partial agonism were approved by the FDA for the treatment of schizophrenia. In the antiepileptic category, targets such as gamma-aminobutyric acid (GABA) receptors and synaptic vesicle glycoprotein 2 (SV2) were explored by pharmaceutical companies in the last five years. Cannabidiol (<b>61</b>), an oral solution, was approved in 2018 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome. According to the FDA, <b>61</b> does not appear to exert its anticonvulsant effects through interaction with cannabinoid receptors.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> GABA which acts through GABA<sub>A</sub> and GABA<sub>B</sub> receptors is the principal inhibitory neurotransmitter in the brain.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Stiripentol (<b>60</b>) and cenobamate (<b>63</b>), positive allosteric modulators of GABA<sub>A</sub> receptors, were approved in 2018 and 2019, respectively, for the treatment of epilepsy. Brivaracetam (<b>55</b>), which binds SV2A with high affinity and thus induces indirect modulation of synaptic GABA release, was approved in 2016 for the treatment of partial-onset seizures. For the treatment of patients of Parkinson’s disease experiencing “off” episodes, safinamide (<b>57</b>), a reversible inhibitor of MAO-B, and opicapone (<b>71</b>), a third-generation inhibitor of COMT, were approved as an add-on treatment to levodopa<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and as an adjunctive therapy, respectively. Istradefylline (<b>62</b>), an A<sub>2A</sub> receptor inhibitor, was approved in 2019 for the treatment of Parkinson’s disease as an adjunct to levodopa therapy. Edaravone (<b>58</b>), a free radical scavenger which increases prostacyclin production and decreases lipoxygenase metabolism of arachidonic acid, was approved for the treatment of amyotrophic lateral sclerosis (ALS). Vesicular monoamine transporter 2 (VMAT2), which is responsible for monoamine (dopamine, norepinephrine, and serotonin) transport across synaptic vesicles, is implicated in tardive dyskinesias (TD) pathology.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Valbenazine (<b>56</b>), an inhibitor of VMAT2, was approved for the treatment of TD. Another VMAT2 inhibitor, deutetrabenazine (<b>59</b>), that depletes the levels of presynaptic dopamine was approved for the treatment of Huntington’s disease (HD).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Flibanserin (<b>53</b>), an agonist of 5-HTA1 and an antagonist of 5-HTA2, and bremelanotide (2019), a melanocortin receptor agonist, were approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Histaminergic neurons play a significant role in the maintenance of wakefulness.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Pitolisant (<b>66</b>), a histamine H3 receptor antagonist or inverse agonist, was approved for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy in adults. Lemborexant (<b>69</b>) is a competitive antagonist of OX1 and OX2 receptors<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> and blocks the binding of neuropeptides orexin-A and -B. The drug suppresses the wake-drive, thereby promoting sleep, and is recommended for the treatment of insomnia. Nusinersen, an antisense oligonucleotide approved in 2016, increases the splicing efficiency of the SMN2 pre-mRNA and corrects the SMN protein deficiency involved in spinal muscular atrophy (SMA).</div><div class="NLM_p">A total of 21 out of 23 small molecule drugs approved for various neurological disorders are intended for administration through the peroral route and 2 through the intravenous route. Three out of 4 monoclonal antibodies are approved for the subcutaneous route, and eptinezumab (a mAb, approved for migraine) was approved for administration through the intravenous route. Approved oligonucleotides are for intrathecal and subcutaneous administration.</div><div class="NLM_p last">CYPs played significant roles in the metabolism of 14 out of 23 small molecules, wherein the major enzyme involved is CYP3A4 (for 13 out of 14 approved drugs). Nucleases are involved in the metabolism of oligonucleotides, and catabolism continues to remain the primary way for elimination of the macromolecules. Seventeen small molecules were implicated as victims during coadministration with drugs causing modulations in enzymes (CYP3A4, CYP2C19, CYP2D6, and CYP1A2) and transporters (P-gp and BCRP), details in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. A majority of the approved small molecules followed the Lipinski’s rule of 5. By the end of 2020, ∼14% of the global population is anticipated to suffer from neurological disorders. Geographically, it is estimated that the largest market for neuro-therapeutics will be led by North America, followed by Europe and Asia-Pacific countries. The key players contributing to the market share will include Abbott, Becton and Dickinson, Novartis, Johnson & Johnson, Pfizer, Sanofi-Aventis, Biogen, GlaxoSmithKline, AstraZeneca, and Merck.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Drugs for the Treatment of Metabolic/Genetic Disorders</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18388" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18388" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Under this category, authors have observed that a total of 35 novel therapeutic agents were approved by the U.S. FDA in the specified period, with one-third of them being small molecules (12). Antibody molecules and oligonucleotides (4 each), peptides and enzymes (5 each), polymers, hormones (2 each), and one fusion protein constituted the remaining approvals. Considering the total 76 new molecular entities approved by the FDA for the treatment of metabolic disorders until 2015, the last 5 years seem to ensure that more number of drugs are available to the patients of metabolic disorders.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The details of all the drugs approved for metabolic disorders during the period 2015–June 2020 are compiled in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, and chemical structures of small molecules are illustrated in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. A brief overview of the compilation is presented here. In the category of antihyperuricemic/antigout drugs, lesinurad (<b>73</b>), an URAT1<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> inhibitor which causes an increase in the excretion of uric acid, was approved. Patiromer, approved in 2015 for hyperkalemia, is a nonabsorbed potassium-binding polymer that binds to potassium in the gastrointestinal system, resulting in excretion of potassium in feces to reduce the serum potassium levels. Natpara (2015), a parathyroid hormone involved in regulating serum calcium levels, was approved for the treatment of hypocalcemia in adults with reduced PTH (parathyroid hormone) levels.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Incretins (glucagon-like peptide-1; GLP-1) are the hormones produced by the intestinal mucosa which regulate the insulin secretion in response to food consumption.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Lixisenatide (2016), a GLP-1 receptor agonist, and semaglutide (2017), a GLP-1 analogue, were approved for the management of type 2 diabetes mellitus. Another antidiabetic drug ertugliflozin (<b>79</b>) targeting SGLT2<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> was approved in 2017. Whereas for the treatment of type 1 diabetes, insulin degludec (2018), an ultralong-acting insulin analogue, was approved. Etelcalcetide (2017), a type 2 calcimimetic, is a positive allosteric modulator which increases the sensitivity of the calcium-sensing receptor (CaSR) to ionized calcium and reduces PTH secretion by the negative feedback mechanism. Pegvaliase, a recombinant phenylalanine ammonia lyase (PAL) enzyme which reduces blood phenylalanine concentrations by converting phenylalanine to ammonia and <i>trans</i>-cinnamic acid, was approved in 2018. Cushing syndrome is caused by chronic elevation of circulating glucocorticoids primarily by overproduction of cortisol by the adrenals as a result of a pituitary or adrenal tumor.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The preferred therapeutic strategy is to reverse hypercortisolemia. Osilodrostat (<b>85</b>), approved in 2020, is an inhibitor of 11β-hydroxylase, an enzyme involved in the biosynthesis of endogenous cortisol and results in reduced cortisol concentrations. Elevated extracellular levels of inorganic pyrophosphate (PPi) results in defective mineralization and leads to bone deformation in infants. Asfotase alfa (2015) treatment replaces the level of TN-SALP (tissue nonspecific alkaline phosphatase) enzyme and reduces the PPi levels. Eteplirsen (2016), is a targeted oligonucleotide that causes exon skipping of exon 51. Deflazacort (<b>78</b>), a corticosteroid was approved for the treatment of Duchenne muscular dystrophy. Cerliponase alfa (2017) contains tripeptidyl peptidase-1 (rhTPP1), a recombinant human lysosomal exopeptidase which cleaves the N-terminal of tripeptides. The drug was approved for the treatment of ceroid lipofuscinosis type 2 (CLN2). Vestronidase alfa (2017), a recombinant human lysosomal beta-glucuronidase (GUS) acts by serving as an exogenous source of GUS enzyme through intravenous infusion.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Migalastat (<b>80</b>), approved for the treatment of Fabry disease, stabilizes the dysfunctional alpha-Gal A enzyme and results in the clearance of accumulated crystalline glycosphingolipids (GSLs).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Increased levels of fibroblast growth factor 23 (FGF23) were observed in patients with X-linked hypophosphatemia (XLH).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Burosumab (2018) is a monoclonal antibody that inhibits the actions of FGF23, which in turn increases the tubular reabsorption of phosphate from the kidney. Voxelotor (<b>81</b>), an HbS polymerization inhibitor prevents the formation of abnormally shaped cells and was approved for sickle cell disease. In the same category, crizanlizumab (2019), an antibody targeting P-selectin was approved for the treatment of vaso-occlusive crisis in patients with sickle cell diseases. Luspatercept (2019), a fusion protein, ameliorates ineffective erythropoiesis in patients with beta thalassemia by acting as a “ligand trap” for various members of the TGF-β superfamily. Afamelanotide (2019), a synthetic analogue of the endogenous α-MSH, was approved to prevent skin damage in people with erythropoietic protoporphyria from UV-induced damage. Cystic fibrosis (CF) is a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which results in the production of abnormally thick mucus that builds up in the lungs, digestive tract, and other parts of the body.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> There are more than 1700 different mutations in the CFTR gene that can cause CF, the most common one is the F508del (F: Phenylalanine) mutation. CFTR modulators are classified into potentiators (ivacaftor, <b>82</b>), correctors (lumacaftor, <b>77</b> and tezacaftor, <b>84</b>), and amplifiers (in clinical development; PTI - 428 and PTI - CH). Combination therapy is anticipated to offer better results than individual drug(s). Orkambi, symdeko, and trikafta are the three CFTR modulators approved during this period wherein orkambi and symdeko were approved for individuals with two copies of the F508del mutation (smaller CF population).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Trikafta (elexacaftor, tezacaftor and ivacaftor) is a triple combination therapy, which was approved for the treatment of CF patients with one or more F508del mutation in the CFTR gene (90% of the CF population). Going forward, the global CF market is expected to register a CAGR of 13.5% and is anticipated to reach USD ∼ 13 000 M by 2025.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Drug discovery efforts for CF are spearheaded by Vertex, AbbVie, Gilead, Actavis (Allergan), Genentech (Roche), and Novartis.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Illustrative Compilation of U.S. FDA Approved Drugs from the Year 2015 until June 2020 for Metabolic Disorders Featuring Their Indication, Year of Approval, Sponsor, Target, Chemical Class, Major Drug Metabolizing Enzyme(s), Route of Administration/Elimination, and Drug Interactions (Perpetrator or/and Victim)<a class="ref internalNav" href="#t4fn3" aria-label="¶">¶</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0030.gif" alt="" id="GRAPHIC-d7e758-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0031.gif" alt="" id="GRAPHIC-d7e759-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">No interaction reported.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">No information available.</p></div><div class="footnote" id="t4fn3"><sup><sup>¶</sup></sup><p class="last">URAT1: uric acid transporter 1; CFTR: cystic fibrosis transmembrane conductance regulator; GLP-1: glucagon-like peptide-1; SGLT: sodium-dependent glucose cotransporters; DMD: duchenne muscular dystrophy; XLH: X-linked hypophosphatemia; FXR: farnesoid X receptor; A, accelerated; B, breakthrough; O, orphan; P, priority; S, standard; PO: peroral: IV: intravenous: SC: subcutaneous; IM: intramuscular; CYP: cytochrome P450; UGT: UDP-glucuronosyltransferase; P-gp: P-glycoprotein; BCRP: breast cancer resistance protein.</p></div></div><div></div></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of small molecule drugs used for the treatment of various metabolic disorders approved by FDA from the year 2015 until June 2020.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Except for <b>77</b> and <b>83</b>, all the approved small molecules under this category followed the Lipinski’s rule. As indicated in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, some of the approved small molecules were implicated as victims during coadministration with drugs causing modulations in enzymes (CYP2C9, CYP2B6, and CYP3A4) and transporters (BSEP).<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Eleven out of 12 small molecule drugs approved for various metabolic disorders are approved for administration through the peroral route and one through the subcutaneous route. Three out of 4 monoclonal antibodies are approved for use through the subcutaneous route, and crizanlizumab (monoclonal antibody, approved for sickle cell anemia to Novartis) was approved for the intravenous route. Oligonucleotides were approved through intravenous (3) and subcutaneous (1) administration. Two polymers are approved through peroral administration during this period for the treatment of hyperkalemia. Only 7 small molecules are metabolized through CYPs, wherein again the major enzyme involved is CYP3A4 (6 out of 7), and all these molecules behave as victims when codosed with CYP3A inducer/inhibitor. Dose adjustment is required for the drugs that are eliminated through the renal pathway (e.g., <b>78</b>).</div><div class="NLM_p last">In 2017, the metabolic diseases market size was valued at ∼USD $50 billion, which is expected to rise at 7.6% of CAGR by 2024. Major contributing regions to research in this area and market for the therapies include Africa, North America, Asia Pacific, Latin America, the Middle East, and Europe. The notable companies involved in this area of research are GlaxoSmithKline, Merck, Amicus, Sanofi, Genzyme, AstraZeneca, and Horizon Pharma.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> For genetic disorders, the market is expected to rise from USD $45 billion in 2017 to USD $86 billion by 2025. Important countries that will drive drug discovery in the area of genetic disorders are North America and the Asia Pacific region.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Drugs for Respiratory Disorders</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01014" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01014" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Respiratory diseases including chronic obstructive pulmonary diseases (COPD), asthma, interstitial lung diseases, and pulmonary sarcoidosis<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> are the third leading cause of worldwide death.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div><div class="NLM_p">The U.S. FDA approved a total of just four drugs in the last five years for the treatment of asthma (3 mAbs) and chronic obstructive pulmonary disease (revefenacin <b>86</b>, a small molecule). The details of the approved drugs for respiratory diseases are compiled in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. The mAbs bind to the interleukin 5 receptor, a key cytokine responsible for the differentiation, maturation, recruitment, and activation of human eosinophils which plays a key role in inflammation associated with asthma. Mepolizumab and benralizumab have been approved by the FDA for administration through subcutaneous route, while reslizumab has been approved for use via the intravenous route. <b>86</b> is a bronchodilator, long acting muscarinic antagonist (LAMA), approved for dosing through the inhalation route. After inhalation, <b>86</b> rapidly undergoes hepatic metabolism to a major active metabolite (THRX-195518), with its systemic exposure being 4- to 6-fold greater than <b>86</b>.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> OATP1B1/1B3 inhibitors may increase serum concentrations of the active metabolite(s) of <b>86</b>.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Illustrative Compilation of U.S. FDA Approved Drugs from the Year 2015 until June 2020 for Respiratory Disease Featuring Their Indication, Year of Approval, Sponsor, Target, Chemical Class, Major Drug Metabolizing Enzyme(s), Route of Administration/Elimination, and Drug Interactions (Perpetrator or/and Victim)<a class="ref internalNav" href="#t5fn2" aria-label="¶">¶</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0032.gif" alt="" id="gr23" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">No interaction reported.</p></div><div class="footnote" id="t5fn2"><sup><sup>¶</sup></sup><p class="last">IL-5: Interleukin-5; S, standard; IV: intravenous; SC: subcutaneous; OATP: organic-anion-transporting polypeptide.</p></div></div><div></div></div><div class="NLM_p last">There has been a recent upsurge in research in respiratory diseases’ drugs because of the Covid-19 pandemic, which primarily affects the respiratory system. The global market for drugs for respiratory diseases was estimated at $65 billion in 2019 and is expected to rise to $93 billion by end of 2020. North America accounted for 49% of the global market, followed by Western Europe (19%). Mylan, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Merck, Roche, Novartis, and Teva are considered to be key players that will drive the market for respiratory drugs.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Anti-Infective Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04057" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04057" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Infectious diseases are caused by pathogens, which include bacteria, fungi, protozoa, worms and viruses. There were 292 approved new molecular entities until late 2013 for the treatment of infectious diseases.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> A total of 33 anti-infective drug/drug combinations were approved by US FDA in the last five years (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>), with 90% being small molecules (30 drug/drug combinations) and 3 mAbs. The drugs approved for the various infectious diseases are briefly discussed with their targets in this section. Complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) are caused by multidrug-resistant bacteria.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Eravacycline <b>95</b>,(2018), a synthetic fluorocycline antibiotic of the tetracycline, which binds to the 30S ribosomal subunit and disrupts bacterial protein synthesis was approved for the treatment of cIAI. Avycaz (the combination of ceftazidime <b>112</b>, a cephalosporin antibiotic, and avibactam <b>113</b>, a β-lactamase inhibitor, 2019), plazomicin <b>98</b>, an aminoglycoside which targets bacterial 30S ribosomal subunit and cefiderocol <b>103</b>, an inhibitor of penicillin-binding proteins (PBPs) were approved for treatment of cUTI. Vabomere, is a combination of Meropenem <b>115</b>, a penam antibacterial, and vaborbactam <b>117</b>, a beta-lactamase inhibitor was approved in 2017 for the treatment of patients with cUTI. Recarbio is a combination of imipenem <b>124</b>, a carbapenem antibacterial, cilastatin <b>126</b>, a renal dehydropeptidase inhibitor, and relebactam <b>125</b>, a beta-lactamase inhibitor. The combination prevents the degradation of <b>124</b> by serine beta-lactamases. Recarbio was approved for the treatment of cIAI and cUTI in 2019. In 2020, the drug is also approved for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Lefamulin (<b>104</b>), which exerts its action by binding to the peptidyl transferase center of the ribosomal bacterial 50S subunit and omadacycline (<b>99</b>), a minomethylcycline subclass of tetracycline antibiotics were approved for the treatment of community-acquired bacterial pneumonia (CABP). Tuberculosis, which is estimated to infect one in every three people is caused by <i>Mycobacterium tuberculosis</i>.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Pretomanid (<b>106</b>) is indicated for the treatment of pulmonary forms of nonresponsive multidrug-resistant (MDR) tuberculosis, in combination with bedaquiline and linezolid.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Illustrative Compilation of U.S. FDA Approved Drugs from the Year 2015 until June 2020 for Infectious and Parasitic Diseases Featuring Their Indication, Year of Approval, Sponsor, Target, Chemical Class, Major Drug Metabolizing Enzyme(s), Route of Administration/Elimination, and Drug Interactions (Perpetrator or/and Victim)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0033.gif" alt="" id="GRAPHIC-d7e935-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0034.gif" alt="" id="GRAPHIC-d7e936-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0035.gif" alt="" id="GRAPHIC-d7e937-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">No interaction reported.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">No information available.</p></div><div class="footnote" id="t6fn3"><sup><sup>¶</sup></sup><p class="last">UTI: urinary tract infections; HIV: human immunodeficiency virus; NRTI: nucleoside reverse transcriptase inhibitor; NS: nonstructural protein; PA: polymerase acidic; CMV: cytomegalovirus; RNA: ribonucleic acid; CD: cluster of differentiation; DHA: dihydroartemisinin; PA: polymerase acidic; A, accelerated; B, breakthrough; O, orphan; P, priority; S, standard; PO: peroral: IV: intravenous: SC: subcutaneous; BCG: Bacillus Calmette-Guérin; HINT1: histidine triad nucleotide-binding protein 1; CYP: cytochrome P450; UGT: UDP-glucuronosyltransferase; P-gp: p-glycoprotein; CES: carboxylesterases.</p></div></div><div></div></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of small molecules as anti-infective agents approved by FDA from the year 2015 until June 2020 (Part 1).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of small molecules used in combination therapy as anti-infective agents approved by the FDA from the year 2015 until June 2020 (Part 2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Delafloxacin (<b>89</b>), an anionic fluoroquinolone, which inhibits the activity of bacterial topoisomerase II was approved in 2017 for the treatment of acute bacterial skin and skin structure infections caused by <i>Staphylococcus</i>, <i>Enterococcus</i>, <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Pseudomonas aeruginosa</i>.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Ozenoxacin (<b>90</b>), which targets bacterial DNA replication enzymes DNA gyrase A and topoisomerase IV was approved in 2017 for the topical treatment of impetigo. Secnidazole (<b>92</b>), a second-generation 5-nitroimidazole was approved in 2017 for the treatment of bacterial vaginosis in adult women.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> In 2016, two mAbs, bezlotoxumab for <i>Clostridium difficile</i> infection<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> and obiltoxaximab for the prevention and treatment of infection caused by anthrax toxin were approved.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Further analysis revealed that three small molecules and one mAb were approved in the anti-HIV category. The approved small molecules, in general, were combination drugs which target HIV-1 integrase strand transfer (involves in concerted integration of viral DNA into the host chromosomes), nucleoside and nucleotide reverse transcriptase (reverse transcribes viral RNA into DNA for insertion into the host DNA sequence). An anti-HIV mAb, Ibalizumab which, targets CD4 receptors on the surface of CD4-positive cells and prevent HIV particle entry into the lymphocytes was approved in 2018. Influenza is an acute respiratory disease caused by the influenza A or B virus with an annual incidence of 3–5 million cases of severe illness and about 250,000 to 500,000 deaths worldwide.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Baloxavir marboxil (<b>101</b>), a prodrug, the hydrolysis of which results in baloxavir, is responsible for activity against influenza A and B virus infection. <b>101</b> exerts its activity by selectively inhibiting influenza cap-dependent endonuclease which prevents polymerase function leading to influenza virus mRNA replication. <b>101</b> is the only new flu drug to be approved since the 1999 approval of Roche’s neuraminidase inhibitor oseltamivir.</div><div class="NLM_p">Hepatitis C virus (HCV), belonging to family <i>Hepadnaviridae</i>, affects around 170 million people worldwide.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Five single and/or combination of small-molecule drugs were approved for the treatment of HCV between 2015 - June 2020. Most of the approved drugs target HCV nonstructural protein 5B (NS5B), the RNA-dependent RNA polymerase responsible for the complete copy of the RNA viral genome, HCV nonstructural 5A (NS5A) protein involved in modulation of the host cell interferon (IFN) response and HCV NS3/4A protein, a membrane-targeted serine protease responsible for maturation of the viral polyprotein.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a></div><div class="NLM_p">Cytomegalovirus and smallpox infections are caused by β-herpesvirus (HHV-5) and variola virus, respectively. Letermovir (<b>93</b>) inhibits the activity of the DNA terminase complex of cytomegalovirus (CMV) and was approved for prophylactic treatment of CMV infection in allogeneic hematopoietic stem cell transplant patients. Tecovirimat (<b>100</b>), an inhibitor of the orthopoxvirus VP37 envelope wrapping protein was approved for the treatment of smallpox.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> As per the World Malaria Report 2018, there were 219 million cases of malaria globally in 2017 with around 4,35,000 malaria deaths.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Artesunate <b>107</b>, (2020) was approved for the treatment of severe malaria and it generates free radicals that inhibit the normal function of <i>Plasmodium</i> parasites. Tafenoquine (<b>96</b>), an 8-aminoquinoline analogue of primaquine which acts through its active moiety 5,6-orthoquinone tafenoquine generates hydrogen peroxide and hydroxyl radicals which further causes the parasitic death.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Benznidazole (<b>91</b>) was approved in 2017 for the treatment of Chagas disease caused by <i>Trypanosoma cruzi</i> in children. For triclabendazole (<b>105</b>), the mechanism of action is not fully known and is currently the only FDA-approved drug for patients affected with fascioliasis. It is postulated to inhibit tubulin function and synthesis of proteins and enzymes in the parasite. Onchocerciasis (river blindness) is caused by a nematode worm, <i>Onchorcerca volvulus</i>. Moxidectin (2018) which binds to the parasite’s GABA-A and glutamate-gated chloride ion channels was approved for the treatment of river blindness. Isavuconazonium (<b>87</b>), a second-generation triazole antifungal inhibits the sterol 14-α-demethylase (Erg11p), and thereby disrupts the fungal membrane integrity. <b>87</b> was approved in the year 2015 by the FDA for the treatment of invasive aspergillosis and invasive mucormycosis.</div><div class="NLM_p">Majority of the drugs in this category were proved for the treatment of bacterial and viral infections. Agreement to Lipinski’s criteria for majority of the approved small molecules (27) continued to be the case with anti-infective drugs. A total of 16 small molecules are metabolized through CYPs, wherein major enzyme involved is CYP3A4 (14 out of 16) and behave as victims when codosed with CYP3A inducer/inhibitor. For ∼70% of the small molecule drugs, peroral route has been approved for administration and 8 drugs are approved for use through intravenous route.</div><div class="NLM_p last">The global market size of anti-infectious agents was valued at ∼ USD 47 billion in the year 2016. The market can be broadly segmented into HIV, malaria, hepatitis, influenza, human Papillomavirus and tuberculosis. In 2016, the HIV segment held the largest share followed by hepatitis therapeutics segment.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> The major pharmaceutical companies dominating anti-infective drug development include Merck & Co., F. Hoffmann-La Roche Ltd., Pfizer, Johnson & Johnson Services and GlaxoSmithKline.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Drugs for Autoimmune Disorders</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02617" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02617" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Autoimmune diseases comprise more than 70 different disorders affecting approximately 5% of the general population.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> The autoimmune disorders are reported to be among the 10 most frequent underlying or contributory causes of mortality in females (women have increased prevalence of autoimmune diseases as compared with men) of all age groups with the peak mortality rate of ∼5% between 55 and 74 years.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div><div class="NLM_p">Unitl 2014, there were a total of 168 new molecular entities approved for the treatment of autoimmune diseases.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> In the last five years, the FDA approved a total of 25 therapeutic agents with a majority of them being mAbs (14 drugs) and one enzyme, while small molecules contributed toward approval of 10 drugs (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> and <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Illustrative Compilation of U.S. FDA Approved Drugs from the Year 2015 until June 2020 for Drugs for Treating Auto-Immune Disorders Featuring Their Indication, Year of Approval, Sponsor, Target, Chemical Class, Major Drug Metabolizing Enzyme(s), Route of Administration/Elimination, and Drug Interactions (Perpetrator or/and Victim)<a class="ref internalNav" href="#t7fn2" aria-label="¶">¶</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0036.gif" alt="" id="GRAPHIC-d7e1103-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0037.gif" alt="" id="GRAPHIC-d7e1104-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">No interaction reported.</p></div><div class="footnote" id="t7fn2"><sup><sup>¶</sup></sup><p class="last">FXR: farnesoid X receptor; IL-6: interleukin-6; IL-4: interleukin-4; IL-23: interleukin-23; JAK1: janus kinase 1; JAK2: janus kinase 2; IFNγ: interferon gamma; S1P: sphingosine 1-phosphate; A, accelerated; B, breakthrough; O, orphan; P, priority; S, standard; PO: peroral: IV: intravenous: SC: subcutaneous; IM: intramuscular; NAT2: N-acetyltransferase 2; CYP: cytochrome P450; UGT: UDP-glucuronosyltransferase; P-gp: p-glycoprotein; CES: carboxylesterases; NA: not applicable; IgG: immunoglobulin G.</p></div></div><div></div></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of small molecules used for the treatment of various autoimmune disorders approved by FDA from the year 2015 until June 2020.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Drugs modulating sphingosine-1-phosphate (S1P) receptors, interleukin-2 (IL-2) receptor, and CD-20 on B lymphocytes were approved for MS in the period of study. The S1P1 receptor family comprises five members with effects on cell proliferation, migration and survival, intercellular communication, vascular tone, and endothelial barrier function.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Two small-molecule modulators, siponimod <b>134</b> (S1P1) and ozanimod <b>136</b> (S1P1 and S1P5), were approved for MS in 2019 and 2020, respectively. Further, in addition to T lymphocytes, B lymphocytes could also produce pro-inflammatory cytokines in MS. Ocrelizumab (2017), a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets the B lymphocytes which express the CD20 antigen was approved for MS.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Interleukin-2 (IL-2) and its receptor play a key role in the proliferation of autoreactive T cells and loss of immune tolerance in MS. Considering this rationale, daclizumab (2016), a humanized mAb that binds to CD25, the alpha subunit of IL-2 receptors was approved for the relapsing forms of MS. However, the drug was withdrawn from the market in March 2018 due to safety concerns involving inflammatory brain disorders in patients.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by strong itching resulting from <i>amplified immune response</i> to environmental pollutants and toxins.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> The prevalence of AD is reported to be 10.7% in children in the United States.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> The amplified immune response is mediated by interleukin (IL)-4 signaling through IL-4 receptor alpha (IL4Rα), which also mediates IL-13 signaling.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Dupilumab (2017) acts against the interleukin-4 receptor subunit α (IL-4Rα) of IL-4 and IL-13 receptors. The phosphodiesterase 4 (PDE4) enzyme is responsible for inflammatory cytokine production. Crisaborole (<b>127</b>), a novel PDE4 inhibitor, was approved by the FDA in 2016 through the topical route for the treatment of moderate AD. Interleukin-23 is a key cytokine connecting the innate and adaptive components of the immune response.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Elevated levels of IL-23 are related to several autoimmune diseases including rheumatoid arthritis and psoriasis.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> The worldwide prevalence of psoriasis is reported to be up to 11.43% in adults. Guselkumab (2017) and risankizumab (2018) are IL-23 antagonists and were approved for the treatment of patients with moderate-to-severe psoriasis for administration through the subcutaneous route. Th17 cells are the subset of helper T cells and are reported to play a major role in the pathology of multiple autoimmune diseases through the production of interleukin-17. Blocking of the Th17 axis, either by inhibition of IL-17 directly or by intercepting Th17 cell differentiation, was considered as one of the therapeutic strategies.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Three IL-17A antagonists, namely, ixekizumab, secukinumab, and brodalumab, were approved for treatment of psoriasis in the period of study. Interleukin-6 (IL-6) is reported to be present in higher levels in both the synovium and serum of rheumatic arthritis (RA) patients.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> The worldwide prevalence of RA was reported to be 0.25%.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Sarilumab (2017), an IL-6 receptor antagonist binds to soluble as well as membrane-bound IL-6 receptors (sIL-6R and mIL-6R) and was approved for the treatment of adult patients with moderately to severely active RA. JAKs (intracellular tyrosine kinases) play a significant role in cytokine signaling pathways involving immunity and hematopoiesis.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> The different types of JAKs identified are JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). JAK signaling inhibition offers a novel mechanism through which a range of cytokines can be inhibited using a small-molecule drug. Tofacitinib (a first-generation JAK inhibitor) is a pan-JAK inhibitor having the ability of inhibiting JAK3/1/2 and to a minor extent TYK2, and it was approved for the treatment of RA. Baricitinib (<b>129</b>), a selective JAK1 and JAK2 inhibitor, was approved for the treatment of RA in 2018.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Recently, second-generation JAK inhibitors that exert a selective inhibition of JAK1 or JAK3 have been explored.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Upadacitinib (<b>135</b>) is an oral JAK1-selective inhibitor, with a negligible effect on JAK3, leading to an improved drug safety profile. <b>135</b> was approved for the treatment of RA in August 2019.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Thrombocytopenia is the most common hematologic complication in patients with chronic liver disease defined by a platelet count below 150 000/μL. The prevalence of thrombocytopenia in patients with chronic hepatitis was reported to be 6%; however, a prevalence of up to 78% was reported in cirrhotic patients.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a><i>Immune thrombocytopenia</i> (<i>ITP</i>) is identified by <i>immune</i>-mediated destruction of platelets which results in thrombocytopenia and mucocutaneous bleeding. Thrombopoietin receptor agonists belong to a class of platelet growth factors that mimic the action of endogenous thrombopoietin (TPO) on megakaryocytes and their precursors leading to promotion of their growth and differentiation and thereby increasing platelet production.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Avatrombopag (<b>131</b>) and lusutrombopag (<b>130</b>) were approved in May and July 2018, respectively, for the treatment of thrombocytopenia as a result of chronic liver disease. Fostamatinib (<b>133</b>) is a small-molecule inhibitor of spleen tyrosine kinase (Syk) and was approved in the year 2018 for the treatment of ITP.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Upregulation of FNγ leads to hemophagocytic lymphohistiocytosis (HLH).<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Emapalumab, a monoclonal antibody that binds to and neutralizes interferon gamma (IFNγ), was approved in the year 2017 for the treatment of primary HLH in patients. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired condition resulting from defective synthesis of GPI-anchored proteins due to a somatic mutation in the Pig-A gene in bone marrow stem cells.<a onclick="showRef(event, 'ref110 ref118'); return false;" href="javascript:void(0);" class="ref ref110 ref118">(110,118)</a> The true incidence of PNH is unknown, but it was estimated at 1.5–2.0 cases per million of the population per year.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Ravulizumab was approved in 2018 for the treatment of PNH. Ravulizumab binds to complement protein 5 (C5) and blocks its activation by complement pathway convertases, thus inhibiting the formation of the terminal complement complex.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular junction disorder that is characterized by the presence of autoantibodies against P/Q type voltage-gated calcium channels, which results in improper release of acetylcholine at presynaptic membrane.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> The estimated global prevalence of LEMS is about 2.8 per million. Amifampridine, approved in 2018, is a symptomatic treatment that increases acetylcholine concentrations at the neuromuscular junction. Adenosine deaminase (ADA) is an important enzyme involved in the purine salvage pathway.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Mutation of the ADA gene results in accumulation of toxic metabolites such as adenosine, 2’deoxyadenosine, and deoxyadenosine triphosphate, which further results in a form of severe combined immunodeficiency (SCID) characterized by severe lymphocytopenia and NK cells.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Adenosine deaminase deficiency is very rare with the global incidence of approximately 1 in 200 000 to 1 000 000 newborns.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Elapegademase has the ability to increase adenosine deaminase activity while reducing the concentrations of toxic metabolites and was approved in 2018.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Primary biliary cholangitis (PBC) is an autoimmune liver disease, characterized by biliary destruction, progressive cholestasis, and liver damage.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Farnesoid X Receptor (FXR) is a bile acid receptor, and its activation controls enterohepatic bile acid homeostasis, inflammation, and fibrosis in response to liver injury.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Obeticholic acid (<b>128</b>), a FXR agonist, was approved in 2016 for the treatment of PBC.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Thyroid eye disease (TED) is an autoimmune disease resulting in permanent facial deformity. Teprotumumab (2020), directed against IGF-1R (insulin-like growth factor-1 receptor), causes internalization and degradation of IGF-1R, which results in ameliorating the symptoms of thyroid eye disease.</div><div class="NLM_p last">Interestingly, 80% of the approved small molecules (8 out of 10) for the treatment of autoimmune disorders followed Lipinski’s rule. Half of the drugs (5 out of 10) were implicated as victims when coadministered with drugs causing modulations in enzymes (CYP3A4, CYP2C9, and CYP2C8) and transporters (BCRP and OAT3). Nine out of 10 small molecule drugs are approved for use through the peroral route and only one drug is approved through the topical route. Five mAbs are approved for administration through the intravenous route, and nine are approved for use through the subcutaneous route. The key players currently involved in discovery and development of drugs for autoimmune diseases are AbbVie, Trinity Biotech, Biorad Laboratories, F. Hoffmann-la Roche, Inova Diagnostics along with Johnson & Johnson, Eli Lilly & Co., Bristol Myers Squibb, Abbott Laboratories, Pfizer, and AstraZeneca.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Cardiovascular Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46330" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46330" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A report from the WHO (2019) indicated that cardiovascular diseases (CVDs) result in a mortality of 17.9 million (31% of all deaths worldwide) globally.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> The CVDs include cerebrovascular disease, deep vein thrombosis, coronary heart disease, rheumatic heart disease, peripheral arterial disease, congenital heart disease, and pulmonary embolism. Among the CVDs, heart attacks and strokes are primarily responsible for the mortality.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> From the period of 1937– 2013, there were 201 new molecular entities approved for treatment of CVDs.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> During the last five years, a total of 15 therapeutic agents for CVDs were approved by US FDA, with a majority of them being small molecules (9 drugs), while macromolecules constituted the remaining (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a> and <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). The drugs approved under this category are described subsequently.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Illustrative Compilation of U.S. FDA Approved Drugs from the Year 2015 until June 2020 for Drugs for Treating Cardiovascular Diseases Featuring Their Indication, Year of Approval, Sponsor, Target, Chemical Class, Major Drug Metabolizing Enzyme(s), Route of Administration/Elimination, and Drug Interactions (Perpetrator or/and Victim)<a class="ref internalNav" href="#t8fn2" aria-label="¶">¶</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0038.gif" alt="" id="GRAPHIC-d7e1268-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">No interaction reported.</p></div><div class="footnote" id="t8fn2"><sup><sup>¶</sup></sup><p class="last">PAH: pulmonary arterial hypertension; HCN: hyperpolarization-activated cyclic nucleotide-gated; PCSK9: proprotein convertase subtilisin kexin type 9; FXa: factor Xa; Fab: monoclonal antibody fragment; vWF: von Willebrand factor; A, accelerated; B, breakthrough; O, orphan; P, priority; S, standard; PO: peroral: IV: intravenous: SC: subcutaneous; CYP: cytochrome P450; UGT: UDP-glucuronosyltransferase; P-gp: p-glycoprotein; NA: not applicable; IgG: immunoglobulin G.</p></div></div><div></div></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structures of small molecules used for the treatment of various cardiovascular diseases approved by FDA from the year 2015 until June 2020.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A drug combination comprising of sacubitril (<b>142</b>) and valsartan (<b>141</b>) was approved in 2015 for the treatment of chronic heart failure.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> The combination is based on the inhibition of neprilysin by active metabolite of <b>142</b>, LBQ657, which in turn increases the bioavailability of brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP), and c-type natriuretic peptide (CNP), which promote vasodilation, while the antihypertensive effect of <b>141</b> was mediated by its selective binding to angiotensin receptor 1 (AT1) and prevents angiotensin II from binding. Ivabradine was approved in 2015 for the management of symptomatic chronic heart failure for its heart rate lowering effect mediated by inhibition of the cardiac pacemaker current, a mixed sodium–potassium inward current. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is reported to play a major role in cholesterol metabolism, by reducing the expression of the LDL receptor.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Nonvitamin K antagonist oral anticoagulants (NOACs) are preferred because of their selective action, shorter half-life, and safety.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Edoxaban (<b>139</b>) exerts its action by inhibiting factor Xa (FXa), an important component of the coagulation cascade, and it was approved in 2015 for reducing the risk of embolism. Selexipag (<b>137</b>), a selective prostacyclin receptor agonist, was approved for the treatment of pulmonary arterial hypertension. Inhibition of PCSK9 results in increased LDL cholesterol receptors with the decrease in serum LDL cholesterol.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Two monoclonal antibodies alirocumab and evolocumab targeting PCSK9 were approved in 2015 for the treatment of hypercholesterolemia. Considering the role of Angiotensin II by causing vasoconstriction with a resultant increase in blood pressure, first synthetic human Angiotensin II was approved in 2017 for increasing blood pressure in patients with septic shock.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Emicizumab, which mimics the function of the coagulation Factor VIII, was approved in 2017 as a prophylaxis to prevent the frequency of episodes of bleeding patients with hemophilia A. Tafamidis (<b>145</b>), a transthyretin stabilizer, was approved in 2019 to treat cardiomyopathy caused by transthyretin-mediated amyloidosis.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Caplacizumab, approved in 2019 for the treatment of thrombotic thrombocytopenic purpura in conjunction with plasma exchange, acts by targeting the A1 domain of the ultralarge von Willebrand factor and prevents the interaction between the von Willebrand factor and platelet aggregation.</div><div class="NLM_p last">Almost all approved small molecules (8 out of 9) in this category followed Lipinski’s rule. Data in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a> show that some of the approved drugs (small molecule) were implicated as victims during coadministration with other drugs causing modulations in enzymes (CYP2C8 and CYP3A4) and transporters (P-glycoprotein). The major route of administration for small molecules cardiovascular drugs continues to be the peroral one, and only two drugs are approved for use through the intravenous route. Five monoclonal antibodies are approved through the subcutaneous route, and one is approved for administration through the intravenous route. Catabolism is primarily responsible for the elimination of all the macromolecules. The cardiovascular drugs market is expected to be dominated by North America, the United States, Canada, the U.K., and Europe (Germany, Spain, Italy, and France). The pharmaceutical companies such as Bristol Myers Squibb, Abbott, AstraZeneca, Takeda, Novartis, Bayer, Roche, GlaxoSmithKline, Daiichi Sankyo, Pfizer, Johnson & Johnson, and Solvay SA are currently researching the discovery and development of novel drugs for cardiovascular diseases. The rise in diabetic patients also holds a potential role in elevating the global cardiovascular drugs market, which is already hampered by stringent regulations and patent expiry of numerous blockbuster drugs in near future.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Diagnostic Agents</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80101" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80101" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Diagnostic agents are primarily used to aid in detecting abnormalities at cellular and molecular levels.<a onclick="showRef(event, 'ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref132 ref133">(132,133)</a> These agents should possess high quantum yield (sensitive) and photostability and should be expeditious to cross the cell membrane with low or no cytotoxicity at a concentration of investigation.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> In the late 19th century, fluorescein and rhodamine derivatives were first reported as diagnostic agents for bioimaging.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> The meagre photostability of these dyes restricts their application in bioimaging applications, where prolonged illumination is essential.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Therefore, <i>de novo</i> design and development of a safe, quick, and effective diagnostic agent continues to be a prominent area of research.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a></div><div class="NLM_p">In the last five years, the FDA has approved eight diagnostic agents (seven small molecules and one polymer). Fluciclovine F18 (<b>148</b>), fluorodopa F18 (<b>150</b>), flortaucipir F18 (<b>152</b>), and fluoroestradiol F18 (<b>153</b>) are approved for the diagnosis of prostate cancer, Parkinsonian syndrome, Alzheimer’s disease, and breast cancer, respectively. Two gallium-containing radioactive diagnostic agents (<b>147</b> and <b>151</b>) have been approved for the diagnosis of a neuroendocrine tumor. A general mechanism behind these diagnostic agents lies in their uptake through the targeted receptors present on the diseased organ; for example, uptake of <b>148</b> will increase through L-type amino acid transporter (LAT) receptors present on the prostate cancer cell. The details of the approved drugs are compiled in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, and chemical structures are illustrated in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>. A majority (6 out of 7) of small-molecule diagnostic agents are approved for use through the intravenous route, and only one is approved through the peroral route. One polymer (Giskit) was approved in 2019 through the intrauterine route for diagnosing fallopian tube patency.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Illustrative Compilations of U.S. FDA Approved Diagnostic Agents from the Year 2015 until June 2020 Featuring Their Indication, Year of Approval, Sponsor, Target, Chemical Class, Major Drug Metabolizing Enzyme(s), Route of Administration/Elimination, and Drug Interactions (Perpetrator or/and Victim)<a class="ref internalNav" href="#t9fn3" aria-label="¶">¶</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0039.gif" alt="" id="GRAPHIC-d7e1391-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">No interaction reported.</p></div><div class="footnote" id="t9fn2"><sup><sup>b</sup></sup><p class="last">No information available.</p></div><div class="footnote" id="t9fn3"><sup><sup>¶</sup></sup><p class="last">GH: growth hormone; PS: parkinsonian syndrome; ER: estrogen receptor; A, accelerated; B, breakthrough; O, orphan; P, priority; S, standard; IV: intravenous: SC: subcutaneous; CYP: cytochrome P450; P-gp: p-glycoprotein; NA: not applicable; IgG: immunoglobulin G.</p></div></div><div></div></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of diagnostic agents approved by FDA from the year 2015 until June 2020.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">According to the recent market trends, the global market for the imaging/diagnostic agents is expected to rise to $2.5 billion USD by 2024 at a CAGR of roughly 3.1%. The diagnostic radiopharmaceuticals are expected to grow at a rate of 3.5% with the market to rise to $6.4 billion USD.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The major global market includes the United States, Europe, and Germany. Aytu BioScience, Bayers Health Care, Bracco Diagnostic Inc., Curium, and Eli Lilly will be emerging key players.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Miscellaneous Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54556" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54556" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Drugs which could not be classified under any of the disease areas discussed in this review are reported under this category (<10% of the total number of approvals). A total of 25 drugs were approved by the FDA in the last five years (20 small molecules, 2 peptides, and 3 macromolecules). These can be further categorized into drugs for ophthalmic disorders (6 drugs), gastrointestinal diseases (10 drugs), reproductive disorder (3 drugs), dermatology (2 drugs), opioid withdrawal (1 drug), and nutrition supplements (3 drugs). The drugs approved under these categories are briefly discussed in this section (see <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a> and <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Illustrative Compilation of U.S. FDA Approved Drugs from the Year 2015 until June 2020 for Drugs for Treating Miscellaneous Drugs Featuring Their Indication, Year of Approval, Sponsor, Target, Chemical Class, Major Drug Metabolizing Enzyme(s), Route of Administration/Elimination, and Drug Interactions (Perpetrator or/and Victim)<a class="ref internalNav" href="#t10fn3" aria-label="¶">¶</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0040.gif" alt="" id="GRAPHIC-d7e1440-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0041.gif" alt="" id="GRAPHIC-d7e1441-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">No interaction reported.</p></div><div class="footnote" id="t10fn2"><sup><sup>b</sup></sup><p class="last">No information available.</p></div><div class="footnote" id="t10fn3"><sup><sup>¶</sup></sup><p class="last">NK1: neurokinin 1; LFA-1: lymphocyte function-associated antigen-1; CGPR: calcitonin gene-related peptide receptor; GnRH: gonadotropin-releasing hormone; VEGF: vascular endothelial growth factor; RAR: retinoic acid receptors; NHE3: sodium/hydrogen exchanger 3; D2: dopamine-2; A, accelerated; B, breakthrough; O, orphan; P, priority; S, standard; IV: intravenous: SC: subcutaneous; CYP: cytochrome P450; P-gp: p-glycoprotein; IgG: immunoglobulin G.</p></div></div><div></div></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structures of miscellaneous drugs approved by the FDA from the year 2015 until June 2020.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Ophthalmology</h3><div class="NLM_p last">The leading causes of blindness and low vision are primarily diseases such as age-related macular degeneration (AMD), cataract, diabetic retinopathy, and glaucoma.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> The global prevalence of vision impairment or blindness is around 2.2 billion. Latanoprostene bunod (<b>158</b>, a prostaglandin analogue) and Netardusil (<b>159</b>) are a Rho kinase and a norepinephrine transporter inhibitor, respectively, approved by the FDA in 2017 for patients with glaucoma or ocular hypertension through reduction of intraocular pressure (IOP). Lifitegrast <b>156</b> (the first lymphocyte function-associated antigen-1 antagonist) is indicated for the treatment of dry eye disease.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Two macromolecules, cenegermin (human nerve growth factor; 2018) and brolucizumab (human VEGF inhibitor; 2019) were approved for the treatment of neurotropic keratitis and wet AMD, respectively.</div></div><div id="sec10_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Gastrointestinal Disorders</h3><div class="NLM_p">Nausea/vomiting, constipation, and irritable bowel syndrome (IBS) broadly constitute functional gastrointestinal disorders (FGID) and are the three conditions for which nine new molecular entities were approved from the year 2015 until June 2020. FGID are reported to cause a serious reduction in the quality of life of people, which in turn put a huge impact on health care worldwide.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Discovering drugs for treating FGID are challenging as these are complex conditions, and the pathophysiology is affected by multiple factors including genetic predispositions, infection, chronic stress, and psychological symptoms.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Drugs approved for nausea and vomiting in this period are rolapitant (<b>154</b>) and amisulpride (<b>169</b>), which act as substance P/NK1 receptor antagonist and D2 antagonist, respectively. Chemotherapy-induced nausea and vomiting (CINV) is the most devastating side effect of chemotherapy in cancer patients.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Akynzeo, a combination of fosnetupitant (<b>171</b>) and palonosetron (<b>172</b>), was approved in 2018 through the intravenous route by the FDA because of its ability to prevent both nausea and vomiting associated with cancer chemotherapy. Irritable bowel syndrome (IBS) affects the large intestine, which results in diarrhea or constipation or both.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Eluxadoline (<b>155</b>) is a mixed opioid receptor agonist (Mu) and antagonist (delta) used for treating patients with diarrhea-predominant IBS.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Another drug, tenapanor (<b>167</b>), was the first sodium/hydrogen exchanger isoform 3 (NHE3) transporter inhibitor. It was approved for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). Chronic idiopathic constipation (CIC) accounts for the global prevalence of 14% and is more common in women.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Three drugs, namely, plecanatide, prucalopride, and lactitol, were introduced into the market for CIC in this period. Plecanatide and lactitol (<b>170</b>) accelerate GI transit through the increased intestinal fluid.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Prucalopride (<b>165a</b>) is a selective 5-HT4 stimulator in the GI tract and increases intestinal motility by releasing acetylcholine.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> The main advantage of prucalopride is that it has no interaction with the hERG channel or 5-HT1 receptors, which further reduces the cardiovascular risk. Opioids are known to cause constipation through inhibition of gastric emptying and peristalsis.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> By antagonizing opioid receptors, naldemedine (<b>157</b>) inhibits opioid-induced constipation.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> The tryptophan hydroxylase inhibitor xermelo (<b>160</b>) was approved for the treatment of carcinoid syndrome diarrhea in the year 2017.</div><div class="NLM_p last">The key players of global gastrointestinal drugs market are Takeda Pharmaceuticals, Allergan Plc, Novo Nordisk, AstraZeneca Plc, and AbbVie.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a></div></div><div id="sec10_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Nutrition Supplements</h3><div class="NLM_p last">Iron deficiency is one of the most common nutritional disorders prevalent in women and children that could result in restless legs syndrome (RLS), impaired cognitive function, fatigue, diminished quality of life, and infertility.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Accrufer (<b>161</b>; ferric maltol), approved in July 2019, is a novel, stable, nonsalt-based oral treatment for adults with iron deficiency. A calorie supplement (fish oil triglycerides and triheptanoin) was also approved in this study period.</div></div><div id="sec10_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Dermatology</h3><div class="NLM_p last">Acne vulgaris is the inflammatory disease characterized by the formation of pustules, comedones, nodules, cysts, and/or papules, due to obstruction and inflammation of pilosebaceous units.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> The market size of global acne drugs was around USD $4.1 billion in 2017. Two small-molecule drugs, sarecycline (<b>165</b>) and tifarotene (<b>163</b>), were approved by the FDA for acne vulgaris treatment during the study period.</div></div><div id="sec10_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Reproductive Disorders</h3><div class="NLM_p">Annovera (a combination of segesterone acetate <b>173</b> and ethinyl estradiol <b>174</b>) was approved for the prevention of pregnancy in 2018.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Elagolix sodium (2018), a GnRH receptor antagonist, which reduces the levels of estrogen, was approved for the management of pain associated with endometriosis.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></div><div class="NLM_p last">Around 70% of the approved small molecules under the miscellaneous category (14 out of 20) followed Lipinski’s rule of 5. Evaluation of DDI data of these drugs revealed a majority of them are classified as victims (5 out of 20) when dosed along with CYP3A inhibitors and inducers. Three drugs are classified as perpetrators based on their role of the substrate to P-gp, OATP1B1, and BCRP.</div></div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Analysis of Approved Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21630" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21630" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As per a report by the Global Burden of Disease (WHO), noncommunicable diseases are expected to be responsible for 7 out of 10 deaths in developing nations. Further, stroke, cardiovascular, respiratory, and neurological disorders along with cancer are the major causes of mortality worldwide. In line with the trend of anticancer drugs leading the total number of approvals, the highest number of approved drugs in any single year was also for this dreaded disease (i.e., 16 in the year 2018). Neurological disorders with high unmet medical need accorded the next spot with 11 approvals in the year 2019. Further, considering the ongoing viral pandemic due to Covid-19, drug approvals for infectious and respiratory diseases are expected to rise along with more immunotherapies coming into the market in the foreseeable future.</div><div class="NLM_p">While the focus of research on large molecules is steadily increasing across the pharmaceutical industry and the number of approvals in this area have increased, the data suggest that during the study period, more than 2/3rd of the approved drugs were small molecules. Approvals for TIDES that include peptides and nucleotides have also increased in the past five years or so, and overall, their contribution is ∼10% of the total approvals. Among the macromolecules, the major share has been taken by mAbs followed by enzymes and oligonucleotides. Most of the biologics have been approved for the treatment of cancer followed by autoimmune and cardiovascular diseases.</div><div class="NLM_p">An interesting observed trend during the study period was the increased number of approvals with the pricier “orphan drug” tag, which are used for the treatment, prevention, or diagnosis of a rare disease. Until 2015, a total of 281 orphan drugs were approved, consisting primarily of biologics (60%). The number of “orphan drug” approvals during the last five years (total approvals: 106) have almost doubled compared with the preceding five years, that is, 2010–2014 (total approvals: 56). <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a> illustrates orphan status versus the total number of approved drugs for different therapeutic areas during the study period. Cancer and metabolic disorders had the maximum number and percent share as orphan drugs.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Bar graph represents approved FDA drugs with orphan status from the year 2015 until June 2020.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further, the major route of administration for the approved drugs during the study period was oral (53%) followed by intravenous (26%) and subcutaneous (14%) routes. Because of ease of administration and increased patient compliance, the oral route continues to be the preferred one. This is in line with a published report which tracked the routes of drug administration for 37 years starting from 1980 to 2017 and concluded that the oral delivery route (62%) makes the largest contribution to pharmaceutical products.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> With increasing contribution from macromolecules including TIDES in the development pipeline and obvious challenges with the oral delivery of these compounds, the percentage of drugs that can be administered through the oral route has started to show a decline, and the overall trend is expected to remain similar in the near future though. The major route of administration of macromolecules might continue to be subcutaneous or intravenous.</div><div id="sec11_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Structural Diversity of Pharmacophores of FDA Approved Drugs</h3><div class="NLM_p">The assessment of 164 FDA approved small-molecule data sets of the last five years (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) indicates a high percentage of N-heterocycles (88%) and aromatic scaffolds (87%), followed by the chiral molecules (63%). The representation of oxygen heterocycles (26%) was less than nitrogen counterparts, and this situation was consistent as observed until 2014<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> and later in 2017.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> As expected, the share of sulfur-containing drugs (39) was approximately 6.5 times higher than phosphorus counterparts (6), which in turn was 2 times higher than boron counterparts (3). Sulfur was constituted either as sulfate, sulfonate, or a heterocyclic ring system.<a onclick="showRef(event, 'ref160 ref161 ref162'); return false;" href="javascript:void(0);" class="ref ref160 ref161 ref162">(160−162)</a> In the recent past, a significant positive effect of fluorine has been observed through its strategic introduction into an aliphatic or aromatic system on drug potency and target selectivity by modulating physicochemical parameters and drug metabolism.<a onclick="showRef(event, 'ref163 ref164 ref165 ref166'); return false;" href="javascript:void(0);" class="ref ref163 ref164 ref165 ref166">(163−166)</a> The authors have noticed that FDA approved 38 drugs containing one or more fluorine atoms on the aromatic ring system (excluding – CF<sub>3</sub> or other combination) in the last five years. Further, the <sup>18</sup>F isotope owing to its optimum and favorable half-life (109.8 min) as compared to other isotopes such as <sup>11</sup>C (20.4 min) and <sup>124</sup>I (4.2 days) is better utilized in positron emission tomography (PET).<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> On the basis of this fact, 4 drugs were approved by the FDA but limited to the diagnosis of cancer only. Further, the literature supports that strategic replacement of hydrogen with deuterium in a drug, in general, reduces the metabolism and toxicity, stabilizes unstable stereoisomers, and increases bioactivation and thus could be explored further in addition to elucidation of mechanism. However, the FDA approved only one drug (e.g., <b>59</b>) for the treatment of choreas associated with Huntington’s disease in the last five years. Pirali et al. recently discussed the possible issues with the development and approvals of deuterium-based drugs in a Perspective.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Recently, deucravacitinib (BMS-986165), a selective tyrosine kinase 2 allosteric inhibitor has exhibited the convincing clinical trial results.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> It is expected that the number of FDA approvals for deuterium containing drugs may rise in the coming years.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Breakdown of U.S. FDA approved small molecules (2015–June 2020).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, medicinal chemists are engaged in exploring boron-based small molecules owing to Lewis acid properties of boron which makes it reactive toward nucleophiles of enzymes, nucleic acid, and carbohydrates.<a onclick="showRef(event, 'ref170 ref171 ref172'); return false;" href="javascript:void(0);" class="ref ref170 ref171 ref172">(170−172)</a> FDA approved three boron-containing compounds: two pertaining to a class of boronic acids (<b>2</b> and <b>117</b>) and one in the benzoxaborole class (i.e., <b>127</b>). Boronic acids act as transition state analogues for enzymes such as proteases and lactamases and therefore are successful in inhibiting them (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>A).<a onclick="showRef(event, 'ref173 ref174'); return false;" href="javascript:void(0);" class="ref ref173 ref174">(173,174)</a> Ixazomib citrate (<b>177</b>), a citrate ester of boronic acid (prodrug), gets hydrolyzed into free boronic acid metabolite (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>B; <b>2</b>), which inhibits proteasome subunit beta type-5 (PSMB5) and produced the anticancer effect.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (A) Boronic acids act as transition state analogues for enzymes; (B) Prodrug activation of ixazomib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last"><b>117</b> is the first boron-containing non-β-lactam but β-lactamase inhibitor of serine β-lactamases approved by the FDA.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> The presence of boron provides the ability to “morph” between sp<sup>2</sup> and sp<sup>3</sup> hybridization states, leading to enzyme inhibition.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a><b>127</b> was approved for atopic dermatitis, and chemically it is a benzoxaborole having a boronic acid hemiester with a phenolic ether. The presence of the boron atom facilitates its skin penetration. Mechanistically, <b>127</b> inhibits PDE4B selectively by binding of boron to the bimetal center of the PDE4B.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a></div></div><div id="sec11_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Nitro-Containing Drugs</h3><div class="NLM_p">Development of nitro-based drugs especially with nitroaromatic and heteroaromatic compounds is challenging because of the association of mutagenicity and genotoxicity.<a onclick="showRef(event, 'ref177 ref178'); return false;" href="javascript:void(0);" class="ref ref177 ref178">(177,178)</a> However, discovery scientists were successful in inducing selective toxicity via bioreduction of nitro functionality by enzymes leading to the killing of bacteria, parasites, or tumor cells.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> The U.S. FDA approved a total of six nitro containing drugs in the last five years. <b>71</b>, a nitro-catechol, was approved for the treatment of PD to increase the blood concentration of levodopa. It inhibits COMT and its nitro-catechol motif coordinates with Mg<sup>2+</sup> ion, and its nitro group is aligned toward protonated Lys144 favoring electrostatic interactions between them.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a><b>91</b>, a 2-nitroimidazole derivative, was approved for the treatment of Chagas disease using the Accelerated Approval pathway. It is believed to inhibit protozoal growth because of parasite DNA damage induced as a result of electrophilic metabolites produced by reduction of a nitro group by nitroreductases inside the parasite.<a onclick="showRef(event, 'ref181 ref182'); return false;" href="javascript:void(0);" class="ref ref181 ref182">(181,182)</a> FDA approved <b>92</b>, a 5-nitroimidazole compound and structurally similar to metronidazole and tinidazole, as an anti-infective. The mechanism of action is similar to other nitroimidazoles. However, the drug possesses a better pharmacokinetic profile in the class.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a><b>106</b>, a nitroimidazopyran derivative, was approved as an antitubercular against drug-resistant hypoxic, nonreplicating <i>Mycobacterium tuberculosis</i> by FDA.<a onclick="showRef(event, 'ref184 ref185'); return false;" href="javascript:void(0);" class="ref ref184 ref185">(184,185)</a> It disrupts mycolic acid synthesis, which is a major constituent of the cell envelope of the mycobacterium. However, Singh et al. illustrated an alternate mechanism of action via deazaflavin-dependent nitroreductase (Ddn) that reduces the drug (hydride ion transfer as the first step) into the corresponding des-nitroimidazole (<b>179</b>, des-nitro; a major metabolite) along with the production of HNO<sub>2</sub>. The reduction is unlike single-electron reduction of other nitroimidazoles and is driven by flavin-dependent F420 - nitroreductases (Ddn). The released HNO<sub>2</sub> would quickly decompose into NO and other reactive nitrogen intermediates leading to the killing of mycobacterium (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> Another NO-releasing drug, <b>158</b>, was approved by the FDA for the treatment of glaucoma. Mechanistically, upon activation by corneal esterases, the drug is transformed into latanoprost acid and butanediol mononitrate, which liberates NO. Latanoprost acid increases humor outflow through metalloproteinase, while NO induces vasodilation.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> In the anticancer category, <b>12</b>, a nitro-containing pyrrolopyridine, was approved for the treatment of CLL or SLL via Bcl-2 inhibition.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Bioactivation of pretomanid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Nitrogen Heterocycles</h3><div class="NLM_p">We further evaluated nitrogen heterocycles to learn about their frequency in the FDA approved drugs during the last five years as they share a high percentage in FDA approved data set of small molecules (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>). It was interesting to note that until the year 2014, piperidine and pyridine were the first and second most frequent nitrogen heterocycles, respectively, in the FDA approved drugs.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> However, our results reveal that pyridine is the most common nitrogen heterocycle among the small molecules. Piperidine and piperazine are the second and third most common nitrogen heterocycles, respectively. Whereas, pyrimidine and pyrazole hold the fourth position followed by indole (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>A). We further observed that benzimidazole, 4-quinolinone, azetidine, thiazole, and triazole were the next most frequent nitrogen heterocycles (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>B). Hiesinger et al. discussed various synthetic routes, and medicinal chemistry aspects of spirocyclic scaffolds of drug molecules in their recent Perspective.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a><a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>C depicts the three important spiro N-heterocycles in the data set of approved drugs.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Top five most frequent nitrogen heterocycles in the FDA approved drugs (2015–June 2020); (B) Other common N-heterocycle in the drugs; (C) Spiro nitrogen heterocycles in the drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Analysis of Chemical Space</h3><div class="NLM_p">Next, we analyzed chemical space of FDA approved drugs considering their six molecular properties: molecular weight (MW), topological polar surface area (TPSA), number of rotatable bonds (nROTB), hydrogen bond donors (nHBDon), hydrogen bond acceptors (nHBAcc) and the octanol–water partition coefficient (AlogP), and molecular similarity (Tanimoto coefficient). The analysis was performed using the Platform for Unified Molecular Analysis (PUMA, version 1),<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> and data are compiled in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01786/suppl_file/jm0c01786_si_001.pdf" class="ext-link">Tables S1–S3</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01786/suppl_file/jm0c01786_si_001.pdf" class="ext-link">Figure S1–S3</a> (see SI).</div><div class="NLM_p">The MW analysis revealed that anticancer drugs approved in the year 2015–16 have statistically broader distribution (SD: 108.80, 384.78), which further got narrower with the preceding years with a median molecular weight (440–492 g/mol) in 2018–20 as compared with former years. The average mean computed for the MW of anticancer agents was 503.72 g/mol during the analysis period. However, the mean MW was 347.31 g/mol in the case of neurological drugs and was within the range of cut-offs defined by Levin (400 g/mol) and Waterbeemd (450 g/mol) to facilitate BBB penetration.<a onclick="showRef(event, 'ref192 ref193'); return false;" href="javascript:void(0);" class="ref ref192 ref193">(192,193)</a> Next, the drugs for metabolic disorders also hovered over a range of MW (227–438 g/mol) with an average mean of 365.84 g/mol. Further, only one drug as a small molecule was approved in the respiratory drug (inhalation route) category during the analysis period with an MW of 597.33, which was above the Lipinski cutoff. This could be the reason that high MW drugs are preferred for respiratory diseases to avoid side effects with the CNS.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> The anti-infective drugs were also found to possess a broad deviation in MW, with an average MW of 478.04 g/mol during the period. Altman’s report suggested that most antibiotics with MW of 500 g/mol are susceptible to drug resistance.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> Newer antibiotics approved by the FDA, particularly in 2015 and 2018, had an average mean MW ranging from 564 to 631 g/mol. Further, the drugs for autoimmune and cardiovascular disorders exhibited a broader MW deviation with a mean MW of 433.11 and 484.78 g/mol, respectively.</div><div class="NLM_p">Many variants of Lipinski’s rule question molecular weight cutoff for ≤500 g/mol and have led to the acceptable variation of the current rule (e.g., Veber rule), which considers the TPSA and nROTB to distinguish between orally active and inactive drugs. According to this rule, compounds meeting the requirement of ≤140 Å<sup>2</sup> TPSA and 10 or fewer rotatable bonds are predicted to possess good oral bioavailability, which could negatively impact intestinal absorption if exceeded.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> TPSA analysis assists in improving cellular potency, oral absorption, and BBB permeation.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> The TPSA analysis of anticancer drugs approved during 2015–20 revealed that drugs abide by TPSA norms with an average mean of 103.97 Å<sup>2</sup>. Further, TPSA analysis of neurological drugs revealed a value less than 90 Å<sup>2</sup> (recommended for CNS drugs)<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> with an average mean of 66.17 Å<sup>2</sup>. Interestingly, TPSA analysis of anti-infective drugs yielded a higher value of 131.88 Å<sup>2</sup> (mean value) than observed until 2014 for marketed antibacterial agents (117 Å<sup>2</sup>).<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> This could be correlated with the increased MW of anti-infective agents during this period. Further, cardiovascular drugs possessed a higher TPSA of 140.13 Å<sup>2</sup>, increasing their peripheral circulation and avoiding BBB permeability.</div><div class="NLM_p">The next parameter we considered was nROTB, which estimates drug candidate flexibility and helps determine oral bioavailability.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> The average mean nROTB was found within the recommended value for all the drug categories analyzed. Next, we analyzed the trend for nHBDon and nHBAcc. Almost all drugs in numerous categories lie within a region of Lipinski-type acceptor and donor values with mean values of 2.33 and 7.88 for nHBDon and nHBAcc, respectively.</div><div class="NLM_p">Another parameter (i.e., AlogP) was considered over ClogP as it takes into account local hydrophobicity, molecular hydrophobicity maps, and hydrophobic interactions common in drug–receptor complexes. The acceptable range for AlogP lies in between −0.4 to +5.6 as per the Ghose filter.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> Our analysis revealed an average AlogP of 0.390 for drugs approved during the investigation period. However, neurological drugs exhibited least AlogP (−0.009) because of high permeability requirements and the tendency to cross the BBB.</div><div class="NLM_p">To deduce the molecular similarity, understand chemical diversity, and fingerprint drugs approved during the analysis period (2015–20), we employed the Tanimoto algorithm (SI; <a href="/doi/suppl/10.1021/acs.jmedchem.0c01786/suppl_file/jm0c01786_si_001.pdf" class="ext-link">Figure S2</a>). The algorithm is used to compare the chemical structures possessing a similar subset of fingerprints. Two chemical structures are considered similar if they possess the Tanimoto coefficient (T) > 0.85.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> The analysis of drugs approved in 2015 revealed: anticancer drugs portrayed chemotype similarity with all other drug categories; anti-infectives were found to show similarity with cardiovascular drugs, and metabolic drugs possessed similarity to neurological drugs. The year 2017 witnessed chemotype similarity between anticancer and metabolic disorders drug categories. Analysis of the year 2018 indicated: chemotype similarity of anticancer drugs with drugs for respiratory disorders and anti-infective agents; cardiovascular drugs exhibited similarity with neurological drugs. The year 2019 again witnessed the molecular similarity of anticancer drugs with all other drug categories. Further, drugs approved for metabolic disorders also exhibited high T values with cardiovascular and autoimmune disorders drugs. Considering 2020, high T values were found for anticancer drugs with all other drug categories except metabolic and anti-infective drugs.</div><div class="NLM_p">Next, we drew a comparison of molecular descriptors based on routes of drug administration of small-molecule drugs. The thorough statistical analysis (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01786/suppl_file/jm0c01786_si_001.pdf" class="ext-link">SI</a>; <a href="/doi/suppl/10.1021/acs.jmedchem.0c01786/suppl_file/jm0c01786_si_001.pdf" class="ext-link">Table S2</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01786/suppl_file/jm0c01786_si_001.pdf" class="ext-link">Figure S3</a>) revealed that drugs intended for intravenous, inhalation, and intramuscular routes exhibited higher MW with a mean of 599.36, 597.33, and 659.32, respectively. As per data available, the mean MW of orally bioavailable drugs approved until 2014 was 449 g/mol.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> The data during the current analysis (the year 2015–20) suggested that mean MW increased slightly and was 458.59 g/mol (SI; <a href="/doi/suppl/10.1021/acs.jmedchem.0c01786/suppl_file/jm0c01786_si_001.pdf" class="ext-link">Figure S3</a>). TPSA analysis revealed that intravenous drugs possessed the highest mean value of 204.83 Å<sup>2</sup>. An interesting trend was seen in the AlogP parameter. Drugs administered via topical (0.68), ocular (0.26), inhalation (0.49), and subcutaneous (0.29) routes portrayed higher mean AlogP to avoid their systemic absorption. However, mean AlogP values were less for drugs administered through intramuscular (−1.75) and intravenous (−2.71) routes for their quick and better systemic tolerability.</div><div class="NLM_p">Furthermore, we observed a good correlation between MW and TPSA (0.802991) and a medium to low correlation in the case of MW and nROTB (0.745) and TPSA and nROTB (0.673) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>A). The key outliers were lutathera, Ibsrela, giapreza, and venclexta with significantly high values of the descriptors employed (SI, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01786/suppl_file/jm0c01786_si_001.pdf" class="ext-link">Table S3</a>). The analysis also predicted aristada and vyzulta to possess high nROTB values (>20). A low correlation was observed between MW and nHBDon (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>B; 0.641). However, a good correlation was observed between MW and nHBAcc (0.8581) and nHBDon and nHBAcc (0.750). Next, we explored the correlation of TPSA with nHBDon and nHBAcc. The analysis revealed a strong correlation (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>C) of TPSA with nHBDon (0.842) and nHBAcc (0.912). However, correlations of nROTB with nHBDon and nHBAcc emerged to be 0.580 and 0.697, respectively (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>D). Lutathera and giapreza were found to be major outliers. A low negative correlation was observed in the case of MW with AlogP (−0.4167) and TPSA with AlogP (−0.609). The analysis indicated that high MW drugs were having high values of TPSA and are likely to be absorbed to a lesser extent by the oral route. Further, if the polarity of the drug candidate is reduced, transcellular routes will dominate and improve fractional absorption.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Three-dimensional representation illustrating the outcome of chemical space visualized on PUMA using the “Chemical Space” tab for FDA approved drugs during 2015–June 2020. The 3D graphs signify correlation between (A) MW with TPSA and nROTB, (B) MW with nHBDon and nHBAcc, (C) TPSA with nHBDon and nHBAcc, and (D) nROTB with nHBDon and nHBAcc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Antibody–Drug Conjugates (ADCs)</h3><div class="NLM_p">Further, chemical investigation of five FDA approved ADCs in cancer therapeutic indicated the mAb was conjugated with a cytotoxic compound via a linker (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). The antibody–drug conjugation was accomplished either through C–S (sacituzumab govitecan, enfortumab vedotin, and polatuzumab vedotin), C–N (inotuzumab ozogamicin), or C–C (fam-trastuzumab deruxtecan) bond formation depending upon the type of linker (6-maleimidohexanoyl linked to the N-amino of Val-Cit, carbonyl-containing carboxylic acid, or maleimide group in deruxtecan).</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structures of FDA approved antibody–drug conjugates (2015–June 2020).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Drug-likeness</h3><div class="NLM_p">The approved drugs were analyzed for a parameter usually applied for small molecules to predict the probability for a compound’s success during development (i.e., Lipinski’s rule of 5 (RO5)). Considering the current study (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>), out of 164 approved small-molecule drugs, more than 3/4th of the approved drugs follow the RO5. This indicates that even after 23 years of its inception, Lipinski’s rule continues to be an indicator of the probability of success for a new chemical entity.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Bar graph represents percent of approved FDA drugs from the year 2015 until June 2020, following and not following Lipinski’s Rule.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Drug Metabolism</h3><div class="NLM_p">Understanding drug metabolism via structure-metabolism relationship studies based on chemical or enzymatic pathways provides ample opportunities to medicinal chemists for performing design strategies to overcome high clearance (e.g., in sonidegib and trifluridine, when a benzylic methyl group is identified as a metabolic soft spot and is replaced with the −CF<sub>3</sub> group), using deuterium replacement to further optimize a lead (<b>59</b>), and implementing prodrug approaches to circumvent formulation and delivery difficulties (<b>101</b> and <b>50</b>) for lead optimization with an aim to deliver clinical candidates. These could be either having new chemical templates with bioisosteric replacements or in the form of prodrugs overcoming the issues related to pharmacokinetic, pharmacodynamics, and safety profiles. We summarized few strategies for optimizing metabolism utilized in the discovery of some FDA approved drugs (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) of the mentioned period. For example, replacement of hydrogen of tetrabenzine (<b>180</b>) with deuterium (<b>59</b>) offered increased metabolic stability toward CYP2D6, increased half-life, and reduced clearance.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Likewise, insertion of the <i>m</i>-trifluoromethyl phenyl group (e.g., <b>96</b>) in primaquine (<b>181</b>) imparted resistance to enzymatic cleavage by CYPs and thus considerably reduced toxicity.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> Furthermore, several more examples and the strategies utilized for optimizing their metabolism<a onclick="showRef(event, 'ref205 ref206 ref207 ref208 ref209 ref210 ref211'); return false;" href="javascript:void(0);" class="ref ref205 ref206 ref207 ref208 ref209 ref210 ref211">(205−211)</a> are illustrated in <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0021.jpeg" id="GRAPHIC-d7e2056-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. An illustration showing several strategies utilized for optimizing metabolism leading to discovery of clinical candidates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0020.jpeg jm0c01786_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also attempted to analyze the percentage share of various metabolic enzymes, such as CYPs, UGTs, AO, and so on, involved in the metabolism of the drugs approved from 2015 to June 2020 by the U.S. FDA (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). CYP-mediated metabolism continues to be the leading pathway for elimination of majority of small molecules.</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0022.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Percentage of the drugs approved in the study period (2015–June 2020) metabolized by various drug-metabolizing enzymes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Only two drugs, <b>46</b> and <b>7</b>, have been approved in this study period that were metabolized by AO. Because of high interspecies variability and challenges associated with selection of appropriate animal species for toxicology studies, many innovator pharmaceutical companies have tried to avoid progressing any compound for which AO contributes significantly to the clearance.<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> Mostly, nucleases are involved in the metabolism of oligonucleotides, and catabolism continues to be the primary pathway for the elimination of macromolecules.</div><div class="NLM_p last">Prodrugs commonly have functional groups of esters, amides, phosphates, carbonates, or carbamates which are mostly cleaved enzymatically in the body. <b>133</b> (a phosphate prodrug; designed to increase solubility of parent) has been approved for the treatment of chronic immune thrombocytopenia and is cleaved through alkaline phosphatase to release the parent, R406.<a onclick="showRef(event, 'ref213 ref214'); return false;" href="javascript:void(0);" class="ref ref213 ref214">(213,214)</a></div></div><div id="sec11_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Drug–Drug Interaction Potential</h3><div class="NLM_p">Around the world, a large number of the patient population consumes two or more drugs concomitantly, and hence, there is a possibility of occurrence of DDI. DDIs could be driven by altered pharmacodynamics through the additive, synergistic, or antagonistic therapeutic effect or pharmacokinetics through alteration in inhibition/induction of drug-metabolizing enzymes or transporters.<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a></div><div class="NLM_p">The term “perpetrator” is used to imply the drug that is responsible for the DDI, while “victim” or “substrate” implies the drug that is being interacted with. In metabolic inhibition, the perpetrator impairs the clearance of the victim drug, systemic exposure increases, and the clinical concern is toxicity. With metabolic induction, clearance of the victim increases, systemic exposure decreases, and the clinical concern is lack of efficacy. <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a> depicts data on the number of victims and perpetrators from drugs approved for various therapeutic categories during the study period.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0023.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Bar graph represents the share of victims and perpetrators during the study period (2015–June 2020).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Diseases such as cancer, neurological disorders, and infections have a significant number of approved drugs with DDI potential. Moreover, it is pertinent to note here that the majority of the drugs for neurological disorders have a narrow therapeutic window, and hence, the potential impact of DDI could be even higher. One of the challenges with clinical DDI studies that are performed regularly during the new drug development is their inability to decipher all the potential DDIs because of polymorphism of drug-metabolizing enzymes, genetic variations among populations, patient-to-patient variability due to altered physiology, and so on. Terfenadine and cisapride are examples of victims that were withdrawn from the market postapproval due to significant DDIs.<a onclick="showRef(event, 'ref216 ref217'); return false;" href="javascript:void(0);" class="ref ref216 ref217">(216,217)</a> The classical anticoagulant warfarin is another example of a victim, which is reported to have severe interactions with multiple marketed drugs.<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(218)</a></div></div></div><div id="sec12" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71633" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71633" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In conclusion, we have comprehensively discussed the U.S. FDA approved drugs and compiled them according to the year of approval, target, chemical class, Lipinski criteria (for small molecules), and potential DDI liability (perpetrator or/and victim) for the last five years or so. The analysis of drugs indicated that the major share of approved drugs belongs to cancer therapeutics. This could be due to the continuous focus on finding the treatment and improving the life expectancy or quality of life for cancer patients. Improved understanding of cancer biology is certainly helpful in finding novel therapies; however, a lot in this area still remains to be understood, especially the spectrum of genetic mutations. Infectious diseases continue to be an area of interest due to the rise of microbial and bacterial resistance and deadly viral diseases such as Covid-19. In the near future, significant efforts are anticipated to be directed in the areas of cancer and infectious diseases. Drugs for the treatment of noncommunicable diseases including but not limited to neurological, genetic, metabolic, autoimmune, and cardiovascular disorders contributed significantly to the approved drugs in the past five years, and because of high unmet medical need in these areas, the trend is likely to continue. Our analysis of structural diversity of pharmacophores revealed that in a data set of small molecules, the percentage and frequency of nitrogen heterocycles continue to rise, of which pyridine is the most common nitrogen heterocycle among the small molecules, followed by piperidine and piperazine. The assessment indicated that drugs with a strategic introduction of groups, such as nitro for inducing bioreductive cytotoxicity, boron for enhancing reactivity toward nucleophiles of enzymes, nucleic acid and carbohydrates or fluorine on aromatic moiety/deuterium for hindering metabolism, induce potency or as diagnostics were approved. The descriptor-based chemical space analysis of FDA approved small molecules could be used for a wide range of endeavors including drug design, drug repurposing, SAR studies, and improving pharmacokinetic parameters. We deliberated approaches that demonstrated a few innovative strategies for optimizing drug metabolism, leading to the drug candidates that could be considered to design new drugs.</div><div class="NLM_p last">Further, the examination of biologics indicated that there had been a rise in approvals of ADCs and TIDES in addition to mAbs, particularly in cancer therapeutics. It is anticipated that the cost of new drug discovery and development will continue to rise, and the median cost is estimated to be upward of USD $2 billion. With a greater number of drugs of biological origin being developed, the cost could go further northwards. Technologies like artificial intelligence and machine learning would help increase the efficiency of the drug discovery engine and make it quicker and cost-effective.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01786" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26018" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26018" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01786?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01786</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Tables S1–S3 and Figures S1–S3 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01786/suppl_file/jm0c01786_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01786/suppl_file/jm0c01786_si_001.pdf">jm0c01786_si_001.pdf (1.5 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01786" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40177" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40177" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Atish T. Paul</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy, Birla Institute of Technology
and Science (BITS) Pilani, Pilani Campus, Rajasthan 333031, India</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b2d3c6dbc1da9cc2d3c7def2c2dbded3dcdb9cd0dbc6c19fc2dbded3dcdb9cd3d19cdbdc"><span class="__cf_email__" data-cfemail="3554415c465d1b4554405975455c59545b5c1b575c414618455c59545b5c1b54561b5c5b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Raj Kumar</span> - <span class="hlFld-Affiliation affiliation">Laboratory
for Drug Design and Synthesis, Department of Pharmaceutical Sciences
and Natural Products, Central University
of Punjab, Bathinda 151001, India</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5113-6627" title="Orcid link">http://orcid.org/0000-0001-5113-6627</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f486959eda9f9c819a939186b49399959d98da979b99d486959eda9f9c819a939186b4978184da919081da9d9a"><span class="__cf_email__" data-cfemail="5426353e7a3f3c213a333126143339353d387a373b39">[email protected]</span> <span class="__cf_email__" data-cfemail="285a49420643405d464f4d5a684b5d58064d4c5d064146">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Priyadeep Bhutani</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre, Syngene International Limited, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmacy, Birla Institute of Technology
and Science (BITS) Pilani, Pilani Campus, Rajasthan 333031, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gaurav Joshi</span> - <span class="hlFld-Affiliation affiliation">Laboratory
for Drug Design and Synthesis, Department of Pharmaceutical Sciences
and Natural Products, Central University
of Punjab, Bathinda 151001, India</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7812-2871" title="Orcid link">http://orcid.org/0000-0002-7812-2871</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nivethitha Raja</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre, Syngene International Limited, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Namrata Bachhav</span> - <span class="hlFld-Affiliation affiliation">1015
E Cozza Drive # 12, Spokane Washington 99208, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Prabhakar K. Rajanna</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre, Syngene International Limited, Bangalore 560099, India</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0765-8609" title="Orcid link">http://orcid.org/0000-0003-0765-8609</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hemant Bhutani</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Development, Biocon Bristol-Myers Squibb R&D Centre, Bristol-Myers Squibb India Private Limited, Bangalore 560099, India</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5443-7257" title="Orcid link">http://orcid.org/0000-0001-5443-7257</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>P.B. and G.J. contributed equally.</p><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written with the contribution of all the authors.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71781" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71781" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Priyadeep Bhutani</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=BIO-d7e2246-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Priyadeep Bhutani</b> is senior scientist in Pharmaceutical Candidate Optimization (PCO) at Biocon-Bristol Myers Squibb R&D Centre (BBRC), Syngene International Limited, Bangalore, India. She earned Masters of Pharmacy from Panjab University, Chandigarh. She has 15 years of industrial research experience in the area of DMPK and preclinical bioanalysis and is currently pursuing Ph.D. from Department of Pharmacy, Birla Institute of Technology and Science (BITS), Pilani, India.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Gaurav Joshi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=BIO-d7e2251-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Gaurav Joshi</b> received his Ph.D. in Medicinal Chemistry at Central University of Punjab, Bathinda, India with Professor Raj Kumar. The area of his interest is the development of small molecules as inhibitors of numerous oncological targets.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Nivethitha Raja</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=BIO-d7e2256-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Nivethitha Raja</b> received the veterinary medicine degree from Tamil Nadu Veterinary and Animal Sciences University in 2016. She currently works at Department of Discovery Toxicology, PCO, BBRC at Syngene International Limited, Bangalore where she along with her colleagues provide safety assessment of new chemical entities during early discovery. She is specialized in applying novel algorithms to quantitatively measure the end points in preclinical studies and their translatability to humans.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Namrata Bachhav</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=BIO-d7e2261-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Namrata Bachhav</b> is a freelancer researcher in the field of pharmaceutical sciences in the USA. She graduated with Master in Pharmaceutics degree in 2014 from Marathwada University, Aurangabad, India and thereafter worked for 3 years in analytical research and development (stability) department at BBRC, Syngene International Limited, Bangalore India.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Prabhakar K. Rajanna</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=BIO-d7e2266-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Prabhakar K. Rajanna</b> received PhD in the field of Experimental Pharmacology from Manipal Academy of Higher Education, Manipal in 2007. He has more than 15 years of experience in academic and industrial research in the areas of preclinical & clinical bioanalysis and DMPK. He is currently associated with PCO, BBRC at Syngene International Limited, Bengaluru as Senior Principal Investigator</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Hemant Bhutani</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=BIO-d7e2272-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hemant Bhutani</b> is Director and Head of Analytical R&D at Pharmaceutical Development, BBRC, Bristol Myers Squibb, Bangalore, India. His team works on analytical and mechanistic aspects of different phases of drug development and life cycle management. His Ph.D. work on antituberculosis fixed-dose combinations with Dr. Saranjit Singh at NIPER, SAS Nagar provided significant input for WHO guidelines on fixed-dose combinations (FDCs).</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Atish T. Paul</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=BIO-d7e2277-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Atish T. Paul</b> obtained his M.S. (Pharm.) and Ph.D. in Natural Products with Prof. KK Bhutani from the National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar. Thereafter, he joined the research group of Prof. Ikhlas Khan as a postdoctoral fellow at the National Center for Natural Product Research (University of Mississippi, USA). Currently, he is working as Assistant Professor, Department of Pharmacy.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Raj Kumar</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=BIO-d7e2282-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Raj Kumar</b> received his Ph.D. in Medicinal Chemistry at National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India with Professor Asit K. Chakraborti following postdoctoral fellowship with Professor Ramachandra S. Hosmane at University of Maryland Baltimore County (UMBC), MD, where he codiscovered RK-33 molecule as DDX-3 inhibitor for lung cancer therapeutic. He started his independent research career at ISF College of Pharmacy, Moga in 2007. Dr. Raj Kumar is at present working as Professor at Central University of Punjab, Bathinda since 2011.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50727" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50727" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">R.K. thanks Vice Chancellor, Professor Raghavendra P. Tiwari, Central University of Punjab, India for providing academic support and SERB for financial support (#EMR/2017/002702). Authors also acknowledge Bristol-Myers Squibb and Syngene International Limited for support during this work. Authors would also like to acknowledge Medha Bhutani for helping in the compilation of the tables.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">ABBREVIATIONS USED</td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody–drug conjugates</p></td></tr><tr><td class="NLM_term">BSEP</td><td class="NLM_def"><p class="first last">bile salt efflux pump</p></td></tr><tr><td class="NLM_term">BCS</td><td class="NLM_def"><p class="first last">Biopharmaceutics Classification Scheme</p></td></tr><tr><td class="NLM_term">CDER</td><td class="NLM_def"><p class="first last">Centre for Drug Evaluation and Research</p></td></tr><tr><td class="NLM_term">CD</td><td class="NLM_def"><p class="first last">cluster of differentiation</p></td></tr><tr><td class="NLM_term">DDI</td><td class="NLM_def"><p class="first last">drug–drug interaction</p></td></tr><tr><td class="NLM_term">DMEs</td><td class="NLM_def"><p class="first last">drug-metabolizing enzymes</p></td></tr><tr><td class="NLM_term">DALYs</td><td class="NLM_def"><p class="first last">global disability adjusted life years</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">Fab</td><td class="NLM_def"><p class="first last">monoclonal antibody fragment</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">OAT3</td><td class="NLM_def"><p class="first last">organic anion transporter 3</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">VMAT2</td><td class="NLM_def"><p class="first last">vesicular monoamine</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66776" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66776" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 218 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drews, J.</span></span> <span> </span><span class="NLM_article-title">Drug discovery: A historical perspective</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">1960</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1126/science.287.5460.1960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1126%2Fscience.287.5460.1960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10720314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvFyrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2000&pages=1960-4&author=J.+Drews&title=Drug+discovery%3A+A+historical+perspective&doi=10.1126%2Fscience.287.5460.1960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery: A historical perspective</span></div><div class="casAuthors">Drews, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">5460</span>),
    <span class="NLM_cas:pages">1960-1963</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with over 60 refs.  Driven by chem. but increasingly guided by pharmacol. and the clin. sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor.  The advent of mol. biol. and, in particular, of genomic sciences is having a deep impact on drug discovery.  Recombinant proteins and monoclonal antibodies have greatly enriched our therapeutic armamentarium.  Genome sciences, combined with bioinformatic tools, allow us to dissect the genetic basis of multifactorial diseases and to det. the most suitable points of attack for future medicines, thereby increasing the no. of treatment options.  The dramatic increase in the complexity of drug research is enforcing changes in the institutional basis of this interdisciplinary endeavor.  The biotech industry is establishing itself as the discovery arm of the pharmaceutical industry.  In bridging the gap between academia and large pharmaceutical companies, the biotech firms have been effective instruments of technol. transfer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdT9qeMTdSTrVg90H21EOLACvtfcHk0li1_CwkvFYcwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvFyrtbc%253D&md5=33804292ba1e2fa5fd8012729d137dff</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.287.5460.1960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.287.5460.1960%26sid%3Dliteratum%253Aachs%26aulast%3DDrews%26aufirst%3DJ.%26atitle%3DDrug%2520discovery%253A%2520A%2520historical%2520perspective%26jtitle%3DScience%26date%3D2000%26volume%3D287%26spage%3D1960%26epage%3D4%26doi%3D10.1126%2Fscience.287.5460.1960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Network pharmacology: The next paradigm in drug discovery</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1038/nchembio.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-90&author=A.+L.+Hopkins&title=Network+pharmacology%3A+The+next+paradigm+in+drug+discovery&doi=10.1038%2Fnchembio.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0li1_CwkvFYcwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520pharmacology%253A%2520The%2520next%2520paradigm%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D682%26epage%3D90%26doi%3D10.1038%2Fnchembio.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Angelis, A.</span>; <span class="NLM_string-name">Phillips, L. D.</span></span> <span> </span><span class="NLM_article-title">Advancing structured decision-making in drug regulation at the fda and ema</span>.  <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>.  <span class="NLM_volume">87</span> <span class="NLM_fpage">395</span><span class="refDoi"> DOI: 10.1111/bcp.14425</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1111%2Fbcp.14425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=32529733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB38rptVaqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2021&pages=395&author=A.+Angelis&author=L.+D.+Phillips&title=Advancing+structured+decision-making+in+drug+regulation+at+the+fda+and+ema&doi=10.1111%2Fbcp.14425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing structured decision-making in drug regulation at the FDA and EMA</span></div><div class="casAuthors">Angelis Aris; Phillips Lawrence D</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">395-405</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The recent benefit-risk framework (BRF) developed by the Food and Drug Administration (FDA) is intended to improve the clarity and consistency in communicating the reasoning behind the FDA's decisions, acting as an important advancement in US drug regulation.  In the PDUFA VI implementation plan, the FDA states that it will continue to explore more structured or quantitative decision analysis approaches; however, it restricts their use within the current BRF that is purely qualitative.  By contrast, European regulators and researchers have been long exploring the use of quantitative decision analysis approaches for evaluating drug benefit-risk balance.  In this paper, we show how quantitative modelling, backed by decision theory, could complement and extend the FDA's BRF to better support the appraisal of evidence and improve decision outcomes.  After providing relevant scientific definitions for benefit-risk assessment and describing the FDA and European Medicines Agency (EMA) frameworks, we explain the components of and differences between qualitative and quantitative approaches.  We present lessons learned from the EMA experience with the use of quantitative modelling and we provide evidence of its benefits, illustrated by a real case study that helped to resolve differences of judgements among EMA regulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQoF9uz7xh8gCSm0e6ZOaemfW6udTcc2eYjyeAtqpx8S7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38rptVaqtQ%253D%253D&md5=2ee868dcb5368f02587728ac76931d16</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fbcp.14425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.14425%26sid%3Dliteratum%253Aachs%26aulast%3DAngelis%26aufirst%3DA.%26atitle%3DAdvancing%2520structured%2520decision-making%2520in%2520drug%2520regulation%2520at%2520the%2520fda%2520and%2520ema%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2021%26volume%3D87%26spage%3D395%26doi%3D10.1111%2Fbcp.14425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kashoki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanaizi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yordanova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veselý, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouygues, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinares, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kweder, S. L.</span></span> <span> </span><span class="NLM_article-title">A comparison of ema and fda decisions for new drug marketing applications 2014–2016: Concordance, discordance, and why</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1002/cpt.1565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fcpt.1565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31306483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3MznsVCltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2020&pages=195-202&author=M.+Kashokiauthor=Z.+Hanaiziauthor=S.+Yordanovaauthor=R.+Vesel%C3%BDauthor=C.+Bouyguesauthor=J.+Llinaresauthor=S.+L.+Kweder&title=A+comparison+of+ema+and+fda+decisions+for+new+drug+marketing+applications+2014%E2%80%932016%3A+Concordance%2C+discordance%2C+and+why&doi=10.1002%2Fcpt.1565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why</span></div><div class="casAuthors">Kashoki Mwango; Kashoki Mwango; Hanaizi Zahra; Yordanova Stella; Vesely Richard; Bouygues Christelle; Llinares Jordi; Kweder Sandra L</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">195-202</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have robust scientific and technical collaborations.  As a window to the impact of these activities we compared the agencies' decisions on drug marketing applications.  Decisions were compared for 107 new drug applications with a regulatory outcome at both agencies in the period 2014-2016.  Further analysis addressed individual applications for which the agencies had differing outcomes in terms of marketing approval, type of approval, and approved indication, including reasons underlying differences.  The EMA and the FDA had high concordance (91-98%) in decisions on marketing approvals.  Divergence in approval decisions, type of approval, and approved indication were primarily due to differences in agencies' conclusions about efficacy based on review of the same data or differing clinical data submitted to support the application.  This high rate of concordance suggests that engagement and collaboration on regulatory science has a positive impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQV-1WkooK594IRAdBLKY41fW6udTcc2eb7QSmfp4enkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MznsVCltw%253D%253D&md5=6408da6719a9514f0c4fca5542e728a1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1565%26sid%3Dliteratum%253Aachs%26aulast%3DKashoki%26aufirst%3DM.%26aulast%3DHanaizi%26aufirst%3DZ.%26aulast%3DYordanova%26aufirst%3DS.%26aulast%3DVesel%25C3%25BD%26aufirst%3DR.%26aulast%3DBouygues%26aufirst%3DC.%26aulast%3DLlinares%26aufirst%3DJ.%26aulast%3DKweder%26aufirst%3DS.%2BL.%26atitle%3DA%2520comparison%2520of%2520ema%2520and%2520fda%2520decisions%2520for%2520new%2520drug%2520marketing%2520applications%25202014%25E2%2580%25932016%253A%2520Concordance%252C%2520discordance%252C%2520and%2520why%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2020%26volume%3D107%26spage%3D195%26epage%3D202%26doi%3D10.1002%2Fcpt.1565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
la Torre, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albericio, F.</span></span> <span> </span><span class="NLM_article-title">The pharmaceutical industry in 2018. An analysis of fda drug approvals from the perspective of molecules</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">809</span>, <span class="refDoi"> DOI: 10.3390/molecules24040809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3390%2Fmolecules24040809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30813407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlCrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=809&author=B.+G.+de%0Ala+Torreauthor=F.+Albericio&title=The+pharmaceutical+industry+in+2018.+An+analysis+of+fda+drug+approvals+from+the+perspective+of+molecules&doi=10.3390%2Fmolecules24040809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmaceutical industry in 2018. an analysis of FDA drug approvals from the perspective of molecules</span></div><div class="casAuthors">de la Torre, Beatriz G.; Albericio, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">809/1-809/12</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The Food and Drug Administration approved 59 new drugs (42 New Chem. Entities and 17 Biologics) during 2018.  This no. breaks the previous record of 53 approved by the same organization in 1996.  The 17 new biologics approved in 2018 also represent an important milestone for this kind of drug and they clearly exceed the 12 approved in 2015 and 2017.  Herein, the 59 new drugs of the class of 2018 are analyzed from a strictly chem. perspective.  The classification has been carried out on the basis of the chem. structure and includes the following: Biologics (antibodies and enzymes); TIDES (peptides and oligonucleotides) and natural products; drug combinations; and small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpl9Nat-uSwbVg90H21EOLACvtfcHk0lgnz3w6qkM4FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlCrtLY%253D&md5=e61d944d90a38fead8920eef07be8246</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24040809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24040809%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2Bla%2BTorre%26aufirst%3DB.%2BG.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DThe%2520pharmaceutical%2520industry%2520in%25202018.%2520An%2520analysis%2520of%2520fda%2520drug%2520approvals%2520from%2520the%2520perspective%2520of%2520molecules%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D809%26doi%3D10.3390%2Fmolecules24040809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
la Torre, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albericio, F.</span></span> <span> </span><span class="NLM_article-title">The pharmaceutical industry in 2017. An analysis of fda drug approvals from the perspective of molecules</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">533</span>, <span class="refDoi"> DOI: 10.3390/molecules23030533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3390%2Fmolecules23030533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslWrtLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=533&author=B.+G.+de%0Ala+Torreauthor=F.+Albericio&title=The+pharmaceutical+industry+in+2017.+An+analysis+of+fda+drug+approvals+from+the+perspective+of+molecules&doi=10.3390%2Fmolecules23030533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmaceutical industry in 2017. An analysis of FDA drug approvals from the perspective of molecules</span></div><div class="casAuthors">de la Torre, Beatriz G.; Albericio, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">533/1-533/8</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  This is an anal. from a chem. point of view of the 46 drugs (34 New Chem. Entities and 12 Biologics) approved by the FDA during 2017.  The drugs included in the 2017 "harvest" have been classified on the basis of their chem. structure: biologics (antibodies and proteins); peptides; amino acids and natural products; drug combinations; and small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2caMkd7KKS7Vg90H21EOLACvtfcHk0lgnz3w6qkM4FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslWrtLnK&md5=60d847c788c02db756fee26d84042c9a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23030533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23030533%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2Bla%2BTorre%26aufirst%3DB.%2BG.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DThe%2520pharmaceutical%2520industry%2520in%25202017.%2520An%2520analysis%2520of%2520fda%2520drug%2520approvals%2520from%2520the%2520perspective%2520of%2520molecules%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26spage%3D533%26doi%3D10.3390%2Fmolecules23030533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
la Torre, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albericio, F.</span></span> <span> </span><span class="NLM_article-title">The pharmaceutical industry in 2019. An analysis of fda drug approvals from the perspective of molecules</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">745</span>, <span class="refDoi"> DOI: 10.3390/molecules25030745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3390%2Fmolecules25030745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXks1yitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=745&author=B.+G.+De%0Ala+Torreauthor=F.+Albericio&title=The+pharmaceutical+industry+in+2019.+An+analysis+of+fda+drug+approvals+from+the+perspective+of+molecules&doi=10.3390%2Fmolecules25030745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmaceutical industry in 2019. an analysis of FDA drug approvals from the perspective of molecules</span></div><div class="casAuthors">de la Torre, Beatriz G.; Albericio, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">745</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  During 2019, the US Food and Drug Administration (FDA) approved 48 new drugs (38 New Chem. Entities and 10 Biologics).  Although this figure is slightly lower than that registered in 2018 (59 divided between 42 New Chem. Entities and 17 Biologics), a year that broke a record with respect to new drugs approved by this agency, it builds on the trend initiated in 2017, when 46 drugs were approved.  Of note, three antibody drug conjugates, three peptides, and two oligonucleotides were approved in 2019.  This report analyzes the 48 new drugs of the class of 2019 from a strictly chem. perspective.  The classification, which was carried out on the basis of chem. structure, includes the following: Biologics (antibody drug conjugates, antibodies, and proteins); TIDES (peptide and oligonucleotides); drug combinations; natural products; and small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKTdcnvpBRKbVg90H21EOLACvtfcHk0ljudXIvDSVCvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXks1yitbo%253D&md5=f7e9db811c93d5ce49d0fa2a85207b18</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3390%2Fmolecules25030745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules25030745%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2Bla%2BTorre%26aufirst%3DB.%2BG.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DThe%2520pharmaceutical%2520industry%2520in%25202019.%2520An%2520analysis%2520of%2520fda%2520drug%2520approvals%2520from%2520the%2520perspective%2520of%2520molecules%26jtitle%3DMolecules%26date%3D2020%26volume%3D25%26spage%3D745%26doi%3D10.3390%2Fmolecules25030745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feunang, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sajed, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayeeda, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assempour, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iynkkaran, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, M.</span></span> <span> </span><span class="NLM_article-title">Drugbank 5.0: A major update to the drugbank database for 2018</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">D1074</span>– <span class="NLM_lpage">D1082</span>, <span class="refDoi"> DOI: 10.1093/nar/gkx1037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1093%2Fnar%2Fgkx1037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29126136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGisbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=D1074-D1082&author=D.+S.+Wishartauthor=Y.+D.+Feunangauthor=A.+C.+Guoauthor=E.+J.+Loauthor=A.+Marcuauthor=J.+R.+Grantauthor=T.+Sajedauthor=D.+Johnsonauthor=C.+Liauthor=Z.+Sayeedaauthor=N.+Assempourauthor=I.+Iynkkaranauthor=Y.+Liuauthor=A.+Maciejewskiauthor=N.+Galeauthor=A.+Wilsonauthor=L.+Chinauthor=R.+Cummingsauthor=D.+Leauthor=A.+Ponauthor=C.+Knoxauthor=M.+Wilson&title=Drugbank+5.0%3A+A+major+update+to+the+drugbank+database+for+2018&doi=10.1093%2Fnar%2Fgkx1037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">DrugBank 5.0: a major update to the DrugBank database for 2018</span></div><div class="casAuthors">Wishart, David S.; Feunang, Yannick D.; Guo, An C.; Lo, Elvis J.; Marcu, Ana; Grant, Jason R.; Sajed, Tanvir; Johnson, Daniel; Li, Carin; Sayeeda, Zinat; Assempour, Nazanin; Iynkkaran, Ithayavani; Liu, Yifeng; Maciejewski, Adam; Gale, Nicola; Wilson, Alex; Chin, Lucy; Cummings, Ryan; Le, Diana; Pon, Allison; Knox, Craig; Wilson, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D1074-D1082</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">DrugBank is a web-enabled database contg. comprehensivemol. information about drugs, their mechanisms, their interactions and their targets.  First described in 2006, Drug- Bank has continued to evolve over the past 12 years in response to marked improvements to web stds. and changing needs for drug research and development.  This year's update, DrugBank 5.0, represents the most significant upgrade to the database in more than 10 years.  In many cases, existing data content has grown by 100% or more over the last update.  For instance, the total no. of investigational drugs in the database has grown by almost 300%, the no. of drug-drug interactions has grown by nearly 600% and the no. of SNP-assocd. drug effects has grown more than 3000%.  Significant improvements have been made to the quantity, quality and consistency of drug indications, drug binding data as well as drug-drug and drug-food interactions.  A great deal of brand new data have also been added to DrugBank 5.0.  This includes information on the influence of hundreds of drugs on metabolite levels (pharmacometabolomics), gene expression levels (pharmacotranscriptomics) and protein expression levels (pharmacoproteomics).  New data have also been added on the status of hundreds of newdrug clin. trials and existing drug repurposing trials.  Many other important improvements in the content, interface and performance of the DrugBank website have been made and these should greatly enhance its ease of use, utility and potential applications in many areas of pharmacol. research, pharmaceutical science and drug education.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc8rfBoMOOyLVg90H21EOLACvtfcHk0ljudXIvDSVCvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGisbvI&md5=986b28c7ea546596a26dd3ba38f05fee</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkx1037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkx1037%26sid%3Dliteratum%253Aachs%26aulast%3DWishart%26aufirst%3DD.%2BS.%26aulast%3DFeunang%26aufirst%3DY.%2BD.%26aulast%3DGuo%26aufirst%3DA.%2BC.%26aulast%3DLo%26aufirst%3DE.%2BJ.%26aulast%3DMarcu%26aufirst%3DA.%26aulast%3DGrant%26aufirst%3DJ.%2BR.%26aulast%3DSajed%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DSayeeda%26aufirst%3DZ.%26aulast%3DAssempour%26aufirst%3DN.%26aulast%3DIynkkaran%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMaciejewski%26aufirst%3DA.%26aulast%3DGale%26aufirst%3DN.%26aulast%3DWilson%26aufirst%3DA.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DCummings%26aufirst%3DR.%26aulast%3DLe%26aufirst%3DD.%26aulast%3DPon%26aufirst%3DA.%26aulast%3DKnox%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DM.%26atitle%3DDrugbank%25205.0%253A%2520A%2520major%2520update%2520to%2520the%2520drugbank%2520database%2520for%25202018%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2018%26volume%3D46%26spage%3DD1074%26epage%3DD1082%26doi%3D10.1093%2Fnar%2Fgkx1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span> </span><span class="NLM_article-title"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="89cdfbfceefac9efede8">[email protected]</a>: Fda-approved drugs</span>. <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process" class="extLink">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process</a> (accessed Jun 30, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drugs%40fda%3A+Fda-approved+drugs.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fdaf%2Findex.cfm%3Fevent%3DreportsSearch.process+%28accessed+Jun+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DDrugs%2540fda%253A%2520Fda-approved%2520drugs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laggner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span> <span> </span><span class="NLM_article-title">Why drugs fail—a study on side effects in new chemical entities</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3545</span>– <span class="NLM_lpage">3559</span>, <span class="refDoi"> DOI: 10.2174/138161205774414510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2174%2F138161205774414510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=16248807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWrs7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=3545-3559&author=D.+Schusterauthor=C.+Laggnerauthor=T.+Langer&title=Why+drugs+fail%E2%80%94a+study+on+side+effects+in+new+chemical+entities&doi=10.2174%2F138161205774414510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Why drugs fail - a study on side effects in new chemical entities</span></div><div class="casAuthors">Schuster, D.; Laggner, C.; Langer, T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3545-3559</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Our study focuses on the reasons for market withdrawals of drugs and drug development project terminations in clin. phases I-III from 1992 to 2002.  Over 90% of the market withdrawals were caused by drug toxicity.  Hepatotoxicity and cardiovascular toxicity proved to be the major causes for two out of three market withdrawals in the resp. time period.  In clin. phases I-III 43% of drug development project terminations were due to insufficient efficacy of the investigated compd.  The second important issue, which caused one third of the projects to be closed, was toxicity.  ADME parameters and economic and other reasons played a minor role.  The results of our study indicate that compared with previous studies on this subject, no major improvements have been achieved in the last decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL6dIqIHxrybVg90H21EOLACvtfcHk0ljudXIvDSVCvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWrs7rE&md5=1bef8ba43d434392969566c3e6052cf8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F138161205774414510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161205774414510%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DD.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DWhy%2520drugs%2520fail%25E2%2580%2594a%2520study%2520on%2520side%2520effects%2520in%2520new%2520chemical%2520entities%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2005%26volume%3D11%26spage%3D3545%26epage%3D3559%26doi%3D10.2174%2F138161205774414510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panchagnula, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, N. S.</span></span> <span> </span><span class="NLM_article-title">Biopharmaceutics and pharmacokinetics in drug research</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/S0378-5173(00)00344-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS0378-5173%2800%2900344-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10878321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlSltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2000&pages=131-50&author=R.+Panchagnulaauthor=N.+S.+Thomas&title=Biopharmaceutics+and+pharmacokinetics+in+drug+research&doi=10.1016%2FS0378-5173%2800%2900344-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Biopharmaceutics and pharmacokinetics in drug research</span></div><div class="casAuthors">Panchagnula, R.; Thomas, N. S.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-150</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with refs.  With the synergistic and multiplicative interactions of rational drug design, recombinant biotechnol., combinatorial chem. and high-throughput screening, millions of compds. are being synthesized by chemists.  However, development of these drug candidates has often been impeded, if not terminated, due to biopharmaceutic and/or pharmacokinetic constraints.  This has resulted in delays in development time and escalation of cost in the drug research programs.  So, the present emphasis is to reduce development time and cost, which is analogous to added patent life besides the enormous redn. in human suffering.  In this compilation the important biopharmaceutic and pharmacokinetic approaches are discussed, which will help in the development of safe and more efficacious drugs with reduced development time and cost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9RtSu9ZL4srVg90H21EOLACvtfcHk0liJGShAEA26Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlSltbY%253D&md5=ec1a27a9171105b3da610fdfee492f21</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0378-5173%2800%2900344-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5173%252800%252900344-6%26sid%3Dliteratum%253Aachs%26aulast%3DPanchagnula%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DN.%2BS.%26atitle%3DBiopharmaceutics%2520and%2520pharmacokinetics%2520in%2520drug%2520research%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2000%26volume%3D201%26spage%3D131%26epage%3D50%26doi%3D10.1016%2FS0378-5173%2800%2900344-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, S. A.</span></span> <span> </span><span class="NLM_article-title">Drug metabolism and pharmacokinetics in drug discovery</span>. <i>Curr. Opin. Drug Discovery Devel.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">80</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=12613278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtFKgtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2003&pages=66-80&author=S.+A.+Roberts&title=Drug+metabolism+and+pharmacokinetics+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Drug metabolism and pharmacokinetics in drug discovery</span></div><div class="casAuthors">Roberts, Simon A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-80</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Current Drugs</span>)
        </div><div class="casAbstract">A review.  The discovery and development of new drugs seems to be an inefficient process, since too few new chem. entities (NCEs) successfully make it to the market.  Because one of the main reasons for failure in development is thought to be poor pharmacokinetics (PK), drug metab. and PK (DMPK) have assumed a central role within the field of drug discovery.  A good development candidate requires a balance of potency, safety, and PK; therefore, techniques that can help understand these characteristics are employed to enable researchers to design more robust candidates.  A no. of new in silico, in vitro, and in vivo techniques are available to screen compds. for key absorption, distribution, metab., and excretion (ADME) characteristics, which, when applied within a rational strategy, can make a major contribution to the design and selection of successful NCEs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK2jra-cFBArVg90H21EOLACvtfcHk0liJGShAEA26Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtFKgtrk%253D&md5=e9955815802e10103820943663127d60</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DS.%2BA.%26atitle%3DDrug%2520metabolism%2520and%2520pharmacokinetics%2520in%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Devel.%26date%3D2003%26volume%3D6%26spage%3D66%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bermejo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casabo, V. G.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics in drug discovery</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">654</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1002/jps.21009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fjps.21009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=17630642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BD2sjmsVegtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2008&pages=654-90&author=A.+Ruiz-Garciaauthor=M.+Bermejoauthor=A.+Mossauthor=V.+G.+Casabo&title=Pharmacokinetics+in+drug+discovery&doi=10.1002%2Fjps.21009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics in drug discovery</span></div><div class="casAuthors">Ruiz-Garcia Ana; Bermejo Marival; Moss Aaron; Casabo Vicente G</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">654-90</span>
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    </div><div class="casAbstract">The aim of this current review is to summarize the present status of pharmacokinetics in Drug Discovery.  The review is structured into four sections.  The first section is a general overview of what we understand by pharmacokinetics and the different LADMET aspects: Liberation, Absorption, Distribution, Metabolism, Excretion, and Toxicity.  The second section highlights the different computational or in silico approaches to estimate/predict one or several aspects of the pharmacokinetic profile of a discovery lead compound.  The third section discusses the most commonly used in vitro methodologies.  The fourth and last section examines the various approaches employed towards the pharmacokinetic assessment of discovery molecules; including all the LADME processes, discussing the different mathematical methodologies available to establish the PK profile of a test compound; what the main differences are and what should be the criteria for using one or another mathematical approach.  The major conclusion of this review is that the use of the appropriate preclinical assays has a key role in the long-term viability of a pharmaceutical company since applying the right tools early in discovery will play a key role in determining the company's ability to discover novel safe and effective therapeutics to patients as quickly as possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRw3j1RasKUdJw7prLlxLOzfW6udTcc2eama7HIZtXRqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjmsVegtw%253D%253D&md5=9451af52abc23fa40ec8868b0b4cec0a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fjps.21009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21009%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz-Garcia%26aufirst%3DA.%26aulast%3DBermejo%26aufirst%3DM.%26aulast%3DMoss%26aufirst%3DA.%26aulast%3DCasabo%26aufirst%3DV.%2BG.%26atitle%3DPharmacokinetics%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2008%26volume%3D97%26spage%3D654%26epage%3D90%26doi%3D10.1002%2Fjps.21009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Segall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champness, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lilien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B.</span></span> <span> </span><span class="NLM_article-title">Applying medicinal chemistry transformations and multiparameter optimization to guide the search for high-quality leads and candidates</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2967</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1021/ci2003208</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci2003208" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlaqsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=2967-76&author=M.+Segallauthor=E.+Champnessauthor=C.+Leedingauthor=R.+Lilienauthor=R.+Mettuauthor=B.+Stevens&title=Applying+medicinal+chemistry+transformations+and+multiparameter+optimization+to+guide+the+search+for+high-quality+leads+and+candidates&doi=10.1021%2Fci2003208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Applying Medicinal Chemistry Transformations and Multiparameter Optimization to Guide the Search for High-Quality Leads and Candidates</span></div><div class="casAuthors">Segall, Matthew; Champness, Ed; Leeding, Chris; Lilien, Ryan; Mettu, Ramgopal; Stevens, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2967-2976</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this article we describe a computational method that automatically generates chem. relevant compd. ideas from an initial mol., closely integrated with in silico models, and a probabilistic scoring algorithm to highlight the compd. ideas most likely to satisfy a user-defined profile of required properties.  The new compd. ideas are generated using medicinal chem. transformation rules' taken from examples in the literature.  We demonstrate that the set of 206 transformations employed is generally applicable, produces a wide range of new compds., and is representative of the types of modifications previously made to move from lead-like to drug-like compds.  Furthermore, we show that more than 94% of the compds. generated by transformation of typical drug-like mols. are acceptable to experienced medicinal chemists.  Finally, we illustrate an application of our approach to the lead that ultimately led to the discovery of duloxetine, a marketed serotonin reuptake inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjE0Vu_6P2LbVg90H21EOLACvtfcHk0liJGShAEA26Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlaqsbbO&md5=af71c9add7eca9967c729710e951fa01</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fci2003208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2003208%26sid%3Dliteratum%253Aachs%26aulast%3DSegall%26aufirst%3DM.%26aulast%3DChampness%26aufirst%3DE.%26aulast%3DLeeding%26aufirst%3DC.%26aulast%3DLilien%26aufirst%3DR.%26aulast%3DMettu%26aufirst%3DR.%26aulast%3DStevens%26aufirst%3DB.%26atitle%3DApplying%2520medicinal%2520chemistry%2520transformations%2520and%2520multiparameter%2520optimization%2520to%2520guide%2520the%2520search%2520for%2520high-quality%2520leads%2520and%2520candidates%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D2967%26epage%3D76%26doi%3D10.1021%2Fci2003208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lesko, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaschke, T. F.</span></span> <span> </span><span class="NLM_article-title">Optimizing the science of drug development: Opportunities for better candidate selection and accelerated evaluation in humans</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">814</span>, <span class="refDoi"> DOI: 10.1177/00912700022009530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1177%2F00912700022009530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10934664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlslartL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2000&pages=803-814&author=L.+J.+Leskoauthor=M.+Rowlandauthor=C.+C.+Peckauthor=T.+F.+Blaschke&title=Optimizing+the+science+of+drug+development%3A+Opportunities+for+better+candidate+selection+and+accelerated+evaluation+in+humans&doi=10.1177%2F00912700022009530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans</span></div><div class="casAuthors">Lesko, Lawrence J.; Rowland, Malcolm; Peck, Carl C.; Blaschke, Terrence F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">803-814</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review with 11 refs. Two international meetings were convened in 1998 to review the current science of drug development and the potential opportunities to optimize the evaluation of new drugs in humans.  This report represents a synopsis of these meetings and focuses on the current state of knowledge pertaining to drug development, future scientific and tech. needs, and the relative merits of various strategies intended to accelerate the clin. development of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXUNcruXyMEbVg90H21EOLACvtfcHk0lir1btqH4yH2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlslartL4%253D&md5=c5be137fa0b62ad04d4af9e2f386417d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1177%2F00912700022009530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F00912700022009530%26sid%3Dliteratum%253Aachs%26aulast%3DLesko%26aufirst%3DL.%2BJ.%26aulast%3DRowland%26aufirst%3DM.%26aulast%3DPeck%26aufirst%3DC.%2BC.%26aulast%3DBlaschke%26aufirst%3DT.%2BF.%26atitle%3DOptimizing%2520the%2520science%2520of%2520drug%2520development%253A%2520Opportunities%2520for%2520better%2520candidate%2520selection%2520and%2520accelerated%2520evaluation%2520in%2520humans%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2000%26volume%3D40%26spage%3D803%26epage%3D814%26doi%3D10.1177%2F00912700022009530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span> <span> </span><span class="NLM_article-title">Finding the sweet spot: The role of nature and nurture in medicinal chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1038/nrd3701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2Fnrd3701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=22543468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1GqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=355-65&author=M.+M.+Hannauthor=G.+M.+Keseru&title=Finding+the+sweet+spot%3A+The+role+of+nature+and+nurture+in+medicinal+chemistry&doi=10.1038%2Fnrd3701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Finding the sweet spot: the role of nature and nurture in medicinal chemistry</span></div><div class="casAuthors">Hann, Michael M.; Keserue, Gyoergy M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">355-365</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Given its position at the heart of small-mol. drug discovery, medicinal chem. has an important role in tackling the well-known productivity challenges in pharmaceutical research and development.  In recent years, extensive analyses of successful and failed discovery compds. and drug candidates have improved our understanding of the role of physicochem. properties in drug attrition.  Based on the clarified challenges in finding the 'sweet spot' in medicinal chem. programs, we suggest that this goal can be achieved through a combination of first identifying chem. starting points with appropriate 'nature' and then rigorously 'nurturing' them during lead optimization.  Here, we discuss scientific, strategic, organizational and cultural considerations for medicinal chem. practices, with the aim of promoting more effective use of what is already known, as well as a wider appreciation of the risks of pursuing suboptimal compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrURciGjB2A3LVg90H21EOLACvtfcHk0lir1btqH4yH2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1GqsLY%253D&md5=90170e3f4e69e52bfa38667df380516a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrd3701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3701%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DFinding%2520the%2520sweet%2520spot%253A%2520The%2520role%2520of%2520nature%2520and%2520nurture%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D355%26epage%3D65%26doi%3D10.1038%2Fnrd3701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ku, M. S.</span></span> <span> </span><span class="NLM_article-title">Use of the biopharmaceutical classification system in early drug development</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1208/s12248-008-9020-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1208%2Fs12248-008-9020-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=18446521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWrsLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=208-212&author=M.+S.+Ku&title=Use+of+the+biopharmaceutical+classification+system+in+early+drug+development&doi=10.1208%2Fs12248-008-9020-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Use of the biopharmaceutical classification system in early drug development</span></div><div class="casAuthors">Ku, M. Sherry</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">208-212</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is not only a useful tool for obtaining waivers for in-vivo bioequivalence studies but also for decision making in the discovery and early development of new drugs.  Measurement of soly. and permeability in the discovery/development settings is described.  These data can be utilized for the preliminary BCS classification of pipeline compds.  A decision tree is described in the prioritization of salt and polymorph screening studies prior to in vivo studies in animals.  For BCS class 1 and 3 compds., polymorphism is less likely to impact on bioavailability.  The polymorph screening study may be postponed after animal studies.  The BCS classification can also be used in the design of animal and human formulations.  A BCS-based animal formulation development decision tree is presented.  A compd. is triaged based on a series of decision points into one of the five formulation strategies.  Human formulation has different requirements than animal formulation.  A comparison between animal and human formulation strategies is presented.  In conclusion, for non-BCS 1 compds., the right-first-time polymorph and formulation selection ensures consistent pharmacokinetic performance and avoids bridging BA/BE studies.  It is in line with FDA's initiative to reduce R&D cycle time through quality by design for pharmaceutical products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbXmd3ljTTG7Vg90H21EOLACvtfcHk0liipi05Yb6RGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWrsLvJ&md5=36c90b50728cebbc1a178a634c952da3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1208%2Fs12248-008-9020-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-008-9020-0%26sid%3Dliteratum%253Aachs%26aulast%3DKu%26aufirst%3DM.%2BS.%26atitle%3DUse%2520of%2520the%2520biopharmaceutical%2520classification%2520system%2520in%2520early%2520drug%2520development%26jtitle%3DAAPS%2520J.%26date%3D2008%26volume%3D10%26spage%3D208%26epage%3D212%26doi%3D10.1208%2Fs12248-008-9020-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span> <span> </span><span class="NLM_article-title">Lead- and drug-like compounds: The rule-of-five revolution</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2004.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.ddtec.2004.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24981612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=337-41&author=C.+A.+Lipinski&title=Lead-+and+drug-like+compounds%3A+The+rule-of-five+revolution&doi=10.1016%2Fj.ddtec.2004.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Lead- and drug-like compounds: the rule-of-five revolution</span></div><div class="casAuthors">Lipinski, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-341</span>CODEN:
                <span class="NLM_cas:coden">DDTTB5</span>;
        ISSN:<span class="NLM_cas:issn">1740-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Citations in CAS SciFinder to the rule-of-five (RO5) publication will exceed 1000 by year-end 2004.  Trends in the RO5 literature explosion that can be discerned are the further definitions of drug-like.  This topic is explored in terms of drug-like physicochem. features, drug-like structural features, a comparison of drug-like and non-drug-like in drug discovery and a discussion of how drug-like features relate to clin. success.  Physicochem. features of CNS drugs and features related to CNS blood-brain transporter affinity are briefly reviewed.  Recent literature on features of non-oral drugs is reviewed and how features of lead-like compds. differ from those of drug-like compds. is discussed.  Most recently, partly driven by NIH roadmap initiatives, considerations have arisen as to what tool-like means in the search for chem. tools to probe biol. space.  All these topics frame the scope of this short review/perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnjiyP3CY7lLVg90H21EOLACvtfcHk0liipi05Yb6RGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D&md5=952c29b47003b884116d790ae9e4721f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2004.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2004.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26atitle%3DLead-%2520and%2520drug-like%2520compounds%253A%2520The%2520rule-of-five%2520revolution%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2004%26volume%3D1%26spage%3D337%26epage%3D41%26doi%3D10.1016%2Fj.ddtec.2004.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, B.</span></span> <span> </span><span class="NLM_article-title">Drug discovery beyond the ‘rule-of-five’</span>. <i>Curr. Opin. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">478</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1016/j.copbio.2007.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.copbio.2007.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=18035532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1cXislOkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=478-488&author=M.-Q.+Zhangauthor=B.+Wilkinson&title=Drug+discovery+beyond+the+%E2%80%98rule-of-five%E2%80%99&doi=10.1016%2Fj.copbio.2007.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery beyond the 'rule-of-five'</span></div><div class="casAuthors">Zhang, Ming-Qiang; Wilkinson, Barrie</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">478-488</span>CODEN:
                <span class="NLM_cas:coden">CUOBE3</span>;
        ISSN:<span class="NLM_cas:issn">0958-1669</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Although a very useful guideline for orally bioavailable small-mol. drug design, the 'rule-of-five' (also known as 'Lipinski's rule of drug-likeness') has to some extent been overemphasized.  Firstly, only 51% of all FDA-approved small-mol. drugs are both used orally and comply with the 'rule-of-five'.  This does not even include the increasing no. of biologicals of which several have reached blockbuster' status.  Secondly, it does not cover natural product and semisynthetic natural product drugs, which constitute over one-third of all marketed small-mol. drugs.  A more balanced and programmatic approach to drug discovery should be more productive than to rely on an overemphasis of 'rule-of-five' compliance.  Rather it should consider proactively the development of parenteral drugs in parallel to oral drugs and to consider the development of therapeutic antibodies in parallel to small-mol. drugs.  These are particularly relevant for efforts against 'first-in-class' and/or particularly challenging targets such as proteases and those involving protein-protein interactions.  In addn., more effort should be invested in natural product research.  Emerging novel technologies such as synthetic biol. (genetic engineering of living organisms to produce small-mol. therapeutics) may address several challenging issues of natural product-based drug discovery including synthetic feasibility and ligand efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGollnOuY9kGrbVg90H21EOLACvtfcHk0liipi05Yb6RGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXislOkug%253D%253D&md5=4121024557295c4f241255e43b43ea44</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.copbio.2007.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.copbio.2007.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.-Q.%26aulast%3DWilkinson%26aufirst%3DB.%26atitle%3DDrug%2520discovery%2520beyond%2520the%2520%25E2%2580%2598rule-of-five%25E2%2580%2599%26jtitle%3DCurr.%2520Opin.%2520Biotechnol.%26date%3D2007%26volume%3D18%26spage%3D478%26epage%3D488%26doi%3D10.1016%2Fj.copbio.2007.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aschmann, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatibovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, S.</span></span> <span> </span><span class="NLM_article-title">When barriers ignore the “rule-of-five</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2016.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.addr.2016.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26877103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XislSktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2016&pages=62-74&author=S.+D.+Kr%C3%A4merauthor=H.+E.+Aschmannauthor=M.+Hatibovicauthor=K.+F.+Hermannauthor=C.+S.+Neuhausauthor=C.+Brunnerauthor=S.+Belli&title=When+barriers+ignore+the+%E2%80%9Crule-of-five&doi=10.1016%2Fj.addr.2016.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">When barriers ignore the "rule-of-five"</span></div><div class="casAuthors">Kramer, Stefanie D.; Aschmann, Helene E.; Hatibovic, Maja; Hermann, Katharina F.; Neuhaus, Claudia S.; Brunner, Cyrill; Belli, Sara</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">62-74</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Why are a few drugs with properties beyond the rule of 5 (bRo5) absorbed across the intestinal mucosa while most other bRo5 compds. are not.  Are such exceptional bRo5 compds. exclusively taken up by carrier-mediated transport or are they able to permeate the lipid bilayer (passive lipoidal diffusion).  Our exptl. data with liposomes indicate that tetracycline, which violates one rule of the Ro5, and rifampicin, violating three of the rules, significantly permeate a phospholipid bilayer with kinetics similar to labetalol and metoprolol, resp.  Published data from exptl. work and mol. dynamics simulations suggest that the formation of intramol. H-bonds and the possibility to adopt an elongated shape besides the presence of a significant fraction of net neutral species facilitate lipid bilayer permeation.  As an alternative to lipid bilayer permeation, carrier proteins can be targeted to improve absorption, with the potential drawbacks of drug-drug interactions and non-linear pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVVuXZ5H2ClrVg90H21EOLACvtfcHk0li4KxlBiQOCVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XislSktLg%253D&md5=50ea288eae047ae4eb6e12e690b01692</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25A4mer%26aufirst%3DS.%2BD.%26aulast%3DAschmann%26aufirst%3DH.%2BE.%26aulast%3DHatibovic%26aufirst%3DM.%26aulast%3DHermann%26aufirst%3DK.%2BF.%26aulast%3DNeuhaus%26aufirst%3DC.%2BS.%26aulast%3DBrunner%26aufirst%3DC.%26aulast%3DBelli%26aufirst%3DS.%26atitle%3DWhen%2520barriers%2520ignore%2520the%2520%25E2%2580%259Crule-of-five%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D101%26spage%3D62%26epage%3D74%26doi%3D10.1016%2Fj.addr.2016.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
la Torre, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albericio, F.</span></span> <span> </span><span class="NLM_article-title">The pharmaceutical industry in 2018. An analysis of fda drug approvals from the perspective of molecules</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">809</span>, <span class="refDoi"> DOI: 10.3390/molecules24040809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3390%2Fmolecules24040809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30813407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlCrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=809&author=B.+G.+de%0Ala+Torreauthor=F.+Albericio&title=The+pharmaceutical+industry+in+2018.+An+analysis+of+fda+drug+approvals+from+the+perspective+of+molecules&doi=10.3390%2Fmolecules24040809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmaceutical industry in 2018. an analysis of FDA drug approvals from the perspective of molecules</span></div><div class="casAuthors">de la Torre, Beatriz G.; Albericio, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">809/1-809/12</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The Food and Drug Administration approved 59 new drugs (42 New Chem. Entities and 17 Biologics) during 2018.  This no. breaks the previous record of 53 approved by the same organization in 1996.  The 17 new biologics approved in 2018 also represent an important milestone for this kind of drug and they clearly exceed the 12 approved in 2015 and 2017.  Herein, the 59 new drugs of the class of 2018 are analyzed from a strictly chem. perspective.  The classification has been carried out on the basis of the chem. structure and includes the following: Biologics (antibodies and enzymes); TIDES (peptides and oligonucleotides) and natural products; drug combinations; and small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpl9Nat-uSwbVg90H21EOLACvtfcHk0li4KxlBiQOCVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlCrtLY%253D&md5=e61d944d90a38fead8920eef07be8246</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24040809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24040809%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2Bla%2BTorre%26aufirst%3DB.%2BG.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DThe%2520pharmaceutical%2520industry%2520in%25202018.%2520An%2520analysis%2520of%2520fda%2520drug%2520approvals%2520from%2520the%2520perspective%2520of%2520molecules%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D809%26doi%3D10.3390%2Fmolecules24040809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griesenauer, R. H.</span></span> <span> </span><span class="NLM_article-title">2018 in review: Fda approvals of new molecular entities</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1710</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2019.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.drudis.2019.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31158510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3M3islWkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1710-1714&author=M.+S.+Kinchauthor=R.+H.+Griesenauer&title=2018+in+review%3A+Fda+approvals+of+new+molecular+entities&doi=10.1016%2Fj.drudis.2019.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">2018 in review: FDA approvals of new molecular entities</span></div><div class="casAuthors">Kinch Michael S; Griesenauer Rebekah H</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1710-1714</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">2018 was a remarkable year, both in terms of the number of new molecular entities (NMEs) approved and the organizations developing them.  In total, 59 NMEs received a nod from the US Food and Drug Administration (FDA), most of which were approved using a priority or breakthrough designation.  Orphan drugs accounted for more than half of new approvals, only the second time in history that level has been achieved.  Moreover, the net number of organizations that received an FDA approval and remain active in new drug research surged in 2018, reflecting both an increase in new organizations and lower levels of industry consolidation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiF58qvHS5Zhcr74wzj5o5fW6udTcc2eYCmmsgCmyDlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3islWkug%253D%253D&md5=4d8695208eff16156df8023f54817cca</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2019.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2019.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DGriesenauer%26aufirst%3DR.%2BH.%26atitle%3D2018%2520in%2520review%253A%2520Fda%2520approvals%2520of%2520new%2520molecular%2520entities%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2019%26volume%3D24%26spage%3D1710%26epage%3D1714%26doi%3D10.1016%2Fj.drudis.2019.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umlauf, S.</span></span> <span> </span><span class="NLM_article-title">Trends in pharmaceutical targeting of clinical indications: 1930–2013</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1682</span>– <span class="NLM_lpage">1685</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.drudis.2014.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24881779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cjns1yhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1682-1685&author=M.+S.+Kinchauthor=J.+Merkelauthor=S.+Umlauf&title=Trends+in+pharmaceutical+targeting+of+clinical+indications%3A+1930%E2%80%932013&doi=10.1016%2Fj.drudis.2014.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in pharmaceutical targeting of clinical indications: 1930-2013</span></div><div class="casAuthors">Kinch Michael S; Merkel Janie; Umlauf Sheila</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1682-1685</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">An analysis of FDA-approved new molecular entities (NMEs) reveals trends in therapeutic applications.  Four groupings (infectious diseases, cardiovascular diseases, autoimmune/inflammatory diseases and cancer) capture more than 60% of NMEs.  Infectious diseases are the most targeted indications.  Near the turn of the new millennium, the rate of new approvals for infectious diseases decreased.  The absolute and relative number of NMEs targeting psychiatric, neurological and pain/itch indications also declined.  By contrast, NMEs targeting cancer have risen in the past two decades as have NMEs targeting orphan indications.  These results suggest the drug development community has largely been responsive to public health and market needs.  However, finite resources might indicate emphasis on some unmet needs could come at the cost of others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQiuwfyx4RSHpp6t8nS6Nc3fW6udTcc2eab3ZNWjyf087ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjns1yhsA%253D%253D&md5=af70b7b3d4945e22574e6a3310ff5199</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DMerkel%26aufirst%3DJ.%26aulast%3DUmlauf%26aufirst%3DS.%26atitle%3DTrends%2520in%2520pharmaceutical%2520targeting%2520of%2520clinical%2520indications%253A%25201930%25E2%2580%25932013%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1682%26epage%3D1685%26doi%3D10.1016%2Fj.drudis.2014.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uttley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Indave, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokuhetty, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cree, I.</span></span> <span> </span><span class="NLM_article-title">Invited commentary—who classification of tumours: How should tumors be classified? Expert consensus, systematic reviews or both?</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">3516</span>– <span class="NLM_lpage">3521</span>, <span class="refDoi"> DOI: 10.1002/ijc.32975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fijc.32975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=32170735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtFWjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2020&pages=3516-3521&author=L.+Uttleyauthor=B.+I.+Indaveauthor=C.+Hydeauthor=V.+Whiteauthor=D.+Lokuhettyauthor=I.+Cree&title=Invited+commentary%E2%80%94who+classification+of+tumours%3A+How+should+tumors+be+classified%3F+Expert+consensus%2C+systematic+reviews+or+both%3F&doi=10.1002%2Fijc.32975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Invited commentary-WHO Classification of Tumours: How should tumors be classified? Expert consensus, systematic reviews or both?</span></div><div class="casAuthors">Uttley, Lesley; Indave, Blanca Iciar; Hyde, Chris; White, Valerie; Lokuhetty, Dilani; Cree, Ian</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3516-3521</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj9uc9VbJ9jrVg90H21EOLACvtfcHk0lg0WxPswiy6MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtFWjsrk%253D&md5=033515255591cf015adf0fa7478e0999</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fijc.32975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.32975%26sid%3Dliteratum%253Aachs%26aulast%3DUttley%26aufirst%3DL.%26aulast%3DIndave%26aufirst%3DB.%2BI.%26aulast%3DHyde%26aufirst%3DC.%26aulast%3DWhite%26aufirst%3DV.%26aulast%3DLokuhetty%26aufirst%3DD.%26aulast%3DCree%26aufirst%3DI.%26atitle%3DInvited%2520commentary%25E2%2580%2594who%2520classification%2520of%2520tumours%253A%2520How%2520should%2520tumors%2520be%2520classified%253F%2520Expert%2520consensus%252C%2520systematic%2520reviews%2520or%2520both%253F%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2020%26volume%3D146%26spage%3D3516%26epage%3D3521%26doi%3D10.1002%2Fijc.32975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rhoads, C. P.</span></span> <span> </span><span class="NLM_article-title">Nitrogen mustards in the treatment of neoplastic disease; official statement</span>. <i>J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">1946</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">656</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1001/jama.1946.02870250010003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1001%2Fjama.1946.02870250010003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=20984885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADyaH28%252Fgt12qsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=1946&pages=656-8&author=C.+P.+Rhoads&title=Nitrogen+mustards+in+the+treatment+of+neoplastic+disease%3B+official+statement&doi=10.1001%2Fjama.1946.02870250010003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrogen mustards in the treatment of neoplastic disease; official statement</span></div><div class="casAuthors">RHOADS C P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">1946</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">656-8</span>
        ISSN:<span class="NLM_cas:issn">0002-9955</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRY1FrpuF4Me_Q9URG6Dx8fW6udTcc2eab3ZNWjyf087ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaH28%252Fgt12qsg%253D%253D&md5=08cf6c1698790fadab3b26e2d9df565d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1001%2Fjama.1946.02870250010003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.1946.02870250010003%26sid%3Dliteratum%253Aachs%26aulast%3DRhoads%26aufirst%3DC.%2BP.%26atitle%3DNitrogen%2520mustards%2520in%2520the%2520treatment%2520of%2520neoplastic%2520disease%253B%2520official%2520statement%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D1946%26volume%3D131%26spage%3D656%26epage%3D8%26doi%3D10.1001%2Fjama.1946.02870250010003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chabner, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. G.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Timeline: Chemotherapy and the war on cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1038/nrc1529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2Fnrc1529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=15630416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVek" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=65-72&author=B.+A.+Chabnerauthor=T.+G.+Roberts&title=Timeline%3A+Chemotherapy+and+the+war+on+cancer&doi=10.1038%2Fnrc1529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy and the war on cancer</span></div><div class="casAuthors">Chabner, Bruce A.; Roberts, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-72</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The era of chemotherapy began in the 1940s with the first uses of nitrogen mustards and antifolate drugs.  Cancer drug development since then has transformed from a low-budget, government-supported research effort to a high-stakes, multi-billion dollar industry.  The targeted-therapy revolution has arrived, but the principles and limitations of chemotherapy discovered by the early researchers still apply.  This article chronicles the history of modern chemotherapy and identifies remaining challenges for the next generation of researchers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrszgbuDuTBobVg90H21EOLACvtfcHk0lhqgSnXWvhjjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVek&md5=d5c8b3dba59b9d6dcca473552525fa14</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrc1529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1529%26sid%3Dliteratum%253Aachs%26aulast%3DChabner%26aufirst%3DB.%2BA.%26aulast%3DRoberts%26aufirst%3DT.%2BG.%26atitle%3DTimeline%253A%2520Chemotherapy%2520and%2520the%2520war%2520on%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D65%26epage%3D72%26doi%3D10.1038%2Fnrc1529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvat, T. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L. A.</span></span> <span> </span><span class="NLM_article-title">Venetoclax: A first-in-class oral bcl-2 inhibitor for the management of lymphoid malignancies</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1177/1060028016685803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1177%2F1060028016685803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28056525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltVOrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2017&pages=410-416&author=A.+C.+Kingauthor=T.+J.+Petersonauthor=T.+Z.+Horvatauthor=M.+Rodriguezauthor=L.+A.+Tang&title=Venetoclax%3A+A+first-in-class+oral+bcl-2+inhibitor+for+the+management+of+lymphoid+malignancies&doi=10.1177%2F1060028016685803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies</span></div><div class="casAuthors">King, Amber C.; Peterson, Tim J.; Horvat, Troy Z.; Rodriguez, Mabel; Tang, Laura A.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">410-416</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1542-6270</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Objective: To review the pharmacol., efficacy, and safety of venetoclax for treatment of lymphoid malignancies.  Data Sources: A literature search was performed of PubMed and MEDLINE databases (2005 to Sept. 2016), abstrs. from the American Society of Hematol. and the American Society of Clin. Oncol., and ongoing studies from clinicaltrials.gov.  Searches were performed utilizing the following key terms: venetoclax, ABT-199, GDC-199, obatoclax, GX15-070, BCL-2 inhibitor, navitoclax, ABT-263, and Venclexta.  Study Selection/Data Extn.: Studies of pharmacol., pharmacokinetics, pharmacodynamics, clin. efficacy, and safety of venetoclax in lymphoid malignancies were identified.  Data Synthesis: Recently, treatment of B-cell lymphoproliferative disorders has shifted from conventional cytotoxic chemotherapy to novel small-mol. inhibitors.  The advent of recently Food and Drug Administration-approved oral agents ibrutinib and idelalisib has shifted the paradigm of chronic lymphocytic leukemia (CLL) treatment; however, complete remission is uncommon, and the outcome for patients progressing on these treatments remains poor.  Attention has been focused on a novel target, the B-cell lymphoma-2 protein (BCL-2), which serves an essential role in regulation of apoptosis.  Venetoclax has demonstrated efficacy in multiple subtypes of lymphoid malignancies, including patients with relapsed/refractory CLL harboring deletion 17p, with an overall response rate of nearly 80%.  Venetoclax is generally well tolerated, with the significant adverse effect being tumor lysis syndrome, for which there are formal management recommendations.  Conclusion: Venetoclax has demonstrated promising results in relapsed/refractory lymphoid malignancies, with an acceptable adverse effect profile.  As the role of BCL-2 inhibition in various malignancies becomes further elucidated, venetoclax may offer benefit to a myriad other patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1YxzHJT0xvbVg90H21EOLACvtfcHk0lhqgSnXWvhjjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltVOrug%253D%253D&md5=e8ad4539c2e09fda834e280f6545b923</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1177%2F1060028016685803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028016685803%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DA.%2BC.%26aulast%3DPeterson%26aufirst%3DT.%2BJ.%26aulast%3DHorvat%26aufirst%3DT.%2BZ.%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DL.%2BA.%26atitle%3DVenetoclax%253A%2520A%2520first-in-class%2520oral%2520bcl-2%2520inhibitor%2520for%2520the%2520management%2520of%2520lymphoid%2520malignancies%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2017%26volume%3D51%26spage%3D410%26epage%3D416%26doi%3D10.1177%2F1060028016685803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milling, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, D. J.</span></span> <span> </span><span class="NLM_article-title">Delivering safer immunotherapies for cancer</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2017.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.addr.2017.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28545888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVantLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=79-101&author=L.+Millingauthor=Y.+Zhangauthor=D.+J.+Irvine&title=Delivering+safer+immunotherapies+for+cancer&doi=10.1016%2Fj.addr.2017.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Delivering safer immunotherapies for cancer</span></div><div class="casAuthors">Milling, Lauren; Zhang, Yuan; Irvine, Darrell J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">79-101</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cancer immunotherapy is now a powerful clin. reality, with a steady progression of new drug approvals and a massive pipeline of addnl. treatments in clin. and preclin. development.  However, modulation of the immune system can be a double-edged sword: Drugs that activate immune effectors are prone to serious non-specific systemic inflammation and autoimmune side effects.  Drug delivery technologies have an important role to play in harnessing the power of immune therapeutics while avoiding on-target/off-tumor toxicities.  Here we review mechanisms of toxicity for clin.-relevant immunotherapeutics, and discuss approaches based in drug delivery technol. to enhance the safety and potency of these treatments.  These include strategies to merge drug delivery with adoptive cellular therapies, targeting immunotherapies to tumors or select immune cells, and localizing therapeutics intratumorally.  Rational design employing lessons learned from the drug delivery and nanomedicine fields has the potential to facilitate immunotherapy reaching its full potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDwnWn29KSE7Vg90H21EOLACvtfcHk0lhqgSnXWvhjjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVantLnO&md5=cce2ffe51f1cfb8b88671b1458f35b01</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2017.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2017.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DMilling%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DIrvine%26aufirst%3DD.%2BJ.%26atitle%3DDelivering%2520safer%2520immunotherapies%2520for%2520cancer%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2017%26volume%3D114%26spage%3D79%26epage%3D101%26doi%3D10.1016%2Fj.addr.2017.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighton, J. K.</span></span> <span> </span><span class="NLM_article-title">An FDA oncology analysis of antibody-drug conjugates</span>. <i>Regul. Toxicol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/j.yrtph.2015.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.yrtph.2015.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25661711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisF2rsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=444-52&author=H.+Saberauthor=J.+K.+Leighton&title=An+FDA+oncology+analysis+of+antibody-drug+conjugates&doi=10.1016%2Fj.yrtph.2015.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">An FDA oncology analysis of antibody-drug conjugates</span></div><div class="casAuthors">Saber, Haleh; Leighton, John K.</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Toxicology and Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">444-452</span>CODEN:
                <span class="NLM_cas:coden">RTOPDW</span>;
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are complex mols. composed of monoclonal antibodies conjugated to potent cytotoxic agents through chem. linkers.  Because of this complexity, sponsors have used different approaches for the design of nonclin. studies to support the safety evaluation of ADCs and first-in-human (FIH) dose selection.  We analyzed this data with the goal of describing the relationship between nonclin. study results and Phase 1 study outcomes.  We summarized the following data from investigational new drug applications (INDs) for ADCs: plasma stability, animal study designs and toxicities, and algorithms used for FIH dose selection.  Our review found that selecting a FIH dose that is 1/6th the highest non-severely toxic dose (HNSTD) in cynomolgus monkeys or 1/10th the STD10 in rodents scaled according to body surface area (BSA) generally resulted in the acceptable balance of safety and efficient dose-escalation in a Phase 1 trial.  Other approaches may also be acceptable, e.g. 1/10th the HNSTD in monkeys using BSA or 1/10th the NOAEL in monkeys or rodents using body wt. for scaling.  While the animal data for the vc-MMAE platform yielded variable range of HNSTDs in cynomolgus monkeys, MTDs were in a narrow range in patients, suggesting that for ADCs sharing the same small mol. drug, linker and drug:antibody ratio, prior clin. data can inform the design of a Phase 1 clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouNKxNbn4b6rVg90H21EOLACvtfcHk0liFMhVsoasgYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisF2rsrY%253D&md5=513d5d669e869260ceb67a4419f5b208</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.yrtph.2015.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yrtph.2015.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DLeighton%26aufirst%3DJ.%2BK.%26atitle%3DAn%2520FDA%2520oncology%2520analysis%2520of%2520antibody-drug%2520conjugates%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2015%26volume%3D71%26spage%3D444%26epage%3D52%26doi%3D10.1016%2Fj.yrtph.2015.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates: An emerging concept in cancer therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3796</span>– <span class="NLM_lpage">3827</span>, <span class="refDoi"> DOI: 10.1002/anie.201307628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fanie.201307628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=3796-3827&author=R.+V.+Chariauthor=M.+L.+Millerauthor=W.+C.+Widdison&title=Antibody-drug+conjugates%3A+An+emerging+concept+in+cancer+therapy&doi=10.1002%2Fanie.201307628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy</span></div><div class="casAuthors">Chari, Ravi V. J.; Miller, Michael L.; Widdison, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3796-3827</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Traditional cancer chemotherapy is often accompanied by systemic toxicity to the patient.  Monoclonal antibodies against antigens on cancer cells offer an alternative tumor-selective treatment approach.  However, most monoclonal antibodies are not sufficiently potent to be therapeutically active on their own.  Antibody-drug conjugates (ADCs) use antibodies to deliver a potent cytotoxic compd. selectively to tumor cells, thus improving the therapeutic index of chemotherapeutic agents.  The recent approval of two ADCs, brentuximab vedotin and ado-trastuzumab emtansine, for cancer treatment has spurred tremendous research interest in this field.  This Review touches upon the early efforts in the field, and describes how the lessons learned from the first-generation ADCs have led to improvements in every aspect of this technol., i.e., the antibody, the cytotoxic compd., and the linker connecting them, leading to the current successes.  The design of ADCs currently in clin. development, and results from mechanistic studies and preclin. and clin. evaluation are discussed.  Emerging technologies that seek to further advance this exciting area of research are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4T2rhmji6DLVg90H21EOLACvtfcHk0liFMhVsoasgYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D&md5=fbfb2f843f516654ea7c0eb98949604c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307628%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DAntibody-drug%2520conjugates%253A%2520An%2520emerging%2520concept%2520in%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D3796%26epage%3D3827%26doi%3D10.1002%2Fanie.201307628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alley, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okeley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates: Targeted drug delivery for cancer</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2010.06.170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.cbpa.2010.06.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=20643572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=529-537&author=S.+C.+Alleyauthor=N.+M.+Okeleyauthor=P.+D.+Senter&title=Antibody-drug+conjugates%3A+Targeted+drug+delivery+for+cancer&doi=10.1016%2Fj.cbpa.2010.06.170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates: Targeted drug delivery for cancer</span></div><div class="casAuthors">Alley, Stephen C.; Okeley, Nicole M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-537</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The antibody-drug conjugate field has made significant progress recently owing to careful optimization of several parameters, including mAb specificity, drug potency, linker technol., and the stoichiometry and placement of conjugated drugs.  The underlying reason for this was obtained in pre-clin. biodistribution and pharmacokinetics studies showing that targeted delivery leads to high intratumoral free drug concns., while non-target tissues are largely spared from chemotherapeutic exposure.  Recent developments in the field have led to an increase in the no. of ADCs being tested clin., with 3 in late stage clin. trials: Brentuximab vedotin (also referred to as SGN-35) for Hodgkin lymphoma; Trastuzumab-DM1 for breast cancer; and Inotuzumab ozogamicin for non-Hodgkin lymphoma.  This review highlights the recent pre-clin. and clin. advances that have been made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-9ugy8pi8C7Vg90H21EOLACvtfcHk0liFMhVsoasgYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtrY%253D&md5=ace266066ea07d49d0e0b4338b48eeb3</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.170%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DAntibody-drug%2520conjugates%253A%2520Targeted%2520drug%2520delivery%2520for%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D529%26epage%3D537%26doi%3D10.1016%2Fj.cbpa.2010.06.170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skvortsova, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span> <span> </span><span class="NLM_article-title">Editorial: Recent trends in anticancer drug development: Challenges and opportunities</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4727</span>– <span class="NLM_lpage">4728</span>, <span class="refDoi"> DOI: 10.2174/092986732442180111141255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2174%2F092986732442180111141255" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=4727-4728&author=I.+I.+Skvortsovaauthor=V.+Kumar&title=Editorial%3A+Recent+trends+in+anticancer+drug+development%3A+Challenges+and+opportunities&doi=10.2174%2F092986732442180111141255"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2174%2F092986732442180111141255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986732442180111141255%26sid%3Dliteratum%253Aachs%26aulast%3DSkvortsova%26aufirst%3DI.%2BI.%26aulast%3DKumar%26aufirst%3DV.%26atitle%3DEditorial%253A%2520Recent%2520trends%2520in%2520anticancer%2520drug%2520development%253A%2520Challenges%2520and%2520opportunities%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2018%26volume%3D24%26spage%3D4727%26epage%3D4728%26doi%3D10.2174%2F092986732442180111141255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertram, J. S.</span></span> <span> </span><span class="NLM_article-title">The molecular biology of cancer</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/S0098-2997(00)00007-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS0098-2997%2800%2900007-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=11173079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BD3M3lvVamtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=167-223&author=J.+S.+Bertram&title=The+molecular+biology+of+cancer&doi=10.1016%2FS0098-2997%2800%2900007-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular biology of cancer</span></div><div class="casAuthors">Bertram J S</div><div class="citationInfo"><span class="NLM_cas:title">Molecular aspects of medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">167-223</span>
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    </div><div class="casAbstract">The process by which normal cells become progressively transformed to malignancy is now known to require the sequential acquisition of mutations which arise as a consequence of damage to the genome.  This damage can be the result of endogenous processes such as errors in replication of DNA, the intrinsic chemical instability of certain DNA bases or from attack by free radicals generated during metabolism.  DNA damage can also result from interactions with exogenous agents such as ionizing radiation, UV radiation and chemical carcinogens.  Cells have evolved means to repair such damage, but for various reasons errors occur and permanent changes in the genome, mutations, are introduced.  Some inactivating mutations occur in genes responsible for maintaining genomic integrity facilitating the acquisition of additional mutations.  This review seeks first to identify sources of mutational damage so as to identify the basic causes of human cancer.  Through an understanding of cause, prevention may be possible.  The evolution of the normal cell to a malignant one involves processes by which genes involved in normal homeostatic mechanisms that control proliferation and cell death suffer mutational damage which results in the activation of genes stimulating proliferation or protection against cell death, the oncogenes, and the inactivation of genes which would normally inhibit proliferation, the tumor suppressor genes.  Finally, having overcome normal controls on cell birth and cell death, an aspiring cancer cell faces two new challenges: it must overcome replicative senescence and become immortal and it must obtain adequate supplies of nutrients and oxygen to maintain this high rate of proliferation.  This review examines the process of the sequential acquisition of mutations from the prospective of Darwinian evolution.  Here, the fittest cell is one that survives to form a new population of genetically distinct cells, the tumor.  This review does not attempt to be comprehensive but identifies key genes directly involved in carcinogenesis and demonstrates how mutations in these genes allow cells to circumvent cellular controls.  This detailed understanding of the process of carcinogenesis at the molecular level has only been possible because of the advent of modern molecular biology.  This new discipline, by precisely identifying the molecular basis of the differences between normal and malignant cells, has created novel opportunities and provided the means to specifically target these modified genes.  Whenever possible this review highlights these opportunities and the attempts being made to generate novel, molecular based therapies against cancer.  Successful use of these new therapies will rely upon a detailed knowledge of the genetic defects in individual tumors.  The review concludes with a discussion of how the use of high throughput molecular arrays will allow the molecular pathologist/therapist to identify these defects and direct specific therapies to specific mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuS4iTaGZIQQHqQV89nF-2fW6udTcc2eYRWPAdgjLxvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3lvVamtA%253D%253D&md5=1fef8a6d810061992b8509353f9e0293</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0098-2997%2800%2900007-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0098-2997%252800%252900007-8%26sid%3Dliteratum%253Aachs%26aulast%3DBertram%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520molecular%2520biology%2520of%2520cancer%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2000%26volume%3D21%26spage%3D167%26epage%3D223%26doi%3D10.1016%2FS0098-2997%2800%2900007-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeBerardinis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. B.</span></span> <span> </span><span class="NLM_article-title">The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2007.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.cmet.2007.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=18177721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=11-20&author=R.+J.+DeBerardinisauthor=J.+J.+Lumauthor=G.+Hatzivassiliouauthor=C.+B.+Thompson&title=The+biology+of+cancer%3A+Metabolic+reprogramming+fuels+cell+growth+and+proliferation&doi=10.1016%2Fj.cmet.2007.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The biology of cancer: metabolic reprogramming fuels cell growth and proliferation</span></div><div class="casAuthors">DeBerardinis, Ralph J.; Lum, Julian J.; Hatzivassiliou, Georgia; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-20</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Cell proliferation requires nutrients, energy and biosynthetic activity to duplicate all macromol. components during each passage through the cell cycle.  It is therefore not surprising that metabolic activities in proliferating cells are fundamentally different from those of nonproliferating cells.  This review examines the idea that several core fluxes, including aerobic glycolysis, de novo lipid biosynthesis, and glutamine-dependent anaplerosis, form a stereotyped platform supporting proliferation of diverse cell types.  We also consider regulation of theses fluxes by cellular mediators of signaling and gene expression, including PI3K/Akt/mTOR system, HIF-1, and Myc, during physiol. cell proliferation and tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6L6_Q7sR9HLVg90H21EOLACvtfcHk0ljnD2rfzI936w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFSnsg%253D%253D&md5=59f193a636a840cde3044da9e08f62e7</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2007.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2007.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DDeBerardinis%26aufirst%3DR.%2BJ.%26aulast%3DLum%26aufirst%3DJ.%2BJ.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DThe%2520biology%2520of%2520cancer%253A%2520Metabolic%2520reprogramming%2520fuels%2520cell%2520growth%2520and%2520proliferation%26jtitle%3DCell%2520Metab.%26date%3D2008%26volume%3D7%26spage%3D11%26epage%3D20%26doi%3D10.1016%2Fj.cmet.2007.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craighead, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Economides, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, J.</span></span> <span> </span><span class="NLM_article-title">Clinical development success rates for investigational drugs</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1038/nbt.2786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2Fnbt.2786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24406927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=40-51&author=M.+Hayauthor=D.+W.+Thomasauthor=J.+L.+Craigheadauthor=C.+Economidesauthor=J.+Rosenthal&title=Clinical+development+success+rates+for+investigational+drugs&doi=10.1038%2Fnbt.2786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development success rates for investigational drugs</span></div><div class="casAuthors">Hay, Michael; Thomas, David W.; Craighead, John L.; Economides, Celia; Rosenthal, Jesse</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-51</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The most comprehensive survey of clin. success rates across the drug industry to date shows productivity may be even lower than previous ests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdqyRgsoFYDbVg90H21EOLACvtfcHk0ljnD2rfzI936w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFyjsA%253D%253D&md5=87a63ec8d8bb213b3d42519395725038</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2786%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DD.%2BW.%26aulast%3DCraighead%26aufirst%3DJ.%2BL.%26aulast%3DEconomides%26aufirst%3DC.%26aulast%3DRosenthal%26aufirst%3DJ.%26atitle%3DClinical%2520development%2520success%2520rates%2520for%2520investigational%2520drugs%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26spage%3D40%26epage%3D51%26doi%3D10.1038%2Fnbt.2786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DiMasi, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, H. G.</span></span> <span> </span><span class="NLM_article-title">Economics of new oncology drug development</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1200/JCO.2006.09.0803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1200%2FJCO.2006.09.0803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=17210942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FhsVCisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=209-16&author=J.+A.+DiMasiauthor=H.+G.+Grabowski&title=Economics+of+new+oncology+drug+development&doi=10.1200%2FJCO.2006.09.0803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Economics of new oncology drug development</span></div><div class="casAuthors">DiMasi Joseph A; Grabowski Henry G</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Review existing studies and provide new results on the development, regulatory, and market aspects of new oncology drug development.  METHODS:  We utilized data from the US Food and Drug Administration (FDA), company surveys, and publicly available commercial business intelligence databases on new oncology drugs approved in the United States and on investigational oncology drugs to estimate average development and regulatory approval times, clinical approval success rates, first-in-class status, and global market diffusion.  RESULTS:  We found that approved new oncology drugs to have a disproportionately high share of FDA priority review ratings, of orphan drug designations at approval, and of drugs that were granted inclusion in at least one of the FDA's expedited access programs.  US regulatory approval times were shorter, on average, for oncology drugs (0.5 years), but US clinical development times were longer on average (1.5 years).  Clinical approval success rates were similar for oncology and other drugs, but proportionately more of the oncology failures reached expensive late-stage clinical testing before being abandoned.  In relation to other drugs, new oncology drug approvals were more often first-in-class and diffused more widely across important international markets.  CONCLUSION:  The market success of oncology drugs has induced a substantial amount of investment in oncology drug development in the last decade or so.  However, given the great need for further progress, the extent to which efforts to develop new oncology drugs will grow depends on future public-sector investment in basic research, developments in translational medicine, and regulatory reforms that advance drug-development science.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRW5CNVotEHwq-9TkgmBqTqfW6udTcc2eZQvuAIrnLfGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FhsVCisg%253D%253D&md5=5afbbdf18918c328552d25a50e4e904d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.09.0803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.09.0803%26sid%3Dliteratum%253Aachs%26aulast%3DDiMasi%26aufirst%3DJ.%2BA.%26aulast%3DGrabowski%26aufirst%3DH.%2BG.%26atitle%3DEconomics%2520of%2520new%2520oncology%2520drug%2520development%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26spage%3D209%26epage%3D16%26doi%3D10.1200%2FJCO.2006.09.0803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jardim, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groves, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitfeld, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span> <span> </span><span class="NLM_article-title">Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2016.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.ctrv.2016.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=27883925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2sjgtVyqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2017&pages=12-21&author=D.+L.+Jardimauthor=E.+S.+Grovesauthor=P.+P.+Breitfeldauthor=R.+Kurzrock&title=Factors+associated+with+failure+of+oncology+drugs+in+late-stage+clinical+development%3A+A+systematic+review&doi=10.1016%2Fj.ctrv.2016.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review</span></div><div class="casAuthors">Jardim Denis L; Groves Eric S; Breitfeld Philip P; Kurzrock Razelle</div><div class="citationInfo"><span class="NLM_cas:title">Cancer treatment reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  We aimed to describe the reasons for failure of experimental anticancer drugs in late-stage clinical development.  MATERIAL AND METHODS:  We searched the PharmaProjects database (https://citeline.com/products/pharmaprojects/) for anticancer drugs discontinued between 01/01/2009 and 06/30/2014.  Drug programs that reached phase III trials, but never gained Food and Drug Administration (FDA) approval were compared to 37 anti-cancer drugs achieving FDA approval in this time period.  RESULTS:  Forty-two drugs fit our criteria for development failures.  These failed drugs (49% targeted, 23% cytotoxics, and 28% other) were tested in 43 cancer indications (drug programs).  Only 16% (7/43) of failed drug programs adopted a biomarker-driven rationale for patient selection versus 57% (21/37) of successful drug programs (P<0.001).  Phase II trial information was available in 32 of 43 failed drug programs and in 32 of 37 successful programs.  Nine of the 32 trials (28%) of failed drugs versus 28 of 32 trials (87%) of successful drugs (P<0.001) achieved proof of concept (single agent response rate (RR)  20% or combination therapy showing a  20% RR increase above the median historical RR without the experimental agent (with a minimal absolute increase of 5%) or a randomized phase II trial showing significance (P 0.05) for its primary outcome).  No pattern of study sites, trial design or funding characteristics emerged from the failed drug analysis.  CONCLUSION:  For drugs that reached Phase III, lack of a biomarker-driven strategy and failure to attain proof of concept in phase II are potential risk factors for later discontinuation, especially for targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUXYoeDs7cUMzK395ZObgVfW6udTcc2eZQvuAIrnLfGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjgtVyqug%253D%253D&md5=db7a5acfd7b471292f35e8447815d9aa</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2016.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2016.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DJardim%26aufirst%3DD.%2BL.%26aulast%3DGroves%26aufirst%3DE.%2BS.%26aulast%3DBreitfeld%26aufirst%3DP.%2BP.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DFactors%2520associated%2520with%2520failure%2520of%2520oncology%2520drugs%2520in%2520late-stage%2520clinical%2520development%253A%2520A%2520systematic%2520review%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2017%26volume%3D52%26spage%3D12%26epage%3D21%26doi%3D10.1016%2Fj.ctrv.2016.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of cancer drug resistance</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1146/annurev.med.53.082901.103929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1146%2Fannurev.med.53.082901.103929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=11818492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD38Xitl2mtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2002&pages=615-27&author=M.+M.+Gottesman&title=Mechanisms+of+cancer+drug+resistance&doi=10.1146%2Fannurev.med.53.082901.103929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of cancer drug resistance</span></div><div class="casAuthors">Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">615-627</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer.  Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumors, even those from the same tissue of origin.  Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common.  The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance.  Studies on mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquuMAtOcoDfbVg90H21EOLACvtfcHk0ljpe9W8dWpPHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xitl2mtLo%253D&md5=8f442a5c749266ad76ad7c7406a4e611</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.53.082901.103929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.53.082901.103929%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DMechanisms%2520of%2520cancer%2520drug%2520resistance%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2002%26volume%3D53%26spage%3D615%26epage%3D27%26doi%3D10.1146%2Fannurev.med.53.082901.103929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span> </span><span class="NLM_article-title">Global oncology/cancer drugs market overview</span>. <a href="https://www.blueweaveconsulting.com/global-oncology-cancer-drugs-market-bwc19381" class="extLink">https://www.blueweaveconsulting.com/global-oncology-cancer-drugs-market-bwc19381</a> (accessed Nov 24, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global+oncology%2Fcancer+drugs+market+overview.+https%3A%2F%2Fwww.blueweaveconsulting.com%2Fglobal-oncology-cancer-drugs-market-bwc19381+%28accessed+Nov+24%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGlobal%2520oncology%252Fcancer%2520drugs%2520market%2520overview%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span> </span><span class="NLM_article-title">Neurological
disorders: Public health challenges</span>. <a href="https://www.who.int/mental_health/neurology/neurodiso/en/" class="extLink">https://www.who.int/mental_health/neurology/neurodiso/en/</a> (accessed Nov 23, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Neurological%0Adisorders%3A+Public+health+challenges.+https%3A%2F%2Fwww.who.int%2Fmental_health%2Fneurology%2Fneurodiso%2Fen%2F+%28accessed+Nov+23%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNeurological%250Adisorders%253A%2520Public%2520health%2520challenges%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feigin, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owolabi, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dichgans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuschl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brainin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C.</span></span> <span> </span><span class="NLM_article-title">The global burden of neurological disorders: Translating evidence into policy</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(19)30411-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS1474-4422%2819%2930411-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31813850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3MfnvVWgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=255-265&author=V.+L.+Feiginauthor=T.+Vosauthor=E.+Nicholsauthor=M.+O.+Owolabiauthor=W.+M.+Carrollauthor=M.+Dichgansauthor=G.+Deuschlauthor=P.+Parmarauthor=M.+Braininauthor=C.+Murray&title=The+global+burden+of+neurological+disorders%3A+Translating+evidence+into+policy&doi=10.1016%2FS1474-4422%2819%2930411-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The global burden of neurological disorders: translating evidence into policy</span></div><div class="casAuthors">Feigin Valery L; Vos Theo; Nichols Emma; Murray Christopher; Owolabi Mayowa O; Carroll William M; Dichgans Martin; Deuschl Gunther; Parmar Priya; Brainin Michael</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-265</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neurological disorders are the leading cause of disability and the second leading cause of death worldwide.  In the past 30 years, the absolute numbers of deaths and people with disabilities owing to neurological diseases have risen substantially, particularly in low-income and middle-income countries, and further increases are expected globally as a result of population growth and ageing.  This rise in absolute numbers of people affected suggests that advances in prevention and management of major neurological disorders are not sufficiently effective to counter global demographic changes.  Urgent measures to reduce this burden are therefore needed.  Because resources for health care and research are already overstretched, priorities need to be set to guide policy makers, governments, and funding organisations to develop and implement action plans for prevention, health care, and research to tackle the growing challenge of neurological disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx6-23J-DSgbJzI8owOhpDfW6udTcc2eY0F6zE-um4H7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfnvVWgtQ%253D%253D&md5=04770e7fbf079d09f64f0fd04a522c8c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2819%2930411-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252819%252930411-9%26sid%3Dliteratum%253Aachs%26aulast%3DFeigin%26aufirst%3DV.%2BL.%26aulast%3DVos%26aufirst%3DT.%26aulast%3DNichols%26aufirst%3DE.%26aulast%3DOwolabi%26aufirst%3DM.%2BO.%26aulast%3DCarroll%26aufirst%3DW.%2BM.%26aulast%3DDichgans%26aufirst%3DM.%26aulast%3DDeuschl%26aufirst%3DG.%26aulast%3DParmar%26aufirst%3DP.%26aulast%3DBrainin%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DC.%26atitle%3DThe%2520global%2520burden%2520of%2520neurological%2520disorders%253A%2520Translating%2520evidence%2520into%2520policy%26jtitle%3DLancet%2520Neurol.%26date%3D2020%26volume%3D19%26spage%3D255%26epage%3D265%26doi%3D10.1016%2FS1474-4422%2819%2930411-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span> <span> </span><span class="NLM_article-title">An analysis of fda-approved drugs for neurological disorders</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1040</span>– <span class="NLM_lpage">3</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.drudis.2015.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25681791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=1040-3&author=M.+S.+Kinch&title=An+analysis+of+fda-approved+drugs+for+neurological+disorders&doi=10.1016%2Fj.drudis.2015.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of FDA-approved drugs for neurological disorders</span></div><div class="casAuthors">Kinch, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1040-1043</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Neuroscience remains a great challenge and opportunity in terms of new drug discovery and development.  An assessment of FDA-approved new mol. entities (NMEs) reveals a low steady rate of new FDA approvals, which is interrupted by two bursts in activity, first in the 1950s and then in the 1990s.  These trends are reflected in the approvals for NMEs targeting multiple indications in this field, including seizure, Parkinson's disease and neuromuscular disorders.  The majority of drugs target ion channels or G-protein-coupled receptors (GPCRs) but the mechanistic basis for many NMEs remains unclear or controversial.  These trends could suggest future opportunities for success in a crucial field with considerable unmet needs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfvKatWK3Fx7Vg90H21EOLACvtfcHk0lhgxhHtIwSKvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWqs7w%253D&md5=05ea0982e6ee282f288c3c337d12579f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DKinch%26aufirst%3DM.%2BS.%26atitle%3DAn%2520analysis%2520of%2520fda-approved%2520drugs%2520for%2520neurological%2520disorders%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D1040%26epage%3D3%26doi%3D10.1016%2Fj.drudis.2015.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vila-Pueyo, M.</span></span> <span> </span><span class="NLM_article-title">Targeted 5-ht 1f therapies for migraine</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1007/s13311-018-0615-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs13311-018-0615-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29488143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktVKjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=291-303&author=M.+Vila-Pueyo&title=Targeted+5-ht+1f+therapies+for+migraine&doi=10.1007%2Fs13311-018-0615-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted 5-HT1F Therapies for Migraine</span></div><div class="casAuthors">Vila-Pueyo, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">291-303</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Migraine is a common neurol. disease characterised by the presence of attacks of unilateral, severe head pain accompanied by other symptoms.  Although it has been classified as the sixth most disabling disorder, the available therapeutic options to treat this condition have not progressed accordingly.  The advance in the development of 5-HT1 receptor agonists for migraine, including 5-HT1B/D and 5-HT1F receptor agonists, has meant a major step forward towards the progression of a better treatment for migraine.  Triptans have a limited efficacy, and their effect on vasoconstriction makes them unsafe for patients with cardiovascular and/or cerebrovascular diseases.  Therefore, novel effective antimigraine treatments without cardiovascular effects are required, such as selective 5-HT1F receptor agonists (ditans).  Lasmiditan has much higher affinity for the 5-HT1F receptor than for the vasoconstrictor 5-HT1B receptor.  This has been confirmed in preclin. studies performed to date, where lasmiditan showed no effect on vasoconstriction, and in clin. trials, where healthy individuals and patients did not report cardiac events due to treatment with lasmiditan, although it should be confirmed in larger cohorts.  Lasmiditan crosses the blood-brain barrier and may act both centrally and peripherally on 5-HT1F receptors expressed on trigeminal neurons.  It is a well-tolerated compd. that does not induce major adverse events.  Although ongoing phase III clin. trials are needed to confirm its efficacy and safety, lasmiditan might offer an alternative to treat acute migraine with no assocd. cardiovascular risk.  This review will focus on the characterization of 5-HT1 receptor agonists and their effects as migraine therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbkLZlm2ydBLVg90H21EOLACvtfcHk0lhgxhHtIwSKvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktVKjsL0%253D&md5=067265f36b52207e80aa98743b8b52ce</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs13311-018-0615-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-018-0615-6%26sid%3Dliteratum%253Aachs%26aulast%3DVila-Pueyo%26aufirst%3DM.%26atitle%3DTargeted%25205-ht%25201f%2520therapies%2520for%2520migraine%26jtitle%3DNeurotherapeutics%26date%3D2018%26volume%3D15%26spage%3D291%26epage%3D303%26doi%3D10.1007%2Fs13311-018-0615-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russell, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smillie, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodji, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brain, S. D.</span></span> <span> </span><span class="NLM_article-title">Calcitonin gene-related peptide: Physiology and pathophysiology</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">1099</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1152/physrev.00034.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1152%2Fphysrev.00034.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25287861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFansbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=1099-142&author=F.+A.+Russellauthor=R.+Kingauthor=S.+J.+Smillieauthor=X.+Kodjiauthor=S.+D.+Brain&title=Calcitonin+gene-related+peptide%3A+Physiology+and+pathophysiology&doi=10.1152%2Fphysrev.00034.2013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Calcitonin gene-related peptide: physiology and pathophysiology</span></div><div class="casAuthors">Russell, F. A.; King, R.; Smillie, S.-J.; Kodji, X.; Brain, S. D.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1099-1142</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide.  Discovered 30 years ago, it is produced as a consequence of alternative RNA processing of the calcitonin gene.  CGRP has two major forms (α and β).  It belongs to a group of peptides that all act on an unusual receptor family.  These receptors consist of calcitonin receptor-like receptor (CLR) linked to an essential receptor activity modifying protein (RAMP) that is necessary for full functionality.  CGRP is a highly potent vasodilator and, partly as a consequence, possesses protective mechanisms that are important for physiol. and pathol. conditions involving the cardiovascular system and wound healing.  CGRP is primarily released from sensory nerves and thus is implicated in pain pathways.  The proven ability of CGRP antagonists to alleviate migraine has been of most interest in terms of drug development, and knowledge to date concerning this potential therapeutic area is discussed.  Other areas covered, where there is less information known on CGRP, include arthritis, skin conditions, diabetes, and obesity.  It is concluded that CGRP is an important peptide in mammalian biol., but it is too early at present to know if new medicines for disease treatment will emerge from our knowledge concerning this mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwIgrpQJ0Bp7Vg90H21EOLACvtfcHk0lhgxhHtIwSKvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFansbnI&md5=dabce66d0b7604444f8366056f1ba2fd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00034.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00034.2013%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DF.%2BA.%26aulast%3DKing%26aufirst%3DR.%26aulast%3DSmillie%26aufirst%3DS.%2BJ.%26aulast%3DKodji%26aufirst%3DX.%26aulast%3DBrain%26aufirst%3DS.%2BD.%26atitle%3DCalcitonin%2520gene-related%2520peptide%253A%2520Physiology%2520and%2520pathophysiology%26jtitle%3DPhysiol.%2520Rev.%26date%3D2014%26volume%3D94%26spage%3D1099%26epage%3D142%26doi%3D10.1152%2Fphysrev.00034.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Billakota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devinsky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, E.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid therapy in epilepsy</span>. <i>Curr. Opin. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1097/WCO.0000000000000660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1097%2FWCO.0000000000000660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30676535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjslKrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2019&pages=220-226&author=S.+Billakotaauthor=O.+Devinskyauthor=E.+Marsh&title=Cannabinoid+therapy+in+epilepsy&doi=10.1097%2FWCO.0000000000000660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid therapy in epilepsy</span></div><div class="casAuthors">Billakota, Santoshi; Devinsky, Orrin; Marsh, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Neurology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">220-226</span>CODEN:
                <span class="NLM_cas:coden">CONEEX</span>;
        ISSN:<span class="NLM_cas:issn">1350-7540</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: To review the history, pharmacol., and clin. science of cannabidiol (CBD) in the treatment of epilepsy.  Recent findings: Phase III randomized controlled trials and prospective open label trials have provided efficacy and safety data for the use of CBD in pediatric onset severe epilepsies.  The product that was studied in the vast majority of these published trials, Epidiolex (>99% of CBD and <0.10% Δ9-tetrahydrocannabinol (THC); GW pharmaceuticals, Cambridge, UK), has now been FDA approved based on this published data.  Summary: Identification of CBD, Δ9-THC, and the endocannabinoid system in the mid-20th century has led to advancement of cannabis-based therapies for epilepsy.  Based on clin. trial data, Epidiolex is the first CBD medication approved by a national regulatory agency (US Food and Drug Administration for Dravet and Lennox Gastaut syndrome; European Medicines Agency for Lennox Gastaut syndrome).  Approval of CBD as a treatment for these rare and severe pediatric-onset epilepsy syndromes is an important milestone, but the complete spectrum of use of cannabis-derived products, and the use of CBD for other epilepsy syndromes remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8AeaHmug0FLVg90H21EOLACvtfcHk0li9U_PgcQgsvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjslKrsL4%253D&md5=deee1dd93b683577605655171a8a8525</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1097%2FWCO.0000000000000660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FWCO.0000000000000660%26sid%3Dliteratum%253Aachs%26aulast%3DBillakota%26aufirst%3DS.%26aulast%3DDevinsky%26aufirst%3DO.%26aulast%3DMarsh%26aufirst%3DE.%26atitle%3DCannabinoid%2520therapy%2520in%2520epilepsy%26jtitle%3DCurr.%2520Opin.%2520Neurol.%26date%3D2019%26volume%3D32%26spage%3D220%26epage%3D226%26doi%3D10.1097%2FWCO.0000000000000660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, D.</span></span> <span> </span><span class="NLM_article-title">Distribution of gabaa and gabab receptors in mammalian brain: Potential targets for drug development</span>. <i>Drug Dev. Res.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1002/ddr.430210303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fddr.430210303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaK3MXlsFygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1990&pages=161-167&author=A.+B.+Youngauthor=D.+Chu&title=Distribution+of+gabaa+and+gabab+receptors+in+mammalian+brain%3A+Potential+targets+for+drug+development&doi=10.1002%2Fddr.430210303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of GABAA and GABAB receptors in mammalian brain:  potential targets for drug development</span></div><div class="casAuthors">Young, Anne B.; Chu, Dorothy</div><div class="citationInfo"><span class="NLM_cas:title">Drug Development Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-7</span>CODEN:
                <span class="NLM_cas:coden">DDREDK</span>;
        ISSN:<span class="NLM_cas:issn">0272-4391</span>.
    </div><div class="casAbstract">A review with 24 refs.  GABA's actions are mediated by 2 different receptors, GABAA, and GABAB receptors.  GABAA receptors are ligand-gated chloride channels that are sensitive to the convulsant alkaloid bicuculline and modulated by benzodiazepines and barbiturates.  GABAB receptors affect Ca and K conductance through GTP-binding proteins and are insensitive to bicuculline and and sensitive to the agonist baclofen.  Both receptors are widely distributed in cerebral cortex, hippocampus, basal ganglia, thalamus, cerebellum, and brain stem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotWVxUyEv5rLVg90H21EOLACvtfcHk0li9U_PgcQgsvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlsFygsg%253D%253D&md5=41f648329c898bb890183f3e3149ebf2</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fddr.430210303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fddr.430210303%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DA.%2BB.%26aulast%3DChu%26aufirst%3DD.%26atitle%3DDistribution%2520of%2520gabaa%2520and%2520gabab%2520receptors%2520in%2520mammalian%2520brain%253A%2520Potential%2520targets%2520for%2520drug%2520development%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D1990%26volume%3D21%26spage%3D161%26epage%3D167%26doi%3D10.1002%2Fddr.430210303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifacio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loureiro, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares-Da-Silva, P.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-o-methyl transferase inhibitor, in the rat</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">1739</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1111/bph.13020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1111%2Fbph.13020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25409768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslemtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=1739-52&author=M.+J.+Bonifacioauthor=L.+Torraoauthor=A.+I.+Loureiroauthor=P.+N.+Palmaauthor=L.+C.+Wrightauthor=P.+Soares-Da-Silva&title=Pharmacological+profile+of+opicapone%2C+a+third-generation+nitrocatechol+catechol-o-methyl+transferase+inhibitor%2C+in+the+rat&doi=10.1111%2Fbph.13020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat</span></div><div class="casAuthors">Bonifacio, M. J.; Torrao, L.; Loureiro, A. I.; Palma, P. N.; Wright, L. C.; Soares-da-Silva, P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1739-1752</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Catechol-O-methyltransferase (COMT) is an important target in the levodopa treatment of Parkinson's disease; however, the inhibitors available have problems, and not all patients benefit from their efficacy.  Opicapone was developed to overcome those limitations.  In this study, opicapone's pharmacol. properties were evaluated as well as its potential cytotoxic effects.  The pharmacodynamic effects of opicapone were explored by evaluating rat COMT activity and levodopa pharmacokinetics, in the periphery through microdialysis and in whole brain.  The potential cytotoxicity risk of opicapone was explored in human hepatocytes by assessing cellular ATP content and mitochondrial membrane potential.  Opicapone inhibited rat peripheral COMT with ED50 values below 1.4 mg·kg-1 up to 6 h post-administration.  The effect was sustained over the first 8 h and by 24 h COMT had not returned to control values.  A single administration of opicapone resulted in increased and sustained plasma levodopa levels with a concomitant redn. in 3-O-methyldopa from 2 h up to 24 h post-administration, while tolcapone produced significant effects only at 2 h post-administration.  The effects of opicapone on brain catecholamines after levodopa administration were sustained up to 24 h post-administration.  Opicapone was also the least potent compd. in decreasing both the mitochondrial membrane potential and the ATP content in human primary hepatocytes after a 24 h incubation period.  Opicapone has a prolonged inhibitory effect on peripheral COMT, which extends the bioavailability of levodopa, without inducing toxicity.  Thus, it exhibits some improved properties compared to the currently available COMT inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8LJIJVwNnkLVg90H21EOLACvtfcHk0li9U_PgcQgsvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslemtrs%253D&md5=a9ab5332b55d8181120f39cdb0c74e85</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1111%2Fbph.13020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13020%26sid%3Dliteratum%253Aachs%26aulast%3DBonifacio%26aufirst%3DM.%2BJ.%26aulast%3DTorrao%26aufirst%3DL.%26aulast%3DLoureiro%26aufirst%3DA.%2BI.%26aulast%3DPalma%26aufirst%3DP.%2BN.%26aulast%3DWright%26aufirst%3DL.%2BC.%26aulast%3DSoares-Da-Silva%26aufirst%3DP.%26atitle%3DPharmacological%2520profile%2520of%2520opicapone%252C%2520a%2520third-generation%2520nitrocatechol%2520catechol-o-methyl%2520transferase%2520inhibitor%252C%2520in%2520the%2520rat%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D1739%26epage%3D52%26doi%3D10.1111%2Fbph.13020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesh
Sreeram, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagadkar, F.</span></span> <span> </span><span class="NLM_article-title">Role of vesicular monoamine transporter 2 inhibitors in tardive dyskinesia management</span>. <i>Cureus</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e5471</span> <span class="refDoi"> DOI: 10.7759/cureus.5471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.7759%2Fcureus.5471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31641566" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=S.+S.+Venkatesh%0ASreeramauthor=F.+Kagadkar&title=Role+of+vesicular+monoamine+transporter+2+inhibitors+in+tardive+dyskinesia+management&doi=10.7759%2Fcureus.5471"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.7759%2Fcureus.5471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7759%252Fcureus.5471%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatesh%2BSreeram%26aufirst%3DS.%2BS.%26aulast%3DKagadkar%26aufirst%3DF.%26atitle%3DRole%2520of%2520vesicular%2520monoamine%2520transporter%25202%2520inhibitors%2520in%2520tardive%2520dyskinesia%2520management%26jtitle%3DCureus%26date%3D2019%26volume%3D11%26doi%3D10.7759%2Fcureus.5471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, S.</span></span> <span> </span><span class="NLM_article-title">Deutetrabenazine in the treatment of huntington’s disease</span>. <i>Neurodegener. Dis. Manag.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.2217/nmt-2018-0040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2217%2Fnmt-2018-0040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30624137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3cnpsFWksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=31-37&author=A.+Richardauthor=S.+Frank&title=Deutetrabenazine+in+the+treatment+of+huntington%E2%80%99s+disease&doi=10.2217%2Fnmt-2018-0040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Deutetrabenazine in the treatment of Huntington's disease</span></div><div class="casAuthors">Richard Alby; Frank Samuel</div><div class="citationInfo"><span class="NLM_cas:title">Neurodegenerative disease management</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Deutetrabenazine (DTBZ) is a US FDA-approved treatment for chorea in Huntington's disease.  The substitution of deuterium for hydrogen at specific positions imparts a longer half-life on DTBZ, allowing for less-frequent daily dosing.  As a reversible vesicular monoamine transporter Type 2 inhibitor, DTBZ depletes monoamines at presynaptic nerve terminals.  DTBZ significantly improved chorea in Huntington's disease patients compared with placebo.  This effect continued in an ongoing open-label extension study in the cohort who switched from tetrabenazine to DTBZ.  Whereas there are currently no head-to-head studies to adequately compare safety profiles between tetrabenazine and DTBZ, an indirect comparison study suggested that the tolerability profile of DTBZ was similar to placebo.  In fact, there are currently no direct comparisons between vesicular monoamine transporter Type 2 inhibitors in humans.  This review will explore DTBZ's pharmacological properties, drug interactions, administration and efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSP0y_HRxo6nNHxxy173TfNfW6udTcc2ebuKwrwJzY7i7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnpsFWksQ%253D%253D&md5=400c75b21d16b2a5a67da3282854107b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.2217%2Fnmt-2018-0040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnmt-2018-0040%26sid%3Dliteratum%253Aachs%26aulast%3DRichard%26aufirst%3DA.%26aulast%3DFrank%26aufirst%3DS.%26atitle%3DDeutetrabenazine%2520in%2520the%2520treatment%2520of%2520huntington%25E2%2580%2599s%2520disease%26jtitle%3DNeurodegener.%2520Dis.%2520Manag.%26date%3D2019%26volume%3D9%26spage%3D31%26epage%3D37%26doi%3D10.2217%2Fnmt-2018-0040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gellad, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, G. C.</span></span> <span> </span><span class="NLM_article-title">Evaluation of flibanserin: Science and advocacy at the fda</span>. <i>J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">870</span>, <span class="refDoi"> DOI: 10.1001/jama.2015.8405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1001%2Fjama.2015.8405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XkslKmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2015&pages=869-870&author=W.+F.+Gelladauthor=K.+E.+Flynnauthor=G.+C.+Alexander&title=Evaluation+of+flibanserin%3A+Science+and+advocacy+at+the+fda&doi=10.1001%2Fjama.2015.8405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of flibanserin: science and advocacy at the FDA</span></div><div class="casAuthors">Gellad, Walid F.; Flynn, Kathryn E.; Alexander, G. Caleb</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">869</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoet9CbCtT9erVg90H21EOLACvtfcHk0liKn_16SlahuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkslKmtg%253D%253D&md5=cfadaafa407db0b9122ce778b82097b3</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1001%2Fjama.2015.8405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2015.8405%26sid%3Dliteratum%253Aachs%26aulast%3DGellad%26aufirst%3DW.%2BF.%26aulast%3DFlynn%26aufirst%3DK.%2BE.%26aulast%3DAlexander%26aufirst%3DG.%2BC.%26atitle%3DEvaluation%2520of%2520flibanserin%253A%2520Science%2520and%2520advocacy%2520at%2520the%2520fda%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2015%26volume%3D314%26spage%3D869%26epage%3D870%26doi%3D10.1001%2Fjama.2015.8405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Lemborexant: First approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01276-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-020-01276-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=32096020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=425-432&author=L.+J.+Scott&title=Lemborexant%3A+First+approval&doi=10.1007%2Fs40265-020-01276-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Lemborexant: First Approval</span></div><div class="casAuthors">Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-432</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Abstr.: Lemborexant (DAYVIGO) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia.  In Dec. 2019, lemborexant received its first approval (with final interim scheduling) in the USA for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.  In Jan. 2020, lemborexant also received approval in Japan for the treatment of insomnia.  It is also being investigated for the treatment of irregular sleep-wake rhythm disorder (ISWRD) assocd. with mild to moderate Alzheimer's disease.  This article summarizes the milestones in the development of lemborexant leading to its first global approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9xrf3D4Hk4rVg90H21EOLACvtfcHk0liKn_16SlahuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslCltro%253D&md5=3d7e881e7ca2d223682081871963761c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01276-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01276-1%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DLemborexant%253A%2520First%2520approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D425%26epage%3D432%26doi%3D10.1007%2Fs40265-020-01276-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span> </span><span class="NLM_article-title">Neurotherapeutic drugs market: Overview</span>. <a href="https://www.mynewsdesk.com/us/tmr/pressreleases/deeper-understanding-of-neurologic-diseases-leads-to-the-growth-of-neurotherapeutic-drugs-market-1946311" class="extLink">https://www.mynewsdesk.com/us/tmr/pressreleases/deeper-understanding-of-neurologic-diseases-leads-to-the-growth-of-neurotherapeutic-drugs-market-1946311</a> (accessed Jun 30, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Neurotherapeutic+drugs+market%3A+Overview.+https%3A%2F%2Fwww.mynewsdesk.com%2Fus%2Ftmr%2Fpressreleases%2Fdeeper-understanding-of-neurologic-diseases-leads-to-the-growth-of-neurotherapeutic-drugs-market-1946311+%28accessed+Jun+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNeurotherapeutic%2520drugs%2520market%253A%2520Overview%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umlauf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, M.</span></span> <span> </span><span class="NLM_article-title">An analysis of fda-approved drugs for metabolic diseases</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.drudis.2015.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25680688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=648-51&author=M.+S.+Kinchauthor=S.+Umlaufauthor=M.+Plummer&title=An+analysis+of+fda-approved+drugs+for+metabolic+diseases&doi=10.1016%2Fj.drudis.2015.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of FDA-approved drugs for metabolic diseases</span></div><div class="casAuthors">Kinch, Michael S.; Umlauf, Sheila; Plummer, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">648-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Metabolic diseases encompass a constellation of maladies including obesity and diabetes that are among the fastest growing epidemics throughout the world.  An anal. of new mol. entities (NMEs) targeting metabolic diseases reveals the rate of approval for new drugs increased in the mid-1990s and now stands at approx. two per yr.  The increase is largely attributed to a recent emphasis on treatments for inborn errors of metab.  In particular, biotechnol. companies have focused on rare genetic disorders, which are often treated with biol.-based NMEs that target novel pathways and qualify for orphan drug status.  By contrast, NME development by pharmaceutical companies tended toward conventional small mol. targeting of nongenetic disorders such as diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov-tx3JD3cb7Vg90H21EOLACvtfcHk0lj--uxjxINIjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWlsbY%253D&md5=f46960cbd106cd957e74140361ae7394</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DUmlauf%26aufirst%3DS.%26aulast%3DPlummer%26aufirst%3DM.%26atitle%3DAn%2520analysis%2520of%2520fda-approved%2520drugs%2520for%2520metabolic%2520diseases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D648%26epage%3D51%26doi%3D10.1016%2Fj.drudis.2015.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Lesinurad: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0550-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-016-0550-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26861027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=509-16&author=S.+M.+Hoy&title=Lesinurad%3A+First+global+approval&doi=10.1007%2Fs40265-016-0550-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Lesinurad: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">509-516</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Lesinurad (ZURAMPIC) is an oral urate-anion exchanger transporter 1 (URAT1) inhibitor developed by Ardea Biosciences (a subsidiary of AstraZeneca) for the treatment of hyperuricemia assocd. with gout.  It reduces serum uric acid (sUA) levels by inhibiting the function of the transporter proteins (URAT1 and org. anion transporter 4) involved in uric acid reabsorption in the kidney.  In Dec. 2015, lesinurad was approved in the USA as combination therapy with a xanthine oxidase inhibitor for the treatment of hyperuricemia assocd. with gout in patients who have not achieved sUA target levels with a xanthine oxidase inhibitor alone.  Lesinurad has also received a pos. opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for this indication and is in phase III development as a combination therapy in several other countries.  This article summarizes the milestones in the development of lesinurad leading to this first approval for hyperuricemia assocd. with gout.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYLnXR_1pferVg90H21EOLACvtfcHk0lj--uxjxINIjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGrsr4%253D&md5=adff81ec4e67f65711573f15444765c8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0550-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0550-y%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DLesinurad%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D509%26epage%3D16%26doi%3D10.1007%2Fs40265-016-0550-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Pepa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandi, M. L.</span></span> <span> </span><span class="NLM_article-title">Natpara for the treatment of hypoparathyroidism</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1417</span>– <span class="NLM_lpage">1424</span>, <span class="refDoi"> DOI: 10.1080/14712598.2016.1238455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1080%2F14712598.2016.1238455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=27689826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1amtrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=1417-1424&author=G.+Marcucciauthor=G.+Della+Pepaauthor=M.+L.+Brandi&title=Natpara+for+the+treatment+of+hypoparathyroidism&doi=10.1080%2F14712598.2016.1238455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Natpara for the treatment of hypoparathyroidism</span></div><div class="casAuthors">Marcucci, Gemma; Della Pepa, Giuseppe; Brandi, Maria Luisa</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1417-1424</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Hypoparathyroidism is a rare endocrine disorder characterized by hypocalcemia and hyperphosphatemia, due to absent or inappropriately low parathyroid hormone levels.  For management of chronic hypoparathyroidism, current treatment options involve oral calcium and vitamin D.  This std. treatment cannot resolve all problematic aspects of the disease, such as abnormal bone remodeling and reduced quality of life, and is assocd. with long-term complications, including nephrolithiasis, nephrocalcinosis, renal impairment, cataracts and cerebral calcifications.: In 2015, the FDA (Food and Drug Administration) approved rhPTH (1-84), named Natpara, a bioengineered recombinant human PTH, for the management of hypoparathyroidism of any etiol., except Autosomal Dominant Hypocalcemia, not well controlled with calcium and active vitamin D.  Herein, the authors review its chem., pharmacodynamics, pharmacokinetics and clin. efficacy for hypoparathyroidism.: Replacement therapy with rhPTH (1-84) is a fundamental step in the treatment of chronic hypoparathyroidism in cases not well controlled by std. therapy, providing the natural hormone that is lacking for the maintenance of normal calcium levels, and reducing long-term risks assocd. with conventional therapy.  Nevertheless, given the chronic nature of the disease, in the future, further studies will have to be performed to evaluate long-term efficacy and safety of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9U1AI9HuGMLVg90H21EOLACvtfcHk0lj--uxjxINIjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1amtrbM&md5=34f22b6790c6c4eb328666250189295c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1080%2F14712598.2016.1238455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14712598.2016.1238455%26sid%3Dliteratum%253Aachs%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DDella%2BPepa%26aufirst%3DG.%26aulast%3DBrandi%26aufirst%3DM.%2BL.%26atitle%3DNatpara%2520for%2520the%2520treatment%2520of%2520hypoparathyroidism%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2016%26volume%3D16%26spage%3D1417%26epage%3D1424%26doi%3D10.1080%2F14712598.2016.1238455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baggio, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span> <span> </span><span class="NLM_article-title">Biology of incretins: Glp-1 and gip</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">2131</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2007.03.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1053%2Fj.gastro.2007.03.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=17498508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsVynsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2007&pages=2131-57&author=L.+L.+Baggioauthor=D.+J.+Drucker&title=Biology+of+incretins%3A+Glp-1+and+gip&doi=10.1053%2Fj.gastro.2007.03.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Biology of incretins: GLP-1 and GIP</span></div><div class="casAuthors">Baggio, Laurie L.; Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2131-2157</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  This review focuses on the mechanisms regulating the synthesis, secretion, biol. actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).  The published literature was reviewed, with emphasis on recent advances in our understanding of the biol. of GIP and GLP-1.  GIP and GLP-1 are both secreted within minutes of nutrient ingestion and facilitate the rapid disposal of ingested nutrients.  Both peptides share common actions on islet β-cells acting through structurally distinct yet related receptors.  Incretin-receptor activation leads to glucose-dependent insulin secretion, induction of β-cell proliferation, and enhanced resistance to apoptosis.  GIP also promotes energy storage via direct actions on adipose tissue, and enhances bone formation via stimulation of osteoblast proliferation and inhibition of apoptosis.  In contrast, GLP-1 exerts glucoregulatory actions via slowing of gastric emptying and glucose-dependent inhibition of glucagon secretion.  GLP-1 also promotes satiety and sustained GLP-1-receptor activation is assocd. with wt. loss in both preclin. and clin. studies.  The rapid degrdn. of both GIP and GLP-1 by the enzyme dipeptidyl peptidase-4 has led to the development of degrdn.-resistant GLP-1-receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.  These agents decrease Hb A1c (HbA1c) safely without wt. gain in subjects with type 2 diabetes.  GLP-1 and GIP integrate nutrient-derived signals to control food intake, energy absorption, and assimilation.  Recently approved therapeutic agents based on potentiation of incretin action provide new physiol. based approaches for the treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreCg0sPucFt7Vg90H21EOLACvtfcHk0lh1nxMzLqmUZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsVynsrY%253D&md5=ec686e630cfa7400345d833b3ea92ad9</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2007.03.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2007.03.054%26sid%3Dliteratum%253Aachs%26aulast%3DBaggio%26aufirst%3DL.%2BL.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DBiology%2520of%2520incretins%253A%2520Glp-1%2520and%2520gip%26jtitle%3DGastroenterology%26date%3D2007%26volume%3D132%26spage%3D2131%26epage%3D57%26doi%3D10.1053%2Fj.gastro.2007.03.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knop, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilsboll, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, J. J.</span></span> <span> </span><span class="NLM_article-title">Lixisenatide for type 2 diabetes mellitus</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">549</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1517/13543784.2011.562191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1517%2F13543784.2011.562191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=21391833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFClsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=549-57&author=M.+Christensenauthor=F.+K.+Knopauthor=T.+Vilsbollauthor=J.+J.+Holst&title=Lixisenatide+for+type+2+diabetes+mellitus&doi=10.1517%2F13543784.2011.562191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Lixisenatide for type 2 diabetes mellitus</span></div><div class="casAuthors">Christensen, Mikkel; Knop, Filip K.; Vilsbooll, Tina; Holst, Jens J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">549-557</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Type 2 diabetes mellitus (T2DM) is an increasing health problem worldwide.  Glucagon-like peptide-1 (GLP-1) receptor agonists are an expanding drug class that target several of the pathophysiol. traits of T2DM.  Lixisenatide is a GLP-1 receptor agonist in development for once-daily treatment of T2DM.Areas covered: Pharmacol., preclin. and clin. evidence demonstrating the applicability of lixisenatide for the treatment of T2DM are reviewed.  Available data and pending clin. development are summarized, critically appraised and compared to competitor drugs.  The most relevant papers and meeting abstrs. published up to Nov. 2010 are used as sources for this review.Expert opinion: Efficacy and safety in T2DM are demonstrated with lixisenatide in monotherapy and in combination with metformin.  However, limited data with the intended once-daily 20 μμg s.c. dosing necessitate further evaluation of lixisenatide as add-on to various antidiabetic treatments.  It remains to be established whether the slightly differing chem. properties compared to other GLP-1 receptor agonists including a rather short duration of action will be a disadvantage or maybe even an advantage, for example, when combined with long-acting insulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbgMyicCrWwLVg90H21EOLACvtfcHk0lh1nxMzLqmUZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFClsbw%253D&md5=658d9b2c40a4f884b7726816f014a1b8</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.562191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.562191%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DM.%26aulast%3DKnop%26aufirst%3DF.%2BK.%26aulast%3DVilsboll%26aufirst%3DT.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DLixisenatide%2520for%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D549%26epage%3D57%26doi%3D10.1517%2F13543784.2011.562191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mazziotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzaruso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giustina, A.</span></span> <span> </span><span class="NLM_article-title">Diabetes in cushing syndrome: Basic and clinical aspects</span>. <i>Trends Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1016/j.tem.2011.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.tem.2011.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=21993190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFKltbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=499-506&author=G.+Mazziottiauthor=C.+Gazzarusoauthor=A.+Giustina&title=Diabetes+in+cushing+syndrome%3A+Basic+and+clinical+aspects&doi=10.1016%2Fj.tem.2011.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetes in Cushing syndrome: basic and clinical aspects</span></div><div class="casAuthors">Mazziotti, Gherardo; Gazzaruso, Carmine; Giustina, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">499-506</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Diabetes mellitus is a frequent complication of Cushing syndrome (CS) which is caused by chronic exposure to glucocorticoid excess, either endogenous or exogenous, and that is characterized by several clin. symptoms such as central obesity, purple striae, proximal muscle weakness, acne, hirsutism and neuropsychol. disturbances.  Diabetes occurs as a consequence of an insulin-resistant state together with impaired insulin secretion which are induced by glucocorticoid excess.  The management of patients with CS and diabetes mellitus includes the treatment of hyperglycemia and, when possible, the correction of glucocorticoid excess.  This review focuses on the disorders of glucose metab. in patients exposed to glucocorticoid excess, addressing both the pathophysiol. aspects and the clin. and therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmBpnDsWLrTbVg90H21EOLACvtfcHk0lh1nxMzLqmUZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFKltbnK&md5=64c3b966d39e9a2d6af95654d7fe261a</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2011.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2011.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DMazziotti%26aufirst%3DG.%26aulast%3DGazzaruso%26aufirst%3DC.%26aulast%3DGiustina%26aufirst%3DA.%26atitle%3DDiabetes%2520in%2520cushing%2520syndrome%253A%2520Basic%2520and%2520clinical%2520aspects%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2011%26volume%3D22%26spage%3D499%26epage%3D506%26doi%3D10.1016%2Fj.tem.2011.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCafferty, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Vestronidase alfa: A review in mucopolysaccharidosis vii</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1007/s40259-019-00344-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40259-019-00344-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30848434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=233-240&author=E.+H.+McCaffertyauthor=L.+J.+Scott&title=Vestronidase+alfa%3A+A+review+in+mucopolysaccharidosis+vii&doi=10.1007%2Fs40259-019-00344-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Vestronidase Alfa: A Review in Mucopolysaccharidosis VII</span></div><div class="casAuthors">McCafferty, Emma H.; Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-240</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Mucopolysaccharidosis VII is an extremely rare, autosomal recessive lysosomal storage disorder characterized by a deficiency of β-glucuronidase activity, resulting in partial degrdn. and accumulation of GAGs in numerous tissues throughout the body, with consequent cellular damage and organ dysfunction.  Enzyme replacement therapy (ERT) with i.v. vestronidase alfa (Mepsevii), a recombinant form of human β-glucuronidase, is the first disease-specific therapy approved for the treatment of mucopolysaccharidosis VII in pediatric and adult patients.  In the pivotal, blind start, phase 3 trial, 24 wk of vestronidase alfa therapy significantly reduced urinary GAG (uGAG) excretion in patients with mucopolysaccharidosis VII.  Based on a Multi-Domain Responder Index (MDRI; comprises six clin. important morbidity domains, with prespecified minimally important differences for each domain), most evaluable patients experienced an improvement in ≥ 1 domain during the 24-wk primary assessment period (overall pos. mean change of 0.5 domains).  The clin. benefits of vestronidase alfa were sustained during longer-term treatment, as was the redn. in uGAG excretion.  Vestronidase alfa has a manageable tolerability profile, with most adverse reactions of mild to moderate severity.  Given the lack of treatment options and the clin. benefits it provides, i.v. vestronidase alfa is an important emerging ERT for patients with mucopolysaccharidosis VII.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3jpd8q29hnrVg90H21EOLACvtfcHk0lh1nxMzLqmUZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyiur8%253D&md5=9ec3df5220966a9c1fb59c25592faefd</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2Fs40259-019-00344-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-019-00344-7%26sid%3Dliteratum%253Aachs%26aulast%3DMcCafferty%26aufirst%3DE.%2BH.%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DVestronidase%2520alfa%253A%2520A%2520review%2520in%2520mucopolysaccharidosis%2520vii%26jtitle%3DBioDrugs%26date%3D2019%26volume%3D33%26spage%3D233%26epage%3D240%26doi%3D10.1007%2Fs40259-019-00344-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Migalastat: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1147</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0607-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-016-0607-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=27351440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2s7ksFegtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1147-52&author=A.+Markham&title=Migalastat%3A+First+global+approval&doi=10.1007%2Fs40265-016-0607-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Migalastat: First Global Approval</span></div><div class="casAuthors">Markham Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1147-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Migalastat (Galafold®)-a small molecule drug developed by Amicus Therapeutics that restores the activity of specific mutant forms of α-galactosidase-has been approved for the treatment of Fabry disease in the EU in patients with amenable mutations.  Fabry disease is a rare disorder that results in a deficiency or absence of α-galactosidase, leading to accumulation of globotriaosylceramide in the lysosomes of various cells.  This article summarizes the milestones in the development of migalastat leading to this first approval in the EU for the long-term treatment of adults and adolescents aged ≥16 years with a confirmed diagnosis of Fabry disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnc_DupHv-_NK0qsdY6Nc1fW6udTcc2ebiV6UxSEtsorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7ksFegtA%253D%253D&md5=20fde86101e0bec10aaaeabad729f05c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0607-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0607-y%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DMigalastat%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1147%26epage%3D52%26doi%3D10.1007%2Fs40265-016-0607-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahradnik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imanishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koshiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljunggren, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyauchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Econs, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavigne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juppner, H.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor 23 in oncogenic osteomalacia and x-linked hypophosphatemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">1656</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa020881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1056%2FNEJMoa020881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=12711740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtFSnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=1656-63&author=K.+B.+Jonssonauthor=R.+Zahradnikauthor=T.+Larssonauthor=K.+E.+Whiteauthor=T.+Sugimotoauthor=Y.+Imanishiauthor=T.+Yamamotoauthor=G.+Hampsonauthor=H.+Koshiyamaauthor=O.+Ljunggrenauthor=K.+Obaauthor=I.+M.+Yangauthor=A.+Miyauchiauthor=M.+J.+Econsauthor=J.+Lavigneauthor=H.+Juppner&title=Fibroblast+growth+factor+23+in+oncogenic+osteomalacia+and+x-linked+hypophosphatemia&doi=10.1056%2FNEJMoa020881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia</span></div><div class="casAuthors">Jonsson, Kenneth B.; Zahradnik, Richard; Larsson, Tobias; White, Kenneth E.; Sugimoto, Toshitsugu; Imanishi, Yasuo; Yamamoto, Takehisa; Hampson, Geeta; Koshiyama, Hiroyuki; Ljunggren, Osten; Oba, Koichi; Yang, Myung; Miyauchi, Akimitsu; Econs, Michael J.; Lavigne, Jeffrey; Juppner, Harald</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1656-1663</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations in fibroblast growth factor 23 (FGF-23) cause autosomal dominant hypophosphatemic rickets.  Clin. and lab. findings in this disorder are similar to those in oncogenic osteomalacia, in which tumors abundantly express FGF-23 mRNA, and to those in X-linked hypophosphatemia, which is caused by inactivating mutations in a phosphate-regulating endopeptidase called PHEX.  Recombinant FGF-23 induces phosphaturia and hypophosphatemia in vivo, suggesting that it has a role in phosphate regulation.  To det. whether FGF-23 circulates in healthy persons and whether it is elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, an immunometric assay was developed to measure it.  Using affinity-purified, polyclonal antibodies against [Tyr223]FGF-23(206-222)amide and [Tyr224]FGF-23(225-244)amide, we developed a two-site ELISA that detects equivalently recombinant human FGF-23, the mutant form in which glutamine is substituted for arginine at position 179 (R179Q), and synthetic human FGF-23(207-244)amide.  Plasma or serum samples from 147 healthy adults (mean [±SD] age, 48.4±19.6 yr) and 26 healthy children (mean age, 10.9±5.5 yr) and from 17 patients with oncogenic osteomalacia (mean age, 43.0±13.3 yr) and 21 patients with X-linked hypophosphatemia (mean age, 34.9±17.2 yr) were studied.  Mean FGF-23 concns. in the healthy adults and children were 55±50 and 69±36 ref. units (RU) per mL, resp.  Four patients with oncogenic osteomalacia had concns. ranging from 426 to 7970 RU per mL, which normalized after tumor resection.  FGF-23 concns. were 481±528 RU per mL in those with suspected oncogenic osteomalacia and 353±510 RU per mL (range, 31 to 2335) in those with X-linked hypophosphatemia.  FGF-23 is readily detectable in the plasma or serum of healthy persons and can be markedly elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, suggesting that this growth factor has a role in phosphate homeostasis.  FGF-23 measurements might improve the management of phosphate-wasting disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQFKZARSC3KrVg90H21EOLACvtfcHk0lhTM3tKizayiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtFSnsbk%253D&md5=0f67ab98e9c8a93a5f1d893410d6ebd7</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020881%26sid%3Dliteratum%253Aachs%26aulast%3DJonsson%26aufirst%3DK.%2BB.%26aulast%3DZahradnik%26aufirst%3DR.%26aulast%3DLarsson%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DK.%2BE.%26aulast%3DSugimoto%26aufirst%3DT.%26aulast%3DImanishi%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DHampson%26aufirst%3DG.%26aulast%3DKoshiyama%26aufirst%3DH.%26aulast%3DLjunggren%26aufirst%3DO.%26aulast%3DOba%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DI.%2BM.%26aulast%3DMiyauchi%26aufirst%3DA.%26aulast%3DEcons%26aufirst%3DM.%2BJ.%26aulast%3DLavigne%26aufirst%3DJ.%26aulast%3DJuppner%26aufirst%3DH.%26atitle%3DFibroblast%2520growth%2520factor%252023%2520in%2520oncogenic%2520osteomalacia%2520and%2520x-linked%2520hypophosphatemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D1656%26epage%3D63%26doi%3D10.1056%2FNEJMoa020881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, J. D.</span></span> <span> </span><span class="NLM_article-title">Cystic fibrosis lung disease and bronchiectasis</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(19)30335-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS2213-2600%2819%2930335-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31570316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3Mnjs1Krtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=12-14&author=J.+D.+Chalmers&title=Cystic+fibrosis+lung+disease+and+bronchiectasis&doi=10.1016%2FS2213-2600%2819%2930335-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic fibrosis lung disease and bronchiectasis</span></div><div class="casAuthors">Chalmers James D</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Respiratory medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSaWRW6W3CE9tFxYDaSSP8XfW6udTcc2ebiV6UxSEtsorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mnjs1Krtg%253D%253D&md5=694630bce50130fb2e545f2acb82018c</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2819%2930335-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252819%252930335-2%26sid%3Dliteratum%253Aachs%26aulast%3DChalmers%26aufirst%3DJ.%2BD.%26atitle%3DCystic%2520fibrosis%2520lung%2520disease%2520and%2520bronchiectasis%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2020%26volume%3D8%26spage%3D12%26epage%3D14%26doi%3D10.1016%2FS2213-2600%2819%2930335-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaudary, N.</span></span> <span> </span><span class="NLM_article-title">Triplet cftr modulators: Future prospects for treatment of cystic fibrosis</span>. <i>Ther. Clin. Risk Manage.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2375</span>– <span class="NLM_lpage">2383</span>, <span class="refDoi"> DOI: 10.2147/TCRM.S147164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2147%2FTCRM.S147164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30584312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOht73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=2375-2383&author=N.+Chaudary&title=Triplet+cftr+modulators%3A+Future+prospects+for+treatment+of+cystic+fibrosis&doi=10.2147%2FTCRM.S147164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Triplet CFTR modulators: future prospects for treatment of cystic fibrosis</span></div><div class="casAuthors">Chaudary, Nauman</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2375-2383</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1178-203X</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is an autosomal recessive genetic disease characterized by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR).  CFTR is a chloride channel responsible for ion flow across epithelial surfaces of lung, sinuses, pancreas, intestine, and liver.  Researchers have grouped CFTR genetic mutations into various protein defects: reduced protein synthesis (class 1 mutations), abnormal protein folding and maturation (class 2 mutation), and abnormal gating (class 3 mutation).  These mutations usually present as severe forms of CF due to complete absence of CFTR at cell surfaces.  Milder forms (eg, protein maturation and conductance defects, classes 4-6) present as less severe forms of CF related to the presence of CFTR at the cell surface.  Differences in severity are directly due to CFTR function which is based on the severity of CFTR mutation.  This knowledge has proven useful for designing therapy for individual mutations and mutation classes.  The discovery and US Food and Drug Administration approval of Kalydeco (ivacaftor) in early 2011 marked the beginning of a new era of therapies that are focused on improving defective CFTR protein function.  However, due to its specificity for the G551D mutation, ivacaftor only benefits ∼5% of CF patients.  Approx. 50% of CF patients have two copies of the F508Del mutation, while other CF patients carry only one copy of this gene.  More recently, Orkambi, a two compd. medication composed of lumacaftor and ivacaftor, has provided the foundation necessary to further build on mol. concepts of: correction of trafficking, potentiation, and amplification of defective CFTR.  These new concepts will form the basis of future CF therapies and extend CFTR treatment to almost 50% of CF patients.  Evolving knowledge of the mol. mechanisms responsible for defective CFTR has prompted new research focused on "repair" of each phase of CFTR expression and function, thus creating a new class of combination "CFTR correctors" referred to as "triplet CFTR compds." This article will review how patients can be selected and treated with these newer agents that are based on specific mutations.  In the future, many CF practitioners have expectations that initiation of treatment for CF patients will occur simply by use of biomarkers of CFTR expression (eg, sweat chloride, nasal p.d., rectal organoids) rather than testing for specific mutations.  As continued research identifies biomarkers with greater specificity and which predict clin. response, therapies can potentially be tailored to individual responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh4w9llfyQ17Vg90H21EOLACvtfcHk0lhKzlrM3NKmpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOht73M&md5=e2e2c46be24a0e4a7aad96e2d1a9c5da</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S147164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S147164%26sid%3Dliteratum%253Aachs%26aulast%3DChaudary%26aufirst%3DN.%26atitle%3DTriplet%2520cftr%2520modulators%253A%2520Future%2520prospects%2520for%2520treatment%2520of%2520cystic%2520fibrosis%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2018%26volume%3D14%26spage%3D2375%26epage%3D2383%26doi%3D10.2147%2FTCRM.S147164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span> </span><span class="NLM_article-title">Cystic fibrosis market: Information by treatment
method (medication,
devices, others) and region (north america, europe, asia-pacific and
the middle east & africa) - forecast till 2025</span>. <a href="https://www.marketresearchfuture.com/reports/cystic-fibrosis-market-1825" class="extLink">https://www.marketresearchfuture.com/reports/cystic-fibrosis-market-1825</a> (accessed Jun 30, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cystic+fibrosis+market%3A+Information+by+treatment%0Amethod+%28medication%2C%0Adevices%2C+others%29+and+region+%28north+america%2C+europe%2C+asia-pacific+and%0Athe+middle+east+%26+africa%29+-+forecast+till+2025.+https%3A%2F%2Fwww.marketresearchfuture.com%2Freports%2Fcystic-fibrosis-market-1825+%28accessed+Jun+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DCystic%2520fibrosis%2520market%253A%2520Information%2520by%2520treatment%250Amethod%2520%2528medication%252C%250Adevices%252C%2520others%2529%2520and%2520region%2520%2528north%2520america%252C%2520europe%252C%2520asia-pacific%2520and%250Athe%2520middle%2520east%2520%2526%2520africa%2529%2520-%2520forecast%2520till%25202025%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O'Brien, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghaddam, M. F.</span></span> <span> </span><span class="NLM_article-title">A systematic analysis of physicochemical and adme properties of all small molecule kinase inhibitors approved by us fda from january 2001 to october 2015</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3159</span>– <span class="NLM_lpage">3184</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170523124441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2174%2F0929867324666170523124441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28545370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1KgsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=3159-3184&author=Z.+O%27Brienauthor=M.+F.+Moghaddam&title=A+systematic+analysis+of+physicochemical+and+adme+properties+of+all+small+molecule+kinase+inhibitors+approved+by+us+fda+from+january+2001+to+october+2015&doi=10.2174%2F0929867324666170523124441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">A Systematic Analysis of Physicochemical and ADME Properties of All Small Molecule Kinase Inhibitors Approved by US FDA from January 2001 to October 2015</span></div><div class="casAuthors">O'Brien, Zhihong; Moghaddam, Mehran F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3159-3184</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: During lead identification and optimization, the advancement criteria may be driven based on scientific principles, prior experiences, and/or by examg. the path paved by approved drugs.  However, accessing the discovery data on physicochem. and ADME properties of the approved kinase inhibitors is a monumental task as these are either scattered in the literature or have not been published. </P><P> Objective: Our goals were: (1) To compile the relevant data on all kinase inhibitors approved prior to 2016 for easy access by the biopharmaceutical community, (2) To provide a retrospective anal. to highlight trends and attributes which may have contributed to the "developability" of these drugs, and (3) To ignite focused debates on what constitutes "actionable", "nice-to-have", and unnecessary data.  Such debates bring about more clarity on stage appropriateness of different types of information and prevent confusion due to abundance of unnecessary data, leading to more efficient and less costly drug discovery programs. </P><P> Methods: A careful and thorough anal. of different bodies of data such as published manuscripts, and available regulatory documents were employed. </P><P> Results: We were able to assemble a large body of data on the first thirty kinase inhibitors approved by US FDA since 2001. </P><P> Conclusion: In conclusion, we have compiled physicochem. and ADME data on the first 30 approved kinase inhibitors and provided our retrospective anal., which we hope is helpful in constructing advancement criteria in discovery programs.  The examn. of this data provides an opportunity to develop an opinion on data prioritization and stage appropriateness of assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_uv62dmVFrLVg90H21EOLACvtfcHk0lhKzlrM3NKmpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1KgsLfF&md5=0bd6e7df021378749c4cdef4a5ee5aa4</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170523124441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170523124441%26sid%3Dliteratum%253Aachs%26aulast%3DO%2527Brien%26aufirst%3DZ.%26aulast%3DMoghaddam%26aufirst%3DM.%2BF.%26atitle%3DA%2520systematic%2520analysis%2520of%2520physicochemical%2520and%2520adme%2520properties%2520of%2520all%2520small%2520molecule%2520kinase%2520inhibitors%2520approved%2520by%2520us%2520fda%2520from%2520january%25202001%2520to%2520october%25202015%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26volume%3D24%26spage%3D3159%26epage%3D3184%26doi%3D10.2174%2F0929867324666170523124441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span> </span><span class="NLM_article-title">Metabolism drugs market growing strongly
with glaxosmithkline plc.,
merck & co., amicus therapeutics, sanofi genzyme, astrazeneca
plc, horizon pharma plc</span>. <a href="http://www.digitaljournal.com/pr/4145873" class="extLink">http://www.digitaljournal.com/pr/4145873</a> (accessed Jun 30, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Metabolism+drugs+market+growing+strongly%0Awith+glaxosmithkline+plc.%2C%0Amerck+%26+co.%2C+amicus+therapeutics%2C+sanofi+genzyme%2C+astrazeneca%0Aplc%2C+horizon+pharma+plc.+http%3A%2F%2Fwww.digitaljournal.com%2Fpr%2F4145873+%28accessed+Jun+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DMetabolism%2520drugs%2520market%2520growing%2520strongly%250Awith%2520glaxosmithkline%2520plc.%252C%250Amerck%2520%2526%2520co.%252C%2520amicus%2520therapeutics%252C%2520sanofi%2520genzyme%252C%2520astrazeneca%250Aplc%252C%2520horizon%2520pharma%2520plc%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhaliwal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahesh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, A. N.</span></span> <span> </span><span class="NLM_article-title">The burden of chronic respiratory diseases and their heterogeneity across the states of india: The global burden of disease study 1990–2016</span>. <i>Lancet Glob. Health</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e1363</span>– <span class="NLM_lpage">e1374</span>, <span class="refDoi"> DOI: 10.1016/S2214-109X(18)30409-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS2214-109X%2818%2930409-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30219316" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=e1363-e1374&author=S.+Salviauthor=G.+A.+Kumarauthor=R.+Dhaliwalauthor=K.+Paulsonauthor=A.+Agrawalauthor=P.+A.+Koulauthor=P.+Maheshauthor=S.+Nairauthor=V.+Singhauthor=A.+N.+Aggarwal&title=The+burden+of+chronic+respiratory+diseases+and+their+heterogeneity+across+the+states+of+india%3A+The+global+burden+of+disease+study+1990%E2%80%932016&doi=10.1016%2FS2214-109X%2818%2930409-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2FS2214-109X%2818%2930409-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2214-109X%252818%252930409-1%26sid%3Dliteratum%253Aachs%26aulast%3DSalvi%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DG.%2BA.%26aulast%3DDhaliwal%26aufirst%3DR.%26aulast%3DPaulson%26aufirst%3DK.%26aulast%3DAgrawal%26aufirst%3DA.%26aulast%3DKoul%26aufirst%3DP.%2BA.%26aulast%3DMahesh%26aufirst%3DP.%26aulast%3DNair%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DV.%26aulast%3DAggarwal%26aufirst%3DA.%2BN.%26atitle%3DThe%2520burden%2520of%2520chronic%2520respiratory%2520diseases%2520and%2520their%2520heterogeneity%2520across%2520the%2520states%2520of%2520india%253A%2520The%2520global%2520burden%2520of%2520disease%2520study%25201990%25E2%2580%25932016%26jtitle%3DLancet%2520Glob.%2520Health%26date%3D2018%26volume%3D6%26spage%3De1363%26epage%3De1374%26doi%3D10.1016%2FS2214-109X%2818%2930409-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quaderi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, J. R.</span></span> <span> </span><span class="NLM_article-title">The unmet global burden of copd</span>. <i>Glob. Health Epidemiol. Genom.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e4</span> <span class="refDoi"> DOI: 10.1017/gheg.2018.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1017%2Fgheg.2018.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29868229" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&author=S.+A.+Quaderiauthor=J.+R.+Hurst&title=The+unmet+global+burden+of+copd&doi=10.1017%2Fgheg.2018.1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1017%2Fgheg.2018.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252Fgheg.2018.1%26sid%3Dliteratum%253Aachs%26aulast%3DQuaderi%26aufirst%3DS.%2BA.%26aulast%3DHurst%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520unmet%2520global%2520burden%2520of%2520copd%26jtitle%3DGlob.%2520Health%2520Epidemiol.%2520Genom.%26date%3D2018%26volume%3D3%26doi%3D10.1017%2Fgheg.2018.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-A.</span></span> <span> </span><span class="NLM_article-title">Revefenacin: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1036-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-018-1036-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30560478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=85-91&author=Y.-A.+Heo&title=Revefenacin%3A+First+global+approval&doi=10.1007%2Fs40265-018-1036-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Revefenacin: First Global Approval</span></div><div class="casAuthors">Heo, Young-A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-91</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Revefenacin (YUPELRI) inhalation soln., a long-acting muscarinic antagonist (i.e. an anticholinergic) developed by Theravance Biopharma and Mylan, is the first and currently the only once-daily, nebulized bronchodilator to be approved in the USA for the treatment of chronic obstructive pulmonary disease (COPD).  In Nov. 2018, based on results of three phase III trials, the US Food and Drug Administration granted market authorization to revefenacin for the maintenance treatment of patients with COPD.  This article summarizes the milestones in the development of revefenacin leading to this first global approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreKt8JGiq2GLVg90H21EOLACvtfcHk0liu3EpmBrPL9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7F&md5=09384e244c9d6b3f9b4d39dd87705057</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1036-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1036-x%26sid%3Dliteratum%253Aachs%26aulast%3DHeo%26aufirst%3DY.-A.%26atitle%3DRevefenacin%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D85%26epage%3D91%26doi%3D10.1007%2Fs40265-018-1036-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalliokoski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, M.</span></span> <span> </span><span class="NLM_article-title">Impact of oatp transporters on pharmacokinetics</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00430.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1111%2Fj.1476-5381.2009.00430.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=693-705&author=A.+Kalliokoskiauthor=M.+Niemi&title=Impact+of+oatp+transporters+on+pharmacokinetics&doi=10.1111%2Fj.1476-5381.2009.00430.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00430.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00430.x%26sid%3Dliteratum%253Aachs%26aulast%3DKalliokoski%26aufirst%3DA.%26aulast%3DNiemi%26aufirst%3DM.%26atitle%3DImpact%2520of%2520oatp%2520transporters%2520on%2520pharmacokinetics%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D693%26epage%3D705%26doi%3D10.1111%2Fj.1476-5381.2009.00430.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span> </span><span class="NLM_article-title">Respiratory diseases drugs global market
report 2020–30: Covid
19 implications and growth</span>. <a href="https://www.thebusinessresearchcompany.com/report/respiratory-diseases-drugs-global-market-report-2020-30-covid-19-implications-and-growth" class="extLink">https://www.thebusinessresearchcompany.com/report/respiratory-diseases-drugs-global-market-report-2020-30-covid-19-implications-and-growth</a> (accessed Jun 15, <span class="NLM_year">2020</span>, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Respiratory+diseases+drugs+global+market%0Areport+2020%E2%80%9330%3A+Covid%0A19+implications+and+growth.+https%3A%2F%2Fwww.thebusinessresearchcompany.com%2Freport%2Frespiratory-diseases-drugs-global-market-report-2020-30-covid-19-implications-and-growth+%28accessed+Jun+15%2C+2020%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DRespiratory%2520diseases%2520drugs%2520global%2520market%250Areport%25202020%25E2%2580%259330%253A%2520Covid%250A19%2520implications%2520and%2520growth%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patridge, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span> <span> </span><span class="NLM_article-title">An analysis of fda-approved drugs for infectious disease: Antibacterial agents</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1283</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.drudis.2014.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25043770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlWkurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1283-7&author=M.+S.+Kinchauthor=E.+Patridgeauthor=M.+Plummerauthor=D.+Hoyer&title=An+analysis+of+fda-approved+drugs+for+infectious+disease%3A+Antibacterial+agents&doi=10.1016%2Fj.drudis.2014.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of FDA-approved drugs for infectious disease: antibacterial agents</span></div><div class="casAuthors">Kinch, Michael S.; Patridge, Eric; Plummer, Mark; Hoyer, Denton</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1283-1287</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Drugs targeting infectious diseases have greatly improved public health.  A study to evaluate all US Food and Drug Administration (FDA)-approved new mol. entities (NMEs) reveals that the no. of new agents targeting infectious disease peaked during the 1990s and declined rapidly thereafter.  Mols. targeting bacterial pathogens represent the most common component of anti-infectives followed by antivirals and antifungals.  Focusing on antibacterial agents, an increase in new NMEs predominated from the 1960s through to the 1990s, dropping sharply thereafter.  Obsolescence and resistance has eliminated one-third of these drugs.  Consequently, the arsenal of antibiotics peaked in 2000 and is declining.  Likewise, the no. of organizations awarded at least one NME for a bacterial indication has declined to a level not seen in more than a half century.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO5j--2mVqaLVg90H21EOLACvtfcHk0liu3EpmBrPL9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlWkurfI&md5=407c7b429adec64ac5f68bdf153bc314</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DPatridge%26aufirst%3DE.%26aulast%3DPlummer%26aufirst%3DM.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DAn%2520analysis%2520of%2520fda-approved%2520drugs%2520for%2520infectious%2520disease%253A%2520Antibacterial%2520agents%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1283%26epage%3D7%26doi%3D10.1016%2Fj.drudis.2014.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adámková, V.</span></span> <span> </span><span class="NLM_article-title">The role of new antibiotics in intra-abdominal infections in the era of multi-resistant bacteria</span>. <i>Rozhl. Chir.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31159547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3M3ivVaitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2019&pages=145-151&author=V.+Ad%C3%A1mkov%C3%A1&title=The+role+of+new+antibiotics+in+intra-abdominal+infections+in+the+era+of+multi-resistant+bacteria"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">The role of new antibiotics in intra-abdominal infections in the era of multi-resistant bacteria</span></div><div class="casAuthors">Adamkova V</div><div class="citationInfo"><span class="NLM_cas:title">Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">145-151</span>
        ISSN:<span class="NLM_cas:issn">0035-9351</span>.
    </div><div class="casAbstract">Complicated intra-abdominal infections (cIAI) are a substantial cause of morbidity at intensive care units. cIAI are frequently caused by multidrug-resistant strains of Enterobacteriaceae and Pseudomonas aeruginosa.  In 592 cIAI patients from the First Department of Surgery, General University Hospital in Prague, we found an alarming increase in resistance of Escherichia coli to amoxicillin/clavulanic acid, piperacillin/tazobactam and third-generation cephalosporins in 2014-2017 (from 28.7% in 2014 to 37.5% in 2017, from 25% to 32% and from 2.3% to 5.6%, respectively).  Ceftolozane/tazobactam and ceftazidime/avibactam are novel cephalosporins available for the treatment of cIAI.  Ceftolozane/tazobactam is highly active against multidrug-resistant strains of P. aeruginosa, including carbapenem-resistant isolates.  The new non-b-lactam b-lactamase inhibitor avibactam plus ceftazidime is active against carbapenemases-producing strains of Enterobacteriaceae.  Both antibiotics are included in the new WSES guidelines for the management of cIAI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkIjmGeHXs79y3lHz94U-GfW6udTcc2ebgzhy5FSvgX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3ivVaitw%253D%253D&md5=58ee667875dcda3d529000ef65e59d2c</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAd%25C3%25A1mkov%25C3%25A1%26aufirst%3DV.%26atitle%3DThe%2520role%2520of%2520new%2520antibiotics%2520in%2520intra-abdominal%2520infections%2520in%2520the%2520era%2520of%2520multi-resistant%2520bacteria%26jtitle%3DRozhl.%2520Chir.%26date%3D2019%26volume%3D98%26spage%3D145%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bussi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, M. G.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis infection of host cells in space and time</span>. <i>FEMS Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1093/femsre/fuz006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1093%2Ffemsre%2Ffuz006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30916769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjvFWrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2019&pages=341-361&author=C.+Bussiauthor=M.+G.+Gutierrez&title=Mycobacterium+tuberculosis+infection+of+host+cells+in+space+and+time&doi=10.1093%2Ffemsre%2Ffuz006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Mycobacterium tuberculosis infection of host cells in space and time</span></div><div class="casAuthors">Bussi, Claudio; Gutierrez, Maximiliano G.</div><div class="citationInfo"><span class="NLM_cas:title">FEMS Microbiology Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">341-361</span>CODEN:
                <span class="NLM_cas:coden">FMREE4</span>;
        ISSN:<span class="NLM_cas:issn">1574-6976</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) caused by the bacterial pathogen Mycobacterium tuberculosis (Mtb) remains one of the deadliest infectious diseases with over a billion deaths in the past 200 years (Paulson 2013).  TB causes more deaths worldwide than any other single infectious agent, with 10.4 million new cases and close to 1.7 million deaths in 2017.  The obstacles that make TB hard to treat and eradicate are intrinsically linked to the intracellular lifestyle of Mtb.  Mtb needs to replicate within human cells to disseminate to other individuals and cause disease.  However, we still do not completely understand how Mtb manages to survive within eukaryotic cells and why some cells are able to eradicate this lethal pathogen.  Here, we summarise the current knowledge of the complex host cell-pathogen interactions in TB and review the cellular mechanisms operating at the interface between Mtb and the human host cell, highlighting the tech. and methodol. challenges to investigating the cell biol. of human host cell-Mtb interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA4PREQVJlXrVg90H21EOLACvtfcHk0ljPHLkUpyrovQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjvFWrs7s%253D&md5=4c9fccfa1992d67241c76fc701faac35</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1093%2Ffemsre%2Ffuz006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ffemsre%252Ffuz006%26sid%3Dliteratum%253Aachs%26aulast%3DBussi%26aufirst%3DC.%26aulast%3DGutierrez%26aufirst%3DM.%2BG.%26atitle%3DMycobacterium%2520tuberculosis%2520infection%2520of%2520host%2520cells%2520in%2520space%2520and%2520time%26jtitle%3DFEMS%2520Microbiol.%2520Rev.%26date%3D2019%26volume%3D43%26spage%3D341%26epage%3D361%26doi%3D10.1093%2Ffemsre%2Ffuz006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Pretomanid: First approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1803</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01207-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-019-01207-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31583606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1797-1803&author=S.+J.+Keam&title=Pretomanid%3A+First+approval&doi=10.1007%2Fs40265-019-01207-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Pretomanid: First Approval</span></div><div class="casAuthors">Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1797-1803</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid, moxifloxacin and pyrazinamide) regimens, has been developed by the Global Alliance for TB Drug Development (TB Alliance) under license from Novartis, for the treatment for tuberculosis (TB).  TB Alliance has licensed Mylan to manufacture and commercialize pretomanid for use as part of the BPaMZ and BPaL regimens.  The license is non-exclusive in low- and middle-income countries and exclusive in high-income markets.  Pretomanid, as part of the BPaL regimen, was recently approved in the USA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) pathway for the treatment of adults with pulmonary extensively drug-resistant (XDR) or treatment-intolerant or non-responsive multidrug-resistant (MDR) TB.  Pretomanid is also under regulatory review in the EU.  This article summarizes the milestones in the development of pretomanid leading to this first regulatory approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ32shufXmAyUNoizSOkG_FfW6udTcc2ebgzhy5FSvgX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D&md5=5c28b82e658d5ce4aa0f1187cf2e7736</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01207-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01207-9%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DPretomanid%253A%2520First%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1797%26epage%3D1803%26doi%3D10.1007%2Fs40265-019-01207-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saravolatz, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, G. E.</span></span> <span> </span><span class="NLM_article-title">Delafloxacin: A new anti-methicillin-resistant staphylococcus aureus fluoroquinolone</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1058</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1093/cid/ciy600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1093%2Fcid%2Fciy600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30060092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFSqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2019&pages=1058-1062&author=L.+D.+Saravolatzauthor=G.+E.+Stein&title=Delafloxacin%3A+A+new+anti-methicillin-resistant+staphylococcus+aureus+fluoroquinolone&doi=10.1093%2Fcid%2Fciy600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Delafloxacin: a new anti-methicillin-resistant Staphylococcus aureus fluoroquinolone</span></div><div class="casAuthors">Saravolatz, Louis D.; Stein, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1058-1062</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Delafloxacin (ABT 492) is a new fluoroquinolone available in both oral and parenteral formulations.  It has recently been approved by the Food and Drug Administration for the management of acute bacterial skin and skin structure infections.  When compared to combination therapy of vancomycin and aztreonam, delafloxacin was not inferior and had a favorable adverse event profile.  Furthermore, its anti-methicillin-resistant Staphylococcus aureus (MRSA) activity and favorable clin. response in MRSA infections distinguishes it from other fluoroquinolones.  This review focuses on the mode of action, antimicrobial activity, pharmacokinetics and pharmacodynamics, clin. indications, and safety profile of this drug.  Considerations for formulary addn. and its place in therapy are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOlwFggldgsLVg90H21EOLACvtfcHk0ljPHLkUpyrovQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFSqs7s%253D&md5=ee75f5bb852dc4d3af6c73b60428e501</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciy600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciy600%26sid%3Dliteratum%253Aachs%26aulast%3DSaravolatz%26aufirst%3DL.%2BD.%26aulast%3DStein%26aufirst%3DG.%2BE.%26atitle%3DDelafloxacin%253A%2520A%2520new%2520anti-methicillin-resistant%2520staphylococcus%2520aureus%2520fluoroquinolone%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2019%26volume%3D68%26spage%3D1058%26epage%3D1062%26doi%3D10.1093%2Fcid%2Fciy600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abd
El Aziz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharifipour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahanfar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judge, H. M.</span></span> <span> </span><span class="NLM_article-title">Secnidazole for treatment of bacterial vaginosis: A systematic review</span>. <i>BMC Women's Health</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">121</span>, <span class="refDoi"> DOI: 10.1186/s12905-019-0822-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1186%2Fs12905-019-0822-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31638955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3MjgsFShsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=121&author=M.+A.+Abd%0AEl+Azizauthor=F.+Sharifipourauthor=P.+Abediauthor=S.+Jahanfarauthor=H.+M.+Judge&title=Secnidazole+for+treatment+of+bacterial+vaginosis%3A+A+systematic+review&doi=10.1186%2Fs12905-019-0822-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Secnidazole for treatment of bacterial vaginosis: a systematic review</span></div><div class="casAuthors">Abd El Aziz Mohamed A; Sharifipour Foruzan; Abedi Parvin; Jahanfar Shayesteh; Judge Helen Marie</div><div class="citationInfo"><span class="NLM_cas:title">BMC women's health</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Bacterial vaginosis (BV) is one of the common vaginal infections among childbearing women.  The usual treatment for BV is metronidazole; hence 30% of women have recurrence within 60 to 90 days after treatment.  There are some studies which assessed the effect of secnidazole on BV.  The aim of this systematic review was to investigate the effectiveness of secnidazole for treatment of BV.  METHODS:  The Cochrane Library, MEDLINE (PubMed), Scopus, and Web of Science (all databases from inception till October 28, 2018) were searched.  Primary outcomes were clinical cure rate and microbiologic cure rate and the secondary outcomes were adverse events.  Data was extracted from eligible studies by two review authors individually and analyzed by RevMan 5.3.  RESULTS:  Our search found six trials involving 1528 participants.  Treatment with 2 g secnidazole could significantly reduce the risk of BV in patients with three or less episodes of BV in the last year by OR: 7.54 (95% CI, 3.89-14.60, p < 0.00001) and in patients with four or more episodes of BV in the last year (OR: 4.74, 95% CI: 1.51-14.84, p = 0.0.008).  Secnidazole (2 g) could significantly increase the microbiologic cure rate in women with 3 or less episodes of BV in the last year (OR: 7.63, 95% CI: 2.30-25.33, p = 0.0009) but not in the women with 4 or more episodes of BV in the last year (OR: 20.17, 95% CI: 1.06-382.45, p = 0.05).  The clinical cure rate, microbiological effect and the therapeutic cure rate of 2 g secnidazole was significantly more than that of 1 g secnidazole.  The results showed that the clinical cure rate of 2 g secnidazole was not different from the following medications: metronidazole (500 mg bid for 5 days), secnidazole plus vaginal metronidazole, 2 g single dose of oral metronidazole and 2 g secnidazole plus vaginal ornidazole.  CONCLUSION:  This review showed that 2 g and 1 g secnidazole were better than placebo, however, 2 g secnidazole was more effective than 1 g.  Secnidazole 2 g was not different from metronidazole (500 mg bid for 5 days), or from secnidazole plus vaginal metronidazole, or 2 g single dose of oral metronidazole or from 2 g secnidazole plus vaginal ornidazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQYTKPPSdwrGUBuFdjgVNKSfW6udTcc2eaP2rTXkzjNarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjgsFShsg%253D%253D&md5=0beb0627a8589b8552458eff0d7e32ad</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1186%2Fs12905-019-0822-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12905-019-0822-2%26sid%3Dliteratum%253Aachs%26aulast%3DAbd%2BEl%2BAziz%26aufirst%3DM.%2BA.%26aulast%3DSharifipour%26aufirst%3DF.%26aulast%3DAbedi%26aufirst%3DP.%26aulast%3DJahanfar%26aufirst%3DS.%26aulast%3DJudge%26aufirst%3DH.%2BM.%26atitle%3DSecnidazole%2520for%2520treatment%2520of%2520bacterial%2520vaginosis%253A%2520A%2520systematic%2520review%26jtitle%3DBMC%2520Women%2527s%2520Health%26date%3D2019%26volume%3D19%26spage%3D121%26doi%3D10.1186%2Fs12905-019-0822-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerding, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poxton, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornely, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahav, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouza, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabryelski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eves, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tipping, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartsonis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorr, M. B.</span></span>; <span class="NLM_contrib-group">for MODIFY I and</span>; <span class="NLM_contrib-group">MODIFY II Investigators</span> <span> </span><span class="NLM_article-title">Bezlotoxumab for prevention of recurrent clostridium difficile infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1602615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1056%2FNEJMoa1602615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28121498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSnsb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=305-317&author=M.+H.+Wilcoxauthor=D.+N.+Gerdingauthor=I.+R.+Poxtonauthor=C.+Kellyauthor=R.+Nathanauthor=T.+Birchauthor=O.+A.+Cornelyauthor=G.+Rahavauthor=E.+Bouzaauthor=C.+Leeauthor=G.+Jenkinauthor=W.+Jensenauthor=Y.+S.+Kimauthor=J.+Yoshidaauthor=L.+Gabryelskiauthor=A.+Pedleyauthor=K.+Evesauthor=R.+Tippingauthor=D.+Gurisauthor=N.+Kartsonisauthor=M.+B.+Dorrauthor=for+MODIFY+I+andauthor=MODIFY+II+Investigators&title=Bezlotoxumab+for+prevention+of+recurrent+clostridium+difficile+infection&doi=10.1056%2FNEJMoa1602615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Bezlotoxumab for prevention of recurrent Clostridium difficile infection</span></div><div class="casAuthors">Wilcox, M. H.; Gerding, D. N.; Poxton, I. R.; Kelly, C.; Nathan, R.; Birch, T.; Cornely, O. A.; Rahav, G.; Bouza, E.; Lee, C.; Jenkin, G.; Jensen, W.; Kim, Y.-S.; Yoshida, J.; Gabryelski, L.; Pedley, A.; Eves, K.; Tipping, R.; Guris, D.; Kartsonis, N.; Dorr, M.-B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-317</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients.  Recurrences are common after antibiotic therapy.  Actoxumab and bezlotoxumab are human monoclonal antibodies against C. difficile toxins A and B, resp.  METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials, MODIFY I and MODIFY II, involving 2655 adults receiving oral std.-of-care antibiotics for primary or recurrent C. difficile infection.  Participants received an infusion of bezlotoxumab (10 mg per kg of body wt.), actoxumab plus bezlotoxumab (10 mg per kg each), or placebo; actoxumab alone (10 mg per kg) was given in MODIFY I but discontinued after a planned interim anal.  The primary end point was recurrent infection (new episode after initial clin. cure) within 12 wk after infusion in the modified intention-to-treat population.  RESULTS: In both trials, the rate of recurrent C. difficile infection was significantly lower with bezlotoxumab alone than with placebo (MODIFY I: 17% [67 of 386] vs. 28% [109 of 395]; adjusted difference, -10.1 percentage points; 95% confidence interval [CI], -15.9 to -4.3; P<0.001; MODIFY II: 16% [62 of 395] vs. 26% [97 of 378]; adjusted difference, -9.9 percentage points; 95% CI, -15.5 to -4.3; P<0.001) and was significantly lower with actoxumab plus bezlotoxumab than with placebo (MODIFY I: 16% [61 of 383] vs. 28% [109 of 395]; adjusted difference, -11.6 percentage points; 95% CI, -17.4 to -5.9; P<0.001; MODIFY II: 15% [58 of 390] vs. 26% [97 of 378]; adjusted difference, -10.7 percentage points; 95% CI, -16.4 to -5.1; P<0.001).  In prespecified subgroup analyses (combined data set), rates of recurrent infection were lower in both groups that received bezlotoxumab than in the placebo group in subpopulations at high risk for recurrent infection or for an adverse outcome.  The rates of initial clin. cure were 80% with bezlotoxumab alone, 73% with actoxumab plus bezlotoxumab, and 80% with placebo; the rates of sustained cure (initial clin. cure without recurrent infection in 12 wk) were 64%, 58%, and 54%, resp.  The rates of adverse events were similar among these groups; the most common events were diarrhea and nausea.  CONCLUSIONS: Among participants receiving antibiotic treatment for primary or recurrent C. difficile infection, bezlotoxumab was assocd. with a substantially lower rate of recurrent infection than placebo and had a safety profile similar to that of placebo.  The addn. of actoxumab did not improve efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV4wySuwYB5LVg90H21EOLACvtfcHk0li3ZaxpWsw9Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSnsb%252FE&md5=de04b2005b3aebc6772c210127008242</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1602615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1602615%26sid%3Dliteratum%253Aachs%26aulast%3DWilcox%26aufirst%3DM.%2BH.%26aulast%3DGerding%26aufirst%3DD.%2BN.%26aulast%3DPoxton%26aufirst%3DI.%2BR.%26aulast%3DKelly%26aufirst%3DC.%26aulast%3DNathan%26aufirst%3DR.%26aulast%3DBirch%26aufirst%3DT.%26aulast%3DCornely%26aufirst%3DO.%2BA.%26aulast%3DRahav%26aufirst%3DG.%26aulast%3DBouza%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJenkin%26aufirst%3DG.%26aulast%3DJensen%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DYoshida%26aufirst%3DJ.%26aulast%3DGabryelski%26aufirst%3DL.%26aulast%3DPedley%26aufirst%3DA.%26aulast%3DEves%26aufirst%3DK.%26aulast%3DTipping%26aufirst%3DR.%26aulast%3DGuris%26aufirst%3DD.%26aulast%3DKartsonis%26aufirst%3DN.%26aulast%3DDorr%26aufirst%3DM.%2BB.%26aulast%3D%26aulast%3D%26atitle%3DBezlotoxumab%2520for%2520prevention%2520of%2520recurrent%2520clostridium%2520difficile%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D305%26epage%3D317%26doi%3D10.1056%2FNEJMoa1602615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foxman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmaseda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, A.</span></span> <span> </span><span class="NLM_article-title">Association between the respiratory microbiome and susceptibility to influenza virus infection</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1195</span>– <span class="NLM_lpage">1203</span>, <span class="refDoi"> DOI: 10.1093/cid/ciz968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1093%2Fcid%2Fciz968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31562814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs12gsrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2020&pages=1195-1203&author=T.+K.+Tsangauthor=K.+H.+Leeauthor=B.+Foxmanauthor=A.+Balmasedaauthor=L.+Greshauthor=N.+Sanchezauthor=S.+Ojedaauthor=R.+Lopezauthor=Y.+Yangauthor=G.+Kuanauthor=A.+Gordon&title=Association+between+the+respiratory+microbiome+and+susceptibility+to+influenza+virus+infection&doi=10.1093%2Fcid%2Fciz968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Association between the respiratory microbiome and susceptibility to influenza virus infection</span></div><div class="casAuthors">Tsang, Tim K.; Lee, Kyu Han; Foxman, Betsy; Balmaseda, Angel; Gresh, Lionel; Sanchez, Nery; Ojeda, Sergio; Lopez, Roger; Yang, Yang; Kuan, Guillermina; Gordon, Aubree</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1195-1203</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Our aim is to quantify the assocn. between the nose/throat microbiome and susceptibility to influenza virus infection.  In this household transmission study, index cases with confirmed influenza virus infection and their household contacts were followed for 9-12 days to identify secondary influenza infections.  Respiratory swabs were collected at enrollment to identify and quantify bacterial species via high-performance sequencing.  Data were analyzed by an individual hazard-based transmission model that was adjusted for age, vaccination, and household size.  We recruited 115 index cases with influenza A(H3N2) or B infection and 436 household contacts.  We estd. that a 10-fold increase in the abundance in Streptococcus spp. and Prevotella salivae was assocd. with 48% (95% credible interval [CrI], 9-69%) and 25% (95% CrI, 0.5-42%) lower susceptibility to influenza A(H3N2) infection, resp.  In contrast, for influenza B infection, a 10-fold increase in the abundance in Streptococcus vestibularis and Prevotella spp. was assocd. with 63% (95% CrI, 17-83%) lower and 83% (95% CrI, 15-210%) higher susceptibility, resp.  Susceptibility to influenza infection is assocd. with the nose/throat microbiome at the time of exposure.  Our results suggest that microbiome may be a useful predictor of susceptibility, with the implication that microbiome could be modulated to reduce influenza infection risk, should these assocns. be causal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouC-owfgIDPbVg90H21EOLACvtfcHk0li3ZaxpWsw9Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs12gsrnE&md5=469b30f7bcf65809e082eba7dbd27a66</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciz968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciz968%26sid%3Dliteratum%253Aachs%26aulast%3DTsang%26aufirst%3DT.%2BK.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DFoxman%26aufirst%3DB.%26aulast%3DBalmaseda%26aufirst%3DA.%26aulast%3DGresh%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DN.%26aulast%3DOjeda%26aufirst%3DS.%26aulast%3DLopez%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DKuan%26aufirst%3DG.%26aulast%3DGordon%26aufirst%3DA.%26atitle%3DAssociation%2520between%2520the%2520respiratory%2520microbiome%2520and%2520susceptibility%2520to%2520influenza%2520virus%2520infection%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2020%26volume%3D71%26spage%3D1195%26epage%3D1203%26doi%3D10.1093%2Fcid%2Fciz968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Indolfi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easterbrook, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dusheiko, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Sayed, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulterys, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siberry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.-H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Hepatitis c virus infection in children and adolescents</span>. <i>Lancet Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1016/S2468-1253(19)30046-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS2468-1253%2819%2930046-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30982721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252Flt1Wjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=477-487&author=G.+Indolfiauthor=P.+Easterbrookauthor=G.+Dusheikoauthor=M.+H.+El-Sayedauthor=M.+M.+Jonasauthor=C.+Thorneauthor=M.+Bulterysauthor=G.+Siberryauthor=N.+Walshauthor=M.-H.+Chang&title=Hepatitis+c+virus+infection+in+children+and+adolescents&doi=10.1016%2FS2468-1253%2819%2930046-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus infection in children and adolescents</span></div><div class="casAuthors">Indolfi Giuseppe; Easterbrook Philippa; Dusheiko Geoffrey; El-Sayed Manal H; Jonas Maureen M; Thorne Claire; Bulterys Marc; Penazzato Martina; Siberry George; Walsh Nick; Chang Mei-Hwei; Meyers Tammy; Giaquinto Carlo; Wirth Stefan; Chan Po-Lin</div><div class="citationInfo"><span class="NLM_cas:title">The lancet. Gastroenterology & hepatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">477-487</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and associated morbidity and mortality worldwide.  Short-course, oral, curative, direct-acting antiviral regimens have transformed treatment for HCV infection.  Since the 2016 launch of the first global strategy towards elimination of viral hepatitis as a public health threat by 2030, the predominant focus of the global response has been on the treatment of adults, who bear the greatest burden of morbidity and mortality of HCV-related chronic liver disease.  Compared with adults, there has been little attention paid to addressing the response to HCV in children and adolescents, in part because of the scarcity of data to inform specific paediatric management practices and policy.  In this Series paper, we summarise knowledge on the epidemiology, natural history, and treatment of chronic HCV infection in adolescents and children, and we highlight key differences from infection acquired in adulthood.  The estimated global prevalence and burden of HCV infection in children aged 1-19 years is 0·15%, corresponding to 3·5 million people (95% CI 3·1-3·9 million).  HCV infection is usually asymptomatic during childhood, and cirrhosis and hepatocellular carcinoma are rare.  Sofosbuvir with ledipasvir and sofosbuvir with ribavirin have received regulatory approval and guidelines recommend their use in adolescents aged 12 years and older with HCV infection.  In April, 2019, glecaprevir with pibrentasvir also received regulatory approval for adolescents aged 12-17 years.  Key actions to address the current policy gaps and achieve treatment scale-up that is comparable to that in adults include: establishment of a campaign on access to testing and treatment that is targeted at children and adolescents; fast-track evaluation of pan-genotypic regimens; and accelerated approval of paediatric formulations.  Research gaps that need to be addressed include: age-specific prevalence studies of HCV viraemia in priority countries; further validation of non-invasive tests for staging of liver disease in children; and establishment of paediatric treatment registries and international consortia to promote collaborative research agendas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgLXyOopm4iHy-c-E1v-fmfW6udTcc2eYIsJNdsWacqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252Flt1Wjsg%253D%253D&md5=f0fa1fb51b934216f2eba3de8a9010fc</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2FS2468-1253%2819%2930046-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2468-1253%252819%252930046-9%26sid%3Dliteratum%253Aachs%26aulast%3DIndolfi%26aufirst%3DG.%26aulast%3DEasterbrook%26aufirst%3DP.%26aulast%3DDusheiko%26aufirst%3DG.%26aulast%3DEl-Sayed%26aufirst%3DM.%2BH.%26aulast%3DJonas%26aufirst%3DM.%2BM.%26aulast%3DThorne%26aufirst%3DC.%26aulast%3DBulterys%26aufirst%3DM.%26aulast%3DSiberry%26aufirst%3DG.%26aulast%3DWalsh%26aufirst%3DN.%26aulast%3DChang%26aufirst%3DM.-H.%26atitle%3DHepatitis%2520c%2520virus%2520infection%2520in%2520children%2520and%2520adolescents%26jtitle%3DLancet%2520Gastroenterol.%2520Hepatol.%26date%3D2019%26volume%3D4%26spage%3D477%26epage%3D487%26doi%3D10.1016%2FS2468-1253%2819%2930046-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, R. T.</span></span> <span> </span><span class="NLM_article-title">Overview of direct-acting antiviral drugs and drug resistance of hepatitis c virus</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1911</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-8976-8_1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2F978-1-4939-8976-8_1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30593615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOlt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1911&publication_year=2019&pages=3-32&author=D.+K.+Liauthor=R.+T.+Chung&title=Overview+of+direct-acting+antiviral+drugs+and+drug+resistance+of+hepatitis+c+virus&doi=10.1007%2F978-1-4939-8976-8_1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of direct-acting antiviral drugs and drug resistance of hepatitis C virus</span></div><div class="casAuthors">Li, Darrick K.; Chung, Raymond T.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1911</span>
        (<span class="NLM_cas:issue">Hepatitis C Virus Protocols</span>),
    <span class="NLM_cas:pages">3-32</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The advent of direct-acting antivirals (DAAs) has brought about a sudden renaissance in the treatment of chronic hepatitis C virus (HCV) infection with SVR rates now routinely >90%.  However, due to the error-prone nature of the HCV RNA polymerase, resistance-assocd. substitutions (RASs) to DAAs may be present at baseline and can result in a significant effect on treatment outcomes and hamper the achievement of sustained virol. response.  By further understanding the patterns and nature of these RASs, it is anticipated that the incidence of treatment failure will continue to decrease in frequency with the development of drug regimens with increasing potency, barrier to resistance, and genotypic efficacy.  This review summarizes our current knowledge of RASs assocd. with HCV infection as well as the clin. effect of RASs on treatment with currently available DAA regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBMp7k4DAgQLVg90H21EOLACvtfcHk0liSpq14IDCcjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOlt73O&md5=2b19812051200f2e53703854f7d64641</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-8976-8_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-8976-8_1%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%2BK.%26aulast%3DChung%26aufirst%3DR.%2BT.%26atitle%3DOverview%2520of%2520direct-acting%2520antiviral%2520drugs%2520and%2520drug%2520resistance%2520of%2520hepatitis%2520c%2520virus%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2019%26volume%3D1911%26spage%3D3%26epage%3D32%26doi%3D10.1007%2F978-1-4939-8976-8_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Tecovirimat: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1377</span>– <span class="NLM_lpage">1382</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0967-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-018-0967-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30120738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFCku7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1377-1382&author=S.+M.+Hoy&title=Tecovirimat%3A+First+global+approval&doi=10.1007%2Fs40265-018-0967-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Tecovirimat: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1377-1382</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Tecovirimat (TPOXX) is an orthopoxvirus-specific antiviral drug developed by SIGA Technologies in conjunction with the US Department of Health and Human Services' Biomedical Advances Research and Development Authority.  It acts by inhibiting the activity of the orthopoxvirus VP37 envelope wrapping protein, thereby preventing the formation of egress-competent enveloped virions, which are essential for dissemination of the virus in the host.  In July 2018, oral tecovirimat was approved in the USA for the treatment of human smallpox disease caused by variola virus in adults and paediatric patients weighing ≥ 13 kg.  Tecovirimat was approved under the US FDA's Animal Rule, in which marketing approval is based on its efficacy in relevant animal models.  An i.v. formulation of tecovirimat is undergoing phase I development for the treatment of smallpox infection.  This article summarises the milestones in the development of tecovirimat leading to this first approval for the treatment of human smallpox disease in adults and paediatric patients weighing ≥ 13 kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsN9oWSErgorVg90H21EOLACvtfcHk0liSpq14IDCcjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFCku7bF&md5=5824b1ec39cfd2be5d1915a25debae3a</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0967-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0967-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DTecovirimat%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1377%26epage%3D1382%26doi%3D10.1007%2Fs40265-018-0967-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feachem, R. G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mpanju-Shumbusho, W.</span></span> <span> </span><span class="NLM_article-title">The lancet commission on malaria eradication</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span>,  <span class="NLM_fpage">1556</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)30911-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS0140-6736%2818%2930911-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29673872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC1MjksFCksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=1556-1558&author=I.+Chenauthor=R.+Cooneyauthor=R.+G.+A.+Feachemauthor=A.+Lalauthor=W.+Mpanju-Shumbusho&title=The+lancet+commission+on+malaria+eradication&doi=10.1016%2FS0140-6736%2818%2930911-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">The Lancet Commission on malaria eradication</span></div><div class="casAuthors">Chen Ingrid; Cooney Rebecca; Feachem Richard G A; Lal Altaf; Mpanju-Shumbusho Winnie</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">10130</span>),
    <span class="NLM_cas:pages">1556-1558</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKwo8-BMi-wpdYoSR9eyvsfW6udTcc2ebKMqRDCXF2rbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjksFCksQ%253D%253D&md5=34e0dc1ab91c668a37c8c90928795efc</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2930911-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252930911-5%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DI.%26aulast%3DCooney%26aufirst%3DR.%26aulast%3DFeachem%26aufirst%3DR.%2BG.%2BA.%26aulast%3DLal%26aufirst%3DA.%26aulast%3DMpanju-Shumbusho%26aufirst%3DW.%26atitle%3DThe%2520lancet%2520commission%2520on%2520malaria%2520eradication%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26spage%3D1556%26epage%3D1558%26doi%3D10.1016%2FS0140-6736%2818%2930911-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucher, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missinou, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangelmaier, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsner, P. G.</span></span> <span> </span><span class="NLM_article-title">Malaria chemoprophylaxis with tafenoquine: A randomised study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">2041</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(00)02352-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS0140-6736%2800%2902352-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10885356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksl2lt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2000&pages=2041-5&author=B.+Lellauthor=J.+F.+Faucherauthor=M.+A.+Missinouauthor=S.+Borrmannauthor=O.+Dangelmaierauthor=J.+Hortonauthor=P.+G.+Kremsner&title=Malaria+chemoprophylaxis+with+tafenoquine%3A+A+randomised+study&doi=10.1016%2FS0140-6736%2800%2902352-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Malaria chemoprophylaxis with tafenoquine: a randomized study</span></div><div class="casAuthors">Lell, Bertrand; Faucher, Jean-Francois; Missinou, Michel Anoumou; Borrmann, Steffen; Dangelmaier, Oliver; Horton, John; Kremsner, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">9220</span>),
    <span class="NLM_cas:pages">2041-2045</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Ltd.</span>)
        </div><div class="casAbstract">Background: Tafenoquine is an analog of primaquine with an improved therapeutic and safety profile.  It has a long half-life and activity against liver-stage malaria parasites, so may be useful for chemoprophylaxis.  In this randomized, double-blind study we assessed the efficacy and safety of tafenoquine in different doses.  Methods: 2144 individuals aged 12-20 yr living in Lambarene, Gabon, an endemic area for Plasmodium falciparum malaria, were invited to take part.  535 Attended, and 426 eligible participants were randomly assigned tafenoquine (250 mg, 125 mg, 62.5 mg, or 31.25 mg) or placebo daily for 3 days.  417 Received initial curative treatment with halofantrine, and 410 completed the assigned prophylaxis regimen.  During follow-up of 70 days, adverse events were recorded and thick blood smears were examd. weekly.  The primary and secondary endpoints were the no. of individuals with pos. blood smears by day 56 and day 77, resp.  Analyses were per-protocol.  Findings: Eight pos. blood smears were recorded by day 56 (four/82 participants in the placebo group; four/79 tafenoquine 31.25 mg group).  By day 77, 34 pos. blood smears had been recorded (14/82 placebo; 16/79 tafenoquine 31.25 mg; three/86 tafenoquine 62.5 mg; one/79 tafenoquine 125 mg; none/84 tafenoquine 250 mg).  Nos. of adverse events did not differ significantly between the treatment groups.  Interpretation: Tafenoquine is effective and well tolerated.  It has the potential to replace currently used drugs for malaria chemoprophylaxis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh-QTW9SUuGrVg90H21EOLACvtfcHk0ljxyOsJTps_Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksl2lt7k%253D&md5=8b2a30a90eefb73f5ccc81db9a4f98e8</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2800%2902352-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252800%252902352-7%26sid%3Dliteratum%253Aachs%26aulast%3DLell%26aufirst%3DB.%26aulast%3DFaucher%26aufirst%3DJ.%2BF.%26aulast%3DMissinou%26aufirst%3DM.%2BA.%26aulast%3DBorrmann%26aufirst%3DS.%26aulast%3DDangelmaier%26aufirst%3DO.%26aulast%3DHorton%26aufirst%3DJ.%26aulast%3DKremsner%26aufirst%3DP.%2BG.%26atitle%3DMalaria%2520chemoprophylaxis%2520with%2520tafenoquine%253A%2520A%2520randomised%2520study%26jtitle%3DLancet%26date%3D2000%26volume%3D355%26spage%3D2041%26epage%3D5%26doi%3D10.1016%2FS0140-6736%2800%2902352-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span> </span><span class="NLM_article-title">Infectious disease therapeutics market emerging
players may yields
new opportunities 2020–2026</span> |  <i>Novartis
AG, Gilead, GlaxoSmithKline plc</i>; <span class="NLM_publisher-name">Janssen
Pharmaceutical Inc., f. Hoffmann-La Roche ltd., Biocryst Pharmaceuticals
Inc., Merck & co. Inc., Boehringer Ingelheim Gmbh etc</span>. <a href="https://primefeed.in/news/4878852/infectious-disease-therapeutics-market-emerging-players-may-yields-new-opportunities-2020-2026-novartis-ag-gilead-glaxosmithkline-plc-janssen-pharmaceutical-inc-f-hoffmann-la-roche-ltd-biocr/" class="extLink">https://primefeed.in/news/4878852/infectious-disease-therapeutics-market-emerging-players-may-yields-new-opportunities-2020-2026-novartis-ag-gilead-glaxosmithkline-plc-janssen-pharmaceutical-inc-f-hoffmann-la-roche-ltd-biocr/</a> (accessed Jun 30, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Infectious+disease+therapeutics+market+emerging%0Aplayers+may+yields%0Anew+opportunities+2020%E2%80%932026+%7C+Novartis%0AAG%2C+Gilead%2C+GlaxoSmithKline+plc%3B+Janssen%0APharmaceutical+Inc.%2C+f.+Hoffmann-La+Roche+ltd.%2C+Biocryst+Pharmaceuticals%0AInc.%2C+Merck+%26+co.+Inc.%2C+Boehringer+Ingelheim+Gmbh+etc.+https%3A%2F%2Fprimefeed.in%2Fnews%2F4878852%2Finfectious-disease-therapeutics-market-emerging-players-may-yields-new-opportunities-2020-2026-novartis-ag-gilead-glaxosmithkline-plc-janssen-pharmaceutical-inc-f-hoffmann-la-roche-ltd-biocr%2F+%28accessed+Jun+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DInfectious%2520disease%2520therapeutics%2520market%2520emerging%250Aplayers%2520may%2520yields%250Anew%2520opportunities%25202020%25E2%2580%25932026%26btitle%3DNovartis%250AAG%252C%2520Gilead%252C%2520GlaxoSmithKline%2520plc%26pub%3DJanssen%250APharmaceutical%2520Inc.%252C%2520f.%2520Hoffmann-La%2520Roche%2520ltd.%252C%2520Biocryst%2520Pharmaceuticals%250AInc.%252C%2520Merck%2520%2526%2520co.%2520Inc.%252C%2520Boehringer%2520Ingelheim%2520Gmbh%2520etc%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span> </span><span class="NLM_article-title">Global
anti-infective drugs market 2020</span>. <a href="https://www.pharmiweb.com/press-release/2020-10-08/covid-19-update-global-anti-infective-drugs-market-2020-major-players-are-merck-co-inc-f-ho" class="extLink">https://www.pharmiweb.com/press-release/2020-10-08/covid-19-update-global-anti-infective-drugs-market-2020-major-players-are-merck-co-inc-f-ho</a> (accessed Nov 24, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global%0Aanti-infective+drugs+market+2020.+https%3A%2F%2Fwww.pharmiweb.com%2Fpress-release%2F2020-10-08%2Fcovid-19-update-global-anti-infective-drugs-market-2020-major-players-are-merck-co-inc-f-ho+%28accessed+Nov+24%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGlobal%250Aanti-infective%2520drugs%2520market%25202020%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, A.</span>; <span class="NLM_string-name">Diamond, B.</span></span> <span> </span><span class="NLM_article-title">General features of autoimmune disease</span>. In  <i>The Autoimmune Diseases</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, N. R.</span>, <span class="NLM_string-name">Mackay, I. R.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_year">2020</span>; pp  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">44</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FB978-0-12-812102-3.00003-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=17-44&author=A.+Davidson&author=B.+Diamondauthor=N.+R.+Rose&author=I.+R.+Mackay&title=The+Autoimmune+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-812102-3.00003-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-812102-3.00003-8%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DA.%26atitle%3DGeneral%2520features%2520of%2520autoimmune%2520disease%26btitle%3DThe%2520Autoimmune%2520Diseases%26aulast%3DRose%26aufirst%3DN.%2BR.%26pub%3DElsevier%26date%3D2020%26spage%3D17%26epage%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeeth, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A. J.</span></span> <span> </span><span class="NLM_article-title">Burden of mortality associated with autoimmune diseases among females in the united kingdom</span>. <i>Am. J. Public Health</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">2279</span>– <span class="NLM_lpage">2287</span>, <span class="refDoi"> DOI: 10.2105/AJPH.2009.180273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2105%2FAJPH.2009.180273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=20864721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC3cfotlChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2010&pages=2279-2287&author=S.+L.+Thomasauthor=C.+Griffithsauthor=L.+Smeethauthor=C.+Rooneyauthor=A.+J.+Hall&title=Burden+of+mortality+associated+with+autoimmune+diseases+among+females+in+the+united+kingdom&doi=10.2105%2FAJPH.2009.180273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Burden of mortality associated with autoimmune diseases among females in the United Kingdom</span></div><div class="casAuthors">Thomas Sara L; Griffiths Clare; Smeeth Liam; Rooney Cleo; Hall Andrew J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of public health</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2279-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  We estimated the collective burden of mortality from autoimmune diseases among females in the United Kingdom and the effects of death certificate coding changes on this estimate.  METHODS:  We analyzed 1993-2003 England and Wales death certificate data for 3,150,267 females aged 1 year or older.  We identified death certificates that listed autoimmune conditions as underlying or contributory causes of death.  The percentages of all female deaths attributed to autoimmune disorders and to UK official mortality categories were ranked to determine the leading causes of death.  RESULTS:  In 2003, autoimmune diseases were the sixth or seventh most frequent underlying cause of death among females in all age groups below 75 years.  Results were similar when both underlying and contributory causes of death were considered.  The proportion of females dying with an autoimmune disorder remained relatively constant from 1993 to 2003.  Analyses indicated that death counts for specific autoimmune diseases had been underestimated.  CONCLUSIONS:  Autoimmune diseases are a leading cause of death among females in England and Wales, but their collective impact remains hidden in current disease classification systems.  Grouping these disorders together may help promote research needed to identify common determinants and future prevention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQbPNGXJJaw0uIHSmpohpd0fW6udTcc2eYzcseNoECMTLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cfotlChtQ%253D%253D&md5=7d6706244bf372939bd6f6a46e75319b</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.2105%2FAJPH.2009.180273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2105%252FAJPH.2009.180273%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DS.%2BL.%26aulast%3DGriffiths%26aufirst%3DC.%26aulast%3DSmeeth%26aufirst%3DL.%26aulast%3DRooney%26aufirst%3DC.%26aulast%3DHall%26aufirst%3DA.%2BJ.%26atitle%3DBurden%2520of%2520mortality%2520associated%2520with%2520autoimmune%2520diseases%2520among%2520females%2520in%2520the%2520united%2520kingdom%26jtitle%3DAm.%2520J.%2520Public%2520Health%26date%3D2010%26volume%3D100%26spage%3D2279%26epage%3D2287%26doi%3D10.2105%2FAJPH.2009.180273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkel, J.</span></span> <span> </span><span class="NLM_article-title">An analysis of fda-approved drugs for inflammation and autoimmune diseases</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">920</span>– <span class="NLM_lpage">3</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.drudis.2015.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25701283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFGmsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=920-3&author=M.+S.+Kinchauthor=J.+Merkel&title=An+analysis+of+fda-approved+drugs+for+inflammation+and+autoimmune+diseases&doi=10.1016%2Fj.drudis.2015.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of FDA-approved drugs for inflammation and autoimmune diseases</span></div><div class="casAuthors">Kinch, Michael S.; Merkel, Janie</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">920-923</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The term 'inflammation' captures a variety of disease processes linked with the immune system.  An anal. of US Food and Drug Administration (FDA)-approved nuclear mol. entities (NMEs) reveals notable trends in terms of acute and chronic inflammatory indications.  The no. of NMEs peaked during the 1990s and has since declined by more than 50%.  Whereas pharmaceutical companies have dominated the field, biotechnol. companies now receive half of new approvals and academia has a relatively large role in terms of pivotal first patents.  Another notable trend is that the relative no. of NMEs targeting allergy has been decreasing, whereas those targeting autoimmune indications is increasing.  Unlike other indications, NMEs for inflammation tend towards nuclear receptors and cytokines, and a disproportionate no. of biologics target cytokine pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwLqHW0ZtPtbVg90H21EOLACvtfcHk0lj7nojcBZ5EiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFGmsbg%253D&md5=8382c2c3efa6b343a08905e5f790358a</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DMerkel%26aufirst%3DJ.%26atitle%3DAn%2520analysis%2520of%2520fda-approved%2520drugs%2520for%2520inflammation%2520and%2520autoimmune%2520diseases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D920%26epage%3D3%26doi%3D10.1016%2Fj.drudis.2015.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapp, B. D.</span></span> <span> </span><span class="NLM_article-title">Relapsing and progressive forms of multiple sclerosis-insights from pathology</span>. <i>Curr. Opin. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">271</span>, <span class="refDoi"> DOI: 10.1097/WCO.0000000000000094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1097%2FWCO.0000000000000094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24722325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cnisFOnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=271&author=R.+Duttaauthor=B.+D.+Trapp&title=Relapsing+and+progressive+forms+of+multiple+sclerosis-insights+from+pathology&doi=10.1097%2FWCO.0000000000000094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Relapsing and progressive forms of multiple sclerosis: insights from pathology</span></div><div class="casAuthors">Dutta Ranjan; Trapp Bruce D</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  The predominant clinical disease course of multiple sclerosis starts with reversible episodes of neurological disability, which transforms into progressive neurological decline.  This review provides insight into the pathological differences during relapsing and progressive phases of multiple sclerosis.  RECENT FINDINGS:  The clinical course of multiple sclerosis is variable, and the disease can be classified into relapsing and progressive phases.  Pathological studies have been successful in distinguishing between these two forms of the disease and correlate with the clinical findings in terms of cellular responses, the inflammatory environment, and the location of lesions.  SUMMARY:  Available therapies for multiple sclerosis patients, while effective during the relapsing phase, have little benefit for progressive multiple sclerosis patients.  Development of therapies to benefit progressive multiple sclerosis patients will require a better understanding of the pathogenesis of progressive multiple sclerosis.  This review discusses and compares the pathological findings in relapsing and progressive multiple sclerosis patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRON0hRST94VBJ5E29YNGvQfW6udTcc2eaxdjLelu4LQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnisFOnsw%253D%253D&md5=e237043c17483968cdb8065fb2ffa844</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1097%2FWCO.0000000000000094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FWCO.0000000000000094%26sid%3Dliteratum%253Aachs%26aulast%3DDutta%26aufirst%3DR.%26aulast%3DTrapp%26aufirst%3DB.%2BD.%26atitle%3DRelapsing%2520and%2520progressive%2520forms%2520of%2520multiple%2520sclerosis-insights%2520from%2520pathology%26jtitle%3DCurr.%2520Opin.%2520Neurol.%26date%3D2014%26volume%3D27%26spage%3D271%26doi%3D10.1097%2FWCO.0000000000000094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan-Thakur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedlitschky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrör, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauch, B. H.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate and its receptors: A mutual link between blood coagulation and inflammation</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">831059</span>, <span class="refDoi"> DOI: 10.1155/2015/831059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1155%2F2015%2F831059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26604433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC28vltlCnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=831059&author=S.+Mahajan-Thakurauthor=A.+B%C3%B6hmauthor=G.+Jedlitschkyauthor=K.+Schr%C3%B6rauthor=B.+H.+Rauch&title=Sphingosine-1-phosphate+and+its+receptors%3A+A+mutual+link+between+blood+coagulation+and+inflammation&doi=10.1155%2F2015%2F831059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-Phosphate and Its Receptors: A Mutual Link between Blood Coagulation and Inflammation</span></div><div class="casAuthors">Mahajan-Thakur Shailaja; Bohm Andreas; Jedlitschky Gabriele; Rauch Bernhard H; Schror Karsten</div><div class="citationInfo"><span class="NLM_cas:title">Mediators of inflammation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">831059</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sphingosine-1-phosphate (S1P) is a versatile lipid signaling molecule and key regulator in vascular inflammation.  S1P is secreted by platelets, monocytes, and vascular endothelial and smooth muscle cells.  It binds specifically to a family of G-protein-coupled receptors, S1P receptors 1 to 5, resulting in downstream signaling and numerous cellular effects.  S1P modulates cell proliferation and migration, and mediates proinflammatory responses and apoptosis.  In the vascular barrier, S1P regulates permeability and endothelial reactions and recruitment of monocytes and may modulate atherosclerosis.  Only recently has S1P emerged as a critical mediator which directly links the coagulation factor system to vascular inflammation.  The multifunctional proteases thrombin and FXa regulate local S1P availability and interact with S1P signaling at multiple levels in various vascular cell types.  Differential expression patterns and intracellular signaling pathways of each receptor enable S1P to exert its widespread functions.  Although a vast amount of information is available about the functions of S1P and its receptors in the regulation of physiological and pathophysiological conditions, S1P-mediated mechanisms in the vasculature remain to be elucidated.  This review summarizes recent findings regarding the role of S1P and its receptors in vascular wall and blood cells, which link the coagulation system to inflammatory responses in the vasculature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgCQ2gQ7-Ixf6xYuD7tu2XfW6udTcc2eaxdjLelu4LQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vltlCnug%253D%253D&md5=65150376c5727f41a7e3cbe4269c0f29</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1155%2F2015%2F831059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F831059%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan-Thakur%26aufirst%3DS.%26aulast%3DB%25C3%25B6hm%26aufirst%3DA.%26aulast%3DJedlitschky%26aufirst%3DG.%26aulast%3DSchr%25C3%25B6r%26aufirst%3DK.%26aulast%3DRauch%26aufirst%3DB.%2BH.%26atitle%3DSphingosine-1-phosphate%2520and%2520its%2520receptors%253A%2520A%2520mutual%2520link%2520between%2520blood%2520coagulation%2520and%2520inflammation%26jtitle%3DMediators%2520Inflammation%26date%3D2015%26volume%3D2015%26spage%3D831059%26doi%3D10.1155%2F2015%2F831059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kausar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawaqed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alawneh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badaracco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niewold, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweiss, N. J.</span></span> <span> </span><span class="NLM_article-title">Ocrelizumab: A step forward in the evolution of b-cell therapy</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1517/14712590903018837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1517%2F14712590903018837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=19463076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Shs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=889-95&author=F.+Kausarauthor=K.+Mustafaauthor=G.+Sweisauthor=R.+Sawaqedauthor=K.+Alawnehauthor=R.+Salloumauthor=M.+Badaraccoauthor=T.+B.+Niewoldauthor=N.+J.+Sweiss&title=Ocrelizumab%3A+A+step+forward+in+the+evolution+of+b-cell+therapy&doi=10.1517%2F14712590903018837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Ocrelizumab: a step forward in the evolution of B-cell therapy</span></div><div class="casAuthors">Kausar, Fariha; Mustafa, Khader; Sweis, Ghaleb; Sawaqed, Ray; Alawneh, Khaldoon; Salloum, Rafah; Badaracco, Maria; Niewold, Timothy B.; Sweiss, Nadera J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">889-895</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Recent advances in our understanding of B-cell dysregulation and its important link to autoimmunity have brought about a radical change in the management of autoimmune diseases.  Over the past few years, encouraging data from several clin. trials of rituximab, a chimeric anti-CD20 antibody, have led to its approval for use in rheumatoid arthritis (RA).  These data, regarding clin. efficacy, safety, improved patient-reported outcomes and cost-effectiveness with the use of rituximab in patients with RA, have led to the exploration of other agents targeting B-cell functions.  Ocrelizumab, a novel humanized anti-CD20 antibody, has shown clin. efficacy and safety in a recently reported trial in patients with RA.  Future clin. trials will help evaluate further the role of ocrelizumab in RA and its potential use in other autoimmune diseases.  This review describes current understanding of B-cell therapy, the role of rituximab in the treatment of RA and the evolving role of ocrelizumab as a B-cell-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCbAgfaNlKfrVg90H21EOLACvtfcHk0lgO2o1TLSBHCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Shs7s%253D&md5=f925dd281664f0dcebe050f6591bdb37</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1517%2F14712590903018837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712590903018837%26sid%3Dliteratum%253Aachs%26aulast%3DKausar%26aufirst%3DF.%26aulast%3DMustafa%26aufirst%3DK.%26aulast%3DSweis%26aufirst%3DG.%26aulast%3DSawaqed%26aufirst%3DR.%26aulast%3DAlawneh%26aufirst%3DK.%26aulast%3DSalloum%26aufirst%3DR.%26aulast%3DBadaracco%26aufirst%3DM.%26aulast%3DNiewold%26aufirst%3DT.%2BB.%26aulast%3DSweiss%26aufirst%3DN.%2BJ.%26atitle%3DOcrelizumab%253A%2520A%2520step%2520forward%2520in%2520the%2520evolution%2520of%2520b-cell%2520therapy%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2009%26volume%3D9%26spage%3D889%26epage%3D95%26doi%3D10.1517%2F14712590903018837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulds, D.</span></span> <span> </span><span class="NLM_article-title">Daclizumab: A review of its use in the prevention of acute rejection in renal transplant recipients</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.2165/00003495-199958060-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2165%2F00003495-199958060-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10651389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3cXpt1Oruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1999&pages=1029-42&author=L.+R.+Wisemanauthor=D.+Faulds&title=Daclizumab%3A+A+review+of+its+use+in+the+prevention+of+acute+rejection+in+renal+transplant+recipients&doi=10.2165%2F00003495-199958060-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients</span></div><div class="casAuthors">Wiseman, Lynda R.; Faulds, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1029-1042</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with 37 refs.  The humanized monoclonal antibody daclizumab is an immunosuppressive agent that reduces acute rejection in renal transplant recipients.  It is specific for the α subunit (Tac/CD25) of the interleukin-2 (IL-2) receptor on activated T cells and achieves immunosuppression by competitive antagonism of IL-2 induced T cell proliferation.  Daclizumab has advantages over murine antibodies to the IL-2 receptor, including improved effector function, a low potential for immunogenicity and long elimination half-life.  When added to std. cyclosporin-based immunosuppressive therapy with or without azathioprine, daclizumab (1 mg/kg prior to surgery and once every 2 wk thereafter for a total of 5 doses) significantly reduced the 6-mo rate of acute rejection compared with placebo in 2 phase III studies.  The mean no. of rejection episodes was significantly reduced and the time to first acute rejection significantly increased in daclizumab vs. placebo recipients.  Patient survival at 1 yr after transplantation was significantly higher with daclizumab than placebo in 1 study and showed a trend in favor of the drug in the other study.  The 1-yr graft survival rate tended to be greater in daclizumab than in placebo recipients in both studies.  In a phase II study, acute rejection rates in patients treated with both daclizumab and mycophenolate mofetil (plus std. cyclosporin-based immunosuppression) were lower than those achieved with mycophenolate mofetil alone.  Preliminary results indicate that daclizumab is also a useful agent in pediatric renal transplant recipients.  Further investigation of the efficacy and tolerability of the drug in this patient group is clearly warranted.  Daclizumab does not increase the incidence of adverse events when added to std. cyclosporin-based therapy.  The incidence of opportunistic infections, lymphoproliferative disorders and malignancies was not increased above that seen with placebo.  Although the effects of daclizumab on long term graft and patient survival require further investigation, available data indicate that daclizumab is an important advance in renal transplant immunosuppression, reducing acute graft rejection without affecting the tolerability of std. cyclosporin-based immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbNaMYRpuk6rVg90H21EOLACvtfcHk0ljLpUQh-J8UsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXpt1Oruw%253D%253D&md5=b4ca1b0bc843c8840d1d60bcacd79fcf</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.2165%2F00003495-199958060-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199958060-00006%26sid%3Dliteratum%253Aachs%26aulast%3DWiseman%26aufirst%3DL.%2BR.%26aulast%3DFaulds%26aufirst%3DD.%26atitle%3DDaclizumab%253A%2520A%2520review%2520of%2520its%2520use%2520in%2520the%2520prevention%2520of%2520acute%2520rejection%2520in%2520renal%2520transplant%2520recipients%26jtitle%3DDrugs%26date%3D1999%26volume%3D58%26spage%3D1029%26epage%3D42%26doi%3D10.2165%2F00003495-199958060-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, S. F.</span></span> <span> </span><span class="NLM_article-title">Atopic dermatitis: Natural history, diagnosis, and treatment</span>. <i>ISRN Allergy</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">354250</span>, <span class="refDoi"> DOI: 10.1155/2014/354250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1155%2F2014%2F354250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25006501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cbgslyqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=354250&author=S.+F.+Thomsen&title=Atopic+dermatitis%3A+Natural+history%2C+diagnosis%2C+and+treatment&doi=10.1155%2F2014%2F354250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Atopic dermatitis: natural history, diagnosis, and treatment</span></div><div class="casAuthors">Thomsen Simon Francis</div><div class="citationInfo"><span class="NLM_cas:title">ISRN allergy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">354250</span>
        ISSN:<span class="NLM_cas:issn">2090-5521</span>.
    </div><div class="casAbstract">Atopic dermatitis is an inflammatory skin disease with early onset and with a lifetime prevalence of approximately 20%.  The aetiology of atopic dermatitis is unknown, but the recent discovery of filaggrin mutations holds promise that the progression of atopic dermatitis to asthma in later childhood may be halted.  Atopic dermatitis is not always easily manageable and every physician should be familiar with the fundamental aspects of treatment.  This paper gives an overview of the natural history, clinical features, and treatment of atopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkT4oI_ibeCZNiNltV31zlfW6udTcc2eamafBXpVsvUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbgslyqug%253D%253D&md5=497df87a6d621ee0e38ff117372ad9c6</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1155%2F2014%2F354250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F354250%26sid%3Dliteratum%253Aachs%26aulast%3DThomsen%26aufirst%3DS.%2BF.%26atitle%3DAtopic%2520dermatitis%253A%2520Natural%2520history%252C%2520diagnosis%252C%2520and%2520treatment%26jtitle%3DISRN%2520Allergy%26date%3D2014%26volume%3D2014%26spage%3D354250%26doi%3D10.1155%2F2014%2F354250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silverberg, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, E. L.</span></span> <span> </span><span class="NLM_article-title">Associations of childhood eczema severity: A us population based study</span>. <i>Dermatitis</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">107</span>, <span class="refDoi"> DOI: 10.1097/DER.0000000000000034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1097%2FDER.0000000000000034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24819283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cjhvFCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=107&author=J.+I.+Silverbergauthor=E.+L.+Simpson&title=Associations+of+childhood+eczema+severity%3A+A+us+population+based+study&doi=10.1097%2FDER.0000000000000034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Associations of childhood eczema severity: a US population-based study</span></div><div class="casAuthors">Silverberg Jonathan I; Simpson Eric L</div><div class="citationInfo"><span class="NLM_cas:title">Dermatitis : contact, atopic, occupational, drug</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">107-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Little is known about the predictors of eczema severity in the US population.  OBJECTIVES:  We sought to determine the distribution and associations of childhood eczema severity in the United States.  METHODS:  We analyzed the data from the 2007 National Survey of Children's Health, a prospective questionnaire-based study of a nationally representative sample of 91,642 children (range, 0-17 years).  RESULTS:  The prevalence of childhood eczema was 12.97% (95% confidence interval [95% CI], 12.42-13.53); 67.0% (95% CI, 64.8-69.2) had mild disease, 26.0% (95% CI, 23.9-28.1) had moderate disease, and 7.0% (95% CI, 5.8-8.3) had severe disease.  There was significant statewide variation of the distribution of eczema severity (Rao-Scott χ, P = 0.004), with highest rates of severe disease in Mid-Atlantic and Midwestern states.  In univariate models, eczema severity was increased with older age, African American and Hispanic race/ethnicity, lower household income, oldest child in the family, home with a single mother, lower paternal/maternal education level, maternal general health, maternal/paternal emotional health, dilapidated housing, and garbage on the streets.  In multivariate survey logistic regression models using stepwise and backward selection, moderate-to-severe eczema was associated with older age, lower household income, and fair or poor maternal health but inversely associated with birthplace outside the United States.  CONCLUSIONS:  These data indicate that environmental and/or lifestyle factors play an important role in eczema severity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfehAGvPZK_UPI-fCgwosgfW6udTcc2eamafBXpVsvUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjhvFCjtQ%253D%253D&md5=6b3ca3d890842a8e393bfbfa5438ea6d</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1097%2FDER.0000000000000034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FDER.0000000000000034%26sid%3Dliteratum%253Aachs%26aulast%3DSilverberg%26aufirst%3DJ.%2BI.%26aulast%3DSimpson%26aufirst%3DE.%2BL.%26atitle%3DAssociations%2520of%2520childhood%2520eczema%2520severity%253A%2520A%2520us%2520population%2520based%2520study%26jtitle%3DDermatitis%26date%3D2014%26volume%3D25%26spage%3D107%26doi%3D10.1097%2FDER.0000000000000034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, R. L.</span></span> <span> </span><span class="NLM_article-title">The differential expression of il-4 and il-13 and its impact on type-2 immunity</span>. <i>Cytokine+</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.cyto.2015.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.cyto.2015.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26073683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsVymtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=25-37&author=K.+Baoauthor=R.+L.+Reinhardt&title=The+differential+expression+of+il-4+and+il-13+and+its+impact+on+type-2+immunity&doi=10.1016%2Fj.cyto.2015.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">The differential expression of IL-4 and IL-13 and its impact on type-2 immunity</span></div><div class="casAuthors">Bao, Katherine; Reinhardt, R. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-37</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Allergic disease represents a significant global health burden, and disease incidence continues to rise in urban areas of the world.  As such, a better understanding of the basic immune mechanisms underlying disease pathol. are key to developing therapeutic interventions to both prevent disease onset as well as to ameliorate disease morbidity in those individuals already suffering from a disorder linked to type-2 inflammation.  Two factors central to type-2 immunity are interleukin (IL)-4 and IL-13, which have been linked to virtually all major hallmarks assocd. with type-2 inflammation.  Therefore, IL-4 and IL-13 and their regulatory pathways represent ideal targets to suppress disease.  Despite sharing many common regulatory pathways and receptors, these cytokines perform very distinct functions during a type-2 immune response.  This review summarizes the literature surrounding the function and expression of IL-4 and IL-13 in CD4+ T cells and innate immune cells.  It highlights recent findings in vivo regarding the differential expression and non-canonical regulation of IL-4 and IL-13 in various immune cells, which likely play important and underappreciated roles in type-2 immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5DYfYNAeHkbVg90H21EOLACvtfcHk0li-5Q5tKuMHuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsVymtbY%253D&md5=3d28d9e63e002fc3f6ed66dc89c3c87c</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2015.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2015.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DK.%26aulast%3DReinhardt%26aufirst%3DR.%2BL.%26atitle%3DThe%2520differential%2520expression%2520of%2520il-4%2520and%2520il-13%2520and%2520its%2520impact%2520on%2520type-2%2520immunity%26jtitle%3DCytokine%252B%26date%3D2015%26volume%3D75%26spage%3D25%26epage%3D37%26doi%3D10.1016%2Fj.cyto.2015.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bealgey, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, S.</span></span> <span> </span><span class="NLM_article-title">Interleukin-23: Immunological roles and clinical implications</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2008.04.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.biocel.2008.04.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=18725317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitFSmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2009&pages=733-5&author=Z.+Y.+Tanauthor=K.+W.+Bealgeyauthor=Y.+Fangauthor=Y.+M.+Gongauthor=S.+Bao&title=Interleukin-23%3A+Immunological+roles+and+clinical+implications&doi=10.1016%2Fj.biocel.2008.04.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-23: Immunological roles and clinical implications</span></div><div class="casAuthors">Tan, Zi Yan; Bealgey, Kenneth W.; Fang, Yong; Gong, Yang Ming; Bao, Shisan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-735</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Increasing evidence has revealed the importance of IL-23, which closely resembles IL-12 both structurally and immunol., in linking innate and adaptive immunity.  IL-23, produced by activated type 1 macrophages and dendritic cells (DC), possesses unique roles in the differentiation and expansion of memory T cells.  IL-23 has been assocd. with several inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease (IBD) and Helicobacter pylori assocd. gastritis, mainly due to its capacity to induce a strong Th1 type immune response.  IL-23 is also assocd. with Th17 responses and the cytokine produced by the antigen presenting cells (APC), i.e.  IL-12 vs. IL-23 dets. in part if a response is Th1 or Th17.  Recent studies have also assocd. chronic inflammatory diseases such as IBD, psoriasis and myocardial infarction with polymorphisms of the IL-23 receptor complex.  The current review focuses on the immunol. role of IL-23 and possible therapeutic avenues for inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfncF9BH-Q9bVg90H21EOLACvtfcHk0li-5Q5tKuMHuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitFSmt7s%253D&md5=638a848d456e0d20c4a58b285278609d</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2008.04.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2008.04.027%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DZ.%2BY.%26aulast%3DBealgey%26aufirst%3DK.%2BW.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DY.%2BM.%26aulast%3DBao%26aufirst%3DS.%26atitle%3DInterleukin-23%253A%2520Immunological%2520roles%2520and%2520clinical%2520implications%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2009%26volume%3D41%26spage%3D733%26epage%3D5%26doi%3D10.1016%2Fj.biocel.2008.04.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span> <span> </span><span class="NLM_article-title">Interleukin-23: As a drug target for autoimmune inflammatory diseases</span>. <i>Immunology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2567.2011.03522.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1111%2Fj.1365-2567.2011.03522.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=22044352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1eitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2012&pages=112-124&author=C.+Tangauthor=S.+Chenauthor=H.+Qianauthor=W.+Huang&title=Interleukin-23%3A+As+a+drug+target+for+autoimmune+inflammatory+diseases&doi=10.1111%2Fj.1365-2567.2011.03522.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-23: as a drug target for autoimmune inflammatory diseases</span></div><div class="casAuthors">Tang, Chunlei; Chen, Shu; Qian, Hai; Huang, Wenlong</div><div class="citationInfo"><span class="NLM_cas:title">Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">112-124</span>CODEN:
                <span class="NLM_cas:coden">IMMUAM</span>;
        ISSN:<span class="NLM_cas:issn">0019-2805</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Interleukin-23 (IL-23) is a member of the IL-12 family of cytokines with pro-inflammatory properties.  Its ability to potently enhance the expansion of T helper type 17 (Th17) cells indicates the responsibility for many of the inflammatory autoimmune responses.  Emerging data demonstrate that IL-23 is a key participant in central regulation of the cellular mechanisms involved in inflammation.  Both IL-23 and IL-17 form a new axis through Th17 cells, which has evolved in response to human diseases assocd. with immunoactivation and immunopathogeny, including bacterial or viral infections and chronic inflammation.  Targeting of IL-23 or the IL-23 receptor or IL-23 axis is a potential therapeutic approach for autoimmune diseases including psoriasis, inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis.  The current review focuses on the immunobiol. of IL-23 and summarizes the most recent findings on the role of IL-23 in the pre-clin. and ongoing clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiMRA-yJqoe7Vg90H21EOLACvtfcHk0li-5Q5tKuMHuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1eitLo%253D&md5=65fb41e874810ffc7aaaaf69ddb819dc</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2567.2011.03522.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2567.2011.03522.x%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DQian%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DW.%26atitle%3DInterleukin-23%253A%2520As%2520a%2520drug%2520target%2520for%2520autoimmune%2520inflammatory%2520diseases%26jtitle%3DImmunology%26date%3D2012%26volume%3D135%26spage%3D112%26epage%3D124%26doi%3D10.1111%2Fj.1365-2567.2011.03522.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fasching, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stradner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graninger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejaco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessler, J.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of targeting the th17/treg axis in autoimmune disorders</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">134</span>, <span class="refDoi"> DOI: 10.3390/molecules22010134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3390%2Fmolecules22010134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVGmtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=134&author=P.+Faschingauthor=M.+Stradnerauthor=W.+Graningerauthor=C.+Dejacoauthor=J.+Fessler&title=Therapeutic+potential+of+targeting+the+th17%2Ftreg+axis+in+autoimmune+disorders&doi=10.3390%2Fmolecules22010134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of targeting the Th17/Treg axis in autoimmune disorders</span></div><div class="casAuthors">Fasching, Patrizia; Stradner, Martin; Graninger, Winfried; Dejaco, Christian; Fessler, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134/1-134/24</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A disruption of the crucial balance between regulatory T-cells (Tregs) and Th17-cells was recently implicated in various autoimmune disorders.  Tregs are responsible for the maintenance of self-tolerance, thus inhibiting autoimmunity, whereas pro-inflammatory Th17-cells contribute to the induction and propagation of inflammation.  Distortion of the Th17/Treg balance favoring the pro-inflammatory Th17 side is hence suspected to contribute to exacerbation of autoimmune disorders.  This review aims to summarize recent data and advances in targeted therapeutic modification of the Th17/Treg-balance, as well as information on the efficacy of candidate therapeutics with respect to the treatment of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvXkj6KpTgU7Vg90H21EOLACvtfcHk0ljKD1cvE0xofw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVGmtLo%253D&md5=e649423f20ab7ff0e4db9c8eb4234005</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22010134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22010134%26sid%3Dliteratum%253Aachs%26aulast%3DFasching%26aufirst%3DP.%26aulast%3DStradner%26aufirst%3DM.%26aulast%3DGraninger%26aufirst%3DW.%26aulast%3DDejaco%26aufirst%3DC.%26aulast%3DFessler%26aufirst%3DJ.%26atitle%3DTherapeutic%2520potential%2520of%2520targeting%2520the%2520th17%252Ftreg%2520axis%2520in%2520autoimmune%2520disorders%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D134%26doi%3D10.3390%2Fmolecules22010134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span> <span> </span><span class="NLM_article-title">Interleukin 6 and rheumatoid arthritis</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">698313</span>, <span class="refDoi"> DOI: 10.1155/2014/698313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1155%2F2014%2F698313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24524085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2crmsVKltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=698313&author=Y.+Yoshidaauthor=T.+Tanaka&title=Interleukin+6+and+rheumatoid+arthritis&doi=10.1155%2F2014%2F698313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin 6 and rheumatoid arthritis</span></div><div class="casAuthors">Yoshida Yuji; Tanaka Toshio</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">698313</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Interleukin-6 (IL-6) is a representative cytokine featuring pleiotropic activity and redundancy.  A transient synthesis of IL-6 contributes to host defense against infectious agents and tissue injuries by inducing acute phase reactions and immunological and hematopoietic responses.  However, uncontrolled persistent production of IL-6 may lead to the development of several immune-mediated diseases.  Rheumatoid arthritis (RA) is a chronic disease with joint and systemic inflammation resulting from immunological abnormalities and it has been found that IL-6 plays a key role in the development of this disease.  Clinical trials in various parts of the world of tocilizumab, a humanized anti-IL-6 receptor antibody, have proved its efficacy and tolerable safety either as monotherapy or in combination with disease-modifying antirheumatic drugs.  As a result, it is currently used as a first-line biologic for the treatment of moderate-to-severe RA in more than 100 countries.  Clarification of the mechanism(s) through which tocilizumab exerts its effect on RA and of the reason(s) why IL-6 is continuously produced in RA can be expected to lead to the best use of this agent for RA patients and aid in investigations into the pathogenesis of RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWZ0g10qbTe0HdcurJClFcfW6udTcc2eYmNL9pCafwyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crmsVKltg%253D%253D&md5=5e1f91da87a60ca9d77d6d80a418881f</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1155%2F2014%2F698313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F698313%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DT.%26atitle%3DInterleukin%25206%2520and%2520rheumatoid%2520arthritis%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2014%26volume%3D2014%26spage%3D698313%26doi%3D10.1155%2F2014%2F698313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dargham, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahirovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammoudeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Emadi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masri, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halabi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badsha, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uthman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahfoud, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashour, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gad El Haq, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayoumy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapiri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenge, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazkaz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arayssi, T.</span></span> <span> </span><span class="NLM_article-title">Epidemiology and treatment patterns of rheumatoid arthritis in a large cohort of arab patients</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0208240</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0208240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1371%2Fjournal.pone.0208240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30566451" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=S.+R.+Darghamauthor=S.+Zahirovicauthor=M.+Hammoudehauthor=S.+Al+Emadiauthor=B.+K.+Masriauthor=H.+Halabiauthor=H.+Badshaauthor=I.+Uthmanauthor=Z.+R.+Mahfoudauthor=H.+Ashourauthor=W.+Gad+El+Haqauthor=K.+Bayoumyauthor=M.+Kapiriauthor=R.+Saxenaauthor=R.+M.+Plengeauthor=L.+Kazkazauthor=T.+Arayssi&title=Epidemiology+and+treatment+patterns+of+rheumatoid+arthritis+in+a+large+cohort+of+arab+patients&doi=10.1371%2Fjournal.pone.0208240"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0208240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0208240%26sid%3Dliteratum%253Aachs%26aulast%3DDargham%26aufirst%3DS.%2BR.%26aulast%3DZahirovic%26aufirst%3DS.%26aulast%3DHammoudeh%26aufirst%3DM.%26aulast%3DAl%2BEmadi%26aufirst%3DS.%26aulast%3DMasri%26aufirst%3DB.%2BK.%26aulast%3DHalabi%26aufirst%3DH.%26aulast%3DBadsha%26aufirst%3DH.%26aulast%3DUthman%26aufirst%3DI.%26aulast%3DMahfoud%26aufirst%3DZ.%2BR.%26aulast%3DAshour%26aufirst%3DH.%26aulast%3DGad%2BEl%2BHaq%26aufirst%3DW.%26aulast%3DBayoumy%26aufirst%3DK.%26aulast%3DKapiri%26aufirst%3DM.%26aulast%3DSaxena%26aufirst%3DR.%26aulast%3DPlenge%26aufirst%3DR.%2BM.%26aulast%3DKazkaz%26aufirst%3DL.%26aulast%3DArayssi%26aufirst%3DT.%26atitle%3DEpidemiology%2520and%2520treatment%2520patterns%2520of%2520rheumatoid%2520arthritis%2520in%2520a%2520large%2520cohort%2520of%2520arab%2520patients%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0208240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raimondo, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggioggero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crotti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becciolini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favalli, E. G.</span></span> <span> </span><span class="NLM_article-title">Profile of sarilumab and its potential in the treatment of rheumatoid arthritis</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1593</span>– <span class="NLM_lpage">1603</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S100302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2147%2FDDDT.S100302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28579757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKns7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=1593-1603&author=M.+G.+Raimondoauthor=M.+Biggioggeroauthor=C.+Crottiauthor=A.+Beccioliniauthor=E.+G.+Favalli&title=Profile+of+sarilumab+and+its+potential+in+the+treatment+of+rheumatoid+arthritis&doi=10.2147%2FDDDT.S100302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of sarilumab and its potential in the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Raimondo, Maria Gabriella; Biggioggero, Martina; Crotti, Chiara; Becciolini, Andrea; Favalli, Ennio Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1593-1603</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">In recent years the use of biotechnol. agents has drastically revolutionized the therapeutic approach and the progression of rheumatoid arthritis (RA).  In particular, interleukin-6 (IL-6) has been demonstrated as a pivotal cytokine in the pathogenesis of the disease by contributing to both the innate and the adaptive immune system perturbation, and to the prodn. of acute-phase proteins involved in the systemic expression of the disorder.  The first marketed IL-6 blocker was tocilizumab, a humanized anti-IL-6 receptor (anti-IL-6R) monoclonal antibody.  The successful use of tocilizumab in RA has encouraged the development of other biol. agents specifically targeting the IL-6 pathway, either directed against IL-6 cytokine (sirukumab, olokizumab, and clazakizumab) or IL-6 receptor (sarilumab).  One Phase II and six Phase III randomized controlled trials demonstrated a broad efficacy of sarilumab across all RA patient subtypes, ranging from methotrexate (MTX) to tumor necrosis factor inhibitor insufficient responders.  In particular, sarilumab as monotherapy demonstrated a clear head-to-head superiority over adalimumab in MTX-intolerant subjects.  In addn., compared with tocilizumab, sarilumab showed a similar safety profile with significantly higher affinity and longer half-life, responsible for a redn. of the frequency of administration (every other week instead weekly).  All these aspects may be important in defining the strategy for positioning sarilumab in the treatment algorithm of RA.  Indeed, observational data coming from post-marketing real-life studies may provide crucial addnl. information for better understanding the role of sarilumab in the management of the disease.  This review summarizes both the biol. role of IL-6 in RA and the clin. data available on sarilumab as an alternative therapeutic option in RA patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot8VGylpwQ0rVg90H21EOLACvtfcHk0ljKD1cvE0xofw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKns7rP&md5=8b8d8fdb091701ee2ff94667c4eb2603</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S100302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S100302%26sid%3Dliteratum%253Aachs%26aulast%3DRaimondo%26aufirst%3DM.%2BG.%26aulast%3DBiggioggero%26aufirst%3DM.%26aulast%3DCrotti%26aufirst%3DC.%26aulast%3DBecciolini%26aufirst%3DA.%26aulast%3DFavalli%26aufirst%3DE.%2BG.%26atitle%3DProfile%2520of%2520sarilumab%2520and%2520its%2520potential%2520in%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D1593%26epage%3D1603%26doi%3D10.2147%2FDDDT.S100302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Baricitinib: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0723-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-017-0723-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28290136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksVOlur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=697-704&author=A.+Markham&title=Baricitinib%3A+First+global+approval&doi=10.1007%2Fs40265-017-0723-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">697-704</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Baricitinib (Olumiant) is an orally-administered, small-mol., janus-assocd. kinase (JAK) inhibitor developed by Eli Lilly and Incyte Corporation for the treatment of rheumatoid arthritis (RA), atopic dermatitis and systemic lupus erythematosus.  JAKs transduce intracellular signals from cell surface receptors for various cytokines and growth factors involved in inflammation and immune function, suggesting JAK inhibitors may be of therapeutic benefit in inflammatory conditions.  In Feb. 2017, baricitinib was approved in the EU, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).  Regulatory approval to market baricitinib as a treatment for RA has also been sought in the USA and Japan.  This article summarizes the milestones in the development of baricitinib leading to this first global approval for the treatment for moderate to severe active RA in adult patients who have responded inadequately to, or are intolerant to one or more DMARDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo-U2lbkEPpbVg90H21EOLACvtfcHk0ljuN2ttxWiLEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksVOlur8%253D&md5=54dbb2c53eb3cfd5831284df95beb184</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0723-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0723-3%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DBaricitinib%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D697%26epage%3D704%26doi%3D10.1007%2Fs40265-017-0723-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Jak inhibition as a therapeutic strategy for immune and inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843-862&author=D.+M.+Schwartzauthor=Y.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=Jak+inhibition+as+a+therapeutic+strategy+for+immune+and+inflammatory+diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0ljuN2ttxWiLEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJak%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520immune%2520and%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26epage%3D862%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Upadacitinib: First approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1819</span>– <span class="NLM_lpage">1828</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01211-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-019-01211-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31642025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3MjgvVSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1819-1828&author=S.+Dugganauthor=S.+J.+Keam&title=Upadacitinib%3A+First+approval&doi=10.1007%2Fs40265-019-01211-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Upadacitinib: First Approval</span></div><div class="casAuthors">Duggan Sean; Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1819-1828</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Upadacitinib (Rinvoq®), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis.  In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of moderately to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate.  This article summarizes the milestones in the development of upadacitinib leading to this first approval for the treatment of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfxtr5CsQWZxWfpMXQLRstfW6udTcc2eYX6QGG2INKr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjgvVSrtg%253D%253D&md5=3ef93907bbec16e744d0fb2b6dae65e0</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01211-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01211-z%26sid%3Dliteratum%253Aachs%26aulast%3DDuggan%26aufirst%3DS.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DUpadacitinib%253A%2520First%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1819%26epage%3D1828%26doi%3D10.1007%2Fs40265-019-01211-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banjade, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhakal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, V. R.</span></span> <span> </span><span class="NLM_article-title">Thrombocytopenia in patients with chronic hepatitis c virus infection</span>. <i>J. Hematol. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e2017019</span> <span class="refDoi"> DOI: 10.4084/mjhid.2017.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.4084%2Fmjhid.2017.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&author=S.+Dahalauthor=S.+Upadhyayauthor=R.+Banjadeauthor=P.+Dhakalauthor=N.+Khanalauthor=V.+R.+Bhatt&title=Thrombocytopenia+in+patients+with+chronic+hepatitis+c+virus+infection&doi=10.4084%2Fmjhid.2017.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.4084%2Fmjhid.2017.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4084%252Fmjhid.2017.019%26sid%3Dliteratum%253Aachs%26aulast%3DDahal%26aufirst%3DS.%26aulast%3DUpadhyay%26aufirst%3DS.%26aulast%3DBanjade%26aufirst%3DR.%26aulast%3DDhakal%26aufirst%3DP.%26aulast%3DKhanal%26aufirst%3DN.%26aulast%3DBhatt%26aufirst%3DV.%2BR.%26atitle%3DThrombocytopenia%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520c%2520virus%2520infection%26jtitle%3DJ.%2520Hematol.%2520Infect.%2520Dis.%26date%3D2016%26volume%3D9%26doi%3D10.4084%2Fmjhid.2017.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Samkari, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuter, D. J.</span></span> <span> </span><span class="NLM_article-title">Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia</span>. <i>Ther. Adv. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">204062071984173</span>, <span class="refDoi"> DOI: 10.1177/2040620719841735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1177%2F2040620719841735" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=204062071984173&author=H.+Al-Samkariauthor=D.+J.+Kuter&title=Optimal+use+of+thrombopoietin+receptor+agonists+in+immune+thrombocytopenia&doi=10.1177%2F2040620719841735"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1177%2F2040620719841735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040620719841735%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Samkari%26aufirst%3DH.%26aulast%3DKuter%26aufirst%3DD.%2BJ.%26atitle%3DOptimal%2520use%2520of%2520thrombopoietin%2520receptor%2520agonists%2520in%2520immune%2520thrombocytopenia%26jtitle%3DTher.%2520Adv.%2520Hematol.%26date%3D2019%26volume%3D10%26spage%3D204062071984173%26doi%3D10.1177%2F2040620719841735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Fostamatinib: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0927-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-018-0927-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29869203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=959-963&author=A.+Markham&title=Fostamatinib%3A+First+global+approval&doi=10.1007%2Fs40265-018-0927-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Fostamatinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">959-963</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Rigel Pharmaceuticals are developing the spleen tyrosine kinase (SYK) inhibitor fostamatinib (TAVALISSE) as a treatment for immune thrombocytopenia (ITP), autoimmune haemolytic anemia and IgA nephropathy.  Based on pos. results in the phase III FIT clin. trial program, the drug was recently approved in the US as a treatment for thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment.  This article summarizes the milestones in the development of fostamatinib leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgnmCw2LTVXrVg90H21EOLACvtfcHk0lh8FCEgjXxzHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsb7M&md5=e58fd226c946b7e2087a74d31eeba972</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0927-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0927-1%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DFostamatinib%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D959%26epage%3D963%26doi%3D10.1007%2Fs40265-018-0927-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulert, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grom, A. A.</span></span> <span> </span><span class="NLM_article-title">Macrophage activation syndrome and cytokine-directed therapies</span>. <i>Best Pract. Res.: Clin. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1016/j.berh.2014.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.berh.2014.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24974063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cbpsF2msg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=277-292&author=G.+S.+Schulertauthor=A.+A.+Grom&title=Macrophage+activation+syndrome+and+cytokine-directed+therapies&doi=10.1016%2Fj.berh.2014.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage activation syndrome and cytokine-directed therapies</span></div><div class="casAuthors">Schulert Grant S; Grom Alexei A</div><div class="citationInfo"><span class="NLM_cas:title">Best practice & research. Clinical rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">277-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Macrophage activation syndrome (MAS) is an episode of overwhelming inflammation that occurs most commonly in children with systemic juvenile idiopathic arthritis (SJIA).  It is characterized by expansion and activation of T lymphocytes and hemophagocytic macrophages and bears great similarity to hemophagocytic lymphohistiocytosis (HLH).  This disorder has substantial morbidity and mortality, and there is frequently a delay in recognition and initiation of treatment.  Here, we will review what is known about the pathogenesis of MAS and, in particular, its similarities to HLH.  The development of MAS is characterized by a cytokine storm, with the elaboration of numerous pro-inflammatory cytokines.  We will examine the evidence for various cytokines in the initiation and pathogenesis of MAS and discuss how new biologic therapies may alter the risk of MAS.  Finally, we will review current treatment options for MAS and examine how cytokine-directed therapy could serve as novel treatment modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHAMquXZywdJggzHGM8X5CfW6udTcc2eYc5cot2Bb8obntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbpsF2msg%253D%253D&md5=6ef0eeed0a0c295df1c822f9c7298d06</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.berh.2014.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.berh.2014.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DSchulert%26aufirst%3DG.%2BS.%26aulast%3DGrom%26aufirst%3DA.%2BA.%26atitle%3DMacrophage%2520activation%2520syndrome%2520and%2520cytokine-directed%2520therapies%26jtitle%3DBest%2520Pract.%2520Res.%253A%2520Clin.%2520Rheumatol.%26date%3D2014%26volume%3D28%26spage%3D277%26epage%3D292%26doi%3D10.1016%2Fj.berh.2014.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosse, W. F.</span></span> <span> </span><span class="NLM_article-title">Paroxysmal nocturnal hemoglobinuria as a molecular disease</span>. <i>Medicine</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1097/00005792-199703000-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1097%2F00005792-199703000-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=9100736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaK2sXntlKjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1997&pages=63-93&author=W.+F.+Rosse&title=Paroxysmal+nocturnal+hemoglobinuria+as+a+molecular+disease&doi=10.1097%2F00005792-199703000-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Paroxysmal nocturnal hemoglobinuria as a molecular disease</span></div><div class="casAuthors">Rosse, Wendell F.</div><div class="citationInfo"><span class="NLM_cas:title">Medicine (Baltimore)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">63-93</span>CODEN:
                <span class="NLM_cas:coden">MEDIAV</span>;
        ISSN:<span class="NLM_cas:issn">0025-7974</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review, with 330 refs., discussing the main clin. characteristics of paroxysmal nocturnal hemoglobinuria, the biochem. abnormalities of the disease and their mol. genetic basis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJv4RYRxLgS7Vg90H21EOLACvtfcHk0lh8FCEgjXxzHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXntlKjsbs%253D&md5=4d0dede71b4abc5c0342938cad3d92d9</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1097%2F00005792-199703000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005792-199703000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DRosse%26aufirst%3DW.%2BF.%26atitle%3DParoxysmal%2520nocturnal%2520hemoglobinuria%2520as%2520a%2520molecular%2520disease%26jtitle%3DMedicine%26date%3D1997%26volume%3D76%26spage%3D63%26epage%3D93%26doi%3D10.1097%2F00005792-199703000-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodsky, R. A.</span></span> <span> </span><span class="NLM_article-title">Paroxysmal nocturnal hemoglobinuria</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">2804</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-02-522128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1182%2Fblood-2014-02-522128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25237200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWqsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=2804-11&author=R.+A.+Brodsky&title=Paroxysmal+nocturnal+hemoglobinuria&doi=10.1182%2Fblood-2014-02-522128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Paroxysmal nocturnal hemoglobinuria</span></div><div class="casAuthors">Brodsky, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2804-2811</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Paroxysmal nocturnal hemoglobinuria (PNH) is a rare bone marrow failure disorder that manifests with hemolytic anemia, thrombosis, and peripheral blood cytopenias.  The absence of two glycosylphosphatidylinositol (GPI)-anchored proteins, CD55 and CD59, leads to uncontrolled complement activation that accounts for hemolysis and other PNH manifestations.  GPI anchor protein deficiency is almost always due to somatic mutations in phosphatidylinositol glycan class A (PIGA), a gene involved in the first step of GPI anchor biosynthesis; however, alternative mutations that cause PNH have recently been discovered.  In addn., hypomorphic germ-line PIGA mutations that do not cause PNH have been shown to be responsible for a condition known as multiple congenital anomalies-hypotonia-seizures syndrome 2.  Eculizumab, a first-in-class monoclonal antibody that inhibits terminal complement, is the treatment of choice for patients with severe manifestations of PNH.  Bone marrow transplantation remains the only cure for PNH but should be reserved for patients with suboptimal response to eculizumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQtU772cCcqLVg90H21EOLACvtfcHk0lhoOi9B1_b9kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWqsL%252FN&md5=b5d064494dbcbdb388bc4f2bf04be3a9</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-02-522128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-02-522128%26sid%3Dliteratum%253Aachs%26aulast%3DBrodsky%26aufirst%3DR.%2BA.%26atitle%3DParoxysmal%2520nocturnal%2520hemoglobinuria%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D2804%26epage%3D11%26doi%3D10.1182%2Fblood-2014-02-522128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKeage, K.</span></span> <span> </span><span class="NLM_article-title">Ravulizumab: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01068-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-019-01068-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30767127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=347-352&author=K.+McKeage&title=Ravulizumab%3A+First+global+approval&doi=10.1007%2Fs40265-019-01068-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Ravulizumab: First Global Approval</span></div><div class="casAuthors">McKeage, Kate</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-352</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Ravulizumab (ravulizumab-cwvz; ULTOMIRIS), a humanized monoclonal antibody, is a complement C5 inhibitor developed by Alexion Pharmaceuticals for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS).  Like the first-generation C5 inhibitor, eculizumab, ravulizumab binds specifically and with high affinity to the complement protein C5, thereby preventing formation of the terminal complement complex C5b-9, which mediates cell lysis.  In Dec. 2018, i.v. ravulizumab received its first global approval in the USA for the treatment of adults with PNH, and is under regulatory review in the European Union and Japan in this indication.  Phase 3 development of i.v. ravulizumab for the treatment of aHUS is underway worldwide.  The use of ravulizumab in myasthenia gravis and IgA nephropathy is also being evaluated in the USA in early-phase and preclin. studies, resp.  Clin. development of a s.c. formulation for PNH and aHUS is also underway.  Ravulizumab has been developed using Xencor's antibody half-life prolongation technol. (Xtend), which utilizes antibody Fc variants to prolong half-life.  Alexion is also evaluating the coadministration of s.c. ravulizumab with Halozyme's ENHANZE drug-delivery technol. (rHuPH20), which may have the potential to further extend the dosing interval.  This article summarizes the milestones in the development of ravulizumab leading to this first approval for PNH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvdIVLKo5qzLVg90H21EOLACvtfcHk0lhoOi9B1_b9kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrw%253D&md5=44d2b4439a007737dcdd8fd3b68dadbf</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01068-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01068-2%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeage%26aufirst%3DK.%26atitle%3DRavulizumab%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D347%26epage%3D352%26doi%3D10.1007%2Fs40265-019-01068-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Titulaer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verschuuren, J. J.</span></span> <span> </span><span class="NLM_article-title">Lambert-eaton myasthenic syndrome: From clinical characteristics to therapeutic strategies</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1107</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(11)70245-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS1474-4422%2811%2970245-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=22094130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC38%252Fgsl2hsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1098-1107&author=M.+J.+Titulaerauthor=B.+Langauthor=J.+J.+Verschuuren&title=Lambert-eaton+myasthenic+syndrome%3A+From+clinical+characteristics+to+therapeutic+strategies&doi=10.1016%2FS1474-4422%2811%2970245-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies</span></div><div class="casAuthors">Titulaer Maarten J; Lang Bethan; Verschuuren Jan Jgm</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1098-107</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular autoimmune disease that has served as a model for autoimmunity and tumour immunology.  In LEMS, the characteristic muscle weakness is thought to be caused by pathogenic autoantibodies directed against voltage-gated calcium channels (VGCC) present on the presynaptic nerve terminal.  Half of patients with LEMS have an associated tumour, small-cell lung carcinoma (SCLC), which also expresses functional VGCC.  Knowledge of this association led to the discovery of a wide range of paraneoplastic and non-tumour-related neurological disorders of the peripheral and central nervous systems.  Detailed clinical studies have improved our diagnostic skills and knowledge of the pathophysiological mechanisms and association of LEMS with SCLC, and have helped with the development of a protocol for early tumour detection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-BMd6_Y4EZbxanA7vODO6fW6udTcc2ebE7zD4UF7qVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252Fgsl2hsg%253D%253D&md5=d0866ae4d39a3b4386a394a806c0f04d</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2811%2970245-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252811%252970245-9%26sid%3Dliteratum%253Aachs%26aulast%3DTitulaer%26aufirst%3DM.%2BJ.%26aulast%3DLang%26aufirst%3DB.%26aulast%3DVerschuuren%26aufirst%3DJ.%2BJ.%26atitle%3DLambert-eaton%2520myasthenic%2520syndrome%253A%2520From%2520clinical%2520characteristics%2520to%2520therapeutic%2520strategies%26jtitle%3DLancet%2520Neurol.%26date%3D2011%26volume%3D10%26spage%3D1098%26epage%3D1107%26doi%3D10.1016%2FS1474-4422%2811%2970245-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voelker, R.</span></span> <span> </span><span class="NLM_article-title">Drug approved for rare muscle weakening syndrome</span>. <i>J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">239</span>, <span class="refDoi"> DOI: 10.1001/jama.2018.21321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1001%2Fjama.2018.21321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3cjjvVCjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2019&pages=239&author=R.+Voelker&title=Drug+approved+for+rare+muscle+weakening+syndrome&doi=10.1001%2Fjama.2018.21321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Device for Cluster Headache</span></div><div class="casAuthors">Voelker Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTc9KFPOurlNp0d-O_J5C0AfW6udTcc2eaR45VMFcZ0H7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjjvVCjug%253D%253D&md5=1291266b3ed69e96707ff6f92160f499</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1001%2Fjama.2018.21321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2018.21321%26sid%3Dliteratum%253Aachs%26aulast%3DVoelker%26aufirst%3DR.%26atitle%3DDrug%2520approved%2520for%2520rare%2520muscle%2520weakening%2520syndrome%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2019%26volume%3D321%26spage%3D239%26doi%3D10.1001%2Fjama.2018.21321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tripodi, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giliani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanfranchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badolato, R.</span></span> <span> </span><span class="NLM_article-title">Heterozygous mutation in adenosine deaminase gene in a patient with severe lymphopenia following corticosteroid treatment of autoimmune hemolytic anemia</span>. <i>Front. Pediatr.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">272</span>, <span class="refDoi"> DOI: 10.3389/fped.2018.00272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3389%2Ffped.2018.00272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30327760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3czpvF2qtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=272&author=S.+I.+Tripodiauthor=P.+Cortiauthor=S.+Gilianiauthor=A.+Lanfranchiauthor=A.+Biondiauthor=R.+Badolato&title=Heterozygous+mutation+in+adenosine+deaminase+gene+in+a+patient+with+severe+lymphopenia+following+corticosteroid+treatment+of+autoimmune+hemolytic+anemia&doi=10.3389%2Ffped.2018.00272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Heterozygous Mutation in Adenosine Deaminase Gene in a Patient With Severe Lymphopenia Following Corticosteroid Treatment of Autoimmune Hemolytic Anemia</span></div><div class="casAuthors">Tripodi Serena I; Badolato Raffaele; Corti Paola; Biondi Andrea; Giliani Silvia; Lanfranchi Arnalda</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pediatrics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">272</span>
        ISSN:<span class="NLM_cas:issn">2296-2360</span>.
    </div><div class="casAbstract">We describe a previously healthy 14-year-old girl with acute onset autoimmune hemolytic anemia, associated with severe but transient lymphopenia during corticosteroid therapy, without infectious episodes during follow-up.  After detailed investigations to rule out an underlying immunodeficiency, we detected a heterozygous ADA gene mutation.  This was associated with slightly increased blood levels of adenosine and deoxyadenosine nucleotides and with reduced ADA activity in red blood cells, but within the normal range.  This observation suggests that heterozygous ADA mutation might be a predisposing factor for lymphopenia in patients receiving corticosteroid therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeu56SyrfSGcRAV4D_Ins_fW6udTcc2eaR45VMFcZ0H7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czpvF2qtA%253D%253D&md5=fc633b17dbdf121a35b0f2619444d36d</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.3389%2Ffped.2018.00272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffped.2018.00272%26sid%3Dliteratum%253Aachs%26aulast%3DTripodi%26aufirst%3DS.%2BI.%26aulast%3DCorti%26aufirst%3DP.%26aulast%3DGiliani%26aufirst%3DS.%26aulast%3DLanfranchi%26aufirst%3DA.%26aulast%3DBiondi%26aufirst%3DA.%26aulast%3DBadolato%26aufirst%3DR.%26atitle%3DHeterozygous%2520mutation%2520in%2520adenosine%2520deaminase%2520gene%2520in%2520a%2520patient%2520with%2520severe%2520lymphopenia%2520following%2520corticosteroid%2520treatment%2520of%2520autoimmune%2520hemolytic%2520anemia%26jtitle%3DFront.%2520Pediatr.%26date%3D2018%26volume%3D6%26spage%3D272%26doi%3D10.3389%2Ffped.2018.00272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gennery, A. R.</span></span> <span> </span><span class="NLM_article-title">Adenosine deaminase deficiency: A review</span>. <i>Orphanet J. Rare Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">65</span>, <span class="refDoi"> DOI: 10.1186/s13023-018-0807-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1186%2Fs13023-018-0807-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29690908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjmt1CrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=65&author=A.+M.+Flinnauthor=A.+R.+Gennery&title=Adenosine+deaminase+deficiency%3A+A+review&doi=10.1186%2Fs13023-018-0807-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine deaminase deficiency: a review</span></div><div class="casAuthors">Flinn Aisling M; Gennery Andrew R; Flinn Aisling M; Gennery Andrew R</div><div class="citationInfo"><span class="NLM_cas:title">Orphanet journal of rare diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Adenosine deaminase (ADA) deficiency leads to an accumulation of toxic purine degradation by-products, most potently affecting lymphocytes, leading to adenosine deaminase-deficient severe combined immunodeficiency.  Whilst most notable affects are on lymphocytes, other manifestations include skeletal abnormalities, neurodevelopmental affects and pulmonary manifestations associated with pulmonary-alveolar proteinosis.  Affected patients present in early infancy, usually with persistent infection, or with pulmonary insufficiency.  Three treatment options are currently available.  Initial treatment with enzyme replacement therapy may alleviate acute symptoms and enable partial immunological reconstitution, but treatment is life-long, immune reconstitution is incomplete, and the reconstituted immune system may nullify the effects of the enzyme replacement.  Hematopoietic stem cell transplant has long been established as the treatment of choice, particularly where a matched sibling or well matched unrelated donor is available.  More recently, the use of gene addition techniques to correct the genetic defect in autologous haematopoietic stem cells treatment has demonstrated immunological and clinical efficacy.  This article reviews the biology, clinical presentation, diagnosis and treatment of ADA-deficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAz_4JB3iSLiM8MEzWGjS9fW6udTcc2ebmCJb9O1owi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjmt1CrtA%253D%253D&md5=f063e0dbfd3167e16864588dbe8d840c</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1186%2Fs13023-018-0807-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13023-018-0807-5%26sid%3Dliteratum%253Aachs%26aulast%3DFlinn%26aufirst%3DA.%2BM.%26aulast%3DGennery%26aufirst%3DA.%2BR.%26atitle%3DAdenosine%2520deaminase%2520deficiency%253A%2520A%2520review%26jtitle%3DOrphanet%2520J.%2520Rare%2520Dis.%26date%3D2018%26volume%3D13%26spage%3D65%26doi%3D10.1186%2Fs13023-018-0807-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeFrancesco, L.</span></span> <span> </span><span class="NLM_article-title">Drug pipeline: 4q18</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1038/s41587-019-0052-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2Fs41587-019-0052-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30833768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosV2qtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=206-208&author=L.+DeFrancesco&title=Drug+pipeline%3A+4q18&doi=10.1038%2Fs41587-019-0052-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Drug pipeline: 4Q18</span></div><div class="casAuthors">DeFrancesco, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">206-208</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7aiMoCjDxnrVg90H21EOLACvtfcHk0lg9us8H5sgR1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosV2qtb8%253D&md5=cb8fa49ecadc365c11c54d8beb41224d</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fs41587-019-0052-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41587-019-0052-z%26sid%3Dliteratum%253Aachs%26aulast%3DDeFrancesco%26aufirst%3DL.%26atitle%3DDrug%2520pipeline%253A%25204q18%26jtitle%3DNat.%2520Biotechnol.%26date%3D2019%26volume%3D37%26spage%3D206%26epage%3D208%26doi%3D10.1038%2Fs41587-019-0052-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherlock, S.</span></span> <span> </span><span class="NLM_article-title">Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis</span>. <i>Clin. Liver Dis.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1016/S1089-3261(05)70098-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS1089-3261%2805%2970098-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=11232193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BD3MvitFyjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2000&pages=97-113&author=S.+Sherlock&title=Primary+biliary+cirrhosis%2C+primary+sclerosing+cholangitis%2C+and+autoimmune+cholangitis&doi=10.1016%2FS1089-3261%2805%2970098-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis</span></div><div class="casAuthors">Sherlock S</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in liver disease</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-113</span>
        ISSN:<span class="NLM_cas:issn">1089-3261</span>.
    </div><div class="casAbstract">Primary biliary cirrhosis (PBC), and autoimmune cholangitis are presumed to be autoimmune cholestatic diseases, but the relevant antigens are unknown.  Primary biliary cirrhosis is diagnosed by a positive serum mitochondrial antibody test.  It usually affects women and has a very long course, culminating in liver transplantation or death.  Ursodeoxycholic acid is probably the appropriate treatment.  Primary sclerosing cholangitis (PSC) is marked by progressive destruction of extrahepatic and intrahepatic bile ducts.  There is no specific diagnostic test or treatment.  Cholangiocarcinoma is the dreaded complication and precludes liver transplantation, the only chance of a cure.  Autoimmune cholangitis overlaps PBC and autoimmune chronic hepatitis.  It is a rare condition, resembling PBC but with a negative serum mitochondrial antibody test; however, serum antinuclear antibodies and smooth muscle antibodies are present in high titers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4gl1aAPuspEewzGPswiWOfW6udTcc2ebmCJb9O1owi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MvitFyjsg%253D%253D&md5=eb265811d84f28e5a72e306b5878a22d</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2FS1089-3261%2805%2970098-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1089-3261%252805%252970098-2%26sid%3Dliteratum%253Aachs%26aulast%3DSherlock%26aufirst%3DS.%26atitle%3DPrimary%2520biliary%2520cirrhosis%252C%2520primary%2520sclerosing%2520cholangitis%252C%2520and%2520autoimmune%2520cholangitis%26jtitle%3DClin.%2520Liver%2520Dis.%26date%3D2000%26volume%3D4%26spage%3D97%26epage%3D113%26doi%3D10.1016%2FS1089-3261%2805%2970098-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, C. Y.</span></span> <span> </span><span class="NLM_article-title">Update on fxr biology: Promising therapeutic target?</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2069</span>, <span class="refDoi"> DOI: 10.3390/ijms19072069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3390%2Fijms19072069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKltLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=2069&author=C.+Y.+Han&title=Update+on+fxr+biology%3A+Promising+therapeutic+target%3F&doi=10.3390%2Fijms19072069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Update on FXR biology: promising therapeutic target</span></div><div class="casAuthors">Han, Chang Yeob</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2069/1-2069/25</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Farnesoid X receptor (FXR), a metabolic nuclear receptor, plays crit. roles in the maintenance of systemic energy homeostasis and the integrity of many organs, including liver and intestine.  It regulates bile acid, lipid, and glucose metab., and contributes to inter-organ communication, in particular the enterohepatic signaling pathway, through bile acids and fibroblast growth factor-15/19 (FGF-15/19).  The metabolic effects of FXR are also involved in gut microbiota.  In addn., FXR has various functions in the kidney, adipose tissue, pancreas, cardiovascular system, and tumorigenesis.  Consequently, the deregulation of FXR may lead to abnormalities of specific organs and metabolic dysfunction, allowing the protein as an attractive therapeutic target for the management of liver and/or metabolic diseases.  Indeed, many FXR agonists have been being developed and are under pre-clin. and clin. investigations.  Although obeticholic acid (OCA) is one of the promising candidates, significant safety issues have remained.  The effects of FXR modulation might be multifaceted according to tissue specificity, disease type, and/or energy status, suggesting the careful use of FXR agonists.  This review summarizes the current knowledge of systemic FXR biol. in various organs and the gut-liver axis, particularly regarding the recent advancement in these fields, and also provides pharmacol. aspects of FXR modulation for rational therapeutic strategies and novel drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbCrrxu6Db4bVg90H21EOLACvtfcHk0lg9us8H5sgR1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKltLbL&md5=b2497c742af491002d92b5bf049040ff</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.3390%2Fijms19072069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19072069%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DC.%2BY.%26atitle%3DUpdate%2520on%2520fxr%2520biology%253A%2520Promising%2520therapeutic%2520target%253F%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D2069%26doi%3D10.3390%2Fijms19072069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Obeticholic acid: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0616-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-016-0616-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=27406083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOlsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1221-6&author=A.+Markhamauthor=S.+J.+Keam&title=Obeticholic+acid%3A+First+global+approval&doi=10.1007%2Fs40265-016-0616-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Obeticholic Acid: First Global Approval</span></div><div class="casAuthors">Markham, A.; Keam, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1221-1226</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Obeticholic acid (OcalivaTM) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid.  The drug is in preregistration for this indication in the EU.  This article summarizes the milestones in the development of obeticholic acid leading to this first approval for primary biliary cholangitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphfGFiF0o6cLVg90H21EOLACvtfcHk0livDYa1Gq5lhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOlsr%252FE&md5=2faa2b2fbe5c5311bd9769983d6b62df</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0616-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0616-x%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DObeticholic%2520acid%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1221%26epage%3D6%26doi%3D10.1007%2Fs40265-016-0616-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span> </span><span class="NLM_article-title">Global autoimmune treatment market is expected
to reach USD $7.95
billion by 2025: Fior markets</span>. <a href="https://www.globenewswire.com/news-release/2020/01/27/1975808/0/en/Global-Autoimmune-Treatment-Market-is-Expected-to-Reach-USD-7-95-Billion-by-2025-Fior-Markets.html" class="extLink">https://www.globenewswire.com/news-release/2020/01/27/1975808/0/en/Global-Autoimmune-Treatment-Market-is-Expected-to-Reach-USD-7-95-Billion-by-2025-Fior-Markets.html</a> (accessed Nov 24, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global+autoimmune+treatment+market+is+expected%0Ato+reach+USD+%247.95%0Abillion+by+2025%3A+Fior+markets.+https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2020%2F01%2F27%2F1975808%2F0%2Fen%2FGlobal-Autoimmune-Treatment-Market-is-Expected-to-Reach-USD-7-95-Billion-by-2025-Fior-Markets.html+%28accessed+Nov+24%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGlobal%2520autoimmune%2520treatment%2520market%2520is%2520expected%250Ato%2520reach%2520USD%2520%25247.95%250Abillion%2520by%25202025%253A%2520Fior%2520markets%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Heart disease and stroke statistics-2019 update: A report from the American heart association</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">e56</span>– <span class="NLM_lpage">e58</span>, <span class="refDoi"> DOI: 10.1161/CIR.0000000000000659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1161%2FCIR.0000000000000659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30700139" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2019&pages=e56-e58&author=+Benjamin&title=Heart+disease+and+stroke+statistics-2019+update%3A+A+report+from+the+American+heart+association&doi=10.1161%2FCIR.0000000000000659"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1161%2FCIR.0000000000000659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIR.0000000000000659%26sid%3Dliteratum%253Aachs%26aulast%3DBenjamin%26atitle%3DHeart%2520disease%2520and%2520stroke%2520statistics-2019%2520update%253A%2520A%2520report%2520from%2520the%2520American%2520heart%2520association%26jtitle%3DCirculation%26date%3D2019%26volume%3D139%26spage%3De56%26epage%3De58%26doi%3D10.1161%2FCIR.0000000000000659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span> </span><span class="NLM_article-title">Cardiovascular diseases (cvds): World health
organization</span>. <a href="https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)" class="extLink">https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)</a> (accessed Nov 23, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cardiovascular+diseases+%28cvds%29%3A+World+health%0Aorganization.+https%3A%2F%2Fwww.who.int%2Fnews-room%2Ffact-sheets%2Fdetail%2Fcardiovascular-diseases-%28cvds%29+%28accessed+Nov+23%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DCardiovascular%2520diseases%2520%2528cvds%2529%253A%2520World%2520health%250Aorganization%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surovtseva, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span> <span> </span><span class="NLM_article-title">An analysis of FDA-approved drugs for cardiovascular diseases</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.drudis.2014.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25218930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKqu7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1-4&author=M.+S.+Kinchauthor=Y.+Surovtsevaauthor=D.+Hoyer&title=An+analysis+of+FDA-approved+drugs+for+cardiovascular+diseases&doi=10.1016%2Fj.drudis.2014.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of FDA-approved drugs for cardiovascular diseases</span></div><div class="casAuthors">Kinch, Michael S.; Surovtseva, Yulia; Hoyer, Denton</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-4</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Following the introduction of antibiotic therapy and widespread inoculations, cardiovascular diseases have leapt ahead of infectious diseases in terms of prevalence in much of the developed and developing world.  Herein, we assess FDA-approved drugs for the treatment of cardiovascular diseases.  The drug development enterprise around cardiovascular diseases has remained stable in contrast to turbulent changes in other therapeutic indications.  However, upon closer inspection, the results identify narrow scope in terms of the breadth of targets and the mechanistic actions of new drugs.  From the public health point of view, it is important to balance incremental change with orthogonal innovations that are needed to combat a leading cause of morbidity and mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHm6HklB1UX7Vg90H21EOLACvtfcHk0livDYa1Gq5lhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKqu7zI&md5=ede55cfec49c1aa87bed03faf845bb3d</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DSurovtseva%26aufirst%3DY.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DAn%2520analysis%2520of%2520FDA-approved%2520drugs%2520for%2520cardiovascular%2520diseases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D1%26epage%3D4%26doi%3D10.1016%2Fj.drudis.2014.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubers, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N. J.</span></span> <span> </span><span class="NLM_article-title">Combined angiotensin receptor antagonism and neprilysin inhibition</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">1115</span>– <span class="NLM_lpage">1124</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.115.018622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1161%2FCIRCULATIONAHA.115.018622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26976916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlGlurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2016&pages=1115-1124&author=S.+A.+Hubersauthor=N.+J.+Brown&title=Combined+angiotensin+receptor+antagonism+and+neprilysin+inhibition&doi=10.1161%2FCIRCULATIONAHA.115.018622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition</span></div><div class="casAuthors">Hubers, Scott A.; Brown, Nancy J.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1115-1124</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Heart failure affects ≈5.7 million people in the United States alone.  Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, and aldosterone antagonists have improved mortality in patients with heart failure and reduced ejection fraction, but mortality remains high.  In July 2015, the US Food and Drug Administration approved the first of a new class of drugs for the treatment of heart failure: Valsartan/sacubitril (formerly known as LCZ696 and currently marketed by Novartis as Entresto) combines the angiotensin receptor blocker valsartan and the neprilysin inhibitor prodrug sacubitril in a 1:1 ratio in a sodium supramol. complex.  Sacubitril is converted by esterases to LBQ657, which inhibits neprilysin, the enzyme responsible for the degrdn. of the natriuretic peptides and many other vasoactive peptides.  Thus, this combined angiotensin receptor antagonist and neprilysin inhibitor addresses 2 of the pathophysiol. mechanisms of heart failure: activation of the renin-angiotensin-aldosterone system and decreased sensitivity to natriuretic peptides.  In the Prospective Comparison of ARNI With ACEI to Det. Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, valsartan/sacubitril significantly reduced mortality and hospitalization for heart failure, as well as blood pressure, compared with enalapril in patients with heart failure, reduced ejection fraction, and an elevated circulating level of brain natriuretic peptide or N-terminal pro-brain natriuretic peptide.  Ongoing clin. trials are evaluating the role of valsartan/sacubitril in the treatment of heart failure with preserved ejection fraction and hypertension.  We review here the mechanisms of action of valsartan/sacubitril, the pharmacol. properties of the drug, and its efficacy and safety in the treatment of heart failure and hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0l46f211CD7Vg90H21EOLACvtfcHk0lj3pAGlR8i0ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlGlurg%253D&md5=a62c1c3bd33cae5d30a4f0136ec20e72</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.115.018622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.115.018622%26sid%3Dliteratum%253Aachs%26aulast%3DHubers%26aufirst%3DS.%2BA.%26aulast%3DBrown%26aufirst%3DN.%2BJ.%26atitle%3DCombined%2520angiotensin%2520receptor%2520antagonism%2520and%2520neprilysin%2520inhibition%26jtitle%3DCirculation%26date%3D2016%26volume%3D133%26spage%3D1115%26epage%3D1124%26doi%3D10.1161%2FCIRCULATIONAHA.115.018622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roubtsova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essalmani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinkiewicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamelin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davignon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidah, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span> <span> </span><span class="NLM_article-title">Proprotein convertase subtilisin/kexin type 9 (pcsk9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1002/hep.22354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fhep.22354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=18666258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCqt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=646-54&author=A.+Zaidauthor=A.+Roubtsovaauthor=R.+Essalmaniauthor=J.+Marcinkiewiczauthor=A.+Chamberlandauthor=J.+Hamelinauthor=M.+Tremblayauthor=H.+Jacquesauthor=W.+Jinauthor=J.+Davignonauthor=N.+G.+Seidahauthor=A.+Prat&title=Proprotein+convertase+subtilisin%2Fkexin+type+9+%28pcsk9%29%3A+Hepatocyte-specific+low-density+lipoprotein+receptor+degradation+and+critical+role+in+mouse+liver+regeneration&doi=10.1002%2Fhep.22354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration</span></div><div class="casAuthors">Zaid, Ahmed; Roubtsova, Anna; Essalmani, Rachid; Marcinkiewicz, Jadwiga; Chamberland, Ann; Hamelin, Josee; Tremblay, Michel; Jacques, Helene; Jin, Weijun; Davignon, Jean; Seidah, Nabil G.; Prat, Annik</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">646-654</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The gene encoding the proprotein convertase subtilisin/kexin type 9 (PCSK9) is linked to familial hypercholesterolemia, as are those of the low-d. lipoprotein receptor (LDLR) and apolipoprotein B.  PCSK9 enhances LDLR degrdn., resulting in low-d. lipoprotein accumulation in plasma.  To analyze the role of hepatic PCSK9, total and hepatocyte-specific knockout mice were generated.  They exhibit 42% and 27% less circulating cholesterol, resp., showing that liver PCSK9 was responsible for two thirds of the phenotype.  We also demonstrated that, in liver, PCSK9 is exclusively expressed in hepatocytes, representing the main source of circulating PCSK9.  The data suggest that local but not circulating PCSK9 regulates cholesterol levels.  Although transgenic mice overexpressing high levels of liver and circulating PCSK9 led to the almost complete disappearance of the hepatic LDLR, they did not recapitulate the plasma cholesterol levels obsd. in LDLR-deficient mice.  Single LDLR or double LDLR/PCSK9 knockout mice exhibited similar cholesterol profiles, indicating that PCSK9 regulates cholesterol homeostasis exclusively through the LDLR.  Finally, the regenerating liver of PCSK9-deficient mice exhibited necrotic lesions, which were prevented by a high-cholesterol diet.  However, lipid accumulation in hepatocytes of these mice was markedly reduced under both chow and high-cholesterol diets, revealing that PCSK9 deficiency confers resistance to liver steatosis.  Conclusion: Although PCSK9 is a target for controlling hypercholesterolemia, our data indicate that upon hepatic damage, patients lacking PCSK9 could be at risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQrSHkv-4skLVg90H21EOLACvtfcHk0lj3pAGlR8i0ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCqt7nO&md5=026d4559852c91092acda88520d3031e</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1002%2Fhep.22354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22354%26sid%3Dliteratum%253Aachs%26aulast%3DZaid%26aufirst%3DA.%26aulast%3DRoubtsova%26aufirst%3DA.%26aulast%3DEssalmani%26aufirst%3DR.%26aulast%3DMarcinkiewicz%26aufirst%3DJ.%26aulast%3DChamberland%26aufirst%3DA.%26aulast%3DHamelin%26aufirst%3DJ.%26aulast%3DTremblay%26aufirst%3DM.%26aulast%3DJacques%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DDavignon%26aufirst%3DJ.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DPrat%26aufirst%3DA.%26atitle%3DProprotein%2520convertase%2520subtilisin%252Fkexin%2520type%25209%2520%2528pcsk9%2529%253A%2520Hepatocyte-specific%2520low-density%2520lipoprotein%2520receptor%2520degradation%2520and%2520critical%2520role%2520in%2520mouse%2520liver%2520regeneration%26jtitle%3DHepatology%26date%3D2008%26volume%3D48%26spage%3D646%26epage%3D54%26doi%3D10.1002%2Fhep.22354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mekaj, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekaj, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duci, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miftari, E. I.</span></span> <span> </span><span class="NLM_article-title">New oral anticoagulants: Their advantages and disadvantages compared with vitamin k antagonists in the prevention and treatment of patients with thromboembolic events</span>. <i>Ther. Clin. Risk Manage.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">967</span>, <span class="refDoi"> DOI: 10.2147/TCRM.S84210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2147%2FTCRM.S84210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26150723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FgvVChsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=967&author=Y.+H.+Mekajauthor=A.+Y.+Mekajauthor=S.+B.+Duciauthor=E.+I.+Miftari&title=New+oral+anticoagulants%3A+Their+advantages+and+disadvantages+compared+with+vitamin+k+antagonists+in+the+prevention+and+treatment+of+patients+with+thromboembolic+events&doi=10.2147%2FTCRM.S84210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events</span></div><div class="casAuthors">Mekaj Ymer H; Mekaj Agon Y; Duci Shkelzen B; Miftari Ermira I</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and clinical risk management</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">967-77</span>
        ISSN:<span class="NLM_cas:issn">1176-6336</span>.
    </div><div class="casAbstract">Despite the discovery and application of many parenteral (unfractionated and low-molecular-weight heparins) and oral anticoagulant vitamin K antagonist (VKA) drugs, the prevention and treatment of venous and arterial thrombotic phenomena remain major medical challenges.  Furthermore, VKAs are the only oral anticoagulants used during the past 60 years.  The main objective of this study is to present recent data on non-vitamin K antagonist oral anticoagulants (NOACs) and to analyze their advantages and disadvantages compared with those of VKAs based on a large number of recent studies.  NOACs are novel direct-acting medications that are selective for one specific coagulation factor, either thrombin (IIa) or activated factor X (Xa).  Several NOACs, such as dabigatran (a direct inhibitor of FIIa) and rivaroxaban, apixaban and edoxaban (direct inhibitors of factor Xa), have been used for at least 5 years but possibly 10 years.  Unlike traditional VKAs, which prevent the coagulation process by suppressing the synthesis of vitamin K-dependent factors, NOACs directly inhibit key proteases (factors IIa and Xa).  The important indications of these drugs are the prevention and treatment of deep vein thrombosis and pulmonary embolisms, and the prevention of atherothrombotic events in the heart and brain of patients with acute coronary syndrome and atrial fibrillation.  They are not fixed, and dose-various strengths are available.  Most studies have reported that more advantages than disadvantages for NOACs when compared with VKAs, with the most important advantages of NOACs including safety issues (ie, a lower incidence of major bleeding), convenience of use, minor drug and food interactions, a wide therapeutic window, and no need for laboratory monitoring.  Nonetheless, there are some conditions for which VKAs remain the drug of choice.  Based on the available data, we can conclude that NOACs have greater advantages and fewer disadvantages compared with VKAs.  New studies are required to further assess the efficacy of NOACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTMQ7SChs9khlMGsG_HTXYFfW6udTcc2eYxWucQbg28Erntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FgvVChsA%253D%253D&md5=e4eab2f297fd06d25a4e9541649d3aba</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S84210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S84210%26sid%3Dliteratum%253Aachs%26aulast%3DMekaj%26aufirst%3DY.%2BH.%26aulast%3DMekaj%26aufirst%3DA.%2BY.%26aulast%3DDuci%26aufirst%3DS.%2BB.%26aulast%3DMiftari%26aufirst%3DE.%2BI.%26atitle%3DNew%2520oral%2520anticoagulants%253A%2520Their%2520advantages%2520and%2520disadvantages%2520compared%2520with%2520vitamin%2520k%2520antagonists%2520in%2520the%2520prevention%2520and%2520treatment%2520of%2520patients%2520with%2520thromboembolic%2520events%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2015%26volume%3D11%26spage%3D967%26doi%3D10.2147%2FTCRM.S84210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nozue, T.</span></span> <span> </span><span class="NLM_article-title">Lipid lowering therapy and circulating pcsk9 concentration</span>. <i>J. Atheroscler. Thromb.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">907</span>, <span class="refDoi"> DOI: 10.5551/jat.RV17012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.5551%2Fjat.RV17012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28804094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGitbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=895-907&author=T.+Nozue&title=Lipid+lowering+therapy+and+circulating+pcsk9+concentration&doi=10.5551%2Fjat.RV17012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Lipid lowering therapy and circulating PCSK9 concentration</span></div><div class="casAuthors">Nozue, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Atherosclerosis and Thrombosis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">895-907</span>CODEN:
                <span class="NLM_cas:coden">JATHEH</span>;
        ISSN:<span class="NLM_cas:issn">1340-3478</span>.
    
            (<span class="NLM_cas:orgname">Japan Atherosclerosis Society</span>)
        </div><div class="casAbstract">Hypercholesterolemia, particularly an increase in low-d. lipoprotein cholesterol (LDL-C) levels, contributes substantially to the development of coronary artery disease and the risk for cardiovascular events.  As the first-line pharmacotherapy, statins have been shown to reduce both LDL-C levels and cardiovascular events.  However, despite intensive statin therapy, a sizable proportion of statin-treated patients are unable to achieve the recommended target LDL-C levels, and not all patients can avoid future cardiovascular events.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in cholesterol homeostasis by enhancing the degrdn. of hepatic low-d. lipoprotein receptor (LDLR).  Owing to its importance in lipid metab., PCSK9 has emerged as a novel pharmacol. target for lowering LDL-C levels.  In this review, the potential role of circulating PCSK9 as a new biomarker of lipid metab. is described.  Next, previous studies evaluating the effects of lipid-modifying pharmacol. agents, particularly statins, on circulating PCSK9 concns. are summarized.  Statins decrease hepatic intracellular cholesterol, resulting in increased LDLRs as well as increased PCSK9 protein.  There is a clear dose-response effect of statin treatment on PCSK9 level, as increasing doses of statins also increase the level of circulating PCSK9.  Finally, the available therapeutic strategies to inhibit PCSK9 are present.  Monoclonal antibodies against PCSK9, in combination with statins, are one of the most promising and novel approaches to achieve further redn. of LDL-C levels and reduce the risk of cardiovascular events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgVAwIzEcWqbVg90H21EOLACvtfcHk0lh4pEV6l1CVIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGitbvL&md5=f44dc5e2b11285f14943c2790672e381</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.5551%2Fjat.RV17012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5551%252Fjat.RV17012%26sid%3Dliteratum%253Aachs%26aulast%3DNozue%26aufirst%3DT.%26atitle%3DLipid%2520lowering%2520therapy%2520and%2520circulating%2520pcsk9%2520concentration%26jtitle%3DJ.%2520Atheroscler.%2520Thromb.%26date%3D2017%26volume%3D24%26spage%3D895%26epage%3D907%26doi%3D10.5551%2Fjat.RV17012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bussard, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busse, L. W.</span></span> <span> </span><span class="NLM_article-title">Angiotensin ii: A new therapeutic option for vasodilatory shock</span>. <i>Ther. Clin. Risk Manage.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1287</span>– <span class="NLM_lpage">1298</span>, <span class="refDoi"> DOI: 10.2147/TCRM.S150434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2147%2FTCRM.S150434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30100727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1OntrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=1287-1298&author=R.+L.+Bussardauthor=L.+W.+Busse&title=Angiotensin+ii%3A+A+new+therapeutic+option+for+vasodilatory+shock&doi=10.2147%2FTCRM.S150434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II : a new therapeutic option for vasodilatory shock</span></div><div class="casAuthors">Bussard, Rachel L.; Busse, Laurence W.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1287-1298</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1178-203X</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Angiotensin II (Ang II), part of the renin-angiotensin-aldosterone system (RAS), is a potent vasoconstrictor and has been recently approved for use by the US Food and Drug Administration in high-output shock.  Though not a new drug, the recently published Angiotensin II for the Treatment of High Output Shock (ATHOS-3) trial, as well as a no. of retrospective analyses have sparked renewed interest in the use of Ang II, which may have a role in treating refractory shock.  We describe refractory shock, the unique mechanism of action of Ang II, RAS dysregulation in shock, and the evidence supporting the use of Ang II to restore blood pressure.  Evidence suggests that Ang II may preferentially be of benefit in acute kidney injury and acute respiratory distress syndrome, where the RAS is known to be disrupted.  Addnl., there may be a role for Ang II in cardiogenic shock, angiotensin converting enzyme inhibitor overdose, cardiac arrest, liver failure, and in settings of extracorporeal circulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq6wfoUcoporVg90H21EOLACvtfcHk0lh4pEV6l1CVIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1OntrvI&md5=56e55e0d8a6d9c7293bff05e5bd3fe16</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S150434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S150434%26sid%3Dliteratum%253Aachs%26aulast%3DBussard%26aufirst%3DR.%2BL.%26aulast%3DBusse%26aufirst%3DL.%2BW.%26atitle%3DAngiotensin%2520ii%253A%2520A%2520new%2520therapeutic%2520option%2520for%2520vasodilatory%2520shock%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2018%26volume%3D14%26spage%3D1287%26epage%3D1298%26doi%3D10.2147%2FTCRM.S150434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mankad, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K. B.</span></span> <span> </span><span class="NLM_article-title">Transthyretin cardiac amyloidosis</span>. <i>Curr. Cardiol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">97</span>, <span class="refDoi"> DOI: 10.1007/s11886-017-0911-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs11886-017-0911-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28840452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC1cbhsF2ntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=97&author=A.+K.+Mankadauthor=K.+B.+Shah&title=Transthyretin+cardiac+amyloidosis&doi=10.1007%2Fs11886-017-0911-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Transthyretin Cardiac Amyloidosis</span></div><div class="casAuthors">Mankad Anit K; Shah Keyur B</div><div class="citationInfo"><span class="NLM_cas:title">Current cardiology reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">97</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  Transthyretin (TTR)-related cardiac amyloidosis is a progressive infiltrative cardiomyopathy that mimics hypertensive, hypertrophic heart disease and may go undiagnosed.  Transthyretin-derived amyloidosis accounts for 18% of all cases of cardiac amyloidosis.  Thus, the study's purpose is to provide a comprehensive review of transthyretin cardiac amyloidosis.  RECENT FINDINGS:  Wild-type transthyretin (ATTRwt) protein causes cardiac amyloidosis sporadically, with 25 to 36% of the population older than 80 years of age are at risk to develop a slowly progressive, infiltrative amyloid cardiomyopathy secondary to ATTRwt.  In contrast, hereditary amyloidosis (ATTRm) is an autosomal dominant inherited disease associated with more than 100 point mutations in the transthyretin gene and has a tendency to affect the heart and nervous system.  Up to 4% of African-Americans carry the Val122Ile mutation in the transthyretin gene, the most prevalent cause of hereditary cardiac amyloidosis in the USA.  Identifying transthyretin cardiac amyloidosis requires increased awareness of the prevalence, signs and symptoms, and diagnostic tools available for discrimination of this progressive form of cardiomyopathy associated with left ventricular hypertrophy.  While there are no FDA-approved medical treatments, investigation is underway on agents to reduce circulating mutated transthyretin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQtwTP9CVGXlsK3uFsUIZtkfW6udTcc2eYkAsVYFp15arntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbhsF2ntQ%253D%253D&md5=934da860c9bd217809891d5844f2272f</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1007%2Fs11886-017-0911-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11886-017-0911-5%26sid%3Dliteratum%253Aachs%26aulast%3DMankad%26aufirst%3DA.%2BK.%26aulast%3DShah%26aufirst%3DK.%2BB.%26atitle%3DTransthyretin%2520cardiac%2520amyloidosis%26jtitle%3DCurr.%2520Cardiol.%2520Rep.%26date%3D2017%26volume%3D19%26spage%3D97%26doi%3D10.1007%2Fs11886-017-0911-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prashant, A.</span></span> <span> </span><span class="NLM_article-title">Global challenges in cardiovascular drug discovery and clinical trials</span>. <i>Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>06</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi"> DOI: 10.4172/2168-9547.1000193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.4172%2F2168-9547.1000193" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=06&publication_year=2017&pages=6&author=A.+Prashant&title=Global+challenges+in+cardiovascular+drug+discovery+and+clinical+trials&doi=10.4172%2F2168-9547.1000193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.4172%2F2168-9547.1000193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2168-9547.1000193%26sid%3Dliteratum%253Aachs%26aulast%3DPrashant%26aufirst%3DA.%26atitle%3DGlobal%2520challenges%2520in%2520cardiovascular%2520drug%2520discovery%2520and%2520clinical%2520trials%26jtitle%3DMol.%2520Biol.%26date%3D2017%26volume%3D06%26spage%3D6%26doi%3D10.4172%2F2168-9547.1000193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimazawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, M.</span></span> <span> </span><span class="NLM_article-title">Drug-diagnostic co-development: Challenges and issues</span>. <i>Expert Rev. Mol. Diagn.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1586/14737159.2016.1132163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1586%2F14737159.2016.1132163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26651878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVarsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=187-204&author=R.+Shimazawaauthor=M.+Ikeda&title=Drug-diagnostic+co-development%3A+Challenges+and+issues&doi=10.1586%2F14737159.2016.1132163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-diagnostic co-development: challenges and issues</span></div><div class="casAuthors">Shimazawa, Rumiko; Ikeda, Masayuki</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Molecular Diagnostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-204</span>CODEN:
                <span class="NLM_cas:coden">ERMDCW</span>;
        ISSN:<span class="NLM_cas:issn">1473-7159</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Diagnostic tests have become increasingly important for optimizing drug use.  Ideally, a companion diagnostic test is developed concurrently with a corresponding therapeutic product (co-development).  However, the diagnostic test may also be developed to optimize treatment with previously approved therapeutic agents (follow-up-development).  In co-development, the effectiveness of an agent in marker-defined patients is confirmed by an enrichment trial design.  In follow-up-development, a biomarker is validated by prospective and/or retrospective analyses of unselected design trials.  A prospectively designed trial is the gold-std. approach to biomarker validation, but retrospective validation can be used to efficiently det. effective treatments for marker-defined patients.  Accumulation and systematization of examples of drug-diagnostic development will aid in the effective development of companion diagnostics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp036w3MuGeU7Vg90H21EOLACvtfcHk0ljm0S-A_54BDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVarsg%253D%253D&md5=1ea3432f37b7c3a4e395b6d39103a823</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1586%2F14737159.2016.1132163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737159.2016.1132163%26sid%3Dliteratum%253Aachs%26aulast%3DShimazawa%26aufirst%3DR.%26aulast%3DIkeda%26aufirst%3DM.%26atitle%3DDrug-diagnostic%2520co-development%253A%2520Challenges%2520and%2520issues%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Diagn.%26date%3D2016%26volume%3D16%26spage%3D187%26epage%3D204%26doi%3D10.1586%2F14737159.2016.1132163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. B.</span></span> <span> </span><span class="NLM_article-title">Discovery, understanding, and bioapplication of organic fluorophore: A case study with an indolizine-based novel fluorophore, seoul-fluor</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1021/ar500370v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar500370v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVegu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2015&pages=538-47&author=E.+Kimauthor=Y.+Leeauthor=S.+Leeauthor=S.+B.+Park&title=Discovery%2C+understanding%2C+and+bioapplication+of+organic+fluorophore%3A+A+case+study+with+an+indolizine-based+novel+fluorophore%2C+seoul-fluor&doi=10.1021%2Far500370v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, Understanding, and Bioapplication of Organic Fluorophore: A Case Study with an Indolizine-Based Novel Fluorophore, Seoul-Fluor</span></div><div class="casAuthors">Kim, Eunha; Lee, Youngjun; Lee, Sanghee; Park, Seung Bum</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">538-547</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Owing to its high sensitivity and great applicability, the fluorescence phenomenon has been considered as an inevitable research tool in the modern scientific fields of chem., biol., materials science, biomedical science, and their interfaces.  Many strategies have been pursued to understand and manipulate the photophys. properties of fluorescent materials, but the scientific community has been focused on the repeated application of existing org. fluorophores or the identification of unique fluorescence properties in a trial-and-error basis without systematic studies.  Moreover, recent studies are emphasizing the necessity of deeper understanding about the structure-photophys. property relation of org. fluorophores for the development of better fluorescent probes.  Herein, the authors provide an overview of a novel fluorescent mol. framework, Seoul-Fluor, which can be rationally engineered to furnish a wide variety of fluorophores in terms of the photophys. properties.  Seoul-Fluor is built on an indolizine-based fluorescent platform with three different positions to introduce various substituents: R1 and R2 substituents for electronic perturbation; R3 substituent as a functional handle for bioconjugation.  Over the past decade, the Seoul-Fluor system has (i) tunable and predictable emission wavelength covering a full visible-color range; (ii) controllable quantum yield via photoinduced electron transfer phenomenon; and (iii) environment-sensitive fluorogenic properties that can be modified through intramol. charge transfer processes.  The authors convincingly demonstrated the prediction of photophys. properties, i.e., emission wavelength and quantum yield, through the construction of a systematic set of analogs and the subsequent anal. of their photophys. properties without the highly sophisticated theor. support.  Guided by quantifiable parameters such as the Hammett substituent consts. or energy levels of the MOs, this unique org. fluorophore can serve as a versatile mol. platform for the development of novel fluorescent switchable biosensors and fluorogenic bioprobes.  In this Account, the authors will discuss the discovery and recent progress made on Seoul-Fluor, the rational design of Seoul-Fluor-based bioprobes, and their practical applications to specific biol. processes that are facilitated by systematic studies of the structure-photophys. property relations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnzZL7nfvoy7Vg90H21EOLACvtfcHk0ljm0S-A_54BDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVegu7g%253D&md5=7581b2b18de843eb105559f68b8f215b</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Far500370v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far500370v%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DS.%2BB.%26atitle%3DDiscovery%252C%2520understanding%252C%2520and%2520bioapplication%2520of%2520organic%2520fluorophore%253A%2520A%2520case%2520study%2520with%2520an%2520indolizine-based%2520novel%2520fluorophore%252C%2520seoul-fluor%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2015%26volume%3D48%26spage%3D538%26epage%3D47%26doi%3D10.1021%2Far500370v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, U. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stedmon, C. A.</span></span> <span> </span><span class="NLM_article-title">Corrigendum: Fluorescence quantum yields of natural organic matter and organic compounds: Implications for the fluorescence-based interpretation of organic matter composition</span>. <i>Front. Mar. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">9</span>, <span class="refDoi"> DOI: 10.3389/fmars.2016.00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3389%2Ffmars.2016.00009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=9&author=U.+J.+W%C3%BCnschauthor=K.+R.+Murphyauthor=C.+A.+Stedmon&title=Corrigendum%3A+Fluorescence+quantum+yields+of+natural+organic+matter+and+organic+compounds%3A+Implications+for+the+fluorescence-based+interpretation+of+organic+matter+composition&doi=10.3389%2Ffmars.2016.00009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.3389%2Ffmars.2016.00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmars.2016.00009%26sid%3Dliteratum%253Aachs%26aulast%3DW%25C3%25BCnsch%26aufirst%3DU.%2BJ.%26aulast%3DMurphy%26aufirst%3DK.%2BR.%26aulast%3DStedmon%26aufirst%3DC.%2BA.%26atitle%3DCorrigendum%253A%2520Fluorescence%2520quantum%2520yields%2520of%2520natural%2520organic%2520matter%2520and%2520organic%2520compounds%253A%2520Implications%2520for%2520the%2520fluorescence-based%2520interpretation%2520of%2520organic%2520matter%2520composition%26jtitle%3DFront.%2520Mar.%2520Sci.%26date%3D2016%26volume%3D3%26spage%3D9%26doi%3D10.3389%2Ffmars.2016.00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kristoffersen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erga, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frette, Ø.</span></span> <span> </span><span class="NLM_article-title">Testing fluorescence lifetime standards using two-photon excitation and time-domain instrumentation: Fluorescein, quinine sulfate and green fluorescent protein</span>. <i>J. Fluoresc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1065</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1007/s10895-018-2270-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs10895-018-2270-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30046998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOntrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1065-1073&author=A.+S.+Kristoffersenauthor=S.+R.+Ergaauthor=B.+Hamreauthor=%C3%98.+Frette&title=Testing+fluorescence+lifetime+standards+using+two-photon+excitation+and+time-domain+instrumentation%3A+Fluorescein%2C+quinine+sulfate+and+green+fluorescent+protein&doi=10.1007%2Fs10895-018-2270-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Testing Fluorescence Lifetime Standards using Two-Photon Excitation and Time-Domain Instrumentation: Fluorescein, Quinine Sulfate and Green Fluorescent Protein</span></div><div class="casAuthors">Kristoffersen, Arne S.; Erga, Svein R.; Hamre, Boerge; Frette, Oeyvind</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Fluorescence</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1065-1073</span>CODEN:
                <span class="NLM_cas:coden">JOFLEN</span>;
        ISSN:<span class="NLM_cas:issn">1053-0509</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">It is essential for everyone working with exptl. science to be certain that their instruments produce reliable results, and for fluorescence lifetime expts., information about fluorescence lifetime stds. is crucial.  A large part of the literature on lifetime stds. dates back to the 1970s and 1980s, and the use of newer and faster measuring devices may deem these results unreliable.  We have tested the three commonly used fluorophores fluorescein, quinine sulfate and green fluorescent protein for their suitability to serve as lifetime stds., esp. to be used with two-photon excitation measurements in the time-domain.  We measured absorption and emission spectra for the fluorophores to det. optimal wavelengths to use for excitation and detector settings.  Fluorescence lifetimes were measured for different concns., ranging from 10- 3 - 10- 5 M, as well as for various solvents.  Fluorescein was sol. in both ethanol, methanol and sulfuric acid, while quinine sulfate was only sol. in sulfuric acid.  Green fluorescent protein was prepd. in a com. Tris-HCl, EDTA soln., and all three fluorophores produced stable lifetime results with low uncertainties.  No siginificant variation with concn. was measured for any of the fluorophores, and all showed single-exponential decays.  All lifetime measurements were carried out using two-photon excitation and lifetime data was obtained in the time-domain using time-correlated single-photon counting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUjug89pp7MbVg90H21EOLACvtfcHk0ljm0S-A_54BDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOntrnE&md5=8e70025b868ea632cc55b066017102a6</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1007%2Fs10895-018-2270-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10895-018-2270-z%26sid%3Dliteratum%253Aachs%26aulast%3DKristoffersen%26aufirst%3DA.%2BS.%26aulast%3DErga%26aufirst%3DS.%2BR.%26aulast%3DHamre%26aufirst%3DB.%26aulast%3DFrette%26aufirst%3D%25C3%2598.%26atitle%3DTesting%2520fluorescence%2520lifetime%2520standards%2520using%2520two-photon%2520excitation%2520and%2520time-domain%2520instrumentation%253A%2520Fluorescein%252C%2520quinine%2520sulfate%2520and%2520green%2520fluorescent%2520protein%26jtitle%3DJ.%2520Fluoresc.%26date%3D2018%26volume%3D28%26spage%3D1065%26epage%3D1073%26doi%3D10.1007%2Fs10895-018-2270-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reisch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klymchenko, A. S.</span></span> <span> </span><span class="NLM_article-title">Fluorescent polymer nanoparticles based on dyes: Seeking brighter tools for bioimaging</span>. <i>Small</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1968</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1002/smll.201503396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fsmll.201503396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26901678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XivFKisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1968-92&author=A.+Reischauthor=A.+S.+Klymchenko&title=Fluorescent+polymer+nanoparticles+based+on+dyes%3A+Seeking+brighter+tools+for+bioimaging&doi=10.1002%2Fsmll.201503396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescent Polymer Nanoparticles Based on Dyes: Seeking Brighter Tools for Bioimaging</span></div><div class="casAuthors">Reisch, Andreas; Klymchenko, Andrey S.</div><div class="citationInfo"><span class="NLM_cas:title">Small</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1968-1992</span>CODEN:
                <span class="NLM_cas:coden">SMALBC</span>;
        ISSN:<span class="NLM_cas:issn">1613-6810</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Speed, resoln. and sensitivity of today's fluorescence bioimaging can be drastically improved by fluorescent nanoparticles (NPs) that are many-fold brighter than org. dyes and fluorescent proteins.  While the field is currently dominated by inorg. NPs, notably quantum dots (QDs), fluorescent polymer NPs encapsulating large quantities of dyes (dye-loaded NPs) have emerged recently as an attractive alternative.  These new nanomaterials, inspired from the fields of polymeric drug delivery vehicles and advanced fluorophores, can combine superior brightness with biodegradability and low toxicity.  Here, the authors describe the strategies for synthesis of dye-loaded polymer NPs by emulsion polymn. and assembly of pre-formed polymers.  Superior brightness requires strong dye loading without aggregation-caused quenching (ACQ).  Only recently several strategies of dye design are proposed to overcome ACQ in polymer NPs: aggregation induced emission (AIE), dye modification with bulky side groups and use of bulky hydrophobic counterions.  The resulting NPs now surpass the brightness of QDs by ≈10-fold for a comparable size, and have started reaching the level of the brightest conjugated polymer NPs.  Other properties, notably photostability, color, blinking, as well as particle size and surface chem. are also systematically analyzed.  Finally, major and emerging applications of dye-loaded NPs for in vitro and in vivo imaging are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXynwKKk2T7rVg90H21EOLACvtfcHk0ljClg6uuNPosg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivFKisrc%253D&md5=979fddb827142090589a3fee8cc4efd3</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fsmll.201503396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsmll.201503396%26sid%3Dliteratum%253Aachs%26aulast%3DReisch%26aufirst%3DA.%26aulast%3DKlymchenko%26aufirst%3DA.%2BS.%26atitle%3DFluorescent%2520polymer%2520nanoparticles%2520based%2520on%2520dyes%253A%2520Seeking%2520brighter%2520tools%2520for%2520bioimaging%26jtitle%3DSmall%26date%3D2016%26volume%3D12%26spage%3D1968%26epage%3D92%26doi%3D10.1002%2Fsmll.201503396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. L. R.</span></span> <span> </span><span class="NLM_article-title">Designed for life: Biocompatible de novo designed proteins and components</span>. <i>J. R. Soc., Interface</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">20180472</span>, <span class="refDoi"> DOI: 10.1098/rsif.2018.0472</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1098%2Frsif.2018.0472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30158186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtlKhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=20180472&author=K.+J.+Graysonauthor=J.+L.+R.+Anderson&title=Designed+for+life%3A+Biocompatible+de+novo+designed+proteins+and+components&doi=10.1098%2Frsif.2018.0472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Designed for life: biocompatible de novo designed proteins and components</span></div><div class="casAuthors">Grayson, Katie J.; Anderson, J. L. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Royal Society, Interface</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">145</span>),
    <span class="NLM_cas:pages">20180472/1-20180472/15</span>CODEN:
                <span class="NLM_cas:coden">JRSICU</span>;
        ISSN:<span class="NLM_cas:issn">1742-5662</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  A principal goal of synthetic biol. is the de novo design or redesign of biomol. components.  In addn. to revealing fundamentally important information regarding natural biomol. engineering and biochem., functional building blocks will ultimately be provided for applications including the manuf. of valuable products and therapeutics.  To fully realize this ambitious goal, the designed components must be biocompatible, working in concert with natural biochem. processes and pathways, while not adversely affecting cellular function.  For example, de novo protein design has provided us with a wide repertoire of structures and functions, including those that can be assembled and function in vivo.  Here we discuss such biocompatible designs, as well as others that have the potential to become biocompatible, including non-protein mols., and routes to achieving full biol. integration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGIHZTW5RK5rVg90H21EOLACvtfcHk0ljClg6uuNPosg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtlKhu7Y%253D&md5=f96fe8cdb63f54c3fd07549f855d1c3d</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1098%2Frsif.2018.0472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frsif.2018.0472%26sid%3Dliteratum%253Aachs%26aulast%3DGrayson%26aufirst%3DK.%2BJ.%26aulast%3DAnderson%26aufirst%3DJ.%2BL.%2BR.%26atitle%3DDesigned%2520for%2520life%253A%2520Biocompatible%2520de%2520novo%2520designed%2520proteins%2520and%2520components%26jtitle%3DJ.%2520R.%2520Soc.%252C%2520Interface%26date%3D2018%26volume%3D15%26spage%3D20180472%26doi%3D10.1098%2Frsif.2018.0472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span> </span><span class="NLM_article-title">Nuclear
medicine equipment market by product (spect (hybrid spect,
standalone spect), hybrid pet, & planar scintigraphy), application
(cardiology, oncology & neurology) & by end user (hospitals,
imaging centers) - global forecasts to 2020</span>. <a href="https://www.marketsandmarkets.com/Market-Reports/nuclear-medicine-equipment-market-242495651.html" class="extLink">https://www.marketsandmarkets.com/Market-Reports/nuclear-medicine-equipment-market-242495651.html</a> (accessed Jun 30, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Nuclear%0Amedicine+equipment+market+by+product+%28spect+%28hybrid+spect%2C%0Astandalone+spect%29%2C+hybrid+pet%2C+%26+planar+scintigraphy%29%2C+application%0A%28cardiology%2C+oncology+%26+neurology%29+%26+by+end+user+%28hospitals%2C%0Aimaging+centers%29+-+global+forecasts+to+2020.+https%3A%2F%2Fwww.marketsandmarkets.com%2FMarket-Reports%2Fnuclear-medicine-equipment-market-242495651.html+%28accessed+Jun+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNuclear%250Amedicine%2520equipment%2520market%2520by%2520product%2520%2528spect%2520%2528hybrid%2520spect%252C%250Astandalone%2520spect%2529%252C%2520hybrid%2520pet%252C%2520%2526%2520planar%2520scintigraphy%2529%252C%2520application%250A%2528cardiology%252C%2520oncology%2520%2526%2520neurology%2529%2520%2526%2520by%2520end%2520user%2520%2528hospitals%252C%250Aimaging%2520centers%2529%2520-%2520global%2520forecasts%2520to%25202020%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span> </span><span class="NLM_article-title">Imaging
agents: Global market trajectory and analytics</span>. <a href="https://www.researchandmarkets.com/reports/338860/imaging_agents_global_market_trajectory_and" class="extLink">https://www.researchandmarkets.com/reports/338860/imaging_agents_global_market_trajectory_and</a> (accessed Nov 24, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Imaging%0Aagents%3A+Global+market+trajectory+and+analytics.+https%3A%2F%2Fwww.researchandmarkets.com%2Freports%2F338860%2Fimaging_agents_global_market_trajectory_and+%28accessed+Nov+24%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DImaging%250Aagents%253A%2520Global%2520market%2520trajectory%2520and%2520analytics%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smigielski, J.</span></span> <span> </span><span class="NLM_article-title">The prevalence of age-related eye diseases and cataract surgery among older adults in the city of lodz, poland</span>. <i>J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">605814</span>, <span class="refDoi"> DOI: 10.1155/2015/605814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1155%2F2015%2F605814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25789169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2MnmtVGhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=605814&author=M.+S.+Nowakauthor=J.+Smigielski&title=The+prevalence+of+age-related+eye+diseases+and+cataract+surgery+among+older+adults+in+the+city+of+lodz%2C+poland&doi=10.1155%2F2015%2F605814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">The Prevalence of Age-Related Eye Diseases and Cataract Surgery among Older Adults in the City of Lodz, Poland</span></div><div class="casAuthors">Nowak Michal Szymon; Smigielski Janusz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of ophthalmology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">605814</span>
        ISSN:<span class="NLM_cas:issn">2090-004X</span>.
    </div><div class="casAbstract">Purpose.  To determine the prevalence of age-related eye diseases and cataract surgery among older adults in the city of Lodz, in central Poland.  Material and Methods.  The study design was cross-sectional and observational study.  A total of 1107 women and men of predominantly Caucasian origin were successfully enumerated and recruited for the study.  All selected subjects were interviewed and underwent detailed ophthalmic examinations.  Results.  Overall 8.04% (95% CI 6.44-9.64) subjects had cataract surgery in either eye.  After excluding subjects with bilateral cataract surgery, the prevalence of cataract was 12.10% (95% CI 10.18-14.03).  AMD was found in 4.33% (95% CI 3.14-5.54 ) of all subjects.  Of them 3.25% (95% CI 2.21-4.30 ) had early AMD and 1.08% (95% CI 0.47-1.69) had late AMD.  Various types of glaucoma were diagnosed in 5.51% (95% CI 4.17-6.85) of subjects and 2.62% (95% CI 1.68-3.56) had OHT.  The prevalence rates of DR and myopic macular degeneration were 1.72% (95% CI 0.95-2.48) and 0.45% (95% CI 0.06-0.85), respectively.  All multiple logistic regression models were only significantly associated with older age.  The highest rate of visual impairment was observed among subjects with retinal diseases.  Conclusions.  The study revealed high prevalence of age-related eye diseases in this older population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9t7rHW-VRsJggzHGM8X5CfW6udTcc2ebwQwQwT1_XXbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnmtVGhtA%253D%253D&md5=50ac9fc66d0c104a29c531cdd3ba33d0</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1155%2F2015%2F605814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F605814%26sid%3Dliteratum%253Aachs%26aulast%3DNowak%26aufirst%3DM.%2BS.%26aulast%3DSmigielski%26aufirst%3DJ.%26atitle%3DThe%2520prevalence%2520of%2520age-related%2520eye%2520diseases%2520and%2520cataract%2520surgery%2520among%2520older%2520adults%2520in%2520the%2520city%2520of%2520lodz%252C%2520poland%26jtitle%3DJ.%2520Ophthalmol.%26date%3D2015%26volume%3D2015%26spage%3D605814%26doi%3D10.1155%2F2015%2F605814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abidi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span> <span> </span><span class="NLM_article-title">Lifitegrast: A novel drug for treatment of dry eye disease</span>. <i>J. Pharmacol. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.4103/0976-500X.195920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.4103%2F0976-500X.195920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28163544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVChsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=194-198&author=A.+Abidiauthor=P.+Shuklaauthor=A.+Ahmad&title=Lifitegrast%3A+A+novel+drug+for+treatment+of+dry+eye+disease&doi=10.4103%2F0976-500X.195920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Lifitegrast: a novel drug for treatment of dry eye disease</span></div><div class="casAuthors">Abidi, Afroz; Shukla, Pooja; Ahmad, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Pharmacotherapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">194-198</span>CODEN:
                <span class="NLM_cas:coden">JPPOGN</span>;
        ISSN:<span class="NLM_cas:issn">0976-500X</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications and Media Pvt. Ltd.</span>)
        </div><div class="casAbstract">Dry eye disease (DED) is an inflammatory disorder of ocular surfaces leading to severe disability, esp. in the elderly age group.  The mainstay of therapy includes artificial tears, punctual plugs, topical antiinflammatory agents, and corticosteroids.  In the past few years, only cyclosporine-A emulsions have been added to the existing therapy, but it is discontinued by most patients as it causes burning sensation in the eye.  Hence, progress in new research for a better therapeutic option led to the discovery of lymphocyte function-assocd. antigen intercellular adhesion mol. 1 antagonist, lifitegrast.  It hinders the T-cell activation, release of inflammatory mediators, and consequently inhibits the inflammatory pathways in DED.  It was approved by the US Food and Drug Administration in July 2016 for the treatment of DED.  This review highlights the development process and approval of lifitegrast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGShJCw1byCrVg90H21EOLACvtfcHk0ljrCjav96JHyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVChsrg%253D&md5=5c2f2e417aa1de1c176b7bca2fe889c6</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.4103%2F0976-500X.195920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-500X.195920%26sid%3Dliteratum%253Aachs%26aulast%3DAbidi%26aufirst%3DA.%26aulast%3DShukla%26aufirst%3DP.%26aulast%3DAhmad%26aufirst%3DA.%26atitle%3DLifitegrast%253A%2520A%2520novel%2520drug%2520for%2520treatment%2520of%2520dry%2520eye%2520disease%26jtitle%3DJ.%2520Pharmacol.%2520Pharmacother.%26date%3D2016%26volume%3D7%26spage%3D194%26epage%3D198%26doi%3D10.4103%2F0976-500X.195920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mearin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malfertheiner, P.</span></span> <span> </span><span class="NLM_article-title">Functional gastrointestinal disorders: Complex treatments for complex pathophysiological mechanisms</span>. <i>Dig. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1159/000485407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1159%2F000485407" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2018&pages=1-4&author=F.+Mearinauthor=P.+Malfertheiner&title=Functional+gastrointestinal+disorders%3A+Complex+treatments+for+complex+pathophysiological+mechanisms&doi=10.1159%2F000485407"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1159%2F000485407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000485407%26sid%3Dliteratum%253Aachs%26aulast%3DMearin%26aufirst%3DF.%26aulast%3DMalfertheiner%26aufirst%3DP.%26atitle%3DFunctional%2520gastrointestinal%2520disorders%253A%2520Complex%2520treatments%2520for%2520complex%2520pathophysiological%2520mechanisms%26jtitle%3DDig.%2520Dis.%26date%3D2018%26volume%3D35%26spage%3D1%26epage%3D4%26doi%3D10.1159%2F000485407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanger, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, L. A.</span></span> <span> </span><span class="NLM_article-title">Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders</span>. <i>Ther. Adv. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1177/1756283X10369922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1177%2F1756283X10369922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=21180610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2jsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=291-305&author=G.+J.+Sangerauthor=L.+Changauthor=C.+Bountraauthor=L.+A.+Houghton&title=Challenges+and+prospects+for+pharmacotherapy+in+functional+gastrointestinal+disorders&doi=10.1177%2F1756283X10369922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders</span></div><div class="casAuthors">Sanger, Gareth J.; Chang, Lin; Bountra, Chas; Houghton, Lesley A.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Gastroenterology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">291-305</span>CODEN:
                <span class="NLM_cas:coden">TAGHAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-283X</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiol.  As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop new and effective treatments.  This review provides an overview of these difficulties and how the industry is reshaping its drug developmental strategies.  It describes some of the more significant and encouraging advances that have occurred, and discusses how future research might embrace the opportunities provided by advances in genetic and in particular, epigenetic research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJuA7JDY-VEbVg90H21EOLACvtfcHk0ljrCjav96JHyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2jsrjP&md5=62a50ecfae5f698a5c315827093de1d5</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1177%2F1756283X10369922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1756283X10369922%26sid%3Dliteratum%253Aachs%26aulast%3DSanger%26aufirst%3DG.%2BJ.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DHoughton%26aufirst%3DL.%2BA.%26atitle%3DChallenges%2520and%2520prospects%2520for%2520pharmacotherapy%2520in%2520functional%2520gastrointestinal%2520disorders%26jtitle%3DTher.%2520Adv.%2520Gastroenterol.%26date%3D2010%26volume%3D3%26spage%3D291%26epage%3D305%26doi%3D10.1177%2F1756283X10369922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, J. L.</span></span> <span> </span><span class="NLM_article-title">Treatment of chemotherapy-induced nausea in cancer patients</span>. <i>Eur. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">14</span>, <span class="refDoi"> DOI: 10.17925/EOH.2010.06.02.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.17925%2FEOH.2010.06.02.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=21984886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2srmsFCksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=14&author=J.+L.+Ryan&title=Treatment+of+chemotherapy-induced+nausea+in+cancer+patients&doi=10.17925%2FEOH.2010.06.02.14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Chemotherapy-Induced Nausea in Cancer Patients</span></div><div class="casAuthors">Ryan Julie L</div><div class="citationInfo"><span class="NLM_cas:title">European oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">14-16</span>
        ISSN:<span class="NLM_cas:issn">1758-3853</span>.
    </div><div class="casAbstract">For over 30 years, chemotherapy-induced nausea and vomiting have been the most severe and troublesome symptoms for cancer patients receiving chemotherapy.  Unresolved chemotherapy-induced nausea and vomiting can lead to metabolic disorders, dehydration, nutritional depletion and esophageal tears, and can reduce patients' daily functioning and quality of life and interfere with treatment schedules.(1, 2) Despite the widespread use of antiemetics, chemotherapy-induced nausea continues to be problematic.  Unlike vomiting, nausea is a subjective and unobservable phenomenon making it extremely difficult to accurately assess and treat.  Current research suggests that management of chemotherapy-induced nausea should focus on treating the symptoms before they occur rather than after they develop.  This review highlights evidence-based interventions for the treatment of chemotherapy-related nausea.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTaqoal3y9Tklm8bhe6roZYfW6udTcc2eY6knAFMHTSiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srmsFCksA%253D%253D&md5=3ca113816dd50e62c70894363c39de3a</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.17925%2FEOH.2010.06.02.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17925%252FEOH.2010.06.02.14%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DJ.%2BL.%26atitle%3DTreatment%2520of%2520chemotherapy-induced%2520nausea%2520in%2520cancer%2520patients%26jtitle%3DEur.%2520Oncol.%26date%3D2010%26volume%3D6%26spage%3D14%26doi%3D10.17925%2FEOH.2010.06.02.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McQuade, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovska, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abalo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornstein, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurgali, K.</span></span> <span> </span><span class="NLM_article-title">Chemotherapy-induced constipation and diarrhea: Pathophysiology, current and emerging treatments</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">414</span>, <span class="refDoi"> DOI: 10.3389/fphar.2016.00414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3389%2Ffphar.2016.00414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=27857691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=414&author=R.+M.+McQuadeauthor=V.+Stojanovskaauthor=R.+Abaloauthor=J.+C.+Bornsteinauthor=K.+Nurgali&title=Chemotherapy-induced+constipation+and+diarrhea%3A+Pathophysiology%2C+current+and+emerging+treatments&doi=10.3389%2Ffphar.2016.00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments</span></div><div class="casAuthors">McQuade, Rachel M.; Stojanovska, Vanesa; Abalo, Raquel; Bornstein, Joel C.; Nurgali, Kulmira</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">414-427</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Gastrointestinal (GI) side-effects of chemotherapy are a debilitating and often overlooked clin. hurdle in cancer management.  Chemotherapy-induced constipation (CIC) and Diarrhea (CID) present a const. challenge in the efficient and tolerable treatment of cancer and are amongst the primary contributors to dose redns., delays and cessation of treatment.  Although prevalence of CIC is hard to est., it is believed to affect approx. 16% of cancer patients, while incidence of CID has been estd. to be as high as 80%.  Despite this, the underlying mechanisms of both CID and CIC remain unclear, but are believed to result from a combination of intersecting mechanisms including inflammation, secretory dysfunctions, GI dysmotility and alterations in GI innervation.  Current treatments for CIC and CID aim to reduce the severity of symptoms rather than combating the pathophysiol. mechanisms of dysfunction, and often result in worsening of already chronic GI symptoms or trigger the onset of a plethora of other side-effects including respiratory depression, uneven heartbeat, seizures, and neurotoxicity.  Emerging treatments including those targeting the enteric nervous system present promising avenues to alleviate CID and CIC.  Identification of potential targets for novel therapies to alleviate chemotherapy-induced toxicity is essential to improve clin. outcomes and quality of life amongst cancer sufferers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrteqGwwA9kW7Vg90H21EOLACvtfcHk0lgrtn_GCQ32pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWntLc%253D&md5=c0bdb919137b2370613cb6ce71bf5fc6</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2016.00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2016.00414%26sid%3Dliteratum%253Aachs%26aulast%3DMcQuade%26aufirst%3DR.%2BM.%26aulast%3DStojanovska%26aufirst%3DV.%26aulast%3DAbalo%26aufirst%3DR.%26aulast%3DBornstein%26aufirst%3DJ.%2BC.%26aulast%3DNurgali%26aufirst%3DK.%26atitle%3DChemotherapy-induced%2520constipation%2520and%2520diarrhea%253A%2520Pathophysiology%252C%2520current%2520and%2520emerging%2520treatments%26jtitle%3DFront.%2520Pharmacol.%26date%3D2016%26volume%3D7%26spage%3D414%26doi%3D10.3389%2Ffphar.2016.00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnock-Jones, K. P.</span></span> <span> </span><span class="NLM_article-title">Eluxadoline: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0436-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-015-0436-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26149369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCjt7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1305-10&author=K.+P.+Garnock-Jones&title=Eluxadoline%3A+First+global+approval&doi=10.1007%2Fs40265-015-0436-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Eluxadoline: First Global Approval</span></div><div class="casAuthors">Garnock-Jones, Karly P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1305-1310</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Eluxadoline (Viberzi), developed by Actavis (now Allergan), is an orally administered, first-in-class compd. that functions as both a μ-opioid receptor agonist and a δ-opioid receptor antagonist, and is indicated for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in adults.  The agent was originally developed by Janssen Pharmaceutica.  Eluxadoline has been approved in the US, and submissions to other global authorities are being contemplated or planned.  This article summarizes the milestones in the development of eluxadoline leading to this first approval for IBS-D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5dpEIm3WsLrVg90H21EOLACvtfcHk0lgrtn_GCQ32pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCjt7jF&md5=bf9bac23ac14a233f703f2d0565558f9</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0436-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0436-4%26sid%3Dliteratum%253Aachs%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DEluxadoline%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1305%26epage%3D10%26doi%3D10.1007%2Fs40265-015-0436-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Black, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A. C.</span></span> <span> </span><span class="NLM_article-title">Chronic idiopathic constipation in adults: Epidemiology, pathophysiology, diagnosis and clinical management</span>. <i>Med. J. Aust.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.5694/mja18.00241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.5694%2Fmja18.00241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29996755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Fnt1SjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2018&pages=86-91&author=C.+J.+Blackauthor=A.+C.+Ford&title=Chronic+idiopathic+constipation+in+adults%3A+Epidemiology%2C+pathophysiology%2C+diagnosis+and+clinical+management&doi=10.5694%2Fmja18.00241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management</span></div><div class="casAuthors">Black Christopher J; Ford Alexander C</div><div class="citationInfo"><span class="NLM_cas:title">The Medical journal of Australia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">86-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic idiopathic constipation (CIC) is one of the most common gastrointestinal disorders, with a global prevalence of 14%.  It is commoner in women and its prevalence increases with age.  There are three subtypes of CIC: dyssynergic defaecation, slow transit constipation and normal transit constipation, which is the most common subtype.  Clinical assessment of the patient with constipation requires careful history taking, in order to identify any red flag symptoms that would necessitate further investigation with colonoscopy to exclude colorectal malignancy.  Screening for hypercalcaemia, hypothyroidism and coeliac disease with appropriate blood tests should be considered.  A digital rectal examination should be performed to assess for evidence of dyssynergic defaecation.  If this is suspected, further investigation with high resolution anorectal manometry should be undertaken.  Anorectal biofeedback can be offered to patients with dyssynergic defaecation as a means of correcting the associated impairment of pelvic floor, abdominal wall and rectal functioning.  Lifestyle modifications, such as increasing dietary fibre, are the first step in managing other causes of CIC.  If patients do not respond to these simple changes, then treatment with osmotic and stimulant laxatives should be trialled.  Patients not responding to traditional laxatives should be offered treatment with prosecretory agents such as lubiprostone, linaclotide and plecanatide, or the 5-HT4 receptor agonist prucalopride, where available.  If there is no response to pharmacological treatment, surgical intervention can be considered, but it is only suitable for a carefully selected subset of patients with proven slow transit constipation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4SIAOqbpBeu2mnZh2OgS0fW6udTcc2eZPNTW56ubA2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Fnt1SjtA%253D%253D&md5=c61e1d1322731f00817a16ae51e08a22</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.5694%2Fmja18.00241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5694%252Fmja18.00241%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DC.%2BJ.%26aulast%3DFord%26aufirst%3DA.%2BC.%26atitle%3DChronic%2520idiopathic%2520constipation%2520in%2520adults%253A%2520Epidemiology%252C%2520pathophysiology%252C%2520diagnosis%2520and%2520clinical%2520management%26jtitle%3DMed.%2520J.%2520Aust.%26date%3D2018%26volume%3D209%26spage%3D86%26epage%3D91%26doi%3D10.5694%2Fmja18.00241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eswaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guentner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chey, W. D.</span></span> <span> </span><span class="NLM_article-title">Emerging pharmacologic therapies for constipation-predominant irritable bowel syndrome and chronic constipation</span>. <i>J. Neurogastroenterol. Motil.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.5056/jnm.2014.20.2.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.5056%2Fjnm.2014.20.2.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24840367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cflvFSmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=141-51&author=S.+Eswaranauthor=A.+Guentnerauthor=W.+D.+Chey&title=Emerging+pharmacologic+therapies+for+constipation-predominant+irritable+bowel+syndrome+and+chronic+constipation&doi=10.5056%2Fjnm.2014.20.2.141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation</span></div><div class="casAuthors">Eswaran Shanti; Guentner Amanda; Chey William D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurogastroenterology and motility</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-51</span>
        ISSN:<span class="NLM_cas:issn">2093-0879</span>.
    </div><div class="casAbstract">Irritable bowel syndrome with constipation and chronic functional constipation are common digestive disorders that negatively impact quality of life and account for billions of dollars in health care costs.  Related to the heterogeneity of pathogenesis that underlie these disorders and the failure of symptoms to reliably predict underlying pathophysiology, traditional therapies provide relief to only a subset of affected individuals.  The evidence surrounding new and emerging pharmacologic treatments, which include both luminally and systemically acting drugs, is discussed here.  These include agents such as lubiprostone, bile acid modulations, guanylate cyclase-C receptor agonists, serotonin receptor modulators and herbal therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9mMH7P4hI_2BAiYWy6n3SfW6udTcc2eZsQ2NtjjBX_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflvFSmsA%253D%253D&md5=c834a203d0529eead955b1865a05adae</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.5056%2Fjnm.2014.20.2.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5056%252Fjnm.2014.20.2.141%26sid%3Dliteratum%253Aachs%26aulast%3DEswaran%26aufirst%3DS.%26aulast%3DGuentner%26aufirst%3DA.%26aulast%3DChey%26aufirst%3DW.%2BD.%26atitle%3DEmerging%2520pharmacologic%2520therapies%2520for%2520constipation-predominant%2520irritable%2520bowel%2520syndrome%2520and%2520chronic%2520constipation%26jtitle%3DJ.%2520Neurogastroenterol.%2520Motil.%26date%3D2014%26volume%3D20%26spage%3D141%26epage%3D51%26doi%3D10.5056%2Fjnm.2014.20.2.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Outryve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerstens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandeplassche, L.</span></span> <span> </span><span class="NLM_article-title">Prucalopride (resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1136/gut.2008.162404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1136%2Fgut.2008.162404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=18987031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFGgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2009&pages=357-65&author=J.+Tackauthor=M.+van+Outryveauthor=G.+Beyensauthor=R.+Kerstensauthor=L.+Vandeplassche&title=Prucalopride+%28resolor%29+in+the+treatment+of+severe+chronic+constipation+in+patients+dissatisfied+with+laxatives&doi=10.1136%2Fgut.2008.162404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives</span></div><div class="casAuthors">Tack, J.; van Outryve, M.; Beyens, G.; Kerstens, R.; Vandeplassche, L.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">357-365</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">To det. the efficacy, impact on quality of life (QOL) and safety of prucalopride, a selective, high-affinity 5-HT4 receptor agonist, in patients with chronic constipation.  In this multicenter, randomized, placebo controlled, parallel-group, phase III study, patients with chronic constipation (two or fewer spontaneous complete bowel movements (SCBM)/wk) received 2 mg or 4 mg prucalopride or placebo, once daily, for 12 wk.  The primary efficacy endpoint was the proportion of patients reaching three of more SCBM/wk.  The key secondary efficacy endpoint was the proportion of patients having an increase of one or more SCBM/wk.  The primary QOL endpoint was the patient assessment of constipation QOL satisfaction subscale score.  Safety parameters included adverse events, lab. values and cardiovascular events.  Efficacy was evaluated over 713 patients.  Averaged over 12 wk, higher proportions of patients on prucalopride 2 mg (19.5%; p<0.01), 4 mg (23.6%; p<0.001) had three or more SCBM/wk (or normalization of bowel function) compared with placebo (9.6%).  Similar results were seen in the subgroup (83%) of patients dissatisfied with previous laxative treatment.  Both doses of prucalopride also significantly improved secondary efficacy and QOL endpoints, including the proportion of patients with an increase of one or more SCBM/wk, evacuation completeness, perceived disease severity and treatment effectiveness and QOL.  Prucalopride 4 mg significantly reduced the need for straining vs. placebo (p<0.05).  The most frequent treatment-related adverse events were headache and diarrhea.  Both doses of prucalopride were safe and well tolerated.  Prucalopride significantly and consistently improved bowel function, assocd. symptoms and satisfaction in chronically constipated patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX9B8ccr_LJLVg90H21EOLACvtfcHk0ljvD-BvlL_7zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFGgt7o%253D&md5=d8aecfa2a78ea4802774f9bacd1768f4</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1136%2Fgut.2008.162404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.2008.162404%26sid%3Dliteratum%253Aachs%26aulast%3DTack%26aufirst%3DJ.%26aulast%3Dvan%2BOutryve%26aufirst%3DM.%26aulast%3DBeyens%26aufirst%3DG.%26aulast%3DKerstens%26aufirst%3DR.%26aulast%3DVandeplassche%26aufirst%3DL.%26atitle%3DPrucalopride%2520%2528resolor%2529%2520in%2520the%2520treatment%2520of%2520severe%2520chronic%2520constipation%2520in%2520patients%2520dissatisfied%2520with%2520laxatives%26jtitle%3DGut%26date%3D2009%26volume%3D58%26spage%3D357%26epage%3D65%26doi%3D10.1136%2Fgut.2008.162404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khansari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohrabi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamani, F.</span></span> <span> </span><span class="NLM_article-title">The useage of opioids and their adverse effects in gastrointestinal practice: A review</span>. <i>Middle East J. Dig. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">5</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24829664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cflvV2jug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=5&author=M.+Khansariauthor=M.+Sohrabiauthor=F.+Zamani&title=The+useage+of+opioids+and+their+adverse+effects+in+gastrointestinal+practice%3A+A+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">The Useage of Opioids and their Adverse Effects in Gastrointestinal Practice: A Review</span></div><div class="casAuthors">Khansari MahmoudReza; Sohrabi MasourReza; Zamani Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Middle East journal of digestive diseases</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-16</span>
        ISSN:<span class="NLM_cas:issn">2008-5230</span>.
    </div><div class="casAbstract">Opium is one of the oldest herbal medicines currently used as an analgesic, sedative and antidiarrheal treatment.  The effects of opium are principally mediated by the μ-, κ- and δ-opioid receptors.  Opioid substances consist of all natural and synthetic alkaloids that are derived from opium.  Most of their effects on gastrointestinal motility and secretion result from suppression of neural activity.  Inhibition of gastric emptying, increase in sphincter tone, changes in motor patterns, and blockage of peristalsis result from opioid use.  Common adverse effects of opioid administration include sedation, dizziness, nausea, vomiting, constipation, dependency and tolerance, and respiratory depression.  The most common adverse effect of opioid use is constipation.  Although stool softeners are frequently used to decrease opioid-induced bowel dysfunction, however they are not efficacious.  Possibly, the use of specific opioid receptor antagonists is a more suitable approach.  Opioid antagonists, both central and peripheral, could affect gastrointestinal function and visceromotor sensitivity, which suggests an important role for endogenous opioid peptides in the control of gastrointestinal physiology.  Underlying diseases or medications known to influence the central nervous system (CNS) often accelerate the opioid's adverse effects.  However, changing the opioid and/or route of administration could also decrease their adverse effects.  Appropriate patient selection, patient education and discussion regarding potential adverse effects may assist physicians in maximizing the effectiveness of opioids, while reducing the number and severity of adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnQb3thmCTV-kdrW1FkXG-fW6udTcc2eZsQ2NtjjBX_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflvV2jug%253D%253D&md5=b6563526454dcb29d186c01218e739ff</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKhansari%26aufirst%3DM.%26aulast%3DSohrabi%26aufirst%3DM.%26aulast%3DZamani%26aufirst%3DF.%26atitle%3DThe%2520useage%2520of%2520opioids%2520and%2520their%2520adverse%2520effects%2520in%2520gastrointestinal%2520practice%253A%2520A%2520review%26jtitle%3DMiddle%2520East%2520J.%2520Dig.%2520Dis.%26date%3D2013%26volume%3D5%26spage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coluzzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scerpa, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pergolizzi, J.</span></span> <span> </span><span class="NLM_article-title">Naldemedine: A new option for oibd</span>. <i>J. Pain Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1209</span>– <span class="NLM_lpage">1222</span>, <span class="refDoi"> DOI: 10.2147/JPR.S243435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2147%2FJPR.S243435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=32547183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFegsrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=1209-1222&author=F.+Coluzziauthor=M.+S.+Scerpaauthor=J.+Pergolizzi&title=Naldemedine%3A+A+new+option+for+oibd&doi=10.2147%2FJPR.S243435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Naldemedine: a new option for OIBD</span></div><div class="casAuthors">Coluzzi, Flaminia; Scerpa, Maria Sole; Pergolizzi, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1209-1222</span>CODEN:
                <span class="NLM_cas:coden">JPROEV</span>;
        ISSN:<span class="NLM_cas:issn">1178-7090</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Opioid-induced bowel dysfunction (OIBD) is a common complication in longterm opioid users and abusers.  It is a burdensome condition, which significantly limits quality of life and is assocd. with increasing health costs.  OIBD affects up to 60% of patients with chronic non-cancer pain and over 80% of patients suffering from cancer pain and is one of the conditions of the most common symptoms assocd. with opioid maintenance.  Given the continued use of opioids for chronic pain management in appropriate patients, OIBD is likely to persist in clin. practice in the coming years.  We will herein review its underlying pathophysiol. mechanisms and the available treatments.  In the last years, pharmaceutical research has focused on the opportunity of targeting peripheral muopioid receptors without affecting their analgesic activity in the central nervous system, and several peripherally acting mu-opioid receptors antagonists (PAMORAs) drugs have been approved.  We will mainly focus on naldemedine, discussing its pharmacol. properties, its clin. efficacy and side effects.  Head-to-head comparisons between naldemedine and the other PAMORAs are not available yet, but some considerations will be discussed based on the pharmacol. and clin. data.  As a whole, the available data suggest that naldemedine is a valid treatment option for OIBD, as it is a well-tolerated drug that alleviates constipation without affecting analgesia or causing symptoms of opioid withdrawal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMco4DbKoeNLVg90H21EOLACvtfcHk0litUMNwlPfjAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFegsrnL&md5=5c84bb0ab08e048bfda431373ea1d2f3</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.2147%2FJPR.S243435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJPR.S243435%26sid%3Dliteratum%253Aachs%26aulast%3DColuzzi%26aufirst%3DF.%26aulast%3DScerpa%26aufirst%3DM.%2BS.%26aulast%3DPergolizzi%26aufirst%3DJ.%26atitle%3DNaldemedine%253A%2520A%2520new%2520option%2520for%2520oibd%26jtitle%3DJ.%2520Pain%2520Res.%26date%3D2020%26volume%3D13%26spage%3D1209%26epage%3D1222%26doi%3D10.2147%2FJPR.S243435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span> </span><span class="NLM_article-title">Global gastrointestinal drugs market research
report</span>. <a href="https://www.marketresearchfuture.com/reports/gastrointestinal-drugs-market-558" class="extLink">https://www.marketresearchfuture.com/reports/gastrointestinal-drugs-market-558</a> (accessed Nov 24, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global+gastrointestinal+drugs+market+research%0Areport.+https%3A%2F%2Fwww.marketresearchfuture.com%2Freports%2Fgastrointestinal-drugs-market-558+%28accessed+Nov+24%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGlobal%2520gastrointestinal%2520drugs%2520market%2520research%250Areport%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulnigg-Dabsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasche, C.</span></span> <span> </span><span class="NLM_article-title">Management of iron deficiency anemia</span>. <i>Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">250</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC28bitFensQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=241-250&author=K.+Jimenezauthor=S.+Kulnigg-Dabschauthor=C.+Gasche&title=Management+of+iron+deficiency+anemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Management of Iron Deficiency Anemia</span></div><div class="casAuthors">Jimenez Kristine; Kulnigg-Dabsch Stefanie; Gasche Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology & hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">241-50</span>
        ISSN:<span class="NLM_cas:issn">1554-7914</span>.
    </div><div class="casAbstract">Anemia affects one-fourth of the world's population, and iron deficiency is the predominant cause.  Anemia is associated with chronic fatigue, impaired cognitive function, and diminished well-being.  Patients with iron deficiency anemia of unknown etiology are frequently referred to a gastroenterologist because in the majority of cases the condition has a gastrointestinal origin.  Proper management improves quality of life, alleviates the symptoms of iron deficiency, and reduces the need for blood transfusions.  Treatment options include oral and intravenous iron therapy; however, the efficacy of oral iron is limited in certain gastrointestinal conditions, such as inflammatory bowel disease, celiac disease, and autoimmune gastritis.  This article provides a critical summary of the diagnosis and treatment of iron deficiency anemia.  In addition, it includes a management algorithm that can help the clinician determine which patients are in need of further gastrointestinal evaluation.  This facilitates the identification and treatment of the underlying condition and avoids the unnecessary use of invasive methods and their associated risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXtoRj3u-KB9bHMBt0mMIXfW6udTcc2eYbp-80iLtmLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bitFensQ%253D%253D&md5=7f298e2b0f6c95dda8178b53ec64d13c</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJimenez%26aufirst%3DK.%26aulast%3DKulnigg-Dabsch%26aufirst%3DS.%26aulast%3DGasche%26aufirst%3DC.%26atitle%3DManagement%2520of%2520iron%2520deficiency%2520anemia%26jtitle%3DGastroenterol.%2520Hepatol.%26date%3D2015%26volume%3D11%26spage%3D241%26epage%3D250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogé, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broussard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, M. D.</span></span> <span> </span><span class="NLM_article-title">Acne vulgaris: Diagnosis and treatment</span>. <i>Arch. Dermatol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">484</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2019&pages=475-484&author=L.+K.+Og%C3%A9author=A.+Broussardauthor=M.+D.+Marshall&title=Acne+vulgaris%3A+Diagnosis+and+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOg%25C3%25A9%26aufirst%3DL.%2BK.%26aulast%3DBroussard%26aufirst%3DA.%26aulast%3DMarshall%26aufirst%3DM.%2BD.%26atitle%3DAcne%2520vulgaris%253A%2520Diagnosis%2520and%2520treatment%26jtitle%3DArch.%2520Dermatol.%2520Res.%26date%3D2019%26volume%3D100%26spage%3D475%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span> </span><span class="NLM_article-title">FDA approves new vaginal ring for one year
of birth control</span>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-vaginal-ring-one-year-birth-control#:~:text=The%20U.S.%20Food%20and%20Drug,used%20for%20an%20entire%20year." class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-vaginal-ring-one-year-birth-control#:~:text=The%20U.S.%20Food%20and%20Drug,used%20for%20an%20entire%20year.</a> (accessed Aug 28, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+approves+new+vaginal+ring+for+one+year%0Aof+birth+control.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-vaginal-ring-one-year-birth-control%23%3A%7E%3Atext%3DThe%2520U.S.%2520Food%2520and%2520Drug%2Cused%2520for%2520an%2520entire%2520year.+%28accessed+Aug+28%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520approves%2520new%2520vaginal%2520ring%2520for%2520one%2520year%250Aof%2520birth%2520control%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Elagolix: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1501</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0977-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-018-0977-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30194661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1ylsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1501-1508&author=Y.+N.+Lamb&title=Elagolix%3A+First+global+approval&doi=10.1007%2Fs40265-018-0977-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Elagolix: First Global Approval</span></div><div class="casAuthors">Lamb, Yvette N.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1501-1508</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Elagolix (ORILISSA), an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist, is being developed AbbVie and Neurocrine Biosciences for the treatment of reproductive hormone-dependent disorders in women.  In July 2018, the US FDA approved elagolix tablets for the management of moderate to severe pain assocd. with endometriosis.  This approval was based on pos. results in two replicate phase III trials; addnl. phase III trials in the USA, Canada and Puerto Rico are currently evaluating elagolix as both monotherapy and in combination with low-dose hormone add-back therapy in the same indication.  Elagolix with and without low-dose hormone add-back therapy is also undergoing phase III clin. development for heavy menstrual bleeding assocd. with uterine fibroids in the aforementioned locations.  This article summarizes the milestones in the development of elagolix leading to its first approval for the management of moderate to severe pain assocd. with endometriosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozwY9v1KHNcLVg90H21EOLACvtfcHk0liPIpSVXDwHBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1ylsLzE&md5=984d0fcdfc38444ac282e0d6f519c1b7</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0977-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0977-4%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DElagolix%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1501%26epage%3D1508%26doi%3D10.1007%2Fs40265-018-0977-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, D.</span></span> <span> </span><span class="NLM_article-title">A comprehensive map of fda-approved pharmaceutical products</span>. <i>Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">263</span>, <span class="refDoi"> DOI: 10.3390/pharmaceutics10040263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3390%2Fpharmaceutics10040263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWktbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=263&author=H.+Zhongauthor=G.+Chanauthor=Y.+Huauthor=H.+Huauthor=D.+Ouyang&title=A+comprehensive+map+of+fda-approved+pharmaceutical+products&doi=10.3390%2Fpharmaceutics10040263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive map of FDA-approved pharmaceutical products</span></div><div class="casAuthors">Zhong, Hao; Chan, Ging; Hu, Yuanjia; Hu, Hao; Ouyang, Defang</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263</span>CODEN:
                <span class="NLM_cas:coden">PHARK5</span>;
        ISSN:<span class="NLM_cas:issn">1999-4923</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">With the increasing research and development (R&D) difficulty of new mol. entities (NMEs), novel drug delivery systems (DDSs) are attracting widespread attention.  This review investigated the current distribution of Food and Drug Administration (FDA)-approved pharmaceutical products and evaluated the tech. barrier for the entry of generic drugs and highlighted the success and failure of advanced drug delivery systems.  According to the ratio of generic to new drugs and the four-quadrant classification scheme for evaluating the commercialization potential of DDSs, the results showed that the traditional dosage forms (e.g., conventional tablets, capsules and injections) with a lower technol. barrier were easier to reproduce, while advanced drug delivery systems (e.g., inhalations and nanomedicines) with highly tech. barriers had less competition and greater market potential.  Our study provides a comprehensive insight into FDA-approved products and deep anal. of the tech. barriers for advanced drug delivery systems.  In the future, the R&D of new mol. entities may combine advanced delivery technologies to make drug candidates into more therapeutically effective formulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZT3StyqxAxLVg90H21EOLACvtfcHk0liPIpSVXDwHBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWktbnN&md5=bee954f35acab9c3e7481c858f4f1eb6</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.3390%2Fpharmaceutics10040263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fpharmaceutics10040263%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DOuyang%26aufirst%3DD.%26atitle%3DA%2520comprehensive%2520map%2520of%2520fda-approved%2520pharmaceutical%2520products%26jtitle%3DPharmaceutics%26date%3D2018%26volume%3D10%26spage%3D263%26doi%3D10.3390%2Fpharmaceutics10040263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delost, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qureshi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">A survey of the structures of us fda approved combination drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4265</span>– <span class="NLM_lpage">4311</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01610</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01610" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Citb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4265-4311&author=P.+Dasauthor=M.+D.+Delostauthor=M.+H.+Qureshiauthor=D.+T.+Smithauthor=J.+T.+Njardarson&title=A+survey+of+the+structures+of+us+fda+approved+combination+drugs&doi=10.1021%2Facs.jmedchem.8b01610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">A Survey of the Structures of US FDA Approved Combination Drugs</span></div><div class="casAuthors">Das, Pradipta; Delost, Michael D.; Qureshi, Munaum H.; Smith, David T.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4265-4311</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combination drugs are an important class of US FDA approved pharmaceuticals.  These drugs have been on a continuous growth trajectory since the first combination drugs were approved in the 1940s.  In this Perspective, we report the first comprehensive compilation and anal. of US FDA approved combination drugs, from the first approval in 1943 through 2018.  Our database contains 419 combination drugs, which are represented by 328 unique small mol. structures.  Breakdown of these drugs according to disease category, structure, combination compn., and year of approval is presented as well as the top 24 most commonly used small mol. combination drug components.  For frequently used small mol. components, we present "relationship diagrams" to aid in the visualization of the many drug combinations these structures are part of.  The main body contains 10 disease-focused sections wherein every small mol. component utilized as part of a combination for each disease category is displayed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8XxgcuwxFEbVg90H21EOLACvtfcHk0liPIpSVXDwHBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Citb7J&md5=caeeef6298591e300a93782176e87ab8</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01610%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DP.%26aulast%3DDelost%26aufirst%3DM.%2BD.%26aulast%3DQureshi%26aufirst%3DM.%2BH.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DA%2520survey%2520of%2520the%2520structures%2520of%2520us%2520fda%2520approved%2520combination%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4265%26epage%3D4311%26doi%3D10.1021%2Facs.jmedchem.8b01610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delost, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">From oxiranes to oligomers: Architectures of us fda approved pharmaceuticals containing oxygen heterocycles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">10996</span>– <span class="NLM_lpage">11020</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00876</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00876" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGit7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10996-11020&author=M.+D.+Delostauthor=D.+T.+Smithauthor=B.+J.+Andersonauthor=J.+T.+Njardarson&title=From+oxiranes+to+oligomers%3A+Architectures+of+us+fda+approved+pharmaceuticals+containing+oxygen+heterocycles&doi=10.1021%2Facs.jmedchem.8b00876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles</span></div><div class="casAuthors">Delost, Michael D.; Smith, David T.; Anderson, Benton J.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10996-11020</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxygen heterocycles are the second most common type of heterocycles that appear as structural components of U.S. Food and Drug Administration (FDA) approved pharmaceuticals.  Anal. of our database of drugs approved through 2017 reveals 311 distinct pharmaceuticals contg. at least one oxygen heterocycle.  Most prevalent among these are pyranoses, with furanoses, macrolactones, morpholines, and dioxolanes rounding off the top five.  The main body of this Perspective is organized according to ring size, commencing with three- and four-membered rings and ending with macrocycles, polymers, and unusual oxygen-contg. heterocycles.  For each section, all oxygen heterocycle-contg. drugs are presented along with a brief discussion about structural and drug application patterns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor-PzQmLXoGbVg90H21EOLACvtfcHk0ljmvJgpQx9eRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGit7nE&md5=18f3979c80513bfbbc263dd5945c63f0</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00876%26sid%3Dliteratum%253Aachs%26aulast%3DDelost%26aufirst%3DM.%2BD.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DAnderson%26aufirst%3DB.%2BJ.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DFrom%2520oxiranes%2520to%2520oligomers%253A%2520Architectures%2520of%2520us%2520fda%2520approved%2520pharmaceuticals%2520containing%2520oxygen%2520heterocycles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D10996%26epage%3D11020%26doi%3D10.1021%2Facs.jmedchem.8b00876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pathania, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narang, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawal, R. K.</span></span> <span> </span><span class="NLM_article-title">Role of sulphur-heterocycles in medicinal chemistry: An update</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.07.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.ejmech.2019.07.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31330449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWksbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2019&pages=486-508&author=S.+Pathaniaauthor=R.+K.+Narangauthor=R.+K.+Rawal&title=Role+of+sulphur-heterocycles+in+medicinal+chemistry%3A+An+update&doi=10.1016%2Fj.ejmech.2019.07.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Role of sulphur-heterocycles in medicinal chemistry: an update</span></div><div class="casAuthors">Pathania, Shelly; Narang, Raj Kumar; Rawal, Ravindra K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">486-508</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  From many decades, S-heterocycles have maintained their status as an important part and core of FDA approved drugs and medicinally active compds.  With exhaustive exploration of nitrogen heterocycles in medicinal chem., researchers have shifted their interest towards other heterocycles, esp., S-heterocycles.  Thus several attempts have been made to synthesize a variety of new sulfur contg. compds. with high medicinal value and low toxicity profile, in comparison to previous N-heterocycles.  Till today, S-heterocycle contg. compds. have been largely reported as anticancer, antidiabetic, antimicrobial, antihypertension, antiviral, anti-inflammatory etc.  In this review, the authors have tried to provide a crit. anal. of synthesis and medicinal attributes of sulfur contg. heterocycles such as thiirane, thiophene, thiazole, thiopyran, thiazolidine etc reported within last five years to emphasize the significance and usefulness of these S-heterocycles in the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB6U8lNztHpLVg90H21EOLACvtfcHk0ljmvJgpQx9eRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWksbbN&md5=f3dd3c21c74cd0fd3525166d33858c6f</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.07.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.07.043%26sid%3Dliteratum%253Aachs%26aulast%3DPathania%26aufirst%3DS.%26aulast%3DNarang%26aufirst%3DR.%2BK.%26aulast%3DRawal%26aufirst%3DR.%2BK.%26atitle%3DRole%2520of%2520sulphur-heterocycles%2520in%2520medicinal%2520chemistry%253A%2520An%2520update%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D180%26spage%3D486%26epage%3D508%26doi%3D10.1016%2Fj.ejmech.2019.07.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beno, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">A survey of the role of noncovalent sulfur interactions in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4383</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1021/jm501853m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501853m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4383-438&author=B.+R.+Benoauthor=K.+S.+Yeungauthor=M.+D.+Bartbergerauthor=L.+D.+Penningtonauthor=N.+A.+Meanwell&title=A+survey+of+the+role+of+noncovalent+sulfur+interactions+in+drug+design&doi=10.1021%2Fjm501853m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design</span></div><div class="casAuthors">Beno, Brett R.; Yeung, Kap-Sun; Bartberger, Michael D.; Pennington, Lewis D.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4383-4438</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Electron deficient, bivalent sulfur atoms have two areas of pos. electrostatic potential, a consequence of the low-lying σ* orbitals of the C-S bond that are available for interaction with electron donors including oxygen and nitrogen atoms and, possibly, π-systems.  Intramol. interactions are by far the most common manifestation of this effect, which offers a means of modulating the conformational preferences of a mol.  Although a well-documented phenomenon, a priori applications in drug design are relatively sparse and this interaction, which is often isosteric with an intramol. hydrogen-bonding interaction, appears to be underappreciated by the medicinal chem. community.  In this Perspective, we discuss the theor. basis for sulfur σ* orbital interactions and illustrate their importance in the context of drug design and org. synthesis.  The role of sulfur interactions in protein structure and function is discussed and although relatively rare, intermol. interactions between ligand C-S σ* orbitals and proteins are illustrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYKXRsl4BQYrVg90H21EOLACvtfcHk0ljmvJgpQx9eRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D&md5=d12f53eb3271c161cfc833fb9f7c02b3</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Fjm501853m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501853m%26sid%3Dliteratum%253Aachs%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DYeung%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DA%2520survey%2520of%2520the%2520role%2520of%2520noncovalent%2520sulfur%2520interactions%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4383%26epage%3D438%26doi%3D10.1021%2Fjm501853m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. A.</span>; <span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Analysis of US FDA-approved drugs containing sulfur atoms</span>. In  <i>Sulfur Chemistry</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>, Ed.; Topics in Current Chemistry Collections; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_year">2019</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">34</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2F978-3-030-25598-5_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=1-34&author=K.+A.+Scott&author=J.+T.+Njardarsonauthor=X.+Jiang&title=Sulfur+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1007%2F978-3-030-25598-5_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-030-25598-5_1%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DK.%2BA.%26atitle%3DAnalysis%2520of%2520US%2520FDA-approved%2520drugs%2520containing%2520sulfur%2520atoms%26btitle%3DSulfur%2520Chemistry%26aulast%3DJiang%26aufirst%3DX.%26pub%3DSpringer%26date%3D2019%26spage%3D1%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Applications of fluorine in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8315</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8315-59&author=E.+P.+Gillisauthor=K.+J.+Eastmanauthor=M.+D.+Hillauthor=D.+J.+Donnellyauthor=N.+A.+Meanwell&title=Applications+of+fluorine+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.5b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Gillis, Eric P.; Eastman, Kyle J.; Hill, Matthew D.; Donnelly, David J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8315-8359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with meta-anal. The role of fluorine in drug design and development is expanding rapidly as we learn more about the unique properties assocd. with this unusual element and how to deploy it with greater sophistication.  The judicious introduction of fluorine into a mol. can productively influence conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and pharmacokinetic properties.  In addn., 18F has been established as a useful positron emitting isotope for use with in vivo imaging technol. that potentially has extensive application in drug discovery and development, often limited only by convenient synthetic accessibility to labeled compds.  The wide ranging applications of fluorine in drug design are providing a strong stimulus for the development of new synthetic methodologies that allow more facile access to a wide range of fluorinated compds.  In this review, we provide an update on the effects of the strategic incorporation of fluorine in drug mols. and applications in positron emission tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8fUUtkPB4L7Vg90H21EOLACvtfcHk0li0KCtYNAsdow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK&md5=9995829a94a8c0b8d9fb0d21bdfd5a1d</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00258%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26aulast%3DEastman%26aufirst%3DK.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DApplications%2520of%2520fluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8315%26epage%3D59%26doi%3D10.1021%2Facs.jmedchem.5b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Metabolic and pharmaceutical aspects of fluorinated compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">6315</span>– <span class="NLM_lpage">6386</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01877</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01877" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvFCrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=6315-6386&author=B.+M.+Johnsonauthor=Y.+Z.+Shuauthor=X.+Zhuoauthor=N.+A.+Meanwell&title=Metabolic+and+pharmaceutical+aspects+of+fluorinated+compounds&doi=10.1021%2Facs.jmedchem.9b01877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic and Pharmaceutical Aspects of Fluorinated Compounds</span></div><div class="casAuthors">Johnson, Benjamin M.; Shu, Yue-Zhong; Zhuo, Xiaoliang; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6315-6386</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The applications of fluorine in drug design continue to expand, facilitated by an improved understanding of its effects on physicochem. properties and the development of synthetic methodologies that are providing access to new fluorinated motifs.  In turn, studies of fluorinated mols. are providing deeper insights into the effects of fluorine on metabolic pathways, distribution, and disposition.  Despite the high strength of the C-F bond, the departure of fluoride from metabolic intermediates can be facile.  This reactivity has been leveraged in the design of mechanism-based enzyme inhibitors and has influenced the metabolic fate of fluorinated compds.  In this Perspective, we summarize the literature assocd. with the metab. of fluorinated mols., focusing on examples where the presence of fluorine influences the metabolic profile.  These studies have revealed potentially problematic outcomes with some fluorinated motifs and are enhancing our understanding of how fluorine should be deployed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi3OTGhjXLXrVg90H21EOLACvtfcHk0li0KCtYNAsdow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvFCrs7o%253D&md5=a8163c3ebf456de6932a4b941bb52d14</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01877%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DB.%2BM.%26aulast%3DShu%26aufirst%3DY.%2BZ.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DMetabolic%2520and%2520pharmaceutical%2520aspects%2520of%2520fluorinated%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D6315%26epage%3D6386%26doi%3D10.1021%2Facs.jmedchem.9b01877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitteringham, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span> <span> </span><span class="NLM_article-title">Metabolism of fluorine-containing drugs</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.41.1.443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1146%2Fannurev.pharmtox.41.1.443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=11264465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsVaqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=443-70&author=B.+K.+Parkauthor=N.+R.+Kitteringhamauthor=P.+M.+O%E2%80%99Neill&title=Metabolism+of+fluorine-containing+drugs&doi=10.1146%2Fannurev.pharmtox.41.1.443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of fluorine-containing drugs</span></div><div class="casAuthors">Park, B. Kevin; Kitteringham, Neil R.; O'Neill, Paul M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">443-470</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 109 refs.  This article reviews current knowledge of the metab. of drugs that contain fluorine.  The strategic value of fluorine substitution in drug design is discussed in terms of chem. structure and basic concepts in drug metab. and drug toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruAja3Ht70KbVg90H21EOLACvtfcHk0lgI9mzXAx58Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsVaqtrc%253D&md5=0e2ee242da0f4cef8d203e92aee03180</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.41.1.443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.41.1.443%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26atitle%3DMetabolism%2520of%2520fluorine-containing%2520drugs%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2001%26volume%3D41%26spage%3D443%26epage%3D70%26doi%3D10.1146%2Fannurev.pharmtox.41.1.443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5822</span>– <span class="NLM_lpage">5880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5822-5880&author=N.+A.+Meanwell&title=Fluorine+and+fluorinated+motifs+in+the+design+and+application+of+bioisosteres+for+drug+design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5822-5880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the Me group while also acting as a functional mimetic of the carbonyl, carbinol, andnitrile moieties.  In this context, fluorine substitution can influence the potency, conformation, metab., membrane permeability, and P-gp recognition of a mol. and temper inhibition of the hERG channel by basic amines.  However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated mol. construction that broadens biol. mimesis.  In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a mol. are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoQvY950L3LVg90H21EOLACvtfcHk0lgI9mzXAx58Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D&md5=2d0ce3326c7ff932da8d7d26972ced14</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520fluorinated%2520motifs%2520in%2520the%2520design%2520and%2520application%2520of%2520bioisosteres%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5822%26epage%3D5880%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Bars, D.</span></span> <span> </span><span class="NLM_article-title">Fluorine-18 and medical imaging: Radiopharmaceuticals for positron emission tomography</span>. <i>J. Fluorine Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1488</span>– <span class="NLM_lpage">1493</span>, <span class="refDoi"> DOI: 10.1016/j.jfluchem.2006.09.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.jfluchem.2006.09.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1CmurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2006&pages=1488-1493&author=D.+Le+Bars&title=Fluorine-18+and+medical+imaging%3A+Radiopharmaceuticals+for+positron+emission+tomography&doi=10.1016%2Fj.jfluchem.2006.09.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine-18 and medical imaging: Radiopharmaceuticals for positron emission tomography</span></div><div class="casAuthors">Le Bars, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Fluorine Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1488-1493</span>CODEN:
                <span class="NLM_cas:coden">JFLCAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-1139</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Fluorine presents among its radioactive isotopes fluorine-18, that decays with a 109 min half-life and a β+ emission, allowing external detection of the 2 coincident γ photons obtained after annihilation.  Prodn. techniques (medical cyclotron), radiochem. reactions for isotope incorporation in radiopharmaceuticals and development of specific detection cameras (positron emission tomographs) allowed development of a vast investigation field in medical imaging.  Applications of PET in oncol. ([18F]fluorodeoxyglucose, FDG) largely improved detection and management of cancers; tracer mols. labeled with fluorine-18 also allow fruitful researches in mol. imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDqQce1ydq2rVg90H21EOLACvtfcHk0lgI9mzXAx58Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1CmurjM&md5=fc917242a297e1a89d97750af9b07b6e</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.jfluchem.2006.09.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jfluchem.2006.09.015%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BBars%26aufirst%3DD.%26atitle%3DFluorine-18%2520and%2520medical%2520imaging%253A%2520Radiopharmaceuticals%2520for%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Fluorine%2520Chem.%26date%3D2006%26volume%3D127%26spage%3D1488%26epage%3D1493%26doi%3D10.1016%2Fj.jfluchem.2006.09.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cargnin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genazzani, A. A.</span></span> <span> </span><span class="NLM_article-title">Applications of deuterium in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5276</span>– <span class="NLM_lpage">5297</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01808</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01808" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFKjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5276-5297&author=T.+Piraliauthor=M.+Serafiniauthor=S.+Cargninauthor=A.+A.+Genazzani&title=Applications+of+deuterium+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.8b01808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of deuterium in medicinal chemistry</span></div><div class="casAuthors">Pirali, Tracey; Serafini, Marta; Cargnin, Sarah; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5276-5297</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The use of deuteration in medicinal chem. has exploded in the past years, and the FDA has recently approved the first deuterium-labeled drug.  Precision deuteration goes beyond the pure and simple amelioration of the pharmacokinetic parameters of a drug and might provide an opportunity when facing problems in terms of metab.-mediated toxicity, drug interactions, and low bioactivation.  The use of deuterium is even broader, offering the opportunity to lower the degree of epimerization, reduce the dose of coadministered boosters, and discover compds. where deuterium is the basis for the mechanism of action.  Nevertheless, designing, synthesizing, and developing a successful deuterated drug is far from straightforward, and the translation from concept to practice is often unpredictable.  This Perspective provides an overview of the recent developments of deuteration, with a focus on deuterated clin. candidates, and highlights both opportunities and challenges of this strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ICy0AH9zGLVg90H21EOLACvtfcHk0lgOazt8LwwWaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFKjtw%253D%253D&md5=1ce58dbff268894dc319bfc00a1ae01f</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01808%26sid%3Dliteratum%253Aachs%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DCargnin%26aufirst%3DS.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DApplications%2520of%2520deuterium%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5276%26epage%3D5297%26doi%3D10.1021%2Facs.jmedchem.8b01808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Highly selective inhibition of tyrosine kinase 2 (tyk2) for the treatment of autoimmune diseases: Discovery of the allosteric inhibitor bms-986165</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8973</span>– <span class="NLM_lpage">8995</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00444</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00444" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8973-8995&author=S.+T.+Wrobleskiauthor=R.+Moslinauthor=S.+Linauthor=Y.+Zhangauthor=S.+Spergelauthor=J.+Kempsonauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=D.+Shusterauthor=K.+Gilloolyauthor=X.+Yangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=C.+Chaudhryauthor=J.+Khanauthor=M.+Ruzanovauthor=J.+Tredupauthor=D.+Mulliganauthor=D.+Xieauthor=H.+Sunauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=N.+Aranibarauthor=M.+Chineyauthor=A.+Chimalakondaauthor=W.+J.+Pittsauthor=L.+Lombardoauthor=P.+H.+Carterauthor=J.+R.+Burkeauthor=D.+S.+Weinstein&title=Highly+selective+inhibition+of+tyrosine+kinase+2+%28tyk2%29+for+the+treatment+of+autoimmune+diseases%3A+Discovery+of+the+allosteric+inhibitor+bms-986165&doi=10.1021%2Facs.jmedchem.9b00444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165</span></div><div class="casAuthors">Wrobleski, Stephen T.; Moslin, Ryan; Lin, Shuqun; Zhang, Yanlei; Spergel, Steven; Kempson, James; Tokarski, John S.; Strnad, Joann; Zupa-Fernandez, Adriana; Cheng, Lihong; Shuster, David; Gillooly, Kathleen; Yang, Xiaoxia; Heimrich, Elizabeth; McIntyre, Kim W.; Chaudhry, Charu; Khan, Javed; Ruzanov, Max; Tredup, Jeffrey; Mulligan, Dawn; Xie, Dianlin; Sun, Huadong; Huang, Christine; D'Arienzo, Celia; Aranibar, Nelly; Chiney, Manoj; Chimalakonda, Anjaneya; Pitts, William J.; Lombardo, Louis; Carter, Percy H.; Burke, James R.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8973-8995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases.  The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formidable challenge.  Our strategy to achieve high selectivity for TYK2 relies on targeting the TYK2 pseudokinase (JH2) domain.  Herein we report the late stage optimization efforts including a structure-guided design and water displacement strategy that led to the discovery of BMS-986165 (11, I) as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2.  In addn. to unprecedented JAK isoform and kinome selectivity, I shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease.  On the basis of these findings, I appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clin. development as an oral treatment for autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmA75TJmytlrVg90H21EOLACvtfcHk0lgOazt8LwwWaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP&md5=ca161c470df002b0bdd2bf6b19920ada</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DKempson%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DMulligan%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DChiney%26aufirst%3DM.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DLombardo%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DHighly%2520selective%2520inhibition%2520of%2520tyrosine%2520kinase%25202%2520%2528tyk2%2529%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%253A%2520Discovery%2520of%2520the%2520allosteric%2520inhibitor%2520bms-986165%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8973%26epage%3D8995%26doi%3D10.1021%2Facs.jmedchem.9b00444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, G. F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dos Santos, J. L.</span></span> <span> </span><span class="NLM_article-title">Boron in drug design: Recent advances in the development of new therapeutic agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.ejmech.2019.06.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31288128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtleju7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=791-804&author=G.+F.+S.+Fernandesauthor=W.+A.+Dennyauthor=J.+L.+Dos+Santos&title=Boron+in+drug+design%3A+Recent+advances+in+the+development+of+new+therapeutic+agents&doi=10.1016%2Fj.ejmech.2019.06.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Boron in drug design: Recent advances in the development of new therapeutic agents</span></div><div class="casAuthors">Fernandes, Guilherme Felipe Santos; Denny, William Alexander; Dos Santos, Jean Leandro</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">791-804</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Advances in the field of boron chem. have expanded the application of this element in Medicinal Chem.  Boron-contg. compds. represent a new class for medicinal chemists to use in their drug designs.  Bortezomib, a dipeptide boronic acid approved by the FDA in 2003 for treatment of multiple myeloma, paved the way for the discovery of new boron-contg. compds. After its approval, two other boron-contg. compds. have been approved, tavaborole for the treatment of onychomycosis and crisaborole for the treatment of mild to moderate atopic dermatitis.  A no. of boron-contg. compds. have been described and evaluated for a plethora of therapeutic applications.  The present review is intended to highlight the recent advances related to boron-contg. compds. and their therapeutic applications.  Here, we focused only in those most biol. active compds. with proven in vitro and/or in vivo efficacy in the therapeutic area published in the last years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNneApZtw8C7Vg90H21EOLACvtfcHk0lhAa0GMporH2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtleju7fE&md5=52c7677a4b6213be8a03b48c3981bba4</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.092%26sid%3Dliteratum%253Aachs%26aulast%3DFernandes%26aufirst%3DG.%2BF.%2BS.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDos%2BSantos%26aufirst%3DJ.%2BL.%26atitle%3DBoron%2520in%2520drug%2520design%253A%2520Recent%2520advances%2520in%2520the%2520development%2520of%2520new%2520therapeutic%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D179%26spage%3D791%26epage%3D804%26doi%3D10.1016%2Fj.ejmech.2019.06.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lesnikowski, Z. J.</span></span> <span> </span><span class="NLM_article-title">Challenges and opportunities for the application of boron clusters in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7738</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01932</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01932" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFSgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7738-58&author=Z.+J.+Lesnikowski&title=Challenges+and+opportunities+for+the+application+of+boron+clusters+in+drug+design&doi=10.1021%2Facs.jmedchem.5b01932"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and Opportunities for the Application of Boron Clusters in Drug Design</span></div><div class="casAuthors">Lesnikowski, Zbigniew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7738-7758</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are two branches in boron medicinal chem.: the first focuses on single boron atom compds., and the second utilizes boron clusters.  Boron clusters and their heteroatom counterparts belong to the family of cage compds.  A subset of this extensive class of compds. includes dicarbadodecaboranes, which have the general formula C2B10H12, and their metal biscarboranyl complexes, metallacarboranes, with the formula [M(C2B10H12)2-2].  The unique properties of boron clusters have resulted in their utilization in applications such as in pharmacophores, as scaffolds in mol. construction, and as modulators of bioactive compds.  This Perspective presents an overview of the properties of boron clusters that are pertinent for drug discovery, recent applications in the design of various classes of drugs, and the potential use of boron clusters in the construction of new pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX92E97ik4ubVg90H21EOLACvtfcHk0lhAa0GMporH2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFSgs7c%253D&md5=1d4c3720cdc649c5fc3de397bea15e83</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01932%26sid%3Dliteratum%253Aachs%26aulast%3DLesnikowski%26aufirst%3DZ.%2BJ.%26atitle%3DChallenges%2520and%2520opportunities%2520for%2520the%2520application%2520of%2520boron%2520clusters%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7738%26epage%3D58%26doi%3D10.1021%2Facs.jmedchem.5b01932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span> <span> </span><span class="NLM_article-title">Boronic acid compounds as potential pharmaceutical agents</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">346</span>– <span class="NLM_lpage">368</span>, <span class="refDoi"> DOI: 10.1002/med.10043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fmed.10043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=12647314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVWitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=346-368&author=W.+Yangauthor=X.+Gaoauthor=B.+Wang&title=Boronic+acid+compounds+as+potential+pharmaceutical+agents&doi=10.1002%2Fmed.10043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Boronic acid compounds as potential pharmaceutical agents</span></div><div class="casAuthors">Yang, Wenqian; Gao, Xingming; Wang, Binghe</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">346-368</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Boronic acid compds. have been used, because of their unique structural features, for the development of potent enzyme inhibitors, boron neutron capture agents for cancer therapy, and as antibody mimics that recognize biol. important saccharides.  Consequently, there has been a surge of interests in boronic acid compds.  This study reviews the recent development in this area during the last six years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB0CvJjV10BbVg90H21EOLACvtfcHk0lhAa0GMporH2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVWitb8%253D&md5=0b841477e2113218d55991e23133bd60</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1002%2Fmed.10043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.10043%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DB.%26atitle%3DBoronic%2520acid%2520compounds%2520as%2520potential%2520pharmaceutical%2520agents%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2003%26volume%3D23%26spage%3D346%26epage%3D368%26doi%3D10.1002%2Fmed.10043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krajnc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panduwawala, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brem, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, C. J.</span></span> <span> </span><span class="NLM_article-title">Will morphing boron-based inhibitors beat the beta-lactamases?</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2019.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.cbpa.2019.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31004962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1yrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=101-110&author=A.+Krajncauthor=P.+A.+Langauthor=T.+D.+Panduwawalaauthor=J.+Bremauthor=C.+J.+Schofield&title=Will+morphing+boron-based+inhibitors+beat+the+beta-lactamases%3F&doi=10.1016%2Fj.cbpa.2019.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Will morphing boron-based inhibitors beat the β-lactamases?</span></div><div class="casAuthors">Krajnc, Alen; Lang, Pauline A.; Panduwawala, Tharindi D.; Brem, Jurgen; Schofield, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">101-110</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The β-lactams remain the most important antibacterials, but their use is increasingly compromised by resistance, importantly by β-lactamases.  Although β-lactam and non-β-lactam inhibitors forming stable acyl-enzyme complexes with nucleophilic serine β-lactamases (SBLs) are widely used, these are increasingly susceptible to evolved SBLs and do not inhibit metallo-β-lactamases (MBLs).  Boronic acids and boronate esters, esp. cyclic ones, can potently inhibit both SBLs and MBLs.  Vaborbactam, a monocyclic boronate, is approved for clin. use, but its β-lactamase coverage is limited.  Bicyclic boronates rapidly react with SBLs and MBLs forming stable enzyme-inhibitor complexes that mimic the common anionic high-energy tetrahedral intermediates in SBL/MBL catalysis, as revealed by crystallog.  The ability of boronic acids to 'morph' between sp2 and sp3 hybridization states may help enable potent inhibition.  There is limited structure-activity relationship information on the (bi)cyclic boronate inhibitors compared to β-lactams, hence scope for creativity towards new boron-based β-lactamase inhibitors/antibacterials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYQIvXncI3a7Vg90H21EOLACvtfcHk0lj_WCTzMSLZzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1yrt7k%253D&md5=7e703c747a254766bda580563fb42a7f</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2019.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2019.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DKrajnc%26aufirst%3DA.%26aulast%3DLang%26aufirst%3DP.%2BA.%26aulast%3DPanduwawala%26aufirst%3DT.%2BD.%26aulast%3DBrem%26aufirst%3DJ.%26aulast%3DSchofield%26aufirst%3DC.%2BJ.%26atitle%3DWill%2520morphing%2520boron-based%2520inhibitors%2520beat%2520the%2520beta-lactamases%253F%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D50%26spage%3D101%26epage%3D110%26doi%3D10.1016%2Fj.cbpa.2019.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hecker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totrov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomovskaya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsivkovski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabet, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a cyclic boronic acid β-lactamase inhibitor (rpx7009) with utility vs class a serine carbapenemases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3682</span>– <span class="NLM_lpage">3692</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00127</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00127" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3682-3692&issue=9&author=S.+J.+Heckerauthor=K.+R.+Reddyauthor=M.+Totrovauthor=G.+C.+Hirstauthor=O.+Lomovskayaauthor=D.+C.+Griffithauthor=P.+Kingauthor=R.+Tsivkovskiauthor=D.+Sunauthor=M.+Sabet&title=Discovery+of+a+cyclic+boronic+acid+%CE%B2-lactamase+inhibitor+%28rpx7009%29+with+utility+vs+class+a+serine+carbapenemases&doi=10.1021%2Facs.jmedchem.5b00127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases</span></div><div class="casAuthors">Hecker, Scott J.; Reddy, K. Raja; Totrov, Maxim; Hirst, Gavin C.; Lomovskaya, Olga; Griffith, David C.; King, Paula; Tsivkovski, Ruslan; Sun, Dongxu; Sabet, Mojgan; Tarazi, Ziad; Clifton, Matthew C.; Atkins, Kateri; Raymond, Amy; Potts, Kristy T.; Abendroth, Jan; Boyer, Serge H.; Loutit, Jeffrey S.; Morgan, Elizabeth E.; Durso, Stephanie; Dudley, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3682-3692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The increasing dissemination of carbapenemases in Gram-neg. bacteria has threatened the clin. usefulness of the β-lactam class of antimicrobials.  A program was initiated to discover a new series of serine β-lactamase inhibitors contg. a boronic acid pharmacophore, with the goal of finding a potent inhibitor of serine carbapenemase enzymes that are currently compromising the utility of the carbapenem class of antibacterials.  Potential lead structures were screened in silico by modeling into the active sites of key serine β-lactamases.  Promising candidate mols. were synthesized and evaluated in biochem. and whole-cell assays.  Inhibitors were identified with potent inhibition of serine carbapenemases, particularly the Klebsiella pneumoniae carbapenemase (KPC), with no inhibition of mammalian serine proteases.  Studies in vitro and in vivo show that RPX7009 (9f) is a broad-spectrum inhibitor, notably restoring the activity of carbapenems against KPC-producing strains.  Combined with a carbapenem, 9f is a promising product for the treatment of multidrug resistant Gram-neg. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXpE5YX_dRNLVg90H21EOLACvtfcHk0lj_WCTzMSLZzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D&md5=965fbf2b42f2e1b38eccc3b23dfa374f</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00127%26sid%3Dliteratum%253Aachs%26aulast%3DHecker%26aufirst%3DS.%2BJ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DTotrov%26aufirst%3DM.%26aulast%3DHirst%26aufirst%3DG.%2BC.%26aulast%3DLomovskaya%26aufirst%3DO.%26aulast%3DGriffith%26aufirst%3DD.%2BC.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DTsivkovski%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DSabet%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520cyclic%2520boronic%2520acid%2520%25CE%25B2-lactamase%2520inhibitor%2520%2528rpx7009%2529%2520with%2520utility%2520vs%2520class%2520a%2520serine%2520carbapenemases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D9%26spage%3D3682%26epage%3D3692%26doi%3D10.1021%2Facs.jmedchem.5b00127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Ixazomib: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0548-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-016-0548-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26846321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=405-11&author=M.+Shirley&title=Ixazomib%3A+First+global+approval&doi=10.1007%2Fs40265-016-0548-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Ixazomib: First Global Approval</span></div><div class="casAuthors">Shirley, Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-411</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ixazomib (Ninlaro) is an orally bioavailable, reversible proteasome inhibitor developed by Millennium Pharmaceuticals, Inc. (now Takeda Oncol.).  Ixazomib acts by binding to and inhibiting the β5 subunit of the 20S proteasome.  In Nov. 2015, the US FDA approved ixazomib for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.  Ixazomib is under regulatory review for this indication in the EU.  Phase III development of ixazomib is underway worldwide for newly-diagnosed multiple myeloma (in patients who are not eligible for stem cell transplant, or as maintenance therapy) and for relapsed or refractory systemic light chain (AL) amyloidosis.  Ixazomib is also under phase I-II development for the treatment of several other haematol. and non-haematol. malignancies, graft-vs.-host disease and lupus nephritis.  This article summarizes the milestones in the development of ixazomib leading to this first approval for multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMK0Ud8_wMNrVg90H21EOLACvtfcHk0lj_WCTzMSLZzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGksbg%253D&md5=a31e66cf68dce72be96fe8e8843919ac</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0548-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0548-5%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DIxazomib%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D405%26epage%3D11%26doi%3D10.1007%2Fs40265-016-0548-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paton, D.</span></span> <span> </span><span class="NLM_article-title">Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1358/dot.2017.53.4.2604174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1358%2Fdot.2017.53.4.2604174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC1crmtVykug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=239-245&author=D.+Paton&title=Crisaborole%3A+Phosphodiesterase+inhibitor+for+treatment+of+atopic+dermatitis&doi=10.1358%2Fdot.2017.53.4.2604174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis</span></div><div class="casAuthors">Paton D M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">239-245</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Atopic dermatitis (AD) is an extremely common condition affecting as many as 10-20% of children and 2-10% of adults.  A particularly distressing symptom of AD is pruritus.  One of the important aspects of AD is inflammation associated with increased activity of phosphodiesterase 4 (PDE4), resulting in decreased intracellular levels of cyclic adenosine monophosphate, which in turn causes increased production of inflammatory cytokines.  Crisaborole was developed as a small-molecule, boron-based, selective PDE4 inhibitor that can be used topically.  Clinical trials have demonstrated its efficacy in treating patients with mild to moderate AD, resulting in significant relief of pruritus.  Unlike PDE4 inhibitors that act systemically, crisaborole does not cause significant gastrointestinal adverse effects.  The most common adverse effect has been temporary stinging and burning in about 4% of patients upon application of the 2% ointment.  To date there is no evidence of atrophy, telangiectasia or hypopigmentation resulting from its use.  Crisaborole is the first topically applied PDE4 inhibitor to be approved by the FDA for use in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTC3c4rt0Hyh4qdXsLcGTEUfW6udTcc2eaooMT5WUbS87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crmtVykug%253D%253D&md5=a854efec1d46127283db4e443c22221f</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1358%2Fdot.2017.53.4.2604174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2017.53.4.2604174%26sid%3Dliteratum%253Aachs%26aulast%3DPaton%26aufirst%3DD.%26atitle%3DCrisaborole%253A%2520Phosphodiesterase%2520inhibitor%2520for%2520treatment%2520of%2520atopic%2520dermatitis%26jtitle%3DDrugs%2520Today%26date%3D2017%26volume%3D53%26spage%3D239%26epage%3D245%26doi%3D10.1358%2Fdot.2017.53.4.2604174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkranz, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mermelstein, R.</span></span> <span> </span><span class="NLM_article-title">Mutagenicity and genotoxicity of nitroarenes: All nitro-containing chemicals were not created equal</span>. <i>Mutat. Res., Rev. Genet. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1016/0165-1110(83)90034-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2F0165-1110%2883%2990034-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=6300670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaL3sXhvFakurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1983&pages=217-267&author=H.+S.+Rosenkranzauthor=R.+Mermelstein&title=Mutagenicity+and+genotoxicity+of+nitroarenes%3A+All+nitro-containing+chemicals+were+not+created+equal&doi=10.1016%2F0165-1110%2883%2990034-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Mutagenicity and genotoxicity of nitroarenes.  All nitro-containing chemicals were not created equal</span></div><div class="casAuthors">Rosenkranz, Herbert S.; Mermelstein, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Reviews in Genetic Toxicology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-67</span>CODEN:
                <span class="NLM_cas:coden">MRRTEP</span>;
        ISSN:<span class="NLM_cas:issn">0615-1110</span>.
    </div><div class="casAbstract">A review with >250 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPuX9Hv79-hbVg90H21EOLACvtfcHk0li9llccivadOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhvFakurc%253D&md5=b71793097bbe6276fdd6dc3c00c8b547</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2F0165-1110%2883%2990034-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-1110%252883%252990034-9%26sid%3Dliteratum%253Aachs%26aulast%3DRosenkranz%26aufirst%3DH.%2BS.%26aulast%3DMermelstein%26aufirst%3DR.%26atitle%3DMutagenicity%2520and%2520genotoxicity%2520of%2520nitroarenes%253A%2520All%2520nitro-containing%2520chemicals%2520were%2520not%2520created%2520equal%26jtitle%3DMutat.%2520Res.%252C%2520Rev.%2520Genet.%2520Toxicol.%26date%3D1983%26volume%3D114%26spage%3D217%26epage%3D267%26doi%3D10.1016%2F0165-1110%2883%2990034-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Toxicophore exploration as a screening technology for drug design and discovery: Techniques, scope and limitations</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1785</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1007/s00204-015-1587-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs00204-015-1587-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26341667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVGntbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=1785-1802&author=P.+K.+Singhauthor=A.+Negiauthor=P.+K.+Guptaauthor=M.+Chauhanauthor=R.+Kumar&title=Toxicophore+exploration+as+a+screening+technology+for+drug+design+and+discovery%3A+Techniques%2C+scope+and+limitations&doi=10.1007%2Fs00204-015-1587-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicophore exploration as a screening technology for drug design and discovery: techniques, scope and limitations</span></div><div class="casAuthors">Singh, Pankaj Kumar; Negi, Arvind; Gupta, Pawan Kumar; Chauhan, Monika; Kumar, Raj</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1785-1802</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Toxicity is a common drawback of newly designed chemotherapeutic agents.  With the exception of pharmacophore-induced toxicity (lack of selectivity at higher concns. of a drug), the toxicity due to chemotherapeutic agents is based on the toxicophore moiety present in the drug.  To date, methodologies implemented to det. toxicophores may be broadly classified into biol., bioanal. and computational approaches.  The biol. approach involves anal. of bioactivated metabolites, whereas the computational approach involves a QSAR-based method, mapping techniques, an inverse docking technique and a few toxicophore identification/estn. tools.  Being one of the major steps in drug discovery process, toxicophore identification has proven to be an essential screening step in drug design and development.  The paper is first of its kind, attempting to cover and compare different methodologies employed in predicting and detg. toxicophores with an emphasis on their scope and limitations.  Such information may prove vital in the appropriate selection of methodol. and can be used as screening technol. by researchers to discover the toxicophoric potentials of their designed and synthesized moieties.  Addnl., it can be utilized in the manipulation of mols. contg. toxicophores in such a manner that their toxicities might be eliminated or removed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB-rSjVTEa57Vg90H21EOLACvtfcHk0li9llccivadOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVGntbvF&md5=019b4bf17f351321b4da87dd538fa361</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1007%2Fs00204-015-1587-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-015-1587-5%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DNegi%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DP.%2BK.%26aulast%3DChauhan%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DToxicophore%2520exploration%2520as%2520a%2520screening%2520technology%2520for%2520drug%2520design%2520and%2520discovery%253A%2520Techniques%252C%2520scope%2520and%2520limitations%26jtitle%3DArch.%2520Toxicol.%26date%3D2016%26volume%3D90%26spage%3D1785%26epage%3D1802%26doi%3D10.1007%2Fs00204-015-1587-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">Nitro-group-containing drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2851</span>– <span class="NLM_lpage">2893</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00147</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00147" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2851-2893&author=K.+Nepaliauthor=H.+Y.+Leeauthor=J.+P.+Liou&title=Nitro-group-containing+drugs&doi=10.1021%2Facs.jmedchem.8b00147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Nitro-Group-Containing Drugs</span></div><div class="casAuthors">Nepali, Kunal; Lee, Hsueh-Yun; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2851-2893</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The nitro group is considered to be a versatile and unique functional group in medicinal chem.  Despite a long history of use in therapeutics, the nitro group has toxicity issues and is often categorized as a structural alert or a toxicophore, and evidence related to drugs contg. nitro groups is rather contradictory.  In general, drugs contg. nitro groups have been extensively assocd. with mutagenicity and genotoxicity.  In this context, efforts toward the structure-mutagenicity or structure-genotoxicity relationships have been undertaken.  The current Perspective covers various aspects of agents that contain nitro groups, their bioreductive activation mechanisms, their toxicities, and approaches to combat their toxicity issues.  In addn., recent advances in the field of anticancer, antitubercular and antiparasitic agents contg. nitro groups, along with a patent survey on hypoxia-activated prodrugs contg. nitro groups, are also covered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqif1Bbj-Ci4bVg90H21EOLACvtfcHk0li9llccivadOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7jO&md5=33969d1c33e2b451a05b3dbdb8574497</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00147%26sid%3Dliteratum%253Aachs%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3DNitro-group-containing%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2851%26epage%3D2893%26doi%3D10.1021%2Facs.jmedchem.8b00147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palma, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifacio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loureiro, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares-Da-Silva, P.</span></span> <span> </span><span class="NLM_article-title">Computation of the binding affinities of catechol-o-methyltransferase inhibitors: Multisubstate relative free energy calculations</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">970</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.1002/jcc.22926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fjcc.22926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=22278964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ygtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=970-986&author=P.+N.+Palmaauthor=M.+J.+Bonifacioauthor=A.+I.+Loureiroauthor=P.+Soares-Da-Silva&title=Computation+of+the+binding+affinities+of+catechol-o-methyltransferase+inhibitors%3A+Multisubstate+relative+free+energy+calculations&doi=10.1002%2Fjcc.22926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Computation of the binding affinities of catechol-O-methyltransferase inhibitors: Multisubstate relative free energy calculations</span></div><div class="casAuthors">Palma, P. Nuno; Bonifacio, Maria Joao; Loureiro, Ana Isabel; Soares-da-Silva, Patricio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">970-986</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Alchem. free energy simulations are amongst the most accurate techniques for the computation of the free energy changes assocd. with noncovalent protein-ligand interactions.  A procedure is presented to est. the relative binding free energies of several ligands to the same protein target where multiple, low-energy configurational substates might coexist, as opposed to one unique structure.  The contributions of all individual substates were estd., explicitly, with the free energy perturbation method, and combined in a rigorous fashion to compute the overall relative binding free energies and dissocn. consts.  It is shown that, unless the most stable bound forms are known a priori, inaccurate results may be obtained if the contributions of multiple substates are ignored.  The method was applied to study the complex formed between human catechol-O-methyltransferase and BIA 9-1067, a newly developed tight-binding inhibitor that is currently under clin. evaluation for the therapy of Parkinson's disease.  Our results reveal an exceptionally high-binding affinity (Kd in subpicomolar range) and provide insightful clues on the interactions and mechanism of inhibition.  The inhibitor is, itself, a slowly reacting substrate of the target enzyme and is released from the complex in the form of O-methylated product.  By comparing the exptl. catalytic rate (kcat) and the estd. dissocn. rate (koff) consts. of the enzyme-inhibitor complex, one can conclude that the obsd. inhibition potency (Ki) is primarily dependent on the catalytic rate const. of the inhibitor's O-methylation, rather than the rate const. of dissocn. of the complex. © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTjDjuZ-BtVbVg90H21EOLACvtfcHk0ljKTLrZNRw2HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ygtbk%253D&md5=548b34974096e60eefb9ad605de2d8ba</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1002%2Fjcc.22926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.22926%26sid%3Dliteratum%253Aachs%26aulast%3DPalma%26aufirst%3DP.%2BN.%26aulast%3DBonifacio%26aufirst%3DM.%2BJ.%26aulast%3DLoureiro%26aufirst%3DA.%2BI.%26aulast%3DSoares-Da-Silva%26aufirst%3DP.%26atitle%3DComputation%2520of%2520the%2520binding%2520affinities%2520of%2520catechol-o-methyltransferase%2520inhibitors%253A%2520Multisubstate%2520relative%2520free%2520energy%2520calculations%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2012%26volume%3D33%26spage%3D970%26epage%3D986%26doi%3D10.1002%2Fjcc.22926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajao, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtado, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passos-Silva, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Moura, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamber-Reis, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunrath-Lima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuma, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira-Da-Rocha, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, J. B. F.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Unveiling benznidazole’s mechanism of action through overexpression of DNA repair proteins in trypanosoma cruzi</span>. <i>Environ. Mol. Mutagen.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1002/em.21839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fem.21839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24347026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFCjtr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=309-321&author=M.+A.+Rajaoauthor=C.+Furtadoauthor=C.+L.+Alvesauthor=D.+G.+Passos-Silvaauthor=M.+B.+de+Mouraauthor=B.+L.+Schamber-Reisauthor=M.+Kunrath-Limaauthor=A.+A.+Zumaauthor=J.+P.+Vieira-Da-Rochaauthor=J.+B.+F.+Garcia&title=Unveiling+benznidazole%E2%80%99s+mechanism+of+action+through+overexpression+of+DNA+repair+proteins+in+trypanosoma+cruzi&doi=10.1002%2Fem.21839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Unveiling Benznidazoles mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi</span></div><div class="casAuthors">Rajao, Matheus Andrade; Furtado, Carolina; Alves, Ceres Luciana; Passos-Silva, Danielle Gomes; Moura, Michelle Barbi; Schamber-Reis, Bruno Luiz; Kunrath-Lima, Marianna; Zuma, Aline Araujo; Vieira-da-Rocha, Joao Pedro; Garcia, Juliana Borio Ferreira; Mendes, Isabela Cecilia; Pena, Sergio Danilo Junho; Macedo, Andrea Mara; Franco, Gloria Regina; Souza-Pinto, Nadja Cristhina; Medeiros, Marisa Helena Gennari; Cruz, Angela Kaysel; Motta, Maria Cristina Machado; Teixeira, Santuza Maria Ribeiro; Machado, Carlos Renato</div><div class="citationInfo"><span class="NLM_cas:title">Environmental and Molecular Mutagenesis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-321</span>CODEN:
                <span class="NLM_cas:coden">EMMUEG</span>;
        ISSN:<span class="NLM_cas:issn">0893-6692</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Benznidazole (BZ) is the most commonly used drug for the treatment of Chagas disease.  Although BZ is known to induce the formation of free radicals and electrophilic metabolites within the parasite Trypanosoma cruzi, its precise mechanisms of action are still elusive.  Here, the authors analyzed the survival of T. cruzi exposed to BZ using genetically modified parasites overexpressing different DNA repair proteins.  The authors' results indicate that BZ induces oxidn. mainly in the nucleotide pool, as heterologous expression of the nucleotide pyrophosphohydrolase MutT (but not overexpression of the glycosylase TcOgg1) increased drug resistance in the parasite.  In addn., electron microscopy indicated that BZ catalyzes the formation of double-stranded breaks in the parasite, as its genomic DNA undergoes extensive heterochromatin unpacking following exposure to the drug.  Furthermore, the overexpression of proteins involved in the recombination-mediated DNA repair increased resistance to BZ, reinforcing the idea that the drug causes double-stranded breaks.  The authors' results also show that the overexpression of mitochondrial DNA repair proteins increase parasite survival upon BZ exposure, indicating that the drug induces lesions in the mitochondrial DNA as well.  These findings suggest that BZ preferentially oxidizes the nucleotide pool, and the extensive incorporation of oxidized nucleotides during DNA replication leads to potentially lethal double-stranded DNA breaks in T. cruzi DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpipqLqr5XxpbVg90H21EOLACvtfcHk0ljKTLrZNRw2HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFCjtr3L&md5=ebb14fc101937d18e805a687f6ba84a7</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1002%2Fem.21839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fem.21839%26sid%3Dliteratum%253Aachs%26aulast%3DRajao%26aufirst%3DM.%2BA.%26aulast%3DFurtado%26aufirst%3DC.%26aulast%3DAlves%26aufirst%3DC.%2BL.%26aulast%3DPassos-Silva%26aufirst%3DD.%2BG.%26aulast%3Dde%2BMoura%26aufirst%3DM.%2BB.%26aulast%3DSchamber-Reis%26aufirst%3DB.%2BL.%26aulast%3DKunrath-Lima%26aufirst%3DM.%26aulast%3DZuma%26aufirst%3DA.%2BA.%26aulast%3DVieira-Da-Rocha%26aufirst%3DJ.%2BP.%26aulast%3DGarcia%26aufirst%3DJ.%2BB.%2BF.%26atitle%3DUnveiling%2520benznidazole%25E2%2580%2599s%2520mechanism%2520of%2520action%2520through%2520overexpression%2520of%2520DNA%2520repair%2520proteins%2520in%2520trypanosoma%2520cruzi%26jtitle%3DEnviron.%2520Mol.%2520Mutagen.%26date%3D2014%26volume%3D55%26spage%3D309%26epage%3D321%26doi%3D10.1002%2Fem.21839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maya, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassels, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iturriaga-Vásquez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faúndez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galanti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morello, A.</span></span> <span> </span><span class="NLM_article-title">Mode of action of natural and synthetic drugs against trypanosoma cruzi and their interaction with the mammalian host</span>. <i>Comp. Biochem. Physiol., Part A: Mol. Integr. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2006.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.cbpa.2006.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=16626984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivVSitbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2007&pages=601-620&author=J.+D.+Mayaauthor=B.+K.+Casselsauthor=P.+Iturriaga-V%C3%A1squezauthor=J.+Ferreiraauthor=M.+Fa%C3%BAndezauthor=N.+Galantiauthor=A.+Ferreiraauthor=A.+Morello&title=Mode+of+action+of+natural+and+synthetic+drugs+against+trypanosoma+cruzi+and+their+interaction+with+the+mammalian+host&doi=10.1016%2Fj.cbpa.2006.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host</span></div><div class="casAuthors">Maya, Juan Diego; Cassels, Bruce K.; Iturriaga-Vasquez, Patricio; Ferreira, Jorge; Faundez, Mario; Galanti, Norbel; Ferreira, Arturo; Morello, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Comparative Biochemistry and Physiology, Part A: Molecular & Integrative Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">146A</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">601-620</span>CODEN:
                <span class="NLM_cas:coden">CBPAB5</span>;
        ISSN:<span class="NLM_cas:issn">1095-6433</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Current knowledge of the biochem. of Trypanosoma cruzi has led to the development of new drugs and the understanding of their mode of action.  Some trypanocidal drugs such as nifurtimox and benznidazole act through free radical generation during their metab.  T. cruzi is very susceptible to the cell damage induced by these metabolites because enzymes scavenging free radicals are absent or have very low activities in the parasite.  Another potential target is the biosynthetic pathway of glutathione and trypanothione, the low mol. wt. thiol found exclusively in trypanosomatids.  These thiols scavenge free radicals and participate in the conjugation and detoxication of numerous drugs.  Inhibition of this key pathway could render the parasite much more susceptible to the toxic action of drugs such as nifurtimox and benznidazole without affecting the host significantly.  Other drugs such as allopurinol and purine analogs inhibit purine transport in T. cruzi, which cannot synthesize purines de novo.  Nitroimidazole derivs. such as itraconazole inhibit sterol metab.  The parasite's respiratory chain is another potential therapeutic target because of its many differences with the host enzyme complexes.  The pharmacol. modulation of the host's immune response against T. cruzi infection as a possible chemotherapeutic target is discussed.  A large set of chems. of plant origin and a few animal metabolites active against T. cruzi are enumerated and their likely modes of action are briefly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT8Z34c4yGCLVg90H21EOLACvtfcHk0ljKTLrZNRw2HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivVSitbk%253D&md5=77e9fa25fdb00faedb7103a390b0582d</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2006.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2006.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DMaya%26aufirst%3DJ.%2BD.%26aulast%3DCassels%26aufirst%3DB.%2BK.%26aulast%3DIturriaga-V%25C3%25A1squez%26aufirst%3DP.%26aulast%3DFerreira%26aufirst%3DJ.%26aulast%3DFa%25C3%25BAndez%26aufirst%3DM.%26aulast%3DGalanti%26aufirst%3DN.%26aulast%3DFerreira%26aufirst%3DA.%26aulast%3DMorello%26aufirst%3DA.%26atitle%3DMode%2520of%2520action%2520of%2520natural%2520and%2520synthetic%2520drugs%2520against%2520trypanosoma%2520cruzi%2520and%2520their%2520interaction%2520with%2520the%2520mammalian%2520host%26jtitle%3DComp.%2520Biochem.%2520Physiol.%252C%2520Part%2520A%253A%2520Mol.%2520Integr.%2520Physiol.%26date%3D2007%26volume%3D146%26spage%3D601%26epage%3D620%26doi%3D10.1016%2Fj.cbpa.2006.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, L. R.</span></span> <span> </span><span class="NLM_article-title">Secnidazole. A Review of its Antimicrobial Activity, Pharmacokinetic Properties and Therapeutic Use in the Management of Protozoal Infections and Bacterial Vaginosis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">638</span>, <span class="refDoi"> DOI: 10.2165/00003495-199651040-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2165%2F00003495-199651040-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=8706597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaK28XislKntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1996&pages=621-638&author=J.+C.+Gillisauthor=L.+R.+Wiseman&title=Secnidazole.+A+Review+of+its+Antimicrobial+Activity%2C+Pharmacokinetic+Properties+and+Therapeutic+Use+in+the+Management+of+Protozoal+Infections+and+Bacterial+Vaginosis&doi=10.2165%2F00003495-199651040-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis</span></div><div class="casAuthors">Gillis, Jane C.; Wiseman, Lynda R.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">621-38</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">Secnidazole is structurally related to the commonly used 5-nitroimidazoles metronidazole and tinidazole.  These drugs share a common spectrum of activity against anaerobic micro-organisms and they appear particularly effective in the treatment of amoebiasis, giardiasis, trichomoniasis and bacterial vaginosis.  Secnidazole is rapidly and completely absorbed after oral administration and has a longer terminal elimination half-life (17 to 29 h) than commonly used drugs in this class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG2LzF8FCJcLVg90H21EOLACvtfcHk0lgqJKMxQz5HQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XislKntrg%253D&md5=d9af25dfe578beecf3f78f2312893158</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.2165%2F00003495-199651040-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199651040-00007%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DJ.%2BC.%26aulast%3DWiseman%26aufirst%3DL.%2BR.%26atitle%3DSecnidazole.%2520A%2520Review%2520of%2520its%2520Antimicrobial%2520Activity%252C%2520Pharmacokinetic%2520Properties%2520and%2520Therapeutic%2520Use%2520in%2520the%2520Management%2520of%2520Protozoal%2520Infections%2520and%2520Bacterial%2520Vaginosis%26jtitle%3DDrugs%26date%3D1996%26volume%3D51%26spage%3D621%26epage%3D638%26doi%3D10.2165%2F00003495-199651040-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanDevanter, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arain, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhorne, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswirth, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span></span> <span> </span><span class="NLM_article-title">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>405</i></span>,  <span class="NLM_fpage">962</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1038/35016103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2F35016103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10879539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2000&pages=962-6&author=C.+K.+Stoverauthor=P.+Warrenerauthor=D.+R.+VanDevanterauthor=D.+R.+Shermanauthor=T.+M.+Arainauthor=M.+H.+Langhorneauthor=S.+W.+Andersonauthor=J.+A.+Towellauthor=Y.+Yuanauthor=D.+N.+McMurrayauthor=B.+N.+Kreiswirthauthor=C.+E.+Barryauthor=W.+R.+Baker&title=A+small-molecule+nitroimidazopyran+drug+candidate+for+the+treatment+of+tuberculosis&doi=10.1038%2F35016103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span></div><div class="casAuthors">Stover, C. Kendall; Warrener, Paul; VanDevanter, Donald R.; Sherman, David R.; Arain, Taraq M.; Langhorne, Michael H.; Anderson, Scott W.; Towell, J. Andrew; Yuan, Ying; McMurray, David N.; Krelswirth, Barry N.; Barry, Clifton E.; Baker, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">405</span>
        (<span class="NLM_cas:issue">6789</span>),
    <span class="NLM_cas:pages">962-966</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis, which causes tuberculosis, is the greatest single infectious cause of mortality worldwide, killing roughly; two million people annually.  Ests. indicate that one-third of the world population is infected with latent M. tuberculosis.  The synergy between tuberculosis and the AIDS epidemic, and the surge of multidrug-resistant clin. isolates of M. tuberculosis have reaffirmed tuberculosis as a primary public health threat.  However, new antitubercular drugs with new mechanisms of action have not been developed in over thirty years.  Here we report a series of compds. contg. a nitroimidazopyran nucleus that possess antitubercular activity.  After activation by a mechanism dependent on M. tuberculosis F420 cofactor, nitroimidazopyrans inhibited the synthesis of protein and cell wall lipid.  In contrast to current antitubercular drugs, nitroimidazopyrans exhibited bactericidal activity against both replicating and static M. tuberculosis.  Lead compd. PA-824 showed potent bactericidal activity against multidrug-resistant M. tuberculosis and promising oral activity in animal infection models.  We conclude that nitroimidazopyrans offer the practical qualities of a small mol. with the potential for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw41eD4TtVwbVg90H21EOLACvtfcHk0lgqJKMxQz5HQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D&md5=f5f6e2935928da72e328bddd4995515f</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2F35016103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35016103%26sid%3Dliteratum%253Aachs%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DWarrener%26aufirst%3DP.%26aulast%3DVanDevanter%26aufirst%3DD.%2BR.%26aulast%3DSherman%26aufirst%3DD.%2BR.%26aulast%3DArain%26aufirst%3DT.%2BM.%26aulast%3DLanghorne%26aufirst%3DM.%2BH.%26aulast%3DAnderson%26aufirst%3DS.%2BW.%26aulast%3DTowell%26aufirst%3DJ.%2BA.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DMcMurray%26aufirst%3DD.%2BN.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBaker%26aufirst%3DW.%2BR.%26atitle%3DA%2520small-molecule%2520nitroimidazopyran%2520drug%2520candidate%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DNature%26date%3D2000%26volume%3D405%26spage%3D962%26epage%3D6%26doi%3D10.1038%2F35016103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span> <span> </span><span class="NLM_article-title">The mechanism of action of pa-824: Novel insights from transcriptional profiling</span>. <i>Commun. Integr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.4161/cib.2.3.7926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.4161%2Fcib.2.3.7926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=19641733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1yru7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=215-8&author=U.+Manjunathaauthor=H.+I.+Boshoffauthor=C.+E.+Barry&title=The+mechanism+of+action+of+pa-824%3A+Novel+insights+from+transcriptional+profiling&doi=10.4161%2Fcib.2.3.7926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of action of PA-824: novel insights from transcriptional profiling</span></div><div class="casAuthors">Manjunatha, Ujjini; Boshoff, Helena I. M.; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Communicative & Integrative Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-218</span>CODEN:
                <span class="NLM_cas:coden">CIBOBQ</span>;
        ISSN:<span class="NLM_cas:issn">1942-0889</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">The bicyclic nitroimidazole PA-824 is a pro-drug with a very complex mechanism of action active against both replicating and hypoxic, non-replicating Mycobacterium tuberculosis.  Microarray anal. of the mode of action of PA-824 showed a puzzling mixed effect both on genes responsive to both cell wall inhibition (like isoniazid) and respiratory poisoning (like cyanide).  The aerobic killing mechanism of this drug appears to involve inhibition of cell wall mycolic acid biosynthesis through an as yet unknown mol. mechanism.  However, the structure-activity relationships governing aerobic activity do not parallel the relationships detg. anaerobic activity.  Based on the metabolite profiling of PA-824 and various derivs. by Ddn-mediated activation, we have shown that PA-824 acts directly as an NO donor.  This respiratory poisoning through nitric oxide release seemed to be a crucial element of anaerobic activity by PA-824.  The effect of PA-824 on the respiratory complex under hypoxic non-replicating conditions was also manifested in a rapid drop in intracellular ATP levels, again similar to that obsd. by cyanide treatment.  Thus, transcriptional profiling provided valuable clues to elucidating the mol. mechanism of mycobacterial killing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRIjCfr9dB9bVg90H21EOLACvtfcHk0lgqJKMxQz5HQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1yru7bF&md5=b7b25a9c2c9b39ff446571c9a2d6d297</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.4161%2Fcib.2.3.7926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcib.2.3.7926%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DThe%2520mechanism%2520of%2520action%2520of%2520pa-824%253A%2520Novel%2520insights%2520from%2520transcriptional%2520profiling%26jtitle%3DCommun.%2520Integr.%2520Biol.%26date%3D2009%26volume%3D2%26spage%3D215%26epage%3D8%26doi%3D10.4161%2Fcib.2.3.7926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niyomrattanakit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledwidge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Pa-824 kills nonreplicating mycobacterium tuberculosis by intracellular no release</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">1392</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1126/science.1164571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1126%2Fscience.1164571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=19039139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVagt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2008&pages=1392-1395&author=R.+Singhauthor=U.+Manjunathaauthor=H.+I.+Boshoffauthor=Y.+H.+Haauthor=P.+Niyomrattanakitauthor=R.+Ledwidgeauthor=C.+S.+Dowdauthor=I.+Y.+Leeauthor=P.+Kimauthor=L.+Zhang&title=Pa-824+kills+nonreplicating+mycobacterium+tuberculosis+by+intracellular+no+release&doi=10.1126%2Fscience.1164571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release</span></div><div class="casAuthors">Singh, Ramandeep; Manjunatha, Ujjini; Boshoff, Helena I. M.; Ha, Young Hwan; Niyomrattanakit, Pornwaratt; Ledwidge, Richard; Dowd, Cynthia S.; Lee, Ill Young; Kim, Pilho; Zhang, Liang; Kang, Sunhee; Keller, Thomas H.; Jiricek, Jan; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">5906</span>),
    <span class="NLM_cas:pages">1392-1395</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Bicyclic nitroimidazoles, including PA-824, are exciting candidates for the treatment of tuberculosis.  These prodrugs require intracellular activation for their biol. function.  We found that Rv3547 is a deazaflavin-dependent nitroreductase (Ddn) that converts PA-824 into three primary metabolites; the major one is the corresponding des-nitroimidazole (des-nitro).  When derivs. of PA-824 were used, the amt. of des-nitro metabolite formed was highly correlated with anaerobic killing of Mycobacterium tuberculosis (Mtb).  Des-nitro metabolite formation generated reactive nitrogen species, including nitric oxide (NO), which are the major effectors of the anaerobic activity of these compds.  Furthermore, NO scavengers protected the bacilli from the lethal effects of the drug.  Thus, these compds. may act as intracellular NO donors and could augment a killing mechanism intrinsic to the innate immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdOQ6XyUn59bVg90H21EOLACvtfcHk0lgqJKMxQz5HQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVagt7jN&md5=5d7d8715b5565938b3ffd9fd35a723da</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1126%2Fscience.1164571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1164571%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DHa%26aufirst%3DY.%2BH.%26aulast%3DNiyomrattanakit%26aufirst%3DP.%26aulast%3DLedwidge%26aufirst%3DR.%26aulast%3DDowd%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DI.%2BY.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DPa-824%2520kills%2520nonreplicating%2520mycobacterium%2520tuberculosis%2520by%2520intracellular%2520no%2520release%26jtitle%3DScience%26date%3D2008%26volume%3D322%26spage%3D1392%26epage%3D1395%26doi%3D10.1126%2Fscience.1164571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Latanoprostene bunod ophthalmic solution 0.024%: A review in open-angle glaucoma and ocular hypertension</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0914-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-018-0914-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29761382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsVCksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=773-780&author=S.+M.+Hoy&title=Latanoprostene+bunod+ophthalmic+solution+0.024%25%3A+A+review+in+open-angle+glaucoma+and+ocular+hypertension&doi=10.1007%2Fs40265-018-0914-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">773-780</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Latanoprostene bunod ophthalmic soln. 0.024% (hereafter referred to as latanoprostene bunod 0.024%) [Vyzulta] is a nitric oxide (NO)-donating prostaglandin F2α analog approved in the USA for the redn. of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension.  It is thought to lower IOP by increasing aq. humor outflow through the uveoscleral pathway (mediated by latanoprost acid) and increasing the facility of aq. humor outflow through the trabecular meshwork pathway (mediated by NO).  Results from two multinational, phase III studies (APOLLO and LUNAR) and a pooled anal. of these studies demonstrated the noninferiority of latanoprostene bunod 0.024% to timolol ophthalmic soln. 0.5% (hereafter referred to as timolol 0.5%) in terms of IOP-lowering efficacy over 3 mo in patients with OAG or ocular hypertension, with the superiority of latanoprostene bunod 0.024% over timolol 0.5% subsequently demonstrated in APOLLO and the pooled anal.  Moreover, there was no apparent loss of IOP-lowering effect in subsequent safety extension periods of up to 9 mo.  The IOP-lowering efficacy seen in APOLLO and LUNAR was confirmed in a phase III study (JUPITER) in Japanese patients, with IOP redns. obsd. early (week 4) and maintained over the longer-term (12 mo).  Latanoprostene bunod 0.024% was well tolerated over up to 12 mo in these studies, with most ocular treatment-emergent adverse events (TEAEs) being mild to moderate in severity.  Thus, current evidence indicates once-daily latanoprostene bunod 0.024% is an effective and well tolerated treatment option for the redn. of IOP in adults with OAG or ocular hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr26pnF0TbnBLVg90H21EOLACvtfcHk0li7VF_6NjGesA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsVCksb0%253D&md5=6d3a7bcdc17c510fdbf4d638f026241b</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0914-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0914-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DLatanoprostene%2520bunod%2520ophthalmic%2520solution%25200.024%2525%253A%2520A%2520review%2520in%2520open-angle%2520glaucoma%2520and%2520ocular%2520hypertension%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D773%26epage%3D780%26doi%3D10.1007%2Fs40265-018-0914-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Venetoclax: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">979</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0596-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-016-0596-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=27260335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVymtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=979-87&author=E.+D.+Deeks&title=Venetoclax%3A+First+global+approval&doi=10.1007%2Fs40265-016-0596-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Venetoclax: First Global Approval</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">979-987</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Venetoclax (Venclexta) is an oral selective inhibitor of the prosurvival protein BCL-2 and therefore restores the apoptotic ability of malignant cells.  The drug arose from research by Abbott Labs. (now AbbVie) during a collaboration with Genentech and is being co-developed by AbbVie and Genentech/Roche primarily for the treatment of haematol. malignancies.  Venetoclax is approved in the USA for use as monotherapy in patients with chronic lymphocytic leukemia (CLL) with the 17p deletion (as detected by an approved FDA test) who have received at least one prior therapy, and is awaiting approval for similar indications in the EU and Canada.  Venetoclax is also in phase I-III development as combination therapy for CLL, phase I/II development as monotherapy and/or combination therapy for non-Hodgkin lymphomas (including diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma) and acute myeloid leukemia, and phase I development for multiple myeloma, systemic lupus erythematosus and breast cancer.  This article summarizes the milestones in the development of venetoclax leading to this first approval for CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo-_C1vJNwpLVg90H21EOLACvtfcHk0li7VF_6NjGesA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVymtLo%253D&md5=e0f99ba8fb7665bba95ac42626c6aaa3</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0596-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0596-x%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DVenetoclax%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D979%26epage%3D87%26doi%3D10.1007%2Fs40265-016-0596-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among us fda approved pharmaceuticals: Miniperspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">10257</span>– <span class="NLM_lpage">10274</span>, <span class="refDoi"> DOI: 10.1021/jm501100b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501100b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10257-10274&author=E.+Vitakuauthor=D.+T.+Smithauthor=J.+T.+Njardarson&title=Analysis+of+the+structural+diversity%2C+substitution+patterns%2C+and+frequency+of+nitrogen+heterocycles+among+us+fda+approved+pharmaceuticals%3A+Miniperspective&doi=10.1021%2Fjm501100b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals</span></div><div class="casAuthors">Vitaku, Edon; Smith, David T.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10257-10274</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nitrogen heterocycles are among the most significant structural components of pharmaceuticals.  Anal. of our database of U.S. FDA approved drugs reveals that 59% of unique small-mol. drugs contain a nitrogen heterocycle.  In this review we report on the top 25 most commonly utilized nitrogen heterocycles found in pharmaceuticals.  The main part of our anal. is divided into seven sections: (1) three- and four-membered heterocycles, (2) five-, (3) six-, and (4) seven- and eight-membered heterocycles, as well as (5) fused, (6) bridged bicyclic, and (7) macrocyclic nitrogen heterocycles.  Each section reveals the top nitrogen heterocyclic structures and their relative impact for that ring type.  For the most commonly used nitrogen heterocycles, we report detailed substitution patterns, highlight common architectural cores, and discuss unusual or rare structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5cUk9KxUSkbVg90H21EOLACvtfcHk0li7VF_6NjGesA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP&md5=7065b3b2fc6f69cede0f87479c7cf472</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1021%2Fjm501100b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501100b%26sid%3Dliteratum%253Aachs%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DAnalysis%2520of%2520the%2520structural%2520diversity%252C%2520substitution%2520patterns%252C%2520and%2520frequency%2520of%2520nitrogen%2520heterocycles%2520among%2520us%2520fda%2520approved%2520pharmaceuticals%253A%2520Miniperspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10257%26epage%3D10274%26doi%3D10.1021%2Fjm501100b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiesinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar’in, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasavin, M.</span></span> <span> </span><span class="NLM_article-title">Spirocyclic scaffolds in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01473</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01473" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXislWlsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=150-183&author=K.+Hiesingerauthor=D.+Dar%E2%80%99inauthor=E.+Proschakauthor=M.+Krasavin&title=Spirocyclic+scaffolds+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.0c01473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Spirocyclic Scaffolds in Medicinal Chemistry</span></div><div class="casAuthors">Hiesinger, Kerstin; Dar'in, Dmitry; Proschak, Ewgenij; Krasavin, Mikhail</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">150-183</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spirocyclic scaffolds are incorporated in various approved drugs and drug candidates.  The increasing interest in less planar bioactive compds. has given rise to the development of synthetic methodologies for the prepn. of spirocyclic scaffolds.  In this Perspective, we summarize the diverse synthetic routes to obtain spirocyclic systems.  The impact of spirocycles on potency and selectivity, including the aspect of stereochem., is discussed.  Furthermore, we examine the changes in physicochem. properties as well as in in vitro and in vivo ADME using selected studies that compare spirocyclic compds. to their nonspirocyclic counterparts.  In conclusion, the value of spirocyclic scaffolds in medicinal chem. is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxeu8qelbAWbVg90H21EOLACvtfcHk0liPYPjlrnVPLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXislWlsL3K&md5=b584a88a9ee65ed93277c946262de216</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01473%26sid%3Dliteratum%253Aachs%26aulast%3DHiesinger%26aufirst%3DK.%26aulast%3DDar%25E2%2580%2599in%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DKrasavin%26aufirst%3DM.%26atitle%3DSpirocyclic%2520scaffolds%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D150%26epage%3D183%26doi%3D10.1021%2Facs.jmedchem.0c01473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Medina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span> <span> </span><span class="NLM_article-title">Platform for unified molecular analysis: Puma</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1735</span>– <span class="NLM_lpage">1740</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.7b00253</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.7b00253" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wgsb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=1735-1740&author=M.+Gonzalez-Medinaauthor=J.+L.+Medina-Franco&title=Platform+for+unified+molecular+analysis%3A+Puma&doi=10.1021%2Facs.jcim.7b00253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Platform for Unified Molecular Analysis: PUMA</span></div><div class="casAuthors">Gonzalez-Medina, Mariana; Medina-Franco, Jose L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1735-1740</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We introduce a free platform for chemoinformatic-based diversity anal. and visualization of chem. space of user supplied data sets.  Platform for Unified Mol. Anal. (PUMA) integrates metrics used to characterize compd. databases including visualization of chem. space, scaffold content, and anal. of chem. diversity.  The user's input is a file with SMILES, database names, and compd. IDs.  PUMA computes mol. properties of pharmaceutical relevance, Murcko scaffolds, and diversity anal.  The user can interactively navigate through the graphs and export image files and the raw data of the diversity calcns.  The platform links two public online resources: Consensus Diversity Plots for the assessment of global diversity and Activity Landscape Plotter to analyze structure-activity relationships.  Herein, we describe the functionalities of PUMA and exemplify its use through the anal. of compd. databases of general interest.  PUMA is freely accessible at the authors web-site https://www.difacquim.com/d-tools/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7UDAHVWCKOLVg90H21EOLACvtfcHk0liPYPjlrnVPLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wgsb7O&md5=84e7b7118d9cc0afdf2a55964e53b1f0</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.7b00253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.7b00253%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Medina%26aufirst%3DM.%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26atitle%3DPlatform%2520for%2520unified%2520molecular%2520analysis%253A%2520Puma%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2017%26volume%3D57%26spage%3D1735%26epage%3D1740%26doi%3D10.1021%2Facs.jcim.7b00253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levin, V. A.</span></span> <span> </span><span class="NLM_article-title">Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1021/jm00180a022</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00180a022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaL3cXktFyrtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1980&pages=682-4&author=V.+A.+Levin&title=Relationship+of+octanol%2Fwater+partition+coefficient+and+molecular+weight+to+rat+brain+capillary+permeability&doi=10.1021%2Fjm00180a022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability</span></div><div class="casAuthors">Levin, Victor A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">682-4</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The rat brain capillary permeability coeff. was detd. for 27 compds.  The relation of permeability to octanol/water partition coeff. and mol. wt. was predictable for drugs with mol. wts. <400.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ANVehpbXmrVg90H21EOLACvtfcHk0liPYPjlrnVPLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXktFyrtro%253D&md5=04c3bc1889c4fc17348163ef492436bf</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1021%2Fjm00180a022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00180a022%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DV.%2BA.%26atitle%3DRelationship%2520of%2520octanol%252Fwater%2520partition%2520coefficient%2520and%2520molecular%2520weight%2520to%2520rat%2520brain%2520capillary%2520permeability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1980%26volume%3D23%26spage%3D682%26epage%3D4%26doi%3D10.1021%2Fjm00180a022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van de Waterbeemd, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camenisch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chretien, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raevsky, O. A.</span></span> <span> </span><span class="NLM_article-title">Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and h-bonding descriptors</span>. <i>J. Drug Target</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.3109/10611869808997889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3109%2F10611869808997889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=9886238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaK1MXkvFKmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=151-165&author=H.+van+de+Waterbeemdauthor=G.+Camenischauthor=G.+Folkersauthor=J.+R.+Chretienauthor=O.+A.+Raevsky&title=Estimation+of+blood-brain+barrier+crossing+of+drugs+using+molecular+size+and+shape%2C+and+h-bonding+descriptors&doi=10.3109%2F10611869808997889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors</span></div><div class="casAuthors">Van de Waterbeemd, Han; Camenisch, Gian; Folkers, Gerd; Chretien, Jacques R.; Raevsky, Oleg A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Targeting</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-165</span>CODEN:
                <span class="NLM_cas:coden">JDTAEH</span>;
        ISSN:<span class="NLM_cas:issn">1061-186X</span>.
    
            (<span class="NLM_cas:orgname">Harwood Academic Publishers</span>)
        </div><div class="casAbstract">The influence of physicochem. properties, including lipophilicity, H-bonding capacity and mol. size and shape descriptors on brain uptake has been investigated using a selection of marketed CNS and CNS-inactive drugs.  It is demonstrated that the polar surface area of a drug can be used as a suitable descriptor for the drugs' H-bonding potential.  A combination of a H-bonding and a mol. size descriptor, i.e., the major components of lipophilicity and permeability, avoiding knowledge of distribution coeffs., is proposed to est. brain penetration potential of new drug candidates.  Previously reported exptl. surface activity data appear to be strongly correlated to mol. size of the drug compds.  Present anal. offers a modern basis for property-based design and targeting of CNS drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0yCKmlzsa37Vg90H21EOLACvtfcHk0liPYPjlrnVPLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkvFKmtg%253D%253D&md5=9106ff6aa0755ff76fd0634822857d4a</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.3109%2F10611869808997889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10611869808997889%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DCamenisch%26aufirst%3DG.%26aulast%3DFolkers%26aufirst%3DG.%26aulast%3DChretien%26aufirst%3DJ.%2BR.%26aulast%3DRaevsky%26aufirst%3DO.%2BA.%26atitle%3DEstimation%2520of%2520blood-brain%2520barrier%2520crossing%2520of%2520drugs%2520using%2520molecular%2520size%2520and%2520shape%252C%2520and%2520h-bonding%2520descriptors%26jtitle%3DJ.%2520Drug%2520Target%26date%3D1998%26volume%3D6%26spage%3D151%26epage%3D165%26doi%3D10.3109%2F10611869808997889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth-Walter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adcock, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benito-Villalvilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjermer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramori, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamant, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguiluz-Gracia, I. J. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An eaaci taskforce on immunopharmacology position paper</span>. <i>Allergy</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">432</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1111/all.13642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1111%2Fall.13642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30353939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3cvis1SjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2019&pages=432-448&author=F.+Roth-Walterauthor=I.+M.+Adcockauthor=C.+Benito-Villalvillaauthor=R.+Bianchiniauthor=L.+Bjermerauthor=G.+Caramoriauthor=L.+Cariauthor=K.+F.+Chungauthor=Z.+Diamantauthor=I.+J.+A.+Eguiluz-Gracia&title=Comparing+biologicals+and+small+molecule+drug+therapies+for+chronic+respiratory+diseases%3A+An+eaaci+taskforce+on+immunopharmacology+position+paper&doi=10.1111%2Fall.13642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper</span></div><div class="casAuthors">Roth-Walter Franziska; Bianchini Rodolfo; Adcock Ian M; Benito-Villalvilla Cristina; Palomares Oscar; Bjermer Leif; Caramori Gaetano; Cari Luigi; Nocentini Giuseppe; Chung Kian Fan; Diamant Zuzana; Diamant Zuzana; Eguiluz-Gracia Ibon; Knol Edward F; Kolios Antonios G A; Levi-Schaffer Francesca; Puzzovio Pier Giorgio; Redegeld Frank A; van Esch Betty C A M; Stellato Cristiana</div><div class="citationInfo"><span class="NLM_cas:title">Allergy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">432-448</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), together with their comorbidities, bear a significant burden on public health.  Increased appreciation of molecular networks underlying inflammatory airway disease needs to be translated into new therapies for distinct phenotypes not controlled by current treatment regimens.  On the other hand, development of new safe and effective therapies for such respiratory diseases is an arduous and expensive process.  Antibody-based (biological) therapies are successful in treating certain respiratory conditions not controlled by standard therapies such as severe allergic and refractory eosinophilic severe asthma, while in other inflammatory respiratory diseases, such as COPD, biologicals are having a more limited impact.  Small molecule drug (SMD)-based therapies represent an active field in pharmaceutical research and development.  SMDs expand biologicals' therapeutic targets by reaching the intracellular compartment by delivery as either an oral or topically based formulation, offering both convenience and lower costs.  Aim of this review was to compare and contrast the distinct pharmacological properties and clinical applications of SMDs- and antibody-based treatment strategies, their limitations and challenges, in order to highlight how they should be integrated for their optimal utilization and to fill the critical gaps in current treatment for these chronic inflammatory respiratory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQUSNHUpZVYb7NkxioyDXTfW6udTcc2eZ2tBaf75GOrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvis1SjsQ%253D%253D&md5=2740f4e550f36f2e6b2d6714647ab85d</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1111%2Fall.13642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fall.13642%26sid%3Dliteratum%253Aachs%26aulast%3DRoth-Walter%26aufirst%3DF.%26aulast%3DAdcock%26aufirst%3DI.%2BM.%26aulast%3DBenito-Villalvilla%26aufirst%3DC.%26aulast%3DBianchini%26aufirst%3DR.%26aulast%3DBjermer%26aufirst%3DL.%26aulast%3DCaramori%26aufirst%3DG.%26aulast%3DCari%26aufirst%3DL.%26aulast%3DChung%26aufirst%3DK.%2BF.%26aulast%3DDiamant%26aufirst%3DZ.%26aulast%3DEguiluz-Gracia%26aufirst%3DI.%2BJ.%2BA.%26atitle%3DComparing%2520biologicals%2520and%2520small%2520molecule%2520drug%2520therapies%2520for%2520chronic%2520respiratory%2520diseases%253A%2520An%2520eaaci%2520taskforce%2520on%2520immunopharmacology%2520position%2520paper%26jtitle%3DAllergy%26date%3D2019%26volume%3D74%26spage%3D432%26epage%3D448%26doi%3D10.1111%2Fall.13642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altman, S.</span></span> <span> </span><span class="NLM_article-title">Antibiotics present and future</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>588</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">2</span>, <span class="refDoi"> DOI: 10.1016/j.febslet.2013.10.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.febslet.2013.10.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24252220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKgtrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=588&publication_year=2014&pages=1-2&author=S.+Altman&title=Antibiotics+present+and+future&doi=10.1016%2Fj.febslet.2013.10.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Antibiotics present and future</span></div><div class="casAuthors">Altman, S.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">588</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-2</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Here the authors make a brief survey of the present state of antibiotic research and use.  The authors also describe a novel antibiotic that contains a basic peptide covalently bound to a morpholino oligonucleotide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouQxOnE2irXbVg90H21EOLACvtfcHk0lihV8ROSNjJFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKgtrzN&md5=eedd6367d027d3350272c1bcf42845a5</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2013.10.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2013.10.048%26sid%3Dliteratum%253Aachs%26aulast%3DAltman%26aufirst%3DS.%26atitle%3DAntibiotics%2520present%2520and%2520future%26jtitle%3DFEBS%2520Lett.%26date%3D2014%26volume%3D588%26spage%3D1%26epage%3D2%26doi%3D10.1016%2Fj.febslet.2013.10.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veber, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopple, K. D.</span></span> <span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2615</span>– <span class="NLM_lpage">2623</span>, <span class="refDoi"> DOI: 10.1021/jm020017n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.-Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates&doi=10.1021%2Fjm020017n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0lihV8ROSNjJFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.-Y.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623%26doi%3D10.1021%2Fjm020017n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, D. E.</span></span> <span> </span><span class="NLM_article-title">What has polar surface area ever done for drug discovery?</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.4155%2Ffmc.11.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=21452982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVClu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=469-484&author=D.+E.+Clark&title=What+has+polar+surface+area+ever+done+for+drug+discovery%3F&doi=10.4155%2Ffmc.11.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">What has polar surface area ever done for drug discovery?</span></div><div class="casAuthors">Clark, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-484</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Over the last decade, polar surface area (PSA) has become a ubiquitous term in medicinal and computational chem. circles.  This article charts the development of the increasingly efficient methods for the calcn. of PSA before illustrating its usefulness through selected examples drawn from the medicinal chem. literature.  Consideration of PSA is shown to assist in the improvement of cellular potency, intestinal absorption and blood--brain barrier permeation or restriction to the peripheral circulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrumWpKrOWP6rVg90H21EOLACvtfcHk0lihV8ROSNjJFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVClu78%253D&md5=92335875ed1efb9721fb63d72844bf09</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.1%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DD.%2BE.%26atitle%3DWhat%2520has%2520polar%2520surface%2520area%2520ever%2520done%2520for%2520drug%2520discovery%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D469%26epage%3D484%26doi%3D10.4155%2Ffmc.11.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span> <span> </span><span class="NLM_article-title">Structure-brain exposure relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">7559</span>– <span class="NLM_lpage">7583</span>, <span class="refDoi"> DOI: 10.1021/jm060642i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060642i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yrtrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7559-7583&author=S.+A.+Hitchcockauthor=L.+D.+Pennington&title=Structure-brain+exposure+relationships&doi=10.1021%2Fjm060642i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-brain exposure relationships</span></div><div class="casAuthors">Hitchcock, Stephen A.; Pennington, Lewis D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7559-7583</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the use of structure modification to influence blood-brain barrier penetration by modulating either passive diffusion or active transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3V-TERRGy07Vg90H21EOLACvtfcHk0lihV8ROSNjJFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yrtrnK&md5=97dff583ffae6d0ef66512ffbee38c34</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1021%2Fjm060642i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060642i%26sid%3Dliteratum%253Aachs%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26atitle%3DStructure-brain%2520exposure%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7559%26epage%3D7583%26doi%3D10.1021%2Fjm060642i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebejer, J.-P.</span>; <span class="NLM_string-name">Charlton, M. H.</span>; <span class="NLM_string-name">Finn, P. W.</span></span> <span> </span><span class="NLM_article-title">Are the physicochemical properties of antibacterial compounds really different from other drugs?</span> <i>J. Cheminf.</i><span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume">8</span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>.<span class="refDoi"> DOI: 10.1186/s13321-016-0143-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1186%2Fs13321-016-0143-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=1-9&author=J.-P.+Ebejer&author=M.+H.+Charlton&author=P.+W.+Finn&title=Are+the+physicochemical+properties+of+antibacterial+compounds+really+different+from+other+drugs%3F&doi=10.1186%2Fs13321-016-0143-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1186%2Fs13321-016-0143-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-016-0143-5%26sid%3Dliteratum%253Aachs%26aulast%3DEbejer%26aufirst%3DJ.-P.%26atitle%3DAre%2520the%2520physicochemical%2520properties%2520of%2520antibacterial%2520compounds%2520really%2520different%2520from%2520other%2520drugs%253F%26jtitle%3DJ.%2520Cheminf.%26date%3D2016%26volume%3D8%26spage%3D1%26epage%3D9%26doi%3D10.1186%2Fs13321-016-0143-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashinson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolman, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zha, M.</span></span> <span> </span><span class="NLM_article-title">Understanding the molecular properties and metabolism of top prescribed drugs</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1290</span>– <span class="NLM_lpage">1307</span>, <span class="refDoi"> DOI: 10.2174/15680266113139990034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2174%2F15680266113139990034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=23675936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wnt7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1290-1307&author=H.+A.+Zhongauthor=V.+Mashinsonauthor=T.+A.+Woolmanauthor=M.+Zha&title=Understanding+the+molecular+properties+and+metabolism+of+top+prescribed+drugs&doi=10.2174%2F15680266113139990034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the Molecular Properties and Metabolism of Top Prescribed Drugs</span></div><div class="casAuthors">Zhong, Haizhen A.; Mashinson, Victoria; Woolman, Theodor A.; Zha, Mengyi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1290-1307</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Mol. properties such as the mol. wt., hydrophobicity parameter logP, and the total polar surface area (TPSA) have been used extensively in modern drug discovery.  We investigated these properties and ADMET scores of the top 200 therapeutic drugs by the U.  S. retail sales (2010) and classified them according to the clin. indications and/or routes of administration.  This list of drugs provides ample information of these mol. descriptors for successfully approved drugs.  The mean logP for oral drugs is 2.5 while the logP for injectable drugs seems to be smaller.  Among different types of clin. indications, drugs used for anti-HIV, and antibiotics tend to have lower logP.  The mol. wts. of anti-HIV drugs, antihypertensives and antibiotics appear to be larger.  The ADMET scores, derived from a combination of mol. wts. and logP, are consistent for oral drugs, with a mean score of 1.5 and a std. deviation of 1.0.  Many clin. drugs that violate Lipinskis rule of five criteria can still exhibit ADMET scores that are very close to the mean value for oral drugs (1.5) and lie within the acceptable std. deviation.  The mol. properties of MW, logP, and TPSA appear to vary according to their clin. indications.  Many drugs form salts or cocrystals with acids or solvents that increase their soly.  Our data show that addn. of hydrochloride is the most common method to increase soly. of drug ingredients.  Cytochrome P 450 isoenzymes 3A4, 2D6, 2C9, 2C8 and 3C5 are the top five proteins that metabolize the 200 most prescribed drugs.  Drugs metabolized by 3A4 appear to have larger mol. wts. and those metabolized by 2D6 have lower mol. wts.  CYP2C8-metabolized drugs appear to be most hydrophilic, with the smallest logP and the largest polar surface areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN07cwBoCAYLVg90H21EOLACvtfcHk0lh76eybZEj2kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wnt7bI&md5=3e09dbf26e440668195df98429f308c9</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.2174%2F15680266113139990034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680266113139990034%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DH.%2BA.%26aulast%3DMashinson%26aufirst%3DV.%26aulast%3DWoolman%26aufirst%3DT.%2BA.%26aulast%3DZha%26aufirst%3DM.%26atitle%3DUnderstanding%2520the%2520molecular%2520properties%2520and%2520metabolism%2520of%2520top%2520prescribed%2520drugs%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D1290%26epage%3D1307%26doi%3D10.2174%2F15680266113139990034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanadhan, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendoloski, J. J.</span></span> <span> </span><span class="NLM_article-title">Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: An analysis of alogp and clogp methods</span>. <i>J. Phys. Chem. A</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">3762</span>– <span class="NLM_lpage">3772</span>, <span class="refDoi"> DOI: 10.1021/jp980230o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp980230o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaK1cXis12rsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=3762-3772&author=A.+K.+Ghoseauthor=V.+N.+Viswanadhanauthor=J.+J.+Wendoloski&title=Prediction+of+hydrophobic+%28lipophilic%29+properties+of+small+organic+molecules+using+fragmental+methods%3A+An+analysis+of+alogp+and+clogp+methods&doi=10.1021%2Fjp980230o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods</span></div><div class="casAuthors">Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry A</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3762-3772</span>CODEN:
                <span class="NLM_cas:coden">JPCAFH</span>;
        ISSN:<span class="NLM_cas:issn">1089-5639</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. hydrophobicity (lipophilicity), usually quantified as log P (the logarithm of 1-octanol/water partition coeff.), is an important mol. characteristic in drug discovery.  ALOGP and CLOGP are two of the most widely used methods for the estn. of log P.  This work describes an extensive reparametrization of the at. log P values and a detailed comparison of the performance of ALOGP and CLOGP methods on the Pomona Medchem database.  Only the "star list" compds. having precisely measured log P values were used in this anal.  While the overall results with both methods are similar, anal. shows that the CLOGP method is better for very small mols. in the range of 1-20 atoms.  The two methods are almost comparable in the range of 21-45 atoms, while the ALOGP method has better accuracy for mols. with more than 45 atoms.  Although the rms deviation and the correlation coeff. for CLOGP predictions were marginally better than those for corresponding ALOGP predictions, the latter showed a very stable performance for all classes of org. compds. analyzed.  Importantly, the ALOGP method can be used to compute ests. for all mols. in the database, whereas the CLOGP method fails to offer ests. for a substantial part of the database.  Finally, unlike CLOGP and other methods of predicting lipophilicity, the ALOGP method has multiple uses, such as the estn. of local hydrophobicity, the visualization of mol. hydrophobicity maps, and the evaluation of hydrophobic interactions in protein-ligand complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXdn8wsqV3frVg90H21EOLACvtfcHk0lh76eybZEj2kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis12rsrY%253D&md5=ef58841437913e164dc2d6e73eb5c87d</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Fjp980230o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp980230o%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26aulast%3DWendoloski%26aufirst%3DJ.%2BJ.%26atitle%3DPrediction%2520of%2520hydrophobic%2520%2528lipophilic%2529%2520properties%2520of%2520small%2520organic%2520molecules%2520using%2520fragmental%2520methods%253A%2520An%2520analysis%2520of%2520alogp%2520and%2520clogp%2520methods%26jtitle%3DJ.%2520Phys.%2520Chem.%2520A%26date%3D1998%26volume%3D102%26spage%3D3762%26epage%3D3772%26doi%3D10.1021%2Fjp980230o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberger, L. E.</span></span> <span> </span><span class="NLM_article-title">Neighborhood behavior: A useful concept for validation of “molecular diversity” descriptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">3049</span>– <span class="NLM_lpage">3059</span>, <span class="refDoi"> DOI: 10.1021/jm960290n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960290n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1alur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=3049-3059&author=D.+E.+Pattersonauthor=R.+D.+Cramerauthor=A.+M.+Fergusonauthor=R.+D.+Clarkauthor=L.+E.+Weinberger&title=Neighborhood+behavior%3A+A+useful+concept+for+validation+of+%E2%80%9Cmolecular+diversity%E2%80%9D+descriptors&doi=10.1021%2Fjm960290n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Neighborhood Behavior: A Useful Concept for Validation of "Molecular Diversity" Descriptors</span></div><div class="casAuthors">Patterson, David E.; Cramer, Richard D.; Ferguson, Allan M.; Clark, Robert D.; Weinberger, Laurence E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3049-3059</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">When searching for new leads, testing mols. that are too "similar" is wasteful, but when investigating a lead, testing mols. that are "similar" to the lead is efficient.  Two questions then arise.  Which are the mol. descriptors that should be "similar".  How much "similarity" is enough.  These questions are answered by demonstrating that, if a mol. descriptor is to be a valid and useful measure of "similarity" in drug discovery, a plot of differences in its values vs. differences in biol. activities for a set of related mols. will exhibit a characteristic trapezoidal distribution enhancement, revealing a "neighborhood behavior" for the descriptor.  Applying this finding to 20 datasets allows 11 mol. diversity descriptors to be ranked by their validity for compd. library design.  In order of increasing frequency of usefulness, these are random nos. = log P = MR = strain energy < connectivity indexes < 2D fingerprints (whole mol.) = atom pairs = autocorrelation indexes < steric CoMFA fields = 2D fingerprints (side chain only) = H-bonding CoMFA fields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEV52sTPRVo7Vg90H21EOLACvtfcHk0ljOWIwKhLfT8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1alur8%253D&md5=cca6888d4b798186ac1946bf654bf01a</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Fjm960290n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960290n%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DD.%2BE.%26aulast%3DCramer%26aufirst%3DR.%2BD.%26aulast%3DFerguson%26aufirst%3DA.%2BM.%26aulast%3DClark%26aufirst%3DR.%2BD.%26aulast%3DWeinberger%26aufirst%3DL.%2BE.%26atitle%3DNeighborhood%2520behavior%253A%2520A%2520useful%2520concept%2520for%2520validation%2520of%2520%25E2%2580%259Cmolecular%2520diversity%25E2%2580%259D%2520descriptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D3049%26epage%3D3059%26doi%3D10.1021%2Fjm960290n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span> <span> </span><span class="NLM_article-title">Molecular property design: Does everyone get it?</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=722-725&author=P.+D.+Leesonauthor=R.+J.+Young&title=Molecular+property+design%3A+Does+everyone+get+it%3F&doi=10.1021%2Facsmedchemlett.5b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Property Design: Does Everyone Get It?</span></div><div class="casAuthors">Leeson, Paul D.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">722-725</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The principles of mol. property optimization in drug design have been understood for decades, yet much drug discovery activity today is conducted at the periphery of historical druglike property space.  Lead optimization trajectories aimed at reducing physicochem. risk, assisted by ligand efficiency metrics, could help to reduce clin. attrition rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_t8gIn79arVg90H21EOLACvtfcHk0ljOWIwKhLfT8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D&md5=5a807a8d049ce8cf4adc186891a9234d</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00157%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DMolecular%2520property%2520design%253A%2520Does%2520everyone%2520get%2520it%253F%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D722%26epage%3D725%26doi%3D10.1021%2Facsmedchemlett.5b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remete, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriwaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fustero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloshonok, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span> <span> </span><span class="NLM_article-title">Fluorine-containing drugs approved by the fda in 2019</span>. <i>Chin. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2401</span>– <span class="NLM_lpage">2413</span>, <span class="refDoi"> DOI: 10.1016/j.cclet.2020.03.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.cclet.2020.03.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmvFKmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2020&pages=2401-2413&author=H.+Meiauthor=A.+M.+Remeteauthor=Y.+Zouauthor=H.+Moriwakiauthor=S.+Fusteroauthor=L.+Kissauthor=V.+A.+Soloshonokauthor=J.+Han&title=Fluorine-containing+drugs+approved+by+the+fda+in+2019&doi=10.1016%2Fj.cclet.2020.03.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine-containing drugs approved by the FDA in 2019</span></div><div class="casAuthors">Mei, Haibo; Remete, Attila Mario; Zou, Yupiao; Moriwaki, Hiroki; Fustero, Santos; Kiss, Lorand; Soloshonok, Vadim A.; Han, Jianlin</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Chemical Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2401-2413</span>CODEN:
                <span class="NLM_cas:coden">CCLEE7</span>;
        ISSN:<span class="NLM_cas:issn">1001-8417</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Eleven new fluorine-contg. FDA-approved drugs have been profiled and details of their discovery and prepn. are discussed.  Therapeutic areas include schizophrenia, migraine, multiple sclerosis, insomnia, rheumatoid arthritis, anti-tuberculosis, breast cancer, lymphoma kinase inhibitor, serotonin receptor antagonist.  New pharmaceuticals feature four examples of arom. fluorine, three arom. CF3 group, three aliph. CF3 and one compd. with arom. CF3O group.  Furthermore, among the new compds., six are chiral and seven are derived from tailor-made amino acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5uLd8wWIoeLVg90H21EOLACvtfcHk0ljOWIwKhLfT8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmvFKmsbo%253D&md5=fcd1c938ddeeb732286992978a076304</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2Fj.cclet.2020.03.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cclet.2020.03.050%26sid%3Dliteratum%253Aachs%26aulast%3DMei%26aufirst%3DH.%26aulast%3DRemete%26aufirst%3DA.%2BM.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DMoriwaki%26aufirst%3DH.%26aulast%3DFustero%26aufirst%3DS.%26aulast%3DKiss%26aufirst%3DL.%26aulast%3DSoloshonok%26aufirst%3DV.%2BA.%26aulast%3DHan%26aufirst%3DJ.%26atitle%3DFluorine-containing%2520drugs%2520approved%2520by%2520the%2520fda%2520in%25202019%26jtitle%3DChin.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D31%26spage%3D2401%26epage%3D2413%26doi%3D10.1016%2Fj.cclet.2020.03.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi-Scharber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, L. E.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of (8 s, 9 r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1 h-1, 2, 4-triazol-5-yl)-2, 7, 8, 9-tetrahydro-3 h-pyrido [4, 3, 2-de] phthalazin-3-one (bmn 673, talazoparib), a novel, highly potent, and orally efficacious poly (adp-ribose) polymerase-1/2 inhibitor, as an anticancer agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01498</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01498" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=335-357&author=B.+Wangauthor=D.+Chuauthor=Y.+Fengauthor=Y.+Shenauthor=M.+Aoyagi-Scharberauthor=L.+E.+Post&title=Discovery+and+characterization+of+%288+s%2C+9+r%29-5-fluoro-8-%284-fluorophenyl%29-9-%281-methyl-1+h-1%2C+2%2C+4-triazol-5-yl%29-2%2C+7%2C+8%2C+9-tetrahydro-3+h-pyrido+%5B4%2C+3%2C+2-de%5D+phthalazin-3-one+%28bmn+673%2C+talazoparib%29%2C+a+novel%2C+highly+potent%2C+and+orally+efficacious+poly+%28adp-ribose%29+polymerase-1%2F2+inhibitor%2C+as+an+anticancer+agent&doi=10.1021%2Facs.jmedchem.5b01498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent</span></div><div class="casAuthors">Wang, Bing; Chu, Daniel; Feng, Ying; Shen, Yuqiao; Aoyagi-Scharber, Mika; Post, Leonard E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">335-357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors discovered and developed a novel series of tetrahydropyridophthlazinones as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors.  Lead optimization led to the identification of (I) (talazoparib; BMN 673; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one).  The novel stereospecific dual chiral-center-embedded structure of this compd. has enabled extensive and unique binding interactions with PARP1/2 proteins. I demonstrates excellent potency, inhibiting PARP1 and PARP2 enzyme activity with Ki = 1.2 and 0.87 nM, resp.  It inhibits PARP-mediated PARylation in a whole-cell assay with an EC50 of 2.51 nM and prevents proliferation of cancer cells carrying mutant BRCA1/2, with EC50 = 0.3 nM (MX-1) and 5 nM (Capan-1), resp. I is orally available, displaying favorable pharmacokinetic (PK) properties and remarkable antitumor efficacy in the BRCA1 mutant MX-1 breast cancer xenograft model following oral administration as a single-agent or in combination with chemotherapy agents such as temozolomide and cisplatin. I has completed phase 1 clin. trial and is currently being studied in phase 2 and 3 clin. trials for the treatment of locally advanced and/or metastatic breast cancer with germline BRCA1/2 deleterious mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBpTb90_rQhLVg90H21EOLACvtfcHk0linoMC4lmRPdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rN&md5=443bfeb7aeda6c6522d41ab52793931a</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01498%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DPost%26aufirst%3DL.%2BE.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520%25288%2520s%252C%25209%2520r%2529-5-fluoro-8-%25284-fluorophenyl%2529-9-%25281-methyl-1%2520h-1%252C%25202%252C%25204-triazol-5-yl%2529-2%252C%25207%252C%25208%252C%25209-tetrahydro-3%2520h-pyrido%2520%255B4%252C%25203%252C%25202-de%255D%2520phthalazin-3-one%2520%2528bmn%2520673%252C%2520talazoparib%2529%252C%2520a%2520novel%252C%2520highly%2520potent%252C%2520and%2520orally%2520efficacious%2520poly%2520%2528adp-ribose%2529%2520polymerase-1%252F2%2520inhibitor%252C%2520as%2520an%2520anticancer%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D335%26epage%3D357%26doi%3D10.1021%2Facs.jmedchem.5b01498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popovici-Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianchetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of ag-120 (ivosidenib): A first-in-class mutant idh1 inhibitor for the treatment of idh1 mutant cancers</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00421</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00421" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=300-305&author=J.+Popovici-Mullerauthor=R.+M.+Lemieuxauthor=E.+Artinauthor=J.+O.+Saundersauthor=F.+G.+Salituroauthor=J.+Travinsauthor=G.+Cianchettaauthor=Z.+Caiauthor=D.+Zhouauthor=D.+Cui&title=Discovery+of+ag-120+%28ivosidenib%29%3A+A+first-in-class+mutant+idh1+inhibitor+for+the+treatment+of+idh1+mutant+cancers&doi=10.1021%2Facsmedchemlett.7b00421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers</span></div><div class="casAuthors">Popovici-Muller, Janeta; Lemieux, Rene M.; Artin, Erin; Saunders, Jeffrey O.; Salituro, Francesco G.; Travins, Jeremy; Cianchetta, Giovanni; Cai, Zhenwei; Zhou, Ding; Cui, Dawei; Chen, Ping; Straley, Kimberly; Tobin, Erica; Wang, Fang; David, Muriel D.; Penard-Lacronique, Virginie; Quivoron, Cyril; Saada, Veronique; de Botton, Stephane; Gross, Stefan; Dang, Lenny; Yang, Hua; Utley, Luke; Chen, Yue; Kim, Hyeryun; Jin, Shengfang; Gu, Zhiwei; Yao, Gui; Luo, Zhiyong; Lv, Xiaobing; Fang, Cheng; Yan, Liping; Olaharski, Andrew; Silverman, Lee; Biller, Scott; Su, Shin-San M.; Yen, Katharine</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">300-305</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the prodn. of D-2-hydroxyglutarate (2-HG), an oncometabolite.  Elevated 2-HG levels are implicated in epigenetic alterations and impaired cellular differentiation.  IDH1 mutations have been described in an array of hematol. malignancies and solid tumors.  Here, we report the discovery of AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo.  Preliminary data from phase 1 clin. trials enrolling patients with cancers harboring an IDH1 mutation indicate that AG-120 has an acceptable safety profile and clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmTLcR37BiPrVg90H21EOLACvtfcHk0linoMC4lmRPdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyrurw%253D&md5=730ac2faa6844e4abe3fd9a360d74d29</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00421%26sid%3Dliteratum%253Aachs%26aulast%3DPopovici-Muller%26aufirst%3DJ.%26aulast%3DLemieux%26aufirst%3DR.%2BM.%26aulast%3DArtin%26aufirst%3DE.%26aulast%3DSaunders%26aufirst%3DJ.%2BO.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DTravins%26aufirst%3DJ.%26aulast%3DCianchetta%26aufirst%3DG.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DCui%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520ag-120%2520%2528ivosidenib%2529%253A%2520A%2520first-in-class%2520mutant%2520idh1%2520inhibitor%2520for%2520the%2520treatment%2520of%2520idh1%2520mutant%2520cancers%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D300%26epage%3D305%26doi%3D10.1021%2Facsmedchemlett.7b00421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of cp-690,550: A potent and selective janus kinase (jak) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hines&title=Discovery+of+cp-690%2C550%3A+A+potent+and+selective+janus+kinase+%28jak%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0linoMC4lmRPdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520cp-690%252C550%253A%2520A%2520potent%2520and%2520selective%2520janus%2520kinase%2520%2528jak%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayase, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isshiki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuguchi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaitani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiratori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(02)00892-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS0960-894X%2802%2900892-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=12482421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsVels7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=191-196&author=J.+Ohwadaauthor=M.+Tsukazakiauthor=T.+Hayaseauthor=N.+Oikawaauthor=Y.+Isshikiauthor=H.+Fukudaauthor=E.+Mizuguchiauthor=M.+Sakaitaniauthor=Y.+Shiratoriauthor=T.+Yamazaki&title=Design%2C+synthesis+and+antifungal+activity+of+a+novel+water+soluble+prodrug+of+antifungal+triazole&doi=10.1016%2FS0960-894X%2802%2900892-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole</span></div><div class="casAuthors">Ohwada, Jun; Tsukazaki, Masao; Hayase, Tadakatsu; Oikawa, Nobuhiro; Isshiki, Yoshiaki; Fukuda, Hiroshi; Mizuguchi, Eisaku; Sakaitani, Masahiro; Shiratori, Yasuhiko; Yamazaki, Toshikazu; Ichihara, Shigeyasu; Umeda, Isao; Shimma, Nobuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">191-196</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A highly potent water sol. triazole antifungal prodrug, RO0098557 (I), has been identified from its parent, the novel antifungal agent RO0094815 (II).  The prodrug, which was obtained by the coupling of II with sarcosine ester III, includes a triazolium salt linked to an aminocarboxyl moiety, which undergoes enzymic activation followed by spontaneous chem. degrdn. to release II.  Prodrug I showed high chem. stability and water soly. and exhibited strong antifungal activity against systemic candidiasis and aspergillosis as well as pulmonary aspergillosis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1j5aGGk3HYrVg90H21EOLACvtfcHk0lgJZz-A7E9Gyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsVels7g%253D&md5=e5fa5ef54f1b4e5420caef0c329b1bfd</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900892-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900892-2%26sid%3Dliteratum%253Aachs%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DHayase%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DIsshiki%26aufirst%3DY.%26aulast%3DFukuda%26aufirst%3DH.%26aulast%3DMizuguchi%26aufirst%3DE.%26aulast%3DSakaitani%26aufirst%3DM.%26aulast%3DShiratori%26aufirst%3DY.%26aulast%3DYamazaki%26aufirst%3DT.%26atitle%3DDesign%252C%2520synthesis%2520and%2520antifungal%2520activity%2520of%2520a%2520novel%2520water%2520soluble%2520prodrug%2520of%2520antifungal%2520triazole%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D191%26epage%3D196%26doi%3D10.1016%2FS0960-894X%2802%2900892-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shotwell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voitenleitner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creech, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Design of n-benzoxaborole benzofuran gsk8175—optimization of human pharmacokinetics inspired by metabolites of a failed clinical hcv inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3254</span>– <span class="NLM_lpage">3267</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01719</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01719" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFCrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3254-3267&author=P.+Y.+Chongauthor=J.+B.+Shotwellauthor=J.+Millerauthor=D.+J.+Priceauthor=A.+Maynardauthor=C.+Voitenleitnerauthor=A.+Mathisauthor=S.+Williamsauthor=J.+J.+Pouliotauthor=K.+Creech&title=Design+of+n-benzoxaborole+benzofuran+gsk8175%E2%80%94optimization+of+human+pharmacokinetics+inspired+by+metabolites+of+a+failed+clinical+hcv+inhibitor&doi=10.1021%2Facs.jmedchem.8b01719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor</span></div><div class="casAuthors">Chong, Pek Y.; Shotwell, J. Brad; Miller, John; Price, Daniel J.; Maynard, Andy; Voitenleitner, Christian; Mathis, Amanda; Williams, Shawn; Pouliot, Jeffrey J.; Creech, Katrina; Wang, Feng; Fang, Jing; Zhang, Huichang; Tai, Vincent W.-F.; Turner, Elizabeth; Kahler, Kirsten M.; Crosby, Renae; Peat, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3254-3267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We previously described the discovery of GSK5852 (1), a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV), in which an N-benzyl boronic acid was essential for potent antiviral activity.  Unfortunately, facile benzylic oxidn. resulted in a short plasma half-life (5 h) in human volunteers, and a backup program was initiated to remove metabolic liabilities assocd. with 1.  Herein, we describe second-generation NS5B inhibitors including GSK8175 (49), a sulfonamide-N-benzoxaborole analog with low in vivo clearance across preclin. species and broad-spectrum activity against HCV replicons.  An X-ray structure of NS5B protein cocrystd. with 49 revealed unique protein-inhibitor interactions mediated by an extensive network of ordered water mols. and the first evidence of boronate complex formation within the binding pocket.  In clin. studies, 49 displayed a 60-63 h half-life and a robust decrease in viral RNA levels in HCV-infected patients, thereby validating our hypothesis that reducing benzylic oxidn. would improve human pharmacokinetics and lower efficacious doses relative to 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod4vHT97N2MbVg90H21EOLACvtfcHk0lgJZz-A7E9Gyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFCrsL8%253D&md5=3c8cbff5f4273f2cf43da3ec14e93f2c</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01719%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DP.%2BY.%26aulast%3DShotwell%26aufirst%3DJ.%2BB.%26aulast%3DMiller%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BJ.%26aulast%3DMaynard%26aufirst%3DA.%26aulast%3DVoitenleitner%26aufirst%3DC.%26aulast%3DMathis%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DS.%26aulast%3DPouliot%26aufirst%3DJ.%2BJ.%26aulast%3DCreech%26aufirst%3DK.%26atitle%3DDesign%2520of%2520n-benzoxaborole%2520benzofuran%2520gsk8175%25E2%2580%2594optimization%2520of%2520human%2520pharmacokinetics%2520inspired%2520by%2520metabolites%2520of%2520a%2520failed%2520clinical%2520hcv%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3254%26epage%3D3267%26doi%3D10.1021%2Facs.jmedchem.8b01719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gant, T. G.</span></span> <span> </span><span class="NLM_article-title">Using deuterium in drug discovery: Leaving the label in the drug</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3595</span>– <span class="NLM_lpage">3611</span>, <span class="refDoi"> DOI: 10.1021/jm4007998</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4007998" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3595-3611&author=T.+G.+Gant&title=Using+deuterium+in+drug+discovery%3A+Leaving+the+label+in+the+drug&doi=10.1021%2Fjm4007998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Using Deuterium in Drug Discovery: Leaving the Label in the Drug</span></div><div class="casAuthors">Gant, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3595-3611</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Deuterium, the stable isotope of hydrogen, is known to medicinal chemists for its utility in mechanistic, spectroscopic, and tracer studies.  In fact, well-known applications utilizing deuterium exist within every subdiscipline in pharmaceutical discovery and development.  Recent emphasis on incorporation of deuterium into the active pharmaceutical ingredient has come about as a result of inquiries into the potential for substantial benefits of the deuterium kinetic isotope effect on the safety and disposition of the drug substance.  This Perspective traces the author's experience in reviving and expanding this potential utility, first suggested many decades prior by the discoverer of this, the simplest of all isotopes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4z14tbfBfBbVg90H21EOLACvtfcHk0lgJZz-A7E9Gyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ&md5=3818a1dba9be431098ad9dd941dababc</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1021%2Fjm4007998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4007998%26sid%3Dliteratum%253Aachs%26aulast%3DGant%26aufirst%3DT.%2BG.%26atitle%3DUsing%2520deuterium%2520in%2520drug%2520discovery%253A%2520Leaving%2520the%2520label%2520in%2520the%2520drug%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3595%26epage%3D3611%26doi%3D10.1021%2Fjm4007998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hageman, M.</span></span> <span> </span><span class="NLM_article-title">The expanding role of prodrugs in contemporary drug design and development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.46</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2Fnrd.2018.46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29700501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=559-587&author=J.+Rautioauthor=N.+A.+Meanwellauthor=L.+Diauthor=M.+Hageman&title=The+expanding+role+of+prodrugs+in+contemporary+drug+design+and+development&doi=10.1038%2Fnrd.2018.46"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">The expanding role of prodrugs in contemporary drug design and development</span></div><div class="casAuthors">Rautio, Jarkko; Meanwell, Nicholas A.; Di, Li; Hageman, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">559-587</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Prodrugs are mols. with little or no pharmacol. activity that are converted to the active parent drug in vivo by enzymic or chem. reactions or by a combination of the two.  Prodrugs have evolved from being serendipitously discovered or used as a salvage effort to being intentionally designed.  Such efforts can avoid drug development challenges that limit formulation options or result in unacceptable biopharmaceutical or pharmacokinetic performance, or poor targeting.  In the past 10 years, the US Food and Drug Administration has approved at least 30 prodrugs, which accounts for more than 12% of all approved small-mol. new chem. entities.  In this Review, we highlight prodrug design strategies for improved formulation and pharmacokinetic and targeting properties, with a focus on the most recently marketed prodrugs.  We also discuss preclin. and clin. challenges and considerations in prodrug design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYKsM1lriJObVg90H21EOLACvtfcHk0lgJZz-A7E9Gyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgsL0%253D&md5=9dea9fd2f30779f4ce182b822f2c9539</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.46%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DHageman%26aufirst%3DM.%26atitle%3DThe%2520expanding%2520role%2520of%2520prodrugs%2520in%2520contemporary%2520drug%2520design%2520and%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D559%26epage%3D587%26doi%3D10.1038%2Fnrd.2018.46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arya, R.</span></span> <span> </span><span class="NLM_article-title">Toward an understanding of structural insights of xanthine and aldehyde oxidases: An overview of their inhibitors and role in various diseases</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1073</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.1002/med.21457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fmed.21457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28672082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1SmsrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=1073-1125&author=R.+Kumarauthor=G.+Joshiauthor=H.+Klerauthor=S.+Kalraauthor=M.+Kaurauthor=R.+Arya&title=Toward+an+understanding+of+structural+insights+of+xanthine+and+aldehyde+oxidases%3A+An+overview+of+their+inhibitors+and+role+in+various+diseases&doi=10.1002%2Fmed.21457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Toward an Understanding of Structural Insights of Xanthine and Aldehyde Oxidases: An Overview of their Inhibitors and Role in Various Diseases</span></div><div class="casAuthors">Kumar, Raj; Joshi, Gaurav; Kler, Harveen; Kalra, Sourav; Kaur, Manpreet; Arya, Ramandeep</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1073-1125</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Almost all drug mols. become the substrates for oxidoreductase enzymes, get metabolized into more hydrophilic products and eliminated from the body.  These metabolites sometime may be more potent, active, inactive, or toxic in nature compared to parent mol.  Xanthine oxidoreductase and aldehyde oxidase belong to molybdenum contg. family and are well characterized for their structures and functions, in particular to their ability to oxidize/hydroxylate the xenobiotics.  Their upregulated clin. levels causing oxidative stress are assocd. with pathways either directly involved in the progression of diseases, gout, or indirectly with the succession of other diseases such as diabetes, cancer, etc.  Herein, we have put forth a comprehensive review on the xanthine and aldehyde oxidases pertaining to their structures, functions, pathophysiol. role, and a comparative anal. of structural insights of xanthine and aldehyde oxidases' binding domains with endogenous ligands or inhibitors.  Though both the enzymes are molybdenum contg. and are likely to share some common pathways and interact with inhibitors in a similar manner but we have focused on structural prerequisites for inhibitor specificity to both the enzymes keeping in view of the existing X-ray structures.  This review also provides futuristic implications in the design of inhibitors derived from inorg. complexes or small org. mols. considering the spatial features and structural insights of both the enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFjkBedwc8M7Vg90H21EOLACvtfcHk0lhoD9sRbE0uGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1SmsrbO&md5=145e2ef5ae656019b53f5459f14d01d2</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1002%2Fmed.21457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21457%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DJoshi%26aufirst%3DG.%26aulast%3DKler%26aufirst%3DH.%26aulast%3DKalra%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DM.%26aulast%3DArya%26aufirst%3DR.%26atitle%3DToward%2520an%2520understanding%2520of%2520structural%2520insights%2520of%2520xanthine%2520and%2520aldehyde%2520oxidases%253A%2520An%2520overview%2520of%2520their%2520inhibitors%2520and%2520role%2520in%2520various%2520diseases%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D1073%26epage%3D1125%26doi%3D10.1002%2Fmed.21457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stella, V.</span></span> <span> </span><span class="NLM_article-title">Prodrugs: Some thoughts and current issues</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">4755</span>– <span class="NLM_lpage">4765</span>, <span class="refDoi"> DOI: 10.1002/jps.22205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fjps.22205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=20821387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKjsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2010&pages=4755-4765&author=V.+Stella&title=Prodrugs%3A+Some+thoughts+and+current+issues&doi=10.1002%2Fjps.22205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs: Some thoughts and current issues</span></div><div class="casAuthors">Stella, Valentino J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4755-4765</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  The prodrug approach to resolving formulation, delivery, and toxicity limitations on problematic drugs has had its proponents and detractors.  Over the last 10 years or so, about 20% of all new small mol. NCEs have been prodrugs-a no. that will surprise some.  As chemists begin to explore new chem. spaces, larger and more complex mols. present greater drug delivery challenges.  Prodrugs provide a means of solving these challenges, but also have their limitations.  Prodrugs are becoming an integral part of the drug discovery paradigm in some large pharma companies, and a no. of small biotech companies have been built around the design and application of prodrugs to improve drug candidates.  Some issues facing the area of prodrug research and the commercialization of prodrugs are discussed. © 2010 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci 99:4755-4765, 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKmIrrYzZmLbVg90H21EOLACvtfcHk0lhoD9sRbE0uGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKjsbfO&md5=0ca40706a47e9f042d3a5e71437ce725</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1002%2Fjps.22205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22205%26sid%3Dliteratum%253Aachs%26aulast%3DStella%26aufirst%3DV.%26atitle%3DProdrugs%253A%2520Some%2520thoughts%2520and%2520current%2520issues%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2010%26volume%3D99%26spage%3D4755%26epage%3D4765%26doi%3D10.1002%2Fjps.22205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweeny, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clough, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhamidipati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baluom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, D. T.-W.</span></span> <span> </span><span class="NLM_article-title">Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor r406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1166</span>– <span class="NLM_lpage">1176</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.032151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1124%2Fdmd.110.032151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=20371637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Klsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1166-1176&author=D.+J.+Sweenyauthor=W.+Liauthor=J.+Cloughauthor=S.+Bhamidipatiauthor=R.+Singhauthor=G.+Parkauthor=M.+Baluomauthor=E.+Grossbardauthor=D.+T.-W.+Lau&title=Metabolism+of+fostamatinib%2C+the+oral+methylene+phosphate+prodrug+of+the+spleen+tyrosine+kinase+inhibitor+r406+in+humans%3A+Contribution+of+hepatic+and+gut+bacterial+processes+to+the+overall+biotransformation&doi=10.1124%2Fdmd.110.032151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation</span></div><div class="casAuthors">Sweeny, David J.; Li, Weiqun; Clough, Jeffrey; Bhamidipati, Somasekhar; Singh, Rajinder; Park, Gary; Baluom, Muhammad; Grossbard, Elliott; Lau, David T.-W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1166-1176</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The metab. of the spleen tyrosine kinase inhibitor N4-(2,2-dimethyl-3-oxo-4-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethyoxyphenyl)-2,4-pyrimidinediamine (R406) and its oral prodrug N4-(2,2-dimethyl-4-[(dihydrogenphosphonoxy)methyl]-3-oxo-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethyoxyphenyl)-2,4-pyrimidinediamine disodium hexahydrate (R788, fostamatinib) was detd. in vitro and in humans.  R788 was rapidly converted to R406 by human intestinal microsomes, and only low levels of R788 were obsd. in plasma of human subjects after oral administration of 14C-R788.  R406 was the major drug-related compd. in plasma from human subjects, and only low levels of metabolites were obsd. in plasma.  The plasma metabolites of R406 were identified as a sulfate conjugate and glucuronide conjugate of the para-O-demethylated metabolite of R406 (R529) and a direct N-glucuronide conjugate of R406.  Elimination of drug-related material into the urine accounted for 19% of the administered dose, and the major metabolite in urine from all the human subjects was the lactam N-glucuronide of R406.  On av., 80% of the total drug was recovered in feces.  Two drug-related peaks were obsd.; one peak was identified as R406, and the other peak was identified as a unique 3,5-benzene diol metabolite of R406.  The 3,5-benzene diol metabolite appeared to result from the subsequent O-demethylations and dehydroxylation of R529 by anaerobic gut bacteria because only R529 was converted to this metabolite after the in vitro incubation with human fecal samples.  These data indicate that the major fecal metabolite of R406 obsd. in humans is a product of a hepatic cytochrome P 450-mediated O-demethylation and subsequent O-demethylations and dehydroxylation by gut bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjYey4HpvXGbVg90H21EOLACvtfcHk0lhoD9sRbE0uGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Klsb0%253D&md5=391fda31851968948d538f70319979e1</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.032151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.032151%26sid%3Dliteratum%253Aachs%26aulast%3DSweeny%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DClough%26aufirst%3DJ.%26aulast%3DBhamidipati%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DG.%26aulast%3DBaluom%26aufirst%3DM.%26aulast%3DGrossbard%26aufirst%3DE.%26aulast%3DLau%26aufirst%3DD.%2BT.-W.%26atitle%3DMetabolism%2520of%2520fostamatinib%252C%2520the%2520oral%2520methylene%2520phosphate%2520prodrug%2520of%2520the%2520spleen%2520tyrosine%2520kinase%2520inhibitor%2520r406%2520in%2520humans%253A%2520Contribution%2520of%2520hepatic%2520and%2520gut%2520bacterial%2520processes%2520to%2520the%2520overall%2520biotransformation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1166%26epage%3D1176%26doi%3D10.1124%2Fdmd.110.032151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palleria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giofrè, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caglioti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leuzzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siniscalchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Sarro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallelli, L.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic drug-drug interaction and their implication in clinical management</span>. <i>J. Res. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">610</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24516494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cfls1Wrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=601-610&author=C.+Palleriaauthor=A.+Di+Paoloauthor=C.+Giofr%C3%A8author=C.+Cagliotiauthor=G.+Leuzziauthor=A.+Siniscalchiauthor=G.+De+Sarroauthor=L.+Gallelli&title=Pharmacokinetic+drug-drug+interaction+and+their+implication+in+clinical+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic drug-drug interaction and their implication in clinical management</span></div><div class="casAuthors">Palleria Caterina; Giofre Chiara; Caglioti Chiara; De Sarro Giovambattista; Gallelli Luca; Di Paolo Antonello; Leuzzi Giacomo; Siniscalchi Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">601-10</span>
        ISSN:<span class="NLM_cas:issn">1735-1995</span>.
    </div><div class="casAbstract">Drug-drug interactions (DDIs) are one of the commonest causes of medication error in developed countries, particularly in the elderly due to poly-therapy, with a prevalence of 20-40%.  In particular, poly-therapy increases the complexity of therapeutic management and thereby the risk of clinically important DDIs, which can both induce the development of adverse drug reactions or reduce the clinical efficacy.  DDIs can be classify into two main groups: pharmacokinetic and pharmacodynamic.  In this review, using Medline, PubMed, Embase, Cochrane library and Reference lists we searched articles published until June 30 2012, and we described the mechanism of pharmacokinetic DDIs focusing the interest on their clinical implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAiCiGNKbA0B0LsK7uFuY7fW6udTcc2eZ7TV_b0S_qe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfls1Wrsw%253D%253D&md5=a868b6e9d31df10f59690328836af522</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPalleria%26aufirst%3DC.%26aulast%3DDi%2BPaolo%26aufirst%3DA.%26aulast%3DGiofr%25C3%25A8%26aufirst%3DC.%26aulast%3DCaglioti%26aufirst%3DC.%26aulast%3DLeuzzi%26aufirst%3DG.%26aulast%3DSiniscalchi%26aufirst%3DA.%26aulast%3DDe%2BSarro%26aufirst%3DG.%26aulast%3DGallelli%26aufirst%3DL.%26atitle%3DPharmacokinetic%2520drug-drug%2520interaction%2520and%2520their%2520implication%2520in%2520clinical%2520management%26jtitle%3DJ.%2520Res.%2520Med.%2520Sci.%26date%3D2013%26volume%3D18%26spage%3D601%26epage%3D610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tornio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filppula, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backman, J. T.</span></span> <span> </span><span class="NLM_article-title">Clinical studies on drug-drug interactions involving metabolism and transport: Methodology, pitfalls, and interpretation</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1361</span>, <span class="refDoi"> DOI: 10.1002/cpt.1435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fcpt.1435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30916389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3cbos1Wmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2019&pages=1345-1361&author=A.+Tornioauthor=A.+M.+Filppulaauthor=M.+Niemiauthor=J.+T.+Backman&title=Clinical+studies+on+drug-drug+interactions+involving+metabolism+and+transport%3A+Methodology%2C+pitfalls%2C+and+interpretation&doi=10.1002%2Fcpt.1435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation</span></div><div class="casAuthors">Tornio Aleksi; Filppula Anne M; Niemi Mikko; Backman Janne T; Tornio Aleksi; Filppula Anne M; Niemi Mikko; Backman Janne T</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1345-1361</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many drug-drug interactions (DDIs) are based on alterations of the plasma concentrations of a victim drug due to another drug causing inhibition and/or induction of the metabolism or transporter-mediated disposition of the victim drug.  In the worst case, such interactions cause more than tenfold increases or decreases in victim drug exposure, with potentially life-threatening consequences.  There has been tremendous progress in the predictability and modeling of DDIs.  Accordingly, the combination of modeling approaches and clinical studies is the current mainstay in evaluation of the pharmacokinetic DDI risks of drugs.  In this paper, we focus on the methodology of clinical studies on DDIs involving drug metabolism or transport.  We specifically present considerations related to general DDI study designs, recommended enzyme and transporter index substrates and inhibitors, pharmacogenetic perspectives, index drug cocktails, endogenous substrates, limited sampling strategies, physiologically-based pharmacokinetic modeling, complex DDIs, methodological pitfalls, and interpretation of DDI information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzB6gE0CNeF8uCWE5mhx1RfW6udTcc2eZ7TV_b0S_qe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbos1Wmuw%253D%253D&md5=e5d0134d25678929f1cf0e9d15fa15f8</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1435%26sid%3Dliteratum%253Aachs%26aulast%3DTornio%26aufirst%3DA.%26aulast%3DFilppula%26aufirst%3DA.%2BM.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DClinical%2520studies%2520on%2520drug-drug%2520interactions%2520involving%2520metabolism%2520and%2520transport%253A%2520Methodology%252C%2520pitfalls%252C%2520and%2520interpretation%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2019%26volume%3D105%26spage%3D1345%26epage%3D1361%26doi%3D10.1002%2Fcpt.1435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiśniowska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tylutki, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyszogrodzka, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polak, S.</span></span> <span> </span><span class="NLM_article-title">Drug-drug interactions and qt prolongation as a commonly assessed cardiac effect-comprehensive overview of clinical trials</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">12</span>, <span class="refDoi"> DOI: 10.1186/s40360-016-0053-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1186%2Fs40360-016-0053-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26960809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVKmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=12&author=B.+Wi%C5%9Bniowskaauthor=Z.+Tylutkiauthor=G.+Wyszogrodzkaauthor=S.+Polak&title=Drug-drug+interactions+and+qt+prolongation+as+a+commonly+assessed+cardiac+effect-comprehensive+overview+of+clinical+trials&doi=10.1186%2Fs40360-016-0053-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials</span></div><div class="casAuthors">Wisniowska, Barbara; Tylutki, Zofia; Wyszogrodzka, Gabriela; Polak, Sebastian</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12/1-12/15</span>CODEN:
                <span class="NLM_cas:coden">BPTMAB</span>;
        ISSN:<span class="NLM_cas:issn">2050-6511</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Proarrhythmia assessment is one of the major concerns for regulatory bodies and pharmaceutical industry.  ICH guidelines recommending preclin. tests have been established in attempt to eliminate the risk of drug-induced arrhythmias.  However, in the clinic, arrhythmia occurrence is detd. not only by the inherent property of a drug to block ion currents and disturb electrophysiol. activity of cardiac myocytes, but also by many other factors modifying individual risk of QT prolongation and subsequent proarrhythmia propensity.  One of those is drug-drug interactions.  Since polypharmacy is a common practice in clin. settings, it can be anticipated that there is a relatively high risk that the patient will receive at least two drugs mutually modifying their proarrhythmic potential and resulting either in triggering the occurrence or mitigating the clin. symptoms.  The mechanism can be obsd. either directly at the pharmacodynamic level by competing for the mol. targets, or indirectly by modifying the physiol. parameters, or at the pharmacokinetic level by alteration of the active concn. of the victim drug.  Methods: This publication provides an overview of published clin. studies on pharmacokinetic and/or pharmacodynamic drug-drug interactions in humans and their electrophysiol. consequences (QT interval modification).  Databases of PubMed and Scopus were searched and combinations of the following keywords were used for Title, Abstr. and Keywords fields: interaction, coadministration, combination, DDI and electrocardiog., QTc interval, ECG.  Only human studies were included.  Over 4500 publications were retrieved and underwent preliminary assessment to identify papers accordant with the topic of this review. 76 papers reporting results for 96 drug combinations were found and analyzed.  Results: The results show the tremendous variability of drug-drug interaction effects, which makes one aware of complexity of the problem, and suggests the need for assessment of an addnl. risk factors and careful ECG monitoring before administration of drugs with anticipated QT prolongation.  Conclusions: DDIs can play significant roles in drugs' cardiac safety, as evidenced by the provided examples.  Assessment of the pharmacodynamic effects of the drug interactions is more challenging as compared to the pharmacokinetic due to the significant diversity in the endpoints which should be analyzed specifically for various clin. effects.  Nevertheless, PD components of DDIs should be accounted for as PK changes alone do not allow to fully explain the electrophysiol. effects in clinic situations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpofpnYg_bLG7Vg90H21EOLACvtfcHk0lhbbyp09NLv6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVKmt7c%253D&md5=5a6f1039b05b8ae2ce1860b57c1bc403</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1186%2Fs40360-016-0053-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40360-016-0053-1%26sid%3Dliteratum%253Aachs%26aulast%3DWi%25C5%259Bniowska%26aufirst%3DB.%26aulast%3DTylutki%26aufirst%3DZ.%26aulast%3DWyszogrodzka%26aufirst%3DG.%26aulast%3DPolak%26aufirst%3DS.%26atitle%3DDrug-drug%2520interactions%2520and%2520qt%2520prolongation%2520as%2520a%2520commonly%2520assessed%2520cardiac%2520effect-comprehensive%2520overview%2520of%2520clinical%2520trials%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2016%26volume%3D17%26spage%3D12%26doi%3D10.1186%2Fs40360-016-0053-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauta-Aho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teperi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korhonen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farinola, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakib, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huupponen, R.</span></span> <span> </span><span class="NLM_article-title">Frailty and co-prescribing of potentially interacting drugs in new users of warfarin</span>. <i>Drugs Aging</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1007/s40266-020-00755-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40266-020-00755-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=32147805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFKqsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=373-382&author=M.+Hauta-Ahoauthor=S.+Teperiauthor=M.+J.+Korhonenauthor=J.+S.+Bellauthor=N.+Farinolaauthor=S.+Johnsauthor=S.+Shakibauthor=R.+Huupponen&title=Frailty+and+co-prescribing+of+potentially+interacting+drugs+in+new+users+of+warfarin&doi=10.1007%2Fs40266-020-00755-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Frailty and Co-Prescribing of Potentially Interacting Drugs in New Users of Warfarin</span></div><div class="casAuthors">Hauta-aho, Milka; Teperi, Simo; Korhonen, Maarit J.; Bell, J. Simon; Farinola, Nicholas; Johns, Sally; Shakib, Sepehr; Huupponen, Risto</div><div class="citationInfo"><span class="NLM_cas:title">Drugs & Aging</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">373-382</span>CODEN:
                <span class="NLM_cas:coden">DRAGE6</span>;
        ISSN:<span class="NLM_cas:issn">1170-229X</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Abstr.: Background: Warfarin is underutilized in frail older people because of the fear of bleeding complications.  Drug interactions are an independent bleeding risk factor.  However, the extent to which potential drug interactions are taken into account at warfarin therapy initiation in frail patients is not known.  Objective: The objective of this study was to investigate the use of potentially interacting drugs increasing the bleeding risk before and after warfarin initiation in frail and non-frail patients.  Methods: We conducted an observational study including inpatients aged ≥ 60 years initiated on warfarin in a tertiary hospital in Adelaide, South Australia.  Frailty status was assessed with the Reported Edmonton Frail Scale.  Medication charts were reviewed before and after warfarin initiation.  Results: In total, 151 patients (102 non-frail and 49 frail) were included.  Before warfarin initiation, the use of clopidogrel and acetaminophen was more common in frail patients compared with non-frail patients (25.5% vs 10.2%, p = 0.0135, 63.8% vs 35.7% p = 0.0014, resp.).  The use of non-steroidal anti-inflammatory drugs, 9.2% in non-frail patients and 6.4% in frail patients before warfarin initiation, was completely stopped after warfarin initiation in both groups.  The use of antiplatelet drugs decreased from 56.1% in non-frail patients and 66.0 % in frail patients to 12.2% and 14.9%, resp.  Instead, the use of drugs affecting the metab. of warfarin or vitamin K increased in both groups.  No statistically significant difference was seen in the exposure to interacting drugs between study groups after warfarin initiation.  Acetaminophen, senna glycosides and cytochrome P 450 2C9 inhibiting drugs were the most common interacting drugs at discharge used in 49.0%, 18.4% and 20.4% of non-frail patients and 53.2%, 29.8% and 19.1% of frail patients, resp.  Conclusions: The overall frequency of potential drug interactions was moderate and frail patients were not exposed to warfarin drug interactions more often than non-frail patients.  Further studies in larger study populations are required to verify these results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWjpApP4MGwbVg90H21EOLACvtfcHk0lgdDrNrvsOcog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFKqsbY%253D&md5=74badb5410f35344de98dc4a3e6d5225</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1007%2Fs40266-020-00755-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40266-020-00755-0%26sid%3Dliteratum%253Aachs%26aulast%3DHauta-Aho%26aufirst%3DM.%26aulast%3DTeperi%26aufirst%3DS.%26aulast%3DKorhonen%26aufirst%3DM.%2BJ.%26aulast%3DBell%26aufirst%3DJ.%2BS.%26aulast%3DFarinola%26aufirst%3DN.%26aulast%3DJohns%26aufirst%3DS.%26aulast%3DShakib%26aufirst%3DS.%26aulast%3DHuupponen%26aufirst%3DR.%26atitle%3DFrailty%2520and%2520co-prescribing%2520of%2520potentially%2520interacting%2520drugs%2520in%2520new%2520users%2520of%2520warfarin%26jtitle%3DDrugs%2520Aging%26date%3D2020%26volume%3D37%26spage%3D373%26epage%3D382%26doi%3D10.1007%2Fs40266-020-00755-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 11 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Marta Serafini, Sarah Cargnin, Alberto Massarotti, Gian Cesare Tron, Tracey Pirali, <span class="NLM_string-name hlFld-ContribAuthor">Armando A. Genazzani</span>. </span><span class="cited-content_cbyCitation_article-title">What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4410-4429. <a href="https://doi.org/10.1021/acs.jmedchem.1c00181" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00181%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhat%2525E2%252580%252599s%252Bin%252Ba%252BName%25253F%252BDrug%252BNomenclature%252Band%252BMedicinal%252BChemistry%252BTrends%252Busing%252BINN%252BPublications%26aulast%3DSerafini%26aufirst%3DMarta%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01022021%26date%3D13042021%26volume%3D64%26issue%3D8%26spage%3D4410%26epage%3D4429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongfei  Jiang</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Qin</span>, <span class="hlFld-ContribAuthor ">Qi  Wang</span>, <span class="hlFld-ContribAuthor ">Qi  Xu</span>, <span class="hlFld-ContribAuthor ">Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Yudong  Wu</span>, <span class="hlFld-ContribAuthor ">Wujun  Chen</span>, <span class="hlFld-ContribAuthor ">Chao  Wang</span>, <span class="hlFld-ContribAuthor ">Tingting  Zhang</span>, <span class="hlFld-ContribAuthor ">Dongming  Xing</span>, <span class="hlFld-ContribAuthor ">Renshuai  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Application of carbohydrates in approved small molecule drugs: A review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>223 </em>, 113633. <a href="https://doi.org/10.1016/j.ejmech.2021.113633" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113633</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113633%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DApplication%252Bof%252Bcarbohydrates%252Bin%252Bapproved%252Bsmall%252Bmolecule%252Bdrugs%25253A%252BA%252Breview%26aulast%3DJiang%26aufirst%3DHongfei%26date%3D2021%26volume%3D223%26spage%3D113633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manpreet  Kaur</span>, <span class="hlFld-ContribAuthor ">Vikrant  Mehta</span>, <span class="hlFld-ContribAuthor ">Aabid  Abdullah Wani</span>, <span class="hlFld-ContribAuthor ">Sahil  Arora</span>, <span class="hlFld-ContribAuthor ">Prasad V.  Bharatam</span>, <span class="hlFld-ContribAuthor ">Ashoke  Sharon</span>, <span class="hlFld-ContribAuthor ">Sandeep  Singh</span>, <span class="hlFld-ContribAuthor ">Raj  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 1,4-dihydropyrazolo[4,3-b]indoles via intramolecular C(sp2)-N bond formation involving nitrene insertion, DFT study and their anticancer assessment. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105114. <a href="https://doi.org/10.1016/j.bioorg.2021.105114" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105114%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Bof%252B1%25252C4-dihydropyrazolo%25255B4%25252C3-b%25255Dindoles%252Bvia%252Bintramolecular%252BC%252528sp2%252529-N%252Bbond%252Bformation%252Binvolving%252Bnitrene%252Binsertion%25252C%252BDFT%252Bstudy%252Band%252Btheir%252Banticancer%252Bassessment%26aulast%3DKaur%26aufirst%3DManpreet%26date%3D2021%26volume%3D114%26spage%3D105114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianlin  Han</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Konno</span>, <span class="hlFld-ContribAuthor ">Tatsunori  Sato</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>, <span class="hlFld-ContribAuthor ">Kunisuke  Izawa</span>. </span><span class="cited-content_cbyCitation_article-title">Tailor-made amino acids in the design of small-molecule blockbuster drugs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113448. <a href="https://doi.org/10.1016/j.ejmech.2021.113448" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113448</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113448%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTailor-made%252Bamino%252Bacids%252Bin%252Bthe%252Bdesign%252Bof%252Bsmall-molecule%252Bblockbuster%252Bdrugs%26aulast%3DHan%26aufirst%3DJianlin%26date%3D2021%26volume%3D220%26spage%3D113448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">José Tiago M.  Correia</span>, <span class="hlFld-ContribAuthor ">Marilia S.  Santos</span>, <span class="hlFld-ContribAuthor ">Emanuele F.  Pissinati</span>, <span class="hlFld-ContribAuthor ">Gustavo P.  Silva</span>, <span class="hlFld-ContribAuthor ">Márcio W.  Paixão</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances on Photoinduced Cascade Strategies for the Synthesis of
              N
              ‐Heterocycles. </span><span class="cited-content_cbyCitation_journal-name">The Chemical Record</span><span> <strong>2021,</strong> <em>23 </em><a href="https://doi.org/10.1002/tcr.202100160" title="DOI URL">https://doi.org/10.1002/tcr.202100160</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/tcr.202100160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Ftcr.202100160%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Chemical%2520Record%26atitle%3DRecent%252BAdvances%252Bon%252BPhotoinduced%252BCascade%252BStrategies%252Bfor%252Bthe%252BSynthesis%252Bof%252BN%252B%2525E2%252580%252590Heterocycles%26aulast%3DCorreia%26aufirst%3DJos%25C3%25A9%2BTiago%2BM.%26date%3D2021%26date%3D2021%26volume%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zai-Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">K. P.  Rakesh</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Hua-Li  Qin</span>, <span class="hlFld-ContribAuthor ">Haolin  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">A general approach to nitrile- and sulfonyl fluoride-substituted cyclopropanes. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (27)
                                     , 6021-6024. <a href="https://doi.org/10.1039/D1OB01043C" title="DOI URL">https://doi.org/10.1039/D1OB01043C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB01043C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB01043C%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DA%252Bgeneral%252Bapproach%252Bto%252Bnitrile-%252Band%252Bsulfonyl%252Bfluoride-substituted%252Bcyclopropanes%26aulast%3DZhang%26aufirst%3DZai-Wei%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D27%26spage%3D6021%26epage%3D6024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manpreet  Kaur</span>, <span class="hlFld-ContribAuthor ">Vikrant  Mehta</span>, <span class="hlFld-ContribAuthor ">Sahil  Arora</span>, <span class="hlFld-ContribAuthor ">Anjana  Munshi</span>, <span class="hlFld-ContribAuthor ">Sandeep  Singh</span>, <span class="hlFld-ContribAuthor ">Raj  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of New 5‐(2‐Nitrophenyl)‐1‐aryl‐1
              H
              ‐pyrazoles as Topoisomerase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (26)
                                     , 6644-6651. <a href="https://doi.org/10.1002/slct.202101459" title="DOI URL">https://doi.org/10.1002/slct.202101459</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202101459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202101459%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNew%252B5%2525E2%252580%252590%2525282%2525E2%252580%252590Nitrophenyl%252529%2525E2%252580%2525901%2525E2%252580%252590aryl%2525E2%252580%2525901%252BH%252B%2525E2%252580%252590pyrazoles%252Bas%252BTopoisomerase%252BInhibitors%26aulast%3DKaur%26aufirst%3DManpreet%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D26%26spage%3D6644%26epage%3D6651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Charlotte  Lorton</span>, <span class="hlFld-ContribAuthor ">Nidal  Saleh</span>, <span class="hlFld-ContribAuthor ">Arnaud  Voituriez</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphine‐Catalyzed Synthesis of Chiral
              N
              ‐Heterocycles through (Asymmetric) P(III)/P(V) Redox Cycling. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (22)
                                     , 3340-3344. <a href="https://doi.org/10.1002/ejoc.202100404" title="DOI URL">https://doi.org/10.1002/ejoc.202100404</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202100404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202100404%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DPhosphine%2525E2%252580%252590Catalyzed%252BSynthesis%252Bof%252BChiral%252BN%252B%2525E2%252580%252590Heterocycles%252Bthrough%252B%252528Asymmetric%252529%252BP%252528III%252529%25252FP%252528V%252529%252BRedox%252BCycling%26aulast%3DLorton%26aufirst%3DCharlotte%26date%3D2021%26date%3D2021%26volume%3D2021%26issue%3D22%26spage%3D3340%26epage%3D3344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gaurav  Joshi</span>, <span class="hlFld-ContribAuthor ">Jayant  Sindhu</span>, <span class="hlFld-ContribAuthor ">Shikha  Thakur</span>, <span class="hlFld-ContribAuthor ">Abhilash  Rana</span>, <span class="hlFld-ContribAuthor ">Geetika  Sharma</span>, <span class="hlFld-ContribAuthor ">Mayank</span>, <span class="hlFld-ContribAuthor ">Ramarao  Poduri</span>. </span><span class="cited-content_cbyCitation_article-title">Recent efforts for drug identification from phytochemicals against SARS-CoV-2: Exploration of the chemical space to identify druggable leads. </span><span class="cited-content_cbyCitation_journal-name">Food and Chemical Toxicology</span><span> <strong>2021,</strong> <em>152 </em>, 112160. <a href="https://doi.org/10.1016/j.fct.2021.112160" title="DOI URL">https://doi.org/10.1016/j.fct.2021.112160</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.fct.2021.112160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.fct.2021.112160%26sid%3Dliteratum%253Aachs%26jtitle%3DFood%2520and%2520Chemical%2520Toxicology%26atitle%3DRecent%252Befforts%252Bfor%252Bdrug%252Bidentification%252Bfrom%252Bphytochemicals%252Bagainst%252BSARS-CoV-2%25253A%252BExploration%252Bof%252Bthe%252Bchemical%252Bspace%252Bto%252Bidentify%252Bdruggable%252Bleads%26aulast%3DJoshi%26aufirst%3DGaurav%26date%3D2021%26volume%3D152%26spage%3D112160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaydeep  Yadav</span>, <span class="hlFld-ContribAuthor ">Mehdi  El Hassani</span>, <span class="hlFld-ContribAuthor ">Jasleen  Sodhi</span>, <span class="hlFld-ContribAuthor ">Volker M.  Lauschke</span>, <span class="hlFld-ContribAuthor ">Jessica H.  Hartman</span>, <span class="hlFld-ContribAuthor ">Laura E.  Russell</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments in
              in vitro
              and
              in vivo
              models for improved translation of preclinical pharmacokinetics and pharmacodynamics data. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism Reviews</span><span> <strong>2021,</strong> <em>53 </em>
                                    (2)
                                     , 207-233. <a href="https://doi.org/10.1080/03602532.2021.1922435" title="DOI URL">https://doi.org/10.1080/03602532.2021.1922435</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/03602532.2021.1922435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F03602532.2021.1922435%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520Reviews%26atitle%3DRecent%252Bdevelopments%252Bin%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252Bmodels%252Bfor%252Bimproved%252Btranslation%252Bof%252Bpreclinical%252Bpharmacokinetics%252Band%252Bpharmacodynamics%252Bdata%26aulast%3DYadav%26aufirst%3DJaydeep%26date%3D2021%26date%3D2021%26volume%3D53%26issue%3D2%26spage%3D207%26epage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianguo  Sun</span>, <span class="hlFld-ContribAuthor ">Taimin  Wang</span>, <span class="hlFld-ContribAuthor ">Xuecheng  Zhu</span>, <span class="hlFld-ContribAuthor ">Wei  Xu</span>, <span class="hlFld-ContribAuthor ">Bin  Cheng</span>, <span class="hlFld-ContribAuthor ">Hongbin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of thiazolidin-4-ones from α-enolic dithioesters and α-halohydroxamates. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2021,</strong> <em>115 </em><a href="https://doi.org/10.1039/D1NJ01970H" title="DOI URL">https://doi.org/10.1039/D1NJ01970H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1NJ01970H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1NJ01970H%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bthiazolidin-4-ones%252Bfrom%252B%2525CE%2525B1-enolic%252Bdithioesters%252Band%252B%2525CE%2525B1-halohydroxamates%26aulast%3DSun%26aufirst%3DJianguo%26date%3D2021%26date%3D2021%26volume%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0042.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Bar graph illustration of the number of year-wise drug approvals for various diseases/disorders. The data pertains to 2015–June 2020. The source of the data is the U.S. FDA Web site<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and DrugBank database.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of small molecules as anticancer agents approved by FDA between 2015 and 2017 (Part-1).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of small molecules approved as anticancer agents approved by FDA between 2018 and June 2020 (Part-2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of small molecules approved for the treatment of various neurological disorders by FDA from the year 2015 until June 2020.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of small molecule drugs used for the treatment of various metabolic disorders approved by FDA from the year 2015 until June 2020.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of small molecules as anti-infective agents approved by FDA from the year 2015 until June 2020 (Part 1).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of small molecules used in combination therapy as anti-infective agents approved by the FDA from the year 2015 until June 2020 (Part 2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of small molecules used for the treatment of various autoimmune disorders approved by FDA from the year 2015 until June 2020.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structures of small molecules used for the treatment of various cardiovascular diseases approved by FDA from the year 2015 until June 2020.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of diagnostic agents approved by FDA from the year 2015 until June 2020.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structures of miscellaneous drugs approved by the FDA from the year 2015 until June 2020.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Bar graph represents approved FDA drugs with orphan status from the year 2015 until June 2020.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Breakdown of U.S. FDA approved small molecules (2015–June 2020).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (A) Boronic acids act as transition state analogues for enzymes; (B) Prodrug activation of ixazomib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Bioactivation of pretomanid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Top five most frequent nitrogen heterocycles in the FDA approved drugs (2015–June 2020); (B) Other common N-heterocycle in the drugs; (C) Spiro nitrogen heterocycles in the drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Three-dimensional representation illustrating the outcome of chemical space visualized on PUMA using the “Chemical Space” tab for FDA approved drugs during 2015–June 2020. The 3D graphs signify correlation between (A) MW with TPSA and nROTB, (B) MW with nHBDon and nHBAcc, (C) TPSA with nHBDon and nHBAcc, and (D) nROTB with nHBDon and nHBAcc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structures of FDA approved antibody–drug conjugates (2015–June 2020).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Bar graph represents percent of approved FDA drugs from the year 2015 until June 2020, following and not following Lipinski’s Rule.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0021.jpeg" id="rightTab-GRAPHIC-d7e2056-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. An illustration showing several strategies utilized for optimizing metabolism leading to discovery of clinical candidates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0020.jpeg jm0c01786_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0022.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Percentage of the drugs approved in the study period (2015–June 2020) metabolized by various drug-metabolizing enzymes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/medium/jm0c01786_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0023.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Bar graph represents the share of victims and perpetrators during the study period (2015–June 2020).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01786/20210305/images/large/jm0c01786_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01786&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i50">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05303" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05303" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 218 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drews, J.</span></span> <span> </span><span class="NLM_article-title">Drug discovery: A historical perspective</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">1960</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1126/science.287.5460.1960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1126%2Fscience.287.5460.1960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10720314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvFyrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2000&pages=1960-4&author=J.+Drews&title=Drug+discovery%3A+A+historical+perspective&doi=10.1126%2Fscience.287.5460.1960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery: A historical perspective</span></div><div class="casAuthors">Drews, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">5460</span>),
    <span class="NLM_cas:pages">1960-1963</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with over 60 refs.  Driven by chem. but increasingly guided by pharmacol. and the clin. sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor.  The advent of mol. biol. and, in particular, of genomic sciences is having a deep impact on drug discovery.  Recombinant proteins and monoclonal antibodies have greatly enriched our therapeutic armamentarium.  Genome sciences, combined with bioinformatic tools, allow us to dissect the genetic basis of multifactorial diseases and to det. the most suitable points of attack for future medicines, thereby increasing the no. of treatment options.  The dramatic increase in the complexity of drug research is enforcing changes in the institutional basis of this interdisciplinary endeavor.  The biotech industry is establishing itself as the discovery arm of the pharmaceutical industry.  In bridging the gap between academia and large pharmaceutical companies, the biotech firms have been effective instruments of technol. transfer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdT9qeMTdSTrVg90H21EOLACvtfcHk0ljvpMIi8eJIvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvFyrtbc%253D&md5=33804292ba1e2fa5fd8012729d137dff</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.287.5460.1960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.287.5460.1960%26sid%3Dliteratum%253Aachs%26aulast%3DDrews%26aufirst%3DJ.%26atitle%3DDrug%2520discovery%253A%2520A%2520historical%2520perspective%26jtitle%3DScience%26date%3D2000%26volume%3D287%26spage%3D1960%26epage%3D4%26doi%3D10.1126%2Fscience.287.5460.1960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Network pharmacology: The next paradigm in drug discovery</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1038/nchembio.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-90&author=A.+L.+Hopkins&title=Network+pharmacology%3A+The+next+paradigm+in+drug+discovery&doi=10.1038%2Fnchembio.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0lhuVHMC2du7Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520pharmacology%253A%2520The%2520next%2520paradigm%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D682%26epage%3D90%26doi%3D10.1038%2Fnchembio.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Angelis, A.</span>; <span class="NLM_string-name">Phillips, L. D.</span></span> <span> </span><span class="NLM_article-title">Advancing structured decision-making in drug regulation at the fda and ema</span>.  <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>.  <span class="NLM_volume">87</span> <span class="NLM_fpage">395</span><span class="refDoi"> DOI: 10.1111/bcp.14425</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1111%2Fbcp.14425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=32529733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB38rptVaqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2021&pages=395&author=A.+Angelis&author=L.+D.+Phillips&title=Advancing+structured+decision-making+in+drug+regulation+at+the+fda+and+ema&doi=10.1111%2Fbcp.14425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing structured decision-making in drug regulation at the FDA and EMA</span></div><div class="casAuthors">Angelis Aris; Phillips Lawrence D</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">395-405</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The recent benefit-risk framework (BRF) developed by the Food and Drug Administration (FDA) is intended to improve the clarity and consistency in communicating the reasoning behind the FDA's decisions, acting as an important advancement in US drug regulation.  In the PDUFA VI implementation plan, the FDA states that it will continue to explore more structured or quantitative decision analysis approaches; however, it restricts their use within the current BRF that is purely qualitative.  By contrast, European regulators and researchers have been long exploring the use of quantitative decision analysis approaches for evaluating drug benefit-risk balance.  In this paper, we show how quantitative modelling, backed by decision theory, could complement and extend the FDA's BRF to better support the appraisal of evidence and improve decision outcomes.  After providing relevant scientific definitions for benefit-risk assessment and describing the FDA and European Medicines Agency (EMA) frameworks, we explain the components of and differences between qualitative and quantitative approaches.  We present lessons learned from the EMA experience with the use of quantitative modelling and we provide evidence of its benefits, illustrated by a real case study that helped to resolve differences of judgements among EMA regulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQoF9uz7xh8gCSm0e6ZOaemfW6udTcc2eZos-wIcPxfurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38rptVaqtQ%253D%253D&md5=2ee868dcb5368f02587728ac76931d16</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fbcp.14425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.14425%26sid%3Dliteratum%253Aachs%26aulast%3DAngelis%26aufirst%3DA.%26atitle%3DAdvancing%2520structured%2520decision-making%2520in%2520drug%2520regulation%2520at%2520the%2520fda%2520and%2520ema%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2021%26volume%3D87%26spage%3D395%26doi%3D10.1111%2Fbcp.14425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kashoki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanaizi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yordanova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veselý, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouygues, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinares, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kweder, S. L.</span></span> <span> </span><span class="NLM_article-title">A comparison of ema and fda decisions for new drug marketing applications 2014–2016: Concordance, discordance, and why</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1002/cpt.1565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fcpt.1565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31306483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3MznsVCltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2020&pages=195-202&author=M.+Kashokiauthor=Z.+Hanaiziauthor=S.+Yordanovaauthor=R.+Vesel%C3%BDauthor=C.+Bouyguesauthor=J.+Llinaresauthor=S.+L.+Kweder&title=A+comparison+of+ema+and+fda+decisions+for+new+drug+marketing+applications+2014%E2%80%932016%3A+Concordance%2C+discordance%2C+and+why&doi=10.1002%2Fcpt.1565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why</span></div><div class="casAuthors">Kashoki Mwango; Kashoki Mwango; Hanaizi Zahra; Yordanova Stella; Vesely Richard; Bouygues Christelle; Llinares Jordi; Kweder Sandra L</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">195-202</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have robust scientific and technical collaborations.  As a window to the impact of these activities we compared the agencies' decisions on drug marketing applications.  Decisions were compared for 107 new drug applications with a regulatory outcome at both agencies in the period 2014-2016.  Further analysis addressed individual applications for which the agencies had differing outcomes in terms of marketing approval, type of approval, and approved indication, including reasons underlying differences.  The EMA and the FDA had high concordance (91-98%) in decisions on marketing approvals.  Divergence in approval decisions, type of approval, and approved indication were primarily due to differences in agencies' conclusions about efficacy based on review of the same data or differing clinical data submitted to support the application.  This high rate of concordance suggests that engagement and collaboration on regulatory science has a positive impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQV-1WkooK594IRAdBLKY41fW6udTcc2eZos-wIcPxfurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MznsVCltw%253D%253D&md5=6408da6719a9514f0c4fca5542e728a1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1565%26sid%3Dliteratum%253Aachs%26aulast%3DKashoki%26aufirst%3DM.%26aulast%3DHanaizi%26aufirst%3DZ.%26aulast%3DYordanova%26aufirst%3DS.%26aulast%3DVesel%25C3%25BD%26aufirst%3DR.%26aulast%3DBouygues%26aufirst%3DC.%26aulast%3DLlinares%26aufirst%3DJ.%26aulast%3DKweder%26aufirst%3DS.%2BL.%26atitle%3DA%2520comparison%2520of%2520ema%2520and%2520fda%2520decisions%2520for%2520new%2520drug%2520marketing%2520applications%25202014%25E2%2580%25932016%253A%2520Concordance%252C%2520discordance%252C%2520and%2520why%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2020%26volume%3D107%26spage%3D195%26epage%3D202%26doi%3D10.1002%2Fcpt.1565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
la Torre, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albericio, F.</span></span> <span> </span><span class="NLM_article-title">The pharmaceutical industry in 2018. An analysis of fda drug approvals from the perspective of molecules</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">809</span>, <span class="refDoi"> DOI: 10.3390/molecules24040809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3390%2Fmolecules24040809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30813407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlCrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=809&author=B.+G.+de%0Ala+Torreauthor=F.+Albericio&title=The+pharmaceutical+industry+in+2018.+An+analysis+of+fda+drug+approvals+from+the+perspective+of+molecules&doi=10.3390%2Fmolecules24040809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmaceutical industry in 2018. an analysis of FDA drug approvals from the perspective of molecules</span></div><div class="casAuthors">de la Torre, Beatriz G.; Albericio, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">809/1-809/12</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The Food and Drug Administration approved 59 new drugs (42 New Chem. Entities and 17 Biologics) during 2018.  This no. breaks the previous record of 53 approved by the same organization in 1996.  The 17 new biologics approved in 2018 also represent an important milestone for this kind of drug and they clearly exceed the 12 approved in 2015 and 2017.  Herein, the 59 new drugs of the class of 2018 are analyzed from a strictly chem. perspective.  The classification has been carried out on the basis of the chem. structure and includes the following: Biologics (antibodies and enzymes); TIDES (peptides and oligonucleotides) and natural products; drug combinations; and small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpl9Nat-uSwbVg90H21EOLACvtfcHk0lhuVHMC2du7Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlCrtLY%253D&md5=e61d944d90a38fead8920eef07be8246</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24040809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24040809%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2Bla%2BTorre%26aufirst%3DB.%2BG.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DThe%2520pharmaceutical%2520industry%2520in%25202018.%2520An%2520analysis%2520of%2520fda%2520drug%2520approvals%2520from%2520the%2520perspective%2520of%2520molecules%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D809%26doi%3D10.3390%2Fmolecules24040809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
la Torre, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albericio, F.</span></span> <span> </span><span class="NLM_article-title">The pharmaceutical industry in 2017. An analysis of fda drug approvals from the perspective of molecules</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">533</span>, <span class="refDoi"> DOI: 10.3390/molecules23030533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3390%2Fmolecules23030533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslWrtLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=533&author=B.+G.+de%0Ala+Torreauthor=F.+Albericio&title=The+pharmaceutical+industry+in+2017.+An+analysis+of+fda+drug+approvals+from+the+perspective+of+molecules&doi=10.3390%2Fmolecules23030533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmaceutical industry in 2017. An analysis of FDA drug approvals from the perspective of molecules</span></div><div class="casAuthors">de la Torre, Beatriz G.; Albericio, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">533/1-533/8</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  This is an anal. from a chem. point of view of the 46 drugs (34 New Chem. Entities and 12 Biologics) approved by the FDA during 2017.  The drugs included in the 2017 "harvest" have been classified on the basis of their chem. structure: biologics (antibodies and proteins); peptides; amino acids and natural products; drug combinations; and small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2caMkd7KKS7Vg90H21EOLACvtfcHk0lgiHdw0vlWIOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslWrtLnK&md5=60d847c788c02db756fee26d84042c9a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23030533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23030533%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2Bla%2BTorre%26aufirst%3DB.%2BG.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DThe%2520pharmaceutical%2520industry%2520in%25202017.%2520An%2520analysis%2520of%2520fda%2520drug%2520approvals%2520from%2520the%2520perspective%2520of%2520molecules%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26spage%3D533%26doi%3D10.3390%2Fmolecules23030533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
la Torre, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albericio, F.</span></span> <span> </span><span class="NLM_article-title">The pharmaceutical industry in 2019. An analysis of fda drug approvals from the perspective of molecules</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">745</span>, <span class="refDoi"> DOI: 10.3390/molecules25030745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3390%2Fmolecules25030745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXks1yitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=745&author=B.+G.+De%0Ala+Torreauthor=F.+Albericio&title=The+pharmaceutical+industry+in+2019.+An+analysis+of+fda+drug+approvals+from+the+perspective+of+molecules&doi=10.3390%2Fmolecules25030745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmaceutical industry in 2019. an analysis of FDA drug approvals from the perspective of molecules</span></div><div class="casAuthors">de la Torre, Beatriz G.; Albericio, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">745</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  During 2019, the US Food and Drug Administration (FDA) approved 48 new drugs (38 New Chem. Entities and 10 Biologics).  Although this figure is slightly lower than that registered in 2018 (59 divided between 42 New Chem. Entities and 17 Biologics), a year that broke a record with respect to new drugs approved by this agency, it builds on the trend initiated in 2017, when 46 drugs were approved.  Of note, three antibody drug conjugates, three peptides, and two oligonucleotides were approved in 2019.  This report analyzes the 48 new drugs of the class of 2019 from a strictly chem. perspective.  The classification, which was carried out on the basis of chem. structure, includes the following: Biologics (antibody drug conjugates, antibodies, and proteins); TIDES (peptide and oligonucleotides); drug combinations; natural products; and small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKTdcnvpBRKbVg90H21EOLACvtfcHk0lgiHdw0vlWIOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXks1yitbo%253D&md5=f7e9db811c93d5ce49d0fa2a85207b18</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3390%2Fmolecules25030745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules25030745%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2Bla%2BTorre%26aufirst%3DB.%2BG.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DThe%2520pharmaceutical%2520industry%2520in%25202019.%2520An%2520analysis%2520of%2520fda%2520drug%2520approvals%2520from%2520the%2520perspective%2520of%2520molecules%26jtitle%3DMolecules%26date%3D2020%26volume%3D25%26spage%3D745%26doi%3D10.3390%2Fmolecules25030745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feunang, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sajed, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayeeda, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assempour, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iynkkaran, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, M.</span></span> <span> </span><span class="NLM_article-title">Drugbank 5.0: A major update to the drugbank database for 2018</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">D1074</span>– <span class="NLM_lpage">D1082</span>, <span class="refDoi"> DOI: 10.1093/nar/gkx1037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1093%2Fnar%2Fgkx1037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29126136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGisbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=D1074-D1082&author=D.+S.+Wishartauthor=Y.+D.+Feunangauthor=A.+C.+Guoauthor=E.+J.+Loauthor=A.+Marcuauthor=J.+R.+Grantauthor=T.+Sajedauthor=D.+Johnsonauthor=C.+Liauthor=Z.+Sayeedaauthor=N.+Assempourauthor=I.+Iynkkaranauthor=Y.+Liuauthor=A.+Maciejewskiauthor=N.+Galeauthor=A.+Wilsonauthor=L.+Chinauthor=R.+Cummingsauthor=D.+Leauthor=A.+Ponauthor=C.+Knoxauthor=M.+Wilson&title=Drugbank+5.0%3A+A+major+update+to+the+drugbank+database+for+2018&doi=10.1093%2Fnar%2Fgkx1037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">DrugBank 5.0: a major update to the DrugBank database for 2018</span></div><div class="casAuthors">Wishart, David S.; Feunang, Yannick D.; Guo, An C.; Lo, Elvis J.; Marcu, Ana; Grant, Jason R.; Sajed, Tanvir; Johnson, Daniel; Li, Carin; Sayeeda, Zinat; Assempour, Nazanin; Iynkkaran, Ithayavani; Liu, Yifeng; Maciejewski, Adam; Gale, Nicola; Wilson, Alex; Chin, Lucy; Cummings, Ryan; Le, Diana; Pon, Allison; Knox, Craig; Wilson, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D1074-D1082</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">DrugBank is a web-enabled database contg. comprehensivemol. information about drugs, their mechanisms, their interactions and their targets.  First described in 2006, Drug- Bank has continued to evolve over the past 12 years in response to marked improvements to web stds. and changing needs for drug research and development.  This year's update, DrugBank 5.0, represents the most significant upgrade to the database in more than 10 years.  In many cases, existing data content has grown by 100% or more over the last update.  For instance, the total no. of investigational drugs in the database has grown by almost 300%, the no. of drug-drug interactions has grown by nearly 600% and the no. of SNP-assocd. drug effects has grown more than 3000%.  Significant improvements have been made to the quantity, quality and consistency of drug indications, drug binding data as well as drug-drug and drug-food interactions.  A great deal of brand new data have also been added to DrugBank 5.0.  This includes information on the influence of hundreds of drugs on metabolite levels (pharmacometabolomics), gene expression levels (pharmacotranscriptomics) and protein expression levels (pharmacoproteomics).  New data have also been added on the status of hundreds of newdrug clin. trials and existing drug repurposing trials.  Many other important improvements in the content, interface and performance of the DrugBank website have been made and these should greatly enhance its ease of use, utility and potential applications in many areas of pharmacol. research, pharmaceutical science and drug education.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc8rfBoMOOyLVg90H21EOLACvtfcHk0lgiHdw0vlWIOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGisbvI&md5=986b28c7ea546596a26dd3ba38f05fee</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkx1037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkx1037%26sid%3Dliteratum%253Aachs%26aulast%3DWishart%26aufirst%3DD.%2BS.%26aulast%3DFeunang%26aufirst%3DY.%2BD.%26aulast%3DGuo%26aufirst%3DA.%2BC.%26aulast%3DLo%26aufirst%3DE.%2BJ.%26aulast%3DMarcu%26aufirst%3DA.%26aulast%3DGrant%26aufirst%3DJ.%2BR.%26aulast%3DSajed%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DSayeeda%26aufirst%3DZ.%26aulast%3DAssempour%26aufirst%3DN.%26aulast%3DIynkkaran%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMaciejewski%26aufirst%3DA.%26aulast%3DGale%26aufirst%3DN.%26aulast%3DWilson%26aufirst%3DA.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DCummings%26aufirst%3DR.%26aulast%3DLe%26aufirst%3DD.%26aulast%3DPon%26aufirst%3DA.%26aulast%3DKnox%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DM.%26atitle%3DDrugbank%25205.0%253A%2520A%2520major%2520update%2520to%2520the%2520drugbank%2520database%2520for%25202018%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2018%26volume%3D46%26spage%3DD1074%26epage%3DD1082%26doi%3D10.1093%2Fnar%2Fgkx1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span> </span><span class="NLM_article-title"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="4e0a3c3b293d0e282a2f">[email protected]</a>: Fda-approved drugs</span>. <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process" class="extLink">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process</a> (accessed Jun 30, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drugs%40fda%3A+Fda-approved+drugs.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fdaf%2Findex.cfm%3Fevent%3DreportsSearch.process+%28accessed+Jun+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DDrugs%2540fda%253A%2520Fda-approved%2520drugs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laggner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span> <span> </span><span class="NLM_article-title">Why drugs fail—a study on side effects in new chemical entities</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3545</span>– <span class="NLM_lpage">3559</span>, <span class="refDoi"> DOI: 10.2174/138161205774414510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2174%2F138161205774414510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=16248807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWrs7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=3545-3559&author=D.+Schusterauthor=C.+Laggnerauthor=T.+Langer&title=Why+drugs+fail%E2%80%94a+study+on+side+effects+in+new+chemical+entities&doi=10.2174%2F138161205774414510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Why drugs fail - a study on side effects in new chemical entities</span></div><div class="casAuthors">Schuster, D.; Laggner, C.; Langer, T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3545-3559</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Our study focuses on the reasons for market withdrawals of drugs and drug development project terminations in clin. phases I-III from 1992 to 2002.  Over 90% of the market withdrawals were caused by drug toxicity.  Hepatotoxicity and cardiovascular toxicity proved to be the major causes for two out of three market withdrawals in the resp. time period.  In clin. phases I-III 43% of drug development project terminations were due to insufficient efficacy of the investigated compd.  The second important issue, which caused one third of the projects to be closed, was toxicity.  ADME parameters and economic and other reasons played a minor role.  The results of our study indicate that compared with previous studies on this subject, no major improvements have been achieved in the last decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL6dIqIHxrybVg90H21EOLACvtfcHk0lgDKTdSdkBY9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWrs7rE&md5=1bef8ba43d434392969566c3e6052cf8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F138161205774414510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161205774414510%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DD.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DWhy%2520drugs%2520fail%25E2%2580%2594a%2520study%2520on%2520side%2520effects%2520in%2520new%2520chemical%2520entities%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2005%26volume%3D11%26spage%3D3545%26epage%3D3559%26doi%3D10.2174%2F138161205774414510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panchagnula, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, N. S.</span></span> <span> </span><span class="NLM_article-title">Biopharmaceutics and pharmacokinetics in drug research</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/S0378-5173(00)00344-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS0378-5173%2800%2900344-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10878321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlSltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2000&pages=131-50&author=R.+Panchagnulaauthor=N.+S.+Thomas&title=Biopharmaceutics+and+pharmacokinetics+in+drug+research&doi=10.1016%2FS0378-5173%2800%2900344-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Biopharmaceutics and pharmacokinetics in drug research</span></div><div class="casAuthors">Panchagnula, R.; Thomas, N. S.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-150</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with refs.  With the synergistic and multiplicative interactions of rational drug design, recombinant biotechnol., combinatorial chem. and high-throughput screening, millions of compds. are being synthesized by chemists.  However, development of these drug candidates has often been impeded, if not terminated, due to biopharmaceutic and/or pharmacokinetic constraints.  This has resulted in delays in development time and escalation of cost in the drug research programs.  So, the present emphasis is to reduce development time and cost, which is analogous to added patent life besides the enormous redn. in human suffering.  In this compilation the important biopharmaceutic and pharmacokinetic approaches are discussed, which will help in the development of safe and more efficacious drugs with reduced development time and cost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9RtSu9ZL4srVg90H21EOLACvtfcHk0lgDKTdSdkBY9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlSltbY%253D&md5=ec1a27a9171105b3da610fdfee492f21</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0378-5173%2800%2900344-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5173%252800%252900344-6%26sid%3Dliteratum%253Aachs%26aulast%3DPanchagnula%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DN.%2BS.%26atitle%3DBiopharmaceutics%2520and%2520pharmacokinetics%2520in%2520drug%2520research%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2000%26volume%3D201%26spage%3D131%26epage%3D50%26doi%3D10.1016%2FS0378-5173%2800%2900344-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, S. A.</span></span> <span> </span><span class="NLM_article-title">Drug metabolism and pharmacokinetics in drug discovery</span>. <i>Curr. Opin. Drug Discovery Devel.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">80</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=12613278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtFKgtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2003&pages=66-80&author=S.+A.+Roberts&title=Drug+metabolism+and+pharmacokinetics+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Drug metabolism and pharmacokinetics in drug discovery</span></div><div class="casAuthors">Roberts, Simon A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-80</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Current Drugs</span>)
        </div><div class="casAbstract">A review.  The discovery and development of new drugs seems to be an inefficient process, since too few new chem. entities (NCEs) successfully make it to the market.  Because one of the main reasons for failure in development is thought to be poor pharmacokinetics (PK), drug metab. and PK (DMPK) have assumed a central role within the field of drug discovery.  A good development candidate requires a balance of potency, safety, and PK; therefore, techniques that can help understand these characteristics are employed to enable researchers to design more robust candidates.  A no. of new in silico, in vitro, and in vivo techniques are available to screen compds. for key absorption, distribution, metab., and excretion (ADME) characteristics, which, when applied within a rational strategy, can make a major contribution to the design and selection of successful NCEs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK2jra-cFBArVg90H21EOLACvtfcHk0lgDKTdSdkBY9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtFKgtrk%253D&md5=e9955815802e10103820943663127d60</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DS.%2BA.%26atitle%3DDrug%2520metabolism%2520and%2520pharmacokinetics%2520in%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Devel.%26date%3D2003%26volume%3D6%26spage%3D66%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bermejo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casabo, V. G.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics in drug discovery</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">654</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1002/jps.21009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fjps.21009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=17630642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BD2sjmsVegtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2008&pages=654-90&author=A.+Ruiz-Garciaauthor=M.+Bermejoauthor=A.+Mossauthor=V.+G.+Casabo&title=Pharmacokinetics+in+drug+discovery&doi=10.1002%2Fjps.21009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics in drug discovery</span></div><div class="casAuthors">Ruiz-Garcia Ana; Bermejo Marival; Moss Aaron; Casabo Vicente G</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">654-90</span>
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    </div><div class="casAbstract">The aim of this current review is to summarize the present status of pharmacokinetics in Drug Discovery.  The review is structured into four sections.  The first section is a general overview of what we understand by pharmacokinetics and the different LADMET aspects: Liberation, Absorption, Distribution, Metabolism, Excretion, and Toxicity.  The second section highlights the different computational or in silico approaches to estimate/predict one or several aspects of the pharmacokinetic profile of a discovery lead compound.  The third section discusses the most commonly used in vitro methodologies.  The fourth and last section examines the various approaches employed towards the pharmacokinetic assessment of discovery molecules; including all the LADME processes, discussing the different mathematical methodologies available to establish the PK profile of a test compound; what the main differences are and what should be the criteria for using one or another mathematical approach.  The major conclusion of this review is that the use of the appropriate preclinical assays has a key role in the long-term viability of a pharmaceutical company since applying the right tools early in discovery will play a key role in determining the company's ability to discover novel safe and effective therapeutics to patients as quickly as possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRw3j1RasKUdJw7prLlxLOzfW6udTcc2ea9GeoEtpvNBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjmsVegtw%253D%253D&md5=9451af52abc23fa40ec8868b0b4cec0a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fjps.21009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21009%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz-Garcia%26aufirst%3DA.%26aulast%3DBermejo%26aufirst%3DM.%26aulast%3DMoss%26aufirst%3DA.%26aulast%3DCasabo%26aufirst%3DV.%2BG.%26atitle%3DPharmacokinetics%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2008%26volume%3D97%26spage%3D654%26epage%3D90%26doi%3D10.1002%2Fjps.21009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Segall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champness, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lilien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B.</span></span> <span> </span><span class="NLM_article-title">Applying medicinal chemistry transformations and multiparameter optimization to guide the search for high-quality leads and candidates</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2967</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1021/ci2003208</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci2003208" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlaqsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=2967-76&author=M.+Segallauthor=E.+Champnessauthor=C.+Leedingauthor=R.+Lilienauthor=R.+Mettuauthor=B.+Stevens&title=Applying+medicinal+chemistry+transformations+and+multiparameter+optimization+to+guide+the+search+for+high-quality+leads+and+candidates&doi=10.1021%2Fci2003208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Applying Medicinal Chemistry Transformations and Multiparameter Optimization to Guide the Search for High-Quality Leads and Candidates</span></div><div class="casAuthors">Segall, Matthew; Champness, Ed; Leeding, Chris; Lilien, Ryan; Mettu, Ramgopal; Stevens, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2967-2976</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this article we describe a computational method that automatically generates chem. relevant compd. ideas from an initial mol., closely integrated with in silico models, and a probabilistic scoring algorithm to highlight the compd. ideas most likely to satisfy a user-defined profile of required properties.  The new compd. ideas are generated using medicinal chem. transformation rules' taken from examples in the literature.  We demonstrate that the set of 206 transformations employed is generally applicable, produces a wide range of new compds., and is representative of the types of modifications previously made to move from lead-like to drug-like compds.  Furthermore, we show that more than 94% of the compds. generated by transformation of typical drug-like mols. are acceptable to experienced medicinal chemists.  Finally, we illustrate an application of our approach to the lead that ultimately led to the discovery of duloxetine, a marketed serotonin reuptake inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjE0Vu_6P2LbVg90H21EOLACvtfcHk0lh4F7bCZ5D6iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlaqsbbO&md5=af71c9add7eca9967c729710e951fa01</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fci2003208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2003208%26sid%3Dliteratum%253Aachs%26aulast%3DSegall%26aufirst%3DM.%26aulast%3DChampness%26aufirst%3DE.%26aulast%3DLeeding%26aufirst%3DC.%26aulast%3DLilien%26aufirst%3DR.%26aulast%3DMettu%26aufirst%3DR.%26aulast%3DStevens%26aufirst%3DB.%26atitle%3DApplying%2520medicinal%2520chemistry%2520transformations%2520and%2520multiparameter%2520optimization%2520to%2520guide%2520the%2520search%2520for%2520high-quality%2520leads%2520and%2520candidates%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D2967%26epage%3D76%26doi%3D10.1021%2Fci2003208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lesko, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaschke, T. F.</span></span> <span> </span><span class="NLM_article-title">Optimizing the science of drug development: Opportunities for better candidate selection and accelerated evaluation in humans</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">814</span>, <span class="refDoi"> DOI: 10.1177/00912700022009530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1177%2F00912700022009530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10934664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlslartL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2000&pages=803-814&author=L.+J.+Leskoauthor=M.+Rowlandauthor=C.+C.+Peckauthor=T.+F.+Blaschke&title=Optimizing+the+science+of+drug+development%3A+Opportunities+for+better+candidate+selection+and+accelerated+evaluation+in+humans&doi=10.1177%2F00912700022009530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans</span></div><div class="casAuthors">Lesko, Lawrence J.; Rowland, Malcolm; Peck, Carl C.; Blaschke, Terrence F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">803-814</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review with 11 refs. Two international meetings were convened in 1998 to review the current science of drug development and the potential opportunities to optimize the evaluation of new drugs in humans.  This report represents a synopsis of these meetings and focuses on the current state of knowledge pertaining to drug development, future scientific and tech. needs, and the relative merits of various strategies intended to accelerate the clin. development of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXUNcruXyMEbVg90H21EOLACvtfcHk0lh4F7bCZ5D6iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlslartL4%253D&md5=c5be137fa0b62ad04d4af9e2f386417d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1177%2F00912700022009530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F00912700022009530%26sid%3Dliteratum%253Aachs%26aulast%3DLesko%26aufirst%3DL.%2BJ.%26aulast%3DRowland%26aufirst%3DM.%26aulast%3DPeck%26aufirst%3DC.%2BC.%26aulast%3DBlaschke%26aufirst%3DT.%2BF.%26atitle%3DOptimizing%2520the%2520science%2520of%2520drug%2520development%253A%2520Opportunities%2520for%2520better%2520candidate%2520selection%2520and%2520accelerated%2520evaluation%2520in%2520humans%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2000%26volume%3D40%26spage%3D803%26epage%3D814%26doi%3D10.1177%2F00912700022009530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span> <span> </span><span class="NLM_article-title">Finding the sweet spot: The role of nature and nurture in medicinal chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1038/nrd3701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2Fnrd3701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=22543468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1GqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=355-65&author=M.+M.+Hannauthor=G.+M.+Keseru&title=Finding+the+sweet+spot%3A+The+role+of+nature+and+nurture+in+medicinal+chemistry&doi=10.1038%2Fnrd3701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Finding the sweet spot: the role of nature and nurture in medicinal chemistry</span></div><div class="casAuthors">Hann, Michael M.; Keserue, Gyoergy M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">355-365</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Given its position at the heart of small-mol. drug discovery, medicinal chem. has an important role in tackling the well-known productivity challenges in pharmaceutical research and development.  In recent years, extensive analyses of successful and failed discovery compds. and drug candidates have improved our understanding of the role of physicochem. properties in drug attrition.  Based on the clarified challenges in finding the 'sweet spot' in medicinal chem. programs, we suggest that this goal can be achieved through a combination of first identifying chem. starting points with appropriate 'nature' and then rigorously 'nurturing' them during lead optimization.  Here, we discuss scientific, strategic, organizational and cultural considerations for medicinal chem. practices, with the aim of promoting more effective use of what is already known, as well as a wider appreciation of the risks of pursuing suboptimal compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrURciGjB2A3LVg90H21EOLACvtfcHk0li7dPaqjNNHAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1GqsLY%253D&md5=90170e3f4e69e52bfa38667df380516a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrd3701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3701%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DFinding%2520the%2520sweet%2520spot%253A%2520The%2520role%2520of%2520nature%2520and%2520nurture%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D355%26epage%3D65%26doi%3D10.1038%2Fnrd3701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ku, M. S.</span></span> <span> </span><span class="NLM_article-title">Use of the biopharmaceutical classification system in early drug development</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1208/s12248-008-9020-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1208%2Fs12248-008-9020-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=18446521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWrsLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=208-212&author=M.+S.+Ku&title=Use+of+the+biopharmaceutical+classification+system+in+early+drug+development&doi=10.1208%2Fs12248-008-9020-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Use of the biopharmaceutical classification system in early drug development</span></div><div class="casAuthors">Ku, M. Sherry</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">208-212</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is not only a useful tool for obtaining waivers for in-vivo bioequivalence studies but also for decision making in the discovery and early development of new drugs.  Measurement of soly. and permeability in the discovery/development settings is described.  These data can be utilized for the preliminary BCS classification of pipeline compds.  A decision tree is described in the prioritization of salt and polymorph screening studies prior to in vivo studies in animals.  For BCS class 1 and 3 compds., polymorphism is less likely to impact on bioavailability.  The polymorph screening study may be postponed after animal studies.  The BCS classification can also be used in the design of animal and human formulations.  A BCS-based animal formulation development decision tree is presented.  A compd. is triaged based on a series of decision points into one of the five formulation strategies.  Human formulation has different requirements than animal formulation.  A comparison between animal and human formulation strategies is presented.  In conclusion, for non-BCS 1 compds., the right-first-time polymorph and formulation selection ensures consistent pharmacokinetic performance and avoids bridging BA/BE studies.  It is in line with FDA's initiative to reduce R&D cycle time through quality by design for pharmaceutical products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbXmd3ljTTG7Vg90H21EOLACvtfcHk0li7dPaqjNNHAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWrsLvJ&md5=36c90b50728cebbc1a178a634c952da3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1208%2Fs12248-008-9020-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-008-9020-0%26sid%3Dliteratum%253Aachs%26aulast%3DKu%26aufirst%3DM.%2BS.%26atitle%3DUse%2520of%2520the%2520biopharmaceutical%2520classification%2520system%2520in%2520early%2520drug%2520development%26jtitle%3DAAPS%2520J.%26date%3D2008%26volume%3D10%26spage%3D208%26epage%3D212%26doi%3D10.1208%2Fs12248-008-9020-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span> <span> </span><span class="NLM_article-title">Lead- and drug-like compounds: The rule-of-five revolution</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2004.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.ddtec.2004.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24981612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=337-41&author=C.+A.+Lipinski&title=Lead-+and+drug-like+compounds%3A+The+rule-of-five+revolution&doi=10.1016%2Fj.ddtec.2004.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Lead- and drug-like compounds: the rule-of-five revolution</span></div><div class="casAuthors">Lipinski, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-341</span>CODEN:
                <span class="NLM_cas:coden">DDTTB5</span>;
        ISSN:<span class="NLM_cas:issn">1740-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Citations in CAS SciFinder to the rule-of-five (RO5) publication will exceed 1000 by year-end 2004.  Trends in the RO5 literature explosion that can be discerned are the further definitions of drug-like.  This topic is explored in terms of drug-like physicochem. features, drug-like structural features, a comparison of drug-like and non-drug-like in drug discovery and a discussion of how drug-like features relate to clin. success.  Physicochem. features of CNS drugs and features related to CNS blood-brain transporter affinity are briefly reviewed.  Recent literature on features of non-oral drugs is reviewed and how features of lead-like compds. differ from those of drug-like compds. is discussed.  Most recently, partly driven by NIH roadmap initiatives, considerations have arisen as to what tool-like means in the search for chem. tools to probe biol. space.  All these topics frame the scope of this short review/perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnjiyP3CY7lLVg90H21EOLACvtfcHk0li7dPaqjNNHAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D&md5=952c29b47003b884116d790ae9e4721f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2004.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2004.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26atitle%3DLead-%2520and%2520drug-like%2520compounds%253A%2520The%2520rule-of-five%2520revolution%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2004%26volume%3D1%26spage%3D337%26epage%3D41%26doi%3D10.1016%2Fj.ddtec.2004.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, B.</span></span> <span> </span><span class="NLM_article-title">Drug discovery beyond the ‘rule-of-five’</span>. <i>Curr. Opin. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">478</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1016/j.copbio.2007.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.copbio.2007.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=18035532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1cXislOkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=478-488&author=M.-Q.+Zhangauthor=B.+Wilkinson&title=Drug+discovery+beyond+the+%E2%80%98rule-of-five%E2%80%99&doi=10.1016%2Fj.copbio.2007.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery beyond the 'rule-of-five'</span></div><div class="casAuthors">Zhang, Ming-Qiang; Wilkinson, Barrie</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">478-488</span>CODEN:
                <span class="NLM_cas:coden">CUOBE3</span>;
        ISSN:<span class="NLM_cas:issn">0958-1669</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Although a very useful guideline for orally bioavailable small-mol. drug design, the 'rule-of-five' (also known as 'Lipinski's rule of drug-likeness') has to some extent been overemphasized.  Firstly, only 51% of all FDA-approved small-mol. drugs are both used orally and comply with the 'rule-of-five'.  This does not even include the increasing no. of biologicals of which several have reached blockbuster' status.  Secondly, it does not cover natural product and semisynthetic natural product drugs, which constitute over one-third of all marketed small-mol. drugs.  A more balanced and programmatic approach to drug discovery should be more productive than to rely on an overemphasis of 'rule-of-five' compliance.  Rather it should consider proactively the development of parenteral drugs in parallel to oral drugs and to consider the development of therapeutic antibodies in parallel to small-mol. drugs.  These are particularly relevant for efforts against 'first-in-class' and/or particularly challenging targets such as proteases and those involving protein-protein interactions.  In addn., more effort should be invested in natural product research.  Emerging novel technologies such as synthetic biol. (genetic engineering of living organisms to produce small-mol. therapeutics) may address several challenging issues of natural product-based drug discovery including synthetic feasibility and ligand efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGollnOuY9kGrbVg90H21EOLACvtfcHk0li7dPaqjNNHAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXislOkug%253D%253D&md5=4121024557295c4f241255e43b43ea44</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.copbio.2007.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.copbio.2007.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.-Q.%26aulast%3DWilkinson%26aufirst%3DB.%26atitle%3DDrug%2520discovery%2520beyond%2520the%2520%25E2%2580%2598rule-of-five%25E2%2580%2599%26jtitle%3DCurr.%2520Opin.%2520Biotechnol.%26date%3D2007%26volume%3D18%26spage%3D478%26epage%3D488%26doi%3D10.1016%2Fj.copbio.2007.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aschmann, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatibovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, S.</span></span> <span> </span><span class="NLM_article-title">When barriers ignore the “rule-of-five</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2016.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.addr.2016.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26877103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XislSktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2016&pages=62-74&author=S.+D.+Kr%C3%A4merauthor=H.+E.+Aschmannauthor=M.+Hatibovicauthor=K.+F.+Hermannauthor=C.+S.+Neuhausauthor=C.+Brunnerauthor=S.+Belli&title=When+barriers+ignore+the+%E2%80%9Crule-of-five&doi=10.1016%2Fj.addr.2016.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">When barriers ignore the "rule-of-five"</span></div><div class="casAuthors">Kramer, Stefanie D.; Aschmann, Helene E.; Hatibovic, Maja; Hermann, Katharina F.; Neuhaus, Claudia S.; Brunner, Cyrill; Belli, Sara</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">62-74</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Why are a few drugs with properties beyond the rule of 5 (bRo5) absorbed across the intestinal mucosa while most other bRo5 compds. are not.  Are such exceptional bRo5 compds. exclusively taken up by carrier-mediated transport or are they able to permeate the lipid bilayer (passive lipoidal diffusion).  Our exptl. data with liposomes indicate that tetracycline, which violates one rule of the Ro5, and rifampicin, violating three of the rules, significantly permeate a phospholipid bilayer with kinetics similar to labetalol and metoprolol, resp.  Published data from exptl. work and mol. dynamics simulations suggest that the formation of intramol. H-bonds and the possibility to adopt an elongated shape besides the presence of a significant fraction of net neutral species facilitate lipid bilayer permeation.  As an alternative to lipid bilayer permeation, carrier proteins can be targeted to improve absorption, with the potential drawbacks of drug-drug interactions and non-linear pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVVuXZ5H2ClrVg90H21EOLACvtfcHk0ljCWfgL5CvlTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XislSktLg%253D&md5=50ea288eae047ae4eb6e12e690b01692</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25A4mer%26aufirst%3DS.%2BD.%26aulast%3DAschmann%26aufirst%3DH.%2BE.%26aulast%3DHatibovic%26aufirst%3DM.%26aulast%3DHermann%26aufirst%3DK.%2BF.%26aulast%3DNeuhaus%26aufirst%3DC.%2BS.%26aulast%3DBrunner%26aufirst%3DC.%26aulast%3DBelli%26aufirst%3DS.%26atitle%3DWhen%2520barriers%2520ignore%2520the%2520%25E2%2580%259Crule-of-five%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D101%26spage%3D62%26epage%3D74%26doi%3D10.1016%2Fj.addr.2016.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
la Torre, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albericio, F.</span></span> <span> </span><span class="NLM_article-title">The pharmaceutical industry in 2018. An analysis of fda drug approvals from the perspective of molecules</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">809</span>, <span class="refDoi"> DOI: 10.3390/molecules24040809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3390%2Fmolecules24040809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30813407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlCrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=809&author=B.+G.+de%0Ala+Torreauthor=F.+Albericio&title=The+pharmaceutical+industry+in+2018.+An+analysis+of+fda+drug+approvals+from+the+perspective+of+molecules&doi=10.3390%2Fmolecules24040809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmaceutical industry in 2018. an analysis of FDA drug approvals from the perspective of molecules</span></div><div class="casAuthors">de la Torre, Beatriz G.; Albericio, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">809/1-809/12</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The Food and Drug Administration approved 59 new drugs (42 New Chem. Entities and 17 Biologics) during 2018.  This no. breaks the previous record of 53 approved by the same organization in 1996.  The 17 new biologics approved in 2018 also represent an important milestone for this kind of drug and they clearly exceed the 12 approved in 2015 and 2017.  Herein, the 59 new drugs of the class of 2018 are analyzed from a strictly chem. perspective.  The classification has been carried out on the basis of the chem. structure and includes the following: Biologics (antibodies and enzymes); TIDES (peptides and oligonucleotides) and natural products; drug combinations; and small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpl9Nat-uSwbVg90H21EOLACvtfcHk0ljCWfgL5CvlTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlCrtLY%253D&md5=e61d944d90a38fead8920eef07be8246</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24040809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24040809%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2Bla%2BTorre%26aufirst%3DB.%2BG.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DThe%2520pharmaceutical%2520industry%2520in%25202018.%2520An%2520analysis%2520of%2520fda%2520drug%2520approvals%2520from%2520the%2520perspective%2520of%2520molecules%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D809%26doi%3D10.3390%2Fmolecules24040809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griesenauer, R. H.</span></span> <span> </span><span class="NLM_article-title">2018 in review: Fda approvals of new molecular entities</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1710</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2019.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.drudis.2019.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31158510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3M3islWkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1710-1714&author=M.+S.+Kinchauthor=R.+H.+Griesenauer&title=2018+in+review%3A+Fda+approvals+of+new+molecular+entities&doi=10.1016%2Fj.drudis.2019.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">2018 in review: FDA approvals of new molecular entities</span></div><div class="casAuthors">Kinch Michael S; Griesenauer Rebekah H</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1710-1714</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">2018 was a remarkable year, both in terms of the number of new molecular entities (NMEs) approved and the organizations developing them.  In total, 59 NMEs received a nod from the US Food and Drug Administration (FDA), most of which were approved using a priority or breakthrough designation.  Orphan drugs accounted for more than half of new approvals, only the second time in history that level has been achieved.  Moreover, the net number of organizations that received an FDA approval and remain active in new drug research surged in 2018, reflecting both an increase in new organizations and lower levels of industry consolidation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiF58qvHS5Zhcr74wzj5o5fW6udTcc2eZRDTfHkKHpE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3islWkug%253D%253D&md5=4d8695208eff16156df8023f54817cca</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2019.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2019.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DGriesenauer%26aufirst%3DR.%2BH.%26atitle%3D2018%2520in%2520review%253A%2520Fda%2520approvals%2520of%2520new%2520molecular%2520entities%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2019%26volume%3D24%26spage%3D1710%26epage%3D1714%26doi%3D10.1016%2Fj.drudis.2019.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umlauf, S.</span></span> <span> </span><span class="NLM_article-title">Trends in pharmaceutical targeting of clinical indications: 1930–2013</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1682</span>– <span class="NLM_lpage">1685</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.drudis.2014.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24881779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cjns1yhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1682-1685&author=M.+S.+Kinchauthor=J.+Merkelauthor=S.+Umlauf&title=Trends+in+pharmaceutical+targeting+of+clinical+indications%3A+1930%E2%80%932013&doi=10.1016%2Fj.drudis.2014.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in pharmaceutical targeting of clinical indications: 1930-2013</span></div><div class="casAuthors">Kinch Michael S; Merkel Janie; Umlauf Sheila</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1682-1685</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">An analysis of FDA-approved new molecular entities (NMEs) reveals trends in therapeutic applications.  Four groupings (infectious diseases, cardiovascular diseases, autoimmune/inflammatory diseases and cancer) capture more than 60% of NMEs.  Infectious diseases are the most targeted indications.  Near the turn of the new millennium, the rate of new approvals for infectious diseases decreased.  The absolute and relative number of NMEs targeting psychiatric, neurological and pain/itch indications also declined.  By contrast, NMEs targeting cancer have risen in the past two decades as have NMEs targeting orphan indications.  These results suggest the drug development community has largely been responsive to public health and market needs.  However, finite resources might indicate emphasis on some unmet needs could come at the cost of others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQiuwfyx4RSHpp6t8nS6Nc3fW6udTcc2eYDxm4CAsVQR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjns1yhsA%253D%253D&md5=af70b7b3d4945e22574e6a3310ff5199</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DMerkel%26aufirst%3DJ.%26aulast%3DUmlauf%26aufirst%3DS.%26atitle%3DTrends%2520in%2520pharmaceutical%2520targeting%2520of%2520clinical%2520indications%253A%25201930%25E2%2580%25932013%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1682%26epage%3D1685%26doi%3D10.1016%2Fj.drudis.2014.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uttley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Indave, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokuhetty, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cree, I.</span></span> <span> </span><span class="NLM_article-title">Invited commentary—who classification of tumours: How should tumors be classified? Expert consensus, systematic reviews or both?</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">3516</span>– <span class="NLM_lpage">3521</span>, <span class="refDoi"> DOI: 10.1002/ijc.32975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fijc.32975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=32170735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtFWjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2020&pages=3516-3521&author=L.+Uttleyauthor=B.+I.+Indaveauthor=C.+Hydeauthor=V.+Whiteauthor=D.+Lokuhettyauthor=I.+Cree&title=Invited+commentary%E2%80%94who+classification+of+tumours%3A+How+should+tumors+be+classified%3F+Expert+consensus%2C+systematic+reviews+or+both%3F&doi=10.1002%2Fijc.32975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Invited commentary-WHO Classification of Tumours: How should tumors be classified? Expert consensus, systematic reviews or both?</span></div><div class="casAuthors">Uttley, Lesley; Indave, Blanca Iciar; Hyde, Chris; White, Valerie; Lokuhetty, Dilani; Cree, Ian</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3516-3521</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj9uc9VbJ9jrVg90H21EOLACvtfcHk0lhrwGXRxftizA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtFWjsrk%253D&md5=033515255591cf015adf0fa7478e0999</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fijc.32975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.32975%26sid%3Dliteratum%253Aachs%26aulast%3DUttley%26aufirst%3DL.%26aulast%3DIndave%26aufirst%3DB.%2BI.%26aulast%3DHyde%26aufirst%3DC.%26aulast%3DWhite%26aufirst%3DV.%26aulast%3DLokuhetty%26aufirst%3DD.%26aulast%3DCree%26aufirst%3DI.%26atitle%3DInvited%2520commentary%25E2%2580%2594who%2520classification%2520of%2520tumours%253A%2520How%2520should%2520tumors%2520be%2520classified%253F%2520Expert%2520consensus%252C%2520systematic%2520reviews%2520or%2520both%253F%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2020%26volume%3D146%26spage%3D3516%26epage%3D3521%26doi%3D10.1002%2Fijc.32975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rhoads, C. P.</span></span> <span> </span><span class="NLM_article-title">Nitrogen mustards in the treatment of neoplastic disease; official statement</span>. <i>J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">1946</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">656</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1001/jama.1946.02870250010003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1001%2Fjama.1946.02870250010003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=20984885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADyaH28%252Fgt12qsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=1946&pages=656-8&author=C.+P.+Rhoads&title=Nitrogen+mustards+in+the+treatment+of+neoplastic+disease%3B+official+statement&doi=10.1001%2Fjama.1946.02870250010003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrogen mustards in the treatment of neoplastic disease; official statement</span></div><div class="casAuthors">RHOADS C P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">1946</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">656-8</span>
        ISSN:<span class="NLM_cas:issn">0002-9955</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRY1FrpuF4Me_Q9URG6Dx8fW6udTcc2eYDxm4CAsVQR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaH28%252Fgt12qsg%253D%253D&md5=08cf6c1698790fadab3b26e2d9df565d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1001%2Fjama.1946.02870250010003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.1946.02870250010003%26sid%3Dliteratum%253Aachs%26aulast%3DRhoads%26aufirst%3DC.%2BP.%26atitle%3DNitrogen%2520mustards%2520in%2520the%2520treatment%2520of%2520neoplastic%2520disease%253B%2520official%2520statement%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D1946%26volume%3D131%26spage%3D656%26epage%3D8%26doi%3D10.1001%2Fjama.1946.02870250010003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chabner, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. G.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Timeline: Chemotherapy and the war on cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1038/nrc1529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2Fnrc1529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=15630416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVek" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=65-72&author=B.+A.+Chabnerauthor=T.+G.+Roberts&title=Timeline%3A+Chemotherapy+and+the+war+on+cancer&doi=10.1038%2Fnrc1529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy and the war on cancer</span></div><div class="casAuthors">Chabner, Bruce A.; Roberts, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-72</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The era of chemotherapy began in the 1940s with the first uses of nitrogen mustards and antifolate drugs.  Cancer drug development since then has transformed from a low-budget, government-supported research effort to a high-stakes, multi-billion dollar industry.  The targeted-therapy revolution has arrived, but the principles and limitations of chemotherapy discovered by the early researchers still apply.  This article chronicles the history of modern chemotherapy and identifies remaining challenges for the next generation of researchers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrszgbuDuTBobVg90H21EOLACvtfcHk0lhrwGXRxftizA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVek&md5=d5c8b3dba59b9d6dcca473552525fa14</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrc1529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1529%26sid%3Dliteratum%253Aachs%26aulast%3DChabner%26aufirst%3DB.%2BA.%26aulast%3DRoberts%26aufirst%3DT.%2BG.%26atitle%3DTimeline%253A%2520Chemotherapy%2520and%2520the%2520war%2520on%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D65%26epage%3D72%26doi%3D10.1038%2Fnrc1529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvat, T. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L. A.</span></span> <span> </span><span class="NLM_article-title">Venetoclax: A first-in-class oral bcl-2 inhibitor for the management of lymphoid malignancies</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1177/1060028016685803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1177%2F1060028016685803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28056525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltVOrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2017&pages=410-416&author=A.+C.+Kingauthor=T.+J.+Petersonauthor=T.+Z.+Horvatauthor=M.+Rodriguezauthor=L.+A.+Tang&title=Venetoclax%3A+A+first-in-class+oral+bcl-2+inhibitor+for+the+management+of+lymphoid+malignancies&doi=10.1177%2F1060028016685803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies</span></div><div class="casAuthors">King, Amber C.; Peterson, Tim J.; Horvat, Troy Z.; Rodriguez, Mabel; Tang, Laura A.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">410-416</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1542-6270</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Objective: To review the pharmacol., efficacy, and safety of venetoclax for treatment of lymphoid malignancies.  Data Sources: A literature search was performed of PubMed and MEDLINE databases (2005 to Sept. 2016), abstrs. from the American Society of Hematol. and the American Society of Clin. Oncol., and ongoing studies from clinicaltrials.gov.  Searches were performed utilizing the following key terms: venetoclax, ABT-199, GDC-199, obatoclax, GX15-070, BCL-2 inhibitor, navitoclax, ABT-263, and Venclexta.  Study Selection/Data Extn.: Studies of pharmacol., pharmacokinetics, pharmacodynamics, clin. efficacy, and safety of venetoclax in lymphoid malignancies were identified.  Data Synthesis: Recently, treatment of B-cell lymphoproliferative disorders has shifted from conventional cytotoxic chemotherapy to novel small-mol. inhibitors.  The advent of recently Food and Drug Administration-approved oral agents ibrutinib and idelalisib has shifted the paradigm of chronic lymphocytic leukemia (CLL) treatment; however, complete remission is uncommon, and the outcome for patients progressing on these treatments remains poor.  Attention has been focused on a novel target, the B-cell lymphoma-2 protein (BCL-2), which serves an essential role in regulation of apoptosis.  Venetoclax has demonstrated efficacy in multiple subtypes of lymphoid malignancies, including patients with relapsed/refractory CLL harboring deletion 17p, with an overall response rate of nearly 80%.  Venetoclax is generally well tolerated, with the significant adverse effect being tumor lysis syndrome, for which there are formal management recommendations.  Conclusion: Venetoclax has demonstrated promising results in relapsed/refractory lymphoid malignancies, with an acceptable adverse effect profile.  As the role of BCL-2 inhibition in various malignancies becomes further elucidated, venetoclax may offer benefit to a myriad other patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1YxzHJT0xvbVg90H21EOLACvtfcHk0ljCgjPsyAeRyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltVOrug%253D%253D&md5=e8ad4539c2e09fda834e280f6545b923</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1177%2F1060028016685803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028016685803%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DA.%2BC.%26aulast%3DPeterson%26aufirst%3DT.%2BJ.%26aulast%3DHorvat%26aufirst%3DT.%2BZ.%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DL.%2BA.%26atitle%3DVenetoclax%253A%2520A%2520first-in-class%2520oral%2520bcl-2%2520inhibitor%2520for%2520the%2520management%2520of%2520lymphoid%2520malignancies%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2017%26volume%3D51%26spage%3D410%26epage%3D416%26doi%3D10.1177%2F1060028016685803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milling, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, D. J.</span></span> <span> </span><span class="NLM_article-title">Delivering safer immunotherapies for cancer</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2017.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.addr.2017.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28545888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVantLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=79-101&author=L.+Millingauthor=Y.+Zhangauthor=D.+J.+Irvine&title=Delivering+safer+immunotherapies+for+cancer&doi=10.1016%2Fj.addr.2017.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Delivering safer immunotherapies for cancer</span></div><div class="casAuthors">Milling, Lauren; Zhang, Yuan; Irvine, Darrell J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">79-101</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cancer immunotherapy is now a powerful clin. reality, with a steady progression of new drug approvals and a massive pipeline of addnl. treatments in clin. and preclin. development.  However, modulation of the immune system can be a double-edged sword: Drugs that activate immune effectors are prone to serious non-specific systemic inflammation and autoimmune side effects.  Drug delivery technologies have an important role to play in harnessing the power of immune therapeutics while avoiding on-target/off-tumor toxicities.  Here we review mechanisms of toxicity for clin.-relevant immunotherapeutics, and discuss approaches based in drug delivery technol. to enhance the safety and potency of these treatments.  These include strategies to merge drug delivery with adoptive cellular therapies, targeting immunotherapies to tumors or select immune cells, and localizing therapeutics intratumorally.  Rational design employing lessons learned from the drug delivery and nanomedicine fields has the potential to facilitate immunotherapy reaching its full potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDwnWn29KSE7Vg90H21EOLACvtfcHk0ljCgjPsyAeRyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVantLnO&md5=cce2ffe51f1cfb8b88671b1458f35b01</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2017.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2017.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DMilling%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DIrvine%26aufirst%3DD.%2BJ.%26atitle%3DDelivering%2520safer%2520immunotherapies%2520for%2520cancer%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2017%26volume%3D114%26spage%3D79%26epage%3D101%26doi%3D10.1016%2Fj.addr.2017.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighton, J. K.</span></span> <span> </span><span class="NLM_article-title">An FDA oncology analysis of antibody-drug conjugates</span>. <i>Regul. Toxicol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/j.yrtph.2015.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.yrtph.2015.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25661711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisF2rsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=444-52&author=H.+Saberauthor=J.+K.+Leighton&title=An+FDA+oncology+analysis+of+antibody-drug+conjugates&doi=10.1016%2Fj.yrtph.2015.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">An FDA oncology analysis of antibody-drug conjugates</span></div><div class="casAuthors">Saber, Haleh; Leighton, John K.</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Toxicology and Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">444-452</span>CODEN:
                <span class="NLM_cas:coden">RTOPDW</span>;
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are complex mols. composed of monoclonal antibodies conjugated to potent cytotoxic agents through chem. linkers.  Because of this complexity, sponsors have used different approaches for the design of nonclin. studies to support the safety evaluation of ADCs and first-in-human (FIH) dose selection.  We analyzed this data with the goal of describing the relationship between nonclin. study results and Phase 1 study outcomes.  We summarized the following data from investigational new drug applications (INDs) for ADCs: plasma stability, animal study designs and toxicities, and algorithms used for FIH dose selection.  Our review found that selecting a FIH dose that is 1/6th the highest non-severely toxic dose (HNSTD) in cynomolgus monkeys or 1/10th the STD10 in rodents scaled according to body surface area (BSA) generally resulted in the acceptable balance of safety and efficient dose-escalation in a Phase 1 trial.  Other approaches may also be acceptable, e.g. 1/10th the HNSTD in monkeys using BSA or 1/10th the NOAEL in monkeys or rodents using body wt. for scaling.  While the animal data for the vc-MMAE platform yielded variable range of HNSTDs in cynomolgus monkeys, MTDs were in a narrow range in patients, suggesting that for ADCs sharing the same small mol. drug, linker and drug:antibody ratio, prior clin. data can inform the design of a Phase 1 clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouNKxNbn4b6rVg90H21EOLACvtfcHk0ljCgjPsyAeRyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisF2rsrY%253D&md5=513d5d669e869260ceb67a4419f5b208</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.yrtph.2015.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yrtph.2015.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DLeighton%26aufirst%3DJ.%2BK.%26atitle%3DAn%2520FDA%2520oncology%2520analysis%2520of%2520antibody-drug%2520conjugates%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2015%26volume%3D71%26spage%3D444%26epage%3D52%26doi%3D10.1016%2Fj.yrtph.2015.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates: An emerging concept in cancer therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3796</span>– <span class="NLM_lpage">3827</span>, <span class="refDoi"> DOI: 10.1002/anie.201307628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fanie.201307628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=3796-3827&author=R.+V.+Chariauthor=M.+L.+Millerauthor=W.+C.+Widdison&title=Antibody-drug+conjugates%3A+An+emerging+concept+in+cancer+therapy&doi=10.1002%2Fanie.201307628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy</span></div><div class="casAuthors">Chari, Ravi V. J.; Miller, Michael L.; Widdison, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3796-3827</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Traditional cancer chemotherapy is often accompanied by systemic toxicity to the patient.  Monoclonal antibodies against antigens on cancer cells offer an alternative tumor-selective treatment approach.  However, most monoclonal antibodies are not sufficiently potent to be therapeutically active on their own.  Antibody-drug conjugates (ADCs) use antibodies to deliver a potent cytotoxic compd. selectively to tumor cells, thus improving the therapeutic index of chemotherapeutic agents.  The recent approval of two ADCs, brentuximab vedotin and ado-trastuzumab emtansine, for cancer treatment has spurred tremendous research interest in this field.  This Review touches upon the early efforts in the field, and describes how the lessons learned from the first-generation ADCs have led to improvements in every aspect of this technol., i.e., the antibody, the cytotoxic compd., and the linker connecting them, leading to the current successes.  The design of ADCs currently in clin. development, and results from mechanistic studies and preclin. and clin. evaluation are discussed.  Emerging technologies that seek to further advance this exciting area of research are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4T2rhmji6DLVg90H21EOLACvtfcHk0ljCgjPsyAeRyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D&md5=fbfb2f843f516654ea7c0eb98949604c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307628%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DAntibody-drug%2520conjugates%253A%2520An%2520emerging%2520concept%2520in%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D3796%26epage%3D3827%26doi%3D10.1002%2Fanie.201307628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alley, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okeley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates: Targeted drug delivery for cancer</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2010.06.170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.cbpa.2010.06.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=20643572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=529-537&author=S.+C.+Alleyauthor=N.+M.+Okeleyauthor=P.+D.+Senter&title=Antibody-drug+conjugates%3A+Targeted+drug+delivery+for+cancer&doi=10.1016%2Fj.cbpa.2010.06.170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates: Targeted drug delivery for cancer</span></div><div class="casAuthors">Alley, Stephen C.; Okeley, Nicole M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-537</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The antibody-drug conjugate field has made significant progress recently owing to careful optimization of several parameters, including mAb specificity, drug potency, linker technol., and the stoichiometry and placement of conjugated drugs.  The underlying reason for this was obtained in pre-clin. biodistribution and pharmacokinetics studies showing that targeted delivery leads to high intratumoral free drug concns., while non-target tissues are largely spared from chemotherapeutic exposure.  Recent developments in the field have led to an increase in the no. of ADCs being tested clin., with 3 in late stage clin. trials: Brentuximab vedotin (also referred to as SGN-35) for Hodgkin lymphoma; Trastuzumab-DM1 for breast cancer; and Inotuzumab ozogamicin for non-Hodgkin lymphoma.  This review highlights the recent pre-clin. and clin. advances that have been made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-9ugy8pi8C7Vg90H21EOLACvtfcHk0lg34VvQP1If7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtrY%253D&md5=ace266066ea07d49d0e0b4338b48eeb3</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.170%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DAntibody-drug%2520conjugates%253A%2520Targeted%2520drug%2520delivery%2520for%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D529%26epage%3D537%26doi%3D10.1016%2Fj.cbpa.2010.06.170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skvortsova, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span> <span> </span><span class="NLM_article-title">Editorial: Recent trends in anticancer drug development: Challenges and opportunities</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4727</span>– <span class="NLM_lpage">4728</span>, <span class="refDoi"> DOI: 10.2174/092986732442180111141255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2174%2F092986732442180111141255" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=4727-4728&author=I.+I.+Skvortsovaauthor=V.+Kumar&title=Editorial%3A+Recent+trends+in+anticancer+drug+development%3A+Challenges+and+opportunities&doi=10.2174%2F092986732442180111141255"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2174%2F092986732442180111141255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986732442180111141255%26sid%3Dliteratum%253Aachs%26aulast%3DSkvortsova%26aufirst%3DI.%2BI.%26aulast%3DKumar%26aufirst%3DV.%26atitle%3DEditorial%253A%2520Recent%2520trends%2520in%2520anticancer%2520drug%2520development%253A%2520Challenges%2520and%2520opportunities%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2018%26volume%3D24%26spage%3D4727%26epage%3D4728%26doi%3D10.2174%2F092986732442180111141255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertram, J. S.</span></span> <span> </span><span class="NLM_article-title">The molecular biology of cancer</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/S0098-2997(00)00007-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS0098-2997%2800%2900007-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=11173079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BD3M3lvVamtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=167-223&author=J.+S.+Bertram&title=The+molecular+biology+of+cancer&doi=10.1016%2FS0098-2997%2800%2900007-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular biology of cancer</span></div><div class="casAuthors">Bertram J S</div><div class="citationInfo"><span class="NLM_cas:title">Molecular aspects of medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">167-223</span>
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    </div><div class="casAbstract">The process by which normal cells become progressively transformed to malignancy is now known to require the sequential acquisition of mutations which arise as a consequence of damage to the genome.  This damage can be the result of endogenous processes such as errors in replication of DNA, the intrinsic chemical instability of certain DNA bases or from attack by free radicals generated during metabolism.  DNA damage can also result from interactions with exogenous agents such as ionizing radiation, UV radiation and chemical carcinogens.  Cells have evolved means to repair such damage, but for various reasons errors occur and permanent changes in the genome, mutations, are introduced.  Some inactivating mutations occur in genes responsible for maintaining genomic integrity facilitating the acquisition of additional mutations.  This review seeks first to identify sources of mutational damage so as to identify the basic causes of human cancer.  Through an understanding of cause, prevention may be possible.  The evolution of the normal cell to a malignant one involves processes by which genes involved in normal homeostatic mechanisms that control proliferation and cell death suffer mutational damage which results in the activation of genes stimulating proliferation or protection against cell death, the oncogenes, and the inactivation of genes which would normally inhibit proliferation, the tumor suppressor genes.  Finally, having overcome normal controls on cell birth and cell death, an aspiring cancer cell faces two new challenges: it must overcome replicative senescence and become immortal and it must obtain adequate supplies of nutrients and oxygen to maintain this high rate of proliferation.  This review examines the process of the sequential acquisition of mutations from the prospective of Darwinian evolution.  Here, the fittest cell is one that survives to form a new population of genetically distinct cells, the tumor.  This review does not attempt to be comprehensive but identifies key genes directly involved in carcinogenesis and demonstrates how mutations in these genes allow cells to circumvent cellular controls.  This detailed understanding of the process of carcinogenesis at the molecular level has only been possible because of the advent of modern molecular biology.  This new discipline, by precisely identifying the molecular basis of the differences between normal and malignant cells, has created novel opportunities and provided the means to specifically target these modified genes.  Whenever possible this review highlights these opportunities and the attempts being made to generate novel, molecular based therapies against cancer.  Successful use of these new therapies will rely upon a detailed knowledge of the genetic defects in individual tumors.  The review concludes with a discussion of how the use of high throughput molecular arrays will allow the molecular pathologist/therapist to identify these defects and direct specific therapies to specific mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuS4iTaGZIQQHqQV89nF-2fW6udTcc2ea8mPahgE2OTLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3lvVamtA%253D%253D&md5=1fef8a6d810061992b8509353f9e0293</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0098-2997%2800%2900007-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0098-2997%252800%252900007-8%26sid%3Dliteratum%253Aachs%26aulast%3DBertram%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520molecular%2520biology%2520of%2520cancer%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2000%26volume%3D21%26spage%3D167%26epage%3D223%26doi%3D10.1016%2FS0098-2997%2800%2900007-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeBerardinis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. B.</span></span> <span> </span><span class="NLM_article-title">The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2007.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.cmet.2007.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=18177721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=11-20&author=R.+J.+DeBerardinisauthor=J.+J.+Lumauthor=G.+Hatzivassiliouauthor=C.+B.+Thompson&title=The+biology+of+cancer%3A+Metabolic+reprogramming+fuels+cell+growth+and+proliferation&doi=10.1016%2Fj.cmet.2007.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The biology of cancer: metabolic reprogramming fuels cell growth and proliferation</span></div><div class="casAuthors">DeBerardinis, Ralph J.; Lum, Julian J.; Hatzivassiliou, Georgia; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-20</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Cell proliferation requires nutrients, energy and biosynthetic activity to duplicate all macromol. components during each passage through the cell cycle.  It is therefore not surprising that metabolic activities in proliferating cells are fundamentally different from those of nonproliferating cells.  This review examines the idea that several core fluxes, including aerobic glycolysis, de novo lipid biosynthesis, and glutamine-dependent anaplerosis, form a stereotyped platform supporting proliferation of diverse cell types.  We also consider regulation of theses fluxes by cellular mediators of signaling and gene expression, including PI3K/Akt/mTOR system, HIF-1, and Myc, during physiol. cell proliferation and tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6L6_Q7sR9HLVg90H21EOLACvtfcHk0lg34VvQP1If7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFSnsg%253D%253D&md5=59f193a636a840cde3044da9e08f62e7</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2007.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2007.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DDeBerardinis%26aufirst%3DR.%2BJ.%26aulast%3DLum%26aufirst%3DJ.%2BJ.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DThe%2520biology%2520of%2520cancer%253A%2520Metabolic%2520reprogramming%2520fuels%2520cell%2520growth%2520and%2520proliferation%26jtitle%3DCell%2520Metab.%26date%3D2008%26volume%3D7%26spage%3D11%26epage%3D20%26doi%3D10.1016%2Fj.cmet.2007.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craighead, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Economides, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, J.</span></span> <span> </span><span class="NLM_article-title">Clinical development success rates for investigational drugs</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1038/nbt.2786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2Fnbt.2786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24406927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=40-51&author=M.+Hayauthor=D.+W.+Thomasauthor=J.+L.+Craigheadauthor=C.+Economidesauthor=J.+Rosenthal&title=Clinical+development+success+rates+for+investigational+drugs&doi=10.1038%2Fnbt.2786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development success rates for investigational drugs</span></div><div class="casAuthors">Hay, Michael; Thomas, David W.; Craighead, John L.; Economides, Celia; Rosenthal, Jesse</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-51</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The most comprehensive survey of clin. success rates across the drug industry to date shows productivity may be even lower than previous ests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdqyRgsoFYDbVg90H21EOLACvtfcHk0liuiK_40OG0ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFyjsA%253D%253D&md5=87a63ec8d8bb213b3d42519395725038</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2786%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DD.%2BW.%26aulast%3DCraighead%26aufirst%3DJ.%2BL.%26aulast%3DEconomides%26aufirst%3DC.%26aulast%3DRosenthal%26aufirst%3DJ.%26atitle%3DClinical%2520development%2520success%2520rates%2520for%2520investigational%2520drugs%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26spage%3D40%26epage%3D51%26doi%3D10.1038%2Fnbt.2786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DiMasi, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, H. G.</span></span> <span> </span><span class="NLM_article-title">Economics of new oncology drug development</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1200/JCO.2006.09.0803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1200%2FJCO.2006.09.0803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=17210942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FhsVCisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=209-16&author=J.+A.+DiMasiauthor=H.+G.+Grabowski&title=Economics+of+new+oncology+drug+development&doi=10.1200%2FJCO.2006.09.0803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Economics of new oncology drug development</span></div><div class="casAuthors">DiMasi Joseph A; Grabowski Henry G</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Review existing studies and provide new results on the development, regulatory, and market aspects of new oncology drug development.  METHODS:  We utilized data from the US Food and Drug Administration (FDA), company surveys, and publicly available commercial business intelligence databases on new oncology drugs approved in the United States and on investigational oncology drugs to estimate average development and regulatory approval times, clinical approval success rates, first-in-class status, and global market diffusion.  RESULTS:  We found that approved new oncology drugs to have a disproportionately high share of FDA priority review ratings, of orphan drug designations at approval, and of drugs that were granted inclusion in at least one of the FDA's expedited access programs.  US regulatory approval times were shorter, on average, for oncology drugs (0.5 years), but US clinical development times were longer on average (1.5 years).  Clinical approval success rates were similar for oncology and other drugs, but proportionately more of the oncology failures reached expensive late-stage clinical testing before being abandoned.  In relation to other drugs, new oncology drug approvals were more often first-in-class and diffused more widely across important international markets.  CONCLUSION:  The market success of oncology drugs has induced a substantial amount of investment in oncology drug development in the last decade or so.  However, given the great need for further progress, the extent to which efforts to develop new oncology drugs will grow depends on future public-sector investment in basic research, developments in translational medicine, and regulatory reforms that advance drug-development science.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRW5CNVotEHwq-9TkgmBqTqfW6udTcc2ebdx4Z0VOqk2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FhsVCisg%253D%253D&md5=5afbbdf18918c328552d25a50e4e904d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.09.0803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.09.0803%26sid%3Dliteratum%253Aachs%26aulast%3DDiMasi%26aufirst%3DJ.%2BA.%26aulast%3DGrabowski%26aufirst%3DH.%2BG.%26atitle%3DEconomics%2520of%2520new%2520oncology%2520drug%2520development%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26spage%3D209%26epage%3D16%26doi%3D10.1200%2FJCO.2006.09.0803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jardim, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groves, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitfeld, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span> <span> </span><span class="NLM_article-title">Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2016.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.ctrv.2016.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=27883925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2sjgtVyqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2017&pages=12-21&author=D.+L.+Jardimauthor=E.+S.+Grovesauthor=P.+P.+Breitfeldauthor=R.+Kurzrock&title=Factors+associated+with+failure+of+oncology+drugs+in+late-stage+clinical+development%3A+A+systematic+review&doi=10.1016%2Fj.ctrv.2016.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review</span></div><div class="casAuthors">Jardim Denis L; Groves Eric S; Breitfeld Philip P; Kurzrock Razelle</div><div class="citationInfo"><span class="NLM_cas:title">Cancer treatment reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  We aimed to describe the reasons for failure of experimental anticancer drugs in late-stage clinical development.  MATERIAL AND METHODS:  We searched the PharmaProjects database (https://citeline.com/products/pharmaprojects/) for anticancer drugs discontinued between 01/01/2009 and 06/30/2014.  Drug programs that reached phase III trials, but never gained Food and Drug Administration (FDA) approval were compared to 37 anti-cancer drugs achieving FDA approval in this time period.  RESULTS:  Forty-two drugs fit our criteria for development failures.  These failed drugs (49% targeted, 23% cytotoxics, and 28% other) were tested in 43 cancer indications (drug programs).  Only 16% (7/43) of failed drug programs adopted a biomarker-driven rationale for patient selection versus 57% (21/37) of successful drug programs (P<0.001).  Phase II trial information was available in 32 of 43 failed drug programs and in 32 of 37 successful programs.  Nine of the 32 trials (28%) of failed drugs versus 28 of 32 trials (87%) of successful drugs (P<0.001) achieved proof of concept (single agent response rate (RR)  20% or combination therapy showing a  20% RR increase above the median historical RR without the experimental agent (with a minimal absolute increase of 5%) or a randomized phase II trial showing significance (P 0.05) for its primary outcome).  No pattern of study sites, trial design or funding characteristics emerged from the failed drug analysis.  CONCLUSION:  For drugs that reached Phase III, lack of a biomarker-driven strategy and failure to attain proof of concept in phase II are potential risk factors for later discontinuation, especially for targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUXYoeDs7cUMzK395ZObgVfW6udTcc2ebdx4Z0VOqk2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjgtVyqug%253D%253D&md5=db7a5acfd7b471292f35e8447815d9aa</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2016.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2016.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DJardim%26aufirst%3DD.%2BL.%26aulast%3DGroves%26aufirst%3DE.%2BS.%26aulast%3DBreitfeld%26aufirst%3DP.%2BP.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DFactors%2520associated%2520with%2520failure%2520of%2520oncology%2520drugs%2520in%2520late-stage%2520clinical%2520development%253A%2520A%2520systematic%2520review%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2017%26volume%3D52%26spage%3D12%26epage%3D21%26doi%3D10.1016%2Fj.ctrv.2016.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of cancer drug resistance</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1146/annurev.med.53.082901.103929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1146%2Fannurev.med.53.082901.103929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=11818492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD38Xitl2mtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2002&pages=615-27&author=M.+M.+Gottesman&title=Mechanisms+of+cancer+drug+resistance&doi=10.1146%2Fannurev.med.53.082901.103929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of cancer drug resistance</span></div><div class="casAuthors">Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">615-627</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer.  Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumors, even those from the same tissue of origin.  Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common.  The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance.  Studies on mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquuMAtOcoDfbVg90H21EOLACvtfcHk0lhh9DcIh9bt3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xitl2mtLo%253D&md5=8f442a5c749266ad76ad7c7406a4e611</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.53.082901.103929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.53.082901.103929%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DMechanisms%2520of%2520cancer%2520drug%2520resistance%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2002%26volume%3D53%26spage%3D615%26epage%3D27%26doi%3D10.1146%2Fannurev.med.53.082901.103929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span> </span><span class="NLM_article-title">Global oncology/cancer drugs market overview</span>. <a href="https://www.blueweaveconsulting.com/global-oncology-cancer-drugs-market-bwc19381" class="extLink">https://www.blueweaveconsulting.com/global-oncology-cancer-drugs-market-bwc19381</a> (accessed Nov 24, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global+oncology%2Fcancer+drugs+market+overview.+https%3A%2F%2Fwww.blueweaveconsulting.com%2Fglobal-oncology-cancer-drugs-market-bwc19381+%28accessed+Nov+24%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGlobal%2520oncology%252Fcancer%2520drugs%2520market%2520overview%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span> </span><span class="NLM_article-title">Neurological
disorders: Public health challenges</span>. <a href="https://www.who.int/mental_health/neurology/neurodiso/en/" class="extLink">https://www.who.int/mental_health/neurology/neurodiso/en/</a> (accessed Nov 23, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Neurological%0Adisorders%3A+Public+health+challenges.+https%3A%2F%2Fwww.who.int%2Fmental_health%2Fneurology%2Fneurodiso%2Fen%2F+%28accessed+Nov+23%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNeurological%250Adisorders%253A%2520Public%2520health%2520challenges%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feigin, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owolabi, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dichgans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuschl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brainin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C.</span></span> <span> </span><span class="NLM_article-title">The global burden of neurological disorders: Translating evidence into policy</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(19)30411-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS1474-4422%2819%2930411-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31813850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3MfnvVWgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=255-265&author=V.+L.+Feiginauthor=T.+Vosauthor=E.+Nicholsauthor=M.+O.+Owolabiauthor=W.+M.+Carrollauthor=M.+Dichgansauthor=G.+Deuschlauthor=P.+Parmarauthor=M.+Braininauthor=C.+Murray&title=The+global+burden+of+neurological+disorders%3A+Translating+evidence+into+policy&doi=10.1016%2FS1474-4422%2819%2930411-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The global burden of neurological disorders: translating evidence into policy</span></div><div class="casAuthors">Feigin Valery L; Vos Theo; Nichols Emma; Murray Christopher; Owolabi Mayowa O; Carroll William M; Dichgans Martin; Deuschl Gunther; Parmar Priya; Brainin Michael</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-265</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neurological disorders are the leading cause of disability and the second leading cause of death worldwide.  In the past 30 years, the absolute numbers of deaths and people with disabilities owing to neurological diseases have risen substantially, particularly in low-income and middle-income countries, and further increases are expected globally as a result of population growth and ageing.  This rise in absolute numbers of people affected suggests that advances in prevention and management of major neurological disorders are not sufficiently effective to counter global demographic changes.  Urgent measures to reduce this burden are therefore needed.  Because resources for health care and research are already overstretched, priorities need to be set to guide policy makers, governments, and funding organisations to develop and implement action plans for prevention, health care, and research to tackle the growing challenge of neurological disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx6-23J-DSgbJzI8owOhpDfW6udTcc2eaDpMar3e07OLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfnvVWgtQ%253D%253D&md5=04770e7fbf079d09f64f0fd04a522c8c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2819%2930411-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252819%252930411-9%26sid%3Dliteratum%253Aachs%26aulast%3DFeigin%26aufirst%3DV.%2BL.%26aulast%3DVos%26aufirst%3DT.%26aulast%3DNichols%26aufirst%3DE.%26aulast%3DOwolabi%26aufirst%3DM.%2BO.%26aulast%3DCarroll%26aufirst%3DW.%2BM.%26aulast%3DDichgans%26aufirst%3DM.%26aulast%3DDeuschl%26aufirst%3DG.%26aulast%3DParmar%26aufirst%3DP.%26aulast%3DBrainin%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DC.%26atitle%3DThe%2520global%2520burden%2520of%2520neurological%2520disorders%253A%2520Translating%2520evidence%2520into%2520policy%26jtitle%3DLancet%2520Neurol.%26date%3D2020%26volume%3D19%26spage%3D255%26epage%3D265%26doi%3D10.1016%2FS1474-4422%2819%2930411-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span> <span> </span><span class="NLM_article-title">An analysis of fda-approved drugs for neurological disorders</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1040</span>– <span class="NLM_lpage">3</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.drudis.2015.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25681791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=1040-3&author=M.+S.+Kinch&title=An+analysis+of+fda-approved+drugs+for+neurological+disorders&doi=10.1016%2Fj.drudis.2015.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of FDA-approved drugs for neurological disorders</span></div><div class="casAuthors">Kinch, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1040-1043</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Neuroscience remains a great challenge and opportunity in terms of new drug discovery and development.  An assessment of FDA-approved new mol. entities (NMEs) reveals a low steady rate of new FDA approvals, which is interrupted by two bursts in activity, first in the 1950s and then in the 1990s.  These trends are reflected in the approvals for NMEs targeting multiple indications in this field, including seizure, Parkinson's disease and neuromuscular disorders.  The majority of drugs target ion channels or G-protein-coupled receptors (GPCRs) but the mechanistic basis for many NMEs remains unclear or controversial.  These trends could suggest future opportunities for success in a crucial field with considerable unmet needs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfvKatWK3Fx7Vg90H21EOLACvtfcHk0lhh9DcIh9bt3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWqs7w%253D&md5=05ea0982e6ee282f288c3c337d12579f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DKinch%26aufirst%3DM.%2BS.%26atitle%3DAn%2520analysis%2520of%2520fda-approved%2520drugs%2520for%2520neurological%2520disorders%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D1040%26epage%3D3%26doi%3D10.1016%2Fj.drudis.2015.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vila-Pueyo, M.</span></span> <span> </span><span class="NLM_article-title">Targeted 5-ht 1f therapies for migraine</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1007/s13311-018-0615-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs13311-018-0615-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29488143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktVKjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=291-303&author=M.+Vila-Pueyo&title=Targeted+5-ht+1f+therapies+for+migraine&doi=10.1007%2Fs13311-018-0615-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted 5-HT1F Therapies for Migraine</span></div><div class="casAuthors">Vila-Pueyo, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">291-303</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Migraine is a common neurol. disease characterised by the presence of attacks of unilateral, severe head pain accompanied by other symptoms.  Although it has been classified as the sixth most disabling disorder, the available therapeutic options to treat this condition have not progressed accordingly.  The advance in the development of 5-HT1 receptor agonists for migraine, including 5-HT1B/D and 5-HT1F receptor agonists, has meant a major step forward towards the progression of a better treatment for migraine.  Triptans have a limited efficacy, and their effect on vasoconstriction makes them unsafe for patients with cardiovascular and/or cerebrovascular diseases.  Therefore, novel effective antimigraine treatments without cardiovascular effects are required, such as selective 5-HT1F receptor agonists (ditans).  Lasmiditan has much higher affinity for the 5-HT1F receptor than for the vasoconstrictor 5-HT1B receptor.  This has been confirmed in preclin. studies performed to date, where lasmiditan showed no effect on vasoconstriction, and in clin. trials, where healthy individuals and patients did not report cardiac events due to treatment with lasmiditan, although it should be confirmed in larger cohorts.  Lasmiditan crosses the blood-brain barrier and may act both centrally and peripherally on 5-HT1F receptors expressed on trigeminal neurons.  It is a well-tolerated compd. that does not induce major adverse events.  Although ongoing phase III clin. trials are needed to confirm its efficacy and safety, lasmiditan might offer an alternative to treat acute migraine with no assocd. cardiovascular risk.  This review will focus on the characterization of 5-HT1 receptor agonists and their effects as migraine therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbkLZlm2ydBLVg90H21EOLACvtfcHk0lh-z_e2frbTLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktVKjsL0%253D&md5=067265f36b52207e80aa98743b8b52ce</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs13311-018-0615-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-018-0615-6%26sid%3Dliteratum%253Aachs%26aulast%3DVila-Pueyo%26aufirst%3DM.%26atitle%3DTargeted%25205-ht%25201f%2520therapies%2520for%2520migraine%26jtitle%3DNeurotherapeutics%26date%3D2018%26volume%3D15%26spage%3D291%26epage%3D303%26doi%3D10.1007%2Fs13311-018-0615-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russell, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smillie, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodji, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brain, S. D.</span></span> <span> </span><span class="NLM_article-title">Calcitonin gene-related peptide: Physiology and pathophysiology</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">1099</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1152/physrev.00034.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1152%2Fphysrev.00034.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25287861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFansbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=1099-142&author=F.+A.+Russellauthor=R.+Kingauthor=S.+J.+Smillieauthor=X.+Kodjiauthor=S.+D.+Brain&title=Calcitonin+gene-related+peptide%3A+Physiology+and+pathophysiology&doi=10.1152%2Fphysrev.00034.2013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Calcitonin gene-related peptide: physiology and pathophysiology</span></div><div class="casAuthors">Russell, F. A.; King, R.; Smillie, S.-J.; Kodji, X.; Brain, S. D.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1099-1142</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide.  Discovered 30 years ago, it is produced as a consequence of alternative RNA processing of the calcitonin gene.  CGRP has two major forms (α and β).  It belongs to a group of peptides that all act on an unusual receptor family.  These receptors consist of calcitonin receptor-like receptor (CLR) linked to an essential receptor activity modifying protein (RAMP) that is necessary for full functionality.  CGRP is a highly potent vasodilator and, partly as a consequence, possesses protective mechanisms that are important for physiol. and pathol. conditions involving the cardiovascular system and wound healing.  CGRP is primarily released from sensory nerves and thus is implicated in pain pathways.  The proven ability of CGRP antagonists to alleviate migraine has been of most interest in terms of drug development, and knowledge to date concerning this potential therapeutic area is discussed.  Other areas covered, where there is less information known on CGRP, include arthritis, skin conditions, diabetes, and obesity.  It is concluded that CGRP is an important peptide in mammalian biol., but it is too early at present to know if new medicines for disease treatment will emerge from our knowledge concerning this mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwIgrpQJ0Bp7Vg90H21EOLACvtfcHk0lh-z_e2frbTLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFansbnI&md5=dabce66d0b7604444f8366056f1ba2fd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00034.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00034.2013%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DF.%2BA.%26aulast%3DKing%26aufirst%3DR.%26aulast%3DSmillie%26aufirst%3DS.%2BJ.%26aulast%3DKodji%26aufirst%3DX.%26aulast%3DBrain%26aufirst%3DS.%2BD.%26atitle%3DCalcitonin%2520gene-related%2520peptide%253A%2520Physiology%2520and%2520pathophysiology%26jtitle%3DPhysiol.%2520Rev.%26date%3D2014%26volume%3D94%26spage%3D1099%26epage%3D142%26doi%3D10.1152%2Fphysrev.00034.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Billakota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devinsky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, E.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid therapy in epilepsy</span>. <i>Curr. Opin. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1097/WCO.0000000000000660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1097%2FWCO.0000000000000660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30676535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjslKrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2019&pages=220-226&author=S.+Billakotaauthor=O.+Devinskyauthor=E.+Marsh&title=Cannabinoid+therapy+in+epilepsy&doi=10.1097%2FWCO.0000000000000660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid therapy in epilepsy</span></div><div class="casAuthors">Billakota, Santoshi; Devinsky, Orrin; Marsh, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Neurology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">220-226</span>CODEN:
                <span class="NLM_cas:coden">CONEEX</span>;
        ISSN:<span class="NLM_cas:issn">1350-7540</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: To review the history, pharmacol., and clin. science of cannabidiol (CBD) in the treatment of epilepsy.  Recent findings: Phase III randomized controlled trials and prospective open label trials have provided efficacy and safety data for the use of CBD in pediatric onset severe epilepsies.  The product that was studied in the vast majority of these published trials, Epidiolex (>99% of CBD and <0.10% Δ9-tetrahydrocannabinol (THC); GW pharmaceuticals, Cambridge, UK), has now been FDA approved based on this published data.  Summary: Identification of CBD, Δ9-THC, and the endocannabinoid system in the mid-20th century has led to advancement of cannabis-based therapies for epilepsy.  Based on clin. trial data, Epidiolex is the first CBD medication approved by a national regulatory agency (US Food and Drug Administration for Dravet and Lennox Gastaut syndrome; European Medicines Agency for Lennox Gastaut syndrome).  Approval of CBD as a treatment for these rare and severe pediatric-onset epilepsy syndromes is an important milestone, but the complete spectrum of use of cannabis-derived products, and the use of CBD for other epilepsy syndromes remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8AeaHmug0FLVg90H21EOLACvtfcHk0lh-z_e2frbTLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjslKrsL4%253D&md5=deee1dd93b683577605655171a8a8525</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1097%2FWCO.0000000000000660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FWCO.0000000000000660%26sid%3Dliteratum%253Aachs%26aulast%3DBillakota%26aufirst%3DS.%26aulast%3DDevinsky%26aufirst%3DO.%26aulast%3DMarsh%26aufirst%3DE.%26atitle%3DCannabinoid%2520therapy%2520in%2520epilepsy%26jtitle%3DCurr.%2520Opin.%2520Neurol.%26date%3D2019%26volume%3D32%26spage%3D220%26epage%3D226%26doi%3D10.1097%2FWCO.0000000000000660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, D.</span></span> <span> </span><span class="NLM_article-title">Distribution of gabaa and gabab receptors in mammalian brain: Potential targets for drug development</span>. <i>Drug Dev. Res.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1002/ddr.430210303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fddr.430210303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaK3MXlsFygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1990&pages=161-167&author=A.+B.+Youngauthor=D.+Chu&title=Distribution+of+gabaa+and+gabab+receptors+in+mammalian+brain%3A+Potential+targets+for+drug+development&doi=10.1002%2Fddr.430210303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of GABAA and GABAB receptors in mammalian brain:  potential targets for drug development</span></div><div class="casAuthors">Young, Anne B.; Chu, Dorothy</div><div class="citationInfo"><span class="NLM_cas:title">Drug Development Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-7</span>CODEN:
                <span class="NLM_cas:coden">DDREDK</span>;
        ISSN:<span class="NLM_cas:issn">0272-4391</span>.
    </div><div class="casAbstract">A review with 24 refs.  GABA's actions are mediated by 2 different receptors, GABAA, and GABAB receptors.  GABAA receptors are ligand-gated chloride channels that are sensitive to the convulsant alkaloid bicuculline and modulated by benzodiazepines and barbiturates.  GABAB receptors affect Ca and K conductance through GTP-binding proteins and are insensitive to bicuculline and and sensitive to the agonist baclofen.  Both receptors are widely distributed in cerebral cortex, hippocampus, basal ganglia, thalamus, cerebellum, and brain stem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotWVxUyEv5rLVg90H21EOLACvtfcHk0liRNgVr0ehYog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlsFygsg%253D%253D&md5=41f648329c898bb890183f3e3149ebf2</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fddr.430210303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fddr.430210303%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DA.%2BB.%26aulast%3DChu%26aufirst%3DD.%26atitle%3DDistribution%2520of%2520gabaa%2520and%2520gabab%2520receptors%2520in%2520mammalian%2520brain%253A%2520Potential%2520targets%2520for%2520drug%2520development%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D1990%26volume%3D21%26spage%3D161%26epage%3D167%26doi%3D10.1002%2Fddr.430210303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifacio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loureiro, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares-Da-Silva, P.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-o-methyl transferase inhibitor, in the rat</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">1739</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1111/bph.13020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1111%2Fbph.13020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25409768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslemtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=1739-52&author=M.+J.+Bonifacioauthor=L.+Torraoauthor=A.+I.+Loureiroauthor=P.+N.+Palmaauthor=L.+C.+Wrightauthor=P.+Soares-Da-Silva&title=Pharmacological+profile+of+opicapone%2C+a+third-generation+nitrocatechol+catechol-o-methyl+transferase+inhibitor%2C+in+the+rat&doi=10.1111%2Fbph.13020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat</span></div><div class="casAuthors">Bonifacio, M. J.; Torrao, L.; Loureiro, A. I.; Palma, P. N.; Wright, L. C.; Soares-da-Silva, P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1739-1752</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Catechol-O-methyltransferase (COMT) is an important target in the levodopa treatment of Parkinson's disease; however, the inhibitors available have problems, and not all patients benefit from their efficacy.  Opicapone was developed to overcome those limitations.  In this study, opicapone's pharmacol. properties were evaluated as well as its potential cytotoxic effects.  The pharmacodynamic effects of opicapone were explored by evaluating rat COMT activity and levodopa pharmacokinetics, in the periphery through microdialysis and in whole brain.  The potential cytotoxicity risk of opicapone was explored in human hepatocytes by assessing cellular ATP content and mitochondrial membrane potential.  Opicapone inhibited rat peripheral COMT with ED50 values below 1.4 mg·kg-1 up to 6 h post-administration.  The effect was sustained over the first 8 h and by 24 h COMT had not returned to control values.  A single administration of opicapone resulted in increased and sustained plasma levodopa levels with a concomitant redn. in 3-O-methyldopa from 2 h up to 24 h post-administration, while tolcapone produced significant effects only at 2 h post-administration.  The effects of opicapone on brain catecholamines after levodopa administration were sustained up to 24 h post-administration.  Opicapone was also the least potent compd. in decreasing both the mitochondrial membrane potential and the ATP content in human primary hepatocytes after a 24 h incubation period.  Opicapone has a prolonged inhibitory effect on peripheral COMT, which extends the bioavailability of levodopa, without inducing toxicity.  Thus, it exhibits some improved properties compared to the currently available COMT inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8LJIJVwNnkLVg90H21EOLACvtfcHk0liRNgVr0ehYog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslemtrs%253D&md5=a9ab5332b55d8181120f39cdb0c74e85</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1111%2Fbph.13020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13020%26sid%3Dliteratum%253Aachs%26aulast%3DBonifacio%26aufirst%3DM.%2BJ.%26aulast%3DTorrao%26aufirst%3DL.%26aulast%3DLoureiro%26aufirst%3DA.%2BI.%26aulast%3DPalma%26aufirst%3DP.%2BN.%26aulast%3DWright%26aufirst%3DL.%2BC.%26aulast%3DSoares-Da-Silva%26aufirst%3DP.%26atitle%3DPharmacological%2520profile%2520of%2520opicapone%252C%2520a%2520third-generation%2520nitrocatechol%2520catechol-o-methyl%2520transferase%2520inhibitor%252C%2520in%2520the%2520rat%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D1739%26epage%3D52%26doi%3D10.1111%2Fbph.13020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesh
Sreeram, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagadkar, F.</span></span> <span> </span><span class="NLM_article-title">Role of vesicular monoamine transporter 2 inhibitors in tardive dyskinesia management</span>. <i>Cureus</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e5471</span> <span class="refDoi"> DOI: 10.7759/cureus.5471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.7759%2Fcureus.5471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31641566" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=S.+S.+Venkatesh%0ASreeramauthor=F.+Kagadkar&title=Role+of+vesicular+monoamine+transporter+2+inhibitors+in+tardive+dyskinesia+management&doi=10.7759%2Fcureus.5471"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.7759%2Fcureus.5471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7759%252Fcureus.5471%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatesh%2BSreeram%26aufirst%3DS.%2BS.%26aulast%3DKagadkar%26aufirst%3DF.%26atitle%3DRole%2520of%2520vesicular%2520monoamine%2520transporter%25202%2520inhibitors%2520in%2520tardive%2520dyskinesia%2520management%26jtitle%3DCureus%26date%3D2019%26volume%3D11%26doi%3D10.7759%2Fcureus.5471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, S.</span></span> <span> </span><span class="NLM_article-title">Deutetrabenazine in the treatment of huntington’s disease</span>. <i>Neurodegener. Dis. Manag.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.2217/nmt-2018-0040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2217%2Fnmt-2018-0040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30624137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3cnpsFWksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=31-37&author=A.+Richardauthor=S.+Frank&title=Deutetrabenazine+in+the+treatment+of+huntington%E2%80%99s+disease&doi=10.2217%2Fnmt-2018-0040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Deutetrabenazine in the treatment of Huntington's disease</span></div><div class="casAuthors">Richard Alby; Frank Samuel</div><div class="citationInfo"><span class="NLM_cas:title">Neurodegenerative disease management</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Deutetrabenazine (DTBZ) is a US FDA-approved treatment for chorea in Huntington's disease.  The substitution of deuterium for hydrogen at specific positions imparts a longer half-life on DTBZ, allowing for less-frequent daily dosing.  As a reversible vesicular monoamine transporter Type 2 inhibitor, DTBZ depletes monoamines at presynaptic nerve terminals.  DTBZ significantly improved chorea in Huntington's disease patients compared with placebo.  This effect continued in an ongoing open-label extension study in the cohort who switched from tetrabenazine to DTBZ.  Whereas there are currently no head-to-head studies to adequately compare safety profiles between tetrabenazine and DTBZ, an indirect comparison study suggested that the tolerability profile of DTBZ was similar to placebo.  In fact, there are currently no direct comparisons between vesicular monoamine transporter Type 2 inhibitors in humans.  This review will explore DTBZ's pharmacological properties, drug interactions, administration and efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSP0y_HRxo6nNHxxy173TfNfW6udTcc2eaelDkASTkexrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnpsFWksQ%253D%253D&md5=400c75b21d16b2a5a67da3282854107b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.2217%2Fnmt-2018-0040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnmt-2018-0040%26sid%3Dliteratum%253Aachs%26aulast%3DRichard%26aufirst%3DA.%26aulast%3DFrank%26aufirst%3DS.%26atitle%3DDeutetrabenazine%2520in%2520the%2520treatment%2520of%2520huntington%25E2%2580%2599s%2520disease%26jtitle%3DNeurodegener.%2520Dis.%2520Manag.%26date%3D2019%26volume%3D9%26spage%3D31%26epage%3D37%26doi%3D10.2217%2Fnmt-2018-0040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gellad, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, G. C.</span></span> <span> </span><span class="NLM_article-title">Evaluation of flibanserin: Science and advocacy at the fda</span>. <i>J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">870</span>, <span class="refDoi"> DOI: 10.1001/jama.2015.8405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1001%2Fjama.2015.8405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XkslKmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2015&pages=869-870&author=W.+F.+Gelladauthor=K.+E.+Flynnauthor=G.+C.+Alexander&title=Evaluation+of+flibanserin%3A+Science+and+advocacy+at+the+fda&doi=10.1001%2Fjama.2015.8405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of flibanserin: science and advocacy at the FDA</span></div><div class="casAuthors">Gellad, Walid F.; Flynn, Kathryn E.; Alexander, G. Caleb</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">869</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoet9CbCtT9erVg90H21EOLACvtfcHk0liRNgVr0ehYog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkslKmtg%253D%253D&md5=cfadaafa407db0b9122ce778b82097b3</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1001%2Fjama.2015.8405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2015.8405%26sid%3Dliteratum%253Aachs%26aulast%3DGellad%26aufirst%3DW.%2BF.%26aulast%3DFlynn%26aufirst%3DK.%2BE.%26aulast%3DAlexander%26aufirst%3DG.%2BC.%26atitle%3DEvaluation%2520of%2520flibanserin%253A%2520Science%2520and%2520advocacy%2520at%2520the%2520fda%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2015%26volume%3D314%26spage%3D869%26epage%3D870%26doi%3D10.1001%2Fjama.2015.8405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Lemborexant: First approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01276-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-020-01276-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=32096020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=425-432&author=L.+J.+Scott&title=Lemborexant%3A+First+approval&doi=10.1007%2Fs40265-020-01276-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Lemborexant: First Approval</span></div><div class="casAuthors">Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-432</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Abstr.: Lemborexant (DAYVIGO) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia.  In Dec. 2019, lemborexant received its first approval (with final interim scheduling) in the USA for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.  In Jan. 2020, lemborexant also received approval in Japan for the treatment of insomnia.  It is also being investigated for the treatment of irregular sleep-wake rhythm disorder (ISWRD) assocd. with mild to moderate Alzheimer's disease.  This article summarizes the milestones in the development of lemborexant leading to its first global approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9xrf3D4Hk4rVg90H21EOLACvtfcHk0lhPnpPjojnVAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslCltro%253D&md5=3d7e881e7ca2d223682081871963761c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01276-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01276-1%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DLemborexant%253A%2520First%2520approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D425%26epage%3D432%26doi%3D10.1007%2Fs40265-020-01276-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span> </span><span class="NLM_article-title">Neurotherapeutic drugs market: Overview</span>. <a href="https://www.mynewsdesk.com/us/tmr/pressreleases/deeper-understanding-of-neurologic-diseases-leads-to-the-growth-of-neurotherapeutic-drugs-market-1946311" class="extLink">https://www.mynewsdesk.com/us/tmr/pressreleases/deeper-understanding-of-neurologic-diseases-leads-to-the-growth-of-neurotherapeutic-drugs-market-1946311</a> (accessed Jun 30, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Neurotherapeutic+drugs+market%3A+Overview.+https%3A%2F%2Fwww.mynewsdesk.com%2Fus%2Ftmr%2Fpressreleases%2Fdeeper-understanding-of-neurologic-diseases-leads-to-the-growth-of-neurotherapeutic-drugs-market-1946311+%28accessed+Jun+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNeurotherapeutic%2520drugs%2520market%253A%2520Overview%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umlauf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, M.</span></span> <span> </span><span class="NLM_article-title">An analysis of fda-approved drugs for metabolic diseases</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.drudis.2015.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25680688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=648-51&author=M.+S.+Kinchauthor=S.+Umlaufauthor=M.+Plummer&title=An+analysis+of+fda-approved+drugs+for+metabolic+diseases&doi=10.1016%2Fj.drudis.2015.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of FDA-approved drugs for metabolic diseases</span></div><div class="casAuthors">Kinch, Michael S.; Umlauf, Sheila; Plummer, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">648-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Metabolic diseases encompass a constellation of maladies including obesity and diabetes that are among the fastest growing epidemics throughout the world.  An anal. of new mol. entities (NMEs) targeting metabolic diseases reveals the rate of approval for new drugs increased in the mid-1990s and now stands at approx. two per yr.  The increase is largely attributed to a recent emphasis on treatments for inborn errors of metab.  In particular, biotechnol. companies have focused on rare genetic disorders, which are often treated with biol.-based NMEs that target novel pathways and qualify for orphan drug status.  By contrast, NME development by pharmaceutical companies tended toward conventional small mol. targeting of nongenetic disorders such as diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov-tx3JD3cb7Vg90H21EOLACvtfcHk0lhPnpPjojnVAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWlsbY%253D&md5=f46960cbd106cd957e74140361ae7394</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DUmlauf%26aufirst%3DS.%26aulast%3DPlummer%26aufirst%3DM.%26atitle%3DAn%2520analysis%2520of%2520fda-approved%2520drugs%2520for%2520metabolic%2520diseases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D648%26epage%3D51%26doi%3D10.1016%2Fj.drudis.2015.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Lesinurad: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0550-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-016-0550-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26861027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=509-16&author=S.+M.+Hoy&title=Lesinurad%3A+First+global+approval&doi=10.1007%2Fs40265-016-0550-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Lesinurad: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">509-516</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Lesinurad (ZURAMPIC) is an oral urate-anion exchanger transporter 1 (URAT1) inhibitor developed by Ardea Biosciences (a subsidiary of AstraZeneca) for the treatment of hyperuricemia assocd. with gout.  It reduces serum uric acid (sUA) levels by inhibiting the function of the transporter proteins (URAT1 and org. anion transporter 4) involved in uric acid reabsorption in the kidney.  In Dec. 2015, lesinurad was approved in the USA as combination therapy with a xanthine oxidase inhibitor for the treatment of hyperuricemia assocd. with gout in patients who have not achieved sUA target levels with a xanthine oxidase inhibitor alone.  Lesinurad has also received a pos. opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for this indication and is in phase III development as a combination therapy in several other countries.  This article summarizes the milestones in the development of lesinurad leading to this first approval for hyperuricemia assocd. with gout.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYLnXR_1pferVg90H21EOLACvtfcHk0lhPnpPjojnVAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGrsr4%253D&md5=adff81ec4e67f65711573f15444765c8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0550-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0550-y%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DLesinurad%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D509%26epage%3D16%26doi%3D10.1007%2Fs40265-016-0550-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Pepa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandi, M. L.</span></span> <span> </span><span class="NLM_article-title">Natpara for the treatment of hypoparathyroidism</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1417</span>– <span class="NLM_lpage">1424</span>, <span class="refDoi"> DOI: 10.1080/14712598.2016.1238455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1080%2F14712598.2016.1238455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=27689826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1amtrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=1417-1424&author=G.+Marcucciauthor=G.+Della+Pepaauthor=M.+L.+Brandi&title=Natpara+for+the+treatment+of+hypoparathyroidism&doi=10.1080%2F14712598.2016.1238455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Natpara for the treatment of hypoparathyroidism</span></div><div class="casAuthors">Marcucci, Gemma; Della Pepa, Giuseppe; Brandi, Maria Luisa</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1417-1424</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Hypoparathyroidism is a rare endocrine disorder characterized by hypocalcemia and hyperphosphatemia, due to absent or inappropriately low parathyroid hormone levels.  For management of chronic hypoparathyroidism, current treatment options involve oral calcium and vitamin D.  This std. treatment cannot resolve all problematic aspects of the disease, such as abnormal bone remodeling and reduced quality of life, and is assocd. with long-term complications, including nephrolithiasis, nephrocalcinosis, renal impairment, cataracts and cerebral calcifications.: In 2015, the FDA (Food and Drug Administration) approved rhPTH (1-84), named Natpara, a bioengineered recombinant human PTH, for the management of hypoparathyroidism of any etiol., except Autosomal Dominant Hypocalcemia, not well controlled with calcium and active vitamin D.  Herein, the authors review its chem., pharmacodynamics, pharmacokinetics and clin. efficacy for hypoparathyroidism.: Replacement therapy with rhPTH (1-84) is a fundamental step in the treatment of chronic hypoparathyroidism in cases not well controlled by std. therapy, providing the natural hormone that is lacking for the maintenance of normal calcium levels, and reducing long-term risks assocd. with conventional therapy.  Nevertheless, given the chronic nature of the disease, in the future, further studies will have to be performed to evaluate long-term efficacy and safety of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9U1AI9HuGMLVg90H21EOLACvtfcHk0lj_BU5WVjdHFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1amtrbM&md5=34f22b6790c6c4eb328666250189295c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1080%2F14712598.2016.1238455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14712598.2016.1238455%26sid%3Dliteratum%253Aachs%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DDella%2BPepa%26aufirst%3DG.%26aulast%3DBrandi%26aufirst%3DM.%2BL.%26atitle%3DNatpara%2520for%2520the%2520treatment%2520of%2520hypoparathyroidism%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2016%26volume%3D16%26spage%3D1417%26epage%3D1424%26doi%3D10.1080%2F14712598.2016.1238455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baggio, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span> <span> </span><span class="NLM_article-title">Biology of incretins: Glp-1 and gip</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">2131</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2007.03.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1053%2Fj.gastro.2007.03.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=17498508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsVynsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2007&pages=2131-57&author=L.+L.+Baggioauthor=D.+J.+Drucker&title=Biology+of+incretins%3A+Glp-1+and+gip&doi=10.1053%2Fj.gastro.2007.03.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Biology of incretins: GLP-1 and GIP</span></div><div class="casAuthors">Baggio, Laurie L.; Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2131-2157</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  This review focuses on the mechanisms regulating the synthesis, secretion, biol. actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).  The published literature was reviewed, with emphasis on recent advances in our understanding of the biol. of GIP and GLP-1.  GIP and GLP-1 are both secreted within minutes of nutrient ingestion and facilitate the rapid disposal of ingested nutrients.  Both peptides share common actions on islet β-cells acting through structurally distinct yet related receptors.  Incretin-receptor activation leads to glucose-dependent insulin secretion, induction of β-cell proliferation, and enhanced resistance to apoptosis.  GIP also promotes energy storage via direct actions on adipose tissue, and enhances bone formation via stimulation of osteoblast proliferation and inhibition of apoptosis.  In contrast, GLP-1 exerts glucoregulatory actions via slowing of gastric emptying and glucose-dependent inhibition of glucagon secretion.  GLP-1 also promotes satiety and sustained GLP-1-receptor activation is assocd. with wt. loss in both preclin. and clin. studies.  The rapid degrdn. of both GIP and GLP-1 by the enzyme dipeptidyl peptidase-4 has led to the development of degrdn.-resistant GLP-1-receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.  These agents decrease Hb A1c (HbA1c) safely without wt. gain in subjects with type 2 diabetes.  GLP-1 and GIP integrate nutrient-derived signals to control food intake, energy absorption, and assimilation.  Recently approved therapeutic agents based on potentiation of incretin action provide new physiol. based approaches for the treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreCg0sPucFt7Vg90H21EOLACvtfcHk0lj_BU5WVjdHFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsVynsrY%253D&md5=ec686e630cfa7400345d833b3ea92ad9</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2007.03.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2007.03.054%26sid%3Dliteratum%253Aachs%26aulast%3DBaggio%26aufirst%3DL.%2BL.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DBiology%2520of%2520incretins%253A%2520Glp-1%2520and%2520gip%26jtitle%3DGastroenterology%26date%3D2007%26volume%3D132%26spage%3D2131%26epage%3D57%26doi%3D10.1053%2Fj.gastro.2007.03.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knop, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilsboll, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, J. J.</span></span> <span> </span><span class="NLM_article-title">Lixisenatide for type 2 diabetes mellitus</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">549</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1517/13543784.2011.562191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1517%2F13543784.2011.562191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=21391833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFClsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=549-57&author=M.+Christensenauthor=F.+K.+Knopauthor=T.+Vilsbollauthor=J.+J.+Holst&title=Lixisenatide+for+type+2+diabetes+mellitus&doi=10.1517%2F13543784.2011.562191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Lixisenatide for type 2 diabetes mellitus</span></div><div class="casAuthors">Christensen, Mikkel; Knop, Filip K.; Vilsbooll, Tina; Holst, Jens J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">549-557</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Type 2 diabetes mellitus (T2DM) is an increasing health problem worldwide.  Glucagon-like peptide-1 (GLP-1) receptor agonists are an expanding drug class that target several of the pathophysiol. traits of T2DM.  Lixisenatide is a GLP-1 receptor agonist in development for once-daily treatment of T2DM.Areas covered: Pharmacol., preclin. and clin. evidence demonstrating the applicability of lixisenatide for the treatment of T2DM are reviewed.  Available data and pending clin. development are summarized, critically appraised and compared to competitor drugs.  The most relevant papers and meeting abstrs. published up to Nov. 2010 are used as sources for this review.Expert opinion: Efficacy and safety in T2DM are demonstrated with lixisenatide in monotherapy and in combination with metformin.  However, limited data with the intended once-daily 20 μμg s.c. dosing necessitate further evaluation of lixisenatide as add-on to various antidiabetic treatments.  It remains to be established whether the slightly differing chem. properties compared to other GLP-1 receptor agonists including a rather short duration of action will be a disadvantage or maybe even an advantage, for example, when combined with long-acting insulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbgMyicCrWwLVg90H21EOLACvtfcHk0lj_BU5WVjdHFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFClsbw%253D&md5=658d9b2c40a4f884b7726816f014a1b8</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.562191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.562191%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DM.%26aulast%3DKnop%26aufirst%3DF.%2BK.%26aulast%3DVilsboll%26aufirst%3DT.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DLixisenatide%2520for%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D549%26epage%3D57%26doi%3D10.1517%2F13543784.2011.562191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mazziotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzaruso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giustina, A.</span></span> <span> </span><span class="NLM_article-title">Diabetes in cushing syndrome: Basic and clinical aspects</span>. <i>Trends Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1016/j.tem.2011.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.tem.2011.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=21993190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFKltbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=499-506&author=G.+Mazziottiauthor=C.+Gazzarusoauthor=A.+Giustina&title=Diabetes+in+cushing+syndrome%3A+Basic+and+clinical+aspects&doi=10.1016%2Fj.tem.2011.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetes in Cushing syndrome: basic and clinical aspects</span></div><div class="casAuthors">Mazziotti, Gherardo; Gazzaruso, Carmine; Giustina, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">499-506</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Diabetes mellitus is a frequent complication of Cushing syndrome (CS) which is caused by chronic exposure to glucocorticoid excess, either endogenous or exogenous, and that is characterized by several clin. symptoms such as central obesity, purple striae, proximal muscle weakness, acne, hirsutism and neuropsychol. disturbances.  Diabetes occurs as a consequence of an insulin-resistant state together with impaired insulin secretion which are induced by glucocorticoid excess.  The management of patients with CS and diabetes mellitus includes the treatment of hyperglycemia and, when possible, the correction of glucocorticoid excess.  This review focuses on the disorders of glucose metab. in patients exposed to glucocorticoid excess, addressing both the pathophysiol. aspects and the clin. and therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmBpnDsWLrTbVg90H21EOLACvtfcHk0lj_BU5WVjdHFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFKltbnK&md5=64c3b966d39e9a2d6af95654d7fe261a</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2011.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2011.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DMazziotti%26aufirst%3DG.%26aulast%3DGazzaruso%26aufirst%3DC.%26aulast%3DGiustina%26aufirst%3DA.%26atitle%3DDiabetes%2520in%2520cushing%2520syndrome%253A%2520Basic%2520and%2520clinical%2520aspects%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2011%26volume%3D22%26spage%3D499%26epage%3D506%26doi%3D10.1016%2Fj.tem.2011.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCafferty, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Vestronidase alfa: A review in mucopolysaccharidosis vii</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1007/s40259-019-00344-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40259-019-00344-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30848434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=233-240&author=E.+H.+McCaffertyauthor=L.+J.+Scott&title=Vestronidase+alfa%3A+A+review+in+mucopolysaccharidosis+vii&doi=10.1007%2Fs40259-019-00344-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Vestronidase Alfa: A Review in Mucopolysaccharidosis VII</span></div><div class="casAuthors">McCafferty, Emma H.; Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-240</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Mucopolysaccharidosis VII is an extremely rare, autosomal recessive lysosomal storage disorder characterized by a deficiency of β-glucuronidase activity, resulting in partial degrdn. and accumulation of GAGs in numerous tissues throughout the body, with consequent cellular damage and organ dysfunction.  Enzyme replacement therapy (ERT) with i.v. vestronidase alfa (Mepsevii), a recombinant form of human β-glucuronidase, is the first disease-specific therapy approved for the treatment of mucopolysaccharidosis VII in pediatric and adult patients.  In the pivotal, blind start, phase 3 trial, 24 wk of vestronidase alfa therapy significantly reduced urinary GAG (uGAG) excretion in patients with mucopolysaccharidosis VII.  Based on a Multi-Domain Responder Index (MDRI; comprises six clin. important morbidity domains, with prespecified minimally important differences for each domain), most evaluable patients experienced an improvement in ≥ 1 domain during the 24-wk primary assessment period (overall pos. mean change of 0.5 domains).  The clin. benefits of vestronidase alfa were sustained during longer-term treatment, as was the redn. in uGAG excretion.  Vestronidase alfa has a manageable tolerability profile, with most adverse reactions of mild to moderate severity.  Given the lack of treatment options and the clin. benefits it provides, i.v. vestronidase alfa is an important emerging ERT for patients with mucopolysaccharidosis VII.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3jpd8q29hnrVg90H21EOLACvtfcHk0lgv5A0Ex1RxYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyiur8%253D&md5=9ec3df5220966a9c1fb59c25592faefd</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2Fs40259-019-00344-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-019-00344-7%26sid%3Dliteratum%253Aachs%26aulast%3DMcCafferty%26aufirst%3DE.%2BH.%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DVestronidase%2520alfa%253A%2520A%2520review%2520in%2520mucopolysaccharidosis%2520vii%26jtitle%3DBioDrugs%26date%3D2019%26volume%3D33%26spage%3D233%26epage%3D240%26doi%3D10.1007%2Fs40259-019-00344-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Migalastat: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1147</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0607-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-016-0607-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=27351440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2s7ksFegtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1147-52&author=A.+Markham&title=Migalastat%3A+First+global+approval&doi=10.1007%2Fs40265-016-0607-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Migalastat: First Global Approval</span></div><div class="casAuthors">Markham Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1147-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Migalastat (Galafold®)-a small molecule drug developed by Amicus Therapeutics that restores the activity of specific mutant forms of α-galactosidase-has been approved for the treatment of Fabry disease in the EU in patients with amenable mutations.  Fabry disease is a rare disorder that results in a deficiency or absence of α-galactosidase, leading to accumulation of globotriaosylceramide in the lysosomes of various cells.  This article summarizes the milestones in the development of migalastat leading to this first approval in the EU for the long-term treatment of adults and adolescents aged ≥16 years with a confirmed diagnosis of Fabry disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnc_DupHv-_NK0qsdY6Nc1fW6udTcc2ebIAlYeggapH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7ksFegtA%253D%253D&md5=20fde86101e0bec10aaaeabad729f05c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0607-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0607-y%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DMigalastat%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1147%26epage%3D52%26doi%3D10.1007%2Fs40265-016-0607-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahradnik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imanishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koshiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljunggren, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyauchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Econs, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavigne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juppner, H.</span></span> <span> </span><span class="NLM_article-title">Fibroblast growth factor 23 in oncogenic osteomalacia and x-linked hypophosphatemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">1656</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa020881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1056%2FNEJMoa020881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=12711740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtFSnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=1656-63&author=K.+B.+Jonssonauthor=R.+Zahradnikauthor=T.+Larssonauthor=K.+E.+Whiteauthor=T.+Sugimotoauthor=Y.+Imanishiauthor=T.+Yamamotoauthor=G.+Hampsonauthor=H.+Koshiyamaauthor=O.+Ljunggrenauthor=K.+Obaauthor=I.+M.+Yangauthor=A.+Miyauchiauthor=M.+J.+Econsauthor=J.+Lavigneauthor=H.+Juppner&title=Fibroblast+growth+factor+23+in+oncogenic+osteomalacia+and+x-linked+hypophosphatemia&doi=10.1056%2FNEJMoa020881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia</span></div><div class="casAuthors">Jonsson, Kenneth B.; Zahradnik, Richard; Larsson, Tobias; White, Kenneth E.; Sugimoto, Toshitsugu; Imanishi, Yasuo; Yamamoto, Takehisa; Hampson, Geeta; Koshiyama, Hiroyuki; Ljunggren, Osten; Oba, Koichi; Yang, Myung; Miyauchi, Akimitsu; Econs, Michael J.; Lavigne, Jeffrey; Juppner, Harald</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1656-1663</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations in fibroblast growth factor 23 (FGF-23) cause autosomal dominant hypophosphatemic rickets.  Clin. and lab. findings in this disorder are similar to those in oncogenic osteomalacia, in which tumors abundantly express FGF-23 mRNA, and to those in X-linked hypophosphatemia, which is caused by inactivating mutations in a phosphate-regulating endopeptidase called PHEX.  Recombinant FGF-23 induces phosphaturia and hypophosphatemia in vivo, suggesting that it has a role in phosphate regulation.  To det. whether FGF-23 circulates in healthy persons and whether it is elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, an immunometric assay was developed to measure it.  Using affinity-purified, polyclonal antibodies against [Tyr223]FGF-23(206-222)amide and [Tyr224]FGF-23(225-244)amide, we developed a two-site ELISA that detects equivalently recombinant human FGF-23, the mutant form in which glutamine is substituted for arginine at position 179 (R179Q), and synthetic human FGF-23(207-244)amide.  Plasma or serum samples from 147 healthy adults (mean [±SD] age, 48.4±19.6 yr) and 26 healthy children (mean age, 10.9±5.5 yr) and from 17 patients with oncogenic osteomalacia (mean age, 43.0±13.3 yr) and 21 patients with X-linked hypophosphatemia (mean age, 34.9±17.2 yr) were studied.  Mean FGF-23 concns. in the healthy adults and children were 55±50 and 69±36 ref. units (RU) per mL, resp.  Four patients with oncogenic osteomalacia had concns. ranging from 426 to 7970 RU per mL, which normalized after tumor resection.  FGF-23 concns. were 481±528 RU per mL in those with suspected oncogenic osteomalacia and 353±510 RU per mL (range, 31 to 2335) in those with X-linked hypophosphatemia.  FGF-23 is readily detectable in the plasma or serum of healthy persons and can be markedly elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, suggesting that this growth factor has a role in phosphate homeostasis.  FGF-23 measurements might improve the management of phosphate-wasting disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQFKZARSC3KrVg90H21EOLACvtfcHk0lgv5A0Ex1RxYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtFSnsbk%253D&md5=0f67ab98e9c8a93a5f1d893410d6ebd7</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020881%26sid%3Dliteratum%253Aachs%26aulast%3DJonsson%26aufirst%3DK.%2BB.%26aulast%3DZahradnik%26aufirst%3DR.%26aulast%3DLarsson%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DK.%2BE.%26aulast%3DSugimoto%26aufirst%3DT.%26aulast%3DImanishi%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DHampson%26aufirst%3DG.%26aulast%3DKoshiyama%26aufirst%3DH.%26aulast%3DLjunggren%26aufirst%3DO.%26aulast%3DOba%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DI.%2BM.%26aulast%3DMiyauchi%26aufirst%3DA.%26aulast%3DEcons%26aufirst%3DM.%2BJ.%26aulast%3DLavigne%26aufirst%3DJ.%26aulast%3DJuppner%26aufirst%3DH.%26atitle%3DFibroblast%2520growth%2520factor%252023%2520in%2520oncogenic%2520osteomalacia%2520and%2520x-linked%2520hypophosphatemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D1656%26epage%3D63%26doi%3D10.1056%2FNEJMoa020881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, J. D.</span></span> <span> </span><span class="NLM_article-title">Cystic fibrosis lung disease and bronchiectasis</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(19)30335-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS2213-2600%2819%2930335-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31570316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3Mnjs1Krtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=12-14&author=J.+D.+Chalmers&title=Cystic+fibrosis+lung+disease+and+bronchiectasis&doi=10.1016%2FS2213-2600%2819%2930335-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic fibrosis lung disease and bronchiectasis</span></div><div class="casAuthors">Chalmers James D</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Respiratory medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSaWRW6W3CE9tFxYDaSSP8XfW6udTcc2ebIAlYeggapH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mnjs1Krtg%253D%253D&md5=694630bce50130fb2e545f2acb82018c</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2819%2930335-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252819%252930335-2%26sid%3Dliteratum%253Aachs%26aulast%3DChalmers%26aufirst%3DJ.%2BD.%26atitle%3DCystic%2520fibrosis%2520lung%2520disease%2520and%2520bronchiectasis%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2020%26volume%3D8%26spage%3D12%26epage%3D14%26doi%3D10.1016%2FS2213-2600%2819%2930335-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaudary, N.</span></span> <span> </span><span class="NLM_article-title">Triplet cftr modulators: Future prospects for treatment of cystic fibrosis</span>. <i>Ther. Clin. Risk Manage.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2375</span>– <span class="NLM_lpage">2383</span>, <span class="refDoi"> DOI: 10.2147/TCRM.S147164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2147%2FTCRM.S147164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30584312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOht73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=2375-2383&author=N.+Chaudary&title=Triplet+cftr+modulators%3A+Future+prospects+for+treatment+of+cystic+fibrosis&doi=10.2147%2FTCRM.S147164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Triplet CFTR modulators: future prospects for treatment of cystic fibrosis</span></div><div class="casAuthors">Chaudary, Nauman</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2375-2383</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1178-203X</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is an autosomal recessive genetic disease characterized by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR).  CFTR is a chloride channel responsible for ion flow across epithelial surfaces of lung, sinuses, pancreas, intestine, and liver.  Researchers have grouped CFTR genetic mutations into various protein defects: reduced protein synthesis (class 1 mutations), abnormal protein folding and maturation (class 2 mutation), and abnormal gating (class 3 mutation).  These mutations usually present as severe forms of CF due to complete absence of CFTR at cell surfaces.  Milder forms (eg, protein maturation and conductance defects, classes 4-6) present as less severe forms of CF related to the presence of CFTR at the cell surface.  Differences in severity are directly due to CFTR function which is based on the severity of CFTR mutation.  This knowledge has proven useful for designing therapy for individual mutations and mutation classes.  The discovery and US Food and Drug Administration approval of Kalydeco (ivacaftor) in early 2011 marked the beginning of a new era of therapies that are focused on improving defective CFTR protein function.  However, due to its specificity for the G551D mutation, ivacaftor only benefits ∼5% of CF patients.  Approx. 50% of CF patients have two copies of the F508Del mutation, while other CF patients carry only one copy of this gene.  More recently, Orkambi, a two compd. medication composed of lumacaftor and ivacaftor, has provided the foundation necessary to further build on mol. concepts of: correction of trafficking, potentiation, and amplification of defective CFTR.  These new concepts will form the basis of future CF therapies and extend CFTR treatment to almost 50% of CF patients.  Evolving knowledge of the mol. mechanisms responsible for defective CFTR has prompted new research focused on "repair" of each phase of CFTR expression and function, thus creating a new class of combination "CFTR correctors" referred to as "triplet CFTR compds." This article will review how patients can be selected and treated with these newer agents that are based on specific mutations.  In the future, many CF practitioners have expectations that initiation of treatment for CF patients will occur simply by use of biomarkers of CFTR expression (eg, sweat chloride, nasal p.d., rectal organoids) rather than testing for specific mutations.  As continued research identifies biomarkers with greater specificity and which predict clin. response, therapies can potentially be tailored to individual responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh4w9llfyQ17Vg90H21EOLACvtfcHk0lhuiQBE5-HfBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOht73M&md5=e2e2c46be24a0e4a7aad96e2d1a9c5da</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S147164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S147164%26sid%3Dliteratum%253Aachs%26aulast%3DChaudary%26aufirst%3DN.%26atitle%3DTriplet%2520cftr%2520modulators%253A%2520Future%2520prospects%2520for%2520treatment%2520of%2520cystic%2520fibrosis%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2018%26volume%3D14%26spage%3D2375%26epage%3D2383%26doi%3D10.2147%2FTCRM.S147164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span> </span><span class="NLM_article-title">Cystic fibrosis market: Information by treatment
method (medication,
devices, others) and region (north america, europe, asia-pacific and
the middle east & africa) - forecast till 2025</span>. <a href="https://www.marketresearchfuture.com/reports/cystic-fibrosis-market-1825" class="extLink">https://www.marketresearchfuture.com/reports/cystic-fibrosis-market-1825</a> (accessed Jun 30, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cystic+fibrosis+market%3A+Information+by+treatment%0Amethod+%28medication%2C%0Adevices%2C+others%29+and+region+%28north+america%2C+europe%2C+asia-pacific+and%0Athe+middle+east+%26+africa%29+-+forecast+till+2025.+https%3A%2F%2Fwww.marketresearchfuture.com%2Freports%2Fcystic-fibrosis-market-1825+%28accessed+Jun+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DCystic%2520fibrosis%2520market%253A%2520Information%2520by%2520treatment%250Amethod%2520%2528medication%252C%250Adevices%252C%2520others%2529%2520and%2520region%2520%2528north%2520america%252C%2520europe%252C%2520asia-pacific%2520and%250Athe%2520middle%2520east%2520%2526%2520africa%2529%2520-%2520forecast%2520till%25202025%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O'Brien, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghaddam, M. F.</span></span> <span> </span><span class="NLM_article-title">A systematic analysis of physicochemical and adme properties of all small molecule kinase inhibitors approved by us fda from january 2001 to october 2015</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3159</span>– <span class="NLM_lpage">3184</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170523124441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2174%2F0929867324666170523124441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28545370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1KgsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=3159-3184&author=Z.+O%27Brienauthor=M.+F.+Moghaddam&title=A+systematic+analysis+of+physicochemical+and+adme+properties+of+all+small+molecule+kinase+inhibitors+approved+by+us+fda+from+january+2001+to+october+2015&doi=10.2174%2F0929867324666170523124441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">A Systematic Analysis of Physicochemical and ADME Properties of All Small Molecule Kinase Inhibitors Approved by US FDA from January 2001 to October 2015</span></div><div class="casAuthors">O'Brien, Zhihong; Moghaddam, Mehran F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3159-3184</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: During lead identification and optimization, the advancement criteria may be driven based on scientific principles, prior experiences, and/or by examg. the path paved by approved drugs.  However, accessing the discovery data on physicochem. and ADME properties of the approved kinase inhibitors is a monumental task as these are either scattered in the literature or have not been published. </P><P> Objective: Our goals were: (1) To compile the relevant data on all kinase inhibitors approved prior to 2016 for easy access by the biopharmaceutical community, (2) To provide a retrospective anal. to highlight trends and attributes which may have contributed to the "developability" of these drugs, and (3) To ignite focused debates on what constitutes "actionable", "nice-to-have", and unnecessary data.  Such debates bring about more clarity on stage appropriateness of different types of information and prevent confusion due to abundance of unnecessary data, leading to more efficient and less costly drug discovery programs. </P><P> Methods: A careful and thorough anal. of different bodies of data such as published manuscripts, and available regulatory documents were employed. </P><P> Results: We were able to assemble a large body of data on the first thirty kinase inhibitors approved by US FDA since 2001. </P><P> Conclusion: In conclusion, we have compiled physicochem. and ADME data on the first 30 approved kinase inhibitors and provided our retrospective anal., which we hope is helpful in constructing advancement criteria in discovery programs.  The examn. of this data provides an opportunity to develop an opinion on data prioritization and stage appropriateness of assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_uv62dmVFrLVg90H21EOLACvtfcHk0lhuiQBE5-HfBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1KgsLfF&md5=0bd6e7df021378749c4cdef4a5ee5aa4</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170523124441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170523124441%26sid%3Dliteratum%253Aachs%26aulast%3DO%2527Brien%26aufirst%3DZ.%26aulast%3DMoghaddam%26aufirst%3DM.%2BF.%26atitle%3DA%2520systematic%2520analysis%2520of%2520physicochemical%2520and%2520adme%2520properties%2520of%2520all%2520small%2520molecule%2520kinase%2520inhibitors%2520approved%2520by%2520us%2520fda%2520from%2520january%25202001%2520to%2520october%25202015%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26volume%3D24%26spage%3D3159%26epage%3D3184%26doi%3D10.2174%2F0929867324666170523124441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span> </span><span class="NLM_article-title">Metabolism drugs market growing strongly
with glaxosmithkline plc.,
merck & co., amicus therapeutics, sanofi genzyme, astrazeneca
plc, horizon pharma plc</span>. <a href="http://www.digitaljournal.com/pr/4145873" class="extLink">http://www.digitaljournal.com/pr/4145873</a> (accessed Jun 30, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Metabolism+drugs+market+growing+strongly%0Awith+glaxosmithkline+plc.%2C%0Amerck+%26+co.%2C+amicus+therapeutics%2C+sanofi+genzyme%2C+astrazeneca%0Aplc%2C+horizon+pharma+plc.+http%3A%2F%2Fwww.digitaljournal.com%2Fpr%2F4145873+%28accessed+Jun+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DMetabolism%2520drugs%2520market%2520growing%2520strongly%250Awith%2520glaxosmithkline%2520plc.%252C%250Amerck%2520%2526%2520co.%252C%2520amicus%2520therapeutics%252C%2520sanofi%2520genzyme%252C%2520astrazeneca%250Aplc%252C%2520horizon%2520pharma%2520plc%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhaliwal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahesh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, A. N.</span></span> <span> </span><span class="NLM_article-title">The burden of chronic respiratory diseases and their heterogeneity across the states of india: The global burden of disease study 1990–2016</span>. <i>Lancet Glob. Health</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e1363</span>– <span class="NLM_lpage">e1374</span>, <span class="refDoi"> DOI: 10.1016/S2214-109X(18)30409-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS2214-109X%2818%2930409-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30219316" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=e1363-e1374&author=S.+Salviauthor=G.+A.+Kumarauthor=R.+Dhaliwalauthor=K.+Paulsonauthor=A.+Agrawalauthor=P.+A.+Koulauthor=P.+Maheshauthor=S.+Nairauthor=V.+Singhauthor=A.+N.+Aggarwal&title=The+burden+of+chronic+respiratory+diseases+and+their+heterogeneity+across+the+states+of+india%3A+The+global+burden+of+disease+study+1990%E2%80%932016&doi=10.1016%2FS2214-109X%2818%2930409-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2FS2214-109X%2818%2930409-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2214-109X%252818%252930409-1%26sid%3Dliteratum%253Aachs%26aulast%3DSalvi%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DG.%2BA.%26aulast%3DDhaliwal%26aufirst%3DR.%26aulast%3DPaulson%26aufirst%3DK.%26aulast%3DAgrawal%26aufirst%3DA.%26aulast%3DKoul%26aufirst%3DP.%2BA.%26aulast%3DMahesh%26aufirst%3DP.%26aulast%3DNair%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DV.%26aulast%3DAggarwal%26aufirst%3DA.%2BN.%26atitle%3DThe%2520burden%2520of%2520chronic%2520respiratory%2520diseases%2520and%2520their%2520heterogeneity%2520across%2520the%2520states%2520of%2520india%253A%2520The%2520global%2520burden%2520of%2520disease%2520study%25201990%25E2%2580%25932016%26jtitle%3DLancet%2520Glob.%2520Health%26date%3D2018%26volume%3D6%26spage%3De1363%26epage%3De1374%26doi%3D10.1016%2FS2214-109X%2818%2930409-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quaderi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, J. R.</span></span> <span> </span><span class="NLM_article-title">The unmet global burden of copd</span>. <i>Glob. Health Epidemiol. Genom.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e4</span> <span class="refDoi"> DOI: 10.1017/gheg.2018.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1017%2Fgheg.2018.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29868229" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&author=S.+A.+Quaderiauthor=J.+R.+Hurst&title=The+unmet+global+burden+of+copd&doi=10.1017%2Fgheg.2018.1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1017%2Fgheg.2018.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252Fgheg.2018.1%26sid%3Dliteratum%253Aachs%26aulast%3DQuaderi%26aufirst%3DS.%2BA.%26aulast%3DHurst%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520unmet%2520global%2520burden%2520of%2520copd%26jtitle%3DGlob.%2520Health%2520Epidemiol.%2520Genom.%26date%3D2018%26volume%3D3%26doi%3D10.1017%2Fgheg.2018.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-A.</span></span> <span> </span><span class="NLM_article-title">Revefenacin: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1036-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-018-1036-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30560478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=85-91&author=Y.-A.+Heo&title=Revefenacin%3A+First+global+approval&doi=10.1007%2Fs40265-018-1036-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Revefenacin: First Global Approval</span></div><div class="casAuthors">Heo, Young-A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-91</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Revefenacin (YUPELRI) inhalation soln., a long-acting muscarinic antagonist (i.e. an anticholinergic) developed by Theravance Biopharma and Mylan, is the first and currently the only once-daily, nebulized bronchodilator to be approved in the USA for the treatment of chronic obstructive pulmonary disease (COPD).  In Nov. 2018, based on results of three phase III trials, the US Food and Drug Administration granted market authorization to revefenacin for the maintenance treatment of patients with COPD.  This article summarizes the milestones in the development of revefenacin leading to this first global approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreKt8JGiq2GLVg90H21EOLACvtfcHk0lgs2gw1Efk3OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7F&md5=09384e244c9d6b3f9b4d39dd87705057</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1036-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1036-x%26sid%3Dliteratum%253Aachs%26aulast%3DHeo%26aufirst%3DY.-A.%26atitle%3DRevefenacin%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D85%26epage%3D91%26doi%3D10.1007%2Fs40265-018-1036-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalliokoski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, M.</span></span> <span> </span><span class="NLM_article-title">Impact of oatp transporters on pharmacokinetics</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00430.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1111%2Fj.1476-5381.2009.00430.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=693-705&author=A.+Kalliokoskiauthor=M.+Niemi&title=Impact+of+oatp+transporters+on+pharmacokinetics&doi=10.1111%2Fj.1476-5381.2009.00430.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00430.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00430.x%26sid%3Dliteratum%253Aachs%26aulast%3DKalliokoski%26aufirst%3DA.%26aulast%3DNiemi%26aufirst%3DM.%26atitle%3DImpact%2520of%2520oatp%2520transporters%2520on%2520pharmacokinetics%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D693%26epage%3D705%26doi%3D10.1111%2Fj.1476-5381.2009.00430.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span> </span><span class="NLM_article-title">Respiratory diseases drugs global market
report 2020–30: Covid
19 implications and growth</span>. <a href="https://www.thebusinessresearchcompany.com/report/respiratory-diseases-drugs-global-market-report-2020-30-covid-19-implications-and-growth" class="extLink">https://www.thebusinessresearchcompany.com/report/respiratory-diseases-drugs-global-market-report-2020-30-covid-19-implications-and-growth</a> (accessed Jun 15, <span class="NLM_year">2020</span>, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Respiratory+diseases+drugs+global+market%0Areport+2020%E2%80%9330%3A+Covid%0A19+implications+and+growth.+https%3A%2F%2Fwww.thebusinessresearchcompany.com%2Freport%2Frespiratory-diseases-drugs-global-market-report-2020-30-covid-19-implications-and-growth+%28accessed+Jun+15%2C+2020%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DRespiratory%2520diseases%2520drugs%2520global%2520market%250Areport%25202020%25E2%2580%259330%253A%2520Covid%250A19%2520implications%2520and%2520growth%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patridge, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span> <span> </span><span class="NLM_article-title">An analysis of fda-approved drugs for infectious disease: Antibacterial agents</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1283</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.drudis.2014.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25043770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlWkurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1283-7&author=M.+S.+Kinchauthor=E.+Patridgeauthor=M.+Plummerauthor=D.+Hoyer&title=An+analysis+of+fda-approved+drugs+for+infectious+disease%3A+Antibacterial+agents&doi=10.1016%2Fj.drudis.2014.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of FDA-approved drugs for infectious disease: antibacterial agents</span></div><div class="casAuthors">Kinch, Michael S.; Patridge, Eric; Plummer, Mark; Hoyer, Denton</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1283-1287</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Drugs targeting infectious diseases have greatly improved public health.  A study to evaluate all US Food and Drug Administration (FDA)-approved new mol. entities (NMEs) reveals that the no. of new agents targeting infectious disease peaked during the 1990s and declined rapidly thereafter.  Mols. targeting bacterial pathogens represent the most common component of anti-infectives followed by antivirals and antifungals.  Focusing on antibacterial agents, an increase in new NMEs predominated from the 1960s through to the 1990s, dropping sharply thereafter.  Obsolescence and resistance has eliminated one-third of these drugs.  Consequently, the arsenal of antibiotics peaked in 2000 and is declining.  Likewise, the no. of organizations awarded at least one NME for a bacterial indication has declined to a level not seen in more than a half century.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO5j--2mVqaLVg90H21EOLACvtfcHk0lgs2gw1Efk3OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlWkurfI&md5=407c7b429adec64ac5f68bdf153bc314</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DPatridge%26aufirst%3DE.%26aulast%3DPlummer%26aufirst%3DM.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DAn%2520analysis%2520of%2520fda-approved%2520drugs%2520for%2520infectious%2520disease%253A%2520Antibacterial%2520agents%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1283%26epage%3D7%26doi%3D10.1016%2Fj.drudis.2014.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adámková, V.</span></span> <span> </span><span class="NLM_article-title">The role of new antibiotics in intra-abdominal infections in the era of multi-resistant bacteria</span>. <i>Rozhl. Chir.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31159547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3M3ivVaitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2019&pages=145-151&author=V.+Ad%C3%A1mkov%C3%A1&title=The+role+of+new+antibiotics+in+intra-abdominal+infections+in+the+era+of+multi-resistant+bacteria"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">The role of new antibiotics in intra-abdominal infections in the era of multi-resistant bacteria</span></div><div class="casAuthors">Adamkova V</div><div class="citationInfo"><span class="NLM_cas:title">Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">145-151</span>
        ISSN:<span class="NLM_cas:issn">0035-9351</span>.
    </div><div class="casAbstract">Complicated intra-abdominal infections (cIAI) are a substantial cause of morbidity at intensive care units. cIAI are frequently caused by multidrug-resistant strains of Enterobacteriaceae and Pseudomonas aeruginosa.  In 592 cIAI patients from the First Department of Surgery, General University Hospital in Prague, we found an alarming increase in resistance of Escherichia coli to amoxicillin/clavulanic acid, piperacillin/tazobactam and third-generation cephalosporins in 2014-2017 (from 28.7% in 2014 to 37.5% in 2017, from 25% to 32% and from 2.3% to 5.6%, respectively).  Ceftolozane/tazobactam and ceftazidime/avibactam are novel cephalosporins available for the treatment of cIAI.  Ceftolozane/tazobactam is highly active against multidrug-resistant strains of P. aeruginosa, including carbapenem-resistant isolates.  The new non-b-lactam b-lactamase inhibitor avibactam plus ceftazidime is active against carbapenemases-producing strains of Enterobacteriaceae.  Both antibiotics are included in the new WSES guidelines for the management of cIAI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkIjmGeHXs79y3lHz94U-GfW6udTcc2eZMV5mi2bu4j7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3ivVaitw%253D%253D&md5=58ee667875dcda3d529000ef65e59d2c</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAd%25C3%25A1mkov%25C3%25A1%26aufirst%3DV.%26atitle%3DThe%2520role%2520of%2520new%2520antibiotics%2520in%2520intra-abdominal%2520infections%2520in%2520the%2520era%2520of%2520multi-resistant%2520bacteria%26jtitle%3DRozhl.%2520Chir.%26date%3D2019%26volume%3D98%26spage%3D145%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bussi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, M. G.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis infection of host cells in space and time</span>. <i>FEMS Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1093/femsre/fuz006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1093%2Ffemsre%2Ffuz006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30916769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjvFWrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2019&pages=341-361&author=C.+Bussiauthor=M.+G.+Gutierrez&title=Mycobacterium+tuberculosis+infection+of+host+cells+in+space+and+time&doi=10.1093%2Ffemsre%2Ffuz006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Mycobacterium tuberculosis infection of host cells in space and time</span></div><div class="casAuthors">Bussi, Claudio; Gutierrez, Maximiliano G.</div><div class="citationInfo"><span class="NLM_cas:title">FEMS Microbiology Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">341-361</span>CODEN:
                <span class="NLM_cas:coden">FMREE4</span>;
        ISSN:<span class="NLM_cas:issn">1574-6976</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) caused by the bacterial pathogen Mycobacterium tuberculosis (Mtb) remains one of the deadliest infectious diseases with over a billion deaths in the past 200 years (Paulson 2013).  TB causes more deaths worldwide than any other single infectious agent, with 10.4 million new cases and close to 1.7 million deaths in 2017.  The obstacles that make TB hard to treat and eradicate are intrinsically linked to the intracellular lifestyle of Mtb.  Mtb needs to replicate within human cells to disseminate to other individuals and cause disease.  However, we still do not completely understand how Mtb manages to survive within eukaryotic cells and why some cells are able to eradicate this lethal pathogen.  Here, we summarise the current knowledge of the complex host cell-pathogen interactions in TB and review the cellular mechanisms operating at the interface between Mtb and the human host cell, highlighting the tech. and methodol. challenges to investigating the cell biol. of human host cell-Mtb interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA4PREQVJlXrVg90H21EOLACvtfcHk0lhLg_mVJ6YygQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjvFWrs7s%253D&md5=4c9fccfa1992d67241c76fc701faac35</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1093%2Ffemsre%2Ffuz006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ffemsre%252Ffuz006%26sid%3Dliteratum%253Aachs%26aulast%3DBussi%26aufirst%3DC.%26aulast%3DGutierrez%26aufirst%3DM.%2BG.%26atitle%3DMycobacterium%2520tuberculosis%2520infection%2520of%2520host%2520cells%2520in%2520space%2520and%2520time%26jtitle%3DFEMS%2520Microbiol.%2520Rev.%26date%3D2019%26volume%3D43%26spage%3D341%26epage%3D361%26doi%3D10.1093%2Ffemsre%2Ffuz006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Pretomanid: First approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1803</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01207-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-019-01207-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31583606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1797-1803&author=S.+J.+Keam&title=Pretomanid%3A+First+approval&doi=10.1007%2Fs40265-019-01207-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Pretomanid: First Approval</span></div><div class="casAuthors">Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1797-1803</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid, moxifloxacin and pyrazinamide) regimens, has been developed by the Global Alliance for TB Drug Development (TB Alliance) under license from Novartis, for the treatment for tuberculosis (TB).  TB Alliance has licensed Mylan to manufacture and commercialize pretomanid for use as part of the BPaMZ and BPaL regimens.  The license is non-exclusive in low- and middle-income countries and exclusive in high-income markets.  Pretomanid, as part of the BPaL regimen, was recently approved in the USA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) pathway for the treatment of adults with pulmonary extensively drug-resistant (XDR) or treatment-intolerant or non-responsive multidrug-resistant (MDR) TB.  Pretomanid is also under regulatory review in the EU.  This article summarizes the milestones in the development of pretomanid leading to this first regulatory approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ32shufXmAyUNoizSOkG_FfW6udTcc2eZMV5mi2bu4j7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D&md5=5c28b82e658d5ce4aa0f1187cf2e7736</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01207-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01207-9%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DPretomanid%253A%2520First%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1797%26epage%3D1803%26doi%3D10.1007%2Fs40265-019-01207-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saravolatz, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, G. E.</span></span> <span> </span><span class="NLM_article-title">Delafloxacin: A new anti-methicillin-resistant staphylococcus aureus fluoroquinolone</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1058</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1093/cid/ciy600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1093%2Fcid%2Fciy600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30060092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFSqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2019&pages=1058-1062&author=L.+D.+Saravolatzauthor=G.+E.+Stein&title=Delafloxacin%3A+A+new+anti-methicillin-resistant+staphylococcus+aureus+fluoroquinolone&doi=10.1093%2Fcid%2Fciy600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Delafloxacin: a new anti-methicillin-resistant Staphylococcus aureus fluoroquinolone</span></div><div class="casAuthors">Saravolatz, Louis D.; Stein, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1058-1062</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Delafloxacin (ABT 492) is a new fluoroquinolone available in both oral and parenteral formulations.  It has recently been approved by the Food and Drug Administration for the management of acute bacterial skin and skin structure infections.  When compared to combination therapy of vancomycin and aztreonam, delafloxacin was not inferior and had a favorable adverse event profile.  Furthermore, its anti-methicillin-resistant Staphylococcus aureus (MRSA) activity and favorable clin. response in MRSA infections distinguishes it from other fluoroquinolones.  This review focuses on the mode of action, antimicrobial activity, pharmacokinetics and pharmacodynamics, clin. indications, and safety profile of this drug.  Considerations for formulary addn. and its place in therapy are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOlwFggldgsLVg90H21EOLACvtfcHk0lhLg_mVJ6YygQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFSqs7s%253D&md5=ee75f5bb852dc4d3af6c73b60428e501</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciy600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciy600%26sid%3Dliteratum%253Aachs%26aulast%3DSaravolatz%26aufirst%3DL.%2BD.%26aulast%3DStein%26aufirst%3DG.%2BE.%26atitle%3DDelafloxacin%253A%2520A%2520new%2520anti-methicillin-resistant%2520staphylococcus%2520aureus%2520fluoroquinolone%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2019%26volume%3D68%26spage%3D1058%26epage%3D1062%26doi%3D10.1093%2Fcid%2Fciy600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abd
El Aziz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharifipour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahanfar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judge, H. M.</span></span> <span> </span><span class="NLM_article-title">Secnidazole for treatment of bacterial vaginosis: A systematic review</span>. <i>BMC Women's Health</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">121</span>, <span class="refDoi"> DOI: 10.1186/s12905-019-0822-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1186%2Fs12905-019-0822-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31638955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3MjgsFShsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=121&author=M.+A.+Abd%0AEl+Azizauthor=F.+Sharifipourauthor=P.+Abediauthor=S.+Jahanfarauthor=H.+M.+Judge&title=Secnidazole+for+treatment+of+bacterial+vaginosis%3A+A+systematic+review&doi=10.1186%2Fs12905-019-0822-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Secnidazole for treatment of bacterial vaginosis: a systematic review</span></div><div class="casAuthors">Abd El Aziz Mohamed A; Sharifipour Foruzan; Abedi Parvin; Jahanfar Shayesteh; Judge Helen Marie</div><div class="citationInfo"><span class="NLM_cas:title">BMC women's health</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Bacterial vaginosis (BV) is one of the common vaginal infections among childbearing women.  The usual treatment for BV is metronidazole; hence 30% of women have recurrence within 60 to 90 days after treatment.  There are some studies which assessed the effect of secnidazole on BV.  The aim of this systematic review was to investigate the effectiveness of secnidazole for treatment of BV.  METHODS:  The Cochrane Library, MEDLINE (PubMed), Scopus, and Web of Science (all databases from inception till October 28, 2018) were searched.  Primary outcomes were clinical cure rate and microbiologic cure rate and the secondary outcomes were adverse events.  Data was extracted from eligible studies by two review authors individually and analyzed by RevMan 5.3.  RESULTS:  Our search found six trials involving 1528 participants.  Treatment with 2 g secnidazole could significantly reduce the risk of BV in patients with three or less episodes of BV in the last year by OR: 7.54 (95% CI, 3.89-14.60, p < 0.00001) and in patients with four or more episodes of BV in the last year (OR: 4.74, 95% CI: 1.51-14.84, p = 0.0.008).  Secnidazole (2 g) could significantly increase the microbiologic cure rate in women with 3 or less episodes of BV in the last year (OR: 7.63, 95% CI: 2.30-25.33, p = 0.0009) but not in the women with 4 or more episodes of BV in the last year (OR: 20.17, 95% CI: 1.06-382.45, p = 0.05).  The clinical cure rate, microbiological effect and the therapeutic cure rate of 2 g secnidazole was significantly more than that of 1 g secnidazole.  The results showed that the clinical cure rate of 2 g secnidazole was not different from the following medications: metronidazole (500 mg bid for 5 days), secnidazole plus vaginal metronidazole, 2 g single dose of oral metronidazole and 2 g secnidazole plus vaginal ornidazole.  CONCLUSION:  This review showed that 2 g and 1 g secnidazole were better than placebo, however, 2 g secnidazole was more effective than 1 g.  Secnidazole 2 g was not different from metronidazole (500 mg bid for 5 days), or from secnidazole plus vaginal metronidazole, or 2 g single dose of oral metronidazole or from 2 g secnidazole plus vaginal ornidazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQYTKPPSdwrGUBuFdjgVNKSfW6udTcc2ebxQfUnleUPA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjgsFShsg%253D%253D&md5=0beb0627a8589b8552458eff0d7e32ad</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1186%2Fs12905-019-0822-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12905-019-0822-2%26sid%3Dliteratum%253Aachs%26aulast%3DAbd%2BEl%2BAziz%26aufirst%3DM.%2BA.%26aulast%3DSharifipour%26aufirst%3DF.%26aulast%3DAbedi%26aufirst%3DP.%26aulast%3DJahanfar%26aufirst%3DS.%26aulast%3DJudge%26aufirst%3DH.%2BM.%26atitle%3DSecnidazole%2520for%2520treatment%2520of%2520bacterial%2520vaginosis%253A%2520A%2520systematic%2520review%26jtitle%3DBMC%2520Women%2527s%2520Health%26date%3D2019%26volume%3D19%26spage%3D121%26doi%3D10.1186%2Fs12905-019-0822-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerding, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poxton, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornely, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahav, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouza, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabryelski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eves, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tipping, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartsonis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorr, M. B.</span></span>; <span class="NLM_contrib-group">for MODIFY I and</span>; <span class="NLM_contrib-group">MODIFY II Investigators</span> <span> </span><span class="NLM_article-title">Bezlotoxumab for prevention of recurrent clostridium difficile infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1602615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1056%2FNEJMoa1602615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28121498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSnsb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=305-317&author=M.+H.+Wilcoxauthor=D.+N.+Gerdingauthor=I.+R.+Poxtonauthor=C.+Kellyauthor=R.+Nathanauthor=T.+Birchauthor=O.+A.+Cornelyauthor=G.+Rahavauthor=E.+Bouzaauthor=C.+Leeauthor=G.+Jenkinauthor=W.+Jensenauthor=Y.+S.+Kimauthor=J.+Yoshidaauthor=L.+Gabryelskiauthor=A.+Pedleyauthor=K.+Evesauthor=R.+Tippingauthor=D.+Gurisauthor=N.+Kartsonisauthor=M.+B.+Dorrauthor=for+MODIFY+I+andauthor=MODIFY+II+Investigators&title=Bezlotoxumab+for+prevention+of+recurrent+clostridium+difficile+infection&doi=10.1056%2FNEJMoa1602615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Bezlotoxumab for prevention of recurrent Clostridium difficile infection</span></div><div class="casAuthors">Wilcox, M. H.; Gerding, D. N.; Poxton, I. R.; Kelly, C.; Nathan, R.; Birch, T.; Cornely, O. A.; Rahav, G.; Bouza, E.; Lee, C.; Jenkin, G.; Jensen, W.; Kim, Y.-S.; Yoshida, J.; Gabryelski, L.; Pedley, A.; Eves, K.; Tipping, R.; Guris, D.; Kartsonis, N.; Dorr, M.-B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-317</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients.  Recurrences are common after antibiotic therapy.  Actoxumab and bezlotoxumab are human monoclonal antibodies against C. difficile toxins A and B, resp.  METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials, MODIFY I and MODIFY II, involving 2655 adults receiving oral std.-of-care antibiotics for primary or recurrent C. difficile infection.  Participants received an infusion of bezlotoxumab (10 mg per kg of body wt.), actoxumab plus bezlotoxumab (10 mg per kg each), or placebo; actoxumab alone (10 mg per kg) was given in MODIFY I but discontinued after a planned interim anal.  The primary end point was recurrent infection (new episode after initial clin. cure) within 12 wk after infusion in the modified intention-to-treat population.  RESULTS: In both trials, the rate of recurrent C. difficile infection was significantly lower with bezlotoxumab alone than with placebo (MODIFY I: 17% [67 of 386] vs. 28% [109 of 395]; adjusted difference, -10.1 percentage points; 95% confidence interval [CI], -15.9 to -4.3; P<0.001; MODIFY II: 16% [62 of 395] vs. 26% [97 of 378]; adjusted difference, -9.9 percentage points; 95% CI, -15.5 to -4.3; P<0.001) and was significantly lower with actoxumab plus bezlotoxumab than with placebo (MODIFY I: 16% [61 of 383] vs. 28% [109 of 395]; adjusted difference, -11.6 percentage points; 95% CI, -17.4 to -5.9; P<0.001; MODIFY II: 15% [58 of 390] vs. 26% [97 of 378]; adjusted difference, -10.7 percentage points; 95% CI, -16.4 to -5.1; P<0.001).  In prespecified subgroup analyses (combined data set), rates of recurrent infection were lower in both groups that received bezlotoxumab than in the placebo group in subpopulations at high risk for recurrent infection or for an adverse outcome.  The rates of initial clin. cure were 80% with bezlotoxumab alone, 73% with actoxumab plus bezlotoxumab, and 80% with placebo; the rates of sustained cure (initial clin. cure without recurrent infection in 12 wk) were 64%, 58%, and 54%, resp.  The rates of adverse events were similar among these groups; the most common events were diarrhea and nausea.  CONCLUSIONS: Among participants receiving antibiotic treatment for primary or recurrent C. difficile infection, bezlotoxumab was assocd. with a substantially lower rate of recurrent infection than placebo and had a safety profile similar to that of placebo.  The addn. of actoxumab did not improve efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV4wySuwYB5LVg90H21EOLACvtfcHk0ljKe2gE8vU6fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSnsb%252FE&md5=de04b2005b3aebc6772c210127008242</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1602615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1602615%26sid%3Dliteratum%253Aachs%26aulast%3DWilcox%26aufirst%3DM.%2BH.%26aulast%3DGerding%26aufirst%3DD.%2BN.%26aulast%3DPoxton%26aufirst%3DI.%2BR.%26aulast%3DKelly%26aufirst%3DC.%26aulast%3DNathan%26aufirst%3DR.%26aulast%3DBirch%26aufirst%3DT.%26aulast%3DCornely%26aufirst%3DO.%2BA.%26aulast%3DRahav%26aufirst%3DG.%26aulast%3DBouza%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJenkin%26aufirst%3DG.%26aulast%3DJensen%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DYoshida%26aufirst%3DJ.%26aulast%3DGabryelski%26aufirst%3DL.%26aulast%3DPedley%26aufirst%3DA.%26aulast%3DEves%26aufirst%3DK.%26aulast%3DTipping%26aufirst%3DR.%26aulast%3DGuris%26aufirst%3DD.%26aulast%3DKartsonis%26aufirst%3DN.%26aulast%3DDorr%26aufirst%3DM.%2BB.%26aulast%3D%26aulast%3D%26atitle%3DBezlotoxumab%2520for%2520prevention%2520of%2520recurrent%2520clostridium%2520difficile%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D305%26epage%3D317%26doi%3D10.1056%2FNEJMoa1602615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foxman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmaseda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, A.</span></span> <span> </span><span class="NLM_article-title">Association between the respiratory microbiome and susceptibility to influenza virus infection</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1195</span>– <span class="NLM_lpage">1203</span>, <span class="refDoi"> DOI: 10.1093/cid/ciz968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1093%2Fcid%2Fciz968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31562814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs12gsrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2020&pages=1195-1203&author=T.+K.+Tsangauthor=K.+H.+Leeauthor=B.+Foxmanauthor=A.+Balmasedaauthor=L.+Greshauthor=N.+Sanchezauthor=S.+Ojedaauthor=R.+Lopezauthor=Y.+Yangauthor=G.+Kuanauthor=A.+Gordon&title=Association+between+the+respiratory+microbiome+and+susceptibility+to+influenza+virus+infection&doi=10.1093%2Fcid%2Fciz968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Association between the respiratory microbiome and susceptibility to influenza virus infection</span></div><div class="casAuthors">Tsang, Tim K.; Lee, Kyu Han; Foxman, Betsy; Balmaseda, Angel; Gresh, Lionel; Sanchez, Nery; Ojeda, Sergio; Lopez, Roger; Yang, Yang; Kuan, Guillermina; Gordon, Aubree</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1195-1203</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Our aim is to quantify the assocn. between the nose/throat microbiome and susceptibility to influenza virus infection.  In this household transmission study, index cases with confirmed influenza virus infection and their household contacts were followed for 9-12 days to identify secondary influenza infections.  Respiratory swabs were collected at enrollment to identify and quantify bacterial species via high-performance sequencing.  Data were analyzed by an individual hazard-based transmission model that was adjusted for age, vaccination, and household size.  We recruited 115 index cases with influenza A(H3N2) or B infection and 436 household contacts.  We estd. that a 10-fold increase in the abundance in Streptococcus spp. and Prevotella salivae was assocd. with 48% (95% credible interval [CrI], 9-69%) and 25% (95% CrI, 0.5-42%) lower susceptibility to influenza A(H3N2) infection, resp.  In contrast, for influenza B infection, a 10-fold increase in the abundance in Streptococcus vestibularis and Prevotella spp. was assocd. with 63% (95% CrI, 17-83%) lower and 83% (95% CrI, 15-210%) higher susceptibility, resp.  Susceptibility to influenza infection is assocd. with the nose/throat microbiome at the time of exposure.  Our results suggest that microbiome may be a useful predictor of susceptibility, with the implication that microbiome could be modulated to reduce influenza infection risk, should these assocns. be causal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouC-owfgIDPbVg90H21EOLACvtfcHk0ljKe2gE8vU6fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs12gsrnE&md5=469b30f7bcf65809e082eba7dbd27a66</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciz968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciz968%26sid%3Dliteratum%253Aachs%26aulast%3DTsang%26aufirst%3DT.%2BK.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DFoxman%26aufirst%3DB.%26aulast%3DBalmaseda%26aufirst%3DA.%26aulast%3DGresh%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DN.%26aulast%3DOjeda%26aufirst%3DS.%26aulast%3DLopez%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DKuan%26aufirst%3DG.%26aulast%3DGordon%26aufirst%3DA.%26atitle%3DAssociation%2520between%2520the%2520respiratory%2520microbiome%2520and%2520susceptibility%2520to%2520influenza%2520virus%2520infection%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2020%26volume%3D71%26spage%3D1195%26epage%3D1203%26doi%3D10.1093%2Fcid%2Fciz968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Indolfi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easterbrook, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dusheiko, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Sayed, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulterys, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siberry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.-H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Hepatitis c virus infection in children and adolescents</span>. <i>Lancet Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1016/S2468-1253(19)30046-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS2468-1253%2819%2930046-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30982721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252Flt1Wjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=477-487&author=G.+Indolfiauthor=P.+Easterbrookauthor=G.+Dusheikoauthor=M.+H.+El-Sayedauthor=M.+M.+Jonasauthor=C.+Thorneauthor=M.+Bulterysauthor=G.+Siberryauthor=N.+Walshauthor=M.-H.+Chang&title=Hepatitis+c+virus+infection+in+children+and+adolescents&doi=10.1016%2FS2468-1253%2819%2930046-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus infection in children and adolescents</span></div><div class="casAuthors">Indolfi Giuseppe; Easterbrook Philippa; Dusheiko Geoffrey; El-Sayed Manal H; Jonas Maureen M; Thorne Claire; Bulterys Marc; Penazzato Martina; Siberry George; Walsh Nick; Chang Mei-Hwei; Meyers Tammy; Giaquinto Carlo; Wirth Stefan; Chan Po-Lin</div><div class="citationInfo"><span class="NLM_cas:title">The lancet. Gastroenterology & hepatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">477-487</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and associated morbidity and mortality worldwide.  Short-course, oral, curative, direct-acting antiviral regimens have transformed treatment for HCV infection.  Since the 2016 launch of the first global strategy towards elimination of viral hepatitis as a public health threat by 2030, the predominant focus of the global response has been on the treatment of adults, who bear the greatest burden of morbidity and mortality of HCV-related chronic liver disease.  Compared with adults, there has been little attention paid to addressing the response to HCV in children and adolescents, in part because of the scarcity of data to inform specific paediatric management practices and policy.  In this Series paper, we summarise knowledge on the epidemiology, natural history, and treatment of chronic HCV infection in adolescents and children, and we highlight key differences from infection acquired in adulthood.  The estimated global prevalence and burden of HCV infection in children aged 1-19 years is 0·15%, corresponding to 3·5 million people (95% CI 3·1-3·9 million).  HCV infection is usually asymptomatic during childhood, and cirrhosis and hepatocellular carcinoma are rare.  Sofosbuvir with ledipasvir and sofosbuvir with ribavirin have received regulatory approval and guidelines recommend their use in adolescents aged 12 years and older with HCV infection.  In April, 2019, glecaprevir with pibrentasvir also received regulatory approval for adolescents aged 12-17 years.  Key actions to address the current policy gaps and achieve treatment scale-up that is comparable to that in adults include: establishment of a campaign on access to testing and treatment that is targeted at children and adolescents; fast-track evaluation of pan-genotypic regimens; and accelerated approval of paediatric formulations.  Research gaps that need to be addressed include: age-specific prevalence studies of HCV viraemia in priority countries; further validation of non-invasive tests for staging of liver disease in children; and establishment of paediatric treatment registries and international consortia to promote collaborative research agendas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgLXyOopm4iHy-c-E1v-fmfW6udTcc2eauaUP9MmJiM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252Flt1Wjsg%253D%253D&md5=f0fa1fb51b934216f2eba3de8a9010fc</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2FS2468-1253%2819%2930046-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2468-1253%252819%252930046-9%26sid%3Dliteratum%253Aachs%26aulast%3DIndolfi%26aufirst%3DG.%26aulast%3DEasterbrook%26aufirst%3DP.%26aulast%3DDusheiko%26aufirst%3DG.%26aulast%3DEl-Sayed%26aufirst%3DM.%2BH.%26aulast%3DJonas%26aufirst%3DM.%2BM.%26aulast%3DThorne%26aufirst%3DC.%26aulast%3DBulterys%26aufirst%3DM.%26aulast%3DSiberry%26aufirst%3DG.%26aulast%3DWalsh%26aufirst%3DN.%26aulast%3DChang%26aufirst%3DM.-H.%26atitle%3DHepatitis%2520c%2520virus%2520infection%2520in%2520children%2520and%2520adolescents%26jtitle%3DLancet%2520Gastroenterol.%2520Hepatol.%26date%3D2019%26volume%3D4%26spage%3D477%26epage%3D487%26doi%3D10.1016%2FS2468-1253%2819%2930046-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, R. T.</span></span> <span> </span><span class="NLM_article-title">Overview of direct-acting antiviral drugs and drug resistance of hepatitis c virus</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1911</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-8976-8_1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2F978-1-4939-8976-8_1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30593615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOlt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1911&publication_year=2019&pages=3-32&author=D.+K.+Liauthor=R.+T.+Chung&title=Overview+of+direct-acting+antiviral+drugs+and+drug+resistance+of+hepatitis+c+virus&doi=10.1007%2F978-1-4939-8976-8_1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of direct-acting antiviral drugs and drug resistance of hepatitis C virus</span></div><div class="casAuthors">Li, Darrick K.; Chung, Raymond T.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1911</span>
        (<span class="NLM_cas:issue">Hepatitis C Virus Protocols</span>),
    <span class="NLM_cas:pages">3-32</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The advent of direct-acting antivirals (DAAs) has brought about a sudden renaissance in the treatment of chronic hepatitis C virus (HCV) infection with SVR rates now routinely >90%.  However, due to the error-prone nature of the HCV RNA polymerase, resistance-assocd. substitutions (RASs) to DAAs may be present at baseline and can result in a significant effect on treatment outcomes and hamper the achievement of sustained virol. response.  By further understanding the patterns and nature of these RASs, it is anticipated that the incidence of treatment failure will continue to decrease in frequency with the development of drug regimens with increasing potency, barrier to resistance, and genotypic efficacy.  This review summarizes our current knowledge of RASs assocd. with HCV infection as well as the clin. effect of RASs on treatment with currently available DAA regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBMp7k4DAgQLVg90H21EOLACvtfcHk0lhDe0q_HHhf_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOlt73O&md5=2b19812051200f2e53703854f7d64641</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-8976-8_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-8976-8_1%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%2BK.%26aulast%3DChung%26aufirst%3DR.%2BT.%26atitle%3DOverview%2520of%2520direct-acting%2520antiviral%2520drugs%2520and%2520drug%2520resistance%2520of%2520hepatitis%2520c%2520virus%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2019%26volume%3D1911%26spage%3D3%26epage%3D32%26doi%3D10.1007%2F978-1-4939-8976-8_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Tecovirimat: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1377</span>– <span class="NLM_lpage">1382</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0967-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-018-0967-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30120738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFCku7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1377-1382&author=S.+M.+Hoy&title=Tecovirimat%3A+First+global+approval&doi=10.1007%2Fs40265-018-0967-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Tecovirimat: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1377-1382</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Tecovirimat (TPOXX) is an orthopoxvirus-specific antiviral drug developed by SIGA Technologies in conjunction with the US Department of Health and Human Services' Biomedical Advances Research and Development Authority.  It acts by inhibiting the activity of the orthopoxvirus VP37 envelope wrapping protein, thereby preventing the formation of egress-competent enveloped virions, which are essential for dissemination of the virus in the host.  In July 2018, oral tecovirimat was approved in the USA for the treatment of human smallpox disease caused by variola virus in adults and paediatric patients weighing ≥ 13 kg.  Tecovirimat was approved under the US FDA's Animal Rule, in which marketing approval is based on its efficacy in relevant animal models.  An i.v. formulation of tecovirimat is undergoing phase I development for the treatment of smallpox infection.  This article summarises the milestones in the development of tecovirimat leading to this first approval for the treatment of human smallpox disease in adults and paediatric patients weighing ≥ 13 kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsN9oWSErgorVg90H21EOLACvtfcHk0lhDe0q_HHhf_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFCku7bF&md5=5824b1ec39cfd2be5d1915a25debae3a</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0967-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0967-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DTecovirimat%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1377%26epage%3D1382%26doi%3D10.1007%2Fs40265-018-0967-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feachem, R. G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mpanju-Shumbusho, W.</span></span> <span> </span><span class="NLM_article-title">The lancet commission on malaria eradication</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span>,  <span class="NLM_fpage">1556</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)30911-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS0140-6736%2818%2930911-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29673872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC1MjksFCksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=1556-1558&author=I.+Chenauthor=R.+Cooneyauthor=R.+G.+A.+Feachemauthor=A.+Lalauthor=W.+Mpanju-Shumbusho&title=The+lancet+commission+on+malaria+eradication&doi=10.1016%2FS0140-6736%2818%2930911-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">The Lancet Commission on malaria eradication</span></div><div class="casAuthors">Chen Ingrid; Cooney Rebecca; Feachem Richard G A; Lal Altaf; Mpanju-Shumbusho Winnie</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">10130</span>),
    <span class="NLM_cas:pages">1556-1558</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKwo8-BMi-wpdYoSR9eyvsfW6udTcc2eZNxExiqJTmjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjksFCksQ%253D%253D&md5=34e0dc1ab91c668a37c8c90928795efc</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2930911-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252930911-5%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DI.%26aulast%3DCooney%26aufirst%3DR.%26aulast%3DFeachem%26aufirst%3DR.%2BG.%2BA.%26aulast%3DLal%26aufirst%3DA.%26aulast%3DMpanju-Shumbusho%26aufirst%3DW.%26atitle%3DThe%2520lancet%2520commission%2520on%2520malaria%2520eradication%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26spage%3D1556%26epage%3D1558%26doi%3D10.1016%2FS0140-6736%2818%2930911-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucher, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missinou, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangelmaier, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsner, P. G.</span></span> <span> </span><span class="NLM_article-title">Malaria chemoprophylaxis with tafenoquine: A randomised study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">2041</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(00)02352-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS0140-6736%2800%2902352-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10885356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksl2lt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2000&pages=2041-5&author=B.+Lellauthor=J.+F.+Faucherauthor=M.+A.+Missinouauthor=S.+Borrmannauthor=O.+Dangelmaierauthor=J.+Hortonauthor=P.+G.+Kremsner&title=Malaria+chemoprophylaxis+with+tafenoquine%3A+A+randomised+study&doi=10.1016%2FS0140-6736%2800%2902352-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Malaria chemoprophylaxis with tafenoquine: a randomized study</span></div><div class="casAuthors">Lell, Bertrand; Faucher, Jean-Francois; Missinou, Michel Anoumou; Borrmann, Steffen; Dangelmaier, Oliver; Horton, John; Kremsner, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">9220</span>),
    <span class="NLM_cas:pages">2041-2045</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Ltd.</span>)
        </div><div class="casAbstract">Background: Tafenoquine is an analog of primaquine with an improved therapeutic and safety profile.  It has a long half-life and activity against liver-stage malaria parasites, so may be useful for chemoprophylaxis.  In this randomized, double-blind study we assessed the efficacy and safety of tafenoquine in different doses.  Methods: 2144 individuals aged 12-20 yr living in Lambarene, Gabon, an endemic area for Plasmodium falciparum malaria, were invited to take part.  535 Attended, and 426 eligible participants were randomly assigned tafenoquine (250 mg, 125 mg, 62.5 mg, or 31.25 mg) or placebo daily for 3 days.  417 Received initial curative treatment with halofantrine, and 410 completed the assigned prophylaxis regimen.  During follow-up of 70 days, adverse events were recorded and thick blood smears were examd. weekly.  The primary and secondary endpoints were the no. of individuals with pos. blood smears by day 56 and day 77, resp.  Analyses were per-protocol.  Findings: Eight pos. blood smears were recorded by day 56 (four/82 participants in the placebo group; four/79 tafenoquine 31.25 mg group).  By day 77, 34 pos. blood smears had been recorded (14/82 placebo; 16/79 tafenoquine 31.25 mg; three/86 tafenoquine 62.5 mg; one/79 tafenoquine 125 mg; none/84 tafenoquine 250 mg).  Nos. of adverse events did not differ significantly between the treatment groups.  Interpretation: Tafenoquine is effective and well tolerated.  It has the potential to replace currently used drugs for malaria chemoprophylaxis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh-QTW9SUuGrVg90H21EOLACvtfcHk0lgf7KKlpT7hOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksl2lt7k%253D&md5=8b2a30a90eefb73f5ccc81db9a4f98e8</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2800%2902352-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252800%252902352-7%26sid%3Dliteratum%253Aachs%26aulast%3DLell%26aufirst%3DB.%26aulast%3DFaucher%26aufirst%3DJ.%2BF.%26aulast%3DMissinou%26aufirst%3DM.%2BA.%26aulast%3DBorrmann%26aufirst%3DS.%26aulast%3DDangelmaier%26aufirst%3DO.%26aulast%3DHorton%26aufirst%3DJ.%26aulast%3DKremsner%26aufirst%3DP.%2BG.%26atitle%3DMalaria%2520chemoprophylaxis%2520with%2520tafenoquine%253A%2520A%2520randomised%2520study%26jtitle%3DLancet%26date%3D2000%26volume%3D355%26spage%3D2041%26epage%3D5%26doi%3D10.1016%2FS0140-6736%2800%2902352-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span> </span><span class="NLM_article-title">Infectious disease therapeutics market emerging
players may yields
new opportunities 2020–2026</span> |  <i>Novartis
AG, Gilead, GlaxoSmithKline plc</i>; <span class="NLM_publisher-name">Janssen
Pharmaceutical Inc., f. Hoffmann-La Roche ltd., Biocryst Pharmaceuticals
Inc., Merck & co. Inc., Boehringer Ingelheim Gmbh etc</span>. <a href="https://primefeed.in/news/4878852/infectious-disease-therapeutics-market-emerging-players-may-yields-new-opportunities-2020-2026-novartis-ag-gilead-glaxosmithkline-plc-janssen-pharmaceutical-inc-f-hoffmann-la-roche-ltd-biocr/" class="extLink">https://primefeed.in/news/4878852/infectious-disease-therapeutics-market-emerging-players-may-yields-new-opportunities-2020-2026-novartis-ag-gilead-glaxosmithkline-plc-janssen-pharmaceutical-inc-f-hoffmann-la-roche-ltd-biocr/</a> (accessed Jun 30, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Infectious+disease+therapeutics+market+emerging%0Aplayers+may+yields%0Anew+opportunities+2020%E2%80%932026+%7C+Novartis%0AAG%2C+Gilead%2C+GlaxoSmithKline+plc%3B+Janssen%0APharmaceutical+Inc.%2C+f.+Hoffmann-La+Roche+ltd.%2C+Biocryst+Pharmaceuticals%0AInc.%2C+Merck+%26+co.+Inc.%2C+Boehringer+Ingelheim+Gmbh+etc.+https%3A%2F%2Fprimefeed.in%2Fnews%2F4878852%2Finfectious-disease-therapeutics-market-emerging-players-may-yields-new-opportunities-2020-2026-novartis-ag-gilead-glaxosmithkline-plc-janssen-pharmaceutical-inc-f-hoffmann-la-roche-ltd-biocr%2F+%28accessed+Jun+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DInfectious%2520disease%2520therapeutics%2520market%2520emerging%250Aplayers%2520may%2520yields%250Anew%2520opportunities%25202020%25E2%2580%25932026%26btitle%3DNovartis%250AAG%252C%2520Gilead%252C%2520GlaxoSmithKline%2520plc%26pub%3DJanssen%250APharmaceutical%2520Inc.%252C%2520f.%2520Hoffmann-La%2520Roche%2520ltd.%252C%2520Biocryst%2520Pharmaceuticals%250AInc.%252C%2520Merck%2520%2526%2520co.%2520Inc.%252C%2520Boehringer%2520Ingelheim%2520Gmbh%2520etc%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span> </span><span class="NLM_article-title">Global
anti-infective drugs market 2020</span>. <a href="https://www.pharmiweb.com/press-release/2020-10-08/covid-19-update-global-anti-infective-drugs-market-2020-major-players-are-merck-co-inc-f-ho" class="extLink">https://www.pharmiweb.com/press-release/2020-10-08/covid-19-update-global-anti-infective-drugs-market-2020-major-players-are-merck-co-inc-f-ho</a> (accessed Nov 24, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global%0Aanti-infective+drugs+market+2020.+https%3A%2F%2Fwww.pharmiweb.com%2Fpress-release%2F2020-10-08%2Fcovid-19-update-global-anti-infective-drugs-market-2020-major-players-are-merck-co-inc-f-ho+%28accessed+Nov+24%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGlobal%250Aanti-infective%2520drugs%2520market%25202020%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, A.</span>; <span class="NLM_string-name">Diamond, B.</span></span> <span> </span><span class="NLM_article-title">General features of autoimmune disease</span>. In  <i>The Autoimmune Diseases</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, N. R.</span>, <span class="NLM_string-name">Mackay, I. R.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_year">2020</span>; pp  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">44</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FB978-0-12-812102-3.00003-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=17-44&author=A.+Davidson&author=B.+Diamondauthor=N.+R.+Rose&author=I.+R.+Mackay&title=The+Autoimmune+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-812102-3.00003-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-812102-3.00003-8%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DA.%26atitle%3DGeneral%2520features%2520of%2520autoimmune%2520disease%26btitle%3DThe%2520Autoimmune%2520Diseases%26aulast%3DRose%26aufirst%3DN.%2BR.%26pub%3DElsevier%26date%3D2020%26spage%3D17%26epage%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeeth, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A. J.</span></span> <span> </span><span class="NLM_article-title">Burden of mortality associated with autoimmune diseases among females in the united kingdom</span>. <i>Am. J. Public Health</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">2279</span>– <span class="NLM_lpage">2287</span>, <span class="refDoi"> DOI: 10.2105/AJPH.2009.180273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2105%2FAJPH.2009.180273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=20864721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC3cfotlChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2010&pages=2279-2287&author=S.+L.+Thomasauthor=C.+Griffithsauthor=L.+Smeethauthor=C.+Rooneyauthor=A.+J.+Hall&title=Burden+of+mortality+associated+with+autoimmune+diseases+among+females+in+the+united+kingdom&doi=10.2105%2FAJPH.2009.180273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Burden of mortality associated with autoimmune diseases among females in the United Kingdom</span></div><div class="casAuthors">Thomas Sara L; Griffiths Clare; Smeeth Liam; Rooney Cleo; Hall Andrew J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of public health</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2279-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  We estimated the collective burden of mortality from autoimmune diseases among females in the United Kingdom and the effects of death certificate coding changes on this estimate.  METHODS:  We analyzed 1993-2003 England and Wales death certificate data for 3,150,267 females aged 1 year or older.  We identified death certificates that listed autoimmune conditions as underlying or contributory causes of death.  The percentages of all female deaths attributed to autoimmune disorders and to UK official mortality categories were ranked to determine the leading causes of death.  RESULTS:  In 2003, autoimmune diseases were the sixth or seventh most frequent underlying cause of death among females in all age groups below 75 years.  Results were similar when both underlying and contributory causes of death were considered.  The proportion of females dying with an autoimmune disorder remained relatively constant from 1993 to 2003.  Analyses indicated that death counts for specific autoimmune diseases had been underestimated.  CONCLUSIONS:  Autoimmune diseases are a leading cause of death among females in England and Wales, but their collective impact remains hidden in current disease classification systems.  Grouping these disorders together may help promote research needed to identify common determinants and future prevention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQbPNGXJJaw0uIHSmpohpd0fW6udTcc2eZNxExiqJTmjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cfotlChtQ%253D%253D&md5=7d6706244bf372939bd6f6a46e75319b</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.2105%2FAJPH.2009.180273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2105%252FAJPH.2009.180273%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DS.%2BL.%26aulast%3DGriffiths%26aufirst%3DC.%26aulast%3DSmeeth%26aufirst%3DL.%26aulast%3DRooney%26aufirst%3DC.%26aulast%3DHall%26aufirst%3DA.%2BJ.%26atitle%3DBurden%2520of%2520mortality%2520associated%2520with%2520autoimmune%2520diseases%2520among%2520females%2520in%2520the%2520united%2520kingdom%26jtitle%3DAm.%2520J.%2520Public%2520Health%26date%3D2010%26volume%3D100%26spage%3D2279%26epage%3D2287%26doi%3D10.2105%2FAJPH.2009.180273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkel, J.</span></span> <span> </span><span class="NLM_article-title">An analysis of fda-approved drugs for inflammation and autoimmune diseases</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">920</span>– <span class="NLM_lpage">3</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.drudis.2015.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25701283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFGmsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=920-3&author=M.+S.+Kinchauthor=J.+Merkel&title=An+analysis+of+fda-approved+drugs+for+inflammation+and+autoimmune+diseases&doi=10.1016%2Fj.drudis.2015.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of FDA-approved drugs for inflammation and autoimmune diseases</span></div><div class="casAuthors">Kinch, Michael S.; Merkel, Janie</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">920-923</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The term 'inflammation' captures a variety of disease processes linked with the immune system.  An anal. of US Food and Drug Administration (FDA)-approved nuclear mol. entities (NMEs) reveals notable trends in terms of acute and chronic inflammatory indications.  The no. of NMEs peaked during the 1990s and has since declined by more than 50%.  Whereas pharmaceutical companies have dominated the field, biotechnol. companies now receive half of new approvals and academia has a relatively large role in terms of pivotal first patents.  Another notable trend is that the relative no. of NMEs targeting allergy has been decreasing, whereas those targeting autoimmune indications is increasing.  Unlike other indications, NMEs for inflammation tend towards nuclear receptors and cytokines, and a disproportionate no. of biologics target cytokine pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwLqHW0ZtPtbVg90H21EOLACvtfcHk0lgaBYe7gbhvxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFGmsbg%253D&md5=8382c2c3efa6b343a08905e5f790358a</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DMerkel%26aufirst%3DJ.%26atitle%3DAn%2520analysis%2520of%2520fda-approved%2520drugs%2520for%2520inflammation%2520and%2520autoimmune%2520diseases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D920%26epage%3D3%26doi%3D10.1016%2Fj.drudis.2015.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapp, B. D.</span></span> <span> </span><span class="NLM_article-title">Relapsing and progressive forms of multiple sclerosis-insights from pathology</span>. <i>Curr. Opin. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">271</span>, <span class="refDoi"> DOI: 10.1097/WCO.0000000000000094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1097%2FWCO.0000000000000094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24722325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cnisFOnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=271&author=R.+Duttaauthor=B.+D.+Trapp&title=Relapsing+and+progressive+forms+of+multiple+sclerosis-insights+from+pathology&doi=10.1097%2FWCO.0000000000000094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Relapsing and progressive forms of multiple sclerosis: insights from pathology</span></div><div class="casAuthors">Dutta Ranjan; Trapp Bruce D</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  The predominant clinical disease course of multiple sclerosis starts with reversible episodes of neurological disability, which transforms into progressive neurological decline.  This review provides insight into the pathological differences during relapsing and progressive phases of multiple sclerosis.  RECENT FINDINGS:  The clinical course of multiple sclerosis is variable, and the disease can be classified into relapsing and progressive phases.  Pathological studies have been successful in distinguishing between these two forms of the disease and correlate with the clinical findings in terms of cellular responses, the inflammatory environment, and the location of lesions.  SUMMARY:  Available therapies for multiple sclerosis patients, while effective during the relapsing phase, have little benefit for progressive multiple sclerosis patients.  Development of therapies to benefit progressive multiple sclerosis patients will require a better understanding of the pathogenesis of progressive multiple sclerosis.  This review discusses and compares the pathological findings in relapsing and progressive multiple sclerosis patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRON0hRST94VBJ5E29YNGvQfW6udTcc2eYsvxqgtWzWArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnisFOnsw%253D%253D&md5=e237043c17483968cdb8065fb2ffa844</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1097%2FWCO.0000000000000094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FWCO.0000000000000094%26sid%3Dliteratum%253Aachs%26aulast%3DDutta%26aufirst%3DR.%26aulast%3DTrapp%26aufirst%3DB.%2BD.%26atitle%3DRelapsing%2520and%2520progressive%2520forms%2520of%2520multiple%2520sclerosis-insights%2520from%2520pathology%26jtitle%3DCurr.%2520Opin.%2520Neurol.%26date%3D2014%26volume%3D27%26spage%3D271%26doi%3D10.1097%2FWCO.0000000000000094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan-Thakur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedlitschky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrör, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauch, B. H.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate and its receptors: A mutual link between blood coagulation and inflammation</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">831059</span>, <span class="refDoi"> DOI: 10.1155/2015/831059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1155%2F2015%2F831059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26604433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC28vltlCnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=831059&author=S.+Mahajan-Thakurauthor=A.+B%C3%B6hmauthor=G.+Jedlitschkyauthor=K.+Schr%C3%B6rauthor=B.+H.+Rauch&title=Sphingosine-1-phosphate+and+its+receptors%3A+A+mutual+link+between+blood+coagulation+and+inflammation&doi=10.1155%2F2015%2F831059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-Phosphate and Its Receptors: A Mutual Link between Blood Coagulation and Inflammation</span></div><div class="casAuthors">Mahajan-Thakur Shailaja; Bohm Andreas; Jedlitschky Gabriele; Rauch Bernhard H; Schror Karsten</div><div class="citationInfo"><span class="NLM_cas:title">Mediators of inflammation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">831059</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sphingosine-1-phosphate (S1P) is a versatile lipid signaling molecule and key regulator in vascular inflammation.  S1P is secreted by platelets, monocytes, and vascular endothelial and smooth muscle cells.  It binds specifically to a family of G-protein-coupled receptors, S1P receptors 1 to 5, resulting in downstream signaling and numerous cellular effects.  S1P modulates cell proliferation and migration, and mediates proinflammatory responses and apoptosis.  In the vascular barrier, S1P regulates permeability and endothelial reactions and recruitment of monocytes and may modulate atherosclerosis.  Only recently has S1P emerged as a critical mediator which directly links the coagulation factor system to vascular inflammation.  The multifunctional proteases thrombin and FXa regulate local S1P availability and interact with S1P signaling at multiple levels in various vascular cell types.  Differential expression patterns and intracellular signaling pathways of each receptor enable S1P to exert its widespread functions.  Although a vast amount of information is available about the functions of S1P and its receptors in the regulation of physiological and pathophysiological conditions, S1P-mediated mechanisms in the vasculature remain to be elucidated.  This review summarizes recent findings regarding the role of S1P and its receptors in vascular wall and blood cells, which link the coagulation system to inflammatory responses in the vasculature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgCQ2gQ7-Ixf6xYuD7tu2XfW6udTcc2eYkmj94_jYN5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vltlCnug%253D%253D&md5=65150376c5727f41a7e3cbe4269c0f29</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1155%2F2015%2F831059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F831059%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan-Thakur%26aufirst%3DS.%26aulast%3DB%25C3%25B6hm%26aufirst%3DA.%26aulast%3DJedlitschky%26aufirst%3DG.%26aulast%3DSchr%25C3%25B6r%26aufirst%3DK.%26aulast%3DRauch%26aufirst%3DB.%2BH.%26atitle%3DSphingosine-1-phosphate%2520and%2520its%2520receptors%253A%2520A%2520mutual%2520link%2520between%2520blood%2520coagulation%2520and%2520inflammation%26jtitle%3DMediators%2520Inflammation%26date%3D2015%26volume%3D2015%26spage%3D831059%26doi%3D10.1155%2F2015%2F831059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kausar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawaqed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alawneh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badaracco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niewold, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweiss, N. J.</span></span> <span> </span><span class="NLM_article-title">Ocrelizumab: A step forward in the evolution of b-cell therapy</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1517/14712590903018837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1517%2F14712590903018837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=19463076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Shs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=889-95&author=F.+Kausarauthor=K.+Mustafaauthor=G.+Sweisauthor=R.+Sawaqedauthor=K.+Alawnehauthor=R.+Salloumauthor=M.+Badaraccoauthor=T.+B.+Niewoldauthor=N.+J.+Sweiss&title=Ocrelizumab%3A+A+step+forward+in+the+evolution+of+b-cell+therapy&doi=10.1517%2F14712590903018837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Ocrelizumab: a step forward in the evolution of B-cell therapy</span></div><div class="casAuthors">Kausar, Fariha; Mustafa, Khader; Sweis, Ghaleb; Sawaqed, Ray; Alawneh, Khaldoon; Salloum, Rafah; Badaracco, Maria; Niewold, Timothy B.; Sweiss, Nadera J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">889-895</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Recent advances in our understanding of B-cell dysregulation and its important link to autoimmunity have brought about a radical change in the management of autoimmune diseases.  Over the past few years, encouraging data from several clin. trials of rituximab, a chimeric anti-CD20 antibody, have led to its approval for use in rheumatoid arthritis (RA).  These data, regarding clin. efficacy, safety, improved patient-reported outcomes and cost-effectiveness with the use of rituximab in patients with RA, have led to the exploration of other agents targeting B-cell functions.  Ocrelizumab, a novel humanized anti-CD20 antibody, has shown clin. efficacy and safety in a recently reported trial in patients with RA.  Future clin. trials will help evaluate further the role of ocrelizumab in RA and its potential use in other autoimmune diseases.  This review describes current understanding of B-cell therapy, the role of rituximab in the treatment of RA and the evolving role of ocrelizumab as a B-cell-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCbAgfaNlKfrVg90H21EOLACvtfcHk0lhj9Erg0YuaAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Shs7s%253D&md5=f925dd281664f0dcebe050f6591bdb37</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1517%2F14712590903018837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712590903018837%26sid%3Dliteratum%253Aachs%26aulast%3DKausar%26aufirst%3DF.%26aulast%3DMustafa%26aufirst%3DK.%26aulast%3DSweis%26aufirst%3DG.%26aulast%3DSawaqed%26aufirst%3DR.%26aulast%3DAlawneh%26aufirst%3DK.%26aulast%3DSalloum%26aufirst%3DR.%26aulast%3DBadaracco%26aufirst%3DM.%26aulast%3DNiewold%26aufirst%3DT.%2BB.%26aulast%3DSweiss%26aufirst%3DN.%2BJ.%26atitle%3DOcrelizumab%253A%2520A%2520step%2520forward%2520in%2520the%2520evolution%2520of%2520b-cell%2520therapy%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2009%26volume%3D9%26spage%3D889%26epage%3D95%26doi%3D10.1517%2F14712590903018837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulds, D.</span></span> <span> </span><span class="NLM_article-title">Daclizumab: A review of its use in the prevention of acute rejection in renal transplant recipients</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.2165/00003495-199958060-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2165%2F00003495-199958060-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10651389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3cXpt1Oruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1999&pages=1029-42&author=L.+R.+Wisemanauthor=D.+Faulds&title=Daclizumab%3A+A+review+of+its+use+in+the+prevention+of+acute+rejection+in+renal+transplant+recipients&doi=10.2165%2F00003495-199958060-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients</span></div><div class="casAuthors">Wiseman, Lynda R.; Faulds, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1029-1042</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with 37 refs.  The humanized monoclonal antibody daclizumab is an immunosuppressive agent that reduces acute rejection in renal transplant recipients.  It is specific for the α subunit (Tac/CD25) of the interleukin-2 (IL-2) receptor on activated T cells and achieves immunosuppression by competitive antagonism of IL-2 induced T cell proliferation.  Daclizumab has advantages over murine antibodies to the IL-2 receptor, including improved effector function, a low potential for immunogenicity and long elimination half-life.  When added to std. cyclosporin-based immunosuppressive therapy with or without azathioprine, daclizumab (1 mg/kg prior to surgery and once every 2 wk thereafter for a total of 5 doses) significantly reduced the 6-mo rate of acute rejection compared with placebo in 2 phase III studies.  The mean no. of rejection episodes was significantly reduced and the time to first acute rejection significantly increased in daclizumab vs. placebo recipients.  Patient survival at 1 yr after transplantation was significantly higher with daclizumab than placebo in 1 study and showed a trend in favor of the drug in the other study.  The 1-yr graft survival rate tended to be greater in daclizumab than in placebo recipients in both studies.  In a phase II study, acute rejection rates in patients treated with both daclizumab and mycophenolate mofetil (plus std. cyclosporin-based immunosuppression) were lower than those achieved with mycophenolate mofetil alone.  Preliminary results indicate that daclizumab is also a useful agent in pediatric renal transplant recipients.  Further investigation of the efficacy and tolerability of the drug in this patient group is clearly warranted.  Daclizumab does not increase the incidence of adverse events when added to std. cyclosporin-based therapy.  The incidence of opportunistic infections, lymphoproliferative disorders and malignancies was not increased above that seen with placebo.  Although the effects of daclizumab on long term graft and patient survival require further investigation, available data indicate that daclizumab is an important advance in renal transplant immunosuppression, reducing acute graft rejection without affecting the tolerability of std. cyclosporin-based immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbNaMYRpuk6rVg90H21EOLACvtfcHk0lhj9Erg0YuaAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXpt1Oruw%253D%253D&md5=b4ca1b0bc843c8840d1d60bcacd79fcf</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.2165%2F00003495-199958060-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199958060-00006%26sid%3Dliteratum%253Aachs%26aulast%3DWiseman%26aufirst%3DL.%2BR.%26aulast%3DFaulds%26aufirst%3DD.%26atitle%3DDaclizumab%253A%2520A%2520review%2520of%2520its%2520use%2520in%2520the%2520prevention%2520of%2520acute%2520rejection%2520in%2520renal%2520transplant%2520recipients%26jtitle%3DDrugs%26date%3D1999%26volume%3D58%26spage%3D1029%26epage%3D42%26doi%3D10.2165%2F00003495-199958060-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, S. F.</span></span> <span> </span><span class="NLM_article-title">Atopic dermatitis: Natural history, diagnosis, and treatment</span>. <i>ISRN Allergy</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">354250</span>, <span class="refDoi"> DOI: 10.1155/2014/354250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1155%2F2014%2F354250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25006501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cbgslyqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=354250&author=S.+F.+Thomsen&title=Atopic+dermatitis%3A+Natural+history%2C+diagnosis%2C+and+treatment&doi=10.1155%2F2014%2F354250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Atopic dermatitis: natural history, diagnosis, and treatment</span></div><div class="casAuthors">Thomsen Simon Francis</div><div class="citationInfo"><span class="NLM_cas:title">ISRN allergy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">354250</span>
        ISSN:<span class="NLM_cas:issn">2090-5521</span>.
    </div><div class="casAbstract">Atopic dermatitis is an inflammatory skin disease with early onset and with a lifetime prevalence of approximately 20%.  The aetiology of atopic dermatitis is unknown, but the recent discovery of filaggrin mutations holds promise that the progression of atopic dermatitis to asthma in later childhood may be halted.  Atopic dermatitis is not always easily manageable and every physician should be familiar with the fundamental aspects of treatment.  This paper gives an overview of the natural history, clinical features, and treatment of atopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkT4oI_ibeCZNiNltV31zlfW6udTcc2eb8YlCg9bzvnLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbgslyqug%253D%253D&md5=497df87a6d621ee0e38ff117372ad9c6</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1155%2F2014%2F354250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F354250%26sid%3Dliteratum%253Aachs%26aulast%3DThomsen%26aufirst%3DS.%2BF.%26atitle%3DAtopic%2520dermatitis%253A%2520Natural%2520history%252C%2520diagnosis%252C%2520and%2520treatment%26jtitle%3DISRN%2520Allergy%26date%3D2014%26volume%3D2014%26spage%3D354250%26doi%3D10.1155%2F2014%2F354250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silverberg, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, E. L.</span></span> <span> </span><span class="NLM_article-title">Associations of childhood eczema severity: A us population based study</span>. <i>Dermatitis</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">107</span>, <span class="refDoi"> DOI: 10.1097/DER.0000000000000034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1097%2FDER.0000000000000034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24819283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cjhvFCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=107&author=J.+I.+Silverbergauthor=E.+L.+Simpson&title=Associations+of+childhood+eczema+severity%3A+A+us+population+based+study&doi=10.1097%2FDER.0000000000000034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Associations of childhood eczema severity: a US population-based study</span></div><div class="casAuthors">Silverberg Jonathan I; Simpson Eric L</div><div class="citationInfo"><span class="NLM_cas:title">Dermatitis : contact, atopic, occupational, drug</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">107-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Little is known about the predictors of eczema severity in the US population.  OBJECTIVES:  We sought to determine the distribution and associations of childhood eczema severity in the United States.  METHODS:  We analyzed the data from the 2007 National Survey of Children's Health, a prospective questionnaire-based study of a nationally representative sample of 91,642 children (range, 0-17 years).  RESULTS:  The prevalence of childhood eczema was 12.97% (95% confidence interval [95% CI], 12.42-13.53); 67.0% (95% CI, 64.8-69.2) had mild disease, 26.0% (95% CI, 23.9-28.1) had moderate disease, and 7.0% (95% CI, 5.8-8.3) had severe disease.  There was significant statewide variation of the distribution of eczema severity (Rao-Scott χ, P = 0.004), with highest rates of severe disease in Mid-Atlantic and Midwestern states.  In univariate models, eczema severity was increased with older age, African American and Hispanic race/ethnicity, lower household income, oldest child in the family, home with a single mother, lower paternal/maternal education level, maternal general health, maternal/paternal emotional health, dilapidated housing, and garbage on the streets.  In multivariate survey logistic regression models using stepwise and backward selection, moderate-to-severe eczema was associated with older age, lower household income, and fair or poor maternal health but inversely associated with birthplace outside the United States.  CONCLUSIONS:  These data indicate that environmental and/or lifestyle factors play an important role in eczema severity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfehAGvPZK_UPI-fCgwosgfW6udTcc2eb8YlCg9bzvnLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjhvFCjtQ%253D%253D&md5=6b3ca3d890842a8e393bfbfa5438ea6d</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1097%2FDER.0000000000000034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FDER.0000000000000034%26sid%3Dliteratum%253Aachs%26aulast%3DSilverberg%26aufirst%3DJ.%2BI.%26aulast%3DSimpson%26aufirst%3DE.%2BL.%26atitle%3DAssociations%2520of%2520childhood%2520eczema%2520severity%253A%2520A%2520us%2520population%2520based%2520study%26jtitle%3DDermatitis%26date%3D2014%26volume%3D25%26spage%3D107%26doi%3D10.1097%2FDER.0000000000000034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, R. L.</span></span> <span> </span><span class="NLM_article-title">The differential expression of il-4 and il-13 and its impact on type-2 immunity</span>. <i>Cytokine+</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.cyto.2015.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.cyto.2015.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26073683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsVymtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=25-37&author=K.+Baoauthor=R.+L.+Reinhardt&title=The+differential+expression+of+il-4+and+il-13+and+its+impact+on+type-2+immunity&doi=10.1016%2Fj.cyto.2015.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">The differential expression of IL-4 and IL-13 and its impact on type-2 immunity</span></div><div class="casAuthors">Bao, Katherine; Reinhardt, R. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-37</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Allergic disease represents a significant global health burden, and disease incidence continues to rise in urban areas of the world.  As such, a better understanding of the basic immune mechanisms underlying disease pathol. are key to developing therapeutic interventions to both prevent disease onset as well as to ameliorate disease morbidity in those individuals already suffering from a disorder linked to type-2 inflammation.  Two factors central to type-2 immunity are interleukin (IL)-4 and IL-13, which have been linked to virtually all major hallmarks assocd. with type-2 inflammation.  Therefore, IL-4 and IL-13 and their regulatory pathways represent ideal targets to suppress disease.  Despite sharing many common regulatory pathways and receptors, these cytokines perform very distinct functions during a type-2 immune response.  This review summarizes the literature surrounding the function and expression of IL-4 and IL-13 in CD4+ T cells and innate immune cells.  It highlights recent findings in vivo regarding the differential expression and non-canonical regulation of IL-4 and IL-13 in various immune cells, which likely play important and underappreciated roles in type-2 immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5DYfYNAeHkbVg90H21EOLACvtfcHk0lhVXWdSD_Qvcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsVymtbY%253D&md5=3d28d9e63e002fc3f6ed66dc89c3c87c</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2015.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2015.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DK.%26aulast%3DReinhardt%26aufirst%3DR.%2BL.%26atitle%3DThe%2520differential%2520expression%2520of%2520il-4%2520and%2520il-13%2520and%2520its%2520impact%2520on%2520type-2%2520immunity%26jtitle%3DCytokine%252B%26date%3D2015%26volume%3D75%26spage%3D25%26epage%3D37%26doi%3D10.1016%2Fj.cyto.2015.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bealgey, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, S.</span></span> <span> </span><span class="NLM_article-title">Interleukin-23: Immunological roles and clinical implications</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2008.04.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.biocel.2008.04.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=18725317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitFSmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2009&pages=733-5&author=Z.+Y.+Tanauthor=K.+W.+Bealgeyauthor=Y.+Fangauthor=Y.+M.+Gongauthor=S.+Bao&title=Interleukin-23%3A+Immunological+roles+and+clinical+implications&doi=10.1016%2Fj.biocel.2008.04.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-23: Immunological roles and clinical implications</span></div><div class="casAuthors">Tan, Zi Yan; Bealgey, Kenneth W.; Fang, Yong; Gong, Yang Ming; Bao, Shisan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-735</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Increasing evidence has revealed the importance of IL-23, which closely resembles IL-12 both structurally and immunol., in linking innate and adaptive immunity.  IL-23, produced by activated type 1 macrophages and dendritic cells (DC), possesses unique roles in the differentiation and expansion of memory T cells.  IL-23 has been assocd. with several inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease (IBD) and Helicobacter pylori assocd. gastritis, mainly due to its capacity to induce a strong Th1 type immune response.  IL-23 is also assocd. with Th17 responses and the cytokine produced by the antigen presenting cells (APC), i.e.  IL-12 vs. IL-23 dets. in part if a response is Th1 or Th17.  Recent studies have also assocd. chronic inflammatory diseases such as IBD, psoriasis and myocardial infarction with polymorphisms of the IL-23 receptor complex.  The current review focuses on the immunol. role of IL-23 and possible therapeutic avenues for inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfncF9BH-Q9bVg90H21EOLACvtfcHk0lhVXWdSD_Qvcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitFSmt7s%253D&md5=638a848d456e0d20c4a58b285278609d</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2008.04.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2008.04.027%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DZ.%2BY.%26aulast%3DBealgey%26aufirst%3DK.%2BW.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DY.%2BM.%26aulast%3DBao%26aufirst%3DS.%26atitle%3DInterleukin-23%253A%2520Immunological%2520roles%2520and%2520clinical%2520implications%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2009%26volume%3D41%26spage%3D733%26epage%3D5%26doi%3D10.1016%2Fj.biocel.2008.04.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span> <span> </span><span class="NLM_article-title">Interleukin-23: As a drug target for autoimmune inflammatory diseases</span>. <i>Immunology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2567.2011.03522.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1111%2Fj.1365-2567.2011.03522.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=22044352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1eitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2012&pages=112-124&author=C.+Tangauthor=S.+Chenauthor=H.+Qianauthor=W.+Huang&title=Interleukin-23%3A+As+a+drug+target+for+autoimmune+inflammatory+diseases&doi=10.1111%2Fj.1365-2567.2011.03522.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-23: as a drug target for autoimmune inflammatory diseases</span></div><div class="casAuthors">Tang, Chunlei; Chen, Shu; Qian, Hai; Huang, Wenlong</div><div class="citationInfo"><span class="NLM_cas:title">Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">112-124</span>CODEN:
                <span class="NLM_cas:coden">IMMUAM</span>;
        ISSN:<span class="NLM_cas:issn">0019-2805</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Interleukin-23 (IL-23) is a member of the IL-12 family of cytokines with pro-inflammatory properties.  Its ability to potently enhance the expansion of T helper type 17 (Th17) cells indicates the responsibility for many of the inflammatory autoimmune responses.  Emerging data demonstrate that IL-23 is a key participant in central regulation of the cellular mechanisms involved in inflammation.  Both IL-23 and IL-17 form a new axis through Th17 cells, which has evolved in response to human diseases assocd. with immunoactivation and immunopathogeny, including bacterial or viral infections and chronic inflammation.  Targeting of IL-23 or the IL-23 receptor or IL-23 axis is a potential therapeutic approach for autoimmune diseases including psoriasis, inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis.  The current review focuses on the immunobiol. of IL-23 and summarizes the most recent findings on the role of IL-23 in the pre-clin. and ongoing clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiMRA-yJqoe7Vg90H21EOLACvtfcHk0lh-l3MvwaG_og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1eitLo%253D&md5=65fb41e874810ffc7aaaaf69ddb819dc</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2567.2011.03522.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2567.2011.03522.x%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DQian%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DW.%26atitle%3DInterleukin-23%253A%2520As%2520a%2520drug%2520target%2520for%2520autoimmune%2520inflammatory%2520diseases%26jtitle%3DImmunology%26date%3D2012%26volume%3D135%26spage%3D112%26epage%3D124%26doi%3D10.1111%2Fj.1365-2567.2011.03522.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fasching, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stradner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graninger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejaco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessler, J.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of targeting the th17/treg axis in autoimmune disorders</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">134</span>, <span class="refDoi"> DOI: 10.3390/molecules22010134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3390%2Fmolecules22010134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVGmtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=134&author=P.+Faschingauthor=M.+Stradnerauthor=W.+Graningerauthor=C.+Dejacoauthor=J.+Fessler&title=Therapeutic+potential+of+targeting+the+th17%2Ftreg+axis+in+autoimmune+disorders&doi=10.3390%2Fmolecules22010134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of targeting the Th17/Treg axis in autoimmune disorders</span></div><div class="casAuthors">Fasching, Patrizia; Stradner, Martin; Graninger, Winfried; Dejaco, Christian; Fessler, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134/1-134/24</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A disruption of the crucial balance between regulatory T-cells (Tregs) and Th17-cells was recently implicated in various autoimmune disorders.  Tregs are responsible for the maintenance of self-tolerance, thus inhibiting autoimmunity, whereas pro-inflammatory Th17-cells contribute to the induction and propagation of inflammation.  Distortion of the Th17/Treg balance favoring the pro-inflammatory Th17 side is hence suspected to contribute to exacerbation of autoimmune disorders.  This review aims to summarize recent data and advances in targeted therapeutic modification of the Th17/Treg-balance, as well as information on the efficacy of candidate therapeutics with respect to the treatment of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvXkj6KpTgU7Vg90H21EOLACvtfcHk0lh-l3MvwaG_og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVGmtLo%253D&md5=e649423f20ab7ff0e4db9c8eb4234005</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22010134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22010134%26sid%3Dliteratum%253Aachs%26aulast%3DFasching%26aufirst%3DP.%26aulast%3DStradner%26aufirst%3DM.%26aulast%3DGraninger%26aufirst%3DW.%26aulast%3DDejaco%26aufirst%3DC.%26aulast%3DFessler%26aufirst%3DJ.%26atitle%3DTherapeutic%2520potential%2520of%2520targeting%2520the%2520th17%252Ftreg%2520axis%2520in%2520autoimmune%2520disorders%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D134%26doi%3D10.3390%2Fmolecules22010134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span> <span> </span><span class="NLM_article-title">Interleukin 6 and rheumatoid arthritis</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">698313</span>, <span class="refDoi"> DOI: 10.1155/2014/698313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1155%2F2014%2F698313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24524085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2crmsVKltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=698313&author=Y.+Yoshidaauthor=T.+Tanaka&title=Interleukin+6+and+rheumatoid+arthritis&doi=10.1155%2F2014%2F698313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin 6 and rheumatoid arthritis</span></div><div class="casAuthors">Yoshida Yuji; Tanaka Toshio</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">698313</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Interleukin-6 (IL-6) is a representative cytokine featuring pleiotropic activity and redundancy.  A transient synthesis of IL-6 contributes to host defense against infectious agents and tissue injuries by inducing acute phase reactions and immunological and hematopoietic responses.  However, uncontrolled persistent production of IL-6 may lead to the development of several immune-mediated diseases.  Rheumatoid arthritis (RA) is a chronic disease with joint and systemic inflammation resulting from immunological abnormalities and it has been found that IL-6 plays a key role in the development of this disease.  Clinical trials in various parts of the world of tocilizumab, a humanized anti-IL-6 receptor antibody, have proved its efficacy and tolerable safety either as monotherapy or in combination with disease-modifying antirheumatic drugs.  As a result, it is currently used as a first-line biologic for the treatment of moderate-to-severe RA in more than 100 countries.  Clarification of the mechanism(s) through which tocilizumab exerts its effect on RA and of the reason(s) why IL-6 is continuously produced in RA can be expected to lead to the best use of this agent for RA patients and aid in investigations into the pathogenesis of RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWZ0g10qbTe0HdcurJClFcfW6udTcc2eaguZemM759vrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crmsVKltg%253D%253D&md5=5e1f91da87a60ca9d77d6d80a418881f</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1155%2F2014%2F698313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F698313%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DT.%26atitle%3DInterleukin%25206%2520and%2520rheumatoid%2520arthritis%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2014%26volume%3D2014%26spage%3D698313%26doi%3D10.1155%2F2014%2F698313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dargham, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahirovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammoudeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Emadi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masri, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halabi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badsha, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uthman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahfoud, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashour, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gad El Haq, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayoumy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapiri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenge, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazkaz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arayssi, T.</span></span> <span> </span><span class="NLM_article-title">Epidemiology and treatment patterns of rheumatoid arthritis in a large cohort of arab patients</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0208240</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0208240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1371%2Fjournal.pone.0208240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30566451" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=S.+R.+Darghamauthor=S.+Zahirovicauthor=M.+Hammoudehauthor=S.+Al+Emadiauthor=B.+K.+Masriauthor=H.+Halabiauthor=H.+Badshaauthor=I.+Uthmanauthor=Z.+R.+Mahfoudauthor=H.+Ashourauthor=W.+Gad+El+Haqauthor=K.+Bayoumyauthor=M.+Kapiriauthor=R.+Saxenaauthor=R.+M.+Plengeauthor=L.+Kazkazauthor=T.+Arayssi&title=Epidemiology+and+treatment+patterns+of+rheumatoid+arthritis+in+a+large+cohort+of+arab+patients&doi=10.1371%2Fjournal.pone.0208240"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0208240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0208240%26sid%3Dliteratum%253Aachs%26aulast%3DDargham%26aufirst%3DS.%2BR.%26aulast%3DZahirovic%26aufirst%3DS.%26aulast%3DHammoudeh%26aufirst%3DM.%26aulast%3DAl%2BEmadi%26aufirst%3DS.%26aulast%3DMasri%26aufirst%3DB.%2BK.%26aulast%3DHalabi%26aufirst%3DH.%26aulast%3DBadsha%26aufirst%3DH.%26aulast%3DUthman%26aufirst%3DI.%26aulast%3DMahfoud%26aufirst%3DZ.%2BR.%26aulast%3DAshour%26aufirst%3DH.%26aulast%3DGad%2BEl%2BHaq%26aufirst%3DW.%26aulast%3DBayoumy%26aufirst%3DK.%26aulast%3DKapiri%26aufirst%3DM.%26aulast%3DSaxena%26aufirst%3DR.%26aulast%3DPlenge%26aufirst%3DR.%2BM.%26aulast%3DKazkaz%26aufirst%3DL.%26aulast%3DArayssi%26aufirst%3DT.%26atitle%3DEpidemiology%2520and%2520treatment%2520patterns%2520of%2520rheumatoid%2520arthritis%2520in%2520a%2520large%2520cohort%2520of%2520arab%2520patients%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0208240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raimondo, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggioggero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crotti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becciolini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favalli, E. G.</span></span> <span> </span><span class="NLM_article-title">Profile of sarilumab and its potential in the treatment of rheumatoid arthritis</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1593</span>– <span class="NLM_lpage">1603</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S100302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2147%2FDDDT.S100302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28579757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKns7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=1593-1603&author=M.+G.+Raimondoauthor=M.+Biggioggeroauthor=C.+Crottiauthor=A.+Beccioliniauthor=E.+G.+Favalli&title=Profile+of+sarilumab+and+its+potential+in+the+treatment+of+rheumatoid+arthritis&doi=10.2147%2FDDDT.S100302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of sarilumab and its potential in the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Raimondo, Maria Gabriella; Biggioggero, Martina; Crotti, Chiara; Becciolini, Andrea; Favalli, Ennio Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1593-1603</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">In recent years the use of biotechnol. agents has drastically revolutionized the therapeutic approach and the progression of rheumatoid arthritis (RA).  In particular, interleukin-6 (IL-6) has been demonstrated as a pivotal cytokine in the pathogenesis of the disease by contributing to both the innate and the adaptive immune system perturbation, and to the prodn. of acute-phase proteins involved in the systemic expression of the disorder.  The first marketed IL-6 blocker was tocilizumab, a humanized anti-IL-6 receptor (anti-IL-6R) monoclonal antibody.  The successful use of tocilizumab in RA has encouraged the development of other biol. agents specifically targeting the IL-6 pathway, either directed against IL-6 cytokine (sirukumab, olokizumab, and clazakizumab) or IL-6 receptor (sarilumab).  One Phase II and six Phase III randomized controlled trials demonstrated a broad efficacy of sarilumab across all RA patient subtypes, ranging from methotrexate (MTX) to tumor necrosis factor inhibitor insufficient responders.  In particular, sarilumab as monotherapy demonstrated a clear head-to-head superiority over adalimumab in MTX-intolerant subjects.  In addn., compared with tocilizumab, sarilumab showed a similar safety profile with significantly higher affinity and longer half-life, responsible for a redn. of the frequency of administration (every other week instead weekly).  All these aspects may be important in defining the strategy for positioning sarilumab in the treatment algorithm of RA.  Indeed, observational data coming from post-marketing real-life studies may provide crucial addnl. information for better understanding the role of sarilumab in the management of the disease.  This review summarizes both the biol. role of IL-6 in RA and the clin. data available on sarilumab as an alternative therapeutic option in RA patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot8VGylpwQ0rVg90H21EOLACvtfcHk0lh0KXyxfEfY6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKns7rP&md5=8b8d8fdb091701ee2ff94667c4eb2603</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S100302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S100302%26sid%3Dliteratum%253Aachs%26aulast%3DRaimondo%26aufirst%3DM.%2BG.%26aulast%3DBiggioggero%26aufirst%3DM.%26aulast%3DCrotti%26aufirst%3DC.%26aulast%3DBecciolini%26aufirst%3DA.%26aulast%3DFavalli%26aufirst%3DE.%2BG.%26atitle%3DProfile%2520of%2520sarilumab%2520and%2520its%2520potential%2520in%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D1593%26epage%3D1603%26doi%3D10.2147%2FDDDT.S100302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Baricitinib: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0723-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-017-0723-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28290136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksVOlur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=697-704&author=A.+Markham&title=Baricitinib%3A+First+global+approval&doi=10.1007%2Fs40265-017-0723-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">697-704</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Baricitinib (Olumiant) is an orally-administered, small-mol., janus-assocd. kinase (JAK) inhibitor developed by Eli Lilly and Incyte Corporation for the treatment of rheumatoid arthritis (RA), atopic dermatitis and systemic lupus erythematosus.  JAKs transduce intracellular signals from cell surface receptors for various cytokines and growth factors involved in inflammation and immune function, suggesting JAK inhibitors may be of therapeutic benefit in inflammatory conditions.  In Feb. 2017, baricitinib was approved in the EU, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).  Regulatory approval to market baricitinib as a treatment for RA has also been sought in the USA and Japan.  This article summarizes the milestones in the development of baricitinib leading to this first global approval for the treatment for moderate to severe active RA in adult patients who have responded inadequately to, or are intolerant to one or more DMARDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo-U2lbkEPpbVg90H21EOLACvtfcHk0lh0KXyxfEfY6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksVOlur8%253D&md5=54dbb2c53eb3cfd5831284df95beb184</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0723-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0723-3%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DBaricitinib%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D697%26epage%3D704%26doi%3D10.1007%2Fs40265-017-0723-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Jak inhibition as a therapeutic strategy for immune and inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843-862&author=D.+M.+Schwartzauthor=Y.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=Jak+inhibition+as+a+therapeutic+strategy+for+immune+and+inflammatory+diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0lh0KXyxfEfY6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJak%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520immune%2520and%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26epage%3D862%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Upadacitinib: First approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1819</span>– <span class="NLM_lpage">1828</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01211-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-019-01211-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31642025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3MjgvVSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1819-1828&author=S.+Dugganauthor=S.+J.+Keam&title=Upadacitinib%3A+First+approval&doi=10.1007%2Fs40265-019-01211-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Upadacitinib: First Approval</span></div><div class="casAuthors">Duggan Sean; Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1819-1828</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Upadacitinib (Rinvoq®), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis.  In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of moderately to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate.  This article summarizes the milestones in the development of upadacitinib leading to this first approval for the treatment of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfxtr5CsQWZxWfpMXQLRstfW6udTcc2eZjvJWYHCoLeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjgvVSrtg%253D%253D&md5=3ef93907bbec16e744d0fb2b6dae65e0</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01211-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01211-z%26sid%3Dliteratum%253Aachs%26aulast%3DDuggan%26aufirst%3DS.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DUpadacitinib%253A%2520First%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1819%26epage%3D1828%26doi%3D10.1007%2Fs40265-019-01211-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banjade, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhakal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, V. R.</span></span> <span> </span><span class="NLM_article-title">Thrombocytopenia in patients with chronic hepatitis c virus infection</span>. <i>J. Hematol. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e2017019</span> <span class="refDoi"> DOI: 10.4084/mjhid.2017.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.4084%2Fmjhid.2017.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&author=S.+Dahalauthor=S.+Upadhyayauthor=R.+Banjadeauthor=P.+Dhakalauthor=N.+Khanalauthor=V.+R.+Bhatt&title=Thrombocytopenia+in+patients+with+chronic+hepatitis+c+virus+infection&doi=10.4084%2Fmjhid.2017.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.4084%2Fmjhid.2017.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4084%252Fmjhid.2017.019%26sid%3Dliteratum%253Aachs%26aulast%3DDahal%26aufirst%3DS.%26aulast%3DUpadhyay%26aufirst%3DS.%26aulast%3DBanjade%26aufirst%3DR.%26aulast%3DDhakal%26aufirst%3DP.%26aulast%3DKhanal%26aufirst%3DN.%26aulast%3DBhatt%26aufirst%3DV.%2BR.%26atitle%3DThrombocytopenia%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520c%2520virus%2520infection%26jtitle%3DJ.%2520Hematol.%2520Infect.%2520Dis.%26date%3D2016%26volume%3D9%26doi%3D10.4084%2Fmjhid.2017.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Samkari, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuter, D. J.</span></span> <span> </span><span class="NLM_article-title">Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia</span>. <i>Ther. Adv. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">204062071984173</span>, <span class="refDoi"> DOI: 10.1177/2040620719841735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1177%2F2040620719841735" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=204062071984173&author=H.+Al-Samkariauthor=D.+J.+Kuter&title=Optimal+use+of+thrombopoietin+receptor+agonists+in+immune+thrombocytopenia&doi=10.1177%2F2040620719841735"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1177%2F2040620719841735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040620719841735%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Samkari%26aufirst%3DH.%26aulast%3DKuter%26aufirst%3DD.%2BJ.%26atitle%3DOptimal%2520use%2520of%2520thrombopoietin%2520receptor%2520agonists%2520in%2520immune%2520thrombocytopenia%26jtitle%3DTher.%2520Adv.%2520Hematol.%26date%3D2019%26volume%3D10%26spage%3D204062071984173%26doi%3D10.1177%2F2040620719841735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Fostamatinib: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0927-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-018-0927-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29869203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=959-963&author=A.+Markham&title=Fostamatinib%3A+First+global+approval&doi=10.1007%2Fs40265-018-0927-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Fostamatinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">959-963</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Rigel Pharmaceuticals are developing the spleen tyrosine kinase (SYK) inhibitor fostamatinib (TAVALISSE) as a treatment for immune thrombocytopenia (ITP), autoimmune haemolytic anemia and IgA nephropathy.  Based on pos. results in the phase III FIT clin. trial program, the drug was recently approved in the US as a treatment for thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment.  This article summarizes the milestones in the development of fostamatinib leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgnmCw2LTVXrVg90H21EOLACvtfcHk0lgJMl2Ak317_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsb7M&md5=e58fd226c946b7e2087a74d31eeba972</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0927-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0927-1%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DFostamatinib%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D959%26epage%3D963%26doi%3D10.1007%2Fs40265-018-0927-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulert, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grom, A. A.</span></span> <span> </span><span class="NLM_article-title">Macrophage activation syndrome and cytokine-directed therapies</span>. <i>Best Pract. Res.: Clin. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1016/j.berh.2014.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.berh.2014.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24974063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cbpsF2msg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=277-292&author=G.+S.+Schulertauthor=A.+A.+Grom&title=Macrophage+activation+syndrome+and+cytokine-directed+therapies&doi=10.1016%2Fj.berh.2014.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage activation syndrome and cytokine-directed therapies</span></div><div class="casAuthors">Schulert Grant S; Grom Alexei A</div><div class="citationInfo"><span class="NLM_cas:title">Best practice & research. Clinical rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">277-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Macrophage activation syndrome (MAS) is an episode of overwhelming inflammation that occurs most commonly in children with systemic juvenile idiopathic arthritis (SJIA).  It is characterized by expansion and activation of T lymphocytes and hemophagocytic macrophages and bears great similarity to hemophagocytic lymphohistiocytosis (HLH).  This disorder has substantial morbidity and mortality, and there is frequently a delay in recognition and initiation of treatment.  Here, we will review what is known about the pathogenesis of MAS and, in particular, its similarities to HLH.  The development of MAS is characterized by a cytokine storm, with the elaboration of numerous pro-inflammatory cytokines.  We will examine the evidence for various cytokines in the initiation and pathogenesis of MAS and discuss how new biologic therapies may alter the risk of MAS.  Finally, we will review current treatment options for MAS and examine how cytokine-directed therapy could serve as novel treatment modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHAMquXZywdJggzHGM8X5CfW6udTcc2eZjvJWYHCoLeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbpsF2msg%253D%253D&md5=6ef0eeed0a0c295df1c822f9c7298d06</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.berh.2014.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.berh.2014.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DSchulert%26aufirst%3DG.%2BS.%26aulast%3DGrom%26aufirst%3DA.%2BA.%26atitle%3DMacrophage%2520activation%2520syndrome%2520and%2520cytokine-directed%2520therapies%26jtitle%3DBest%2520Pract.%2520Res.%253A%2520Clin.%2520Rheumatol.%26date%3D2014%26volume%3D28%26spage%3D277%26epage%3D292%26doi%3D10.1016%2Fj.berh.2014.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosse, W. F.</span></span> <span> </span><span class="NLM_article-title">Paroxysmal nocturnal hemoglobinuria as a molecular disease</span>. <i>Medicine</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1097/00005792-199703000-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1097%2F00005792-199703000-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=9100736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaK2sXntlKjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1997&pages=63-93&author=W.+F.+Rosse&title=Paroxysmal+nocturnal+hemoglobinuria+as+a+molecular+disease&doi=10.1097%2F00005792-199703000-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Paroxysmal nocturnal hemoglobinuria as a molecular disease</span></div><div class="casAuthors">Rosse, Wendell F.</div><div class="citationInfo"><span class="NLM_cas:title">Medicine (Baltimore)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">63-93</span>CODEN:
                <span class="NLM_cas:coden">MEDIAV</span>;
        ISSN:<span class="NLM_cas:issn">0025-7974</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review, with 330 refs., discussing the main clin. characteristics of paroxysmal nocturnal hemoglobinuria, the biochem. abnormalities of the disease and their mol. genetic basis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJv4RYRxLgS7Vg90H21EOLACvtfcHk0lj57SsW0gCAfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXntlKjsbs%253D&md5=4d0dede71b4abc5c0342938cad3d92d9</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1097%2F00005792-199703000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005792-199703000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DRosse%26aufirst%3DW.%2BF.%26atitle%3DParoxysmal%2520nocturnal%2520hemoglobinuria%2520as%2520a%2520molecular%2520disease%26jtitle%3DMedicine%26date%3D1997%26volume%3D76%26spage%3D63%26epage%3D93%26doi%3D10.1097%2F00005792-199703000-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodsky, R. A.</span></span> <span> </span><span class="NLM_article-title">Paroxysmal nocturnal hemoglobinuria</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">2804</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-02-522128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1182%2Fblood-2014-02-522128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25237200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWqsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=2804-11&author=R.+A.+Brodsky&title=Paroxysmal+nocturnal+hemoglobinuria&doi=10.1182%2Fblood-2014-02-522128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Paroxysmal nocturnal hemoglobinuria</span></div><div class="casAuthors">Brodsky, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2804-2811</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Paroxysmal nocturnal hemoglobinuria (PNH) is a rare bone marrow failure disorder that manifests with hemolytic anemia, thrombosis, and peripheral blood cytopenias.  The absence of two glycosylphosphatidylinositol (GPI)-anchored proteins, CD55 and CD59, leads to uncontrolled complement activation that accounts for hemolysis and other PNH manifestations.  GPI anchor protein deficiency is almost always due to somatic mutations in phosphatidylinositol glycan class A (PIGA), a gene involved in the first step of GPI anchor biosynthesis; however, alternative mutations that cause PNH have recently been discovered.  In addn., hypomorphic germ-line PIGA mutations that do not cause PNH have been shown to be responsible for a condition known as multiple congenital anomalies-hypotonia-seizures syndrome 2.  Eculizumab, a first-in-class monoclonal antibody that inhibits terminal complement, is the treatment of choice for patients with severe manifestations of PNH.  Bone marrow transplantation remains the only cure for PNH but should be reserved for patients with suboptimal response to eculizumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQtU772cCcqLVg90H21EOLACvtfcHk0lj57SsW0gCAfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWqsL%252FN&md5=b5d064494dbcbdb388bc4f2bf04be3a9</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-02-522128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-02-522128%26sid%3Dliteratum%253Aachs%26aulast%3DBrodsky%26aufirst%3DR.%2BA.%26atitle%3DParoxysmal%2520nocturnal%2520hemoglobinuria%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D2804%26epage%3D11%26doi%3D10.1182%2Fblood-2014-02-522128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKeage, K.</span></span> <span> </span><span class="NLM_article-title">Ravulizumab: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01068-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-019-01068-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30767127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=347-352&author=K.+McKeage&title=Ravulizumab%3A+First+global+approval&doi=10.1007%2Fs40265-019-01068-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Ravulizumab: First Global Approval</span></div><div class="casAuthors">McKeage, Kate</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-352</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Ravulizumab (ravulizumab-cwvz; ULTOMIRIS), a humanized monoclonal antibody, is a complement C5 inhibitor developed by Alexion Pharmaceuticals for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS).  Like the first-generation C5 inhibitor, eculizumab, ravulizumab binds specifically and with high affinity to the complement protein C5, thereby preventing formation of the terminal complement complex C5b-9, which mediates cell lysis.  In Dec. 2018, i.v. ravulizumab received its first global approval in the USA for the treatment of adults with PNH, and is under regulatory review in the European Union and Japan in this indication.  Phase 3 development of i.v. ravulizumab for the treatment of aHUS is underway worldwide.  The use of ravulizumab in myasthenia gravis and IgA nephropathy is also being evaluated in the USA in early-phase and preclin. studies, resp.  Clin. development of a s.c. formulation for PNH and aHUS is also underway.  Ravulizumab has been developed using Xencor's antibody half-life prolongation technol. (Xtend), which utilizes antibody Fc variants to prolong half-life.  Alexion is also evaluating the coadministration of s.c. ravulizumab with Halozyme's ENHANZE drug-delivery technol. (rHuPH20), which may have the potential to further extend the dosing interval.  This article summarizes the milestones in the development of ravulizumab leading to this first approval for PNH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvdIVLKo5qzLVg90H21EOLACvtfcHk0lj57SsW0gCAfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrw%253D&md5=44d2b4439a007737dcdd8fd3b68dadbf</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01068-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01068-2%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeage%26aufirst%3DK.%26atitle%3DRavulizumab%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D347%26epage%3D352%26doi%3D10.1007%2Fs40265-019-01068-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Titulaer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verschuuren, J. J.</span></span> <span> </span><span class="NLM_article-title">Lambert-eaton myasthenic syndrome: From clinical characteristics to therapeutic strategies</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1107</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(11)70245-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS1474-4422%2811%2970245-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=22094130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC38%252Fgsl2hsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1098-1107&author=M.+J.+Titulaerauthor=B.+Langauthor=J.+J.+Verschuuren&title=Lambert-eaton+myasthenic+syndrome%3A+From+clinical+characteristics+to+therapeutic+strategies&doi=10.1016%2FS1474-4422%2811%2970245-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies</span></div><div class="casAuthors">Titulaer Maarten J; Lang Bethan; Verschuuren Jan Jgm</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1098-107</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular autoimmune disease that has served as a model for autoimmunity and tumour immunology.  In LEMS, the characteristic muscle weakness is thought to be caused by pathogenic autoantibodies directed against voltage-gated calcium channels (VGCC) present on the presynaptic nerve terminal.  Half of patients with LEMS have an associated tumour, small-cell lung carcinoma (SCLC), which also expresses functional VGCC.  Knowledge of this association led to the discovery of a wide range of paraneoplastic and non-tumour-related neurological disorders of the peripheral and central nervous systems.  Detailed clinical studies have improved our diagnostic skills and knowledge of the pathophysiological mechanisms and association of LEMS with SCLC, and have helped with the development of a protocol for early tumour detection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-BMd6_Y4EZbxanA7vODO6fW6udTcc2eZI18b1axQjBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252Fgsl2hsg%253D%253D&md5=d0866ae4d39a3b4386a394a806c0f04d</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2811%2970245-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252811%252970245-9%26sid%3Dliteratum%253Aachs%26aulast%3DTitulaer%26aufirst%3DM.%2BJ.%26aulast%3DLang%26aufirst%3DB.%26aulast%3DVerschuuren%26aufirst%3DJ.%2BJ.%26atitle%3DLambert-eaton%2520myasthenic%2520syndrome%253A%2520From%2520clinical%2520characteristics%2520to%2520therapeutic%2520strategies%26jtitle%3DLancet%2520Neurol.%26date%3D2011%26volume%3D10%26spage%3D1098%26epage%3D1107%26doi%3D10.1016%2FS1474-4422%2811%2970245-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voelker, R.</span></span> <span> </span><span class="NLM_article-title">Drug approved for rare muscle weakening syndrome</span>. <i>J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">239</span>, <span class="refDoi"> DOI: 10.1001/jama.2018.21321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1001%2Fjama.2018.21321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3cjjvVCjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2019&pages=239&author=R.+Voelker&title=Drug+approved+for+rare+muscle+weakening+syndrome&doi=10.1001%2Fjama.2018.21321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Device for Cluster Headache</span></div><div class="casAuthors">Voelker Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTc9KFPOurlNp0d-O_J5C0AfW6udTcc2eZD26BbrX0KsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjjvVCjug%253D%253D&md5=1291266b3ed69e96707ff6f92160f499</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1001%2Fjama.2018.21321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2018.21321%26sid%3Dliteratum%253Aachs%26aulast%3DVoelker%26aufirst%3DR.%26atitle%3DDrug%2520approved%2520for%2520rare%2520muscle%2520weakening%2520syndrome%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2019%26volume%3D321%26spage%3D239%26doi%3D10.1001%2Fjama.2018.21321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tripodi, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giliani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanfranchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badolato, R.</span></span> <span> </span><span class="NLM_article-title">Heterozygous mutation in adenosine deaminase gene in a patient with severe lymphopenia following corticosteroid treatment of autoimmune hemolytic anemia</span>. <i>Front. Pediatr.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">272</span>, <span class="refDoi"> DOI: 10.3389/fped.2018.00272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3389%2Ffped.2018.00272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30327760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3czpvF2qtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=272&author=S.+I.+Tripodiauthor=P.+Cortiauthor=S.+Gilianiauthor=A.+Lanfranchiauthor=A.+Biondiauthor=R.+Badolato&title=Heterozygous+mutation+in+adenosine+deaminase+gene+in+a+patient+with+severe+lymphopenia+following+corticosteroid+treatment+of+autoimmune+hemolytic+anemia&doi=10.3389%2Ffped.2018.00272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Heterozygous Mutation in Adenosine Deaminase Gene in a Patient With Severe Lymphopenia Following Corticosteroid Treatment of Autoimmune Hemolytic Anemia</span></div><div class="casAuthors">Tripodi Serena I; Badolato Raffaele; Corti Paola; Biondi Andrea; Giliani Silvia; Lanfranchi Arnalda</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pediatrics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">272</span>
        ISSN:<span class="NLM_cas:issn">2296-2360</span>.
    </div><div class="casAbstract">We describe a previously healthy 14-year-old girl with acute onset autoimmune hemolytic anemia, associated with severe but transient lymphopenia during corticosteroid therapy, without infectious episodes during follow-up.  After detailed investigations to rule out an underlying immunodeficiency, we detected a heterozygous ADA gene mutation.  This was associated with slightly increased blood levels of adenosine and deoxyadenosine nucleotides and with reduced ADA activity in red blood cells, but within the normal range.  This observation suggests that heterozygous ADA mutation might be a predisposing factor for lymphopenia in patients receiving corticosteroid therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeu56SyrfSGcRAV4D_Ins_fW6udTcc2eZD26BbrX0KsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czpvF2qtA%253D%253D&md5=fc633b17dbdf121a35b0f2619444d36d</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.3389%2Ffped.2018.00272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffped.2018.00272%26sid%3Dliteratum%253Aachs%26aulast%3DTripodi%26aufirst%3DS.%2BI.%26aulast%3DCorti%26aufirst%3DP.%26aulast%3DGiliani%26aufirst%3DS.%26aulast%3DLanfranchi%26aufirst%3DA.%26aulast%3DBiondi%26aufirst%3DA.%26aulast%3DBadolato%26aufirst%3DR.%26atitle%3DHeterozygous%2520mutation%2520in%2520adenosine%2520deaminase%2520gene%2520in%2520a%2520patient%2520with%2520severe%2520lymphopenia%2520following%2520corticosteroid%2520treatment%2520of%2520autoimmune%2520hemolytic%2520anemia%26jtitle%3DFront.%2520Pediatr.%26date%3D2018%26volume%3D6%26spage%3D272%26doi%3D10.3389%2Ffped.2018.00272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gennery, A. R.</span></span> <span> </span><span class="NLM_article-title">Adenosine deaminase deficiency: A review</span>. <i>Orphanet J. Rare Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">65</span>, <span class="refDoi"> DOI: 10.1186/s13023-018-0807-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1186%2Fs13023-018-0807-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29690908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjmt1CrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=65&author=A.+M.+Flinnauthor=A.+R.+Gennery&title=Adenosine+deaminase+deficiency%3A+A+review&doi=10.1186%2Fs13023-018-0807-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine deaminase deficiency: a review</span></div><div class="casAuthors">Flinn Aisling M; Gennery Andrew R; Flinn Aisling M; Gennery Andrew R</div><div class="citationInfo"><span class="NLM_cas:title">Orphanet journal of rare diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Adenosine deaminase (ADA) deficiency leads to an accumulation of toxic purine degradation by-products, most potently affecting lymphocytes, leading to adenosine deaminase-deficient severe combined immunodeficiency.  Whilst most notable affects are on lymphocytes, other manifestations include skeletal abnormalities, neurodevelopmental affects and pulmonary manifestations associated with pulmonary-alveolar proteinosis.  Affected patients present in early infancy, usually with persistent infection, or with pulmonary insufficiency.  Three treatment options are currently available.  Initial treatment with enzyme replacement therapy may alleviate acute symptoms and enable partial immunological reconstitution, but treatment is life-long, immune reconstitution is incomplete, and the reconstituted immune system may nullify the effects of the enzyme replacement.  Hematopoietic stem cell transplant has long been established as the treatment of choice, particularly where a matched sibling or well matched unrelated donor is available.  More recently, the use of gene addition techniques to correct the genetic defect in autologous haematopoietic stem cells treatment has demonstrated immunological and clinical efficacy.  This article reviews the biology, clinical presentation, diagnosis and treatment of ADA-deficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAz_4JB3iSLiM8MEzWGjS9fW6udTcc2eZD26BbrX0KsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjmt1CrtA%253D%253D&md5=f063e0dbfd3167e16864588dbe8d840c</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1186%2Fs13023-018-0807-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13023-018-0807-5%26sid%3Dliteratum%253Aachs%26aulast%3DFlinn%26aufirst%3DA.%2BM.%26aulast%3DGennery%26aufirst%3DA.%2BR.%26atitle%3DAdenosine%2520deaminase%2520deficiency%253A%2520A%2520review%26jtitle%3DOrphanet%2520J.%2520Rare%2520Dis.%26date%3D2018%26volume%3D13%26spage%3D65%26doi%3D10.1186%2Fs13023-018-0807-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeFrancesco, L.</span></span> <span> </span><span class="NLM_article-title">Drug pipeline: 4q18</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1038/s41587-019-0052-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2Fs41587-019-0052-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30833768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosV2qtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=206-208&author=L.+DeFrancesco&title=Drug+pipeline%3A+4q18&doi=10.1038%2Fs41587-019-0052-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Drug pipeline: 4Q18</span></div><div class="casAuthors">DeFrancesco, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">206-208</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7aiMoCjDxnrVg90H21EOLACvtfcHk0li2N6ChmI8kEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosV2qtb8%253D&md5=cb8fa49ecadc365c11c54d8beb41224d</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fs41587-019-0052-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41587-019-0052-z%26sid%3Dliteratum%253Aachs%26aulast%3DDeFrancesco%26aufirst%3DL.%26atitle%3DDrug%2520pipeline%253A%25204q18%26jtitle%3DNat.%2520Biotechnol.%26date%3D2019%26volume%3D37%26spage%3D206%26epage%3D208%26doi%3D10.1038%2Fs41587-019-0052-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherlock, S.</span></span> <span> </span><span class="NLM_article-title">Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis</span>. <i>Clin. Liver Dis.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1016/S1089-3261(05)70098-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS1089-3261%2805%2970098-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=11232193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BD3MvitFyjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2000&pages=97-113&author=S.+Sherlock&title=Primary+biliary+cirrhosis%2C+primary+sclerosing+cholangitis%2C+and+autoimmune+cholangitis&doi=10.1016%2FS1089-3261%2805%2970098-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis</span></div><div class="casAuthors">Sherlock S</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in liver disease</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-113</span>
        ISSN:<span class="NLM_cas:issn">1089-3261</span>.
    </div><div class="casAbstract">Primary biliary cirrhosis (PBC), and autoimmune cholangitis are presumed to be autoimmune cholestatic diseases, but the relevant antigens are unknown.  Primary biliary cirrhosis is diagnosed by a positive serum mitochondrial antibody test.  It usually affects women and has a very long course, culminating in liver transplantation or death.  Ursodeoxycholic acid is probably the appropriate treatment.  Primary sclerosing cholangitis (PSC) is marked by progressive destruction of extrahepatic and intrahepatic bile ducts.  There is no specific diagnostic test or treatment.  Cholangiocarcinoma is the dreaded complication and precludes liver transplantation, the only chance of a cure.  Autoimmune cholangitis overlaps PBC and autoimmune chronic hepatitis.  It is a rare condition, resembling PBC but with a negative serum mitochondrial antibody test; however, serum antinuclear antibodies and smooth muscle antibodies are present in high titers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4gl1aAPuspEewzGPswiWOfW6udTcc2eZdd3_ldVxs2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MvitFyjsg%253D%253D&md5=eb265811d84f28e5a72e306b5878a22d</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2FS1089-3261%2805%2970098-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1089-3261%252805%252970098-2%26sid%3Dliteratum%253Aachs%26aulast%3DSherlock%26aufirst%3DS.%26atitle%3DPrimary%2520biliary%2520cirrhosis%252C%2520primary%2520sclerosing%2520cholangitis%252C%2520and%2520autoimmune%2520cholangitis%26jtitle%3DClin.%2520Liver%2520Dis.%26date%3D2000%26volume%3D4%26spage%3D97%26epage%3D113%26doi%3D10.1016%2FS1089-3261%2805%2970098-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, C. Y.</span></span> <span> </span><span class="NLM_article-title">Update on fxr biology: Promising therapeutic target?</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2069</span>, <span class="refDoi"> DOI: 10.3390/ijms19072069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3390%2Fijms19072069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKltLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=2069&author=C.+Y.+Han&title=Update+on+fxr+biology%3A+Promising+therapeutic+target%3F&doi=10.3390%2Fijms19072069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Update on FXR biology: promising therapeutic target</span></div><div class="casAuthors">Han, Chang Yeob</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2069/1-2069/25</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Farnesoid X receptor (FXR), a metabolic nuclear receptor, plays crit. roles in the maintenance of systemic energy homeostasis and the integrity of many organs, including liver and intestine.  It regulates bile acid, lipid, and glucose metab., and contributes to inter-organ communication, in particular the enterohepatic signaling pathway, through bile acids and fibroblast growth factor-15/19 (FGF-15/19).  The metabolic effects of FXR are also involved in gut microbiota.  In addn., FXR has various functions in the kidney, adipose tissue, pancreas, cardiovascular system, and tumorigenesis.  Consequently, the deregulation of FXR may lead to abnormalities of specific organs and metabolic dysfunction, allowing the protein as an attractive therapeutic target for the management of liver and/or metabolic diseases.  Indeed, many FXR agonists have been being developed and are under pre-clin. and clin. investigations.  Although obeticholic acid (OCA) is one of the promising candidates, significant safety issues have remained.  The effects of FXR modulation might be multifaceted according to tissue specificity, disease type, and/or energy status, suggesting the careful use of FXR agonists.  This review summarizes the current knowledge of systemic FXR biol. in various organs and the gut-liver axis, particularly regarding the recent advancement in these fields, and also provides pharmacol. aspects of FXR modulation for rational therapeutic strategies and novel drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbCrrxu6Db4bVg90H21EOLACvtfcHk0lgR7jR4_AGBbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKltLbL&md5=b2497c742af491002d92b5bf049040ff</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.3390%2Fijms19072069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19072069%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DC.%2BY.%26atitle%3DUpdate%2520on%2520fxr%2520biology%253A%2520Promising%2520therapeutic%2520target%253F%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D2069%26doi%3D10.3390%2Fijms19072069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Obeticholic acid: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0616-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-016-0616-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=27406083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOlsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1221-6&author=A.+Markhamauthor=S.+J.+Keam&title=Obeticholic+acid%3A+First+global+approval&doi=10.1007%2Fs40265-016-0616-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Obeticholic Acid: First Global Approval</span></div><div class="casAuthors">Markham, A.; Keam, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1221-1226</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Obeticholic acid (OcalivaTM) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid.  The drug is in preregistration for this indication in the EU.  This article summarizes the milestones in the development of obeticholic acid leading to this first approval for primary biliary cholangitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphfGFiF0o6cLVg90H21EOLACvtfcHk0lgR7jR4_AGBbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOlsr%252FE&md5=2faa2b2fbe5c5311bd9769983d6b62df</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0616-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0616-x%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DObeticholic%2520acid%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1221%26epage%3D6%26doi%3D10.1007%2Fs40265-016-0616-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span> </span><span class="NLM_article-title">Global autoimmune treatment market is expected
to reach USD $7.95
billion by 2025: Fior markets</span>. <a href="https://www.globenewswire.com/news-release/2020/01/27/1975808/0/en/Global-Autoimmune-Treatment-Market-is-Expected-to-Reach-USD-7-95-Billion-by-2025-Fior-Markets.html" class="extLink">https://www.globenewswire.com/news-release/2020/01/27/1975808/0/en/Global-Autoimmune-Treatment-Market-is-Expected-to-Reach-USD-7-95-Billion-by-2025-Fior-Markets.html</a> (accessed Nov 24, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global+autoimmune+treatment+market+is+expected%0Ato+reach+USD+%247.95%0Abillion+by+2025%3A+Fior+markets.+https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2020%2F01%2F27%2F1975808%2F0%2Fen%2FGlobal-Autoimmune-Treatment-Market-is-Expected-to-Reach-USD-7-95-Billion-by-2025-Fior-Markets.html+%28accessed+Nov+24%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGlobal%2520autoimmune%2520treatment%2520market%2520is%2520expected%250Ato%2520reach%2520USD%2520%25247.95%250Abillion%2520by%25202025%253A%2520Fior%2520markets%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Heart disease and stroke statistics-2019 update: A report from the American heart association</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">e56</span>– <span class="NLM_lpage">e58</span>, <span class="refDoi"> DOI: 10.1161/CIR.0000000000000659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1161%2FCIR.0000000000000659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30700139" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2019&pages=e56-e58&author=+Benjamin&title=Heart+disease+and+stroke+statistics-2019+update%3A+A+report+from+the+American+heart+association&doi=10.1161%2FCIR.0000000000000659"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1161%2FCIR.0000000000000659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIR.0000000000000659%26sid%3Dliteratum%253Aachs%26aulast%3DBenjamin%26atitle%3DHeart%2520disease%2520and%2520stroke%2520statistics-2019%2520update%253A%2520A%2520report%2520from%2520the%2520American%2520heart%2520association%26jtitle%3DCirculation%26date%3D2019%26volume%3D139%26spage%3De56%26epage%3De58%26doi%3D10.1161%2FCIR.0000000000000659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span> </span><span class="NLM_article-title">Cardiovascular diseases (cvds): World health
organization</span>. <a href="https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)" class="extLink">https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)</a> (accessed Nov 23, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cardiovascular+diseases+%28cvds%29%3A+World+health%0Aorganization.+https%3A%2F%2Fwww.who.int%2Fnews-room%2Ffact-sheets%2Fdetail%2Fcardiovascular-diseases-%28cvds%29+%28accessed+Nov+23%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DCardiovascular%2520diseases%2520%2528cvds%2529%253A%2520World%2520health%250Aorganization%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surovtseva, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span> <span> </span><span class="NLM_article-title">An analysis of FDA-approved drugs for cardiovascular diseases</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.drudis.2014.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25218930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKqu7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1-4&author=M.+S.+Kinchauthor=Y.+Surovtsevaauthor=D.+Hoyer&title=An+analysis+of+FDA-approved+drugs+for+cardiovascular+diseases&doi=10.1016%2Fj.drudis.2014.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of FDA-approved drugs for cardiovascular diseases</span></div><div class="casAuthors">Kinch, Michael S.; Surovtseva, Yulia; Hoyer, Denton</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-4</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Following the introduction of antibiotic therapy and widespread inoculations, cardiovascular diseases have leapt ahead of infectious diseases in terms of prevalence in much of the developed and developing world.  Herein, we assess FDA-approved drugs for the treatment of cardiovascular diseases.  The drug development enterprise around cardiovascular diseases has remained stable in contrast to turbulent changes in other therapeutic indications.  However, upon closer inspection, the results identify narrow scope in terms of the breadth of targets and the mechanistic actions of new drugs.  From the public health point of view, it is important to balance incremental change with orthogonal innovations that are needed to combat a leading cause of morbidity and mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHm6HklB1UX7Vg90H21EOLACvtfcHk0lhjE5Jk5OqocQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKqu7zI&md5=ede55cfec49c1aa87bed03faf845bb3d</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DSurovtseva%26aufirst%3DY.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DAn%2520analysis%2520of%2520FDA-approved%2520drugs%2520for%2520cardiovascular%2520diseases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D1%26epage%3D4%26doi%3D10.1016%2Fj.drudis.2014.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubers, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N. J.</span></span> <span> </span><span class="NLM_article-title">Combined angiotensin receptor antagonism and neprilysin inhibition</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">1115</span>– <span class="NLM_lpage">1124</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.115.018622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1161%2FCIRCULATIONAHA.115.018622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26976916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlGlurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2016&pages=1115-1124&author=S.+A.+Hubersauthor=N.+J.+Brown&title=Combined+angiotensin+receptor+antagonism+and+neprilysin+inhibition&doi=10.1161%2FCIRCULATIONAHA.115.018622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition</span></div><div class="casAuthors">Hubers, Scott A.; Brown, Nancy J.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1115-1124</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Heart failure affects ≈5.7 million people in the United States alone.  Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, and aldosterone antagonists have improved mortality in patients with heart failure and reduced ejection fraction, but mortality remains high.  In July 2015, the US Food and Drug Administration approved the first of a new class of drugs for the treatment of heart failure: Valsartan/sacubitril (formerly known as LCZ696 and currently marketed by Novartis as Entresto) combines the angiotensin receptor blocker valsartan and the neprilysin inhibitor prodrug sacubitril in a 1:1 ratio in a sodium supramol. complex.  Sacubitril is converted by esterases to LBQ657, which inhibits neprilysin, the enzyme responsible for the degrdn. of the natriuretic peptides and many other vasoactive peptides.  Thus, this combined angiotensin receptor antagonist and neprilysin inhibitor addresses 2 of the pathophysiol. mechanisms of heart failure: activation of the renin-angiotensin-aldosterone system and decreased sensitivity to natriuretic peptides.  In the Prospective Comparison of ARNI With ACEI to Det. Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, valsartan/sacubitril significantly reduced mortality and hospitalization for heart failure, as well as blood pressure, compared with enalapril in patients with heart failure, reduced ejection fraction, and an elevated circulating level of brain natriuretic peptide or N-terminal pro-brain natriuretic peptide.  Ongoing clin. trials are evaluating the role of valsartan/sacubitril in the treatment of heart failure with preserved ejection fraction and hypertension.  We review here the mechanisms of action of valsartan/sacubitril, the pharmacol. properties of the drug, and its efficacy and safety in the treatment of heart failure and hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0l46f211CD7Vg90H21EOLACvtfcHk0lhjE5Jk5OqocQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlGlurg%253D&md5=a62c1c3bd33cae5d30a4f0136ec20e72</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.115.018622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.115.018622%26sid%3Dliteratum%253Aachs%26aulast%3DHubers%26aufirst%3DS.%2BA.%26aulast%3DBrown%26aufirst%3DN.%2BJ.%26atitle%3DCombined%2520angiotensin%2520receptor%2520antagonism%2520and%2520neprilysin%2520inhibition%26jtitle%3DCirculation%26date%3D2016%26volume%3D133%26spage%3D1115%26epage%3D1124%26doi%3D10.1161%2FCIRCULATIONAHA.115.018622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roubtsova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essalmani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinkiewicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamelin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davignon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidah, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span> <span> </span><span class="NLM_article-title">Proprotein convertase subtilisin/kexin type 9 (pcsk9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1002/hep.22354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fhep.22354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=18666258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCqt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=646-54&author=A.+Zaidauthor=A.+Roubtsovaauthor=R.+Essalmaniauthor=J.+Marcinkiewiczauthor=A.+Chamberlandauthor=J.+Hamelinauthor=M.+Tremblayauthor=H.+Jacquesauthor=W.+Jinauthor=J.+Davignonauthor=N.+G.+Seidahauthor=A.+Prat&title=Proprotein+convertase+subtilisin%2Fkexin+type+9+%28pcsk9%29%3A+Hepatocyte-specific+low-density+lipoprotein+receptor+degradation+and+critical+role+in+mouse+liver+regeneration&doi=10.1002%2Fhep.22354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration</span></div><div class="casAuthors">Zaid, Ahmed; Roubtsova, Anna; Essalmani, Rachid; Marcinkiewicz, Jadwiga; Chamberland, Ann; Hamelin, Josee; Tremblay, Michel; Jacques, Helene; Jin, Weijun; Davignon, Jean; Seidah, Nabil G.; Prat, Annik</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">646-654</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The gene encoding the proprotein convertase subtilisin/kexin type 9 (PCSK9) is linked to familial hypercholesterolemia, as are those of the low-d. lipoprotein receptor (LDLR) and apolipoprotein B.  PCSK9 enhances LDLR degrdn., resulting in low-d. lipoprotein accumulation in plasma.  To analyze the role of hepatic PCSK9, total and hepatocyte-specific knockout mice were generated.  They exhibit 42% and 27% less circulating cholesterol, resp., showing that liver PCSK9 was responsible for two thirds of the phenotype.  We also demonstrated that, in liver, PCSK9 is exclusively expressed in hepatocytes, representing the main source of circulating PCSK9.  The data suggest that local but not circulating PCSK9 regulates cholesterol levels.  Although transgenic mice overexpressing high levels of liver and circulating PCSK9 led to the almost complete disappearance of the hepatic LDLR, they did not recapitulate the plasma cholesterol levels obsd. in LDLR-deficient mice.  Single LDLR or double LDLR/PCSK9 knockout mice exhibited similar cholesterol profiles, indicating that PCSK9 regulates cholesterol homeostasis exclusively through the LDLR.  Finally, the regenerating liver of PCSK9-deficient mice exhibited necrotic lesions, which were prevented by a high-cholesterol diet.  However, lipid accumulation in hepatocytes of these mice was markedly reduced under both chow and high-cholesterol diets, revealing that PCSK9 deficiency confers resistance to liver steatosis.  Conclusion: Although PCSK9 is a target for controlling hypercholesterolemia, our data indicate that upon hepatic damage, patients lacking PCSK9 could be at risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQrSHkv-4skLVg90H21EOLACvtfcHk0lhjE5Jk5OqocQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCqt7nO&md5=026d4559852c91092acda88520d3031e</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1002%2Fhep.22354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22354%26sid%3Dliteratum%253Aachs%26aulast%3DZaid%26aufirst%3DA.%26aulast%3DRoubtsova%26aufirst%3DA.%26aulast%3DEssalmani%26aufirst%3DR.%26aulast%3DMarcinkiewicz%26aufirst%3DJ.%26aulast%3DChamberland%26aufirst%3DA.%26aulast%3DHamelin%26aufirst%3DJ.%26aulast%3DTremblay%26aufirst%3DM.%26aulast%3DJacques%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DDavignon%26aufirst%3DJ.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DPrat%26aufirst%3DA.%26atitle%3DProprotein%2520convertase%2520subtilisin%252Fkexin%2520type%25209%2520%2528pcsk9%2529%253A%2520Hepatocyte-specific%2520low-density%2520lipoprotein%2520receptor%2520degradation%2520and%2520critical%2520role%2520in%2520mouse%2520liver%2520regeneration%26jtitle%3DHepatology%26date%3D2008%26volume%3D48%26spage%3D646%26epage%3D54%26doi%3D10.1002%2Fhep.22354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mekaj, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekaj, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duci, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miftari, E. I.</span></span> <span> </span><span class="NLM_article-title">New oral anticoagulants: Their advantages and disadvantages compared with vitamin k antagonists in the prevention and treatment of patients with thromboembolic events</span>. <i>Ther. Clin. Risk Manage.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">967</span>, <span class="refDoi"> DOI: 10.2147/TCRM.S84210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2147%2FTCRM.S84210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26150723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FgvVChsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=967&author=Y.+H.+Mekajauthor=A.+Y.+Mekajauthor=S.+B.+Duciauthor=E.+I.+Miftari&title=New+oral+anticoagulants%3A+Their+advantages+and+disadvantages+compared+with+vitamin+k+antagonists+in+the+prevention+and+treatment+of+patients+with+thromboembolic+events&doi=10.2147%2FTCRM.S84210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events</span></div><div class="casAuthors">Mekaj Ymer H; Mekaj Agon Y; Duci Shkelzen B; Miftari Ermira I</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and clinical risk management</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">967-77</span>
        ISSN:<span class="NLM_cas:issn">1176-6336</span>.
    </div><div class="casAbstract">Despite the discovery and application of many parenteral (unfractionated and low-molecular-weight heparins) and oral anticoagulant vitamin K antagonist (VKA) drugs, the prevention and treatment of venous and arterial thrombotic phenomena remain major medical challenges.  Furthermore, VKAs are the only oral anticoagulants used during the past 60 years.  The main objective of this study is to present recent data on non-vitamin K antagonist oral anticoagulants (NOACs) and to analyze their advantages and disadvantages compared with those of VKAs based on a large number of recent studies.  NOACs are novel direct-acting medications that are selective for one specific coagulation factor, either thrombin (IIa) or activated factor X (Xa).  Several NOACs, such as dabigatran (a direct inhibitor of FIIa) and rivaroxaban, apixaban and edoxaban (direct inhibitors of factor Xa), have been used for at least 5 years but possibly 10 years.  Unlike traditional VKAs, which prevent the coagulation process by suppressing the synthesis of vitamin K-dependent factors, NOACs directly inhibit key proteases (factors IIa and Xa).  The important indications of these drugs are the prevention and treatment of deep vein thrombosis and pulmonary embolisms, and the prevention of atherothrombotic events in the heart and brain of patients with acute coronary syndrome and atrial fibrillation.  They are not fixed, and dose-various strengths are available.  Most studies have reported that more advantages than disadvantages for NOACs when compared with VKAs, with the most important advantages of NOACs including safety issues (ie, a lower incidence of major bleeding), convenience of use, minor drug and food interactions, a wide therapeutic window, and no need for laboratory monitoring.  Nonetheless, there are some conditions for which VKAs remain the drug of choice.  Based on the available data, we can conclude that NOACs have greater advantages and fewer disadvantages compared with VKAs.  New studies are required to further assess the efficacy of NOACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTMQ7SChs9khlMGsG_HTXYFfW6udTcc2ebWIG0M1VuSE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FgvVChsA%253D%253D&md5=e4eab2f297fd06d25a4e9541649d3aba</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S84210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S84210%26sid%3Dliteratum%253Aachs%26aulast%3DMekaj%26aufirst%3DY.%2BH.%26aulast%3DMekaj%26aufirst%3DA.%2BY.%26aulast%3DDuci%26aufirst%3DS.%2BB.%26aulast%3DMiftari%26aufirst%3DE.%2BI.%26atitle%3DNew%2520oral%2520anticoagulants%253A%2520Their%2520advantages%2520and%2520disadvantages%2520compared%2520with%2520vitamin%2520k%2520antagonists%2520in%2520the%2520prevention%2520and%2520treatment%2520of%2520patients%2520with%2520thromboembolic%2520events%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2015%26volume%3D11%26spage%3D967%26doi%3D10.2147%2FTCRM.S84210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nozue, T.</span></span> <span> </span><span class="NLM_article-title">Lipid lowering therapy and circulating pcsk9 concentration</span>. <i>J. Atheroscler. Thromb.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">907</span>, <span class="refDoi"> DOI: 10.5551/jat.RV17012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.5551%2Fjat.RV17012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28804094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGitbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=895-907&author=T.+Nozue&title=Lipid+lowering+therapy+and+circulating+pcsk9+concentration&doi=10.5551%2Fjat.RV17012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Lipid lowering therapy and circulating PCSK9 concentration</span></div><div class="casAuthors">Nozue, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Atherosclerosis and Thrombosis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">895-907</span>CODEN:
                <span class="NLM_cas:coden">JATHEH</span>;
        ISSN:<span class="NLM_cas:issn">1340-3478</span>.
    
            (<span class="NLM_cas:orgname">Japan Atherosclerosis Society</span>)
        </div><div class="casAbstract">Hypercholesterolemia, particularly an increase in low-d. lipoprotein cholesterol (LDL-C) levels, contributes substantially to the development of coronary artery disease and the risk for cardiovascular events.  As the first-line pharmacotherapy, statins have been shown to reduce both LDL-C levels and cardiovascular events.  However, despite intensive statin therapy, a sizable proportion of statin-treated patients are unable to achieve the recommended target LDL-C levels, and not all patients can avoid future cardiovascular events.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in cholesterol homeostasis by enhancing the degrdn. of hepatic low-d. lipoprotein receptor (LDLR).  Owing to its importance in lipid metab., PCSK9 has emerged as a novel pharmacol. target for lowering LDL-C levels.  In this review, the potential role of circulating PCSK9 as a new biomarker of lipid metab. is described.  Next, previous studies evaluating the effects of lipid-modifying pharmacol. agents, particularly statins, on circulating PCSK9 concns. are summarized.  Statins decrease hepatic intracellular cholesterol, resulting in increased LDLRs as well as increased PCSK9 protein.  There is a clear dose-response effect of statin treatment on PCSK9 level, as increasing doses of statins also increase the level of circulating PCSK9.  Finally, the available therapeutic strategies to inhibit PCSK9 are present.  Monoclonal antibodies against PCSK9, in combination with statins, are one of the most promising and novel approaches to achieve further redn. of LDL-C levels and reduce the risk of cardiovascular events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgVAwIzEcWqbVg90H21EOLACvtfcHk0liRQ6w1a_aPGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGitbvL&md5=f44dc5e2b11285f14943c2790672e381</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.5551%2Fjat.RV17012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5551%252Fjat.RV17012%26sid%3Dliteratum%253Aachs%26aulast%3DNozue%26aufirst%3DT.%26atitle%3DLipid%2520lowering%2520therapy%2520and%2520circulating%2520pcsk9%2520concentration%26jtitle%3DJ.%2520Atheroscler.%2520Thromb.%26date%3D2017%26volume%3D24%26spage%3D895%26epage%3D907%26doi%3D10.5551%2Fjat.RV17012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bussard, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busse, L. W.</span></span> <span> </span><span class="NLM_article-title">Angiotensin ii: A new therapeutic option for vasodilatory shock</span>. <i>Ther. Clin. Risk Manage.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1287</span>– <span class="NLM_lpage">1298</span>, <span class="refDoi"> DOI: 10.2147/TCRM.S150434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2147%2FTCRM.S150434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30100727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1OntrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=1287-1298&author=R.+L.+Bussardauthor=L.+W.+Busse&title=Angiotensin+ii%3A+A+new+therapeutic+option+for+vasodilatory+shock&doi=10.2147%2FTCRM.S150434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II : a new therapeutic option for vasodilatory shock</span></div><div class="casAuthors">Bussard, Rachel L.; Busse, Laurence W.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1287-1298</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1178-203X</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Angiotensin II (Ang II), part of the renin-angiotensin-aldosterone system (RAS), is a potent vasoconstrictor and has been recently approved for use by the US Food and Drug Administration in high-output shock.  Though not a new drug, the recently published Angiotensin II for the Treatment of High Output Shock (ATHOS-3) trial, as well as a no. of retrospective analyses have sparked renewed interest in the use of Ang II, which may have a role in treating refractory shock.  We describe refractory shock, the unique mechanism of action of Ang II, RAS dysregulation in shock, and the evidence supporting the use of Ang II to restore blood pressure.  Evidence suggests that Ang II may preferentially be of benefit in acute kidney injury and acute respiratory distress syndrome, where the RAS is known to be disrupted.  Addnl., there may be a role for Ang II in cardiogenic shock, angiotensin converting enzyme inhibitor overdose, cardiac arrest, liver failure, and in settings of extracorporeal circulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq6wfoUcoporVg90H21EOLACvtfcHk0liRQ6w1a_aPGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1OntrvI&md5=56e55e0d8a6d9c7293bff05e5bd3fe16</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S150434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S150434%26sid%3Dliteratum%253Aachs%26aulast%3DBussard%26aufirst%3DR.%2BL.%26aulast%3DBusse%26aufirst%3DL.%2BW.%26atitle%3DAngiotensin%2520ii%253A%2520A%2520new%2520therapeutic%2520option%2520for%2520vasodilatory%2520shock%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2018%26volume%3D14%26spage%3D1287%26epage%3D1298%26doi%3D10.2147%2FTCRM.S150434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mankad, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K. B.</span></span> <span> </span><span class="NLM_article-title">Transthyretin cardiac amyloidosis</span>. <i>Curr. Cardiol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">97</span>, <span class="refDoi"> DOI: 10.1007/s11886-017-0911-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs11886-017-0911-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28840452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC1cbhsF2ntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=97&author=A.+K.+Mankadauthor=K.+B.+Shah&title=Transthyretin+cardiac+amyloidosis&doi=10.1007%2Fs11886-017-0911-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Transthyretin Cardiac Amyloidosis</span></div><div class="casAuthors">Mankad Anit K; Shah Keyur B</div><div class="citationInfo"><span class="NLM_cas:title">Current cardiology reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">97</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  Transthyretin (TTR)-related cardiac amyloidosis is a progressive infiltrative cardiomyopathy that mimics hypertensive, hypertrophic heart disease and may go undiagnosed.  Transthyretin-derived amyloidosis accounts for 18% of all cases of cardiac amyloidosis.  Thus, the study's purpose is to provide a comprehensive review of transthyretin cardiac amyloidosis.  RECENT FINDINGS:  Wild-type transthyretin (ATTRwt) protein causes cardiac amyloidosis sporadically, with 25 to 36% of the population older than 80 years of age are at risk to develop a slowly progressive, infiltrative amyloid cardiomyopathy secondary to ATTRwt.  In contrast, hereditary amyloidosis (ATTRm) is an autosomal dominant inherited disease associated with more than 100 point mutations in the transthyretin gene and has a tendency to affect the heart and nervous system.  Up to 4% of African-Americans carry the Val122Ile mutation in the transthyretin gene, the most prevalent cause of hereditary cardiac amyloidosis in the USA.  Identifying transthyretin cardiac amyloidosis requires increased awareness of the prevalence, signs and symptoms, and diagnostic tools available for discrimination of this progressive form of cardiomyopathy associated with left ventricular hypertrophy.  While there are no FDA-approved medical treatments, investigation is underway on agents to reduce circulating mutated transthyretin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQtwTP9CVGXlsK3uFsUIZtkfW6udTcc2ebWIG0M1VuSE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbhsF2ntQ%253D%253D&md5=934da860c9bd217809891d5844f2272f</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1007%2Fs11886-017-0911-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11886-017-0911-5%26sid%3Dliteratum%253Aachs%26aulast%3DMankad%26aufirst%3DA.%2BK.%26aulast%3DShah%26aufirst%3DK.%2BB.%26atitle%3DTransthyretin%2520cardiac%2520amyloidosis%26jtitle%3DCurr.%2520Cardiol.%2520Rep.%26date%3D2017%26volume%3D19%26spage%3D97%26doi%3D10.1007%2Fs11886-017-0911-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prashant, A.</span></span> <span> </span><span class="NLM_article-title">Global challenges in cardiovascular drug discovery and clinical trials</span>. <i>Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>06</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi"> DOI: 10.4172/2168-9547.1000193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.4172%2F2168-9547.1000193" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=06&publication_year=2017&pages=6&author=A.+Prashant&title=Global+challenges+in+cardiovascular+drug+discovery+and+clinical+trials&doi=10.4172%2F2168-9547.1000193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.4172%2F2168-9547.1000193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2168-9547.1000193%26sid%3Dliteratum%253Aachs%26aulast%3DPrashant%26aufirst%3DA.%26atitle%3DGlobal%2520challenges%2520in%2520cardiovascular%2520drug%2520discovery%2520and%2520clinical%2520trials%26jtitle%3DMol.%2520Biol.%26date%3D2017%26volume%3D06%26spage%3D6%26doi%3D10.4172%2F2168-9547.1000193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimazawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, M.</span></span> <span> </span><span class="NLM_article-title">Drug-diagnostic co-development: Challenges and issues</span>. <i>Expert Rev. Mol. Diagn.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1586/14737159.2016.1132163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1586%2F14737159.2016.1132163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26651878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVarsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=187-204&author=R.+Shimazawaauthor=M.+Ikeda&title=Drug-diagnostic+co-development%3A+Challenges+and+issues&doi=10.1586%2F14737159.2016.1132163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-diagnostic co-development: challenges and issues</span></div><div class="casAuthors">Shimazawa, Rumiko; Ikeda, Masayuki</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Molecular Diagnostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-204</span>CODEN:
                <span class="NLM_cas:coden">ERMDCW</span>;
        ISSN:<span class="NLM_cas:issn">1473-7159</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Diagnostic tests have become increasingly important for optimizing drug use.  Ideally, a companion diagnostic test is developed concurrently with a corresponding therapeutic product (co-development).  However, the diagnostic test may also be developed to optimize treatment with previously approved therapeutic agents (follow-up-development).  In co-development, the effectiveness of an agent in marker-defined patients is confirmed by an enrichment trial design.  In follow-up-development, a biomarker is validated by prospective and/or retrospective analyses of unselected design trials.  A prospectively designed trial is the gold-std. approach to biomarker validation, but retrospective validation can be used to efficiently det. effective treatments for marker-defined patients.  Accumulation and systematization of examples of drug-diagnostic development will aid in the effective development of companion diagnostics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp036w3MuGeU7Vg90H21EOLACvtfcHk0lirBcbvXr_RbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVarsg%253D%253D&md5=1ea3432f37b7c3a4e395b6d39103a823</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1586%2F14737159.2016.1132163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737159.2016.1132163%26sid%3Dliteratum%253Aachs%26aulast%3DShimazawa%26aufirst%3DR.%26aulast%3DIkeda%26aufirst%3DM.%26atitle%3DDrug-diagnostic%2520co-development%253A%2520Challenges%2520and%2520issues%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Diagn.%26date%3D2016%26volume%3D16%26spage%3D187%26epage%3D204%26doi%3D10.1586%2F14737159.2016.1132163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. B.</span></span> <span> </span><span class="NLM_article-title">Discovery, understanding, and bioapplication of organic fluorophore: A case study with an indolizine-based novel fluorophore, seoul-fluor</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1021/ar500370v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar500370v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVegu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2015&pages=538-47&author=E.+Kimauthor=Y.+Leeauthor=S.+Leeauthor=S.+B.+Park&title=Discovery%2C+understanding%2C+and+bioapplication+of+organic+fluorophore%3A+A+case+study+with+an+indolizine-based+novel+fluorophore%2C+seoul-fluor&doi=10.1021%2Far500370v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, Understanding, and Bioapplication of Organic Fluorophore: A Case Study with an Indolizine-Based Novel Fluorophore, Seoul-Fluor</span></div><div class="casAuthors">Kim, Eunha; Lee, Youngjun; Lee, Sanghee; Park, Seung Bum</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">538-547</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Owing to its high sensitivity and great applicability, the fluorescence phenomenon has been considered as an inevitable research tool in the modern scientific fields of chem., biol., materials science, biomedical science, and their interfaces.  Many strategies have been pursued to understand and manipulate the photophys. properties of fluorescent materials, but the scientific community has been focused on the repeated application of existing org. fluorophores or the identification of unique fluorescence properties in a trial-and-error basis without systematic studies.  Moreover, recent studies are emphasizing the necessity of deeper understanding about the structure-photophys. property relation of org. fluorophores for the development of better fluorescent probes.  Herein, the authors provide an overview of a novel fluorescent mol. framework, Seoul-Fluor, which can be rationally engineered to furnish a wide variety of fluorophores in terms of the photophys. properties.  Seoul-Fluor is built on an indolizine-based fluorescent platform with three different positions to introduce various substituents: R1 and R2 substituents for electronic perturbation; R3 substituent as a functional handle for bioconjugation.  Over the past decade, the Seoul-Fluor system has (i) tunable and predictable emission wavelength covering a full visible-color range; (ii) controllable quantum yield via photoinduced electron transfer phenomenon; and (iii) environment-sensitive fluorogenic properties that can be modified through intramol. charge transfer processes.  The authors convincingly demonstrated the prediction of photophys. properties, i.e., emission wavelength and quantum yield, through the construction of a systematic set of analogs and the subsequent anal. of their photophys. properties without the highly sophisticated theor. support.  Guided by quantifiable parameters such as the Hammett substituent consts. or energy levels of the MOs, this unique org. fluorophore can serve as a versatile mol. platform for the development of novel fluorescent switchable biosensors and fluorogenic bioprobes.  In this Account, the authors will discuss the discovery and recent progress made on Seoul-Fluor, the rational design of Seoul-Fluor-based bioprobes, and their practical applications to specific biol. processes that are facilitated by systematic studies of the structure-photophys. property relations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnzZL7nfvoy7Vg90H21EOLACvtfcHk0lirBcbvXr_RbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVegu7g%253D&md5=7581b2b18de843eb105559f68b8f215b</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Far500370v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far500370v%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DS.%2BB.%26atitle%3DDiscovery%252C%2520understanding%252C%2520and%2520bioapplication%2520of%2520organic%2520fluorophore%253A%2520A%2520case%2520study%2520with%2520an%2520indolizine-based%2520novel%2520fluorophore%252C%2520seoul-fluor%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2015%26volume%3D48%26spage%3D538%26epage%3D47%26doi%3D10.1021%2Far500370v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, U. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stedmon, C. A.</span></span> <span> </span><span class="NLM_article-title">Corrigendum: Fluorescence quantum yields of natural organic matter and organic compounds: Implications for the fluorescence-based interpretation of organic matter composition</span>. <i>Front. Mar. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">9</span>, <span class="refDoi"> DOI: 10.3389/fmars.2016.00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3389%2Ffmars.2016.00009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=9&author=U.+J.+W%C3%BCnschauthor=K.+R.+Murphyauthor=C.+A.+Stedmon&title=Corrigendum%3A+Fluorescence+quantum+yields+of+natural+organic+matter+and+organic+compounds%3A+Implications+for+the+fluorescence-based+interpretation+of+organic+matter+composition&doi=10.3389%2Ffmars.2016.00009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.3389%2Ffmars.2016.00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmars.2016.00009%26sid%3Dliteratum%253Aachs%26aulast%3DW%25C3%25BCnsch%26aufirst%3DU.%2BJ.%26aulast%3DMurphy%26aufirst%3DK.%2BR.%26aulast%3DStedmon%26aufirst%3DC.%2BA.%26atitle%3DCorrigendum%253A%2520Fluorescence%2520quantum%2520yields%2520of%2520natural%2520organic%2520matter%2520and%2520organic%2520compounds%253A%2520Implications%2520for%2520the%2520fluorescence-based%2520interpretation%2520of%2520organic%2520matter%2520composition%26jtitle%3DFront.%2520Mar.%2520Sci.%26date%3D2016%26volume%3D3%26spage%3D9%26doi%3D10.3389%2Ffmars.2016.00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kristoffersen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erga, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frette, Ø.</span></span> <span> </span><span class="NLM_article-title">Testing fluorescence lifetime standards using two-photon excitation and time-domain instrumentation: Fluorescein, quinine sulfate and green fluorescent protein</span>. <i>J. Fluoresc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1065</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1007/s10895-018-2270-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs10895-018-2270-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30046998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOntrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1065-1073&author=A.+S.+Kristoffersenauthor=S.+R.+Ergaauthor=B.+Hamreauthor=%C3%98.+Frette&title=Testing+fluorescence+lifetime+standards+using+two-photon+excitation+and+time-domain+instrumentation%3A+Fluorescein%2C+quinine+sulfate+and+green+fluorescent+protein&doi=10.1007%2Fs10895-018-2270-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Testing Fluorescence Lifetime Standards using Two-Photon Excitation and Time-Domain Instrumentation: Fluorescein, Quinine Sulfate and Green Fluorescent Protein</span></div><div class="casAuthors">Kristoffersen, Arne S.; Erga, Svein R.; Hamre, Boerge; Frette, Oeyvind</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Fluorescence</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1065-1073</span>CODEN:
                <span class="NLM_cas:coden">JOFLEN</span>;
        ISSN:<span class="NLM_cas:issn">1053-0509</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">It is essential for everyone working with exptl. science to be certain that their instruments produce reliable results, and for fluorescence lifetime expts., information about fluorescence lifetime stds. is crucial.  A large part of the literature on lifetime stds. dates back to the 1970s and 1980s, and the use of newer and faster measuring devices may deem these results unreliable.  We have tested the three commonly used fluorophores fluorescein, quinine sulfate and green fluorescent protein for their suitability to serve as lifetime stds., esp. to be used with two-photon excitation measurements in the time-domain.  We measured absorption and emission spectra for the fluorophores to det. optimal wavelengths to use for excitation and detector settings.  Fluorescence lifetimes were measured for different concns., ranging from 10- 3 - 10- 5 M, as well as for various solvents.  Fluorescein was sol. in both ethanol, methanol and sulfuric acid, while quinine sulfate was only sol. in sulfuric acid.  Green fluorescent protein was prepd. in a com. Tris-HCl, EDTA soln., and all three fluorophores produced stable lifetime results with low uncertainties.  No siginificant variation with concn. was measured for any of the fluorophores, and all showed single-exponential decays.  All lifetime measurements were carried out using two-photon excitation and lifetime data was obtained in the time-domain using time-correlated single-photon counting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUjug89pp7MbVg90H21EOLACvtfcHk0lhoIaUA9d1n-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOntrnE&md5=8e70025b868ea632cc55b066017102a6</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1007%2Fs10895-018-2270-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10895-018-2270-z%26sid%3Dliteratum%253Aachs%26aulast%3DKristoffersen%26aufirst%3DA.%2BS.%26aulast%3DErga%26aufirst%3DS.%2BR.%26aulast%3DHamre%26aufirst%3DB.%26aulast%3DFrette%26aufirst%3D%25C3%2598.%26atitle%3DTesting%2520fluorescence%2520lifetime%2520standards%2520using%2520two-photon%2520excitation%2520and%2520time-domain%2520instrumentation%253A%2520Fluorescein%252C%2520quinine%2520sulfate%2520and%2520green%2520fluorescent%2520protein%26jtitle%3DJ.%2520Fluoresc.%26date%3D2018%26volume%3D28%26spage%3D1065%26epage%3D1073%26doi%3D10.1007%2Fs10895-018-2270-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reisch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klymchenko, A. S.</span></span> <span> </span><span class="NLM_article-title">Fluorescent polymer nanoparticles based on dyes: Seeking brighter tools for bioimaging</span>. <i>Small</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1968</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1002/smll.201503396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fsmll.201503396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26901678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XivFKisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1968-92&author=A.+Reischauthor=A.+S.+Klymchenko&title=Fluorescent+polymer+nanoparticles+based+on+dyes%3A+Seeking+brighter+tools+for+bioimaging&doi=10.1002%2Fsmll.201503396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescent Polymer Nanoparticles Based on Dyes: Seeking Brighter Tools for Bioimaging</span></div><div class="casAuthors">Reisch, Andreas; Klymchenko, Andrey S.</div><div class="citationInfo"><span class="NLM_cas:title">Small</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1968-1992</span>CODEN:
                <span class="NLM_cas:coden">SMALBC</span>;
        ISSN:<span class="NLM_cas:issn">1613-6810</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Speed, resoln. and sensitivity of today's fluorescence bioimaging can be drastically improved by fluorescent nanoparticles (NPs) that are many-fold brighter than org. dyes and fluorescent proteins.  While the field is currently dominated by inorg. NPs, notably quantum dots (QDs), fluorescent polymer NPs encapsulating large quantities of dyes (dye-loaded NPs) have emerged recently as an attractive alternative.  These new nanomaterials, inspired from the fields of polymeric drug delivery vehicles and advanced fluorophores, can combine superior brightness with biodegradability and low toxicity.  Here, the authors describe the strategies for synthesis of dye-loaded polymer NPs by emulsion polymn. and assembly of pre-formed polymers.  Superior brightness requires strong dye loading without aggregation-caused quenching (ACQ).  Only recently several strategies of dye design are proposed to overcome ACQ in polymer NPs: aggregation induced emission (AIE), dye modification with bulky side groups and use of bulky hydrophobic counterions.  The resulting NPs now surpass the brightness of QDs by ≈10-fold for a comparable size, and have started reaching the level of the brightest conjugated polymer NPs.  Other properties, notably photostability, color, blinking, as well as particle size and surface chem. are also systematically analyzed.  Finally, major and emerging applications of dye-loaded NPs for in vitro and in vivo imaging are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXynwKKk2T7rVg90H21EOLACvtfcHk0lhoIaUA9d1n-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivFKisrc%253D&md5=979fddb827142090589a3fee8cc4efd3</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fsmll.201503396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsmll.201503396%26sid%3Dliteratum%253Aachs%26aulast%3DReisch%26aufirst%3DA.%26aulast%3DKlymchenko%26aufirst%3DA.%2BS.%26atitle%3DFluorescent%2520polymer%2520nanoparticles%2520based%2520on%2520dyes%253A%2520Seeking%2520brighter%2520tools%2520for%2520bioimaging%26jtitle%3DSmall%26date%3D2016%26volume%3D12%26spage%3D1968%26epage%3D92%26doi%3D10.1002%2Fsmll.201503396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. L. R.</span></span> <span> </span><span class="NLM_article-title">Designed for life: Biocompatible de novo designed proteins and components</span>. <i>J. R. Soc., Interface</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">20180472</span>, <span class="refDoi"> DOI: 10.1098/rsif.2018.0472</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1098%2Frsif.2018.0472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30158186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtlKhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=20180472&author=K.+J.+Graysonauthor=J.+L.+R.+Anderson&title=Designed+for+life%3A+Biocompatible+de+novo+designed+proteins+and+components&doi=10.1098%2Frsif.2018.0472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Designed for life: biocompatible de novo designed proteins and components</span></div><div class="casAuthors">Grayson, Katie J.; Anderson, J. L. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Royal Society, Interface</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">145</span>),
    <span class="NLM_cas:pages">20180472/1-20180472/15</span>CODEN:
                <span class="NLM_cas:coden">JRSICU</span>;
        ISSN:<span class="NLM_cas:issn">1742-5662</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  A principal goal of synthetic biol. is the de novo design or redesign of biomol. components.  In addn. to revealing fundamentally important information regarding natural biomol. engineering and biochem., functional building blocks will ultimately be provided for applications including the manuf. of valuable products and therapeutics.  To fully realize this ambitious goal, the designed components must be biocompatible, working in concert with natural biochem. processes and pathways, while not adversely affecting cellular function.  For example, de novo protein design has provided us with a wide repertoire of structures and functions, including those that can be assembled and function in vivo.  Here we discuss such biocompatible designs, as well as others that have the potential to become biocompatible, including non-protein mols., and routes to achieving full biol. integration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGIHZTW5RK5rVg90H21EOLACvtfcHk0lhoIaUA9d1n-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtlKhu7Y%253D&md5=f96fe8cdb63f54c3fd07549f855d1c3d</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1098%2Frsif.2018.0472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frsif.2018.0472%26sid%3Dliteratum%253Aachs%26aulast%3DGrayson%26aufirst%3DK.%2BJ.%26aulast%3DAnderson%26aufirst%3DJ.%2BL.%2BR.%26atitle%3DDesigned%2520for%2520life%253A%2520Biocompatible%2520de%2520novo%2520designed%2520proteins%2520and%2520components%26jtitle%3DJ.%2520R.%2520Soc.%252C%2520Interface%26date%3D2018%26volume%3D15%26spage%3D20180472%26doi%3D10.1098%2Frsif.2018.0472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span> </span><span class="NLM_article-title">Nuclear
medicine equipment market by product (spect (hybrid spect,
standalone spect), hybrid pet, & planar scintigraphy), application
(cardiology, oncology & neurology) & by end user (hospitals,
imaging centers) - global forecasts to 2020</span>. <a href="https://www.marketsandmarkets.com/Market-Reports/nuclear-medicine-equipment-market-242495651.html" class="extLink">https://www.marketsandmarkets.com/Market-Reports/nuclear-medicine-equipment-market-242495651.html</a> (accessed Jun 30, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Nuclear%0Amedicine+equipment+market+by+product+%28spect+%28hybrid+spect%2C%0Astandalone+spect%29%2C+hybrid+pet%2C+%26+planar+scintigraphy%29%2C+application%0A%28cardiology%2C+oncology+%26+neurology%29+%26+by+end+user+%28hospitals%2C%0Aimaging+centers%29+-+global+forecasts+to+2020.+https%3A%2F%2Fwww.marketsandmarkets.com%2FMarket-Reports%2Fnuclear-medicine-equipment-market-242495651.html+%28accessed+Jun+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNuclear%250Amedicine%2520equipment%2520market%2520by%2520product%2520%2528spect%2520%2528hybrid%2520spect%252C%250Astandalone%2520spect%2529%252C%2520hybrid%2520pet%252C%2520%2526%2520planar%2520scintigraphy%2529%252C%2520application%250A%2528cardiology%252C%2520oncology%2520%2526%2520neurology%2529%2520%2526%2520by%2520end%2520user%2520%2528hospitals%252C%250Aimaging%2520centers%2529%2520-%2520global%2520forecasts%2520to%25202020%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span> </span><span class="NLM_article-title">Imaging
agents: Global market trajectory and analytics</span>. <a href="https://www.researchandmarkets.com/reports/338860/imaging_agents_global_market_trajectory_and" class="extLink">https://www.researchandmarkets.com/reports/338860/imaging_agents_global_market_trajectory_and</a> (accessed Nov 24, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Imaging%0Aagents%3A+Global+market+trajectory+and+analytics.+https%3A%2F%2Fwww.researchandmarkets.com%2Freports%2F338860%2Fimaging_agents_global_market_trajectory_and+%28accessed+Nov+24%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DImaging%250Aagents%253A%2520Global%2520market%2520trajectory%2520and%2520analytics%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smigielski, J.</span></span> <span> </span><span class="NLM_article-title">The prevalence of age-related eye diseases and cataract surgery among older adults in the city of lodz, poland</span>. <i>J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">605814</span>, <span class="refDoi"> DOI: 10.1155/2015/605814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1155%2F2015%2F605814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=25789169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2MnmtVGhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=605814&author=M.+S.+Nowakauthor=J.+Smigielski&title=The+prevalence+of+age-related+eye+diseases+and+cataract+surgery+among+older+adults+in+the+city+of+lodz%2C+poland&doi=10.1155%2F2015%2F605814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">The Prevalence of Age-Related Eye Diseases and Cataract Surgery among Older Adults in the City of Lodz, Poland</span></div><div class="casAuthors">Nowak Michal Szymon; Smigielski Janusz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of ophthalmology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">605814</span>
        ISSN:<span class="NLM_cas:issn">2090-004X</span>.
    </div><div class="casAbstract">Purpose.  To determine the prevalence of age-related eye diseases and cataract surgery among older adults in the city of Lodz, in central Poland.  Material and Methods.  The study design was cross-sectional and observational study.  A total of 1107 women and men of predominantly Caucasian origin were successfully enumerated and recruited for the study.  All selected subjects were interviewed and underwent detailed ophthalmic examinations.  Results.  Overall 8.04% (95% CI 6.44-9.64) subjects had cataract surgery in either eye.  After excluding subjects with bilateral cataract surgery, the prevalence of cataract was 12.10% (95% CI 10.18-14.03).  AMD was found in 4.33% (95% CI 3.14-5.54 ) of all subjects.  Of them 3.25% (95% CI 2.21-4.30 ) had early AMD and 1.08% (95% CI 0.47-1.69) had late AMD.  Various types of glaucoma were diagnosed in 5.51% (95% CI 4.17-6.85) of subjects and 2.62% (95% CI 1.68-3.56) had OHT.  The prevalence rates of DR and myopic macular degeneration were 1.72% (95% CI 0.95-2.48) and 0.45% (95% CI 0.06-0.85), respectively.  All multiple logistic regression models were only significantly associated with older age.  The highest rate of visual impairment was observed among subjects with retinal diseases.  Conclusions.  The study revealed high prevalence of age-related eye diseases in this older population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9t7rHW-VRsJggzHGM8X5CfW6udTcc2eZlyHmJ9FP8ebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnmtVGhtA%253D%253D&md5=50ac9fc66d0c104a29c531cdd3ba33d0</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1155%2F2015%2F605814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F605814%26sid%3Dliteratum%253Aachs%26aulast%3DNowak%26aufirst%3DM.%2BS.%26aulast%3DSmigielski%26aufirst%3DJ.%26atitle%3DThe%2520prevalence%2520of%2520age-related%2520eye%2520diseases%2520and%2520cataract%2520surgery%2520among%2520older%2520adults%2520in%2520the%2520city%2520of%2520lodz%252C%2520poland%26jtitle%3DJ.%2520Ophthalmol.%26date%3D2015%26volume%3D2015%26spage%3D605814%26doi%3D10.1155%2F2015%2F605814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abidi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span> <span> </span><span class="NLM_article-title">Lifitegrast: A novel drug for treatment of dry eye disease</span>. <i>J. Pharmacol. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.4103/0976-500X.195920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.4103%2F0976-500X.195920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28163544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVChsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=194-198&author=A.+Abidiauthor=P.+Shuklaauthor=A.+Ahmad&title=Lifitegrast%3A+A+novel+drug+for+treatment+of+dry+eye+disease&doi=10.4103%2F0976-500X.195920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Lifitegrast: a novel drug for treatment of dry eye disease</span></div><div class="casAuthors">Abidi, Afroz; Shukla, Pooja; Ahmad, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Pharmacotherapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">194-198</span>CODEN:
                <span class="NLM_cas:coden">JPPOGN</span>;
        ISSN:<span class="NLM_cas:issn">0976-500X</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications and Media Pvt. Ltd.</span>)
        </div><div class="casAbstract">Dry eye disease (DED) is an inflammatory disorder of ocular surfaces leading to severe disability, esp. in the elderly age group.  The mainstay of therapy includes artificial tears, punctual plugs, topical antiinflammatory agents, and corticosteroids.  In the past few years, only cyclosporine-A emulsions have been added to the existing therapy, but it is discontinued by most patients as it causes burning sensation in the eye.  Hence, progress in new research for a better therapeutic option led to the discovery of lymphocyte function-assocd. antigen intercellular adhesion mol. 1 antagonist, lifitegrast.  It hinders the T-cell activation, release of inflammatory mediators, and consequently inhibits the inflammatory pathways in DED.  It was approved by the US Food and Drug Administration in July 2016 for the treatment of DED.  This review highlights the development process and approval of lifitegrast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGShJCw1byCrVg90H21EOLACvtfcHk0liCKIfGbQ9KWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVChsrg%253D&md5=5c2f2e417aa1de1c176b7bca2fe889c6</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.4103%2F0976-500X.195920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-500X.195920%26sid%3Dliteratum%253Aachs%26aulast%3DAbidi%26aufirst%3DA.%26aulast%3DShukla%26aufirst%3DP.%26aulast%3DAhmad%26aufirst%3DA.%26atitle%3DLifitegrast%253A%2520A%2520novel%2520drug%2520for%2520treatment%2520of%2520dry%2520eye%2520disease%26jtitle%3DJ.%2520Pharmacol.%2520Pharmacother.%26date%3D2016%26volume%3D7%26spage%3D194%26epage%3D198%26doi%3D10.4103%2F0976-500X.195920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mearin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malfertheiner, P.</span></span> <span> </span><span class="NLM_article-title">Functional gastrointestinal disorders: Complex treatments for complex pathophysiological mechanisms</span>. <i>Dig. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1159/000485407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1159%2F000485407" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2018&pages=1-4&author=F.+Mearinauthor=P.+Malfertheiner&title=Functional+gastrointestinal+disorders%3A+Complex+treatments+for+complex+pathophysiological+mechanisms&doi=10.1159%2F000485407"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1159%2F000485407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000485407%26sid%3Dliteratum%253Aachs%26aulast%3DMearin%26aufirst%3DF.%26aulast%3DMalfertheiner%26aufirst%3DP.%26atitle%3DFunctional%2520gastrointestinal%2520disorders%253A%2520Complex%2520treatments%2520for%2520complex%2520pathophysiological%2520mechanisms%26jtitle%3DDig.%2520Dis.%26date%3D2018%26volume%3D35%26spage%3D1%26epage%3D4%26doi%3D10.1159%2F000485407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanger, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, L. A.</span></span> <span> </span><span class="NLM_article-title">Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders</span>. <i>Ther. Adv. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1177/1756283X10369922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1177%2F1756283X10369922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=21180610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2jsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=291-305&author=G.+J.+Sangerauthor=L.+Changauthor=C.+Bountraauthor=L.+A.+Houghton&title=Challenges+and+prospects+for+pharmacotherapy+in+functional+gastrointestinal+disorders&doi=10.1177%2F1756283X10369922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders</span></div><div class="casAuthors">Sanger, Gareth J.; Chang, Lin; Bountra, Chas; Houghton, Lesley A.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Gastroenterology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">291-305</span>CODEN:
                <span class="NLM_cas:coden">TAGHAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-283X</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiol.  As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop new and effective treatments.  This review provides an overview of these difficulties and how the industry is reshaping its drug developmental strategies.  It describes some of the more significant and encouraging advances that have occurred, and discusses how future research might embrace the opportunities provided by advances in genetic and in particular, epigenetic research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJuA7JDY-VEbVg90H21EOLACvtfcHk0liCKIfGbQ9KWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2jsrjP&md5=62a50ecfae5f698a5c315827093de1d5</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1177%2F1756283X10369922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1756283X10369922%26sid%3Dliteratum%253Aachs%26aulast%3DSanger%26aufirst%3DG.%2BJ.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DHoughton%26aufirst%3DL.%2BA.%26atitle%3DChallenges%2520and%2520prospects%2520for%2520pharmacotherapy%2520in%2520functional%2520gastrointestinal%2520disorders%26jtitle%3DTher.%2520Adv.%2520Gastroenterol.%26date%3D2010%26volume%3D3%26spage%3D291%26epage%3D305%26doi%3D10.1177%2F1756283X10369922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, J. L.</span></span> <span> </span><span class="NLM_article-title">Treatment of chemotherapy-induced nausea in cancer patients</span>. <i>Eur. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">14</span>, <span class="refDoi"> DOI: 10.17925/EOH.2010.06.02.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.17925%2FEOH.2010.06.02.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=21984886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2srmsFCksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=14&author=J.+L.+Ryan&title=Treatment+of+chemotherapy-induced+nausea+in+cancer+patients&doi=10.17925%2FEOH.2010.06.02.14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Chemotherapy-Induced Nausea in Cancer Patients</span></div><div class="casAuthors">Ryan Julie L</div><div class="citationInfo"><span class="NLM_cas:title">European oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">14-16</span>
        ISSN:<span class="NLM_cas:issn">1758-3853</span>.
    </div><div class="casAbstract">For over 30 years, chemotherapy-induced nausea and vomiting have been the most severe and troublesome symptoms for cancer patients receiving chemotherapy.  Unresolved chemotherapy-induced nausea and vomiting can lead to metabolic disorders, dehydration, nutritional depletion and esophageal tears, and can reduce patients' daily functioning and quality of life and interfere with treatment schedules.(1, 2) Despite the widespread use of antiemetics, chemotherapy-induced nausea continues to be problematic.  Unlike vomiting, nausea is a subjective and unobservable phenomenon making it extremely difficult to accurately assess and treat.  Current research suggests that management of chemotherapy-induced nausea should focus on treating the symptoms before they occur rather than after they develop.  This review highlights evidence-based interventions for the treatment of chemotherapy-related nausea.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTaqoal3y9Tklm8bhe6roZYfW6udTcc2eZlyHmJ9FP8ebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srmsFCksA%253D%253D&md5=3ca113816dd50e62c70894363c39de3a</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.17925%2FEOH.2010.06.02.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17925%252FEOH.2010.06.02.14%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DJ.%2BL.%26atitle%3DTreatment%2520of%2520chemotherapy-induced%2520nausea%2520in%2520cancer%2520patients%26jtitle%3DEur.%2520Oncol.%26date%3D2010%26volume%3D6%26spage%3D14%26doi%3D10.17925%2FEOH.2010.06.02.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McQuade, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovska, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abalo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornstein, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurgali, K.</span></span> <span> </span><span class="NLM_article-title">Chemotherapy-induced constipation and diarrhea: Pathophysiology, current and emerging treatments</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">414</span>, <span class="refDoi"> DOI: 10.3389/fphar.2016.00414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3389%2Ffphar.2016.00414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=27857691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=414&author=R.+M.+McQuadeauthor=V.+Stojanovskaauthor=R.+Abaloauthor=J.+C.+Bornsteinauthor=K.+Nurgali&title=Chemotherapy-induced+constipation+and+diarrhea%3A+Pathophysiology%2C+current+and+emerging+treatments&doi=10.3389%2Ffphar.2016.00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments</span></div><div class="casAuthors">McQuade, Rachel M.; Stojanovska, Vanesa; Abalo, Raquel; Bornstein, Joel C.; Nurgali, Kulmira</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">414-427</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Gastrointestinal (GI) side-effects of chemotherapy are a debilitating and often overlooked clin. hurdle in cancer management.  Chemotherapy-induced constipation (CIC) and Diarrhea (CID) present a const. challenge in the efficient and tolerable treatment of cancer and are amongst the primary contributors to dose redns., delays and cessation of treatment.  Although prevalence of CIC is hard to est., it is believed to affect approx. 16% of cancer patients, while incidence of CID has been estd. to be as high as 80%.  Despite this, the underlying mechanisms of both CID and CIC remain unclear, but are believed to result from a combination of intersecting mechanisms including inflammation, secretory dysfunctions, GI dysmotility and alterations in GI innervation.  Current treatments for CIC and CID aim to reduce the severity of symptoms rather than combating the pathophysiol. mechanisms of dysfunction, and often result in worsening of already chronic GI symptoms or trigger the onset of a plethora of other side-effects including respiratory depression, uneven heartbeat, seizures, and neurotoxicity.  Emerging treatments including those targeting the enteric nervous system present promising avenues to alleviate CID and CIC.  Identification of potential targets for novel therapies to alleviate chemotherapy-induced toxicity is essential to improve clin. outcomes and quality of life amongst cancer sufferers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrteqGwwA9kW7Vg90H21EOLACvtfcHk0lhKhp_OEo4rtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWntLc%253D&md5=c0bdb919137b2370613cb6ce71bf5fc6</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2016.00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2016.00414%26sid%3Dliteratum%253Aachs%26aulast%3DMcQuade%26aufirst%3DR.%2BM.%26aulast%3DStojanovska%26aufirst%3DV.%26aulast%3DAbalo%26aufirst%3DR.%26aulast%3DBornstein%26aufirst%3DJ.%2BC.%26aulast%3DNurgali%26aufirst%3DK.%26atitle%3DChemotherapy-induced%2520constipation%2520and%2520diarrhea%253A%2520Pathophysiology%252C%2520current%2520and%2520emerging%2520treatments%26jtitle%3DFront.%2520Pharmacol.%26date%3D2016%26volume%3D7%26spage%3D414%26doi%3D10.3389%2Ffphar.2016.00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnock-Jones, K. P.</span></span> <span> </span><span class="NLM_article-title">Eluxadoline: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0436-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-015-0436-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26149369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCjt7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1305-10&author=K.+P.+Garnock-Jones&title=Eluxadoline%3A+First+global+approval&doi=10.1007%2Fs40265-015-0436-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Eluxadoline: First Global Approval</span></div><div class="casAuthors">Garnock-Jones, Karly P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1305-1310</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Eluxadoline (Viberzi), developed by Actavis (now Allergan), is an orally administered, first-in-class compd. that functions as both a μ-opioid receptor agonist and a δ-opioid receptor antagonist, and is indicated for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in adults.  The agent was originally developed by Janssen Pharmaceutica.  Eluxadoline has been approved in the US, and submissions to other global authorities are being contemplated or planned.  This article summarizes the milestones in the development of eluxadoline leading to this first approval for IBS-D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5dpEIm3WsLrVg90H21EOLACvtfcHk0lhKhp_OEo4rtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCjt7jF&md5=bf9bac23ac14a233f703f2d0565558f9</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0436-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0436-4%26sid%3Dliteratum%253Aachs%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DEluxadoline%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1305%26epage%3D10%26doi%3D10.1007%2Fs40265-015-0436-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Black, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A. C.</span></span> <span> </span><span class="NLM_article-title">Chronic idiopathic constipation in adults: Epidemiology, pathophysiology, diagnosis and clinical management</span>. <i>Med. J. Aust.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.5694/mja18.00241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.5694%2Fmja18.00241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29996755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Fnt1SjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2018&pages=86-91&author=C.+J.+Blackauthor=A.+C.+Ford&title=Chronic+idiopathic+constipation+in+adults%3A+Epidemiology%2C+pathophysiology%2C+diagnosis+and+clinical+management&doi=10.5694%2Fmja18.00241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management</span></div><div class="casAuthors">Black Christopher J; Ford Alexander C</div><div class="citationInfo"><span class="NLM_cas:title">The Medical journal of Australia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">86-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic idiopathic constipation (CIC) is one of the most common gastrointestinal disorders, with a global prevalence of 14%.  It is commoner in women and its prevalence increases with age.  There are three subtypes of CIC: dyssynergic defaecation, slow transit constipation and normal transit constipation, which is the most common subtype.  Clinical assessment of the patient with constipation requires careful history taking, in order to identify any red flag symptoms that would necessitate further investigation with colonoscopy to exclude colorectal malignancy.  Screening for hypercalcaemia, hypothyroidism and coeliac disease with appropriate blood tests should be considered.  A digital rectal examination should be performed to assess for evidence of dyssynergic defaecation.  If this is suspected, further investigation with high resolution anorectal manometry should be undertaken.  Anorectal biofeedback can be offered to patients with dyssynergic defaecation as a means of correcting the associated impairment of pelvic floor, abdominal wall and rectal functioning.  Lifestyle modifications, such as increasing dietary fibre, are the first step in managing other causes of CIC.  If patients do not respond to these simple changes, then treatment with osmotic and stimulant laxatives should be trialled.  Patients not responding to traditional laxatives should be offered treatment with prosecretory agents such as lubiprostone, linaclotide and plecanatide, or the 5-HT4 receptor agonist prucalopride, where available.  If there is no response to pharmacological treatment, surgical intervention can be considered, but it is only suitable for a carefully selected subset of patients with proven slow transit constipation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4SIAOqbpBeu2mnZh2OgS0fW6udTcc2eaGtMKblUa1C7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Fnt1SjtA%253D%253D&md5=c61e1d1322731f00817a16ae51e08a22</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.5694%2Fmja18.00241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5694%252Fmja18.00241%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DC.%2BJ.%26aulast%3DFord%26aufirst%3DA.%2BC.%26atitle%3DChronic%2520idiopathic%2520constipation%2520in%2520adults%253A%2520Epidemiology%252C%2520pathophysiology%252C%2520diagnosis%2520and%2520clinical%2520management%26jtitle%3DMed.%2520J.%2520Aust.%26date%3D2018%26volume%3D209%26spage%3D86%26epage%3D91%26doi%3D10.5694%2Fmja18.00241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eswaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guentner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chey, W. D.</span></span> <span> </span><span class="NLM_article-title">Emerging pharmacologic therapies for constipation-predominant irritable bowel syndrome and chronic constipation</span>. <i>J. Neurogastroenterol. Motil.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.5056/jnm.2014.20.2.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.5056%2Fjnm.2014.20.2.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24840367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cflvFSmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=141-51&author=S.+Eswaranauthor=A.+Guentnerauthor=W.+D.+Chey&title=Emerging+pharmacologic+therapies+for+constipation-predominant+irritable+bowel+syndrome+and+chronic+constipation&doi=10.5056%2Fjnm.2014.20.2.141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation</span></div><div class="casAuthors">Eswaran Shanti; Guentner Amanda; Chey William D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurogastroenterology and motility</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-51</span>
        ISSN:<span class="NLM_cas:issn">2093-0879</span>.
    </div><div class="casAbstract">Irritable bowel syndrome with constipation and chronic functional constipation are common digestive disorders that negatively impact quality of life and account for billions of dollars in health care costs.  Related to the heterogeneity of pathogenesis that underlie these disorders and the failure of symptoms to reliably predict underlying pathophysiology, traditional therapies provide relief to only a subset of affected individuals.  The evidence surrounding new and emerging pharmacologic treatments, which include both luminally and systemically acting drugs, is discussed here.  These include agents such as lubiprostone, bile acid modulations, guanylate cyclase-C receptor agonists, serotonin receptor modulators and herbal therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9mMH7P4hI_2BAiYWy6n3SfW6udTcc2eaGtMKblUa1C7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflvFSmsA%253D%253D&md5=c834a203d0529eead955b1865a05adae</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.5056%2Fjnm.2014.20.2.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5056%252Fjnm.2014.20.2.141%26sid%3Dliteratum%253Aachs%26aulast%3DEswaran%26aufirst%3DS.%26aulast%3DGuentner%26aufirst%3DA.%26aulast%3DChey%26aufirst%3DW.%2BD.%26atitle%3DEmerging%2520pharmacologic%2520therapies%2520for%2520constipation-predominant%2520irritable%2520bowel%2520syndrome%2520and%2520chronic%2520constipation%26jtitle%3DJ.%2520Neurogastroenterol.%2520Motil.%26date%3D2014%26volume%3D20%26spage%3D141%26epage%3D51%26doi%3D10.5056%2Fjnm.2014.20.2.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Outryve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerstens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandeplassche, L.</span></span> <span> </span><span class="NLM_article-title">Prucalopride (resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1136/gut.2008.162404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1136%2Fgut.2008.162404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=18987031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFGgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2009&pages=357-65&author=J.+Tackauthor=M.+van+Outryveauthor=G.+Beyensauthor=R.+Kerstensauthor=L.+Vandeplassche&title=Prucalopride+%28resolor%29+in+the+treatment+of+severe+chronic+constipation+in+patients+dissatisfied+with+laxatives&doi=10.1136%2Fgut.2008.162404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives</span></div><div class="casAuthors">Tack, J.; van Outryve, M.; Beyens, G.; Kerstens, R.; Vandeplassche, L.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">357-365</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">To det. the efficacy, impact on quality of life (QOL) and safety of prucalopride, a selective, high-affinity 5-HT4 receptor agonist, in patients with chronic constipation.  In this multicenter, randomized, placebo controlled, parallel-group, phase III study, patients with chronic constipation (two or fewer spontaneous complete bowel movements (SCBM)/wk) received 2 mg or 4 mg prucalopride or placebo, once daily, for 12 wk.  The primary efficacy endpoint was the proportion of patients reaching three of more SCBM/wk.  The key secondary efficacy endpoint was the proportion of patients having an increase of one or more SCBM/wk.  The primary QOL endpoint was the patient assessment of constipation QOL satisfaction subscale score.  Safety parameters included adverse events, lab. values and cardiovascular events.  Efficacy was evaluated over 713 patients.  Averaged over 12 wk, higher proportions of patients on prucalopride 2 mg (19.5%; p<0.01), 4 mg (23.6%; p<0.001) had three or more SCBM/wk (or normalization of bowel function) compared with placebo (9.6%).  Similar results were seen in the subgroup (83%) of patients dissatisfied with previous laxative treatment.  Both doses of prucalopride also significantly improved secondary efficacy and QOL endpoints, including the proportion of patients with an increase of one or more SCBM/wk, evacuation completeness, perceived disease severity and treatment effectiveness and QOL.  Prucalopride 4 mg significantly reduced the need for straining vs. placebo (p<0.05).  The most frequent treatment-related adverse events were headache and diarrhea.  Both doses of prucalopride were safe and well tolerated.  Prucalopride significantly and consistently improved bowel function, assocd. symptoms and satisfaction in chronically constipated patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX9B8ccr_LJLVg90H21EOLACvtfcHk0lgPP5YueKpAQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFGgt7o%253D&md5=d8aecfa2a78ea4802774f9bacd1768f4</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1136%2Fgut.2008.162404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.2008.162404%26sid%3Dliteratum%253Aachs%26aulast%3DTack%26aufirst%3DJ.%26aulast%3Dvan%2BOutryve%26aufirst%3DM.%26aulast%3DBeyens%26aufirst%3DG.%26aulast%3DKerstens%26aufirst%3DR.%26aulast%3DVandeplassche%26aufirst%3DL.%26atitle%3DPrucalopride%2520%2528resolor%2529%2520in%2520the%2520treatment%2520of%2520severe%2520chronic%2520constipation%2520in%2520patients%2520dissatisfied%2520with%2520laxatives%26jtitle%3DGut%26date%3D2009%26volume%3D58%26spage%3D357%26epage%3D65%26doi%3D10.1136%2Fgut.2008.162404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khansari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohrabi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamani, F.</span></span> <span> </span><span class="NLM_article-title">The useage of opioids and their adverse effects in gastrointestinal practice: A review</span>. <i>Middle East J. Dig. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">5</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24829664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cflvV2jug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=5&author=M.+Khansariauthor=M.+Sohrabiauthor=F.+Zamani&title=The+useage+of+opioids+and+their+adverse+effects+in+gastrointestinal+practice%3A+A+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">The Useage of Opioids and their Adverse Effects in Gastrointestinal Practice: A Review</span></div><div class="casAuthors">Khansari MahmoudReza; Sohrabi MasourReza; Zamani Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Middle East journal of digestive diseases</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-16</span>
        ISSN:<span class="NLM_cas:issn">2008-5230</span>.
    </div><div class="casAbstract">Opium is one of the oldest herbal medicines currently used as an analgesic, sedative and antidiarrheal treatment.  The effects of opium are principally mediated by the μ-, κ- and δ-opioid receptors.  Opioid substances consist of all natural and synthetic alkaloids that are derived from opium.  Most of their effects on gastrointestinal motility and secretion result from suppression of neural activity.  Inhibition of gastric emptying, increase in sphincter tone, changes in motor patterns, and blockage of peristalsis result from opioid use.  Common adverse effects of opioid administration include sedation, dizziness, nausea, vomiting, constipation, dependency and tolerance, and respiratory depression.  The most common adverse effect of opioid use is constipation.  Although stool softeners are frequently used to decrease opioid-induced bowel dysfunction, however they are not efficacious.  Possibly, the use of specific opioid receptor antagonists is a more suitable approach.  Opioid antagonists, both central and peripheral, could affect gastrointestinal function and visceromotor sensitivity, which suggests an important role for endogenous opioid peptides in the control of gastrointestinal physiology.  Underlying diseases or medications known to influence the central nervous system (CNS) often accelerate the opioid's adverse effects.  However, changing the opioid and/or route of administration could also decrease their adverse effects.  Appropriate patient selection, patient education and discussion regarding potential adverse effects may assist physicians in maximizing the effectiveness of opioids, while reducing the number and severity of adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnQb3thmCTV-kdrW1FkXG-fW6udTcc2eb5w4ueZ82Wxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflvV2jug%253D%253D&md5=b6563526454dcb29d186c01218e739ff</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKhansari%26aufirst%3DM.%26aulast%3DSohrabi%26aufirst%3DM.%26aulast%3DZamani%26aufirst%3DF.%26atitle%3DThe%2520useage%2520of%2520opioids%2520and%2520their%2520adverse%2520effects%2520in%2520gastrointestinal%2520practice%253A%2520A%2520review%26jtitle%3DMiddle%2520East%2520J.%2520Dig.%2520Dis.%26date%3D2013%26volume%3D5%26spage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coluzzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scerpa, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pergolizzi, J.</span></span> <span> </span><span class="NLM_article-title">Naldemedine: A new option for oibd</span>. <i>J. Pain Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1209</span>– <span class="NLM_lpage">1222</span>, <span class="refDoi"> DOI: 10.2147/JPR.S243435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2147%2FJPR.S243435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=32547183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFegsrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=1209-1222&author=F.+Coluzziauthor=M.+S.+Scerpaauthor=J.+Pergolizzi&title=Naldemedine%3A+A+new+option+for+oibd&doi=10.2147%2FJPR.S243435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Naldemedine: a new option for OIBD</span></div><div class="casAuthors">Coluzzi, Flaminia; Scerpa, Maria Sole; Pergolizzi, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1209-1222</span>CODEN:
                <span class="NLM_cas:coden">JPROEV</span>;
        ISSN:<span class="NLM_cas:issn">1178-7090</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Opioid-induced bowel dysfunction (OIBD) is a common complication in longterm opioid users and abusers.  It is a burdensome condition, which significantly limits quality of life and is assocd. with increasing health costs.  OIBD affects up to 60% of patients with chronic non-cancer pain and over 80% of patients suffering from cancer pain and is one of the conditions of the most common symptoms assocd. with opioid maintenance.  Given the continued use of opioids for chronic pain management in appropriate patients, OIBD is likely to persist in clin. practice in the coming years.  We will herein review its underlying pathophysiol. mechanisms and the available treatments.  In the last years, pharmaceutical research has focused on the opportunity of targeting peripheral muopioid receptors without affecting their analgesic activity in the central nervous system, and several peripherally acting mu-opioid receptors antagonists (PAMORAs) drugs have been approved.  We will mainly focus on naldemedine, discussing its pharmacol. properties, its clin. efficacy and side effects.  Head-to-head comparisons between naldemedine and the other PAMORAs are not available yet, but some considerations will be discussed based on the pharmacol. and clin. data.  As a whole, the available data suggest that naldemedine is a valid treatment option for OIBD, as it is a well-tolerated drug that alleviates constipation without affecting analgesia or causing symptoms of opioid withdrawal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMco4DbKoeNLVg90H21EOLACvtfcHk0lgPP5YueKpAQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFegsrnL&md5=5c84bb0ab08e048bfda431373ea1d2f3</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.2147%2FJPR.S243435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJPR.S243435%26sid%3Dliteratum%253Aachs%26aulast%3DColuzzi%26aufirst%3DF.%26aulast%3DScerpa%26aufirst%3DM.%2BS.%26aulast%3DPergolizzi%26aufirst%3DJ.%26atitle%3DNaldemedine%253A%2520A%2520new%2520option%2520for%2520oibd%26jtitle%3DJ.%2520Pain%2520Res.%26date%3D2020%26volume%3D13%26spage%3D1209%26epage%3D1222%26doi%3D10.2147%2FJPR.S243435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span> </span><span class="NLM_article-title">Global gastrointestinal drugs market research
report</span>. <a href="https://www.marketresearchfuture.com/reports/gastrointestinal-drugs-market-558" class="extLink">https://www.marketresearchfuture.com/reports/gastrointestinal-drugs-market-558</a> (accessed Nov 24, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global+gastrointestinal+drugs+market+research%0Areport.+https%3A%2F%2Fwww.marketresearchfuture.com%2Freports%2Fgastrointestinal-drugs-market-558+%28accessed+Nov+24%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGlobal%2520gastrointestinal%2520drugs%2520market%2520research%250Areport%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulnigg-Dabsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasche, C.</span></span> <span> </span><span class="NLM_article-title">Management of iron deficiency anemia</span>. <i>Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">250</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC28bitFensQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=241-250&author=K.+Jimenezauthor=S.+Kulnigg-Dabschauthor=C.+Gasche&title=Management+of+iron+deficiency+anemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Management of Iron Deficiency Anemia</span></div><div class="casAuthors">Jimenez Kristine; Kulnigg-Dabsch Stefanie; Gasche Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology & hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">241-50</span>
        ISSN:<span class="NLM_cas:issn">1554-7914</span>.
    </div><div class="casAbstract">Anemia affects one-fourth of the world's population, and iron deficiency is the predominant cause.  Anemia is associated with chronic fatigue, impaired cognitive function, and diminished well-being.  Patients with iron deficiency anemia of unknown etiology are frequently referred to a gastroenterologist because in the majority of cases the condition has a gastrointestinal origin.  Proper management improves quality of life, alleviates the symptoms of iron deficiency, and reduces the need for blood transfusions.  Treatment options include oral and intravenous iron therapy; however, the efficacy of oral iron is limited in certain gastrointestinal conditions, such as inflammatory bowel disease, celiac disease, and autoimmune gastritis.  This article provides a critical summary of the diagnosis and treatment of iron deficiency anemia.  In addition, it includes a management algorithm that can help the clinician determine which patients are in need of further gastrointestinal evaluation.  This facilitates the identification and treatment of the underlying condition and avoids the unnecessary use of invasive methods and their associated risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXtoRj3u-KB9bHMBt0mMIXfW6udTcc2ebFq4NFhe7Uzrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bitFensQ%253D%253D&md5=7f298e2b0f6c95dda8178b53ec64d13c</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJimenez%26aufirst%3DK.%26aulast%3DKulnigg-Dabsch%26aufirst%3DS.%26aulast%3DGasche%26aufirst%3DC.%26atitle%3DManagement%2520of%2520iron%2520deficiency%2520anemia%26jtitle%3DGastroenterol.%2520Hepatol.%26date%3D2015%26volume%3D11%26spage%3D241%26epage%3D250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogé, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broussard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, M. D.</span></span> <span> </span><span class="NLM_article-title">Acne vulgaris: Diagnosis and treatment</span>. <i>Arch. Dermatol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">484</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2019&pages=475-484&author=L.+K.+Og%C3%A9author=A.+Broussardauthor=M.+D.+Marshall&title=Acne+vulgaris%3A+Diagnosis+and+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOg%25C3%25A9%26aufirst%3DL.%2BK.%26aulast%3DBroussard%26aufirst%3DA.%26aulast%3DMarshall%26aufirst%3DM.%2BD.%26atitle%3DAcne%2520vulgaris%253A%2520Diagnosis%2520and%2520treatment%26jtitle%3DArch.%2520Dermatol.%2520Res.%26date%3D2019%26volume%3D100%26spage%3D475%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span> </span><span class="NLM_article-title">FDA approves new vaginal ring for one year
of birth control</span>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-vaginal-ring-one-year-birth-control#:~:text=The%20U.S.%20Food%20and%20Drug,used%20for%20an%20entire%20year." class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-vaginal-ring-one-year-birth-control#:~:text=The%20U.S.%20Food%20and%20Drug,used%20for%20an%20entire%20year.</a> (accessed Aug 28, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+approves+new+vaginal+ring+for+one+year%0Aof+birth+control.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-vaginal-ring-one-year-birth-control%23%3A%7E%3Atext%3DThe%2520U.S.%2520Food%2520and%2520Drug%2Cused%2520for%2520an%2520entire%2520year.+%28accessed+Aug+28%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520approves%2520new%2520vaginal%2520ring%2520for%2520one%2520year%250Aof%2520birth%2520control%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Elagolix: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1501</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0977-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-018-0977-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30194661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1ylsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1501-1508&author=Y.+N.+Lamb&title=Elagolix%3A+First+global+approval&doi=10.1007%2Fs40265-018-0977-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Elagolix: First Global Approval</span></div><div class="casAuthors">Lamb, Yvette N.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1501-1508</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Elagolix (ORILISSA), an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist, is being developed AbbVie and Neurocrine Biosciences for the treatment of reproductive hormone-dependent disorders in women.  In July 2018, the US FDA approved elagolix tablets for the management of moderate to severe pain assocd. with endometriosis.  This approval was based on pos. results in two replicate phase III trials; addnl. phase III trials in the USA, Canada and Puerto Rico are currently evaluating elagolix as both monotherapy and in combination with low-dose hormone add-back therapy in the same indication.  Elagolix with and without low-dose hormone add-back therapy is also undergoing phase III clin. development for heavy menstrual bleeding assocd. with uterine fibroids in the aforementioned locations.  This article summarizes the milestones in the development of elagolix leading to its first approval for the management of moderate to severe pain assocd. with endometriosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozwY9v1KHNcLVg90H21EOLACvtfcHk0lhQMlAyc4RUew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1ylsLzE&md5=984d0fcdfc38444ac282e0d6f519c1b7</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0977-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0977-4%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DElagolix%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1501%26epage%3D1508%26doi%3D10.1007%2Fs40265-018-0977-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, D.</span></span> <span> </span><span class="NLM_article-title">A comprehensive map of fda-approved pharmaceutical products</span>. <i>Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">263</span>, <span class="refDoi"> DOI: 10.3390/pharmaceutics10040263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3390%2Fpharmaceutics10040263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWktbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=263&author=H.+Zhongauthor=G.+Chanauthor=Y.+Huauthor=H.+Huauthor=D.+Ouyang&title=A+comprehensive+map+of+fda-approved+pharmaceutical+products&doi=10.3390%2Fpharmaceutics10040263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive map of FDA-approved pharmaceutical products</span></div><div class="casAuthors">Zhong, Hao; Chan, Ging; Hu, Yuanjia; Hu, Hao; Ouyang, Defang</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263</span>CODEN:
                <span class="NLM_cas:coden">PHARK5</span>;
        ISSN:<span class="NLM_cas:issn">1999-4923</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">With the increasing research and development (R&D) difficulty of new mol. entities (NMEs), novel drug delivery systems (DDSs) are attracting widespread attention.  This review investigated the current distribution of Food and Drug Administration (FDA)-approved pharmaceutical products and evaluated the tech. barrier for the entry of generic drugs and highlighted the success and failure of advanced drug delivery systems.  According to the ratio of generic to new drugs and the four-quadrant classification scheme for evaluating the commercialization potential of DDSs, the results showed that the traditional dosage forms (e.g., conventional tablets, capsules and injections) with a lower technol. barrier were easier to reproduce, while advanced drug delivery systems (e.g., inhalations and nanomedicines) with highly tech. barriers had less competition and greater market potential.  Our study provides a comprehensive insight into FDA-approved products and deep anal. of the tech. barriers for advanced drug delivery systems.  In the future, the R&D of new mol. entities may combine advanced delivery technologies to make drug candidates into more therapeutically effective formulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZT3StyqxAxLVg90H21EOLACvtfcHk0lhQMlAyc4RUew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWktbnN&md5=bee954f35acab9c3e7481c858f4f1eb6</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.3390%2Fpharmaceutics10040263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fpharmaceutics10040263%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DOuyang%26aufirst%3DD.%26atitle%3DA%2520comprehensive%2520map%2520of%2520fda-approved%2520pharmaceutical%2520products%26jtitle%3DPharmaceutics%26date%3D2018%26volume%3D10%26spage%3D263%26doi%3D10.3390%2Fpharmaceutics10040263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delost, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qureshi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">A survey of the structures of us fda approved combination drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4265</span>– <span class="NLM_lpage">4311</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01610</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01610" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Citb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4265-4311&author=P.+Dasauthor=M.+D.+Delostauthor=M.+H.+Qureshiauthor=D.+T.+Smithauthor=J.+T.+Njardarson&title=A+survey+of+the+structures+of+us+fda+approved+combination+drugs&doi=10.1021%2Facs.jmedchem.8b01610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">A Survey of the Structures of US FDA Approved Combination Drugs</span></div><div class="casAuthors">Das, Pradipta; Delost, Michael D.; Qureshi, Munaum H.; Smith, David T.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4265-4311</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combination drugs are an important class of US FDA approved pharmaceuticals.  These drugs have been on a continuous growth trajectory since the first combination drugs were approved in the 1940s.  In this Perspective, we report the first comprehensive compilation and anal. of US FDA approved combination drugs, from the first approval in 1943 through 2018.  Our database contains 419 combination drugs, which are represented by 328 unique small mol. structures.  Breakdown of these drugs according to disease category, structure, combination compn., and year of approval is presented as well as the top 24 most commonly used small mol. combination drug components.  For frequently used small mol. components, we present "relationship diagrams" to aid in the visualization of the many drug combinations these structures are part of.  The main body contains 10 disease-focused sections wherein every small mol. component utilized as part of a combination for each disease category is displayed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8XxgcuwxFEbVg90H21EOLACvtfcHk0ljlsERQb7zfjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Citb7J&md5=caeeef6298591e300a93782176e87ab8</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01610%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DP.%26aulast%3DDelost%26aufirst%3DM.%2BD.%26aulast%3DQureshi%26aufirst%3DM.%2BH.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DA%2520survey%2520of%2520the%2520structures%2520of%2520us%2520fda%2520approved%2520combination%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4265%26epage%3D4311%26doi%3D10.1021%2Facs.jmedchem.8b01610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delost, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">From oxiranes to oligomers: Architectures of us fda approved pharmaceuticals containing oxygen heterocycles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">10996</span>– <span class="NLM_lpage">11020</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00876</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00876" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGit7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10996-11020&author=M.+D.+Delostauthor=D.+T.+Smithauthor=B.+J.+Andersonauthor=J.+T.+Njardarson&title=From+oxiranes+to+oligomers%3A+Architectures+of+us+fda+approved+pharmaceuticals+containing+oxygen+heterocycles&doi=10.1021%2Facs.jmedchem.8b00876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles</span></div><div class="casAuthors">Delost, Michael D.; Smith, David T.; Anderson, Benton J.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10996-11020</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxygen heterocycles are the second most common type of heterocycles that appear as structural components of U.S. Food and Drug Administration (FDA) approved pharmaceuticals.  Anal. of our database of drugs approved through 2017 reveals 311 distinct pharmaceuticals contg. at least one oxygen heterocycle.  Most prevalent among these are pyranoses, with furanoses, macrolactones, morpholines, and dioxolanes rounding off the top five.  The main body of this Perspective is organized according to ring size, commencing with three- and four-membered rings and ending with macrocycles, polymers, and unusual oxygen-contg. heterocycles.  For each section, all oxygen heterocycle-contg. drugs are presented along with a brief discussion about structural and drug application patterns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor-PzQmLXoGbVg90H21EOLACvtfcHk0ljlsERQb7zfjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGit7nE&md5=18f3979c80513bfbbc263dd5945c63f0</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00876%26sid%3Dliteratum%253Aachs%26aulast%3DDelost%26aufirst%3DM.%2BD.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DAnderson%26aufirst%3DB.%2BJ.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DFrom%2520oxiranes%2520to%2520oligomers%253A%2520Architectures%2520of%2520us%2520fda%2520approved%2520pharmaceuticals%2520containing%2520oxygen%2520heterocycles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D10996%26epage%3D11020%26doi%3D10.1021%2Facs.jmedchem.8b00876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pathania, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narang, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawal, R. K.</span></span> <span> </span><span class="NLM_article-title">Role of sulphur-heterocycles in medicinal chemistry: An update</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.07.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.ejmech.2019.07.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31330449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWksbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2019&pages=486-508&author=S.+Pathaniaauthor=R.+K.+Narangauthor=R.+K.+Rawal&title=Role+of+sulphur-heterocycles+in+medicinal+chemistry%3A+An+update&doi=10.1016%2Fj.ejmech.2019.07.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Role of sulphur-heterocycles in medicinal chemistry: an update</span></div><div class="casAuthors">Pathania, Shelly; Narang, Raj Kumar; Rawal, Ravindra K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">486-508</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  From many decades, S-heterocycles have maintained their status as an important part and core of FDA approved drugs and medicinally active compds.  With exhaustive exploration of nitrogen heterocycles in medicinal chem., researchers have shifted their interest towards other heterocycles, esp., S-heterocycles.  Thus several attempts have been made to synthesize a variety of new sulfur contg. compds. with high medicinal value and low toxicity profile, in comparison to previous N-heterocycles.  Till today, S-heterocycle contg. compds. have been largely reported as anticancer, antidiabetic, antimicrobial, antihypertension, antiviral, anti-inflammatory etc.  In this review, the authors have tried to provide a crit. anal. of synthesis and medicinal attributes of sulfur contg. heterocycles such as thiirane, thiophene, thiazole, thiopyran, thiazolidine etc reported within last five years to emphasize the significance and usefulness of these S-heterocycles in the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB6U8lNztHpLVg90H21EOLACvtfcHk0ljlsERQb7zfjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWksbbN&md5=f3dd3c21c74cd0fd3525166d33858c6f</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.07.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.07.043%26sid%3Dliteratum%253Aachs%26aulast%3DPathania%26aufirst%3DS.%26aulast%3DNarang%26aufirst%3DR.%2BK.%26aulast%3DRawal%26aufirst%3DR.%2BK.%26atitle%3DRole%2520of%2520sulphur-heterocycles%2520in%2520medicinal%2520chemistry%253A%2520An%2520update%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D180%26spage%3D486%26epage%3D508%26doi%3D10.1016%2Fj.ejmech.2019.07.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beno, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">A survey of the role of noncovalent sulfur interactions in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4383</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1021/jm501853m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501853m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4383-438&author=B.+R.+Benoauthor=K.+S.+Yeungauthor=M.+D.+Bartbergerauthor=L.+D.+Penningtonauthor=N.+A.+Meanwell&title=A+survey+of+the+role+of+noncovalent+sulfur+interactions+in+drug+design&doi=10.1021%2Fjm501853m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design</span></div><div class="casAuthors">Beno, Brett R.; Yeung, Kap-Sun; Bartberger, Michael D.; Pennington, Lewis D.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4383-4438</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Electron deficient, bivalent sulfur atoms have two areas of pos. electrostatic potential, a consequence of the low-lying σ* orbitals of the C-S bond that are available for interaction with electron donors including oxygen and nitrogen atoms and, possibly, π-systems.  Intramol. interactions are by far the most common manifestation of this effect, which offers a means of modulating the conformational preferences of a mol.  Although a well-documented phenomenon, a priori applications in drug design are relatively sparse and this interaction, which is often isosteric with an intramol. hydrogen-bonding interaction, appears to be underappreciated by the medicinal chem. community.  In this Perspective, we discuss the theor. basis for sulfur σ* orbital interactions and illustrate their importance in the context of drug design and org. synthesis.  The role of sulfur interactions in protein structure and function is discussed and although relatively rare, intermol. interactions between ligand C-S σ* orbitals and proteins are illustrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYKXRsl4BQYrVg90H21EOLACvtfcHk0ljlsERQb7zfjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D&md5=d12f53eb3271c161cfc833fb9f7c02b3</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Fjm501853m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501853m%26sid%3Dliteratum%253Aachs%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DYeung%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DA%2520survey%2520of%2520the%2520role%2520of%2520noncovalent%2520sulfur%2520interactions%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4383%26epage%3D438%26doi%3D10.1021%2Fjm501853m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. A.</span>; <span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Analysis of US FDA-approved drugs containing sulfur atoms</span>. In  <i>Sulfur Chemistry</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>, Ed.; Topics in Current Chemistry Collections; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_year">2019</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">34</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2F978-3-030-25598-5_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=1-34&author=K.+A.+Scott&author=J.+T.+Njardarsonauthor=X.+Jiang&title=Sulfur+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1007%2F978-3-030-25598-5_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-030-25598-5_1%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DK.%2BA.%26atitle%3DAnalysis%2520of%2520US%2520FDA-approved%2520drugs%2520containing%2520sulfur%2520atoms%26btitle%3DSulfur%2520Chemistry%26aulast%3DJiang%26aufirst%3DX.%26pub%3DSpringer%26date%3D2019%26spage%3D1%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Applications of fluorine in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8315</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8315-59&author=E.+P.+Gillisauthor=K.+J.+Eastmanauthor=M.+D.+Hillauthor=D.+J.+Donnellyauthor=N.+A.+Meanwell&title=Applications+of+fluorine+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.5b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Gillis, Eric P.; Eastman, Kyle J.; Hill, Matthew D.; Donnelly, David J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8315-8359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with meta-anal. The role of fluorine in drug design and development is expanding rapidly as we learn more about the unique properties assocd. with this unusual element and how to deploy it with greater sophistication.  The judicious introduction of fluorine into a mol. can productively influence conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and pharmacokinetic properties.  In addn., 18F has been established as a useful positron emitting isotope for use with in vivo imaging technol. that potentially has extensive application in drug discovery and development, often limited only by convenient synthetic accessibility to labeled compds.  The wide ranging applications of fluorine in drug design are providing a strong stimulus for the development of new synthetic methodologies that allow more facile access to a wide range of fluorinated compds.  In this review, we provide an update on the effects of the strategic incorporation of fluorine in drug mols. and applications in positron emission tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8fUUtkPB4L7Vg90H21EOLACvtfcHk0lgsRp1f5s3pgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK&md5=9995829a94a8c0b8d9fb0d21bdfd5a1d</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00258%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26aulast%3DEastman%26aufirst%3DK.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DApplications%2520of%2520fluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8315%26epage%3D59%26doi%3D10.1021%2Facs.jmedchem.5b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Metabolic and pharmaceutical aspects of fluorinated compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">6315</span>– <span class="NLM_lpage">6386</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01877</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01877" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvFCrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=6315-6386&author=B.+M.+Johnsonauthor=Y.+Z.+Shuauthor=X.+Zhuoauthor=N.+A.+Meanwell&title=Metabolic+and+pharmaceutical+aspects+of+fluorinated+compounds&doi=10.1021%2Facs.jmedchem.9b01877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic and Pharmaceutical Aspects of Fluorinated Compounds</span></div><div class="casAuthors">Johnson, Benjamin M.; Shu, Yue-Zhong; Zhuo, Xiaoliang; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6315-6386</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The applications of fluorine in drug design continue to expand, facilitated by an improved understanding of its effects on physicochem. properties and the development of synthetic methodologies that are providing access to new fluorinated motifs.  In turn, studies of fluorinated mols. are providing deeper insights into the effects of fluorine on metabolic pathways, distribution, and disposition.  Despite the high strength of the C-F bond, the departure of fluoride from metabolic intermediates can be facile.  This reactivity has been leveraged in the design of mechanism-based enzyme inhibitors and has influenced the metabolic fate of fluorinated compds.  In this Perspective, we summarize the literature assocd. with the metab. of fluorinated mols., focusing on examples where the presence of fluorine influences the metabolic profile.  These studies have revealed potentially problematic outcomes with some fluorinated motifs and are enhancing our understanding of how fluorine should be deployed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi3OTGhjXLXrVg90H21EOLACvtfcHk0lgsRp1f5s3pgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvFCrs7o%253D&md5=a8163c3ebf456de6932a4b941bb52d14</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01877%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DB.%2BM.%26aulast%3DShu%26aufirst%3DY.%2BZ.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DMetabolic%2520and%2520pharmaceutical%2520aspects%2520of%2520fluorinated%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D6315%26epage%3D6386%26doi%3D10.1021%2Facs.jmedchem.9b01877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitteringham, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span> <span> </span><span class="NLM_article-title">Metabolism of fluorine-containing drugs</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.41.1.443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1146%2Fannurev.pharmtox.41.1.443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=11264465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsVaqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=443-70&author=B.+K.+Parkauthor=N.+R.+Kitteringhamauthor=P.+M.+O%E2%80%99Neill&title=Metabolism+of+fluorine-containing+drugs&doi=10.1146%2Fannurev.pharmtox.41.1.443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of fluorine-containing drugs</span></div><div class="casAuthors">Park, B. Kevin; Kitteringham, Neil R.; O'Neill, Paul M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">443-470</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 109 refs.  This article reviews current knowledge of the metab. of drugs that contain fluorine.  The strategic value of fluorine substitution in drug design is discussed in terms of chem. structure and basic concepts in drug metab. and drug toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruAja3Ht70KbVg90H21EOLACvtfcHk0lgsRp1f5s3pgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsVaqtrc%253D&md5=0e2ee242da0f4cef8d203e92aee03180</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.41.1.443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.41.1.443%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26atitle%3DMetabolism%2520of%2520fluorine-containing%2520drugs%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2001%26volume%3D41%26spage%3D443%26epage%3D70%26doi%3D10.1146%2Fannurev.pharmtox.41.1.443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5822</span>– <span class="NLM_lpage">5880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5822-5880&author=N.+A.+Meanwell&title=Fluorine+and+fluorinated+motifs+in+the+design+and+application+of+bioisosteres+for+drug+design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5822-5880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the Me group while also acting as a functional mimetic of the carbonyl, carbinol, andnitrile moieties.  In this context, fluorine substitution can influence the potency, conformation, metab., membrane permeability, and P-gp recognition of a mol. and temper inhibition of the hERG channel by basic amines.  However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated mol. construction that broadens biol. mimesis.  In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a mol. are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoQvY950L3LVg90H21EOLACvtfcHk0lhS6uzxnPl6lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D&md5=2d0ce3326c7ff932da8d7d26972ced14</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520fluorinated%2520motifs%2520in%2520the%2520design%2520and%2520application%2520of%2520bioisosteres%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5822%26epage%3D5880%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Bars, D.</span></span> <span> </span><span class="NLM_article-title">Fluorine-18 and medical imaging: Radiopharmaceuticals for positron emission tomography</span>. <i>J. Fluorine Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1488</span>– <span class="NLM_lpage">1493</span>, <span class="refDoi"> DOI: 10.1016/j.jfluchem.2006.09.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.jfluchem.2006.09.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1CmurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2006&pages=1488-1493&author=D.+Le+Bars&title=Fluorine-18+and+medical+imaging%3A+Radiopharmaceuticals+for+positron+emission+tomography&doi=10.1016%2Fj.jfluchem.2006.09.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine-18 and medical imaging: Radiopharmaceuticals for positron emission tomography</span></div><div class="casAuthors">Le Bars, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Fluorine Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1488-1493</span>CODEN:
                <span class="NLM_cas:coden">JFLCAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-1139</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Fluorine presents among its radioactive isotopes fluorine-18, that decays with a 109 min half-life and a β+ emission, allowing external detection of the 2 coincident γ photons obtained after annihilation.  Prodn. techniques (medical cyclotron), radiochem. reactions for isotope incorporation in radiopharmaceuticals and development of specific detection cameras (positron emission tomographs) allowed development of a vast investigation field in medical imaging.  Applications of PET in oncol. ([18F]fluorodeoxyglucose, FDG) largely improved detection and management of cancers; tracer mols. labeled with fluorine-18 also allow fruitful researches in mol. imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDqQce1ydq2rVg90H21EOLACvtfcHk0lhS6uzxnPl6lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1CmurjM&md5=fc917242a297e1a89d97750af9b07b6e</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.jfluchem.2006.09.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jfluchem.2006.09.015%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BBars%26aufirst%3DD.%26atitle%3DFluorine-18%2520and%2520medical%2520imaging%253A%2520Radiopharmaceuticals%2520for%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Fluorine%2520Chem.%26date%3D2006%26volume%3D127%26spage%3D1488%26epage%3D1493%26doi%3D10.1016%2Fj.jfluchem.2006.09.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cargnin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genazzani, A. A.</span></span> <span> </span><span class="NLM_article-title">Applications of deuterium in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5276</span>– <span class="NLM_lpage">5297</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01808</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01808" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFKjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5276-5297&author=T.+Piraliauthor=M.+Serafiniauthor=S.+Cargninauthor=A.+A.+Genazzani&title=Applications+of+deuterium+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.8b01808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of deuterium in medicinal chemistry</span></div><div class="casAuthors">Pirali, Tracey; Serafini, Marta; Cargnin, Sarah; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5276-5297</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The use of deuteration in medicinal chem. has exploded in the past years, and the FDA has recently approved the first deuterium-labeled drug.  Precision deuteration goes beyond the pure and simple amelioration of the pharmacokinetic parameters of a drug and might provide an opportunity when facing problems in terms of metab.-mediated toxicity, drug interactions, and low bioactivation.  The use of deuterium is even broader, offering the opportunity to lower the degree of epimerization, reduce the dose of coadministered boosters, and discover compds. where deuterium is the basis for the mechanism of action.  Nevertheless, designing, synthesizing, and developing a successful deuterated drug is far from straightforward, and the translation from concept to practice is often unpredictable.  This Perspective provides an overview of the recent developments of deuteration, with a focus on deuterated clin. candidates, and highlights both opportunities and challenges of this strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ICy0AH9zGLVg90H21EOLACvtfcHk0lhS6uzxnPl6lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFKjtw%253D%253D&md5=1ce58dbff268894dc319bfc00a1ae01f</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01808%26sid%3Dliteratum%253Aachs%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DCargnin%26aufirst%3DS.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DApplications%2520of%2520deuterium%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5276%26epage%3D5297%26doi%3D10.1021%2Facs.jmedchem.8b01808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Highly selective inhibition of tyrosine kinase 2 (tyk2) for the treatment of autoimmune diseases: Discovery of the allosteric inhibitor bms-986165</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8973</span>– <span class="NLM_lpage">8995</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00444</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00444" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8973-8995&author=S.+T.+Wrobleskiauthor=R.+Moslinauthor=S.+Linauthor=Y.+Zhangauthor=S.+Spergelauthor=J.+Kempsonauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=D.+Shusterauthor=K.+Gilloolyauthor=X.+Yangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=C.+Chaudhryauthor=J.+Khanauthor=M.+Ruzanovauthor=J.+Tredupauthor=D.+Mulliganauthor=D.+Xieauthor=H.+Sunauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=N.+Aranibarauthor=M.+Chineyauthor=A.+Chimalakondaauthor=W.+J.+Pittsauthor=L.+Lombardoauthor=P.+H.+Carterauthor=J.+R.+Burkeauthor=D.+S.+Weinstein&title=Highly+selective+inhibition+of+tyrosine+kinase+2+%28tyk2%29+for+the+treatment+of+autoimmune+diseases%3A+Discovery+of+the+allosteric+inhibitor+bms-986165&doi=10.1021%2Facs.jmedchem.9b00444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165</span></div><div class="casAuthors">Wrobleski, Stephen T.; Moslin, Ryan; Lin, Shuqun; Zhang, Yanlei; Spergel, Steven; Kempson, James; Tokarski, John S.; Strnad, Joann; Zupa-Fernandez, Adriana; Cheng, Lihong; Shuster, David; Gillooly, Kathleen; Yang, Xiaoxia; Heimrich, Elizabeth; McIntyre, Kim W.; Chaudhry, Charu; Khan, Javed; Ruzanov, Max; Tredup, Jeffrey; Mulligan, Dawn; Xie, Dianlin; Sun, Huadong; Huang, Christine; D'Arienzo, Celia; Aranibar, Nelly; Chiney, Manoj; Chimalakonda, Anjaneya; Pitts, William J.; Lombardo, Louis; Carter, Percy H.; Burke, James R.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8973-8995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases.  The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formidable challenge.  Our strategy to achieve high selectivity for TYK2 relies on targeting the TYK2 pseudokinase (JH2) domain.  Herein we report the late stage optimization efforts including a structure-guided design and water displacement strategy that led to the discovery of BMS-986165 (11, I) as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2.  In addn. to unprecedented JAK isoform and kinome selectivity, I shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease.  On the basis of these findings, I appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clin. development as an oral treatment for autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmA75TJmytlrVg90H21EOLACvtfcHk0lgVuJRRnrEZZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP&md5=ca161c470df002b0bdd2bf6b19920ada</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DKempson%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DMulligan%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DChiney%26aufirst%3DM.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DLombardo%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DHighly%2520selective%2520inhibition%2520of%2520tyrosine%2520kinase%25202%2520%2528tyk2%2529%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%253A%2520Discovery%2520of%2520the%2520allosteric%2520inhibitor%2520bms-986165%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8973%26epage%3D8995%26doi%3D10.1021%2Facs.jmedchem.9b00444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, G. F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dos Santos, J. L.</span></span> <span> </span><span class="NLM_article-title">Boron in drug design: Recent advances in the development of new therapeutic agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.ejmech.2019.06.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31288128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtleju7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=791-804&author=G.+F.+S.+Fernandesauthor=W.+A.+Dennyauthor=J.+L.+Dos+Santos&title=Boron+in+drug+design%3A+Recent+advances+in+the+development+of+new+therapeutic+agents&doi=10.1016%2Fj.ejmech.2019.06.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Boron in drug design: Recent advances in the development of new therapeutic agents</span></div><div class="casAuthors">Fernandes, Guilherme Felipe Santos; Denny, William Alexander; Dos Santos, Jean Leandro</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">791-804</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Advances in the field of boron chem. have expanded the application of this element in Medicinal Chem.  Boron-contg. compds. represent a new class for medicinal chemists to use in their drug designs.  Bortezomib, a dipeptide boronic acid approved by the FDA in 2003 for treatment of multiple myeloma, paved the way for the discovery of new boron-contg. compds. After its approval, two other boron-contg. compds. have been approved, tavaborole for the treatment of onychomycosis and crisaborole for the treatment of mild to moderate atopic dermatitis.  A no. of boron-contg. compds. have been described and evaluated for a plethora of therapeutic applications.  The present review is intended to highlight the recent advances related to boron-contg. compds. and their therapeutic applications.  Here, we focused only in those most biol. active compds. with proven in vitro and/or in vivo efficacy in the therapeutic area published in the last years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNneApZtw8C7Vg90H21EOLACvtfcHk0lgVuJRRnrEZZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtleju7fE&md5=52c7677a4b6213be8a03b48c3981bba4</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.092%26sid%3Dliteratum%253Aachs%26aulast%3DFernandes%26aufirst%3DG.%2BF.%2BS.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDos%2BSantos%26aufirst%3DJ.%2BL.%26atitle%3DBoron%2520in%2520drug%2520design%253A%2520Recent%2520advances%2520in%2520the%2520development%2520of%2520new%2520therapeutic%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D179%26spage%3D791%26epage%3D804%26doi%3D10.1016%2Fj.ejmech.2019.06.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lesnikowski, Z. J.</span></span> <span> </span><span class="NLM_article-title">Challenges and opportunities for the application of boron clusters in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7738</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01932</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01932" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFSgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7738-58&author=Z.+J.+Lesnikowski&title=Challenges+and+opportunities+for+the+application+of+boron+clusters+in+drug+design&doi=10.1021%2Facs.jmedchem.5b01932"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and Opportunities for the Application of Boron Clusters in Drug Design</span></div><div class="casAuthors">Lesnikowski, Zbigniew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7738-7758</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are two branches in boron medicinal chem.: the first focuses on single boron atom compds., and the second utilizes boron clusters.  Boron clusters and their heteroatom counterparts belong to the family of cage compds.  A subset of this extensive class of compds. includes dicarbadodecaboranes, which have the general formula C2B10H12, and their metal biscarboranyl complexes, metallacarboranes, with the formula [M(C2B10H12)2-2].  The unique properties of boron clusters have resulted in their utilization in applications such as in pharmacophores, as scaffolds in mol. construction, and as modulators of bioactive compds.  This Perspective presents an overview of the properties of boron clusters that are pertinent for drug discovery, recent applications in the design of various classes of drugs, and the potential use of boron clusters in the construction of new pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX92E97ik4ubVg90H21EOLACvtfcHk0lgVuJRRnrEZZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFSgs7c%253D&md5=1d4c3720cdc649c5fc3de397bea15e83</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01932%26sid%3Dliteratum%253Aachs%26aulast%3DLesnikowski%26aufirst%3DZ.%2BJ.%26atitle%3DChallenges%2520and%2520opportunities%2520for%2520the%2520application%2520of%2520boron%2520clusters%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7738%26epage%3D58%26doi%3D10.1021%2Facs.jmedchem.5b01932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span> <span> </span><span class="NLM_article-title">Boronic acid compounds as potential pharmaceutical agents</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">346</span>– <span class="NLM_lpage">368</span>, <span class="refDoi"> DOI: 10.1002/med.10043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fmed.10043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=12647314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVWitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=346-368&author=W.+Yangauthor=X.+Gaoauthor=B.+Wang&title=Boronic+acid+compounds+as+potential+pharmaceutical+agents&doi=10.1002%2Fmed.10043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Boronic acid compounds as potential pharmaceutical agents</span></div><div class="casAuthors">Yang, Wenqian; Gao, Xingming; Wang, Binghe</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">346-368</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Boronic acid compds. have been used, because of their unique structural features, for the development of potent enzyme inhibitors, boron neutron capture agents for cancer therapy, and as antibody mimics that recognize biol. important saccharides.  Consequently, there has been a surge of interests in boronic acid compds.  This study reviews the recent development in this area during the last six years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB0CvJjV10BbVg90H21EOLACvtfcHk0lgVuJRRnrEZZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVWitb8%253D&md5=0b841477e2113218d55991e23133bd60</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1002%2Fmed.10043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.10043%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DB.%26atitle%3DBoronic%2520acid%2520compounds%2520as%2520potential%2520pharmaceutical%2520agents%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2003%26volume%3D23%26spage%3D346%26epage%3D368%26doi%3D10.1002%2Fmed.10043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krajnc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panduwawala, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brem, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, C. J.</span></span> <span> </span><span class="NLM_article-title">Will morphing boron-based inhibitors beat the beta-lactamases?</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2019.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.cbpa.2019.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=31004962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1yrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=101-110&author=A.+Krajncauthor=P.+A.+Langauthor=T.+D.+Panduwawalaauthor=J.+Bremauthor=C.+J.+Schofield&title=Will+morphing+boron-based+inhibitors+beat+the+beta-lactamases%3F&doi=10.1016%2Fj.cbpa.2019.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Will morphing boron-based inhibitors beat the β-lactamases?</span></div><div class="casAuthors">Krajnc, Alen; Lang, Pauline A.; Panduwawala, Tharindi D.; Brem, Jurgen; Schofield, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">101-110</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The β-lactams remain the most important antibacterials, but their use is increasingly compromised by resistance, importantly by β-lactamases.  Although β-lactam and non-β-lactam inhibitors forming stable acyl-enzyme complexes with nucleophilic serine β-lactamases (SBLs) are widely used, these are increasingly susceptible to evolved SBLs and do not inhibit metallo-β-lactamases (MBLs).  Boronic acids and boronate esters, esp. cyclic ones, can potently inhibit both SBLs and MBLs.  Vaborbactam, a monocyclic boronate, is approved for clin. use, but its β-lactamase coverage is limited.  Bicyclic boronates rapidly react with SBLs and MBLs forming stable enzyme-inhibitor complexes that mimic the common anionic high-energy tetrahedral intermediates in SBL/MBL catalysis, as revealed by crystallog.  The ability of boronic acids to 'morph' between sp2 and sp3 hybridization states may help enable potent inhibition.  There is limited structure-activity relationship information on the (bi)cyclic boronate inhibitors compared to β-lactams, hence scope for creativity towards new boron-based β-lactamase inhibitors/antibacterials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYQIvXncI3a7Vg90H21EOLACvtfcHk0lidKOCFI4xbwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1yrt7k%253D&md5=7e703c747a254766bda580563fb42a7f</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2019.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2019.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DKrajnc%26aufirst%3DA.%26aulast%3DLang%26aufirst%3DP.%2BA.%26aulast%3DPanduwawala%26aufirst%3DT.%2BD.%26aulast%3DBrem%26aufirst%3DJ.%26aulast%3DSchofield%26aufirst%3DC.%2BJ.%26atitle%3DWill%2520morphing%2520boron-based%2520inhibitors%2520beat%2520the%2520beta-lactamases%253F%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D50%26spage%3D101%26epage%3D110%26doi%3D10.1016%2Fj.cbpa.2019.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hecker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totrov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomovskaya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsivkovski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabet, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a cyclic boronic acid β-lactamase inhibitor (rpx7009) with utility vs class a serine carbapenemases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3682</span>– <span class="NLM_lpage">3692</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00127</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00127" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3682-3692&issue=9&author=S.+J.+Heckerauthor=K.+R.+Reddyauthor=M.+Totrovauthor=G.+C.+Hirstauthor=O.+Lomovskayaauthor=D.+C.+Griffithauthor=P.+Kingauthor=R.+Tsivkovskiauthor=D.+Sunauthor=M.+Sabet&title=Discovery+of+a+cyclic+boronic+acid+%CE%B2-lactamase+inhibitor+%28rpx7009%29+with+utility+vs+class+a+serine+carbapenemases&doi=10.1021%2Facs.jmedchem.5b00127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases</span></div><div class="casAuthors">Hecker, Scott J.; Reddy, K. Raja; Totrov, Maxim; Hirst, Gavin C.; Lomovskaya, Olga; Griffith, David C.; King, Paula; Tsivkovski, Ruslan; Sun, Dongxu; Sabet, Mojgan; Tarazi, Ziad; Clifton, Matthew C.; Atkins, Kateri; Raymond, Amy; Potts, Kristy T.; Abendroth, Jan; Boyer, Serge H.; Loutit, Jeffrey S.; Morgan, Elizabeth E.; Durso, Stephanie; Dudley, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3682-3692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The increasing dissemination of carbapenemases in Gram-neg. bacteria has threatened the clin. usefulness of the β-lactam class of antimicrobials.  A program was initiated to discover a new series of serine β-lactamase inhibitors contg. a boronic acid pharmacophore, with the goal of finding a potent inhibitor of serine carbapenemase enzymes that are currently compromising the utility of the carbapenem class of antibacterials.  Potential lead structures were screened in silico by modeling into the active sites of key serine β-lactamases.  Promising candidate mols. were synthesized and evaluated in biochem. and whole-cell assays.  Inhibitors were identified with potent inhibition of serine carbapenemases, particularly the Klebsiella pneumoniae carbapenemase (KPC), with no inhibition of mammalian serine proteases.  Studies in vitro and in vivo show that RPX7009 (9f) is a broad-spectrum inhibitor, notably restoring the activity of carbapenems against KPC-producing strains.  Combined with a carbapenem, 9f is a promising product for the treatment of multidrug resistant Gram-neg. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXpE5YX_dRNLVg90H21EOLACvtfcHk0lidKOCFI4xbwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D&md5=965fbf2b42f2e1b38eccc3b23dfa374f</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00127%26sid%3Dliteratum%253Aachs%26aulast%3DHecker%26aufirst%3DS.%2BJ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DTotrov%26aufirst%3DM.%26aulast%3DHirst%26aufirst%3DG.%2BC.%26aulast%3DLomovskaya%26aufirst%3DO.%26aulast%3DGriffith%26aufirst%3DD.%2BC.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DTsivkovski%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DSabet%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520cyclic%2520boronic%2520acid%2520%25CE%25B2-lactamase%2520inhibitor%2520%2528rpx7009%2529%2520with%2520utility%2520vs%2520class%2520a%2520serine%2520carbapenemases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D9%26spage%3D3682%26epage%3D3692%26doi%3D10.1021%2Facs.jmedchem.5b00127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Ixazomib: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0548-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-016-0548-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26846321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=405-11&author=M.+Shirley&title=Ixazomib%3A+First+global+approval&doi=10.1007%2Fs40265-016-0548-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Ixazomib: First Global Approval</span></div><div class="casAuthors">Shirley, Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-411</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ixazomib (Ninlaro) is an orally bioavailable, reversible proteasome inhibitor developed by Millennium Pharmaceuticals, Inc. (now Takeda Oncol.).  Ixazomib acts by binding to and inhibiting the β5 subunit of the 20S proteasome.  In Nov. 2015, the US FDA approved ixazomib for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.  Ixazomib is under regulatory review for this indication in the EU.  Phase III development of ixazomib is underway worldwide for newly-diagnosed multiple myeloma (in patients who are not eligible for stem cell transplant, or as maintenance therapy) and for relapsed or refractory systemic light chain (AL) amyloidosis.  Ixazomib is also under phase I-II development for the treatment of several other haematol. and non-haematol. malignancies, graft-vs.-host disease and lupus nephritis.  This article summarizes the milestones in the development of ixazomib leading to this first approval for multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMK0Ud8_wMNrVg90H21EOLACvtfcHk0lidKOCFI4xbwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGksbg%253D&md5=a31e66cf68dce72be96fe8e8843919ac</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0548-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0548-5%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DIxazomib%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D405%26epage%3D11%26doi%3D10.1007%2Fs40265-016-0548-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paton, D.</span></span> <span> </span><span class="NLM_article-title">Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1358/dot.2017.53.4.2604174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1358%2Fdot.2017.53.4.2604174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC1crmtVykug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=239-245&author=D.+Paton&title=Crisaborole%3A+Phosphodiesterase+inhibitor+for+treatment+of+atopic+dermatitis&doi=10.1358%2Fdot.2017.53.4.2604174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis</span></div><div class="casAuthors">Paton D M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">239-245</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Atopic dermatitis (AD) is an extremely common condition affecting as many as 10-20% of children and 2-10% of adults.  A particularly distressing symptom of AD is pruritus.  One of the important aspects of AD is inflammation associated with increased activity of phosphodiesterase 4 (PDE4), resulting in decreased intracellular levels of cyclic adenosine monophosphate, which in turn causes increased production of inflammatory cytokines.  Crisaborole was developed as a small-molecule, boron-based, selective PDE4 inhibitor that can be used topically.  Clinical trials have demonstrated its efficacy in treating patients with mild to moderate AD, resulting in significant relief of pruritus.  Unlike PDE4 inhibitors that act systemically, crisaborole does not cause significant gastrointestinal adverse effects.  The most common adverse effect has been temporary stinging and burning in about 4% of patients upon application of the 2% ointment.  To date there is no evidence of atrophy, telangiectasia or hypopigmentation resulting from its use.  Crisaborole is the first topically applied PDE4 inhibitor to be approved by the FDA for use in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTC3c4rt0Hyh4qdXsLcGTEUfW6udTcc2eaNQQIatrCnzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crmtVykug%253D%253D&md5=a854efec1d46127283db4e443c22221f</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1358%2Fdot.2017.53.4.2604174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2017.53.4.2604174%26sid%3Dliteratum%253Aachs%26aulast%3DPaton%26aufirst%3DD.%26atitle%3DCrisaborole%253A%2520Phosphodiesterase%2520inhibitor%2520for%2520treatment%2520of%2520atopic%2520dermatitis%26jtitle%3DDrugs%2520Today%26date%3D2017%26volume%3D53%26spage%3D239%26epage%3D245%26doi%3D10.1358%2Fdot.2017.53.4.2604174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkranz, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mermelstein, R.</span></span> <span> </span><span class="NLM_article-title">Mutagenicity and genotoxicity of nitroarenes: All nitro-containing chemicals were not created equal</span>. <i>Mutat. Res., Rev. Genet. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1016/0165-1110(83)90034-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2F0165-1110%2883%2990034-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=6300670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaL3sXhvFakurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1983&pages=217-267&author=H.+S.+Rosenkranzauthor=R.+Mermelstein&title=Mutagenicity+and+genotoxicity+of+nitroarenes%3A+All+nitro-containing+chemicals+were+not+created+equal&doi=10.1016%2F0165-1110%2883%2990034-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Mutagenicity and genotoxicity of nitroarenes.  All nitro-containing chemicals were not created equal</span></div><div class="casAuthors">Rosenkranz, Herbert S.; Mermelstein, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Reviews in Genetic Toxicology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-67</span>CODEN:
                <span class="NLM_cas:coden">MRRTEP</span>;
        ISSN:<span class="NLM_cas:issn">0615-1110</span>.
    </div><div class="casAbstract">A review with >250 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPuX9Hv79-hbVg90H21EOLACvtfcHk0lguDZZTmFkkDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhvFakurc%253D&md5=b71793097bbe6276fdd6dc3c00c8b547</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2F0165-1110%2883%2990034-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-1110%252883%252990034-9%26sid%3Dliteratum%253Aachs%26aulast%3DRosenkranz%26aufirst%3DH.%2BS.%26aulast%3DMermelstein%26aufirst%3DR.%26atitle%3DMutagenicity%2520and%2520genotoxicity%2520of%2520nitroarenes%253A%2520All%2520nitro-containing%2520chemicals%2520were%2520not%2520created%2520equal%26jtitle%3DMutat.%2520Res.%252C%2520Rev.%2520Genet.%2520Toxicol.%26date%3D1983%26volume%3D114%26spage%3D217%26epage%3D267%26doi%3D10.1016%2F0165-1110%2883%2990034-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Toxicophore exploration as a screening technology for drug design and discovery: Techniques, scope and limitations</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1785</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1007/s00204-015-1587-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs00204-015-1587-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26341667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVGntbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=1785-1802&author=P.+K.+Singhauthor=A.+Negiauthor=P.+K.+Guptaauthor=M.+Chauhanauthor=R.+Kumar&title=Toxicophore+exploration+as+a+screening+technology+for+drug+design+and+discovery%3A+Techniques%2C+scope+and+limitations&doi=10.1007%2Fs00204-015-1587-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicophore exploration as a screening technology for drug design and discovery: techniques, scope and limitations</span></div><div class="casAuthors">Singh, Pankaj Kumar; Negi, Arvind; Gupta, Pawan Kumar; Chauhan, Monika; Kumar, Raj</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1785-1802</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Toxicity is a common drawback of newly designed chemotherapeutic agents.  With the exception of pharmacophore-induced toxicity (lack of selectivity at higher concns. of a drug), the toxicity due to chemotherapeutic agents is based on the toxicophore moiety present in the drug.  To date, methodologies implemented to det. toxicophores may be broadly classified into biol., bioanal. and computational approaches.  The biol. approach involves anal. of bioactivated metabolites, whereas the computational approach involves a QSAR-based method, mapping techniques, an inverse docking technique and a few toxicophore identification/estn. tools.  Being one of the major steps in drug discovery process, toxicophore identification has proven to be an essential screening step in drug design and development.  The paper is first of its kind, attempting to cover and compare different methodologies employed in predicting and detg. toxicophores with an emphasis on their scope and limitations.  Such information may prove vital in the appropriate selection of methodol. and can be used as screening technol. by researchers to discover the toxicophoric potentials of their designed and synthesized moieties.  Addnl., it can be utilized in the manipulation of mols. contg. toxicophores in such a manner that their toxicities might be eliminated or removed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB-rSjVTEa57Vg90H21EOLACvtfcHk0lguDZZTmFkkDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVGntbvF&md5=019b4bf17f351321b4da87dd538fa361</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1007%2Fs00204-015-1587-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-015-1587-5%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DNegi%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DP.%2BK.%26aulast%3DChauhan%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DToxicophore%2520exploration%2520as%2520a%2520screening%2520technology%2520for%2520drug%2520design%2520and%2520discovery%253A%2520Techniques%252C%2520scope%2520and%2520limitations%26jtitle%3DArch.%2520Toxicol.%26date%3D2016%26volume%3D90%26spage%3D1785%26epage%3D1802%26doi%3D10.1007%2Fs00204-015-1587-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">Nitro-group-containing drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2851</span>– <span class="NLM_lpage">2893</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00147</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00147" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2851-2893&author=K.+Nepaliauthor=H.+Y.+Leeauthor=J.+P.+Liou&title=Nitro-group-containing+drugs&doi=10.1021%2Facs.jmedchem.8b00147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Nitro-Group-Containing Drugs</span></div><div class="casAuthors">Nepali, Kunal; Lee, Hsueh-Yun; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2851-2893</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The nitro group is considered to be a versatile and unique functional group in medicinal chem.  Despite a long history of use in therapeutics, the nitro group has toxicity issues and is often categorized as a structural alert or a toxicophore, and evidence related to drugs contg. nitro groups is rather contradictory.  In general, drugs contg. nitro groups have been extensively assocd. with mutagenicity and genotoxicity.  In this context, efforts toward the structure-mutagenicity or structure-genotoxicity relationships have been undertaken.  The current Perspective covers various aspects of agents that contain nitro groups, their bioreductive activation mechanisms, their toxicities, and approaches to combat their toxicity issues.  In addn., recent advances in the field of anticancer, antitubercular and antiparasitic agents contg. nitro groups, along with a patent survey on hypoxia-activated prodrugs contg. nitro groups, are also covered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqif1Bbj-Ci4bVg90H21EOLACvtfcHk0lguDZZTmFkkDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7jO&md5=33969d1c33e2b451a05b3dbdb8574497</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00147%26sid%3Dliteratum%253Aachs%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3DNitro-group-containing%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2851%26epage%3D2893%26doi%3D10.1021%2Facs.jmedchem.8b00147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palma, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifacio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loureiro, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares-Da-Silva, P.</span></span> <span> </span><span class="NLM_article-title">Computation of the binding affinities of catechol-o-methyltransferase inhibitors: Multisubstate relative free energy calculations</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">970</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.1002/jcc.22926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fjcc.22926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=22278964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ygtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=970-986&author=P.+N.+Palmaauthor=M.+J.+Bonifacioauthor=A.+I.+Loureiroauthor=P.+Soares-Da-Silva&title=Computation+of+the+binding+affinities+of+catechol-o-methyltransferase+inhibitors%3A+Multisubstate+relative+free+energy+calculations&doi=10.1002%2Fjcc.22926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Computation of the binding affinities of catechol-O-methyltransferase inhibitors: Multisubstate relative free energy calculations</span></div><div class="casAuthors">Palma, P. Nuno; Bonifacio, Maria Joao; Loureiro, Ana Isabel; Soares-da-Silva, Patricio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">970-986</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Alchem. free energy simulations are amongst the most accurate techniques for the computation of the free energy changes assocd. with noncovalent protein-ligand interactions.  A procedure is presented to est. the relative binding free energies of several ligands to the same protein target where multiple, low-energy configurational substates might coexist, as opposed to one unique structure.  The contributions of all individual substates were estd., explicitly, with the free energy perturbation method, and combined in a rigorous fashion to compute the overall relative binding free energies and dissocn. consts.  It is shown that, unless the most stable bound forms are known a priori, inaccurate results may be obtained if the contributions of multiple substates are ignored.  The method was applied to study the complex formed between human catechol-O-methyltransferase and BIA 9-1067, a newly developed tight-binding inhibitor that is currently under clin. evaluation for the therapy of Parkinson's disease.  Our results reveal an exceptionally high-binding affinity (Kd in subpicomolar range) and provide insightful clues on the interactions and mechanism of inhibition.  The inhibitor is, itself, a slowly reacting substrate of the target enzyme and is released from the complex in the form of O-methylated product.  By comparing the exptl. catalytic rate (kcat) and the estd. dissocn. rate (koff) consts. of the enzyme-inhibitor complex, one can conclude that the obsd. inhibition potency (Ki) is primarily dependent on the catalytic rate const. of the inhibitor's O-methylation, rather than the rate const. of dissocn. of the complex. © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTjDjuZ-BtVbVg90H21EOLACvtfcHk0li7E3u_hM-nCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ygtbk%253D&md5=548b34974096e60eefb9ad605de2d8ba</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1002%2Fjcc.22926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.22926%26sid%3Dliteratum%253Aachs%26aulast%3DPalma%26aufirst%3DP.%2BN.%26aulast%3DBonifacio%26aufirst%3DM.%2BJ.%26aulast%3DLoureiro%26aufirst%3DA.%2BI.%26aulast%3DSoares-Da-Silva%26aufirst%3DP.%26atitle%3DComputation%2520of%2520the%2520binding%2520affinities%2520of%2520catechol-o-methyltransferase%2520inhibitors%253A%2520Multisubstate%2520relative%2520free%2520energy%2520calculations%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2012%26volume%3D33%26spage%3D970%26epage%3D986%26doi%3D10.1002%2Fjcc.22926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajao, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtado, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passos-Silva, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Moura, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamber-Reis, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunrath-Lima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuma, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira-Da-Rocha, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, J. B. F.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Unveiling benznidazole’s mechanism of action through overexpression of DNA repair proteins in trypanosoma cruzi</span>. <i>Environ. Mol. Mutagen.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1002/em.21839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fem.21839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24347026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFCjtr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=309-321&author=M.+A.+Rajaoauthor=C.+Furtadoauthor=C.+L.+Alvesauthor=D.+G.+Passos-Silvaauthor=M.+B.+de+Mouraauthor=B.+L.+Schamber-Reisauthor=M.+Kunrath-Limaauthor=A.+A.+Zumaauthor=J.+P.+Vieira-Da-Rochaauthor=J.+B.+F.+Garcia&title=Unveiling+benznidazole%E2%80%99s+mechanism+of+action+through+overexpression+of+DNA+repair+proteins+in+trypanosoma+cruzi&doi=10.1002%2Fem.21839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Unveiling Benznidazoles mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi</span></div><div class="casAuthors">Rajao, Matheus Andrade; Furtado, Carolina; Alves, Ceres Luciana; Passos-Silva, Danielle Gomes; Moura, Michelle Barbi; Schamber-Reis, Bruno Luiz; Kunrath-Lima, Marianna; Zuma, Aline Araujo; Vieira-da-Rocha, Joao Pedro; Garcia, Juliana Borio Ferreira; Mendes, Isabela Cecilia; Pena, Sergio Danilo Junho; Macedo, Andrea Mara; Franco, Gloria Regina; Souza-Pinto, Nadja Cristhina; Medeiros, Marisa Helena Gennari; Cruz, Angela Kaysel; Motta, Maria Cristina Machado; Teixeira, Santuza Maria Ribeiro; Machado, Carlos Renato</div><div class="citationInfo"><span class="NLM_cas:title">Environmental and Molecular Mutagenesis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-321</span>CODEN:
                <span class="NLM_cas:coden">EMMUEG</span>;
        ISSN:<span class="NLM_cas:issn">0893-6692</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Benznidazole (BZ) is the most commonly used drug for the treatment of Chagas disease.  Although BZ is known to induce the formation of free radicals and electrophilic metabolites within the parasite Trypanosoma cruzi, its precise mechanisms of action are still elusive.  Here, the authors analyzed the survival of T. cruzi exposed to BZ using genetically modified parasites overexpressing different DNA repair proteins.  The authors' results indicate that BZ induces oxidn. mainly in the nucleotide pool, as heterologous expression of the nucleotide pyrophosphohydrolase MutT (but not overexpression of the glycosylase TcOgg1) increased drug resistance in the parasite.  In addn., electron microscopy indicated that BZ catalyzes the formation of double-stranded breaks in the parasite, as its genomic DNA undergoes extensive heterochromatin unpacking following exposure to the drug.  Furthermore, the overexpression of proteins involved in the recombination-mediated DNA repair increased resistance to BZ, reinforcing the idea that the drug causes double-stranded breaks.  The authors' results also show that the overexpression of mitochondrial DNA repair proteins increase parasite survival upon BZ exposure, indicating that the drug induces lesions in the mitochondrial DNA as well.  These findings suggest that BZ preferentially oxidizes the nucleotide pool, and the extensive incorporation of oxidized nucleotides during DNA replication leads to potentially lethal double-stranded DNA breaks in T. cruzi DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpipqLqr5XxpbVg90H21EOLACvtfcHk0li7E3u_hM-nCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFCjtr3L&md5=ebb14fc101937d18e805a687f6ba84a7</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1002%2Fem.21839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fem.21839%26sid%3Dliteratum%253Aachs%26aulast%3DRajao%26aufirst%3DM.%2BA.%26aulast%3DFurtado%26aufirst%3DC.%26aulast%3DAlves%26aufirst%3DC.%2BL.%26aulast%3DPassos-Silva%26aufirst%3DD.%2BG.%26aulast%3Dde%2BMoura%26aufirst%3DM.%2BB.%26aulast%3DSchamber-Reis%26aufirst%3DB.%2BL.%26aulast%3DKunrath-Lima%26aufirst%3DM.%26aulast%3DZuma%26aufirst%3DA.%2BA.%26aulast%3DVieira-Da-Rocha%26aufirst%3DJ.%2BP.%26aulast%3DGarcia%26aufirst%3DJ.%2BB.%2BF.%26atitle%3DUnveiling%2520benznidazole%25E2%2580%2599s%2520mechanism%2520of%2520action%2520through%2520overexpression%2520of%2520DNA%2520repair%2520proteins%2520in%2520trypanosoma%2520cruzi%26jtitle%3DEnviron.%2520Mol.%2520Mutagen.%26date%3D2014%26volume%3D55%26spage%3D309%26epage%3D321%26doi%3D10.1002%2Fem.21839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maya, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassels, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iturriaga-Vásquez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faúndez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galanti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morello, A.</span></span> <span> </span><span class="NLM_article-title">Mode of action of natural and synthetic drugs against trypanosoma cruzi and their interaction with the mammalian host</span>. <i>Comp. Biochem. Physiol., Part A: Mol. Integr. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2006.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.cbpa.2006.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=16626984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivVSitbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2007&pages=601-620&author=J.+D.+Mayaauthor=B.+K.+Casselsauthor=P.+Iturriaga-V%C3%A1squezauthor=J.+Ferreiraauthor=M.+Fa%C3%BAndezauthor=N.+Galantiauthor=A.+Ferreiraauthor=A.+Morello&title=Mode+of+action+of+natural+and+synthetic+drugs+against+trypanosoma+cruzi+and+their+interaction+with+the+mammalian+host&doi=10.1016%2Fj.cbpa.2006.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host</span></div><div class="casAuthors">Maya, Juan Diego; Cassels, Bruce K.; Iturriaga-Vasquez, Patricio; Ferreira, Jorge; Faundez, Mario; Galanti, Norbel; Ferreira, Arturo; Morello, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Comparative Biochemistry and Physiology, Part A: Molecular & Integrative Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">146A</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">601-620</span>CODEN:
                <span class="NLM_cas:coden">CBPAB5</span>;
        ISSN:<span class="NLM_cas:issn">1095-6433</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Current knowledge of the biochem. of Trypanosoma cruzi has led to the development of new drugs and the understanding of their mode of action.  Some trypanocidal drugs such as nifurtimox and benznidazole act through free radical generation during their metab.  T. cruzi is very susceptible to the cell damage induced by these metabolites because enzymes scavenging free radicals are absent or have very low activities in the parasite.  Another potential target is the biosynthetic pathway of glutathione and trypanothione, the low mol. wt. thiol found exclusively in trypanosomatids.  These thiols scavenge free radicals and participate in the conjugation and detoxication of numerous drugs.  Inhibition of this key pathway could render the parasite much more susceptible to the toxic action of drugs such as nifurtimox and benznidazole without affecting the host significantly.  Other drugs such as allopurinol and purine analogs inhibit purine transport in T. cruzi, which cannot synthesize purines de novo.  Nitroimidazole derivs. such as itraconazole inhibit sterol metab.  The parasite's respiratory chain is another potential therapeutic target because of its many differences with the host enzyme complexes.  The pharmacol. modulation of the host's immune response against T. cruzi infection as a possible chemotherapeutic target is discussed.  A large set of chems. of plant origin and a few animal metabolites active against T. cruzi are enumerated and their likely modes of action are briefly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT8Z34c4yGCLVg90H21EOLACvtfcHk0li7E3u_hM-nCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivVSitbk%253D&md5=77e9fa25fdb00faedb7103a390b0582d</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2006.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2006.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DMaya%26aufirst%3DJ.%2BD.%26aulast%3DCassels%26aufirst%3DB.%2BK.%26aulast%3DIturriaga-V%25C3%25A1squez%26aufirst%3DP.%26aulast%3DFerreira%26aufirst%3DJ.%26aulast%3DFa%25C3%25BAndez%26aufirst%3DM.%26aulast%3DGalanti%26aufirst%3DN.%26aulast%3DFerreira%26aufirst%3DA.%26aulast%3DMorello%26aufirst%3DA.%26atitle%3DMode%2520of%2520action%2520of%2520natural%2520and%2520synthetic%2520drugs%2520against%2520trypanosoma%2520cruzi%2520and%2520their%2520interaction%2520with%2520the%2520mammalian%2520host%26jtitle%3DComp.%2520Biochem.%2520Physiol.%252C%2520Part%2520A%253A%2520Mol.%2520Integr.%2520Physiol.%26date%3D2007%26volume%3D146%26spage%3D601%26epage%3D620%26doi%3D10.1016%2Fj.cbpa.2006.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, L. R.</span></span> <span> </span><span class="NLM_article-title">Secnidazole. A Review of its Antimicrobial Activity, Pharmacokinetic Properties and Therapeutic Use in the Management of Protozoal Infections and Bacterial Vaginosis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">638</span>, <span class="refDoi"> DOI: 10.2165/00003495-199651040-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2165%2F00003495-199651040-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=8706597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaK28XislKntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1996&pages=621-638&author=J.+C.+Gillisauthor=L.+R.+Wiseman&title=Secnidazole.+A+Review+of+its+Antimicrobial+Activity%2C+Pharmacokinetic+Properties+and+Therapeutic+Use+in+the+Management+of+Protozoal+Infections+and+Bacterial+Vaginosis&doi=10.2165%2F00003495-199651040-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis</span></div><div class="casAuthors">Gillis, Jane C.; Wiseman, Lynda R.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">621-38</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">Secnidazole is structurally related to the commonly used 5-nitroimidazoles metronidazole and tinidazole.  These drugs share a common spectrum of activity against anaerobic micro-organisms and they appear particularly effective in the treatment of amoebiasis, giardiasis, trichomoniasis and bacterial vaginosis.  Secnidazole is rapidly and completely absorbed after oral administration and has a longer terminal elimination half-life (17 to 29 h) than commonly used drugs in this class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG2LzF8FCJcLVg90H21EOLACvtfcHk0ljucOLlT3EgaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XislKntrg%253D&md5=d9af25dfe578beecf3f78f2312893158</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.2165%2F00003495-199651040-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199651040-00007%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DJ.%2BC.%26aulast%3DWiseman%26aufirst%3DL.%2BR.%26atitle%3DSecnidazole.%2520A%2520Review%2520of%2520its%2520Antimicrobial%2520Activity%252C%2520Pharmacokinetic%2520Properties%2520and%2520Therapeutic%2520Use%2520in%2520the%2520Management%2520of%2520Protozoal%2520Infections%2520and%2520Bacterial%2520Vaginosis%26jtitle%3DDrugs%26date%3D1996%26volume%3D51%26spage%3D621%26epage%3D638%26doi%3D10.2165%2F00003495-199651040-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanDevanter, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arain, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhorne, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswirth, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span></span> <span> </span><span class="NLM_article-title">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>405</i></span>,  <span class="NLM_fpage">962</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1038/35016103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2F35016103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10879539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2000&pages=962-6&author=C.+K.+Stoverauthor=P.+Warrenerauthor=D.+R.+VanDevanterauthor=D.+R.+Shermanauthor=T.+M.+Arainauthor=M.+H.+Langhorneauthor=S.+W.+Andersonauthor=J.+A.+Towellauthor=Y.+Yuanauthor=D.+N.+McMurrayauthor=B.+N.+Kreiswirthauthor=C.+E.+Barryauthor=W.+R.+Baker&title=A+small-molecule+nitroimidazopyran+drug+candidate+for+the+treatment+of+tuberculosis&doi=10.1038%2F35016103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span></div><div class="casAuthors">Stover, C. Kendall; Warrener, Paul; VanDevanter, Donald R.; Sherman, David R.; Arain, Taraq M.; Langhorne, Michael H.; Anderson, Scott W.; Towell, J. Andrew; Yuan, Ying; McMurray, David N.; Krelswirth, Barry N.; Barry, Clifton E.; Baker, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">405</span>
        (<span class="NLM_cas:issue">6789</span>),
    <span class="NLM_cas:pages">962-966</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis, which causes tuberculosis, is the greatest single infectious cause of mortality worldwide, killing roughly; two million people annually.  Ests. indicate that one-third of the world population is infected with latent M. tuberculosis.  The synergy between tuberculosis and the AIDS epidemic, and the surge of multidrug-resistant clin. isolates of M. tuberculosis have reaffirmed tuberculosis as a primary public health threat.  However, new antitubercular drugs with new mechanisms of action have not been developed in over thirty years.  Here we report a series of compds. contg. a nitroimidazopyran nucleus that possess antitubercular activity.  After activation by a mechanism dependent on M. tuberculosis F420 cofactor, nitroimidazopyrans inhibited the synthesis of protein and cell wall lipid.  In contrast to current antitubercular drugs, nitroimidazopyrans exhibited bactericidal activity against both replicating and static M. tuberculosis.  Lead compd. PA-824 showed potent bactericidal activity against multidrug-resistant M. tuberculosis and promising oral activity in animal infection models.  We conclude that nitroimidazopyrans offer the practical qualities of a small mol. with the potential for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw41eD4TtVwbVg90H21EOLACvtfcHk0ljucOLlT3EgaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D&md5=f5f6e2935928da72e328bddd4995515f</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2F35016103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35016103%26sid%3Dliteratum%253Aachs%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DWarrener%26aufirst%3DP.%26aulast%3DVanDevanter%26aufirst%3DD.%2BR.%26aulast%3DSherman%26aufirst%3DD.%2BR.%26aulast%3DArain%26aufirst%3DT.%2BM.%26aulast%3DLanghorne%26aufirst%3DM.%2BH.%26aulast%3DAnderson%26aufirst%3DS.%2BW.%26aulast%3DTowell%26aufirst%3DJ.%2BA.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DMcMurray%26aufirst%3DD.%2BN.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBaker%26aufirst%3DW.%2BR.%26atitle%3DA%2520small-molecule%2520nitroimidazopyran%2520drug%2520candidate%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DNature%26date%3D2000%26volume%3D405%26spage%3D962%26epage%3D6%26doi%3D10.1038%2F35016103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span> <span> </span><span class="NLM_article-title">The mechanism of action of pa-824: Novel insights from transcriptional profiling</span>. <i>Commun. Integr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.4161/cib.2.3.7926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.4161%2Fcib.2.3.7926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=19641733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1yru7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=215-8&author=U.+Manjunathaauthor=H.+I.+Boshoffauthor=C.+E.+Barry&title=The+mechanism+of+action+of+pa-824%3A+Novel+insights+from+transcriptional+profiling&doi=10.4161%2Fcib.2.3.7926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of action of PA-824: novel insights from transcriptional profiling</span></div><div class="casAuthors">Manjunatha, Ujjini; Boshoff, Helena I. M.; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Communicative & Integrative Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-218</span>CODEN:
                <span class="NLM_cas:coden">CIBOBQ</span>;
        ISSN:<span class="NLM_cas:issn">1942-0889</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">The bicyclic nitroimidazole PA-824 is a pro-drug with a very complex mechanism of action active against both replicating and hypoxic, non-replicating Mycobacterium tuberculosis.  Microarray anal. of the mode of action of PA-824 showed a puzzling mixed effect both on genes responsive to both cell wall inhibition (like isoniazid) and respiratory poisoning (like cyanide).  The aerobic killing mechanism of this drug appears to involve inhibition of cell wall mycolic acid biosynthesis through an as yet unknown mol. mechanism.  However, the structure-activity relationships governing aerobic activity do not parallel the relationships detg. anaerobic activity.  Based on the metabolite profiling of PA-824 and various derivs. by Ddn-mediated activation, we have shown that PA-824 acts directly as an NO donor.  This respiratory poisoning through nitric oxide release seemed to be a crucial element of anaerobic activity by PA-824.  The effect of PA-824 on the respiratory complex under hypoxic non-replicating conditions was also manifested in a rapid drop in intracellular ATP levels, again similar to that obsd. by cyanide treatment.  Thus, transcriptional profiling provided valuable clues to elucidating the mol. mechanism of mycobacterial killing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRIjCfr9dB9bVg90H21EOLACvtfcHk0ljucOLlT3EgaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1yru7bF&md5=b7b25a9c2c9b39ff446571c9a2d6d297</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.4161%2Fcib.2.3.7926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcib.2.3.7926%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DThe%2520mechanism%2520of%2520action%2520of%2520pa-824%253A%2520Novel%2520insights%2520from%2520transcriptional%2520profiling%26jtitle%3DCommun.%2520Integr.%2520Biol.%26date%3D2009%26volume%3D2%26spage%3D215%26epage%3D8%26doi%3D10.4161%2Fcib.2.3.7926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niyomrattanakit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledwidge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Pa-824 kills nonreplicating mycobacterium tuberculosis by intracellular no release</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">1392</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1126/science.1164571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1126%2Fscience.1164571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=19039139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVagt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2008&pages=1392-1395&author=R.+Singhauthor=U.+Manjunathaauthor=H.+I.+Boshoffauthor=Y.+H.+Haauthor=P.+Niyomrattanakitauthor=R.+Ledwidgeauthor=C.+S.+Dowdauthor=I.+Y.+Leeauthor=P.+Kimauthor=L.+Zhang&title=Pa-824+kills+nonreplicating+mycobacterium+tuberculosis+by+intracellular+no+release&doi=10.1126%2Fscience.1164571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release</span></div><div class="casAuthors">Singh, Ramandeep; Manjunatha, Ujjini; Boshoff, Helena I. M.; Ha, Young Hwan; Niyomrattanakit, Pornwaratt; Ledwidge, Richard; Dowd, Cynthia S.; Lee, Ill Young; Kim, Pilho; Zhang, Liang; Kang, Sunhee; Keller, Thomas H.; Jiricek, Jan; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">5906</span>),
    <span class="NLM_cas:pages">1392-1395</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Bicyclic nitroimidazoles, including PA-824, are exciting candidates for the treatment of tuberculosis.  These prodrugs require intracellular activation for their biol. function.  We found that Rv3547 is a deazaflavin-dependent nitroreductase (Ddn) that converts PA-824 into three primary metabolites; the major one is the corresponding des-nitroimidazole (des-nitro).  When derivs. of PA-824 were used, the amt. of des-nitro metabolite formed was highly correlated with anaerobic killing of Mycobacterium tuberculosis (Mtb).  Des-nitro metabolite formation generated reactive nitrogen species, including nitric oxide (NO), which are the major effectors of the anaerobic activity of these compds.  Furthermore, NO scavengers protected the bacilli from the lethal effects of the drug.  Thus, these compds. may act as intracellular NO donors and could augment a killing mechanism intrinsic to the innate immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdOQ6XyUn59bVg90H21EOLACvtfcHk0liUcsiu5lBv-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVagt7jN&md5=5d7d8715b5565938b3ffd9fd35a723da</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1126%2Fscience.1164571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1164571%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DHa%26aufirst%3DY.%2BH.%26aulast%3DNiyomrattanakit%26aufirst%3DP.%26aulast%3DLedwidge%26aufirst%3DR.%26aulast%3DDowd%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DI.%2BY.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DPa-824%2520kills%2520nonreplicating%2520mycobacterium%2520tuberculosis%2520by%2520intracellular%2520no%2520release%26jtitle%3DScience%26date%3D2008%26volume%3D322%26spage%3D1392%26epage%3D1395%26doi%3D10.1126%2Fscience.1164571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Latanoprostene bunod ophthalmic solution 0.024%: A review in open-angle glaucoma and ocular hypertension</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0914-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-018-0914-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29761382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsVCksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=773-780&author=S.+M.+Hoy&title=Latanoprostene+bunod+ophthalmic+solution+0.024%25%3A+A+review+in+open-angle+glaucoma+and+ocular+hypertension&doi=10.1007%2Fs40265-018-0914-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">773-780</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Latanoprostene bunod ophthalmic soln. 0.024% (hereafter referred to as latanoprostene bunod 0.024%) [Vyzulta] is a nitric oxide (NO)-donating prostaglandin F2α analog approved in the USA for the redn. of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension.  It is thought to lower IOP by increasing aq. humor outflow through the uveoscleral pathway (mediated by latanoprost acid) and increasing the facility of aq. humor outflow through the trabecular meshwork pathway (mediated by NO).  Results from two multinational, phase III studies (APOLLO and LUNAR) and a pooled anal. of these studies demonstrated the noninferiority of latanoprostene bunod 0.024% to timolol ophthalmic soln. 0.5% (hereafter referred to as timolol 0.5%) in terms of IOP-lowering efficacy over 3 mo in patients with OAG or ocular hypertension, with the superiority of latanoprostene bunod 0.024% over timolol 0.5% subsequently demonstrated in APOLLO and the pooled anal.  Moreover, there was no apparent loss of IOP-lowering effect in subsequent safety extension periods of up to 9 mo.  The IOP-lowering efficacy seen in APOLLO and LUNAR was confirmed in a phase III study (JUPITER) in Japanese patients, with IOP redns. obsd. early (week 4) and maintained over the longer-term (12 mo).  Latanoprostene bunod 0.024% was well tolerated over up to 12 mo in these studies, with most ocular treatment-emergent adverse events (TEAEs) being mild to moderate in severity.  Thus, current evidence indicates once-daily latanoprostene bunod 0.024% is an effective and well tolerated treatment option for the redn. of IOP in adults with OAG or ocular hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr26pnF0TbnBLVg90H21EOLACvtfcHk0liUcsiu5lBv-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsVCksb0%253D&md5=6d3a7bcdc17c510fdbf4d638f026241b</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0914-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0914-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DLatanoprostene%2520bunod%2520ophthalmic%2520solution%25200.024%2525%253A%2520A%2520review%2520in%2520open-angle%2520glaucoma%2520and%2520ocular%2520hypertension%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D773%26epage%3D780%26doi%3D10.1007%2Fs40265-018-0914-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Venetoclax: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">979</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0596-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40265-016-0596-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=27260335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVymtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=979-87&author=E.+D.+Deeks&title=Venetoclax%3A+First+global+approval&doi=10.1007%2Fs40265-016-0596-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Venetoclax: First Global Approval</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">979-987</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Venetoclax (Venclexta) is an oral selective inhibitor of the prosurvival protein BCL-2 and therefore restores the apoptotic ability of malignant cells.  The drug arose from research by Abbott Labs. (now AbbVie) during a collaboration with Genentech and is being co-developed by AbbVie and Genentech/Roche primarily for the treatment of haematol. malignancies.  Venetoclax is approved in the USA for use as monotherapy in patients with chronic lymphocytic leukemia (CLL) with the 17p deletion (as detected by an approved FDA test) who have received at least one prior therapy, and is awaiting approval for similar indications in the EU and Canada.  Venetoclax is also in phase I-III development as combination therapy for CLL, phase I/II development as monotherapy and/or combination therapy for non-Hodgkin lymphomas (including diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma) and acute myeloid leukemia, and phase I development for multiple myeloma, systemic lupus erythematosus and breast cancer.  This article summarizes the milestones in the development of venetoclax leading to this first approval for CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo-_C1vJNwpLVg90H21EOLACvtfcHk0liUcsiu5lBv-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVymtLo%253D&md5=e0f99ba8fb7665bba95ac42626c6aaa3</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0596-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0596-x%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DVenetoclax%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D979%26epage%3D87%26doi%3D10.1007%2Fs40265-016-0596-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among us fda approved pharmaceuticals: Miniperspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">10257</span>– <span class="NLM_lpage">10274</span>, <span class="refDoi"> DOI: 10.1021/jm501100b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501100b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10257-10274&author=E.+Vitakuauthor=D.+T.+Smithauthor=J.+T.+Njardarson&title=Analysis+of+the+structural+diversity%2C+substitution+patterns%2C+and+frequency+of+nitrogen+heterocycles+among+us+fda+approved+pharmaceuticals%3A+Miniperspective&doi=10.1021%2Fjm501100b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals</span></div><div class="casAuthors">Vitaku, Edon; Smith, David T.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10257-10274</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nitrogen heterocycles are among the most significant structural components of pharmaceuticals.  Anal. of our database of U.S. FDA approved drugs reveals that 59% of unique small-mol. drugs contain a nitrogen heterocycle.  In this review we report on the top 25 most commonly utilized nitrogen heterocycles found in pharmaceuticals.  The main part of our anal. is divided into seven sections: (1) three- and four-membered heterocycles, (2) five-, (3) six-, and (4) seven- and eight-membered heterocycles, as well as (5) fused, (6) bridged bicyclic, and (7) macrocyclic nitrogen heterocycles.  Each section reveals the top nitrogen heterocyclic structures and their relative impact for that ring type.  For the most commonly used nitrogen heterocycles, we report detailed substitution patterns, highlight common architectural cores, and discuss unusual or rare structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5cUk9KxUSkbVg90H21EOLACvtfcHk0liBPzIrv0WHwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP&md5=7065b3b2fc6f69cede0f87479c7cf472</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1021%2Fjm501100b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501100b%26sid%3Dliteratum%253Aachs%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DAnalysis%2520of%2520the%2520structural%2520diversity%252C%2520substitution%2520patterns%252C%2520and%2520frequency%2520of%2520nitrogen%2520heterocycles%2520among%2520us%2520fda%2520approved%2520pharmaceuticals%253A%2520Miniperspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10257%26epage%3D10274%26doi%3D10.1021%2Fjm501100b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiesinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar’in, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasavin, M.</span></span> <span> </span><span class="NLM_article-title">Spirocyclic scaffolds in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01473</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01473" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXislWlsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=150-183&author=K.+Hiesingerauthor=D.+Dar%E2%80%99inauthor=E.+Proschakauthor=M.+Krasavin&title=Spirocyclic+scaffolds+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.0c01473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Spirocyclic Scaffolds in Medicinal Chemistry</span></div><div class="casAuthors">Hiesinger, Kerstin; Dar'in, Dmitry; Proschak, Ewgenij; Krasavin, Mikhail</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">150-183</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spirocyclic scaffolds are incorporated in various approved drugs and drug candidates.  The increasing interest in less planar bioactive compds. has given rise to the development of synthetic methodologies for the prepn. of spirocyclic scaffolds.  In this Perspective, we summarize the diverse synthetic routes to obtain spirocyclic systems.  The impact of spirocycles on potency and selectivity, including the aspect of stereochem., is discussed.  Furthermore, we examine the changes in physicochem. properties as well as in in vitro and in vivo ADME using selected studies that compare spirocyclic compds. to their nonspirocyclic counterparts.  In conclusion, the value of spirocyclic scaffolds in medicinal chem. is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxeu8qelbAWbVg90H21EOLACvtfcHk0liBPzIrv0WHwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXislWlsL3K&md5=b584a88a9ee65ed93277c946262de216</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01473%26sid%3Dliteratum%253Aachs%26aulast%3DHiesinger%26aufirst%3DK.%26aulast%3DDar%25E2%2580%2599in%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DKrasavin%26aufirst%3DM.%26atitle%3DSpirocyclic%2520scaffolds%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D150%26epage%3D183%26doi%3D10.1021%2Facs.jmedchem.0c01473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Medina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span> <span> </span><span class="NLM_article-title">Platform for unified molecular analysis: Puma</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1735</span>– <span class="NLM_lpage">1740</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.7b00253</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.7b00253" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wgsb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=1735-1740&author=M.+Gonzalez-Medinaauthor=J.+L.+Medina-Franco&title=Platform+for+unified+molecular+analysis%3A+Puma&doi=10.1021%2Facs.jcim.7b00253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Platform for Unified Molecular Analysis: PUMA</span></div><div class="casAuthors">Gonzalez-Medina, Mariana; Medina-Franco, Jose L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1735-1740</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We introduce a free platform for chemoinformatic-based diversity anal. and visualization of chem. space of user supplied data sets.  Platform for Unified Mol. Anal. (PUMA) integrates metrics used to characterize compd. databases including visualization of chem. space, scaffold content, and anal. of chem. diversity.  The user's input is a file with SMILES, database names, and compd. IDs.  PUMA computes mol. properties of pharmaceutical relevance, Murcko scaffolds, and diversity anal.  The user can interactively navigate through the graphs and export image files and the raw data of the diversity calcns.  The platform links two public online resources: Consensus Diversity Plots for the assessment of global diversity and Activity Landscape Plotter to analyze structure-activity relationships.  Herein, we describe the functionalities of PUMA and exemplify its use through the anal. of compd. databases of general interest.  PUMA is freely accessible at the authors web-site https://www.difacquim.com/d-tools/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7UDAHVWCKOLVg90H21EOLACvtfcHk0liBPzIrv0WHwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wgsb7O&md5=84e7b7118d9cc0afdf2a55964e53b1f0</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.7b00253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.7b00253%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Medina%26aufirst%3DM.%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26atitle%3DPlatform%2520for%2520unified%2520molecular%2520analysis%253A%2520Puma%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2017%26volume%3D57%26spage%3D1735%26epage%3D1740%26doi%3D10.1021%2Facs.jcim.7b00253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levin, V. A.</span></span> <span> </span><span class="NLM_article-title">Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1021/jm00180a022</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00180a022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaL3cXktFyrtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1980&pages=682-4&author=V.+A.+Levin&title=Relationship+of+octanol%2Fwater+partition+coefficient+and+molecular+weight+to+rat+brain+capillary+permeability&doi=10.1021%2Fjm00180a022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability</span></div><div class="casAuthors">Levin, Victor A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">682-4</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The rat brain capillary permeability coeff. was detd. for 27 compds.  The relation of permeability to octanol/water partition coeff. and mol. wt. was predictable for drugs with mol. wts. <400.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ANVehpbXmrVg90H21EOLACvtfcHk0liBPzIrv0WHwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXktFyrtro%253D&md5=04c3bc1889c4fc17348163ef492436bf</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1021%2Fjm00180a022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00180a022%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DV.%2BA.%26atitle%3DRelationship%2520of%2520octanol%252Fwater%2520partition%2520coefficient%2520and%2520molecular%2520weight%2520to%2520rat%2520brain%2520capillary%2520permeability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1980%26volume%3D23%26spage%3D682%26epage%3D4%26doi%3D10.1021%2Fjm00180a022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van de Waterbeemd, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camenisch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chretien, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raevsky, O. A.</span></span> <span> </span><span class="NLM_article-title">Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and h-bonding descriptors</span>. <i>J. Drug Target</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.3109/10611869808997889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.3109%2F10611869808997889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=9886238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaK1MXkvFKmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=151-165&author=H.+van+de+Waterbeemdauthor=G.+Camenischauthor=G.+Folkersauthor=J.+R.+Chretienauthor=O.+A.+Raevsky&title=Estimation+of+blood-brain+barrier+crossing+of+drugs+using+molecular+size+and+shape%2C+and+h-bonding+descriptors&doi=10.3109%2F10611869808997889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors</span></div><div class="casAuthors">Van de Waterbeemd, Han; Camenisch, Gian; Folkers, Gerd; Chretien, Jacques R.; Raevsky, Oleg A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Targeting</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-165</span>CODEN:
                <span class="NLM_cas:coden">JDTAEH</span>;
        ISSN:<span class="NLM_cas:issn">1061-186X</span>.
    
            (<span class="NLM_cas:orgname">Harwood Academic Publishers</span>)
        </div><div class="casAbstract">The influence of physicochem. properties, including lipophilicity, H-bonding capacity and mol. size and shape descriptors on brain uptake has been investigated using a selection of marketed CNS and CNS-inactive drugs.  It is demonstrated that the polar surface area of a drug can be used as a suitable descriptor for the drugs' H-bonding potential.  A combination of a H-bonding and a mol. size descriptor, i.e., the major components of lipophilicity and permeability, avoiding knowledge of distribution coeffs., is proposed to est. brain penetration potential of new drug candidates.  Previously reported exptl. surface activity data appear to be strongly correlated to mol. size of the drug compds.  Present anal. offers a modern basis for property-based design and targeting of CNS drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0yCKmlzsa37Vg90H21EOLACvtfcHk0liksuNkE_8-zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkvFKmtg%253D%253D&md5=9106ff6aa0755ff76fd0634822857d4a</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.3109%2F10611869808997889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10611869808997889%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DCamenisch%26aufirst%3DG.%26aulast%3DFolkers%26aufirst%3DG.%26aulast%3DChretien%26aufirst%3DJ.%2BR.%26aulast%3DRaevsky%26aufirst%3DO.%2BA.%26atitle%3DEstimation%2520of%2520blood-brain%2520barrier%2520crossing%2520of%2520drugs%2520using%2520molecular%2520size%2520and%2520shape%252C%2520and%2520h-bonding%2520descriptors%26jtitle%3DJ.%2520Drug%2520Target%26date%3D1998%26volume%3D6%26spage%3D151%26epage%3D165%26doi%3D10.3109%2F10611869808997889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth-Walter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adcock, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benito-Villalvilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjermer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramori, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamant, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguiluz-Gracia, I. J. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An eaaci taskforce on immunopharmacology position paper</span>. <i>Allergy</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">432</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1111/all.13642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1111%2Fall.13642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30353939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3cvis1SjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2019&pages=432-448&author=F.+Roth-Walterauthor=I.+M.+Adcockauthor=C.+Benito-Villalvillaauthor=R.+Bianchiniauthor=L.+Bjermerauthor=G.+Caramoriauthor=L.+Cariauthor=K.+F.+Chungauthor=Z.+Diamantauthor=I.+J.+A.+Eguiluz-Gracia&title=Comparing+biologicals+and+small+molecule+drug+therapies+for+chronic+respiratory+diseases%3A+An+eaaci+taskforce+on+immunopharmacology+position+paper&doi=10.1111%2Fall.13642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper</span></div><div class="casAuthors">Roth-Walter Franziska; Bianchini Rodolfo; Adcock Ian M; Benito-Villalvilla Cristina; Palomares Oscar; Bjermer Leif; Caramori Gaetano; Cari Luigi; Nocentini Giuseppe; Chung Kian Fan; Diamant Zuzana; Diamant Zuzana; Eguiluz-Gracia Ibon; Knol Edward F; Kolios Antonios G A; Levi-Schaffer Francesca; Puzzovio Pier Giorgio; Redegeld Frank A; van Esch Betty C A M; Stellato Cristiana</div><div class="citationInfo"><span class="NLM_cas:title">Allergy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">432-448</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), together with their comorbidities, bear a significant burden on public health.  Increased appreciation of molecular networks underlying inflammatory airway disease needs to be translated into new therapies for distinct phenotypes not controlled by current treatment regimens.  On the other hand, development of new safe and effective therapies for such respiratory diseases is an arduous and expensive process.  Antibody-based (biological) therapies are successful in treating certain respiratory conditions not controlled by standard therapies such as severe allergic and refractory eosinophilic severe asthma, while in other inflammatory respiratory diseases, such as COPD, biologicals are having a more limited impact.  Small molecule drug (SMD)-based therapies represent an active field in pharmaceutical research and development.  SMDs expand biologicals' therapeutic targets by reaching the intracellular compartment by delivery as either an oral or topically based formulation, offering both convenience and lower costs.  Aim of this review was to compare and contrast the distinct pharmacological properties and clinical applications of SMDs- and antibody-based treatment strategies, their limitations and challenges, in order to highlight how they should be integrated for their optimal utilization and to fill the critical gaps in current treatment for these chronic inflammatory respiratory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQUSNHUpZVYb7NkxioyDXTfW6udTcc2eaBKLAg3LTAO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvis1SjsQ%253D%253D&md5=2740f4e550f36f2e6b2d6714647ab85d</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1111%2Fall.13642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fall.13642%26sid%3Dliteratum%253Aachs%26aulast%3DRoth-Walter%26aufirst%3DF.%26aulast%3DAdcock%26aufirst%3DI.%2BM.%26aulast%3DBenito-Villalvilla%26aufirst%3DC.%26aulast%3DBianchini%26aufirst%3DR.%26aulast%3DBjermer%26aufirst%3DL.%26aulast%3DCaramori%26aufirst%3DG.%26aulast%3DCari%26aufirst%3DL.%26aulast%3DChung%26aufirst%3DK.%2BF.%26aulast%3DDiamant%26aufirst%3DZ.%26aulast%3DEguiluz-Gracia%26aufirst%3DI.%2BJ.%2BA.%26atitle%3DComparing%2520biologicals%2520and%2520small%2520molecule%2520drug%2520therapies%2520for%2520chronic%2520respiratory%2520diseases%253A%2520An%2520eaaci%2520taskforce%2520on%2520immunopharmacology%2520position%2520paper%26jtitle%3DAllergy%26date%3D2019%26volume%3D74%26spage%3D432%26epage%3D448%26doi%3D10.1111%2Fall.13642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altman, S.</span></span> <span> </span><span class="NLM_article-title">Antibiotics present and future</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>588</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">2</span>, <span class="refDoi"> DOI: 10.1016/j.febslet.2013.10.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.febslet.2013.10.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24252220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKgtrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=588&publication_year=2014&pages=1-2&author=S.+Altman&title=Antibiotics+present+and+future&doi=10.1016%2Fj.febslet.2013.10.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Antibiotics present and future</span></div><div class="casAuthors">Altman, S.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">588</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-2</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Here the authors make a brief survey of the present state of antibiotic research and use.  The authors also describe a novel antibiotic that contains a basic peptide covalently bound to a morpholino oligonucleotide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouQxOnE2irXbVg90H21EOLACvtfcHk0liksuNkE_8-zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKgtrzN&md5=eedd6367d027d3350272c1bcf42845a5</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2013.10.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2013.10.048%26sid%3Dliteratum%253Aachs%26aulast%3DAltman%26aufirst%3DS.%26atitle%3DAntibiotics%2520present%2520and%2520future%26jtitle%3DFEBS%2520Lett.%26date%3D2014%26volume%3D588%26spage%3D1%26epage%3D2%26doi%3D10.1016%2Fj.febslet.2013.10.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veber, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopple, K. D.</span></span> <span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2615</span>– <span class="NLM_lpage">2623</span>, <span class="refDoi"> DOI: 10.1021/jm020017n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.-Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates&doi=10.1021%2Fjm020017n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0li8I1mla1Eiiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.-Y.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623%26doi%3D10.1021%2Fjm020017n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, D. E.</span></span> <span> </span><span class="NLM_article-title">What has polar surface area ever done for drug discovery?</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.4155%2Ffmc.11.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=21452982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVClu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=469-484&author=D.+E.+Clark&title=What+has+polar+surface+area+ever+done+for+drug+discovery%3F&doi=10.4155%2Ffmc.11.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">What has polar surface area ever done for drug discovery?</span></div><div class="casAuthors">Clark, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-484</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Over the last decade, polar surface area (PSA) has become a ubiquitous term in medicinal and computational chem. circles.  This article charts the development of the increasingly efficient methods for the calcn. of PSA before illustrating its usefulness through selected examples drawn from the medicinal chem. literature.  Consideration of PSA is shown to assist in the improvement of cellular potency, intestinal absorption and blood--brain barrier permeation or restriction to the peripheral circulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrumWpKrOWP6rVg90H21EOLACvtfcHk0li8I1mla1Eiiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVClu78%253D&md5=92335875ed1efb9721fb63d72844bf09</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.1%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DD.%2BE.%26atitle%3DWhat%2520has%2520polar%2520surface%2520area%2520ever%2520done%2520for%2520drug%2520discovery%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D469%26epage%3D484%26doi%3D10.4155%2Ffmc.11.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span> <span> </span><span class="NLM_article-title">Structure-brain exposure relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">7559</span>– <span class="NLM_lpage">7583</span>, <span class="refDoi"> DOI: 10.1021/jm060642i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060642i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yrtrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7559-7583&author=S.+A.+Hitchcockauthor=L.+D.+Pennington&title=Structure-brain+exposure+relationships&doi=10.1021%2Fjm060642i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-brain exposure relationships</span></div><div class="casAuthors">Hitchcock, Stephen A.; Pennington, Lewis D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7559-7583</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the use of structure modification to influence blood-brain barrier penetration by modulating either passive diffusion or active transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3V-TERRGy07Vg90H21EOLACvtfcHk0li8I1mla1Eiiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yrtrnK&md5=97dff583ffae6d0ef66512ffbee38c34</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1021%2Fjm060642i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060642i%26sid%3Dliteratum%253Aachs%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26atitle%3DStructure-brain%2520exposure%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7559%26epage%3D7583%26doi%3D10.1021%2Fjm060642i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebejer, J.-P.</span>; <span class="NLM_string-name">Charlton, M. H.</span>; <span class="NLM_string-name">Finn, P. W.</span></span> <span> </span><span class="NLM_article-title">Are the physicochemical properties of antibacterial compounds really different from other drugs?</span> <i>J. Cheminf.</i><span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume">8</span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>.<span class="refDoi"> DOI: 10.1186/s13321-016-0143-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1186%2Fs13321-016-0143-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=1-9&author=J.-P.+Ebejer&author=M.+H.+Charlton&author=P.+W.+Finn&title=Are+the+physicochemical+properties+of+antibacterial+compounds+really+different+from+other+drugs%3F&doi=10.1186%2Fs13321-016-0143-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1186%2Fs13321-016-0143-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-016-0143-5%26sid%3Dliteratum%253Aachs%26aulast%3DEbejer%26aufirst%3DJ.-P.%26atitle%3DAre%2520the%2520physicochemical%2520properties%2520of%2520antibacterial%2520compounds%2520really%2520different%2520from%2520other%2520drugs%253F%26jtitle%3DJ.%2520Cheminf.%26date%3D2016%26volume%3D8%26spage%3D1%26epage%3D9%26doi%3D10.1186%2Fs13321-016-0143-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashinson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolman, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zha, M.</span></span> <span> </span><span class="NLM_article-title">Understanding the molecular properties and metabolism of top prescribed drugs</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1290</span>– <span class="NLM_lpage">1307</span>, <span class="refDoi"> DOI: 10.2174/15680266113139990034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.2174%2F15680266113139990034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=23675936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wnt7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1290-1307&author=H.+A.+Zhongauthor=V.+Mashinsonauthor=T.+A.+Woolmanauthor=M.+Zha&title=Understanding+the+molecular+properties+and+metabolism+of+top+prescribed+drugs&doi=10.2174%2F15680266113139990034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the Molecular Properties and Metabolism of Top Prescribed Drugs</span></div><div class="casAuthors">Zhong, Haizhen A.; Mashinson, Victoria; Woolman, Theodor A.; Zha, Mengyi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1290-1307</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Mol. properties such as the mol. wt., hydrophobicity parameter logP, and the total polar surface area (TPSA) have been used extensively in modern drug discovery.  We investigated these properties and ADMET scores of the top 200 therapeutic drugs by the U.  S. retail sales (2010) and classified them according to the clin. indications and/or routes of administration.  This list of drugs provides ample information of these mol. descriptors for successfully approved drugs.  The mean logP for oral drugs is 2.5 while the logP for injectable drugs seems to be smaller.  Among different types of clin. indications, drugs used for anti-HIV, and antibiotics tend to have lower logP.  The mol. wts. of anti-HIV drugs, antihypertensives and antibiotics appear to be larger.  The ADMET scores, derived from a combination of mol. wts. and logP, are consistent for oral drugs, with a mean score of 1.5 and a std. deviation of 1.0.  Many clin. drugs that violate Lipinskis rule of five criteria can still exhibit ADMET scores that are very close to the mean value for oral drugs (1.5) and lie within the acceptable std. deviation.  The mol. properties of MW, logP, and TPSA appear to vary according to their clin. indications.  Many drugs form salts or cocrystals with acids or solvents that increase their soly.  Our data show that addn. of hydrochloride is the most common method to increase soly. of drug ingredients.  Cytochrome P 450 isoenzymes 3A4, 2D6, 2C9, 2C8 and 3C5 are the top five proteins that metabolize the 200 most prescribed drugs.  Drugs metabolized by 3A4 appear to have larger mol. wts. and those metabolized by 2D6 have lower mol. wts.  CYP2C8-metabolized drugs appear to be most hydrophilic, with the smallest logP and the largest polar surface areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN07cwBoCAYLVg90H21EOLACvtfcHk0lgkxCVFTPFr4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wnt7bI&md5=3e09dbf26e440668195df98429f308c9</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.2174%2F15680266113139990034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680266113139990034%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DH.%2BA.%26aulast%3DMashinson%26aufirst%3DV.%26aulast%3DWoolman%26aufirst%3DT.%2BA.%26aulast%3DZha%26aufirst%3DM.%26atitle%3DUnderstanding%2520the%2520molecular%2520properties%2520and%2520metabolism%2520of%2520top%2520prescribed%2520drugs%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D1290%26epage%3D1307%26doi%3D10.2174%2F15680266113139990034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanadhan, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendoloski, J. J.</span></span> <span> </span><span class="NLM_article-title">Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: An analysis of alogp and clogp methods</span>. <i>J. Phys. Chem. A</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">3762</span>– <span class="NLM_lpage">3772</span>, <span class="refDoi"> DOI: 10.1021/jp980230o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp980230o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaK1cXis12rsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=3762-3772&author=A.+K.+Ghoseauthor=V.+N.+Viswanadhanauthor=J.+J.+Wendoloski&title=Prediction+of+hydrophobic+%28lipophilic%29+properties+of+small+organic+molecules+using+fragmental+methods%3A+An+analysis+of+alogp+and+clogp+methods&doi=10.1021%2Fjp980230o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods</span></div><div class="casAuthors">Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry A</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3762-3772</span>CODEN:
                <span class="NLM_cas:coden">JPCAFH</span>;
        ISSN:<span class="NLM_cas:issn">1089-5639</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. hydrophobicity (lipophilicity), usually quantified as log P (the logarithm of 1-octanol/water partition coeff.), is an important mol. characteristic in drug discovery.  ALOGP and CLOGP are two of the most widely used methods for the estn. of log P.  This work describes an extensive reparametrization of the at. log P values and a detailed comparison of the performance of ALOGP and CLOGP methods on the Pomona Medchem database.  Only the "star list" compds. having precisely measured log P values were used in this anal.  While the overall results with both methods are similar, anal. shows that the CLOGP method is better for very small mols. in the range of 1-20 atoms.  The two methods are almost comparable in the range of 21-45 atoms, while the ALOGP method has better accuracy for mols. with more than 45 atoms.  Although the rms deviation and the correlation coeff. for CLOGP predictions were marginally better than those for corresponding ALOGP predictions, the latter showed a very stable performance for all classes of org. compds. analyzed.  Importantly, the ALOGP method can be used to compute ests. for all mols. in the database, whereas the CLOGP method fails to offer ests. for a substantial part of the database.  Finally, unlike CLOGP and other methods of predicting lipophilicity, the ALOGP method has multiple uses, such as the estn. of local hydrophobicity, the visualization of mol. hydrophobicity maps, and the evaluation of hydrophobic interactions in protein-ligand complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXdn8wsqV3frVg90H21EOLACvtfcHk0lgkxCVFTPFr4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis12rsrY%253D&md5=ef58841437913e164dc2d6e73eb5c87d</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Fjp980230o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp980230o%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26aulast%3DWendoloski%26aufirst%3DJ.%2BJ.%26atitle%3DPrediction%2520of%2520hydrophobic%2520%2528lipophilic%2529%2520properties%2520of%2520small%2520organic%2520molecules%2520using%2520fragmental%2520methods%253A%2520An%2520analysis%2520of%2520alogp%2520and%2520clogp%2520methods%26jtitle%3DJ.%2520Phys.%2520Chem.%2520A%26date%3D1998%26volume%3D102%26spage%3D3762%26epage%3D3772%26doi%3D10.1021%2Fjp980230o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberger, L. E.</span></span> <span> </span><span class="NLM_article-title">Neighborhood behavior: A useful concept for validation of “molecular diversity” descriptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">3049</span>– <span class="NLM_lpage">3059</span>, <span class="refDoi"> DOI: 10.1021/jm960290n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960290n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1alur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=3049-3059&author=D.+E.+Pattersonauthor=R.+D.+Cramerauthor=A.+M.+Fergusonauthor=R.+D.+Clarkauthor=L.+E.+Weinberger&title=Neighborhood+behavior%3A+A+useful+concept+for+validation+of+%E2%80%9Cmolecular+diversity%E2%80%9D+descriptors&doi=10.1021%2Fjm960290n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Neighborhood Behavior: A Useful Concept for Validation of "Molecular Diversity" Descriptors</span></div><div class="casAuthors">Patterson, David E.; Cramer, Richard D.; Ferguson, Allan M.; Clark, Robert D.; Weinberger, Laurence E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3049-3059</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">When searching for new leads, testing mols. that are too "similar" is wasteful, but when investigating a lead, testing mols. that are "similar" to the lead is efficient.  Two questions then arise.  Which are the mol. descriptors that should be "similar".  How much "similarity" is enough.  These questions are answered by demonstrating that, if a mol. descriptor is to be a valid and useful measure of "similarity" in drug discovery, a plot of differences in its values vs. differences in biol. activities for a set of related mols. will exhibit a characteristic trapezoidal distribution enhancement, revealing a "neighborhood behavior" for the descriptor.  Applying this finding to 20 datasets allows 11 mol. diversity descriptors to be ranked by their validity for compd. library design.  In order of increasing frequency of usefulness, these are random nos. = log P = MR = strain energy < connectivity indexes < 2D fingerprints (whole mol.) = atom pairs = autocorrelation indexes < steric CoMFA fields = 2D fingerprints (side chain only) = H-bonding CoMFA fields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEV52sTPRVo7Vg90H21EOLACvtfcHk0lgkxCVFTPFr4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1alur8%253D&md5=cca6888d4b798186ac1946bf654bf01a</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Fjm960290n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960290n%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DD.%2BE.%26aulast%3DCramer%26aufirst%3DR.%2BD.%26aulast%3DFerguson%26aufirst%3DA.%2BM.%26aulast%3DClark%26aufirst%3DR.%2BD.%26aulast%3DWeinberger%26aufirst%3DL.%2BE.%26atitle%3DNeighborhood%2520behavior%253A%2520A%2520useful%2520concept%2520for%2520validation%2520of%2520%25E2%2580%259Cmolecular%2520diversity%25E2%2580%259D%2520descriptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D3049%26epage%3D3059%26doi%3D10.1021%2Fjm960290n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span> <span> </span><span class="NLM_article-title">Molecular property design: Does everyone get it?</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=722-725&author=P.+D.+Leesonauthor=R.+J.+Young&title=Molecular+property+design%3A+Does+everyone+get+it%3F&doi=10.1021%2Facsmedchemlett.5b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Property Design: Does Everyone Get It?</span></div><div class="casAuthors">Leeson, Paul D.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">722-725</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The principles of mol. property optimization in drug design have been understood for decades, yet much drug discovery activity today is conducted at the periphery of historical druglike property space.  Lead optimization trajectories aimed at reducing physicochem. risk, assisted by ligand efficiency metrics, could help to reduce clin. attrition rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_t8gIn79arVg90H21EOLACvtfcHk0ljh0M7ae-nUdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D&md5=5a807a8d049ce8cf4adc186891a9234d</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00157%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DMolecular%2520property%2520design%253A%2520Does%2520everyone%2520get%2520it%253F%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D722%26epage%3D725%26doi%3D10.1021%2Facsmedchemlett.5b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remete, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriwaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fustero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloshonok, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span> <span> </span><span class="NLM_article-title">Fluorine-containing drugs approved by the fda in 2019</span>. <i>Chin. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2401</span>– <span class="NLM_lpage">2413</span>, <span class="refDoi"> DOI: 10.1016/j.cclet.2020.03.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2Fj.cclet.2020.03.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmvFKmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2020&pages=2401-2413&author=H.+Meiauthor=A.+M.+Remeteauthor=Y.+Zouauthor=H.+Moriwakiauthor=S.+Fusteroauthor=L.+Kissauthor=V.+A.+Soloshonokauthor=J.+Han&title=Fluorine-containing+drugs+approved+by+the+fda+in+2019&doi=10.1016%2Fj.cclet.2020.03.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine-containing drugs approved by the FDA in 2019</span></div><div class="casAuthors">Mei, Haibo; Remete, Attila Mario; Zou, Yupiao; Moriwaki, Hiroki; Fustero, Santos; Kiss, Lorand; Soloshonok, Vadim A.; Han, Jianlin</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Chemical Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2401-2413</span>CODEN:
                <span class="NLM_cas:coden">CCLEE7</span>;
        ISSN:<span class="NLM_cas:issn">1001-8417</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Eleven new fluorine-contg. FDA-approved drugs have been profiled and details of their discovery and prepn. are discussed.  Therapeutic areas include schizophrenia, migraine, multiple sclerosis, insomnia, rheumatoid arthritis, anti-tuberculosis, breast cancer, lymphoma kinase inhibitor, serotonin receptor antagonist.  New pharmaceuticals feature four examples of arom. fluorine, three arom. CF3 group, three aliph. CF3 and one compd. with arom. CF3O group.  Furthermore, among the new compds., six are chiral and seven are derived from tailor-made amino acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5uLd8wWIoeLVg90H21EOLACvtfcHk0ljh0M7ae-nUdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmvFKmsbo%253D&md5=fcd1c938ddeeb732286992978a076304</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2Fj.cclet.2020.03.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cclet.2020.03.050%26sid%3Dliteratum%253Aachs%26aulast%3DMei%26aufirst%3DH.%26aulast%3DRemete%26aufirst%3DA.%2BM.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DMoriwaki%26aufirst%3DH.%26aulast%3DFustero%26aufirst%3DS.%26aulast%3DKiss%26aufirst%3DL.%26aulast%3DSoloshonok%26aufirst%3DV.%2BA.%26aulast%3DHan%26aufirst%3DJ.%26atitle%3DFluorine-containing%2520drugs%2520approved%2520by%2520the%2520fda%2520in%25202019%26jtitle%3DChin.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D31%26spage%3D2401%26epage%3D2413%26doi%3D10.1016%2Fj.cclet.2020.03.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi-Scharber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, L. E.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of (8 s, 9 r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1 h-1, 2, 4-triazol-5-yl)-2, 7, 8, 9-tetrahydro-3 h-pyrido [4, 3, 2-de] phthalazin-3-one (bmn 673, talazoparib), a novel, highly potent, and orally efficacious poly (adp-ribose) polymerase-1/2 inhibitor, as an anticancer agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01498</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01498" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=335-357&author=B.+Wangauthor=D.+Chuauthor=Y.+Fengauthor=Y.+Shenauthor=M.+Aoyagi-Scharberauthor=L.+E.+Post&title=Discovery+and+characterization+of+%288+s%2C+9+r%29-5-fluoro-8-%284-fluorophenyl%29-9-%281-methyl-1+h-1%2C+2%2C+4-triazol-5-yl%29-2%2C+7%2C+8%2C+9-tetrahydro-3+h-pyrido+%5B4%2C+3%2C+2-de%5D+phthalazin-3-one+%28bmn+673%2C+talazoparib%29%2C+a+novel%2C+highly+potent%2C+and+orally+efficacious+poly+%28adp-ribose%29+polymerase-1%2F2+inhibitor%2C+as+an+anticancer+agent&doi=10.1021%2Facs.jmedchem.5b01498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent</span></div><div class="casAuthors">Wang, Bing; Chu, Daniel; Feng, Ying; Shen, Yuqiao; Aoyagi-Scharber, Mika; Post, Leonard E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">335-357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors discovered and developed a novel series of tetrahydropyridophthlazinones as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors.  Lead optimization led to the identification of (I) (talazoparib; BMN 673; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one).  The novel stereospecific dual chiral-center-embedded structure of this compd. has enabled extensive and unique binding interactions with PARP1/2 proteins. I demonstrates excellent potency, inhibiting PARP1 and PARP2 enzyme activity with Ki = 1.2 and 0.87 nM, resp.  It inhibits PARP-mediated PARylation in a whole-cell assay with an EC50 of 2.51 nM and prevents proliferation of cancer cells carrying mutant BRCA1/2, with EC50 = 0.3 nM (MX-1) and 5 nM (Capan-1), resp. I is orally available, displaying favorable pharmacokinetic (PK) properties and remarkable antitumor efficacy in the BRCA1 mutant MX-1 breast cancer xenograft model following oral administration as a single-agent or in combination with chemotherapy agents such as temozolomide and cisplatin. I has completed phase 1 clin. trial and is currently being studied in phase 2 and 3 clin. trials for the treatment of locally advanced and/or metastatic breast cancer with germline BRCA1/2 deleterious mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBpTb90_rQhLVg90H21EOLACvtfcHk0ljh0M7ae-nUdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rN&md5=443bfeb7aeda6c6522d41ab52793931a</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01498%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DPost%26aufirst%3DL.%2BE.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520%25288%2520s%252C%25209%2520r%2529-5-fluoro-8-%25284-fluorophenyl%2529-9-%25281-methyl-1%2520h-1%252C%25202%252C%25204-triazol-5-yl%2529-2%252C%25207%252C%25208%252C%25209-tetrahydro-3%2520h-pyrido%2520%255B4%252C%25203%252C%25202-de%255D%2520phthalazin-3-one%2520%2528bmn%2520673%252C%2520talazoparib%2529%252C%2520a%2520novel%252C%2520highly%2520potent%252C%2520and%2520orally%2520efficacious%2520poly%2520%2528adp-ribose%2529%2520polymerase-1%252F2%2520inhibitor%252C%2520as%2520an%2520anticancer%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D335%26epage%3D357%26doi%3D10.1021%2Facs.jmedchem.5b01498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popovici-Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianchetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of ag-120 (ivosidenib): A first-in-class mutant idh1 inhibitor for the treatment of idh1 mutant cancers</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00421</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00421" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=300-305&author=J.+Popovici-Mullerauthor=R.+M.+Lemieuxauthor=E.+Artinauthor=J.+O.+Saundersauthor=F.+G.+Salituroauthor=J.+Travinsauthor=G.+Cianchettaauthor=Z.+Caiauthor=D.+Zhouauthor=D.+Cui&title=Discovery+of+ag-120+%28ivosidenib%29%3A+A+first-in-class+mutant+idh1+inhibitor+for+the+treatment+of+idh1+mutant+cancers&doi=10.1021%2Facsmedchemlett.7b00421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers</span></div><div class="casAuthors">Popovici-Muller, Janeta; Lemieux, Rene M.; Artin, Erin; Saunders, Jeffrey O.; Salituro, Francesco G.; Travins, Jeremy; Cianchetta, Giovanni; Cai, Zhenwei; Zhou, Ding; Cui, Dawei; Chen, Ping; Straley, Kimberly; Tobin, Erica; Wang, Fang; David, Muriel D.; Penard-Lacronique, Virginie; Quivoron, Cyril; Saada, Veronique; de Botton, Stephane; Gross, Stefan; Dang, Lenny; Yang, Hua; Utley, Luke; Chen, Yue; Kim, Hyeryun; Jin, Shengfang; Gu, Zhiwei; Yao, Gui; Luo, Zhiyong; Lv, Xiaobing; Fang, Cheng; Yan, Liping; Olaharski, Andrew; Silverman, Lee; Biller, Scott; Su, Shin-San M.; Yen, Katharine</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">300-305</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the prodn. of D-2-hydroxyglutarate (2-HG), an oncometabolite.  Elevated 2-HG levels are implicated in epigenetic alterations and impaired cellular differentiation.  IDH1 mutations have been described in an array of hematol. malignancies and solid tumors.  Here, we report the discovery of AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo.  Preliminary data from phase 1 clin. trials enrolling patients with cancers harboring an IDH1 mutation indicate that AG-120 has an acceptable safety profile and clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmTLcR37BiPrVg90H21EOLACvtfcHk0lh0Bqiapj1Aeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyrurw%253D&md5=730ac2faa6844e4abe3fd9a360d74d29</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00421%26sid%3Dliteratum%253Aachs%26aulast%3DPopovici-Muller%26aufirst%3DJ.%26aulast%3DLemieux%26aufirst%3DR.%2BM.%26aulast%3DArtin%26aufirst%3DE.%26aulast%3DSaunders%26aufirst%3DJ.%2BO.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DTravins%26aufirst%3DJ.%26aulast%3DCianchetta%26aufirst%3DG.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DCui%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520ag-120%2520%2528ivosidenib%2529%253A%2520A%2520first-in-class%2520mutant%2520idh1%2520inhibitor%2520for%2520the%2520treatment%2520of%2520idh1%2520mutant%2520cancers%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D300%26epage%3D305%26doi%3D10.1021%2Facsmedchemlett.7b00421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of cp-690,550: A potent and selective janus kinase (jak) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hines&title=Discovery+of+cp-690%2C550%3A+A+potent+and+selective+janus+kinase+%28jak%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lh0Bqiapj1Aeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520cp-690%252C550%253A%2520A%2520potent%2520and%2520selective%2520janus%2520kinase%2520%2528jak%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayase, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isshiki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuguchi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaitani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiratori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, T.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(02)00892-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1016%2FS0960-894X%2802%2900892-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=12482421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsVels7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=191-196&author=J.+Ohwadaauthor=M.+Tsukazakiauthor=T.+Hayaseauthor=N.+Oikawaauthor=Y.+Isshikiauthor=H.+Fukudaauthor=E.+Mizuguchiauthor=M.+Sakaitaniauthor=Y.+Shiratoriauthor=T.+Yamazaki&title=Design%2C+synthesis+and+antifungal+activity+of+a+novel+water+soluble+prodrug+of+antifungal+triazole&doi=10.1016%2FS0960-894X%2802%2900892-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole</span></div><div class="casAuthors">Ohwada, Jun; Tsukazaki, Masao; Hayase, Tadakatsu; Oikawa, Nobuhiro; Isshiki, Yoshiaki; Fukuda, Hiroshi; Mizuguchi, Eisaku; Sakaitani, Masahiro; Shiratori, Yasuhiko; Yamazaki, Toshikazu; Ichihara, Shigeyasu; Umeda, Isao; Shimma, Nobuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">191-196</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A highly potent water sol. triazole antifungal prodrug, RO0098557 (I), has been identified from its parent, the novel antifungal agent RO0094815 (II).  The prodrug, which was obtained by the coupling of II with sarcosine ester III, includes a triazolium salt linked to an aminocarboxyl moiety, which undergoes enzymic activation followed by spontaneous chem. degrdn. to release II.  Prodrug I showed high chem. stability and water soly. and exhibited strong antifungal activity against systemic candidiasis and aspergillosis as well as pulmonary aspergillosis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1j5aGGk3HYrVg90H21EOLACvtfcHk0lh0Bqiapj1Aeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsVels7g%253D&md5=e5fa5ef54f1b4e5420caef0c329b1bfd</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900892-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900892-2%26sid%3Dliteratum%253Aachs%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DHayase%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DIsshiki%26aufirst%3DY.%26aulast%3DFukuda%26aufirst%3DH.%26aulast%3DMizuguchi%26aufirst%3DE.%26aulast%3DSakaitani%26aufirst%3DM.%26aulast%3DShiratori%26aufirst%3DY.%26aulast%3DYamazaki%26aufirst%3DT.%26atitle%3DDesign%252C%2520synthesis%2520and%2520antifungal%2520activity%2520of%2520a%2520novel%2520water%2520soluble%2520prodrug%2520of%2520antifungal%2520triazole%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D191%26epage%3D196%26doi%3D10.1016%2FS0960-894X%2802%2900892-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shotwell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voitenleitner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creech, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Design of n-benzoxaborole benzofuran gsk8175—optimization of human pharmacokinetics inspired by metabolites of a failed clinical hcv inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3254</span>– <span class="NLM_lpage">3267</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01719</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01719" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFCrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3254-3267&author=P.+Y.+Chongauthor=J.+B.+Shotwellauthor=J.+Millerauthor=D.+J.+Priceauthor=A.+Maynardauthor=C.+Voitenleitnerauthor=A.+Mathisauthor=S.+Williamsauthor=J.+J.+Pouliotauthor=K.+Creech&title=Design+of+n-benzoxaborole+benzofuran+gsk8175%E2%80%94optimization+of+human+pharmacokinetics+inspired+by+metabolites+of+a+failed+clinical+hcv+inhibitor&doi=10.1021%2Facs.jmedchem.8b01719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor</span></div><div class="casAuthors">Chong, Pek Y.; Shotwell, J. Brad; Miller, John; Price, Daniel J.; Maynard, Andy; Voitenleitner, Christian; Mathis, Amanda; Williams, Shawn; Pouliot, Jeffrey J.; Creech, Katrina; Wang, Feng; Fang, Jing; Zhang, Huichang; Tai, Vincent W.-F.; Turner, Elizabeth; Kahler, Kirsten M.; Crosby, Renae; Peat, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3254-3267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We previously described the discovery of GSK5852 (1), a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV), in which an N-benzyl boronic acid was essential for potent antiviral activity.  Unfortunately, facile benzylic oxidn. resulted in a short plasma half-life (5 h) in human volunteers, and a backup program was initiated to remove metabolic liabilities assocd. with 1.  Herein, we describe second-generation NS5B inhibitors including GSK8175 (49), a sulfonamide-N-benzoxaborole analog with low in vivo clearance across preclin. species and broad-spectrum activity against HCV replicons.  An X-ray structure of NS5B protein cocrystd. with 49 revealed unique protein-inhibitor interactions mediated by an extensive network of ordered water mols. and the first evidence of boronate complex formation within the binding pocket.  In clin. studies, 49 displayed a 60-63 h half-life and a robust decrease in viral RNA levels in HCV-infected patients, thereby validating our hypothesis that reducing benzylic oxidn. would improve human pharmacokinetics and lower efficacious doses relative to 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod4vHT97N2MbVg90H21EOLACvtfcHk0ljwPWgz2zJWSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFCrsL8%253D&md5=3c8cbff5f4273f2cf43da3ec14e93f2c</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01719%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DP.%2BY.%26aulast%3DShotwell%26aufirst%3DJ.%2BB.%26aulast%3DMiller%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BJ.%26aulast%3DMaynard%26aufirst%3DA.%26aulast%3DVoitenleitner%26aufirst%3DC.%26aulast%3DMathis%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DS.%26aulast%3DPouliot%26aufirst%3DJ.%2BJ.%26aulast%3DCreech%26aufirst%3DK.%26atitle%3DDesign%2520of%2520n-benzoxaborole%2520benzofuran%2520gsk8175%25E2%2580%2594optimization%2520of%2520human%2520pharmacokinetics%2520inspired%2520by%2520metabolites%2520of%2520a%2520failed%2520clinical%2520hcv%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3254%26epage%3D3267%26doi%3D10.1021%2Facs.jmedchem.8b01719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gant, T. G.</span></span> <span> </span><span class="NLM_article-title">Using deuterium in drug discovery: Leaving the label in the drug</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3595</span>– <span class="NLM_lpage">3611</span>, <span class="refDoi"> DOI: 10.1021/jm4007998</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4007998" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3595-3611&author=T.+G.+Gant&title=Using+deuterium+in+drug+discovery%3A+Leaving+the+label+in+the+drug&doi=10.1021%2Fjm4007998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Using Deuterium in Drug Discovery: Leaving the Label in the Drug</span></div><div class="casAuthors">Gant, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3595-3611</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Deuterium, the stable isotope of hydrogen, is known to medicinal chemists for its utility in mechanistic, spectroscopic, and tracer studies.  In fact, well-known applications utilizing deuterium exist within every subdiscipline in pharmaceutical discovery and development.  Recent emphasis on incorporation of deuterium into the active pharmaceutical ingredient has come about as a result of inquiries into the potential for substantial benefits of the deuterium kinetic isotope effect on the safety and disposition of the drug substance.  This Perspective traces the author's experience in reviving and expanding this potential utility, first suggested many decades prior by the discoverer of this, the simplest of all isotopes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4z14tbfBfBbVg90H21EOLACvtfcHk0ljwPWgz2zJWSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ&md5=3818a1dba9be431098ad9dd941dababc</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1021%2Fjm4007998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4007998%26sid%3Dliteratum%253Aachs%26aulast%3DGant%26aufirst%3DT.%2BG.%26atitle%3DUsing%2520deuterium%2520in%2520drug%2520discovery%253A%2520Leaving%2520the%2520label%2520in%2520the%2520drug%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3595%26epage%3D3611%26doi%3D10.1021%2Fjm4007998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hageman, M.</span></span> <span> </span><span class="NLM_article-title">The expanding role of prodrugs in contemporary drug design and development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.46</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1038%2Fnrd.2018.46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=29700501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=559-587&author=J.+Rautioauthor=N.+A.+Meanwellauthor=L.+Diauthor=M.+Hageman&title=The+expanding+role+of+prodrugs+in+contemporary+drug+design+and+development&doi=10.1038%2Fnrd.2018.46"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">The expanding role of prodrugs in contemporary drug design and development</span></div><div class="casAuthors">Rautio, Jarkko; Meanwell, Nicholas A.; Di, Li; Hageman, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">559-587</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Prodrugs are mols. with little or no pharmacol. activity that are converted to the active parent drug in vivo by enzymic or chem. reactions or by a combination of the two.  Prodrugs have evolved from being serendipitously discovered or used as a salvage effort to being intentionally designed.  Such efforts can avoid drug development challenges that limit formulation options or result in unacceptable biopharmaceutical or pharmacokinetic performance, or poor targeting.  In the past 10 years, the US Food and Drug Administration has approved at least 30 prodrugs, which accounts for more than 12% of all approved small-mol. new chem. entities.  In this Review, we highlight prodrug design strategies for improved formulation and pharmacokinetic and targeting properties, with a focus on the most recently marketed prodrugs.  We also discuss preclin. and clin. challenges and considerations in prodrug design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYKsM1lriJObVg90H21EOLACvtfcHk0ljwPWgz2zJWSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgsL0%253D&md5=9dea9fd2f30779f4ce182b822f2c9539</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.46%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DHageman%26aufirst%3DM.%26atitle%3DThe%2520expanding%2520role%2520of%2520prodrugs%2520in%2520contemporary%2520drug%2520design%2520and%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D559%26epage%3D587%26doi%3D10.1038%2Fnrd.2018.46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arya, R.</span></span> <span> </span><span class="NLM_article-title">Toward an understanding of structural insights of xanthine and aldehyde oxidases: An overview of their inhibitors and role in various diseases</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1073</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.1002/med.21457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fmed.21457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=28672082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1SmsrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=1073-1125&author=R.+Kumarauthor=G.+Joshiauthor=H.+Klerauthor=S.+Kalraauthor=M.+Kaurauthor=R.+Arya&title=Toward+an+understanding+of+structural+insights+of+xanthine+and+aldehyde+oxidases%3A+An+overview+of+their+inhibitors+and+role+in+various+diseases&doi=10.1002%2Fmed.21457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Toward an Understanding of Structural Insights of Xanthine and Aldehyde Oxidases: An Overview of their Inhibitors and Role in Various Diseases</span></div><div class="casAuthors">Kumar, Raj; Joshi, Gaurav; Kler, Harveen; Kalra, Sourav; Kaur, Manpreet; Arya, Ramandeep</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1073-1125</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Almost all drug mols. become the substrates for oxidoreductase enzymes, get metabolized into more hydrophilic products and eliminated from the body.  These metabolites sometime may be more potent, active, inactive, or toxic in nature compared to parent mol.  Xanthine oxidoreductase and aldehyde oxidase belong to molybdenum contg. family and are well characterized for their structures and functions, in particular to their ability to oxidize/hydroxylate the xenobiotics.  Their upregulated clin. levels causing oxidative stress are assocd. with pathways either directly involved in the progression of diseases, gout, or indirectly with the succession of other diseases such as diabetes, cancer, etc.  Herein, we have put forth a comprehensive review on the xanthine and aldehyde oxidases pertaining to their structures, functions, pathophysiol. role, and a comparative anal. of structural insights of xanthine and aldehyde oxidases' binding domains with endogenous ligands or inhibitors.  Though both the enzymes are molybdenum contg. and are likely to share some common pathways and interact with inhibitors in a similar manner but we have focused on structural prerequisites for inhibitor specificity to both the enzymes keeping in view of the existing X-ray structures.  This review also provides futuristic implications in the design of inhibitors derived from inorg. complexes or small org. mols. considering the spatial features and structural insights of both the enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFjkBedwc8M7Vg90H21EOLACvtfcHk0ljwPWgz2zJWSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1SmsrbO&md5=145e2ef5ae656019b53f5459f14d01d2</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1002%2Fmed.21457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21457%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DJoshi%26aufirst%3DG.%26aulast%3DKler%26aufirst%3DH.%26aulast%3DKalra%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DM.%26aulast%3DArya%26aufirst%3DR.%26atitle%3DToward%2520an%2520understanding%2520of%2520structural%2520insights%2520of%2520xanthine%2520and%2520aldehyde%2520oxidases%253A%2520An%2520overview%2520of%2520their%2520inhibitors%2520and%2520role%2520in%2520various%2520diseases%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D1073%26epage%3D1125%26doi%3D10.1002%2Fmed.21457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stella, V.</span></span> <span> </span><span class="NLM_article-title">Prodrugs: Some thoughts and current issues</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">4755</span>– <span class="NLM_lpage">4765</span>, <span class="refDoi"> DOI: 10.1002/jps.22205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fjps.22205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=20821387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKjsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2010&pages=4755-4765&author=V.+Stella&title=Prodrugs%3A+Some+thoughts+and+current+issues&doi=10.1002%2Fjps.22205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs: Some thoughts and current issues</span></div><div class="casAuthors">Stella, Valentino J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4755-4765</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  The prodrug approach to resolving formulation, delivery, and toxicity limitations on problematic drugs has had its proponents and detractors.  Over the last 10 years or so, about 20% of all new small mol. NCEs have been prodrugs-a no. that will surprise some.  As chemists begin to explore new chem. spaces, larger and more complex mols. present greater drug delivery challenges.  Prodrugs provide a means of solving these challenges, but also have their limitations.  Prodrugs are becoming an integral part of the drug discovery paradigm in some large pharma companies, and a no. of small biotech companies have been built around the design and application of prodrugs to improve drug candidates.  Some issues facing the area of prodrug research and the commercialization of prodrugs are discussed. © 2010 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci 99:4755-4765, 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKmIrrYzZmLbVg90H21EOLACvtfcHk0ljK_TN73ybdow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKjsbfO&md5=0ca40706a47e9f042d3a5e71437ce725</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1002%2Fjps.22205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22205%26sid%3Dliteratum%253Aachs%26aulast%3DStella%26aufirst%3DV.%26atitle%3DProdrugs%253A%2520Some%2520thoughts%2520and%2520current%2520issues%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2010%26volume%3D99%26spage%3D4755%26epage%3D4765%26doi%3D10.1002%2Fjps.22205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweeny, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clough, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhamidipati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baluom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, D. T.-W.</span></span> <span> </span><span class="NLM_article-title">Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor r406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1166</span>– <span class="NLM_lpage">1176</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.032151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1124%2Fdmd.110.032151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=20371637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Klsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1166-1176&author=D.+J.+Sweenyauthor=W.+Liauthor=J.+Cloughauthor=S.+Bhamidipatiauthor=R.+Singhauthor=G.+Parkauthor=M.+Baluomauthor=E.+Grossbardauthor=D.+T.-W.+Lau&title=Metabolism+of+fostamatinib%2C+the+oral+methylene+phosphate+prodrug+of+the+spleen+tyrosine+kinase+inhibitor+r406+in+humans%3A+Contribution+of+hepatic+and+gut+bacterial+processes+to+the+overall+biotransformation&doi=10.1124%2Fdmd.110.032151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation</span></div><div class="casAuthors">Sweeny, David J.; Li, Weiqun; Clough, Jeffrey; Bhamidipati, Somasekhar; Singh, Rajinder; Park, Gary; Baluom, Muhammad; Grossbard, Elliott; Lau, David T.-W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1166-1176</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The metab. of the spleen tyrosine kinase inhibitor N4-(2,2-dimethyl-3-oxo-4-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethyoxyphenyl)-2,4-pyrimidinediamine (R406) and its oral prodrug N4-(2,2-dimethyl-4-[(dihydrogenphosphonoxy)methyl]-3-oxo-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethyoxyphenyl)-2,4-pyrimidinediamine disodium hexahydrate (R788, fostamatinib) was detd. in vitro and in humans.  R788 was rapidly converted to R406 by human intestinal microsomes, and only low levels of R788 were obsd. in plasma of human subjects after oral administration of 14C-R788.  R406 was the major drug-related compd. in plasma from human subjects, and only low levels of metabolites were obsd. in plasma.  The plasma metabolites of R406 were identified as a sulfate conjugate and glucuronide conjugate of the para-O-demethylated metabolite of R406 (R529) and a direct N-glucuronide conjugate of R406.  Elimination of drug-related material into the urine accounted for 19% of the administered dose, and the major metabolite in urine from all the human subjects was the lactam N-glucuronide of R406.  On av., 80% of the total drug was recovered in feces.  Two drug-related peaks were obsd.; one peak was identified as R406, and the other peak was identified as a unique 3,5-benzene diol metabolite of R406.  The 3,5-benzene diol metabolite appeared to result from the subsequent O-demethylations and dehydroxylation of R529 by anaerobic gut bacteria because only R529 was converted to this metabolite after the in vitro incubation with human fecal samples.  These data indicate that the major fecal metabolite of R406 obsd. in humans is a product of a hepatic cytochrome P 450-mediated O-demethylation and subsequent O-demethylations and dehydroxylation by gut bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjYey4HpvXGbVg90H21EOLACvtfcHk0ljK_TN73ybdow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Klsb0%253D&md5=391fda31851968948d538f70319979e1</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.032151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.032151%26sid%3Dliteratum%253Aachs%26aulast%3DSweeny%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DClough%26aufirst%3DJ.%26aulast%3DBhamidipati%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DG.%26aulast%3DBaluom%26aufirst%3DM.%26aulast%3DGrossbard%26aufirst%3DE.%26aulast%3DLau%26aufirst%3DD.%2BT.-W.%26atitle%3DMetabolism%2520of%2520fostamatinib%252C%2520the%2520oral%2520methylene%2520phosphate%2520prodrug%2520of%2520the%2520spleen%2520tyrosine%2520kinase%2520inhibitor%2520r406%2520in%2520humans%253A%2520Contribution%2520of%2520hepatic%2520and%2520gut%2520bacterial%2520processes%2520to%2520the%2520overall%2520biotransformation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1166%26epage%3D1176%26doi%3D10.1124%2Fdmd.110.032151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palleria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giofrè, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caglioti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leuzzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siniscalchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Sarro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallelli, L.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic drug-drug interaction and their implication in clinical management</span>. <i>J. Res. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">610</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=24516494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BC2cfls1Wrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=601-610&author=C.+Palleriaauthor=A.+Di+Paoloauthor=C.+Giofr%C3%A8author=C.+Cagliotiauthor=G.+Leuzziauthor=A.+Siniscalchiauthor=G.+De+Sarroauthor=L.+Gallelli&title=Pharmacokinetic+drug-drug+interaction+and+their+implication+in+clinical+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic drug-drug interaction and their implication in clinical management</span></div><div class="casAuthors">Palleria Caterina; Giofre Chiara; Caglioti Chiara; De Sarro Giovambattista; Gallelli Luca; Di Paolo Antonello; Leuzzi Giacomo; Siniscalchi Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">601-10</span>
        ISSN:<span class="NLM_cas:issn">1735-1995</span>.
    </div><div class="casAbstract">Drug-drug interactions (DDIs) are one of the commonest causes of medication error in developed countries, particularly in the elderly due to poly-therapy, with a prevalence of 20-40%.  In particular, poly-therapy increases the complexity of therapeutic management and thereby the risk of clinically important DDIs, which can both induce the development of adverse drug reactions or reduce the clinical efficacy.  DDIs can be classify into two main groups: pharmacokinetic and pharmacodynamic.  In this review, using Medline, PubMed, Embase, Cochrane library and Reference lists we searched articles published until June 30 2012, and we described the mechanism of pharmacokinetic DDIs focusing the interest on their clinical implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAiCiGNKbA0B0LsK7uFuY7fW6udTcc2eYqoeNkqWu0f7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfls1Wrsw%253D%253D&md5=a868b6e9d31df10f59690328836af522</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPalleria%26aufirst%3DC.%26aulast%3DDi%2BPaolo%26aufirst%3DA.%26aulast%3DGiofr%25C3%25A8%26aufirst%3DC.%26aulast%3DCaglioti%26aufirst%3DC.%26aulast%3DLeuzzi%26aufirst%3DG.%26aulast%3DSiniscalchi%26aufirst%3DA.%26aulast%3DDe%2BSarro%26aufirst%3DG.%26aulast%3DGallelli%26aufirst%3DL.%26atitle%3DPharmacokinetic%2520drug-drug%2520interaction%2520and%2520their%2520implication%2520in%2520clinical%2520management%26jtitle%3DJ.%2520Res.%2520Med.%2520Sci.%26date%3D2013%26volume%3D18%26spage%3D601%26epage%3D610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tornio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filppula, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backman, J. T.</span></span> <span> </span><span class="NLM_article-title">Clinical studies on drug-drug interactions involving metabolism and transport: Methodology, pitfalls, and interpretation</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1361</span>, <span class="refDoi"> DOI: 10.1002/cpt.1435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1002%2Fcpt.1435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=30916389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A280%3ADC%252BB3cbos1Wmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2019&pages=1345-1361&author=A.+Tornioauthor=A.+M.+Filppulaauthor=M.+Niemiauthor=J.+T.+Backman&title=Clinical+studies+on+drug-drug+interactions+involving+metabolism+and+transport%3A+Methodology%2C+pitfalls%2C+and+interpretation&doi=10.1002%2Fcpt.1435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation</span></div><div class="casAuthors">Tornio Aleksi; Filppula Anne M; Niemi Mikko; Backman Janne T; Tornio Aleksi; Filppula Anne M; Niemi Mikko; Backman Janne T</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1345-1361</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many drug-drug interactions (DDIs) are based on alterations of the plasma concentrations of a victim drug due to another drug causing inhibition and/or induction of the metabolism or transporter-mediated disposition of the victim drug.  In the worst case, such interactions cause more than tenfold increases or decreases in victim drug exposure, with potentially life-threatening consequences.  There has been tremendous progress in the predictability and modeling of DDIs.  Accordingly, the combination of modeling approaches and clinical studies is the current mainstay in evaluation of the pharmacokinetic DDI risks of drugs.  In this paper, we focus on the methodology of clinical studies on DDIs involving drug metabolism or transport.  We specifically present considerations related to general DDI study designs, recommended enzyme and transporter index substrates and inhibitors, pharmacogenetic perspectives, index drug cocktails, endogenous substrates, limited sampling strategies, physiologically-based pharmacokinetic modeling, complex DDIs, methodological pitfalls, and interpretation of DDI information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzB6gE0CNeF8uCWE5mhx1RfW6udTcc2eZaVKREksEcULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbos1Wmuw%253D%253D&md5=e5d0134d25678929f1cf0e9d15fa15f8</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1435%26sid%3Dliteratum%253Aachs%26aulast%3DTornio%26aufirst%3DA.%26aulast%3DFilppula%26aufirst%3DA.%2BM.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DClinical%2520studies%2520on%2520drug-drug%2520interactions%2520involving%2520metabolism%2520and%2520transport%253A%2520Methodology%252C%2520pitfalls%252C%2520and%2520interpretation%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2019%26volume%3D105%26spage%3D1345%26epage%3D1361%26doi%3D10.1002%2Fcpt.1435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiśniowska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tylutki, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyszogrodzka, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polak, S.</span></span> <span> </span><span class="NLM_article-title">Drug-drug interactions and qt prolongation as a commonly assessed cardiac effect-comprehensive overview of clinical trials</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">12</span>, <span class="refDoi"> DOI: 10.1186/s40360-016-0053-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1186%2Fs40360-016-0053-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=26960809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVKmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=12&author=B.+Wi%C5%9Bniowskaauthor=Z.+Tylutkiauthor=G.+Wyszogrodzkaauthor=S.+Polak&title=Drug-drug+interactions+and+qt+prolongation+as+a+commonly+assessed+cardiac+effect-comprehensive+overview+of+clinical+trials&doi=10.1186%2Fs40360-016-0053-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials</span></div><div class="casAuthors">Wisniowska, Barbara; Tylutki, Zofia; Wyszogrodzka, Gabriela; Polak, Sebastian</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12/1-12/15</span>CODEN:
                <span class="NLM_cas:coden">BPTMAB</span>;
        ISSN:<span class="NLM_cas:issn">2050-6511</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Proarrhythmia assessment is one of the major concerns for regulatory bodies and pharmaceutical industry.  ICH guidelines recommending preclin. tests have been established in attempt to eliminate the risk of drug-induced arrhythmias.  However, in the clinic, arrhythmia occurrence is detd. not only by the inherent property of a drug to block ion currents and disturb electrophysiol. activity of cardiac myocytes, but also by many other factors modifying individual risk of QT prolongation and subsequent proarrhythmia propensity.  One of those is drug-drug interactions.  Since polypharmacy is a common practice in clin. settings, it can be anticipated that there is a relatively high risk that the patient will receive at least two drugs mutually modifying their proarrhythmic potential and resulting either in triggering the occurrence or mitigating the clin. symptoms.  The mechanism can be obsd. either directly at the pharmacodynamic level by competing for the mol. targets, or indirectly by modifying the physiol. parameters, or at the pharmacokinetic level by alteration of the active concn. of the victim drug.  Methods: This publication provides an overview of published clin. studies on pharmacokinetic and/or pharmacodynamic drug-drug interactions in humans and their electrophysiol. consequences (QT interval modification).  Databases of PubMed and Scopus were searched and combinations of the following keywords were used for Title, Abstr. and Keywords fields: interaction, coadministration, combination, DDI and electrocardiog., QTc interval, ECG.  Only human studies were included.  Over 4500 publications were retrieved and underwent preliminary assessment to identify papers accordant with the topic of this review. 76 papers reporting results for 96 drug combinations were found and analyzed.  Results: The results show the tremendous variability of drug-drug interaction effects, which makes one aware of complexity of the problem, and suggests the need for assessment of an addnl. risk factors and careful ECG monitoring before administration of drugs with anticipated QT prolongation.  Conclusions: DDIs can play significant roles in drugs' cardiac safety, as evidenced by the provided examples.  Assessment of the pharmacodynamic effects of the drug interactions is more challenging as compared to the pharmacokinetic due to the significant diversity in the endpoints which should be analyzed specifically for various clin. effects.  Nevertheless, PD components of DDIs should be accounted for as PK changes alone do not allow to fully explain the electrophysiol. effects in clinic situations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpofpnYg_bLG7Vg90H21EOLACvtfcHk0lj08IHifq3I-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVKmt7c%253D&md5=5a6f1039b05b8ae2ce1860b57c1bc403</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1186%2Fs40360-016-0053-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40360-016-0053-1%26sid%3Dliteratum%253Aachs%26aulast%3DWi%25C5%259Bniowska%26aufirst%3DB.%26aulast%3DTylutki%26aufirst%3DZ.%26aulast%3DWyszogrodzka%26aufirst%3DG.%26aulast%3DPolak%26aufirst%3DS.%26atitle%3DDrug-drug%2520interactions%2520and%2520qt%2520prolongation%2520as%2520a%2520commonly%2520assessed%2520cardiac%2520effect-comprehensive%2520overview%2520of%2520clinical%2520trials%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2016%26volume%3D17%26spage%3D12%26doi%3D10.1186%2Fs40360-016-0053-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauta-Aho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teperi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korhonen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farinola, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakib, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huupponen, R.</span></span> <span> </span><span class="NLM_article-title">Frailty and co-prescribing of potentially interacting drugs in new users of warfarin</span>. <i>Drugs Aging</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1007/s40266-020-00755-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=10.1007%2Fs40266-020-00755-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=32147805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFKqsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=373-382&author=M.+Hauta-Ahoauthor=S.+Teperiauthor=M.+J.+Korhonenauthor=J.+S.+Bellauthor=N.+Farinolaauthor=S.+Johnsauthor=S.+Shakibauthor=R.+Huupponen&title=Frailty+and+co-prescribing+of+potentially+interacting+drugs+in+new+users+of+warfarin&doi=10.1007%2Fs40266-020-00755-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Frailty and Co-Prescribing of Potentially Interacting Drugs in New Users of Warfarin</span></div><div class="casAuthors">Hauta-aho, Milka; Teperi, Simo; Korhonen, Maarit J.; Bell, J. Simon; Farinola, Nicholas; Johns, Sally; Shakib, Sepehr; Huupponen, Risto</div><div class="citationInfo"><span class="NLM_cas:title">Drugs & Aging</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">373-382</span>CODEN:
                <span class="NLM_cas:coden">DRAGE6</span>;
        ISSN:<span class="NLM_cas:issn">1170-229X</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Abstr.: Background: Warfarin is underutilized in frail older people because of the fear of bleeding complications.  Drug interactions are an independent bleeding risk factor.  However, the extent to which potential drug interactions are taken into account at warfarin therapy initiation in frail patients is not known.  Objective: The objective of this study was to investigate the use of potentially interacting drugs increasing the bleeding risk before and after warfarin initiation in frail and non-frail patients.  Methods: We conducted an observational study including inpatients aged ≥ 60 years initiated on warfarin in a tertiary hospital in Adelaide, South Australia.  Frailty status was assessed with the Reported Edmonton Frail Scale.  Medication charts were reviewed before and after warfarin initiation.  Results: In total, 151 patients (102 non-frail and 49 frail) were included.  Before warfarin initiation, the use of clopidogrel and acetaminophen was more common in frail patients compared with non-frail patients (25.5% vs 10.2%, p = 0.0135, 63.8% vs 35.7% p = 0.0014, resp.).  The use of non-steroidal anti-inflammatory drugs, 9.2% in non-frail patients and 6.4% in frail patients before warfarin initiation, was completely stopped after warfarin initiation in both groups.  The use of antiplatelet drugs decreased from 56.1% in non-frail patients and 66.0 % in frail patients to 12.2% and 14.9%, resp.  Instead, the use of drugs affecting the metab. of warfarin or vitamin K increased in both groups.  No statistically significant difference was seen in the exposure to interacting drugs between study groups after warfarin initiation.  Acetaminophen, senna glycosides and cytochrome P 450 2C9 inhibiting drugs were the most common interacting drugs at discharge used in 49.0%, 18.4% and 20.4% of non-frail patients and 53.2%, 29.8% and 19.1% of frail patients, resp.  Conclusions: The overall frequency of potential drug interactions was moderate and frail patients were not exposed to warfarin drug interactions more often than non-frail patients.  Further studies in larger study populations are required to verify these results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWjpApP4MGwbVg90H21EOLACvtfcHk0lj08IHifq3I-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFKqsbY%253D&md5=74badb5410f35344de98dc4a3e6d5225</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1007%2Fs40266-020-00755-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40266-020-00755-0%26sid%3Dliteratum%253Aachs%26aulast%3DHauta-Aho%26aufirst%3DM.%26aulast%3DTeperi%26aufirst%3DS.%26aulast%3DKorhonen%26aufirst%3DM.%2BJ.%26aulast%3DBell%26aufirst%3DJ.%2BS.%26aulast%3DFarinola%26aufirst%3DN.%26aulast%3DJohns%26aufirst%3DS.%26aulast%3DShakib%26aufirst%3DS.%26aulast%3DHuupponen%26aufirst%3DR.%26atitle%3DFrailty%2520and%2520co-prescribing%2520of%2520potentially%2520interacting%2520drugs%2520in%2520new%2520users%2520of%2520warfarin%26jtitle%3DDrugs%2520Aging%26date%3D2020%26volume%3D37%26spage%3D373%26epage%3D382%26doi%3D10.1007%2Fs40266-020-00755-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i37"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01786">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_11105"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01786?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01786</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Tables S1–S3 and Figures S1–S3 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01786/suppl_file/jm0c01786_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01786/suppl_file/jm0c01786_si_001.pdf">jm0c01786_si_001.pdf (1.5 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01786%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01786" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                24MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994c940c84247f","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
